<SEC-DOCUMENT>0001367644-22-000144.txt : 20221109
<SEC-HEADER>0001367644-22-000144.hdr.sgml : 20221109
<ACCEPTANCE-DATETIME>20221108181951
ACCESSION NUMBER:		0001367644-22-000144
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		98
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221109
DATE AS OF CHANGE:		20221108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emergent BioSolutions Inc.
		CENTRAL INDEX KEY:			0001367644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				141902018
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33137
		FILM NUMBER:		221370245

	BUSINESS ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-631-3200

	MAIL ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ebs-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:e49bcad1-b3a3-4429-b549-b7280da8936a,g:b60fc6ff-4763-459f-a134-feb07b4a5302,d:9bec4b75ff354735b09dcc9c604dfa92--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ebs="http://emergentbiosolutions.com/20220930" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ebs-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80L2ZyYWc6ODkyNmEzMDZmZjA1NDQzM2FhMTViNTBmOWQ1MmE3NTAvdGFibGU6MDVlOGE0MjM4ODlhNGE4OWEzN2NkMTgyZjE0ODNmNWYvdGFibGVyYW5nZTowNWU4YTQyMzg4OWE0YTg5YTM3Y2QxODJmMTQ4M2Y1Zl8zLTEtMS0xLTEwODE2MQ_7dac4449-36aa-4e36-a2c9-604fa3305661">0001367644</ix:nonNumeric><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80L2ZyYWc6ODkyNmEzMDZmZjA1NDQzM2FhMTViNTBmOWQ1MmE3NTAvdGFibGU6MDVlOGE0MjM4ODlhNGE4OWEzN2NkMTgyZjE0ODNmNWYvdGFibGVyYW5nZTowNWU4YTQyMzg4OWE0YTg5YTM3Y2QxODJmMTQ4M2Y1Zl80LTEtMS0xLTEwODE2MQ_26e425bb-297d-4749-a792-deef0bc7b853">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80L2ZyYWc6ODkyNmEzMDZmZjA1NDQzM2FhMTViNTBmOWQ1MmE3NTAvdGFibGU6MDVlOGE0MjM4ODlhNGE4OWEzN2NkMTgyZjE0ODNmNWYvdGFibGVyYW5nZTowNWU4YTQyMzg4OWE0YTg5YTM3Y2QxODJmMTQ4M2Y1Zl8xMC0xLTEtMS0xMDgxNjE_d01f61c2-d043-4d68-9804-49e900f956e0">false</ix:nonNumeric><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80L2ZyYWc6ODkyNmEzMDZmZjA1NDQzM2FhMTViNTBmOWQ1MmE3NTAvdGFibGU6MDVlOGE0MjM4ODlhNGE4OWEzN2NkMTgyZjE0ODNmNWYvdGFibGVyYW5nZTowNWU4YTQyMzg4OWE0YTg5YTM3Y2QxODJmMTQ4M2Y1Zl8xMi0xLTEtMS0xMDgxNjE_b6cf8265-e0a0-4768-b9b7-1b6bd2b1a3bc">2022</ix:nonNumeric><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80L2ZyYWc6ODkyNmEzMDZmZjA1NDQzM2FhMTViNTBmOWQ1MmE3NTAvdGFibGU6MDVlOGE0MjM4ODlhNGE4OWEzN2NkMTgyZjE0ODNmNWYvdGFibGVyYW5nZTowNWU4YTQyMzg4OWE0YTg5YTM3Y2QxODJmMTQ4M2Y1Zl8xMy0xLTEtMS0xMDgxNjE_6ab8e469-3d3e-4b3b-9940-c7feef7e4905">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_5151ab9f-c47e-463d-8aa2-48943e0afded">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_fa39117a-d454-4120-99bf-3662bcd5aca2">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_4cea9722-b807-4cb6-aacd-3b045145d7ac">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_55a8c7c0-1418-4c46-86d6-6bf5a5d3114f">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_1a37c2b9-d83a-4cc7-9218-97115c59e9de">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_e5713eb8-636e-4658-b39f-755a6d1cadca">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i1eb46693aa644293a59a4421942c528f_D20200807-20200807" name="ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82MS9mcmFnOmZiMDYxNmRkYTlkMjQ5NWI5YTg1OTliMDk4ZWFhMGQ3L3RleHRyZWdpb246ZmIwNjE2ZGRhOWQyNDk1YjlhODU5OWIwOThlYWEwZDdfMzIx_fd672508-3b83-4524-a780-8ce6e1697bb1">12</ix:nonNumeric><ix:nonNumeric contextRef="i44ef3a51186e41038ea49e018725fc47_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82Ny9mcmFnOjc0ODRkZDhhY2Q5MTQwNWJhMTk0Y2YwZWM4MjhjOWI3L3RhYmxlOjc2Zjg0ODlmOTUwODQzMTU4YzI5MGE5OTZhYTAxMzhlL3RhYmxlcmFuZ2U6NzZmODQ4OWY5NTA4NDMxNThjMjkwYTk5NmFhMDEzOGVfMS0xLTEtMS0xMDgxNjE_9bf9cc62-2c65-4568-8738-53fc766cf216">P3M</ix:nonNumeric><ix:nonNumeric contextRef="i0c28ec30bdcd4241b718857d94f0738f_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82Ny9mcmFnOjc0ODRkZDhhY2Q5MTQwNWJhMTk0Y2YwZWM4MjhjOWI3L3RhYmxlOjc2Zjg0ODlmOTUwODQzMTU4YzI5MGE5OTZhYTAxMzhlL3RhYmxlcmFuZ2U6NzZmODQ4OWY5NTA4NDMxNThjMjkwYTk5NmFhMDEzOGVfMi0xLTEtMS0xMDgxNjE_ee2c7eee-3390-405c-a01d-6669a3ba0c0f">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i6d0613c15a9a4b2891e92b0cb74673fa_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82Ny9mcmFnOjc0ODRkZDhhY2Q5MTQwNWJhMTk0Y2YwZWM4MjhjOWI3L3RhYmxlOjc2Zjg0ODlmOTUwODQzMTU4YzI5MGE5OTZhYTAxMzhlL3RhYmxlcmFuZ2U6NzZmODQ4OWY5NTA4NDMxNThjMjkwYTk5NmFhMDEzOGVfMy0xLTEtMS0xMDgxNjE_1b1d95e2-63c3-4ff4-b31a-a9a1823b132d">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="if50fd0c04e7b433595e1fc59565af1ac_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82Ny9mcmFnOjc0ODRkZDhhY2Q5MTQwNWJhMTk0Y2YwZWM4MjhjOWI3L3RhYmxlOjc2Zjg0ODlmOTUwODQzMTU4YzI5MGE5OTZhYTAxMzhlL3RhYmxlcmFuZ2U6NzZmODQ4OWY5NTA4NDMxNThjMjkwYTk5NmFhMDEzOGVfNC0xLTEtMS0xMDgxNjE_49ea3828-91e5-434e-8852-4366c895c233">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ied97412e542e49649f895e9d8fca082b_I20220930" xsi:nil="true" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82Ny9mcmFnOjc0ODRkZDhhY2Q5MTQwNWJhMTk0Y2YwZWM4MjhjOWI3L3RhYmxlOjc2Zjg0ODlmOTUwODQzMTU4YzI5MGE5OTZhYTAxMzhlL3RhYmxlcmFuZ2U6NzZmODQ4OWY5NTA4NDMxNThjMjkwYTk5NmFhMDEzOGVfNS0xLTEtMS0xMDgxNjE_0614c7d3-af9d-490b-ab68-a27ec3ef3ad6"></ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i91da1234e99c48fba4f1671ade54bc4d_D20220101-20220930" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMS0xLTEtMS0xMDgxNjE_824cd1bd-e1d1-4407-8498-deb63f66d68e">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i2bdca5071efe4471843b78ab54d1d399_D20220101-20220930" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMS0yLTEtMS0xMDgxNjE_f37bf0f8-a317-4312-99f3-99ef53057072">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i9ea336f29716489a8ee918ca7587d4fe_D20220101-20220930" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMi0xLTEtMS0xMDgxNjE_3dc78f27-a3ad-4f4c-b3e1-efa9e5aee840">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iedf32fa013a5453f99dd18ef9591e2ac_D20220101-20220930" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMi0yLTEtMS0xMDgxNjE_78ce435d-dd98-4230-b2c5-35f1e5845a7c">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i02291c57c21b4a2c8a7441b2cb71c41a_D20220101-20220930" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMy0xLTEtMS0xMDgxNjE_cce1fd76-fb48-4dfb-a777-861a458633b9">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib0c7a59cd0bc45efb119c53f96ba1842_D20220101-20220930" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMy0yLTEtMS0xMDgxNjE_9dd72b09-1c74-48f8-bcc0-caa4546d0432">33.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ebs-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2be5b42ff0b4471c908cf57d97a2e71f_I20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i52646bb207c64e15902c5f7cebbaa5a9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c1314a596fa4be2be2dbbc905e0e0ce_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6605ab0b24d4a3a95cd07e88110dd0e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac0c2ed83d34c43b639039d2831ada9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3ea905c3a1d48a9a374e41f47cd9e7e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i293e88d455b74b89b6ea596c99361768_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94946a3df68a4894a63cc93522fd6ca4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e3af1259505476faa37180bca0dbed6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25e36ed15c584f8abca1aae53e56c499_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5106d154262648b8966552fa34ac668e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ae88a70cad04a6f9c132484c353e5b9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30625a73d79a4164a68a490ce85445d6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7c744e01ccc4b70a3f8d3f033d69fc7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefc13edfdf22466c94aef0c6826da80b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eff28a2bc3a4e869ed6725ec343457b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e2dd808a6bb49acaba894087e88aab6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee99b848e7d34f24ba7ebd4d2abf4f85_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5105f0204af64b01a45ffaaf2c96b86e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc86efbf51c9459a924cb8855de7d59d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dd3f76fb0234ae9898dcecdd750649a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0444415079d48bca0450996b92c9137_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc984f7cf64a4ac6ad2b90f5b12b27ea_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief03e38f153e479b9c16cf1572d2d802_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i858bc01bcffe4fcc818b41f3490126e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i025e25b63cf240efb8c5c078757469d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4698414e7c1401c82d1bdd7bd331f7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73297e52dd7b4d0f94c279cc3501cbca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94685af212e84378abd02869fc65b116_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c721871d86b4c9d92da8f3576d3c37c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44614402dda1433ab395ed9472240cf0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8990366d48494f1b8a20b74e61189484_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a84624f46d42f4b0f9c18da44b11de_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809764d7e9a84800b82506178a13b313_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3449978510494de9985378c4af49f5af_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d47500381c4a06a021712d3d13c022_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib32c62eb60fc4dc39b819eb33d2ecd33_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88701e64171b4b4dbfc52b23a8dd15b7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c07897dcdde4d89a128d2ed15fc5ad1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14f2fb7cdf644c66b524b020f443b7a3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65f2af0d2c0b4a15bc6e7423ba835ade_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i215adb10fcbf40a5a7ec2fc2088354e3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86413dba3b9141c89275b7ef4f89903a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i513d610eeb964439903192db1ecb51ed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc0fb7f94b4b4633bba35f83b8ce0a44_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d3b9f37fd21490c816e8c33b0d191df_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97535e302cdd4eae990d766576feefac_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61f687c252da498ea3071b9bef0dae99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i345b6ed13f3d4fe5a3c2aa0fb402b26c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e607ecbd5b74b8c8b0184925410bf01_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9334dc4e6d884a7cbb7f455bf2f9af61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fc5b8a85402486c8e7e3ae07b0a3871_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f4e99d6d47b4c0faf6ea720533b7521_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ccbc79df52c4d15b022b9a21c0ca27a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03643882b32948aa88d7c7088c47243d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1907d7b857734e8fa8e27c5ba195c7cd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9501b3606d3748baa7f730985abc93d3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i120aedf84da0491da3c474183e2c4892_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b982988d59741509a3340a4affea571_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i234810222a77469a8d310e47d2fa2f03_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3d773caeec44dac875f1fc14041b176_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebd066da54a34dadb2cfaddc80097222_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61a54d77cf52423fa152a2b6df738697_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2109c764e423427782835d0108e52bb0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e6a2188c167465d9720bcd73f722dcd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib96436736dac42149fc4524b381689e6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafc0f0f6c6e34f86a10f18a780bc594b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if472db7e4ddc4d8abb7803c05ad8a4fc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3ae0efe55364ceebbd48beeaa1b5f0d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i249e76b2e30b449d9cd1d10e9e44a617_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="category"><xbrli:measure>ebs:category</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>ebs:product</xbrli:measure></xbrli:unit><xbrli:unit id="productcandidate"><xbrli:measure>ebs:productCandidate</xbrli:measure></xbrli:unit><xbrli:unit id="businessline"><xbrli:measure>ebs:businessLine</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ebs:segment</xbrli:measure></xbrli:unit><xbrli:context id="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26c8454cef2f47789cf2d3ee6746429f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:MilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d15cdbf01f5414d8ebe10c27040be71_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="treatmentcourse"><xbrli:measure>ebs:treatmentCourse</xbrli:measure></xbrli:unit><xbrli:context id="i7432986424e74ac09ac1dd272585adcb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb0a527f718246d39439945aa519e89c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a5d3c91817245f8a781e98678ca71b4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief03c3babd264580b8f993d58e2f7399_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i432591c3907547a4a78ac6a89b2d6d9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i749bb1b516384ad09235dfaddfccbfb3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide2d35bc08594b3ea21d8f60f7762840_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cf3406660784396880636ec6d64ce18_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b571dae77f04edfb1556f8d08c9d6e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766a15cf4ffb4c6d8115bd955a940932_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdc0a33e12b849de810968cc193f06d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3d94b6f79364cc1899b13f7a72f0e27_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e27b276ca764530b7005d22d6316077_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50157349177f44679e4ff5b00c2b690a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a811ac3bfcc4c29a2a87b5ad51a6fde_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ebs:RockvilleManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc90073631a04e08b6793e36b6aad73e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ebs:RockvilleManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb1900f7b4c44cedb875acc241c0bee3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i261b255bd2fc4596b335217f2db169aa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93e3346dbc84460d924b2e6aa25b270d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b49e361c9c547df983b25e75f050a95_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f8980f84e54596a2bf0df6314e9c89_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ff2b788ad74a47a087d6ebd487fff7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide0e3032f9614c6682f2d4f2a0717a79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01ccd0bec4264051b3136200d1ada025_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabb40ddb95bf4ae692da5f4e955899fa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i222957670d1047ca907e168d91aaf306_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2196bd047dc467a8d54bb1d0d7ad901_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a10a22a6f834e04b52f8cb6f61ac369_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib304027feebe4bf294aa22162bc25292_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88816d3c5490459795a5e08eb0d42dba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca9b3f099074a319fce082bb2f89bec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b7a7a2b19ba41c289818e166af517c7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f9711a7eb5243dda529179658dd5830_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4699322b4ad742c4a1d4274126058576_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d55fa0666854b7caae1ece36564984a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc5d91a03d4847649b2be05d67b2263c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ddf4cbc6d484433973d4f77a1b65e21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibad5698b8174430c8ff31576aa9ee134_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48426d78db35469b9fbe78182bc15858_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7b6bac14fa948a599d617d797f9992b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i794b255dfaa5457d8b625a3b63515086_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eade752296e444ba664833e0780951f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacb283273e704425a0c32a9149376f6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8007fc99edc04934866754634405d8ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1054758dc0d14fa3bddb52120fbac120_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcd99f4d0bd44df5ac51fd3f92b88bd4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb22a87cdfe14a7c84c7650473417364_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic622b8b9acb24f6b88e8c6886000cf77_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c2baff68b54a718464354731cbe1ff_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef5c35c4662482c96b3838cdb9d6edd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i300780e3ce444b4cb0b0c9c10968ac86_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i291befa2eae3402ebb90a91957b5b46f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b3b07fe44be43f1b02c1b877f8d8f60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19788cf415e44731a7ac316933902c13_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d38ed2b0b1c4eaa8ca77f4744eb8d44_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="instrument"><xbrli:measure>ebs:instrument</xbrli:measure></xbrli:unit><xbrli:context id="i2e48ea4760d64c29a1425b6484a220d7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i838e26b2874e4c6a900e96dfeaeb7fcf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i150ebed92e8e40479da8c8a6f0513b75_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e600ddb0a1748578ccc9e9d07f955f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic90b9835f0d24ac1a182a07dd228a238_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4d660de4664e77b8ff1707a368864a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida4dbb8aac844392a35bca16af3b8ba6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fde38f223f94ec0bedb7aaf2da71b3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i738ecdd912c348ff897fd9f1546835a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic61dd5c549874f80b397d42cc9717abc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74b2a89fef854325a21558ba470a63ad_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04969e1a51cb42c89f1471eb8ace2e4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50ceba61f3047f1834721079b974236_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i027fba7fbff04d03860a6cb1878e9580_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaffc9253e79f4fcebff3b4c90c35286e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i685e03fb0a4c4543b949a4d6d792d36a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5375d3691d1d44bc8c0347410a5bea7e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08291fa7af0b411b9ad50845378e5f4f_I20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e7c1aaf68b942a4862dd65bfc9fb9b0_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i920e76d8a6b143808c57dd4353d67903_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f8efea66de4544a5582830d8b59691_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6200f8d1ae104ba18d6fdb545b3e9d53_I20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e35fd549cd4231be789d968dfd1543_I20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8605ed75b07d49a3b547f97fccb0e405_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b05a62bd63445cb568d4c2e2c3d9e0_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic84be99323cc4584be4962051ab7756d_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0b9e211f3b94cda86f8d463e61a3a6c_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17b0291bd1dd47a7b7ee65d4fecc6232_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i655fab78c8164add9eea8222ce75abaf_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1479ba7c4c8141da9c266a76d41c699c_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida101d603b624a549b887226e83027b1_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb46693aa644293a59a4421942c528f_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28a266eb53e04df59d47c4a05b3e2244_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c02245efe03492d998177bd87378e02_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a88ddbd25d44236801b5ce80ff820a0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ec2984c86b4778b38ae6b4badb7f46_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c4a64e596d45aea88a95a509f10f86_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee319a3e184c49c88a65354d45c0fcb5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68059df57d924b6c9a6d571ce4686d06_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a498fe04f304b2bb151292ea1f5194c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85d2fdbc895b41fe8983ba64d0d2ffb0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93ce7d6831194524b6acb971a73c8b1a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ea4a6a0de647a8a6d921dd7b209282_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad159380abc745509e18c7cd554939da_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4317852774f4594bf7d43b26a0b6f3d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d65c5dfe69a49298805ed95c23e4944_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d79a2aa8e1a4715897d56ad0693e4a1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff568f9147f143f48975cc8ccf7bb4d9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie21ef4d129104b7a8ae5cd39ae894a3f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ce67d2e233d4f5786192e1687c3c262_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if950b033c22d4b22a7e329ed5dbe41cd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c0ec50c43b41b5899fc5e10c1d9ea3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc42b30bb7694aa3bd4d198c2dc52e32_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5a6612cb27940cd836298ddf8f13245_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6fe41cba330404f809cbe23888df0e9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia96662ac0ab84db9a8a6492b07c4e033_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e7025c3b25f4602939fc3db062b06cb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59ac47cd04fe4a45ba8a9128f2df0c0c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib714d01e5ecf4cd28cfdd767aab24593_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic74b2084ca8b4016920a9bb39463c71e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb1d9ae26ce84cf1851284c7e4edc162_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0d2c7c6dafc46998c4e95a9750239ee_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad57e6166b6f48cabbffd992ec0bae18_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a8c2b7b92db42f19333bc4e4af5abf1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb131a1d8ee2411bbdf86420dba67a16_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5748c1fd8864631b676f49aec67c5f9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5afd6d5f0de4b5a880e3f897b519fff_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759d3f20525a4e73a29ad36cd1f9ad52_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d296d42d02f4c53851eb8bbaa2f0904_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9444f3dda52346f994f9fa3d1d5f265e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i230926cc93b94f13a0f1ea180f586c99_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbfcd3defae147349f8488c0ed4ae6b3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf3d857066a346c9b7cc2f77fc9cf913_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f054a91031f430392248a4bca839f9f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb67dea42a90430caaa50cf5bb540f53_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15644a22cf32438bb4e89c230573cc53_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee7392a5534e4fed8a494faf3156d30a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7686e78d6544ad4ab6f238d59a463ae_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0599ce5bf334bcd978cd677b9ce3488_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac249b92a2c34f4786aaa61ef1798afc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if052ae8be962412ca908a8ec55ce01bb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f1c052aa974422c8e8de6bf7e629008_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c15bfbd578f4b02a335a5f53693bd78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:ReservationOfManufacturingCapacityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cc548c971bc4ddab945aa7c2daa9c29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:AcceleratedExpansionOfFillFinishCapacityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eb263408fe5444cbc0c106687b0c0bf_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5f414c7b3a34d038d192fa7b90dcfbe_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44ef3a51186e41038ea49e018725fc47_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c28ec30bdcd4241b718857d94f0738f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d0613c15a9a4b2891e92b0cb74673fa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50fd0c04e7b433595e1fc59565af1ac_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied97412e542e49649f895e9d8fca082b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ec7f41ed1e466ea8c8265cc217d1c9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e7ce5556ca4a7fb06da82e3898d7b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eabe1e8d9c443b4aba12a1f4dfe8104_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4d3da6f40f548208c86343dfbb7f66e_I20211111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6a69a9d549d4a7f9e5cca915ff81ac2_D20211111-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-11</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c17179d3e4b4293af0a828cab7b1e54_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i741c417cf3c5438e926f3c181037b75a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icec9923b70dd4963ad63bbf6fbe6313b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b1f195ba044f8fba31c82ade107986_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76cbbd4bcdbd481f9e12b0c3a5cf4906_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35e87d35bfd4ff89237fb26b10d3744_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i598359cdd71c4de1a7ee59cbd115af40_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff9ad4afb37944048472b35bed2debf0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic29a7152fbf34b57b22e53b5f6a77694_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib20b602b02994e55bb8f5ff08e429097_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37dbd3322fa84e95b69930efeffb24f6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19613f0852b447be92b4d26268de48b6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibefbe152ae4b4ce4a115b201334e73c7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd27e1e917ee436d8d215b793434f26a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bff5d9f1c2e45429a4c8237c99b05c8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica2181992bf34758ae89111c96b05c4a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e2b94c99ce4c32bf8a4a143327d9e3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia02d17b7af424e47932221e5cb92610d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22dbe6000d7d4fb6bb7bafebd2ab2977_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2c4b48c5bf44b583764343364acd18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e4037d8d3a6449baf24676b5b39d131_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73cb1d2c06c148969484c4bf9e7eb0eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b67a9c1ec7349d18cbb84f1528227b8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7b70bf533d44156972098e72400de35_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2be39dc33a614a138b0a5fa59b102996_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iced5a2acfffc465fa00678af5ae50f55_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7c28ab284a34fd99cbac681f30c7f59_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac12e2048894448abb1be8d9798b112_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67e98f514b5248989bc8c524e454fe4b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a289bb66e084884817817146aa5a26f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f38ed14c4bf4de6b87cd4d750fc372c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43143025a48b44c0a71392046d272649_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c5ea12368ef4ae3bb23c26ed19c8995_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63b169b1e50643f2add731b5b39f04c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4f63f2b44854c31bb36daeefef5eb2a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5dd4144da824a99afec23d0225b46ec_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccb2cd37199e4c108d7c667ed7106280_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0020c5f97ae64effb8f68a65a66da7b3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i580d7f5f89514a8d9a9655a5cb84908b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5938e145ac85492f83e842b212b1e504_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i563cf1b2420d41c1ba3c84e069d89c8a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i329b945040704750b621490e14ce1c15_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd7dfbc7f90e4bce9bca0903609cb140_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91da1234e99c48fba4f1671ade54bc4d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bdca5071efe4471843b78ab54d1d399_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ea336f29716489a8ee918ca7587d4fe_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf32fa013a5453f99dd18ef9591e2ac_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02291c57c21b4a2c8a7441b2cb71c41a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0c7a59cd0bc45efb119c53f96ba1842_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7856b9f8f6d49b08fcf4b3d7646741d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a9d457339c7409eb76312880e7a9ad8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3c3d681b76e40419af6d49da37af710_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied76f18f442f4ab69a0615274373a47b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bf31d14f117481daf2044655dd6e7ad_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16214c20216b4ae9b2e00cb861cc0703_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97728d771d6646119c3295cf7509eb03_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icae6520aeb4c4128b277d196b54c5c64_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6d422d97fbb4e9c9744b614e2bf12b0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7460e31e951a480b816dfe2ae15feac6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i801413427f1f43babdb24055bb4bd90c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4dc9efc2b614e0dab48fd0fdb3134a0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0058f71a7708496abfdf19ad817835bb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a9984fa01164445b43977c0e9fc6107_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia28dc2c9d43e4b13a7778805dc25c68c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32b2a80ee4ec410d9527e186fd40b2bd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a49e5be45554d6d948e7369dce4055d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia00293a7076049e7979650ad37c66b83_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie24035e19dcb4f0a9e08c4030356556d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d9a1c9cc0b4c1281e5652109cbc1df_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM4_70ec13ea-16c4-4fd5-b9eb-9323a520136e">10-Q</ix:nonNumeric></span><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6Zjc3NTk2YTRkNWRlNGVjNTkwOTVlZmMyOThjMzlhZGEvdGFibGVyYW5nZTpmNzc1OTZhNGQ1ZGU0ZWM1OTA5NWVmYzI5OGMzOWFkYV8wLTAtMS0xLTEwODE2MQ_43611b1c-4057-443d-acaf-fc18375cc6eb">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xMjE_800c5e15-c747-4c8c-85f8-729ebd5180c1">September&#160;30, 2022</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YmZkZWY1NGFhNTM1NDNlZmE5NDlmNjUwMWIyMWQ1Y2UvdGFibGVyYW5nZTpiZmRlZjU0YWE1MzU0M2VmYTk0OWY2NTAxYjIxZDVjZV8wLTAtMS0xLTEwODE2MQ_b1fce878-6518-4f52-b7c1-481f92af967a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from    to        </span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODQw_3f25b3ec-8124-4ca9-a06f-f8d61ae0b9dd">001-33137</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><img src="ebs-20220930_g1.jpg" alt="ebs-20220930_g1.jpg" style="height:20px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODMz_91ebad24-1c38-4263-9b88-c015fba639eb">EMERGENT BIOSOLUTIONS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:44.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF8wLTAtMS0xLTEwODE2MQ_e7ec67ab-64a1-4f90-b83d-445d0a05dd82">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF8wLTItMS0xLTEwODE2MQ_15d7a1b3-845f-46b1-bbf0-0780f469c403">14-1902018</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF8zLTAtMS0xLTEwODE2MQ_c9d7fa12-3670-4baf-8c08-4a1ecc69b1d6">400 Professional Drive Suite 400</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF80LTAtMS0xLTEwODE2MQ_ea074d15-bcda-4b7d-b5bb-837cd0a05636">Gaithersburg,</ix:nonNumeric>  </span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF80LTEtMS0xLTEwODE2MQ_35d3c652-23c0-4700-8459-2ded2195654a">Maryland</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF80LTItMS0xLTEwODE2MQ_25a23f78-6936-4c9e-ba86-804e54d72527">20879</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address and zip code of Principal Executive Offices)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM5_f9f6e34f-1b5b-4c13-8e63-3d96bb6b399c">240</ix:nonNumeric>) <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM0_b32127b4-a831-44e6-8bc5-246aea69cafb">631-3200</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Registrant's Telephone Number, Including Area Code)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:34.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6MzgyOWJjZDBkMWFlNDhlZWI0YTI4N2RkNjFiNTAxMjIvdGFibGVyYW5nZTozODI5YmNkMGQxYWU0OGVlYjRhMjg3ZGQ2MWI1MDEyMl8yLTAtMS0xLTEwODE2MQ_6b35d3ef-2504-45db-99f1-51871ed9a48a">Common Stock, Par Value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6MzgyOWJjZDBkMWFlNDhlZWI0YTI4N2RkNjFiNTAxMjIvdGFibGVyYW5nZTozODI5YmNkMGQxYWU0OGVlYjRhMjg3ZGQ2MWI1MDEyMl8yLTEtMS0xLTEwODE2MQ_74d93c47-dd39-4ccb-959e-f83ff5ef52b7">EBS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6MzgyOWJjZDBkMWFlNDhlZWI0YTI4N2RkNjFiNTAxMjIvdGFibGVyYW5nZTozODI5YmNkMGQxYWU0OGVlYjRhMjg3ZGQ2MWI1MDEyMl8yLTItMS0xLTEwODE2MQ_36fc0eee-ed61-47bb-a896-15c3725ec148">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746; <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM1_e3c8b989-4b3d-4ce7-80f9-cb4e57748118">Yes</ix:nonNumeric> &#9744;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746; <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM2_3b69d231-6278-4884-abc3-68ee479f2752">Yes</ix:nonNumeric> &#9744;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:41.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6Yjk3NDUxNjAzNzhiNDUzYTk0NzA4ZTNhMmVlYjM1MWQvdGFibGVyYW5nZTpiOTc0NTE2MDM3OGI0NTNhOTQ3MDhlM2EyZWViMzUxZF8wLTAtMS0xLTEwODE2MQ_2935073a-e325-4cc1-aaf9-45cddfe94243">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6Yjk3NDUxNjAzNzhiNDUzYTk0NzA4ZTNhMmVlYjM1MWQvdGFibGVyYW5nZTpiOTc0NTE2MDM3OGI0NTNhOTQ3MDhlM2EyZWViMzUxZF8xLTMtMS0xLTEwODE2MQ_5ea82fc8-c1de-48d4-8e77-138cbe27449e">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><span style="font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6Yjk3NDUxNjAzNzhiNDUzYTk0NzA4ZTNhMmVlYjM1MWQvdGFibGVyYW5nZTpiOTc0NTE2MDM3OGI0NTNhOTQ3MDhlM2EyZWViMzUxZF8yLTMtMS0xLTEwODE2MQ_88ff22af-76c1-4cf0-b905-5a907910ff81">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes &#9744; No </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM3_aa39d37c-1150-47f1-bc84-5ec10bffa116">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of November&#160;1, 2022 the registrant ha</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">d</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="i2be5b42ff0b4471c908cf57d97a2e71f_I20221101" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xNzk2_18275cdc-ec83-43e6-a30b-a229fb601611">49,888,218</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sh</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ares of common stock outstanding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 10-Q</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%;text-decoration:underline">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_10">Part I. Financial Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_13">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_16">Condensed Consolidated Balance Sheets&#8212;September 30, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_19">Condensed Consolidated Statements of Operations&#8212;Three and Nine Months Ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_22">Condensed Consolidated Statements of Comprehensive Income</a><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_22"> (Loss)</a><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_22">&#8212;Three and Nine Months Ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_22">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_25">Condensed Consolidated Statements of Cash Flow&#8212;Nine Months Ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_28">Condensed Consolidated Statements of Changes in Stockholders' Equity&#8212;Three and Nine Months Ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_31">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_91">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_91">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_91">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_115">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_115">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_115">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_118">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_118">44</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_121">Part II. Other Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_124">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_124">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_124">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_127">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_127">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_127">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_130">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_130">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_130">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_133">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_133">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_133">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_136">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_136">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_136">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_139">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_139">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_142">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_142">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_142">78</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9bec4b75ff354735b09dcc9c604dfa92_148">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:none" href="#i9bec4b75ff354735b09dcc9c604dfa92_148">80</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and the documents we incorporate by reference include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future performance of Emergent BioSolutions Inc. or our business strategy, future operations, future financial position, future revenues and earnings, projected costs, prospects, plans and objectives of management and the ongoing impact of the COVID-19 pandemic, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "estimate," "expect," "forecast," "intend," "may," "plan," should," "will," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. You are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by law and the rules of the Securities and exchange Commission (the "SEC"), we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others:</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the availability of U.S. Government ("USG") funding for contracts related to procurement of our medical countermeasures, including AV7909 (Anthrax vaccine adsorbed (AVA), adjuvanted), BioThrax&#174; (Anthrax Vaccine Adsorbed) and ACAM2000&#174;, (Smallpox (Vaccinia) Vaccine, Live), among others, as well as contracts related to development of medical countermeasures;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to meet our commitments to quality and compliance in all of our manufacturing operations;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the impact of the generic marketplace on NARCAN</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCI) Nasal Spray and future NARCAN sales;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to perform under our contracts with the USG, including the timing of and specifications relating to deliveries;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to provide contract development and manufacturing ("CDMO") services for the development and/or manufacture of product and/or product candidates of our customers at required levels and on required timelines;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to obtain and maintain regulatory approvals for our product candidates and the timing of any such approvals; </span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to negotiate additional USG procurement or follow-on contracts for our Public Health Threat ("PHT") products that have expired or will be expiring;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to negotiate new CDMO contracts and the negotiation of further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing under our existing CDMO contracts;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">our ability to collect reimbursement for raw materials and payment of services fees from Janssen Pharmaceuticals, Inc. or other CDMO customers;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the outcomes associated with pending shareholder litigation and government investigations;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to comply with the operating and financial covenants required by our senior secured credit facilities (Senior Secured Credit Facilities) and our 3.875% Senior Unsecured Notes due 2028;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the procurement of products by USG entities under regulatory exemptions prior to approval by the U.S. Food and Drug Administration ("FDA") and corresponding procurement by government entities outside of the United States under regulatory exemptions prior to approval by the corresponding regulatory authorities in the applicable country;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the extent of any ongoing impact of the COVID-19 pandemic on our supply chains and potential future impact thereof on our markets, operations and employees as well as those of our customers and suppliers;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the impact on our revenues from and duration of declines in sales of our vaccine products that target travelers due to the reduction of international travel caused by the COVID-19 pandemic;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria, contribute to our overall business strategy, and align with our underlying assumptions that formed the basis of acquisition;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to commercialize, market and manufacture new product candidates successfully; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the accuracy of our estimates regarding future revenues, expenses, capital requirements and needs for additional financing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. When evaluating our forward-looking statements, you should consider this cautionary statement along with the risk factors identified elsewhere in this document, including in the sections entitled "Risk Factor Summary", "Risk Factors", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures about Market Risk", as well as the risks identified in our other reports filed with the SEC. New factors emerge from time to time, and it is not possible for management to predict all such factors, nor can it assess the impact of any such factor on the business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE REGARDING COMPANY REFERENCES</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Emergent BioSolutions Inc. and its consolidated subsidiaries.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE REGARDING TRADE NAMES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BioThrax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BaciThrax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RSDL</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAT</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trobigard</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Anthrasil</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CNJ-016</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ACAM2000</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vivotif</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vaxchora</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NARCAN</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ebanga&#8482;, TEMBEXA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners.</span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_13"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMEN</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions, except per share amounts)</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.759%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNC0xLTEtMS0xMDgxNjE_92d31a7b-2acc-4641-bb90-bf7e589426c9">240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNC0zLTEtMS0xMDgxNjE_fc2c0af7-ec66-4315-9b0f-901ca9675049">576.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNS0xLTEtMS0xMDgxNjE_fd6fc330-11d4-4bc6-af63-b71bf1a6477d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNS0zLTEtMS0xMDgxNjE_9999dd3d-9eeb-4da1-8730-7c92650a7247">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNi0xLTEtMS0xMDgxNjE_71ea48ae-f004-4586-a103-97f7bdce39a8">191.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNi0zLTEtMS0xMDgxNjE_49188506-c7db-47f7-bad2-8cc4b242a6c6">274.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Inventories, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNy0xLTEtMS0xMDgxNjE_65f0b18f-c00f-45ad-9ab6-e04137414911">546.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNy0zLTEtMS0xMDgxNjE_3313d5e2-8176-435e-afd2-b5624a74390f">350.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfOC0xLTEtMS0xMDgxNjE_0c36eba6-bcb8-4beb-a4a5-522045b9ce1d">139.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfOC0zLTEtMS0xMDgxNjE_934a9550-8aa6-4f34-85d2-b1ee5210ccb7">70.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfOS0xLTEtMS0xMDgxNjE_7f43d548-1f4f-474c-ab8a-9ef3afd1b48b">1,118.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfOS0zLTEtMS0xMDgxNjE_79c064dd-5f3c-4d00-bb64-66f1c2659231">1,272.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTEtMS0xLTEtMTA4MTYx_f29c7cde-dc70-4cd4-b2f9-cda58fef7338">806.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTEtMy0xLTEtMTA4MTYx_2a5aa477-8353-4dfb-b8ae-60f3c2a22a07">800.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTItMS0xLTEtMTA4MTYx_79e65ff5-0a2e-49c3-9eca-003f15107ac0">722.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTItMy0xLTEtMTA4MTYx_ff644617-a27b-4c75-b5f3-a262a36f8cd8">604.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTMtMS0xLTEtMTA4MTYx_0ebca770-af5b-45a4-ae97-d7bc7efcd948">224.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTMtMy0xLTEtMTA4MTYx_8b8e26a3-8f00-4aa4-86f6-9893d06eaf98">224.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTQtMS0xLTEtMTA4MTYx_6561c66c-ca74-40e1-bab7-6df66adfbccb">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTQtMy0xLTEtMTA4MTYx_5869fdfd-ce51-48e3-8d7c-b24bfa979abe">57.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTUtMS0xLTEtMTA4MTYx_ca1dc88b-6419-4464-8f80-ca531fed7ffd">2,908.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTUtMy0xLTEtMTA4MTYx_d1aab227-83d0-43d2-a8a5-a55dbca89ad8">2,959.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTktMS0xLTEtMTA4MTYx_3a559237-3460-4d1e-8cf2-fca41e9ff539">103.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTktMy0xLTEtMTA4MTYx_6076c051-5777-4b60-b16d-9a26a8c6b95a">128.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accrued expenses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjAtMS0xLTEtMTA4MTYx_15e83df6-68d2-463c-b864-6178eca8b925">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjAtMy0xLTEtMTA4MTYx_3cfb8bba-9b11-439d-808b-0759a33ef486">51.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjEtMS0xLTEtMTA4MTYx_9fecd210-75c1-4d1c-b494-8906adda87a3">82.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjEtMy0xLTEtMTA4MTYx_6c6aeb29-b884-4059-9563-bb8f3baa5cbb">88.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Debt, current portion</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjItMS0xLTEtMTA4MTYx_00fbf3d9-5921-4492-af71-f7d91d8e7848">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjItMy0xLTEtMTA4MTYx_d82e123a-98c6-4ef1-b3b4-1aea549c2852">31.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjMtMS0xLTEtMTA4MTYx_69f37c6c-576b-4bb0-a100-9b08f990ed49">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjMtMy0xLTEtMTA4MTYx_2f9eed91-fdd2-42f5-9925-ffbda5932d7c">72.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjQtMS0xLTEtMTA4MTYx_7255f208-4639-4ecf-ba38-b8f8e0a6833f">268.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjQtMy0xLTEtMTA4MTYx_2bb86c63-210b-46e9-b794-027bd3b64980">373.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Debt, net of current portion</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjYtMS0xLTEtMTA4MTYx_eae83faf-6990-416b-8a0c-906aba41654d">1,032.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjYtMy0xLTEtMTA4MTYx_8ad80c18-52b7-47ee-ac87-d4f76bbed07c">809.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Deferred tax liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjctMS0xLTEtMTA4MTYx_7637bbbf-7524-401c-8c85-6cc1cb7ac46d">113.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjctMy0xLTEtMTA4MTYx_f73b34e5-d44a-4938-b197-fda04b45cd3a">94.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjgtMS0xLTEtMTA4MTYx_8fade240-0aad-4308-940f-dee721110db3">44.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjgtMy0xLTEtMTA4MTYx_00e3f6c5-620b-4dc3-9d11-8fe1b8b3f7a7">61.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjktMS0xLTEtMTA4MTYx_f6abe8b3-6cfa-4ea2-87cb-c1f852182852">1,459.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjktMy0xLTEtMTA4MTYx_09213c2f-aafe-493a-8668-4031d5492b7b">1,340.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Stockholders' equity:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfMjE_7f576fb3-7114-4a3e-8c80-036172b99780"><ix:nonFraction unitRef="usdPerShare" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfMjE_a59246b5-67b9-407c-9ca2-fc14e39139c0">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfMzU_2befc88c-fd3d-49b6-882d-aeff9e150e2d"><ix:nonFraction unitRef="shares" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfMzU_e81dab48-f6d0-4279-9d43-3303780d9550">15.0</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfNTc_37558ecd-c3cc-432a-9c87-c3439b313a54"><ix:nonFraction unitRef="shares" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfNTc_64311f8a-760e-4553-b9ca-b97a664f8432"><ix:nonFraction unitRef="shares" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfNTc_6dc38935-b9ce-4508-877e-e969346ea705"><ix:nonFraction unitRef="shares" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfNTc_f6bc5025-cf81-498d-9bef-7879d7092d3e">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMS0xLTEtMTA4MTYx_0f89bd2c-729d-41ac-af97-15441179517c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMy0xLTEtMTA4MTYx_3ebfb6f9-72f1-414a-b452-dd12684d501e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfMTg_3392539d-1f3a-4776-98ad-b32b0fd4135b"><ix:nonFraction unitRef="usdPerShare" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfMTg_4c77708e-b499-4a19-a778-5209ca548a13">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfMzI_2b6835a6-2896-4fd4-9c33-c2bcdea140fb"><ix:nonFraction unitRef="shares" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfMzI_a50d5707-6a95-4535-9006-2741cc699003">200.0</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfNTQ_23d7ef2f-e6ef-4bf8-acb9-c479f7dd69db">55.5</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfNjE_4ce7d1bd-55c9-430a-a78a-08256d77a3e8">55.1</ix:nonFraction> shares issued; <ix:nonFraction unitRef="shares" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfNzk_39f0937a-a466-4603-904a-220197e43855">49.9</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfODY_0213cb82-4dfe-426f-b6a1-3e855d9fe45b">51.3</ix:nonFraction> shares outstanding, respectively</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMS0xLTEtMTA4MTYx_9211bd51-f90f-4b1c-812d-f014afc2aedb">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMy0xLTEtMTA4MTYx_ba848d86-b212-443e-87c4-490d3b21544b">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzQtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246MGQxOTBlYjIwYjdhNDA2OWJjNjE2N2U3YTlmMmU3YzZfMjk_6306c17b-5dd8-4246-a018-9f2afaff1593">5.6</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzQtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246MGQxOTBlYjIwYjdhNDA2OWJjNjE2N2U3YTlmMmU3YzZfMzY_8dd2d9ff-e638-4ef0-b70e-f86a477ba31f">3.8</ix:nonFraction> common shares, respectively</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzQtMS0xLTEtMTA4MTYx_720b93de-77cd-497e-a391-f4c703ba4f91">227.7</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzQtMy0xLTEtMTA4MTYx_4aebd2a5-bcef-4c61-8467-50bf676658ef">152.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzUtMS0xLTEtMTA4MTYx_f3d19e5f-170e-4a60-b153-197495372c55">860.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzUtMy0xLTEtMTA4MTYx_b179f6f3-3d26-4ea0-965e-b72c348904b5">829.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzYtMS0xLTEtMTA4MTYx_14569c16-4a4a-4882-bd50-b25e005d17a8">5.2</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzYtMy0xLTEtMTA4MTYx_38e4d047-d899-41f9-a61a-1518181c9d0e">16.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzctMS0xLTEtMTA4MTYx_8e07dcba-d77a-4564-9817-737322315e4c">822.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzctMy0xLTEtMTA4MTYx_12aaa66e-6b14-4f84-8c60-3525423e671f">957.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total stockholders' equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzgtMS0xLTEtMTA4MTYx_45fc0ab9-1287-4764-a07b-7c9358386bb0">1,449.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzgtMy0xLTEtMTA4MTYx_21a103ab-d3f3-4c45-a291-f2ddbd5e1789">1,619.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzktMS0xLTEtMTA4MTYx_17bfa148-4ca4-4f37-9b29-122e9d691030">2,908.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzktMy0xLTEtMTA4MTYx_40a30a99-2045-4c32-b29c-54f145cb6e4a">2,959.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i52646bb207c64e15902c5f7cebbaa5a9_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMy0xLTEtMS0xMDgxNjE_258840f2-c36e-4fd6-aa20-bcb6a361cf13">186.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3c1314a596fa4be2be2dbbc905e0e0ce_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMy0zLTEtMS0xMDgxNjE_a73698d2-3062-4155-bb6c-e7761e4f4ea9">270.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if6605ab0b24d4a3a95cd07e88110dd0e_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMy01LTEtMS0xMDgxNjE_42b094d9-c0cd-4fec-8d98-273cb522dc1f">660.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3ac0c2ed83d34c43b639039d2831ada9_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMy03LTEtMS0xMDgxNjE_ba19a762-134d-4d3c-bcdb-26575ba5ce04">589.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3ea905c3a1d48a9a374e41f47cd9e7e_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNS0xLTEtMS0xMDgxNjE_65979170-8346-4a98-8853-ea3aa14d9209">36.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i293e88d455b74b89b6ea596c99361768_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNS0zLTEtMS0xMDgxNjE_0c01448c-1c37-4832-9a37-69e25426ddd3">112.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i94946a3df68a4894a63cc93522fd6ca4_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNS01LTEtMS0xMDgxNjE_d5cd474f-fd42-4cd2-b8ba-fad8f0bc9429">90.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8e3af1259505476faa37180bca0dbed6_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNS03LTEtMS0xMDgxNjE_cc9eca3f-12f6-4408-b394-43e8290fed97">283.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25e36ed15c584f8abca1aae53e56c499_D20220701-20220930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNi0xLTEtMS0xMDgxNjE_2cf91643-5ac1-459d-a55f-12804c2d16b9">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5106d154262648b8966552fa34ac668e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNi0zLTEtMS0xMDgxNjE_8bb2fd86-dff9-4ec6-9400-9e37a8fc199e">71.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3ae88a70cad04a6f9c132484c353e5b9_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNi01LTEtMS0xMDgxNjE_c83d4791-7142-485f-ad51-80099f6f5801">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30625a73d79a4164a68a490ce85445d6_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNi03LTEtMS0xMDgxNjE_a5f718eb-5d00-4d98-b5a4-5fc2386d7f99">132.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7c744e01ccc4b70a3f8d3f033d69fc7_D20220701-20220930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNy0xLTEtMS0xMDgxNjE_c743bc76-2ef1-4a40-84a7-3d10b4f8ae9e">36.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iefc13edfdf22466c94aef0c6826da80b_D20210701-20210930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNy0zLTEtMS0xMDgxNjE_1626d515-0704-4867-8140-a73833615a26">41.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8eff28a2bc3a4e869ed6725ec343457b_D20220101-20220930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNy01LTEtMS0xMDgxNjE_f98dcf7e-77e4-40cb-aac4-1c6e84f32886">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e2dd808a6bb49acaba894087e88aab6_D20210101-20210930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNy03LTEtMS0xMDgxNjE_9655094f-f48f-4ec6-874b-1c67b264d069">416.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iee99b848e7d34f24ba7ebd4d2abf4f85_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOC0xLTEtMS0xMDgxNjE_d5577ccb-7f40-4359-98f0-c7e3c78afd1e">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5105f0204af64b01a45ffaaf2c96b86e_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOC0zLTEtMS0xMDgxNjE_89056e94-64b8-40d8-9d00-d1f8b36e72c1">16.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icc86efbf51c9459a924cb8855de7d59d_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOC01LTEtMS0xMDgxNjE_856bc690-99a4-44d9-b751-fcbf74f57b0f">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1dd3f76fb0234ae9898dcecdd750649a_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOC03LTEtMS0xMDgxNjE_9dd540dd-b566-4e9a-af35-7a0a57e5fb21">63.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOS0xLTEtMS0xMDgxNjE_a9ae0308-59ea-455b-af02-da0ade7faf40">240.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOS0zLTEtMS0xMDgxNjE_00537dab-e476-4258-908d-d7027c3ea444">329.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOS01LTEtMS0xMDgxNjE_e6c12576-dcd1-43bb-bea8-90917a295a0c">790.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOS03LTEtMS0xMDgxNjE_90e21cf2-13c2-4e12-b378-cfbcdce7e570">1,069.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i52646bb207c64e15902c5f7cebbaa5a9_D20220701-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTItMS0xLTEtMTA4MTYx_1cd2b9ed-6f02-474a-b7f0-b7ad94c5310d">85.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3c1314a596fa4be2be2dbbc905e0e0ce_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTItMy0xLTEtMTA4MTYx_3ff9ed0e-bd47-425a-9565-d59459ffdf5c">103.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if6605ab0b24d4a3a95cd07e88110dd0e_D20220101-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTItNS0xLTEtMTA4MTYx_ee430db2-09d1-4151-82eb-3bd43983752d">256.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3ac0c2ed83d34c43b639039d2831ada9_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTItNy0xLTEtMTA4MTYx_bbdce447-fb5d-43b2-9f71-be41c92ece01">237.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3ea905c3a1d48a9a374e41f47cd9e7e_D20220701-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTMtMS0xLTEtMTA4MTYx_a7cb62d8-d25b-432d-a43a-f03ad3d627e1">63.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i293e88d455b74b89b6ea596c99361768_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTMtMy0xLTEtMTA4MTYx_674ef047-d6f1-4288-a411-2fe395944baa">114.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i94946a3df68a4894a63cc93522fd6ca4_D20220101-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTMtNS0xLTEtMTA4MTYx_b5c98a1e-061c-4e4b-a2c3-c497ef0bb774">217.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8e3af1259505476faa37180bca0dbed6_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTMtNy0xLTEtMTA4MTYx_995fffea-71b4-4c74-b009-1b4e2481fc9c">307.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTQtMS0xLTEtMTA4MTYx_459bf344-3df2-4285-9131-bdfd62e61d8e">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTQtMy0xLTEtMTA4MTYx_4fb7aaa8-dd4b-407a-8c86-4de759b95952">49.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTQtNS0xLTEtMTA4MTYx_3d6e2346-2821-4a01-93c8-f3e622324c12">135.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTQtNy0xLTEtMTA4MTYx_3f62122d-6994-4f26-bd39-567a832792c5">151.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTUtMS0xLTEtMTA4MTYx_31b58f3e-72bf-480b-bdf0-42390048c909">80.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTUtMy0xLTEtMTA4MTYx_10951eeb-3b5e-4776-9629-e59595926ab9">82.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTUtNS0xLTEtMTA4MTYx_5518397b-bace-41e7-9460-8b995fdc992f">246.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTUtNy0xLTEtMTA4MTYx_be3bfea8-0e03-4279-9366-c48b1437fbad">254.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTYtMS0xLTEtMTA4MTYx_bd12587a-5919-4533-8a07-ee355d792af8">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTYtMy0xLTEtMTA4MTYx_0dfc6ce9-4906-4acb-9452-373ef397b8c3">14.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTYtNS0xLTEtMTA4MTYx_510a844c-ad37-4f64-a2ce-6ad3e2832106">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTYtNy0xLTEtMTA4MTYx_a46c0fda-7732-4cf0-9eeb-096deaf27ebd">44.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTctMS0xLTEtMTA4MTYx_d711316c-7719-4ce9-9ba0-9fedf0971863">282.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTctMy0xLTEtMTA4MTYx_47b21478-ea0e-4798-939d-77a97093ecfc">363.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTctNS0xLTEtMTA4MTYx_953d334e-6d2e-4760-ab1d-688788746cb9">897.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTctNy0xLTEtMTA4MTYx_ca637ee6-8804-4c94-92a2-eac1315c7642">994.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTktMS0xLTEtMTA4MTYx_94dd6793-2847-4b3e-a24c-a7bf4624c7b5">42.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTktMy0xLTEtMTA4MTYx_07eea34d-869d-42b4-a936-41a7c53d5cc2">34.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTktNS0xLTEtMTA4MTYx_ed1462aa-bd07-4b54-8cfa-2afd0626b03b">107.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTktNy0xLTEtMTA4MTYx_a9240659-a1af-425a-805c-b4c26c450cf0">75.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjItMS0xLTEtMTA4MTYx_691c6e1d-c873-4f37-9b34-2202bb0facc6">8.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjItMy0xLTEtMTA4MTYx_c1299755-bda7-45e2-8ac4-849f3fb347d9">8.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjItNS0xLTEtMTA4MTYx_8d6cd0f6-b15c-4c5a-837d-27acad174533">24.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjItNy0xLTEtMTA4MTYx_4589dc8d-b70b-4ccf-8e07-baaf1c36719d">25.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjMtMS0xLTEtMTA4MTYx_322a0390-496b-404a-a8bc-0141ed46b0df">13.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjMtMy0xLTEtMTA4MTYx_34317ae8-2e71-415d-a2b1-e73d1fe50d92">2.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjMtNS0xLTEtMTA4MTYx_43ff0dc4-692d-4b0d-9e9d-a62fc92ae924">18.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjMtNy0xLTEtMTA4MTYx_9c87f94f-b942-4a32-8dea-d2a2cf520d7b">2.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjQtMS0xLTEtMTA4MTYx_ec99d9c3-7541-48a8-a105-b5d844f26431">21.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjQtMy0xLTEtMTA4MTYx_6bc0b299-f8c6-4cf1-a28a-cff683a783c4">10.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjQtNS0xLTEtMTA4MTYx_fbaa98ee-bd31-46bc-96e3-50f82d6d99de">42.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjQtNy0xLTEtMTA4MTYx_bce5319a-6b2d-4272-9cb5-38d263a14b34">28.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjYtMS0xLTEtMTA4MTYx_539051cf-a524-4b9a-bb1c-6cbaa05ee257">63.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjYtMy0xLTEtMTA4MTYx_bcffd12a-f439-4498-8534-937c1eec554c">45.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjYtNS0xLTEtMTA4MTYx_fba3629f-f032-4128-947b-4e4760826576">150.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjYtNy0xLTEtMTA4MTYx_03a0c0de-e391-470b-93f8-d59b807a3086">46.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Income tax benefit (provision)</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjctMS0xLTEtMTA4MTYx_79ac3c2b-8fbb-4d90-8e51-d41930a8d023">11.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjctMy0xLTEtMTA4MTYx_c07e9773-22c9-4718-a24e-afe95e2a16e9">12.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjctNS0xLTEtMTA4MTYx_fe0a333c-b640-4985-8c8a-482a94b63678">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjctNy0xLTEtMTA4MTYx_96a76f98-7cc8-47a5-b4ab-cde15a0e8463">5.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjgtMS0xLTEtMTA4MTYx_253e1f7f-d887-4cd6-b883-76171b6bed85">75.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjgtMy0xLTEtMTA4MTYx_39487e61-a2bb-40ff-8618-5f61dbd0dddb">32.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjgtNS0xLTEtMTA4MTYx_d6465ecb-2daa-4d09-859e-9d7e89e053b1">135.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjgtNy0xLTEtMTA4MTYx_06a00c3a-860e-400e-a3f6-4377fcba284a">41.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss) per common share</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Basic</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzEtMS0xLTEtMTA4MTYx_5e98262d-d2fd-4efd-bc1e-6b65c4ff9d83">1.52</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzEtMy0xLTEtMTA4MTYx_aa36deee-af7c-484a-9130-811f69317ed1">0.61</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzEtNS0xLTEtMTA4MTYx_738bb648-de99-43be-9023-17f22c188aab">2.71</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzEtNy0xLTEtMTA4MTYx_8b27c2e5-b758-4092-a65e-624da4550e06">0.78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Diluted</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzItMS0xLTEtMTA4MTYx_781029c8-f1c5-4e9d-bb8d-dc328bd91b66">1.52</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzItMy0xLTEtMTA4MTYx_15574572-467c-4460-bc30-41b2e6c2308a">0.61</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzItNS0xLTEtMTA4MTYx_ca0aad2d-1b29-46b8-a5f8-43432d2f6da7">2.71</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzItNy0xLTEtMTA4MTYx_425bec35-8c1a-4428-9939-501e7746bb2d">0.77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Shares used in computing net loss per common share</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzUtMS0xLTEtMTA4MTYx_1c409f7a-02a1-4a65-8d78-d9f66c5f56bf">49.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzUtMy0xLTEtMTA4MTYx_5fe2e5a4-e464-43d2-a9f8-bedef61c3014">53.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzUtNS0xLTEtMTA4MTYx_1667c65c-c149-467c-b6e8-6e22106045bf">50.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzUtNy0xLTEtMTA4MTYx_6e8d3d54-dd37-4220-a5ba-760acd7d3a3c">53.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzYtMS0xLTEtMTA4MTYx_a05876a2-ee5a-43eb-b4c3-11455256f22c">49.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzYtMy0xLTEtMTA4MTYx_b31ffe1d-9258-4b0b-9e6c-e6ba6db77bd4">53.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzYtNS0xLTEtMTA4MTYx_632bdedd-eb0d-4c30-9114-a73e3a1e1a40">50.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzYtNy0xLTEtMTA4MTYx_f5807b10-fe04-45ea-8db5-474cba7b3eea">54.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">`</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfMi0xLTEtMS0xMDgxNjE_b80b0cd1-8ac6-4a7f-9172-f58d3706d8cf">75.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfMi0zLTEtMS0xMDgxNjE_24e61322-c47c-4348-a40a-089a0d56b63f">32.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfMi01LTEtMS0xMDgxNjE_bb8359bb-1b96-4423-a0c7-08b4f96b4df5">135.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfMi03LTEtMS0xMDgxNjE_ce792e87-e2cc-4b10-81f5-c862f7e7c5d5">41.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNC0xLTEtMS0xMDgxNjE_0663daeb-a5a7-45e7-a263-0b76096fdd60">1.3</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNC0zLTEtMS0xMDgxNjE_935c6277-e974-466e-a6bb-dd048ae9506e">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNC01LTEtMS0xMDgxNjE_416f02fd-d494-4bbe-80a2-cf9a68654a52">0.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNC03LTEtMS0xMDgxNjE_3e78774d-00bc-49a1-9c5c-1039e4c718d5">1.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Unrealized gains (losses) on hedging activities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNS0xLTEtMS0xMDgxNjE_f2457527-6d93-4fda-9c97-73c16e7c6a29">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNS0zLTEtMS0xMDgxNjE_58106cd0-3a21-48f5-a6f8-44413c9c7bec">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNS01LTEtMS0xMDgxNjE_b95a65ca-4235-4e50-a028-728f6c709d68">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNS03LTEtMS0xMDgxNjE_41cff866-548a-491a-914d-aae1770ac531">3.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNy0xLTEtMS0xMDgxNjE_2fbdbf63-06d5-40a5-a12d-c5c986b25d13">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNy0zLTEtMS0xMDgxNjE_203dac93-e2a1-4262-a563-0fc880edf677">0.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNy01LTEtMS0xMDgxNjE_a3c2c286-ba52-4909-9c2a-bfb858f021fe">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNy03LTEtMS0xMDgxNjE_52641fd7-9434-4971-883a-6d8865ca6b99">2.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Comprehensive income (loss), net of tax</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfOC0xLTEtMS0xMDgxNjE_41e171e9-a54d-4d0a-a972-f67f7817947f">74.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfOC0zLTEtMS0xMDgxNjE_7fe48790-5176-4123-a287-dd694a2efe98">33.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfOC01LTEtMS0xMDgxNjE_dd2110eb-0a50-4e6a-8ec4-bc86c84cd4c4">124.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfOC03LTEtMS0xMDgxNjE_bdf47b71-72aa-430f-aa8c-6a105fa5c537">43.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:58.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cash flows used in operating activities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMy0xLTEtMS0xMDgxNjE_bac20954-d77a-45f1-ac23-4868aa768893">135.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMy0zLTEtMS0xMDgxNjE_56a43668-dcea-4fbf-bc37-e50b3354da07">41.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNS0xLTEtMS0xMDgxNjE_18523164-524a-494d-90bb-105fa9f9499d">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNS0zLTEtMS0xMDgxNjE_4a53a02f-a229-45da-bf9c-9071de468f8e">32.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNi0xLTEtMS0xMDgxNjE_eb73dfc7-8f57-4582-bc2c-dcc4909cce24">107.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNi0zLTEtMS0xMDgxNjE_2ad7156e-4645-4ae6-8f34-753268892118">94.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Adjustment for prior period lease receivables (Note 10)</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeReversal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNy0xLTEtMS0xMDg2NDQ_549a18ee-0791-4958-870b-c85c38e7cf9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeReversal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNy0zLTEtMS0xMDg2NTA_bc1949e6-fada-4101-8474-665a618010ca">86.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNy0xLTEtMS0xMDgxNjE_4b90cd7c-1c8c-4f3a-980a-d323b1e9cd8f">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNy0zLTEtMS0xMDgxNjE_ef3c1993-0638-4629-993b-f5856f0dc6fd">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfOC0xLTEtMS0xMDgxNjE_1a92166d-16be-4eb0-8df7-8694b018b047">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfOC0zLTEtMS0xMDgxNjE_a46d7a4a-1c69-440c-b625-0018055b4099">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfOS0xLTEtMS0xMDgxNjE_f0cddabf-257e-498e-97b4-f2d97ad28411">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfOS0zLTEtMS0xMDgxNjE_9b576462-eea8-4f97-bf1b-ce3579bf6696">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTAtMS0xLTEtMTA4MTYx_f5c01ad7-9a9c-467f-b0a4-ed7dd44acaa4">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTAtMy0xLTEtMTA4MTYx_f4b87a40-a154-4408-9390-c68d84f355be">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTItMS0xLTEtMTA4MTYx_80cb163d-f5b9-4c60-8e30-565eefdb4ad1">76.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTItMy0xLTEtMTA4MTYx_7638f477-2b43-47d4-a9a4-6f3d1f3a07ad">114.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTMtMS0xLTEtMTA4MTYx_9bf4e8a6-4eb7-4a4d-95f3-e774e305288a">112.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTMtMy0xLTEtMTA4MTYx_8f6c6551-bb5e-4ae4-8eb3-d98b458c277d">58.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTQtMS0xLTEtMTA4MTYx_fb5e6b89-a6e6-4e9e-b4bd-43dc5bd91201">29.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTQtMy0xLTEtMTA4MTYx_a2e910e6-db46-4ecb-b601-154d6b51baa2">54.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTUtMS0xLTEtMTA4MTYx_4e288e87-3603-4df1-b1be-306cb6be851b">9.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTUtMy0xLTEtMTA4MTYx_4c6f71fe-58ea-4b6c-8e99-32b99cc40c4b">3.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTYtMS0xLTEtMTA4MTYx_abd73943-eac0-48a5-be2c-49c1b1f9c4fe">98.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTYtMy0xLTEtMTA4MTYx_b2f6cb2f-22cb-41bf-b021-0f84f155ef07">19.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTctMS0xLTEtMTA4MTYx_6af3e184-a9b8-4261-ae87-5c7c41152a2d">5.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTctMy0xLTEtMTA4MTYx_40772dfe-9d06-4b58-9657-89fe50a31437">11.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTgtMS0xLTEtMTA4MTYx_3cc4d707-f848-4312-8665-ef9964b26b87">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTgtMy0xLTEtMTA4MTYx_2c830416-a63e-4779-8f6b-1345774e0e6e">19.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net cash used in operating activities:</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTktMS0xLTEtMTA4MTYx_dc489c35-1ee7-4faf-8fba-a17c29c9fcfa">126.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTktMy0xLTEtMTA4MTYx_9b89acb1-980d-423f-a7d1-11c5634bb951">7.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cash flows used in investing activities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjEtMS0xLTEtMTA4MTYx_a6cf9ae2-4ef9-427d-9610-0dd554c3f399">92.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjEtMy0xLTEtMTA4MTYx_a15b3979-d42b-4300-a14e-94384a18aad9">178.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Asset acquisitions</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjMtMS0xLTEtMTIwNDY3_ba11f3b6-eef1-4ffb-9643-fe8eb2618c63">243.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjMtMy0xLTEtMTIwNDgz_caf91be0-7d0a-45d8-8726-4e7d14d37fd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net cash used in investing activities:</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjItMS0xLTEtMTA4MTYx_3734834e-9117-4cf5-9f13-84ac8363a655">335.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjItMy0xLTEtMTA4MTYx_58e37fe2-7409-44af-9d83-89c76a44cc78">178.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cash flows provided by (used in) financing activities:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Proceeds from revolving credit facility</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjYtMS0xLTEtMTIwNTAw_91652c35-490d-4558-9b48-112562aec4a3">238.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjYtMy0xLTEtMTIwNTA3_01321c99-3e68-4d93-a369-002ca466e231">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjQtMS0xLTEtMTA4MTYx_45416806-4501-4766-96e4-09f17ed3ee13">81.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjQtMy0xLTEtMTA4MTYx_9960ad07-51f1-433c-98b2-61c69c2f88ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Principal payments on term loan facility</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:RepaymentsOfMediumTermNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjUtMS0xLTEtMTA4MTYx_cc601208-b3fa-4c76-a398-d6837a568edb">25.3</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:RepaymentsOfMediumTermNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjUtMy0xLTEtMTA4MTYx_787b420b-d758-438c-a499-7781ecd64cd9">16.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Principal payments on convertible senior notes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjYtMS0xLTEtMTA4MTYx_4f876cf2-67f0-4f6e-9fe8-78a85e7ad338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjYtMy0xLTEtMTA4MTYx_c70322b4-b174-4071-8bbc-579f128f941b">10.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Proceeds from share-based compensation activity</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjctMS0xLTEtMTA4MTYx_18ec4798-803a-4578-a2b6-7559880cb929">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjctMy0xLTEtMTA4MTYx_b87ae4ce-d503-4670-9d9c-65998ec41232">12.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Taxes paid for share-based compensation activity</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjgtMS0xLTEtMTA4MTYx_77e1d70f-9e9d-42d8-a04c-4fbe2af8eb2c">5.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjgtMy0xLTEtMTA4MTYx_6a5ad8ab-707a-46c8-947d-09794adf3144">13.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjktMS0xLTEtMTA4MTYx_1a7fd35f-818f-4afd-8544-b9432042509b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjktMy0xLTEtMTA4MTYx_ff49a48b-157d-4ea2-b25d-c495f91c75f0">2.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net cash provided by (used in) financing activities:</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzAtMS0xLTEtMTA4MTYx_62ef582b-ac36-456c-8397-a69da9404e27">128.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzAtMy0xLTEtMTA4MTYx_81a7ea90-643a-4196-8110-528306d0c1ec">31.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzEtMS0xLTEtMTA4MTYx_20feeb4f-1ccd-426e-aa57-bd82d5eb4a1f">0.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzEtMy0xLTEtMTA4MTYx_73488e58-1dfd-4b08-a27c-dc7e71ec15af">0.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzItMS0xLTEtMTA4MTYx_9bc87fa4-4288-473a-9667-7641e2686025">335.3</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzItMy0xLTEtMTA4MTYx_b5fd8256-0f93-43d6-9b32-81ae7929d1bd">217.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzMtMS0xLTEtMTA4MTYx_43dafb00-e4ec-428d-a924-2f11cb05dff4">576.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0444415079d48bca0450996b92c9137_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzMtMy0xLTEtMTA4MTYx_a0e37da5-c1e2-4488-bdef-b101f6345ece">621.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzQtMS0xLTEtMTA4MTYx_bc650727-c1d7-40a6-acd5-a681bffc785b">241.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc984f7cf64a4ac6ad2b90f5b12b27ea_I20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzQtMy0xLTEtMTA4MTYx_9ecd3816-fddb-4492-9489-eb6dc0d9e8db">404.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cash paid during the period for interest</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzYtMS0xLTEtMTA4MTYx_2e674529-a312-4186-ae8a-2c9a1fc3a600">26.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzYtMy0xLTEtMTA4MTYx_ab85fe35-7605-4d15-a451-3fac4f9a0169">27.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cash paid during the period for income taxes</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzctMS0xLTEtMTA4MTYx_75aa3561-9009-4b0b-9a94-e8bc428cea23">23.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzctMy0xLTEtMTA4MTYx_8b96f523-adde-41ff-bc99-4dd980e38bd1">57.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Supplemental information on non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Purchases of property, plant and equipment unpaid at period end</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzktMS0xLTEtMTA4MTYx_960fca19-28c7-4a6e-ad8b-67be06e3cf0c">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzktMy0xLTEtMTA4MTYx_35e9f9d4-cece-40cd-a078-470ed7744c48">20.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Reconciliation of cash and cash equivalents and restricted cash at September&#160;30, 2022 and December&#160;31, 2021:</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDEtMS0xLTEtMTA4MTYx_92d31a7b-2acc-4641-bb90-bf7e589426c9">240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDEtMy0xLTEtMTA4MTYx_8e39bc60-617d-4e4a-996a-75275cf8b07f">576.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDItMS0xLTEtMTA4MTYx_fd6fc330-11d4-4bc6-af63-b71bf1a6477d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDItMy0xLTEtMTA4MTYx_81677f2a-fbbe-4769-be54-bac81eb5dc1d">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDMtMS0xLTEtMTA4MTYx_5c30b42a-ee6c-4495-9405-35c93744a1e2">241.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDMtMy0xLTEtMTA4MTYx_cf00082d-0e5c-4380-bb11-8f444d6b8116">576.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:5pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibc984f7cf64a4ac6ad2b90f5b12b27ea_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMC0yLTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo1ZTU1YjJhYTA5MGE0MjMyOGJjNGFiNWVmNzUwZGI1OF81_3fd582c7-6d54-4fc8-91fd-ba15ae2f3775"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMC0yLTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo1ZTU1YjJhYTA5MGE0MjMyOGJjNGFiNWVmNzUwZGI1OF81_e990d616-6efe-4507-9488-6cb3ed39d621">0.001</ix:nonFraction></ix:nonFraction> Par Value </span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Treasury Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Retained Earnings</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ief03e38f153e479b9c16cf1572d2d802_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy0yLTEtMS0xMDgxNjE_af69ac82-dbeb-44dd-a176-d4e23ccc0664">55.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ief03e38f153e479b9c16cf1572d2d802_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy00LTEtMS0xMDgxNjE_fa4bcdd4-8ccd-43ac-ade1-9712c889f25c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i858bc01bcffe4fcc818b41f3490126e8_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy02LTEtMS0xMDgxNjE_e71f8c5c-f154-4dd7-9332-7b273fa2635a">3.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i858bc01bcffe4fcc818b41f3490126e8_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy04LTEtMS0xMDgxNjE_40f0b3db-949c-45d2-bc5b-e501f3490979">152.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i025e25b63cf240efb8c5c078757469d3_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy0xMC0xLTEtMTA4MTYx_b692d6ac-0abc-4009-a6ef-4f9c46ef0bda">829.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id4698414e7c1401c82d1bdd7bd331f7f_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy0xMi0xLTEtMTA4MTYx_58babfea-89dc-47f9-a4ee-4fcb1daff2af">16.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i73297e52dd7b4d0f94c279cc3501cbca_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy0xNC0xLTEtMTA4MTYx_bae29db8-258c-416b-98a1-52e4255ff6c4">957.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy0xNi0xLTEtMTA4MTYx_26310bbc-4998-48c7-ad34-dc2b8b1163a0">1,619.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i94685af212e84378abd02869fc65b116_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNC0yLTEtMS0xMDgxNjE_e3f891f1-6a6c-4b78-aa4d-ded66dd6cb7e">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6c721871d86b4c9d92da8f3576d3c37c_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNC0xMC0xLTEtMTA4MTYx_5ffbd576-1ccb-4ebb-9de8-ec8fc5953308">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNC0xNi0xLTEtMTA4MTYx_5fe65b8f-0b99-425c-83d0-ff7ae42ee50f">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i44614402dda1433ab395ed9472240cf0_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNS0xNC0xLTEtMTA4MTYx_3e75f4ba-e48a-40f0-8c0e-9e9d1aadf212">135.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNS0xNi0xLTEtMTA4MTYx_a4f73caa-a230-4e97-82cd-29fa32dad86b">135.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Repurchases of stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i8990366d48494f1b8a20b74e61189484_D20220101-20220930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNi02LTEtMS0xMDgxNjE_e61f43fb-7b44-4b22-94c6-c096d0579041">1.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8990366d48494f1b8a20b74e61189484_D20220101-20220930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNi04LTEtMS0xMDgxNjE_6e0d9b33-050d-4e01-8a33-9e2a26f6fe3d">75.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNi0xNi0xLTEtMTA4MTYx_fd8000ed-14df-42c4-ac8d-66af6d8da0af">75.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id9a84624f46d42f4b0f9c18da44b11de_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNy0xMi0xLTEtMTA4MTYx_f74ea8e2-aec5-4306-aeb9-fdfc356e24eb">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNy0xNi0xLTEtMTA4MTYx_1db6e4f0-9215-48b0-9d7e-cba00dda13ba">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i809764d7e9a84800b82506178a13b313_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC0yLTEtMS0xMDgxNjE_1c411ab9-ed3b-4dfe-b26d-f0d6b3d3687d">55.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i809764d7e9a84800b82506178a13b313_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC00LTEtMS0xMDgxNjE_bd645758-7793-4f7d-9990-e4457214b2a8">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i3449978510494de9985378c4af49f5af_I20220930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC02LTEtMS0xMDgxNjE_057d5881-752b-40c6-b036-a30c31c4d2d2">5.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3449978510494de9985378c4af49f5af_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC04LTEtMS0xMDgxNjE_a4b7c279-1913-4748-9cf2-dcb4bf5a3c50">227.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81d47500381c4a06a021712d3d13c022_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC0xMC0xLTEtMTA4MTYx_2d43bdc1-6f24-4c16-bc62-52537d3fc59a">860.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib32c62eb60fc4dc39b819eb33d2ecd33_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC0xMi0xLTEtMTA4MTYx_637b2d8a-6801-47a6-bbc4-43fd83466154">5.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88701e64171b4b4dbfc52b23a8dd15b7_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC0xNC0xLTEtMTA4MTYx_a6240ac2-590e-452d-8329-605fa5834a4c">822.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC0xNi0xLTEtMTA4MTYx_00781ffe-ed1c-491a-88e2-2efb25780312">1,449.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7c07897dcdde4d89a128d2ed15fc5ad1_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtMi0xLTEtMTA4MTYx_9c7c4ce8-1ecb-4e61-9d25-eae71ef303f8">55.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7c07897dcdde4d89a128d2ed15fc5ad1_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtNC0xLTEtMTA4MTYx_f9a580cf-c011-47cf-8c4c-8c503ecbd589">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i14f2fb7cdf644c66b524b020f443b7a3_I20220630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtNi0xLTEtMTA4MTYx_aa3e6865-9486-431a-85f3-209f74220ac5">5.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i14f2fb7cdf644c66b524b020f443b7a3_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtOC0xLTEtMTA4MTYx_a2559b0f-927e-4514-b663-2307e1d75ba2">227.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65f2af0d2c0b4a15bc6e7423ba835ade_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtMTAtMS0xLTEwODE2MQ_781025eb-9a45-4108-a0f7-ae82176990fe">849.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i215adb10fcbf40a5a7ec2fc2088354e3_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtMTItMS0xLTEwODE2MQ_230b85ce-37dd-4ae8-a9e7-b39282eaa623">6.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i86413dba3b9141c89275b7ef4f89903a_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtMTQtMS0xLTEwODE2MQ_20435e3c-c171-4739-80ea-4b6544b6a578">897.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i513d610eeb964439903192db1ecb51ed_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtMTYtMS0xLTEwODE2MQ_bd445e04-672a-4d4e-ab10-9c646845a386">1,513.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc0fb7f94b4b4633bba35f83b8ce0a44_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTEtMTAtMS0xLTEwODE2MQ_c6ae2f61-6732-41c9-aef4-81a0320e3bba">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTEtMTYtMS0xLTEwODE2MQ_9978b0fb-9f8f-4679-a12e-4513b8a7253c">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d3b9f37fd21490c816e8c33b0d191df_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTItMTQtMS0xLTEwODE2MQ_2135ccd4-423b-4d7d-af40-04f2d7a23854">75.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTItMTYtMS0xLTEwODE2MQ_28e236e8-0dbe-4b7d-92ed-a0300d2da4ff">75.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Repurchases of stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTMtMTYtMS0xLTEwODE2MQ_121d12f2-b1b3-4a0c-a892-8c72033eb3e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i97535e302cdd4eae990d766576feefac_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTQtMTItMS0xLTEwODE2MQ_bd1b8d69-6eec-4f92-9c35-01ee9e11c68e">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTQtMTYtMS0xLTEwODE2MQ_0b583455-f9ee-4b14-b052-672a07b6d37d">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i809764d7e9a84800b82506178a13b313_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtMi0xLTEtMTA4MTYx_f8eb534d-54a7-42ba-8e1a-3b4660ae070c">55.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i809764d7e9a84800b82506178a13b313_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtNC0xLTEtMTA4MTYx_3b6a2266-312e-4e6f-b888-c898920eade7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i3449978510494de9985378c4af49f5af_I20220930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtNi0xLTEtMTA4MTYx_ce45606b-3c85-45e6-b325-da1f144ebfca">5.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3449978510494de9985378c4af49f5af_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtOC0xLTEtMTA4MTYx_f75e3be8-6024-4f43-b4ec-fca2dacee779">227.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81d47500381c4a06a021712d3d13c022_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtMTAtMS0xLTEwODE2MQ_83a26a15-700c-4bc6-abda-7d5aca8dc650">860.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib32c62eb60fc4dc39b819eb33d2ecd33_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtMTItMS0xLTEwODE2MQ_8cb7dfcc-1f2f-4a4a-ac02-26d3f32a59b3">5.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88701e64171b4b4dbfc52b23a8dd15b7_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtMTQtMS0xLTEwODE2MQ_67565c5d-e6ac-4c61-af27-b45e74edb9bc">822.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtMTYtMS0xLTEwODE2MQ_58e8b702-6e53-4bea-8c0e-2d87c0f46d57">1,449.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i61f687c252da498ea3071b9bef0dae99_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctMi0xLTEtMTA4MTYx_75e5935e-a275-4981-b58d-ad269e4019c7">54.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i61f687c252da498ea3071b9bef0dae99_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctNC0xLTEtMTA4MTYx_411ed535-45d5-41fc-916f-b3dda5054c53">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i345b6ed13f3d4fe5a3c2aa0fb402b26c_I20201231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctNi0xLTEtMTA4MTYx_709fe501-e625-4628-b3eb-248da6d3c6fe">1.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i345b6ed13f3d4fe5a3c2aa0fb402b26c_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctOC0xLTEtMTA4MTYx_ee6c3f46-7ce3-4880-bce9-9ad56bfc5086">39.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e607ecbd5b74b8c8b0184925410bf01_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctMTAtMS0xLTEwODE2MQ_58a3b5e3-7a6b-40f2-9900-41284dff4e0b">784.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9334dc4e6d884a7cbb7f455bf2f9af61_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctMTItMS0xLTEwODE2MQ_28d71b92-2863-4a28-9e32-5fdfead8071b">25.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4fc5b8a85402486c8e7e3ae07b0a3871_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctMTQtMS0xLTEwODE2MQ_b96d03e4-66f8-4b43-9259-607e6e41b70d">726.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0444415079d48bca0450996b92c9137_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctMTYtMS0xLTEwODE2MQ_0b504fa1-b571-4378-9a5f-b3e48e771b4a">1,447.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9f4e99d6d47b4c0faf6ea720533b7521_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTgtMi0xLTEtMTA4MTYx_47c977f0-d1da-44c7-8149-92e4c967b788">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1ccbc79df52c4d15b022b9a21c0ca27a_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTgtMTAtMS0xLTEwODE2MQ_8081e723-f02d-4a8c-a704-7a21ffc57eea">31.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTgtMTYtMS0xLTEwODE2MQ_c77b088e-62d6-48f6-9b1f-54d21562bb93">31.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i03643882b32948aa88d7c7088c47243d_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTktMTQtMS0xLTEwODE2MQ_5b774d17-db23-4dc0-8494-a571d4e71a54">41.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTktMTYtMS0xLTEwODE2MQ_4d933147-e287-4dce-9729-492839a08675">41.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other comprehensive income, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1907d7b857734e8fa8e27c5ba195c7cd_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjAtMTItMS0xLTEwODE2MQ_487e96cc-681a-428f-90b8-2388de36c80e">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjAtMTYtMS0xLTEwODE2MQ_fa5c01c0-754a-4b1b-8c99-ad49e1fc22c2">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9501b3606d3748baa7f730985abc93d3_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtMi0xLTEtMTA4MTYx_d04fbad4-82c7-4af2-abf8-661503114e5a">54.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9501b3606d3748baa7f730985abc93d3_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtNC0xLTEtMTA4MTYx_1a07d4af-5773-48e3-84a4-d6499ece8121">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i120aedf84da0491da3c474183e2c4892_I20210930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtNi0xLTEtMTA4MTYx_d23bfd0c-9e8e-469b-8817-70fb031bac48">1.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i120aedf84da0491da3c474183e2c4892_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtOC0xLTEtMTA4MTYx_72f38b5a-41a7-4b02-9708-822ae2d47775">39.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7b982988d59741509a3340a4affea571_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtMTAtMS0xLTEwODE2MQ_9c105b26-bca8-4573-9265-ef5e3df9acd4">816.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i234810222a77469a8d310e47d2fa2f03_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtMTItMS0xLTEwODE2MQ_92653597-60aa-464f-a0c1-af12a0b06fca">23.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib3d773caeec44dac875f1fc14041b176_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtMTQtMS0xLTEwODE2MQ_93e6fa8b-7a87-47c3-a8a0-615b7db63239">768.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc984f7cf64a4ac6ad2b90f5b12b27ea_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtMTYtMS0xLTEwODE2MQ_8ab81c42-70c0-4b5b-b7d3-e29d80a27ade">1,522.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iebd066da54a34dadb2cfaddc80097222_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtMi0xLTEtMTA4MTYx_a6037c19-83cb-4c53-8887-5f468bb27ba9">54.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iebd066da54a34dadb2cfaddc80097222_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtNC0xLTEtMTA4MTYx_48c529de-79bd-4c18-aab8-30b6f600439b">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i61a54d77cf52423fa152a2b6df738697_I20210630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtNi0xLTEtMTA4MTYx_8f43c715-abeb-4aab-8bfe-abd4642978a0">1.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i61a54d77cf52423fa152a2b6df738697_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtOC0xLTEtMTA4MTYx_d6ce6c96-14a0-40b2-87c4-e4ad72114f8d">39.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2109c764e423427782835d0108e52bb0_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtMTAtMS0xLTEwODE2MQ_8285eb54-8ee9-4051-bfad-d3d8cd41c295">804.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9e6a2188c167465d9720bcd73f722dcd_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtMTItMS0xLTEwODE2MQ_e7bcafd0-14eb-4024-af5d-30fd17c55efb">22.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib96436736dac42149fc4524b381689e6_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtMTQtMS0xLTEwODE2MQ_b06b984e-d8a0-45fa-963c-6308b9cc28be">801.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iafc0f0f6c6e34f86a10f18a780bc594b_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtMTYtMS0xLTEwODE2MQ_44fca5fc-1444-49d6-be20-0943f82622d7">1,543.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Share-based compensation activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if472db7e4ddc4d8abb7803c05ad8a4fc_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjQtMTAtMS0xLTEwODE2MQ_de1d99c3-e7d0-4c23-ba74-4fe38a2c6cc1">12.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjQtMTYtMS0xLTEwODE2MQ_9a05a875-609e-4682-98d1-9e39739634d2">12.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3ae0efe55364ceebbd48beeaa1b5f0d_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjUtMTQtMS0xLTEwODE2MQ_4a729790-c506-416d-bf69-d315c3babcad">32.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjUtMTYtMS0xLTEwODE2MQ_638a810b-386c-4391-a25d-c7a547760d34">32.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i249e76b2e30b449d9cd1d10e9e44a617_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjYtMTItMS0xLTEwODE2MQ_d6e7d952-226c-4927-b787-75fc3530e839">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjYtMTYtMS0xLTEwODE2MQ_0a98f1b2-78d2-4003-9b3d-3b312d0c8f2c">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Balance at September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9501b3606d3748baa7f730985abc93d3_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctMi0xLTEtMTA4MTYx_c49a3739-4631-4168-8de2-1a40fb0d3bb7">54.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9501b3606d3748baa7f730985abc93d3_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctNC0xLTEtMTA4MTYx_b24c0931-eb5e-428f-9615-09189cf330dd">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i120aedf84da0491da3c474183e2c4892_I20210930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctNi0xLTEtMTA4MTYx_3cbc7a3b-3160-4757-81aa-8dbe57e38a87">1.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i120aedf84da0491da3c474183e2c4892_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctOC0xLTEtMTA4MTYx_0345adf7-d2d9-4603-ac79-900786bb93c7">39.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7b982988d59741509a3340a4affea571_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctMTAtMS0xLTEwODE2MQ_8bb4063e-948f-4f6c-af24-566237056b11">816.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i234810222a77469a8d310e47d2fa2f03_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctMTItMS0xLTEwODE2MQ_cec5aaaf-62ce-4959-a077-388eedb29056">23.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib3d773caeec44dac875f1fc14041b176_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctMTQtMS0xLTEwODE2MQ_31e74eac-e480-4d15-9f7c-418e549aea05">768.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc984f7cf64a4ac6ad2b90f5b12b27ea_I20210930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctMTYtMS0xLTEwODE2MQ_8bdd325d-45fb-4536-95d1-1ac58df491b3">1,522.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_31"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_34"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.01pt"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfODQwNg_58d25b86-e2b8-48a7-ab66-3774f20ca440" continuedAt="i1438dec944d645beb9ca09b502fdf332" escape="true">Business</ix:nonNumeric></span></div><ix:continuation id="i1438dec944d645beb9ca09b502fdf332" continuedAt="i77f20318e5504a89bb2eab0b48cca7e2"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (&#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (CDMO) services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following <ix:nonFraction unitRef="category" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="ebs:NumberOfCategoriesOfPublicHealthThreats" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfNDY4_ac0a937b-c257-4176-88b3-736294688783">five</ix:nonFraction> distinct PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; and acute/emergency care. The Company has a product portfolio of <ix:nonFraction unitRef="product" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="ebs:NumberOfRevenueGeneratingProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfODQxMA_c3cf6f70-0535-4bcd-8dd9-54c2123bcac4">thirteen</ix:nonFraction> products (vaccines, therapeutics and drug-device combination products). The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company also has <ix:nonFraction unitRef="productcandidate" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="ebs:NumberOfProductCandidates" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfODQwOA_4a67b6d0-adc1-41e8-bf08-ee478a7d931d">one</ix:nonFraction> product candidate that is procured under special circumstances by the U.S. government (USG), although it is not approved by the U.S. Food and Drug Administration (FDA). The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following <ix:nonFraction unitRef="businessline" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="ebs:NumberOfBusinessLines" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMjE5OTAyMzI3NTI4Mw_ae8ed2a0-eee6-4184-80ce-cecaa8310b67">three</ix:nonFraction> business lines: Government - Medical Countermeasures (MCM) Products, Commercial Products, and CDMO Services. The Company operates as <ix:nonFraction unitRef="segment" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTY0OTI2NzQ2MTM1Nw_83999cc4-ff49-48c3-9fd0-714701d38614"><ix:nonFraction unitRef="segment" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTY0OTI2NzQ2MTM1Nw_ec67a01a-2c1e-4636-9b75-53d42761c544">two</ix:nonFraction></ix:nonFraction> operating segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and 2) a services segment (Services) focused on CDMO (Note 14, "</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment information"</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Government - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">AV7909</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is a procured product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has largely switched from procuring BioThrax to AV7909 for the Strategic National Stockpile (SNS) prior to its approval by the FDA;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">BioThrax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only vaccine licensed by the FDA, for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">ACAM2000</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">BAT</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of botulism; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">CNJ-016</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also referred to as VIGIV, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Raxibacumab injection, a fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Anthrasil</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">RSDL</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Trobigard</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">atropine sulfate, obidoxime chloride AUTO-INJECTOR, is a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA, but it is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">TEMBEXA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. It has been approved by the FDA for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i77f20318e5504a89bb2eab0b48cca7e2" continuedAt="ie219a021d1884c9ca75209c0c045662b"><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Ebanga&#8482; (ansuvimab-zykl, formerly referred to as mAb114) is a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the United States and Canada, and Ridgeback Biotherapeutics will serve as the global access partner for Ebanga&#8482;.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Commercial Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">NARCAN</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Vaxchora</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the only single-dose oral vaccine licensed by the FDA and the European Medicines Agency (EMA) for the prevention of cholera; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Vivotif</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services - Contract Development and Manufacturing</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's services line focused on CDMO offerings covers development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided to customers spanning the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale.&#160;Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, the Company acquired from Chimerix ("the Seller") the exclusive worldwide rights to brincidofovir, including TEMBEXA&#174; and related assets (the &#8220;Transaction&#8221;). TEMBEXA is a medical countermeasure for smallpox approved by the FDA in June 2021. Under the terms of the Asset Purchase Agreement (the "Purchase Agreement"), the Company paid $<ix:nonFraction unitRef="usd" contextRef="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc2ODc_335c1290-5885-4147-8a8e-5abcf329e745">238.0</ix:nonFraction>&#160;million upon closing of the Transaction, and is subject to potential milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i26c8454cef2f47789cf2d3ee6746429f_D20220701-20220930" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc2ODM_48724e82-9d33-4172-b085-664c70a5cd30">124.0</ix:nonFraction>&#160;million contingent on the potential exercise by the U.S. government of procurement options. The closing payment and the milestone payments were based on the actual procurement value of the procurement contract (the "BARDA Contract") with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;). Each milestone payment is associated with the exercise of future BARDA procurement options of TEMBEXA following the BARDA Contract base period. The Seller is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i6d15cdbf01f5414d8ebe10c27040be71_D20220701-20220930" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc2OTU_89be3214-89d1-4845-9a99-aa3b598b8f24">12.5</ix:nonFraction>&#160;million in regulatory milestones associated with the SymBio Pharmaceuticals Ltd. brincidofovir licensing arrangements assumed by the Company in the Transaction. The milestone payments will be recorded when the associated procurement options have been exercised and/or the regulatory milestones have been met and the consideration is paid or becomes payable.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie219a021d1884c9ca75209c0c045662b">The Seller may also earn a <ix:nonFraction unitRef="number" contextRef="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930" decimals="2" name="ebs:AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc2OTk_1fa6d505-2457-414d-823d-c3ebd65f7a16">20</ix:nonFraction>% royalty on future gross profit of TEMBEXA in the United States associated with volumes above <ix:nonFraction unitRef="treatmentcourse" contextRef="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930" decimals="-5" name="ebs:AssetAcquisitionTreatmentVolumeThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc3MDM_dd18ae55-8aa5-4587-8250-9f714cec5a68">1.7</ix:nonFraction>&#160;million treatment courses of therapy during the exclusivity period of TEMBEXA. Outside of the United States, the Purchase Agreement also allows the Seller to earn a <ix:nonFraction unitRef="number" contextRef="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930" decimals="2" name="ebs:AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc3MDc_15ab7fb0-fd9c-4ea4-b0bf-6a72dbf2fef4">15</ix:nonFraction>% royalty on all gross profit associated with TEMBEXA sales during the exclusivity period of TEMBEXA on a market-to-market basis. Refer to Note 6, "Intangible assets" for additional information around the impacts of this asset acquisition on the current period results.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYyNQ_0a47874b-d76a-4fe6-a17f-d2b20fff7072" continuedAt="i6c47d6b4d0f449d7a0c8f5ddccba82f0" escape="true">Basis of presentation and principles of consolidation</ix:nonNumeric></span></div><ix:continuation id="i6c47d6b4d0f449d7a0c8f5ddccba82f0" continuedAt="i99a2044ac99f40e484e9a80b1fbb714e"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYzNA_4a64b276-28a1-4a25-a0a2-dc687770442b" continuedAt="ic4a5d85d45fe418b9938fe12cec0b2d9" escape="true">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic4a5d85d45fe418b9938fe12cec0b2d9">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September&#160;30, 2022. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</ix:continuation><br/><br/></span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, there is $<ix:nonFraction unitRef="usd" contextRef="i7432986424e74ac09ac1dd272585adcb_I20220930" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfMTY0OTI2NzQ2MjU2NA_f9e61e44-2f94-490d-b140-aabc66732e1e">238.0</ix:nonFraction>&#160;million outstanding on the revolver loan and $<ix:nonFraction unitRef="usd" contextRef="icb0a527f718246d39439945aa519e89c_I20220930" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfMTY0OTI2NzQ2MjU4MQ_af49451e-dbf8-4012-9a2f-7fa7ce9300e5">371.3</ix:nonFraction>&#160;million on the term loan that matures in October 2023, which is within one year of the date that the consolidated financial statements are issued for the quarter ended September&#160;30, 2022. The Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation considered the potential mitigating effect of management&#8217;s plans that have not been fully implemented. Management may evaluate the mitigating effect of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern. The Company's plan to alleviate the substantial doubt includes amending its existing revolver loan and term loan that are due October 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company is in the process of and expects to replace the current credit facility before it matures, management cannot make the assumption that it is probable that the Company will be able to obtain such debt refinancing on commercially reasonable terms or at all until the new credit facility is in place. The Company is currently working with its lenders and expects to refinance the credit facility with revised terms and conditions. The extent to which the Company will be able to affect such refinancing, replacement or maturity extension on terms that are favorable or at all is dependent on a number of uncertain factors, including then-prevailing credit and other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, disruptions or volatility caused by factors such as COVID-19, regional conflicts, inflation, and supply chain disruptions. In addition, rising interest rates could limit our ability to refinance our existing credit facility when it matures or cause us to pay higher interest rates upon refinancing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the replacement of the Company&#8217;s current debt facility is conditional upon the execution of agreements with new or existing third parties, which are considered outside of the Company&#8217;s control, until such time as they are completed, the refinancing cannot be considered to be probable to occur as of the date of this report. The Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC that have materially impacted the presentation of the Company's financial statements. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company revised the reporting that the chief operating decision maker ("the CODM") reviews in order to assess Company performance. The CODM manages the business with a focus on <ix:nonFraction unitRef="segment" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYyNg_83999cc4-ff49-48c3-9fd0-714701d38614"><ix:nonFraction unitRef="segment" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYyNg_ec67a01a-2c1e-4636-9b75-53d42761c544">two</ix:nonFraction></ix:nonFraction> reportable segments: 1) Products segment consisting of the Government - MCM and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i99a2044ac99f40e484e9a80b1fbb714e"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial business lines and 2) Services segment focused on CDMO. This change is further outlined in Note 14, "Segment information".</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYyNA_61824e62-0260-4b5d-bd39-eedd59f4bc16" continuedAt="ia3eea3b93ad24316af3c151630f8351f" escape="true">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1) and time deposits (level 2), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7, "Fair value measurements" and Note 8, "Derivative instruments and hedging activities").</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia3eea3b93ad24316af3c151630f8351f"> On a non-recurring basis, the Company measures its long-lived assets as part of impairment evaluations using fair value measurements. Goodwill is allocated to the Company's reporting units, which are one level below its operating segments. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and earlier if an event or other circumstance indicates that the carrying value of the asset may not be recoverable. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required. Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, long-lived assets are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when there is an adverse change in the market relating to those related assets. The impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. Determining the need for a detailed impairment analysis requires the exercise of judgment about several business factors, including the timing of expected future cash flows and assumptions about the economic environment.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the Company had no other significant assets or liabilities that were measured at fair value.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting standards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) that the Company adopts as of the pronouncement's specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the consolidated financial statements or disclosures.</span></div><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYyNw_f83b6aec-cb93-469a-b7e9-9341a10eeac6" escape="true"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Topic 848, which was further amended in January 2021. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. It contains optional expedients and exceptions to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. As of September 30, 2022, the Company adopted this ASU with no material impact to our consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_40"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RleHRyZWdpb246NmM0MjkyNzUzNGI2NDY3NDk4NWRhOWEzZDdlNWYwOGFfMzY5_0dec93c7-d29b-40f7-8ced-67be9d740391" continuedAt="i0783f4d37b67476cbd27cd9240240abc" escape="true">Inventories, net</ix:nonNumeric></span></div><ix:continuation id="i0783f4d37b67476cbd27cd9240240abc" continuedAt="i00e591e064f5454e873f22cd92d7461f"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RleHRyZWdpb246NmM0MjkyNzUzNGI2NDY3NDk4NWRhOWEzZDdlNWYwOGFfMzY2_3ae37e8e-e1ab-43a1-9028-316f33288f18" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMS0xLTEtMS0xMDgxNjE_e222795a-74c5-4f87-9f34-d3534f826786">277.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMS0zLTEtMS0xMDgxNjE_8ef6b87d-9c59-4d66-a4cf-dc1bd19341bf">217.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMi0xLTEtMS0xMDgxNjE_5a05c438-d572-4fc1-a1e9-5ad0ca6aba38">138.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMi0zLTEtMS0xMDgxNjE_74a0ab9a-f398-4fec-a3ce-e5a6b05853b2">95.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMy0xLTEtMS0xMDgxNjE_698e87fd-42f4-4afe-a9bd-ed3e47e5f984">130.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMy0zLTEtMS0xMDgxNjE_8123e087-1220-4601-b4a9-b63dec09c755">37.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total inventories, net </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfNC0xLTEtMS0xMDgxNjE_a9145300-c8eb-41e6-8099-3adee457b5b2">546.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfNC0zLTEtMS0xMDgxNjE_dc8422ec-0821-4edc-bbaf-6d03a852cd15">350.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"> During the three months ended September 30, 2022, the Company acquired certain assets through an asset acquisition, the Transaction, and the related inventories of $<ix:nonFraction unitRef="usd" contextRef="i0a5d3c91817245f8a781e98678ca71b4_I20220930" decimals="-5" name="ebs:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfNS0wLTEtMS0xMTI2ODYvdGV4dHJlZ2lvbjozMWQxMjMxMTk2NDc0Yjc5YTVlYzEwOGE2ODQ3YTY5YV80OTQ3ODAyMzI1ODgx_e0f39e10-8ac5-44d0-b0aa-310fb9212e3b">84.8</ix:nonFraction> million were included in our inventories balances as of September&#160;30, 2022.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><ix:continuation id="i00e591e064f5454e873f22cd92d7461f" continuedAt="ifc74de48178641f0a1f931ed413e4923"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is stated at the lower of cost or net realizable value</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifc74de48178641f0a1f931ed413e4923">. For additional information related to the termination of the manufacturing services agreement (the &#8220;Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) and associated evaluation of inventory as of September&#160;30, 2022, refer to Note 10, "Revenue recognition."</ix:continuation> </span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_43"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RleHRyZWdpb246ZTkzMzllM2UyZDc3NGYxMGE5Mjg5ZGZiMzA2MjI1YzJfNzI3_ffc7dc2f-3711-4767-b0e8-af4c66c2a5f8" continuedAt="ia93159f08c8947ba84eef286c720c22d" escape="true">Property, plant and equipment, net</ix:nonNumeric></span></div><ix:continuation id="ia93159f08c8947ba84eef286c720c22d"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RleHRyZWdpb246ZTkzMzllM2UyZDc3NGYxMGE5Mjg5ZGZiMzA2MjI1YzJfNzI5_48b49c3b-8abd-4f17-b9b5-09beb7f6d1df" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Land and improvements</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ief03c3babd264580b8f993d58e2f7399_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMS0xLTEtMS0xMDgxNjE_5666d7fa-f6c4-4680-a3a0-bf4bb500c6ce">53.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i432591c3907547a4a78ac6a89b2d6d9b_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMS0zLTEtMS0xMDgxNjE_b8b5c6bc-3e8e-4b4e-a93d-2d36ec98e03b">52.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i749bb1b516384ad09235dfaddfccbfb3_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMi0xLTEtMS0xMDgxNjE_86a769f9-2ac3-4888-83b6-c2811586728a">321.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide2d35bc08594b3ea21d8f60f7762840_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMi0zLTEtMS0xMDgxNjE_ee195bf7-6b43-49c1-86de-101914f8b49b">269.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6cf3406660784396880636ec6d64ce18_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMy0xLTEtMS0xMDgxNjE_332332ba-39be-4ef0-aedc-140fa378f9c2">551.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7b571dae77f04edfb1556f8d08c9d6e4_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMy0zLTEtMS0xMDgxNjE_d43cb88d-7462-4d14-aaf8-3855b3a7620d">513.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i766a15cf4ffb4c6d8115bd955a940932_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNC0xLTEtMS0xMDgxNjE_352e9024-bcfd-41aa-8c96-027791079127">65.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icdc0a33e12b849de810968cc193f06d8_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNC0zLTEtMS0xMDgxNjE_588646e0-7d90-4b38-9058-9c040ea7cdcb">60.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if3d94b6f79364cc1899b13f7a72f0e27_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNS0xLTEtMS0xMDgxNjE_effb368c-a1aa-41e5-9da1-688edd014f4f">181.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e27b276ca764530b7005d22d6316077_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNS0zLTEtMS0xMDgxNjE_d8753574-304b-41a6-bb07-ce70d2f3e0d7">223.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNi0xLTEtMS0xMDgxNjE_efbcb9b9-0e97-4ca9-bbd8-82dca321aa42">1,172.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNi0zLTEtMS0xMDgxNjE_e560eff6-96fb-4214-90ba-7a04f458acac">1,119.2</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Less: Accumulated depreciation &amp; amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNy0xLTEtMS0xMDgxNjE_b6e07e6d-64e6-4848-8931-7203a541efa4">366.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNy0zLTEtMS0xMDgxNjE_62621336-63f4-4066-b108-475eead88146">319.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total property, plant and equipment, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfOC0xLTEtMS0xMDgxNjE_ea7085b1-591c-48ef-9ea8-fbac1d53d393">806.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfOC0zLTEtMS0xMDgxNjE_8acffe19-c3c6-423a-9187-ab9e041513c0">800.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December&#160;31, 2021</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, construction-in-progress primarily included costs incurred related to construction to advance the Company's CDMO capabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. During the nine months ended September 30, 2022, the Company recorded accelerated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i50157349177f44679e4ff5b00c2b690a_D20220101-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RleHRyZWdpb246ZTkzMzllM2UyZDc3NGYxMGE5Mjg5ZGZiMzA2MjI1YzJfMTU1MA_a6d14366-6a8b-493f-8a36-bd6f21cbb9de">12.7</ix:nonFraction>&#160;million reflecting a shortening of the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement with Janssen. For additional information related to the termination of the Agreement, refer to Note 10, "Revenue recognition".</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_46"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RleHRyZWdpb246ODlkM2E4NjJhMzBhNDA2Y2EwOTAxODg5NGJjM2U2MTdfNjgz_efe1405e-ecbe-470a-a1dd-08bac6a2cd1c" continuedAt="i484e1009f2114b888defa40d2354c554" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i484e1009f2114b888defa40d2354c554" continuedAt="id8993b1d29e74541a06611a1bc32de4a"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the lessee for operating leases for offices, research and development facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. For a discussion of lessor activities, see Note 10, "Revenue recognition".</span></div><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RleHRyZWdpb246ODlkM2E4NjJhMzBhNDA2Y2EwOTAxODg5NGJjM2U2MTdfNjc4_5ce64689-00a2-4071-a03f-876b5a4c5b13" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease cost:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfMy0xLTEtMS0xMDgxNjE_10482b52-a213-449b-b451-5352f054fd0e">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfMy0zLTEtMS0xMDgxNjE_952606e5-403b-49ae-b860-9ec438eddb72">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfMy01LTEtMS0xMDgxNjE_c359f0dc-91c3-45b0-b81d-303347690b08">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfMy03LTEtMS0xMDgxNjE_d6b3ba6c-a8c6-422d-b31b-199aac34b9b8">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNC0xLTEtMS0xMDgxNjE_8f09756a-f4ba-4a92-afce-ad80ca3111bf">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNC0zLTEtMS0xMDgxNjE_502e8092-d0c8-4a84-9c9e-fcdba47cb970">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNC01LTEtMS0xMDgxNjE_2b08aa0a-31b2-4d97-b1b3-cfb98ce771f2">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNC03LTEtMS0xMDgxNjE_eda25699-3c16-4f76-9368-3779893e13d5">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total operating lease cost</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNS0xLTEtMS0xMDgxNjE_c080c289-a932-415c-8db2-6a9516d725e5">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNS0zLTEtMS0xMDgxNjE_42dfc25c-7250-4c60-a460-c50ad72004ba">1.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNS01LTEtMS0xMDgxNjE_6e9aac66-a3fe-497d-a143-9ab991cb470c">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNS03LTEtMS0xMDgxNjE_ffb4e495-3a54-423a-88db-315ade4afac0">5.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are reflected as components of cost of product sales, cost of contract development and manufacturing, research and development expense and selling, general and administrative expense.</span></div><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="ebs:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RleHRyZWdpb246ODlkM2E4NjJhMzBhNDA2Y2EwOTAxODg5NGJjM2U2MTdfNjg3_9e9ad412-bb43-45ca-876f-5e278993c262" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.880%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except lease term and discount rate)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_5151ab9f-c47e-463d-8aa2-48943e0afded"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_fa39117a-d454-4120-99bf-3662bcd5aca2">Other assets</span></span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0zLTEtMS0xMDgxNjE_eea7890f-bdf8-4aec-9e2c-6862c5a2214a">20.5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS01LTEtMS0xMDgxNjE_b21686cf-a910-4f69-9298-f8a218a4a195">28.3</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_4cea9722-b807-4cb6-aacd-3b045145d7ac"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_55a8c7c0-1418-4c46-86d6-6bf5a5d3114f">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0zLTEtMS0xMDgxNjE_eaf876bf-c61a-4b2d-b623-e885171da324">5.7</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy01LTEtMS0xMDgxNjE_6049d8e1-473f-4006-884a-72eea649d460">5.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_1a37c2b9-d83a-4cc7-9218-97115c59e9de"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_e5713eb8-636e-4658-b39f-755a6d1cadca">Other liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0zLTEtMS0xMDgxNjE_f4cd80de-4d7d-428d-b5ff-753164e6f234">15.8</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC01LTEtMS0xMDgxNjE_f7e0b90f-5a14-4cf2-a6f4-625fe925be96">24.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNS0zLTEtMS0xMDgxNjE_282af5ff-c4a0-4789-a844-ba94e4ef55ea">21.5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNS01LTEtMS0xMDgxNjE_7f3d1a55-1af0-4a88-91e4-96a7a90d733f">30.0</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating leases:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfOC0zLTEtMS0xMDgxNjE_300cf570-e675-4a83-8e22-cd20f4b69a66">5.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfOC01LTEtMS0xMDgxNjE_fba532da-dbd9-417d-9b28-9587336f00ae">7.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfOS0zLTEtMS0xMDgxNjE_d48edea4-f441-4f4b-9cc6-0922de24491a">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfOS01LTEtMS0xMDgxNjE_d8890012-8f36-460c-8582-d124f20cdc61">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id8993b1d29e74541a06611a1bc32de4a">During the three months ended September 30, 2022, the Company exercised the option to purchase our Rockville manufacturing facility. As a result, the Company removed the related operating lease right-of-use asset and operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="i5a811ac3bfcc4c29a2a87b5ad51a6fde_I20220930" decimals="-5" name="ebs:OperatingLeaseRightOfUseAssetRemoval" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RleHRyZWdpb246ODlkM2E4NjJhMzBhNDA2Y2EwOTAxODg5NGJjM2U2MTdfMTY0OTI2NzQ0MzMxNA_2fd867ae-1790-4434-a72a-2d5073ccc423">3.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idc90073631a04e08b6793e36b6aad73e_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RleHRyZWdpb246ODlkM2E4NjJhMzBhNDA2Y2EwOTAxODg5NGJjM2U2MTdfMTY0OTI2NzQ0MzMxOA_69fab19f-dd12-4c3a-bc76-cb78584b6309">3.4</ix:nonFraction>&#160;million, respectively. The purchased assets have been properly included in "Property, plant and equipment, net" on our condensed consolidated balance sheet as of September&#160;30, 2022.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_49"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTg2_7778990b-bceb-42dc-ab6e-48dbed75e3e4" continuedAt="ib3403c191f944790917074cce5b8e6f5" escape="true">Intangible assets</ix:nonNumeric></span></div><ix:continuation id="ib3403c191f944790917074cce5b8e6f5"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTg3_f56f54da-4eb4-428a-a586-0c1685a428f6" continuedAt="id4df162afc7142edb104b1ba3a41da21" escape="true">The following table summarizes the Company's Intangible assets, net:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><ix:continuation id="id4df162afc7142edb104b1ba3a41da21"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Asset Type</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Estimated Life</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Products </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idb1900f7b4c44cedb875acc241c0bee3_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi0xLTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo4YWJlNGUzMWY1OGQ0ZTMyODA5ZWU5NDY4MGMzYzc3OV80_ffa2f36e-aaa2-4884-b82a-796e2d5e6cdc">8</ix:nonNumeric>-<ix:nonNumeric contextRef="i261b255bd2fc4596b335217f2db169aa_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi0xLTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo4YWJlNGUzMWY1OGQ0ZTMyODA5ZWU5NDY4MGMzYzc3OV83_2c0dd0b2-c429-4b0c-bcad-b552faf32ef3">22</ix:nonNumeric> years</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i93e3346dbc84460d924b2e6aa25b270d_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi0zLTEtMS0xMDgxNjE_db75706b-7140-4c17-b43b-10208035ef03">958.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i93e3346dbc84460d924b2e6aa25b270d_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi00LTEtMS0xMDgxNjE_a89775f5-3d06-4fe9-af55-70d3e6f94127">235.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i93e3346dbc84460d924b2e6aa25b270d_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi01LTEtMS0xMDgxNjE_1cf88c6e-498e-4d93-8186-91e428ce1e61">722.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7b49e361c9c547df983b25e75f050a95_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi03LTEtMS0xMDgxNjE_204d2804-1465-47fd-9be5-45aff1357d16">798.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7b49e361c9c547df983b25e75f050a95_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi04LTEtMS0xMDgxNjE_7fe0442e-1563-4090-b9c0-4ff76ff34233">193.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7b49e361c9c547df983b25e75f050a95_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi05LTEtMS0xMDgxNjE_dbc461c2-1477-4714-b245-8f91ad388c33">604.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i53f8980f84e54596a2bf0df6314e9c89_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy0xLTEtMS0xMDgxNjE_6858a902-86b6-4386-b32e-42c1791c97fb">8</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9ff2b788ad74a47a087d6ebd487fff7_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy0zLTEtMS0xMDgxNjE_43ef18af-c074-4952-b405-097b15dbcd70">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9ff2b788ad74a47a087d6ebd487fff7_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy00LTEtMS0xMDgxNjE_2d048c0b-c786-4fe0-bbd7-3cb0d0d729fd">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9ff2b788ad74a47a087d6ebd487fff7_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy01LTEtMS0xMDgxNjE_2ffbc092-aeef-4292-8a7c-aaf27cf93182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide0e3032f9614c6682f2d4f2a0717a79_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy03LTEtMS0xMDgxNjE_60d312e3-8668-46eb-bcc0-0af38ad23867">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide0e3032f9614c6682f2d4f2a0717a79_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy04LTEtMS0xMDgxNjE_390fd9a0-b4f0-4c79-8b87-7580006935b9">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide0e3032f9614c6682f2d4f2a0717a79_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy05LTEtMS0xMDgxNjE_0a0a99eb-a529-4100-a38d-4e7746284411">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC0zLTEtMS0xMDgxNjE_e8dcc410-7fef-4ef5-b410-d12cea5b4580">963.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC00LTEtMS0xMDgxNjE_679ff911-0e68-4acf-80f0-77d8d33a1d26">240.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC01LTEtMS0xMDgxNjE_bf81607e-d9ba-47f3-b1fc-4b45ada2318b">722.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC03LTEtMS0xMDgxNjE_8c570bd3-d2d5-4e3d-8f95-4f82d91b47f2">803.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC04LTEtMS0xMDgxNjE_c5776278-1e3b-4ea6-8c8c-4dd469253149">198.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC05LTEtMS0xMDgxNjE_d8a4af26-0dae-4e2f-891a-8dc0ac205fff">604.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"> During the three months ended September 30, 2022, we acquired certain assets through asset acquisitions, and the related intangible assets were assigned to the "Products" asset type, of which $<ix:nonFraction unitRef="usd" contextRef="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNS0wLTEtMS0xMTI1MzAvdGV4dHJlZ2lvbjo0OGI4NTc3NmFkMjQ0N2U0YjYxMTk5MjVkMjMyYjI0Y18xNjQ5MjY3NDQzMTUy_68f57d99-4c6d-49ba-ba93-fe45c8de7052">154.7</ix:nonFraction> million was related to the Transaction.</span></div></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTk0_384842de-6118-4c0e-ab08-ed8ac47d1607" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company's intangible assets was recorded as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:39.101%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amortization Expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmZiNWE4ZjM2NjE3OTRlNzk4ZTRiYWQ2OWU4ODkxNTEyL3RhYmxlcmFuZ2U6ZmI1YThmMzY2MTc5NGU3OThlNGJhZDY5ZTg4OTE1MTJfMi0xLTEtMS0xMDgxNjE_b6acfe1c-186e-4774-804b-cee5133f2f92">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmZiNWE4ZjM2NjE3OTRlNzk4ZTRiYWQ2OWU4ODkxNTEyL3RhYmxlcmFuZ2U6ZmI1YThmMzY2MTc5NGU3OThlNGJhZDY5ZTg4OTE1MTJfMi0zLTEtMS0xMDgxNjE_1c35c5d6-fc5b-4f8b-98aa-76d3a5fe90b4">14.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmZiNWE4ZjM2NjE3OTRlNzk4ZTRiYWQ2OWU4ODkxNTEyL3RhYmxlcmFuZ2U6ZmI1YThmMzY2MTc5NGU3OThlNGJhZDY5ZTg4OTE1MTJfMi01LTEtMS0xMDgxNjE_f27f6216-c570-4839-afba-4f7e3ac8c02a">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmZiNWE4ZjM2NjE3OTRlNzk4ZTRiYWQ2OWU4ODkxNTEyL3RhYmxlcmFuZ2U6ZmI1YThmMzY2MTc5NGU3OThlNGJhZDY5ZTg4OTE1MTJfMi03LTEtMS0xMDgxNjE_6b23779e-0923-40f8-8e9d-faaa43f9ac06">44.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the weighted average amortization period remaining for intangible assets was <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfMzkw_0c5ec6fa-52c3-4b8e-b90c-ed2d974cf766">11.4</ix:nonNumeric> years. </span></div><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTg1_1daa4a91-c115-4bcf-a5c7-cd29bf8cb746" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the changes in the carrying amount of the Company's goodwill balance:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.171%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Goodwill, December&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOjJjZGQ1MDA2MDUyYzRmODY4NTI1MTc4OTQ0YjUzZDEwL3RhYmxlcmFuZ2U6MmNkZDUwMDYwNTJjNGY4Njg1MjUxNzg5NDRiNTNkMTBfMS0xLTEtMS0xMDgxNjE_8b8e26a3-8f00-4aa4-86f6-9893d06eaf98">224.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOjJjZGQ1MDA2MDUyYzRmODY4NTI1MTc4OTQ0YjUzZDEwL3RhYmxlcmFuZ2U6MmNkZDUwMDYwNTJjNGY4Njg1MjUxNzg5NDRiNTNkMTBfMi0xLTEtMS0xMDgxNjE_c8bb4bca-f275-46cf-8785-a2e86b6fb8a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Goodwill, September&#160;30, 2022</span></div></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOjJjZGQ1MDA2MDUyYzRmODY4NTI1MTc4OTQ0YjUzZDEwL3RhYmxlcmFuZ2U6MmNkZDUwMDYwNTJjNGY4Njg1MjUxNzg5NDRiNTNkMTBfMy0xLTEtMS0xMDgxNjE_0ebca770-af5b-45a4-ae97-d7bc7efcd948">224.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of goodwill included accumulated impairments of $<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTUx_1f710ec1-947d-4904-bb88-c572e1a2587b"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTUx_233d9e5f-1bdf-4e6b-a64a-66e9703397cf">41.7</ix:nonFraction></ix:nonFraction> million as of September&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has $<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfMjE5OTAyMzI2MDA2NA_38364a60-9364-417b-b8bd-91a716c6e036">224.9</ix:nonFraction>&#160;million of total goodwill which is composed of our Products and Services segments. There is the risk of future impairments in our reporting units as any further deterioration in their performance compared to forecast, changes in order volumes or delivery schedules for major customers, as well as any changes in economic forecasts and expected recovery in the biopharmaceutical industry, may require the Company to complete additional impairment tests in future quarters and could result in the reporting unit&#8217;s fair value falling below carrying value in subsequent quarters. In the event the Company experiences factors that it believes indicate a decline in fair value, including negative changes to long-term growth rates or if discount rates increase, we may be required to record impairments of goodwill and other identified intangible assets. Further, if the composition of the Company&#8217;s reporting unit&#8217;s assets and liabilities were to change and result in an increase in the reporting unit&#8217;s carrying value, it could lead to additional impairment testing and further impairment losses.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_52"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMjE3Ng_aac6e791-d77a-4149-8851-40f6380235aa" continuedAt="i937c7c6176c84d42baa378ba0914e9ab" escape="true">Fair value measurements</ix:nonNumeric></span></div><ix:continuation id="i937c7c6176c84d42baa378ba0914e9ab" continuedAt="i22faa225783c41bca3ee4e5fda4a0169"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMjE4MQ_e4f21f3d-a81e-4d9a-b9fa-f95bdf3f451c" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i01ccd0bec4264051b3136200d1ada025_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy0xLTEtMS0xMDgxNjE_abed8c4d-b596-40b5-b5dc-1771d90d551d">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iabb40ddb95bf4ae692da5f4e955899fa_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy0yLTEtMS0xMDgxNjE_0b8b4f4d-ce79-421d-a970-eb5df760b5ff">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i222957670d1047ca907e168d91aaf306_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy0zLTEtMS0xMDgxNjE_87ee6298-3f43-48ae-8e85-9604f61f89ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic2196bd047dc467a8d54bb1d0d7ad901_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy00LTEtMS0xMDgxNjE_3bad86ba-63e4-4ec1-a37f-e27783641038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6a10a22a6f834e04b52f8cb6f61ac369_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy02LTEtMS0xMDgxNjE_169b9376-bf2f-46b6-92f5-f8f589b8eefb">152.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib304027feebe4bf294aa22162bc25292_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy03LTEtMS0xMDgxNjE_c96c2114-a451-4e42-85bc-fc303071af57">152.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88816d3c5490459795a5e08eb0d42dba_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy04LTEtMS0xMDgxNjE_0b1d6e10-08e5-481e-ae29-57a728c73ab9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5ca9b3f099074a319fce082bb2f89bec_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy05LTEtMS0xMDgxNjE_87081561-f5dc-440d-a633-fe4526866de7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b7a7a2b19ba41c289818e166af517c7_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC0xLTEtMS0xMDgxNjE_efe9dfdb-def1-4ac7-b22e-41a1deb0f3d9">50.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0f9711a7eb5243dda529179658dd5830_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC0yLTEtMS0xMDgxNjE_f3e81cc8-ba8f-46dc-88f5-9e0a3775accf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4699322b4ad742c4a1d4274126058576_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC0zLTEtMS0xMDgxNjE_c5e148bf-f1b3-4ae2-90ce-e47f9bb124db">50.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d55fa0666854b7caae1ece36564984a_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC00LTEtMS0xMDgxNjE_38493196-0151-4878-9122-8fd2b435c628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibc5d91a03d4847649b2be05d67b2263c_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC02LTEtMS0xMDgxNjE_0d1ced12-d340-4d1b-b5bd-fcec544bbe69">200.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ddf4cbc6d484433973d4f77a1b65e21_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC03LTEtMS0xMDgxNjE_e5f2390d-b024-4fd3-bc0b-98a97063fcbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibad5698b8174430c8ff31576aa9ee134_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC04LTEtMS0xMDgxNjE_0ef98e0c-8065-42fb-b578-7882b87fce2d">200.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i48426d78db35469b9fbe78182bc15858_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC05LTEtMS0xMDgxNjE_59eb071c-dfef-4013-8c6c-92c224115d50">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS0xLTEtMS0xMDgxNjE_54571c80-5acc-44f1-801f-a52a2ce54601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if7b6bac14fa948a599d617d797f9992b_I20220930" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS0yLTEtMS0xMDgxNjE_a351634a-f15d-48f0-8d56-2ba5bda0f8e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i794b255dfaa5457d8b625a3b63515086_I20220930" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS0zLTEtMS0xMDgxNjE_0b2bff3e-ab58-44e9-9898-5ce240a4a3b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8eade752296e444ba664833e0780951f_I20220930" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS00LTEtMS0xMDgxNjE_d9effc6d-a5b7-4c80-b149-7344e3f52b6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS02LTEtMS0xMDgxNjE_a54463f1-e137-45c8-9bce-67bc2c2b252f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iacb283273e704425a0c32a9149376f6b_I20211231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS03LTEtMS0xMDgxNjE_649de86f-affc-40fb-b9bc-c3fa59a11de7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8007fc99edc04934866754634405d8ea_I20211231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS04LTEtMS0xMDgxNjE_e0f67d4f-7d74-4bc4-8600-5d481caba21a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1054758dc0d14fa3bddb52120fbac120_I20211231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS05LTEtMS0xMDgxNjE_8413b5df-75fd-4eca-8e9f-0ae3551a4dab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi0xLTEtMS0xMDgxNjE_39446f79-c2d3-4aaf-8821-ce42a7736436">75.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if7b6bac14fa948a599d617d797f9992b_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi0yLTEtMS0xMDgxNjE_f941514b-3029-4c10-b025-4b1e0a95d2e7">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i794b255dfaa5457d8b625a3b63515086_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi0zLTEtMS0xMDgxNjE_59021adf-e42f-4906-80f7-753c2fe328ab">50.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8eade752296e444ba664833e0780951f_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi00LTEtMS0xMDgxNjE_82b8d6db-e7b2-4ab5-a7e1-a08e65ce9c14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi02LTEtMS0xMDgxNjE_248a52b3-18b2-4366-bc37-d049e9af5045">352.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iacb283273e704425a0c32a9149376f6b_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi03LTEtMS0xMDgxNjE_91e745d1-f345-4f82-8747-74440e424253">152.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8007fc99edc04934866754634405d8ea_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi04LTEtMS0xMDgxNjE_378ac953-c5de-414c-a635-ea2a71ed9223">200.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1054758dc0d14fa3bddb52120fbac120_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi05LTEtMS0xMDgxNjE_5bee556c-8f5e-4dcc-84a2-923b0c8b722c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC0xLTEtMS0xMDgxNjE_8e838d91-7c18-45cf-a8b6-020b1099d5ef">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if7b6bac14fa948a599d617d797f9992b_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC0yLTEtMS0xMDgxNjE_c63bada0-4e64-4c1f-9b75-104df863f10d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i794b255dfaa5457d8b625a3b63515086_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC0zLTEtMS0xMDgxNjE_6d487907-51ce-44b2-bca1-a639eaf6703d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8eade752296e444ba664833e0780951f_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC00LTEtMS0xMDgxNjE_6242f490-52f1-4197-a19d-f97afdb2ba70">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC02LTEtMS0xMDgxNjE_61a89d46-4420-4524-8c6f-96e16f7ebf4e">37.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iacb283273e704425a0c32a9149376f6b_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC03LTEtMS0xMDgxNjE_44263b86-de55-439f-b77e-f5576b1b305b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8007fc99edc04934866754634405d8ea_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC04LTEtMS0xMDgxNjE_8bed0da1-575e-4ccb-ba36-af183954192b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1054758dc0d14fa3bddb52120fbac120_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC05LTEtMS0xMDgxNjE_56711277-29d9-4621-812b-d2c015aa11d2">37.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS0xLTEtMS0xMDgxNjE_231e1a11-3fb8-4b33-9495-f5e3848a35f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if7b6bac14fa948a599d617d797f9992b_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS0yLTEtMS0xMDgxNjE_d8e69325-fbc9-4192-81c6-1e5e17af49e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i794b255dfaa5457d8b625a3b63515086_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS0zLTEtMS0xMDgxNjE_6a73ac0c-c2bf-4f83-962f-186591eecb2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8eade752296e444ba664833e0780951f_I20220930" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS00LTEtMS0xMDgxNjE_077f2897-977a-4d61-90eb-4438ef53c1fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS02LTEtMS0xMDgxNjE_09f0fbc7-d4d7-4f52-ab39-f17cb227e717">6.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iacb283273e704425a0c32a9149376f6b_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS03LTEtMS0xMDgxNjE_43b01a24-e991-43cb-ba5b-93d4aa643101">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8007fc99edc04934866754634405d8ea_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS04LTEtMS0xMDgxNjE_b06a1012-5bab-4afe-9514-9c6a39bdaf82">6.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1054758dc0d14fa3bddb52120fbac120_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS05LTEtMS0xMDgxNjE_f9f61cb8-bab3-4996-a0e1-b15e2445fd15">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtMS0xLTEtMTA4MTYx_a87839f3-ea72-46b1-8bd4-290c42080f6f">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if7b6bac14fa948a599d617d797f9992b_I20220930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtMi0xLTEtMTA4MTYx_e0cb7964-8808-4dd8-813d-d2b4676b9a89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i794b255dfaa5457d8b625a3b63515086_I20220930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtMy0xLTEtMTA4MTYx_e9de5c4c-85d0-4f31-a8d2-fc8208c2305c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8eade752296e444ba664833e0780951f_I20220930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtNC0xLTEtMTA4MTYx_f3a40941-331f-4d03-8413-b657848b49d6">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtNi0xLTEtMTA4MTYx_6be06c46-905f-485d-8fde-1683820d5676">43.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iacb283273e704425a0c32a9149376f6b_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtNy0xLTEtMTA4MTYx_fc090cc0-7e9d-48bc-9b4e-637277e0baa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8007fc99edc04934866754634405d8ea_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtOC0xLTEtMTA4MTYx_fce1aba8-0665-4119-82ab-03a7a4145b97">6.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1054758dc0d14fa3bddb52120fbac120_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtOS0xLTEtMTA4MTYx_64a8fc86-053c-401c-b90e-7065c1a8f27c">37.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#8217;s products are classified in the Company's statement of operations as cost of product sales. </span></div><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMjE3OA_0d3ed007-0fc2-4ea8-b1c8-39c38cd26b68" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a reconciliation of the beginning and ending balance of the Company's contingent consideration liability: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Liability for Contingent Consideration</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOmQwNjcxMGRmMzAwMDQyOGViNThhMGQ5ZDdkMGI4MzdlL3RhYmxlcmFuZ2U6ZDA2NzEwZGYzMDAwNDI4ZWI1OGEwZDlkN2QwYjgzN2VfMS0yLTEtMS0xMDgxNjE_d5daad6a-bbd0-4644-8d73-9e9bc815671f">37.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOmQwNjcxMGRmMzAwMDQyOGViNThhMGQ5ZDdkMGI4MzdlL3RhYmxlcmFuZ2U6ZDA2NzEwZGYzMDAwNDI4ZWI1OGEwZDlkN2QwYjgzN2VfMi0yLTEtMS0xMDgxNjE_4b90cd7c-1c8c-4f3a-980a-d323b1e9cd8f">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOmQwNjcxMGRmMzAwMDQyOGViNThhMGQ5ZDdkMGI4MzdlL3RhYmxlcmFuZ2U6ZDA2NzEwZGYzMDAwNDI4ZWI1OGEwZDlkN2QwYjgzN2VfMy0yLTEtMS0xMDgxNjE_a88b3813-b9d2-4d2d-bf0f-497c5e9e64ee">31.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOmQwNjcxMGRmMzAwMDQyOGViNThhMGQ5ZDdkMGI4MzdlL3RhYmxlcmFuZ2U6ZDA2NzEwZGYzMDAwNDI4ZWI1OGEwZDlkN2QwYjgzN2VfNC0yLTEtMS0xMDgxNjE_74961b86-f5d6-4201-8272-fddbf036e6da">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the current portion of the contingent consideration liability was </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTI2OQ_0262c9b2-f926-4412-bb66-909a99737bf3">3.5</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTI3Ng_5c0518f4-6c87-4958-8b84-78e62484ef41">32.7</ix:nonFraction>&#160;million, respectively, and was included in other current liabilities on the condensed consolidated balance sheets. The non-current portion of the contingent consideration liability is included in other liabilities on the condensed consolidated balance sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i22faa225783c41bca3ee4e5fda4a0169"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMjE4MA_4e22a1f1-19f4-45fd-80e7-655032b6a584" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:16.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Contingent Consideration Liability</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value as of September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Range</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Weighted Average</span></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenue milestone and royalty based</span></td><td colspan="3" rowspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idcd99f4d0bd44df5ac51fd3f92b88bd4_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMS0xLTEtMS0xMDgxNjE_ac1175fd-5cbd-4f2f-9dfd-9a5b3296364e">7.8</ix:nonFraction></span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Discounted cash flow</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ieb22a87cdfe14a7c84c7650473417364_I20220930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMS00LTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo4Zjk0MDdjYjk0Yzg0ODJlOGMzN2I0ODhiM2Y1ODEwZV80_60d7dcca-ebda-46e8-ab4c-18d956b6700c">10.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic622b8b9acb24f6b88e8c6886000cf77_I20220930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMS01LTEtMS0xMDgxNjE_53a635bd-3fc1-499b-a56f-7a23a250cc7a">10.1</ix:nonFraction>%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Probability of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i69c2baff68b54a718464354731cbe1ff_I20220930" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMi00LTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjpiMDViMGMxOTAyNmI0Mzg1YWNiMDZhZjNiZTVlMjA4NF80_4c0c40ad-71e1-409d-a86b-608d960474a0">25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3ef5c35c4662482c96b3838cdb9d6edd_I20220930" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMi00LTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjpiMDViMGMxOTAyNmI0Mzg1YWNiMDZhZjNiZTVlMjA4NF85_b97efaa6-8c45-440d-b67e-5a3c6e08df18">50</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i300780e3ce444b4cb0b0c9c10968ac86_I20220930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMi01LTEtMS0xMDgxNjE_a389c733-4378-4399-9e3b-7f9830078266">40.0</ix:nonFraction>%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Projected year of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2022 - 2028</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2024</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 8, "Derivative instruments and hedging activities"</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information about the Company's derivative instruments.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-variable rate debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022 and December&#160;31, 2021, t</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he fair value of the Company's <ix:nonFraction unitRef="number" contextRef="i291befa2eae3402ebb90a91957b5b46f_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTg5NQ_00aac4b5-7817-4fab-9493-34f1e6e69693"><ix:nonFraction unitRef="number" contextRef="i8b3b07fe44be43f1b02c1b877f8d8f60_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTg5NQ_808dcf40-3c2d-4b86-bcec-a66ae8280bc1">3.875</ix:nonFraction></ix:nonFraction>% Senior Unsecured Notes was $<ix:nonFraction unitRef="usd" contextRef="i291befa2eae3402ebb90a91957b5b46f_I20220930" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTkyNQ_39c65712-0ad5-4915-b4d7-b89567684b17">299.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8b3b07fe44be43f1b02c1b877f8d8f60_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTkzMg_902f5370-7d79-4006-bf2e-a8d24183cded">433.3</ix:nonFraction>&#160;million, respectively. The fair value was determined through market sources, which are level 2 inputs and directly observable. The carrying amounts of the Company&#8217;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 9, "Debt").</span></div></ix:continuation><div id="i9bec4b75ff354735b09dcc9c604dfa92_55"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfMjk2Ng_216c0333-8322-4fe7-a60f-684e5f99dcdb" continuedAt="i9978f33c257d433090634714c8521196" escape="true">Derivative instruments and hedging activities</ix:nonNumeric></span></div><ix:continuation id="i9978f33c257d433090634714c8521196" continuedAt="i1cb57530ac374807b9f8e166e8aa3e41"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk management objective of using derivatives</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from payments of variable interest rate debt associated with the Company's senior secured credit agreements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If current fair values of designated interest rate swaps&#160;remained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;$<ix:nonFraction unitRef="usd" contextRef="i19788cf415e44731a7ac316933902c13_D20220101-20220930" decimals="-5" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfODk4_ad39568c-6fc1-4b74-aba3-3a4866212ed7">9.0</ix:nonFraction> million of net deferred gains from&#160;accumulated other comprehensive loss&#160;into the condensed consolidated statement of operations over the next&#160;twelve-month period. All outstanding cash flow hedges mature in October 2023.</span></div><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfMjk2OA_a906e2ab-d8f4-4bb0-9935-bc2c0a05aa27" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions, except number of instruments)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Number of Instruments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Notional</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="instrument" contextRef="i7d38ed2b0b1c4eaa8ca77f4744eb8d44_I20220930" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOmZiMjViZjMzNTcwMzQ3YmM4ZmI5MGRlOWI2YmE0MGFmL3RhYmxlcmFuZ2U6ZmIyNWJmMzM1NzAzNDdiYzhmYjkwZGU5YjZiYTQwYWZfMS0xLTEtMS0xMDgxNjE_6d4beb3d-9872-4ebd-9006-62d524d6cc38">7</ix:nonFraction></span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i7d38ed2b0b1c4eaa8ca77f4744eb8d44_I20220930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOmZiMjViZjMzNTcwMzQ3YmM4ZmI5MGRlOWI2YmE0MGFmL3RhYmxlcmFuZ2U6ZmIyNWJmMzM1NzAzNDdiYzhmYjkwZGU5YjZiYTQwYWZfMS0zLTEtMS0xMDgxNjE_55d88852-0556-4f3d-b3e1-ed3155821532">350.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i1cb57530ac374807b9f8e166e8aa3e41"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfMjk2NQ_6fd3d204-e0da-4e23-a452-0af18b461545" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Asset Derivatives</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Assets</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e48ea4760d64c29a1425b6484a220d7_I20220930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfMy0yLTEtMS0xMDgxNjE_813cb296-af8e-4b46-bea5-15b8be43eab7">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Assets</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i838e26b2874e4c6a900e96dfeaeb7fcf_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfMy00LTEtMS0xMDgxNjE_5ff98dd8-0c33-4fc1-8a6c-fc132a7b015c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Liabilities </span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i150ebed92e8e40479da8c8a6f0513b75_I20220930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfMy03LTEtMS0xMDgxNjE_6e32a11c-431d-4ef0-95fd-7ecd5a9ee0bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Liabilities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8e600ddb0a1748578ccc9e9d07f955f3_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfMy05LTEtMS0xMDgxNjE_6db5ed0e-9bef-4b74-8da6-99b4df5ba64d">4.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic90b9835f0d24ac1a182a07dd228a238_I20220930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfNC0yLTEtMS0xMDgxNjE_7884f9e0-2f2c-44c0-bbaa-3c9abdd9ce35">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1e4d660de4664e77b8ff1707a368864a_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfNC00LTEtMS0xMDgxNjE_afe4c9c4-2173-45fc-9ebe-b9017cf1afe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Liabilities</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ida4dbb8aac844392a35bca16af3b8ba6_I20220930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfNC03LTEtMS0xMDgxNjE_2640f856-d31d-4a2f-9617-2ca0596ce1f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7fde38f223f94ec0bedb7aaf2da71b3c_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfNC05LTEtMS0xMDgxNjE_5ceb6e3d-4694-44a4-b400-f4e679d46d69">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfMjk3Nw_4575b5ab-d49a-4c94-9813-692bfa806311" escape="true">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfMjk2OQ_6b73f55e-180c-48fe-abe9-5aa4464ba766" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive loss.</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:20.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.311%"></td><td style="width:0.1%"></td></tr><tr style="height:38pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivatives</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Location of Loss Reclassified from</span></td><td colspan="6" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amount of Loss Reclassified from Accumulated OCL into Income (Loss)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30,</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31,</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated OCL into Income (Loss)</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19788cf415e44731a7ac316933902c13_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjkyMDIxNGQ1NTViNjRiYzY5MzY5MDc1MzMyZWQ0YjY2L3RhYmxlcmFuZ2U6OTIwMjE0ZDU1NWI2NGJjNjkzNjkwNzUzMzJlZDRiNjZfMy0xLTEtMS0xMDgxNjE_315cb659-0154-4608-93d8-439719a645a9">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i738ecdd912c348ff897fd9f1546835a8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjkyMDIxNGQ1NTViNjRiYzY5MzY5MDc1MzMyZWQ0YjY2L3RhYmxlcmFuZ2U6OTIwMjE0ZDU1NWI2NGJjNjkzNjkwNzUzMzJlZDRiNjZfMy0yLTEtMS0xMDgxNjE_0b0d5d8c-01c4-47ca-aad6-5534d3949558">6.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic61dd5c549874f80b397d42cc9717abc_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjkyMDIxNGQ1NTViNjRiYzY5MzY5MDc1MzMyZWQ0YjY2L3RhYmxlcmFuZ2U6OTIwMjE0ZDU1NWI2NGJjNjkzNjkwNzUzMzJlZDRiNjZfMy00LTEtMS0xMDgxNjE_1b4584d0-03c8-4992-8618-9ef63945442b">1.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i74b2a89fef854325a21558ba470a63ad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjkyMDIxNGQ1NTViNjRiYzY5MzY5MDc1MzMyZWQ0YjY2L3RhYmxlcmFuZ2U6OTIwMjE0ZDU1NWI2NGJjNjkzNjkwNzUzMzJlZDRiNjZfMy01LTEtMS0xMDgxNjE_457a5161-b3b4-4820-aa48-9cfd20db3a7f">4.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9bec4b75ff354735b09dcc9c604dfa92_58"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjgwMg_af408a03-1cad-4491-ad19-7a224438b478" continuedAt="i8b76e01d12474176be99c114a007b0e2" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i8b76e01d12474176be99c114a007b0e2" continuedAt="i52ff7e19b291454e8bfdc9447c1f3ea7"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjgwNQ_c8adc3fd-945b-4a4c-a744-febd2302e92e" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of debt were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Senior secured credit agreement - Term loan due 2023</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icb0a527f718246d39439945aa519e89c_I20220930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMS0xLTEtMS0xMDgxNjE_af49451e-dbf8-4012-9a2f-7fa7ce9300e5">371.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i04969e1a51cb42c89f1471eb8ace2e4d_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMS0zLTEtMS0xMDgxNjE_02b80607-508d-4e36-996f-9c1d9b3ab0cb">396.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Senior secured credit agreement - Revolver loan due 2023</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7432986424e74ac09ac1dd272585adcb_I20220930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMi0xLTEtMS0xMDgxNjE_f9e61e44-2f94-490d-b140-aabc66732e1e">238.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if50ceba61f3047f1834721079b974236_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMi0zLTEtMS0xMDgxNjE_73b2c60a-7f4a-410e-bba9-ddb77b70d7bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i291befa2eae3402ebb90a91957b5b46f_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMy0wLTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo3MzlmNmJkYWFiNGM0NzVmYTZjOGFhOGYyNWNhN2ZmYl80_98e35f9f-0399-4305-9cc6-499290595c88">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i291befa2eae3402ebb90a91957b5b46f_I20220930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMy0xLTEtMS0xMDgxNjE_a1a780b1-63ba-4c1b-8f3a-0502a50fabe5">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8b3b07fe44be43f1b02c1b877f8d8f60_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMy0zLTEtMS0xMDgxNjE_b24d141a-6ca4-4ca3-998d-dc027cbd41c0">450.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i027fba7fbff04d03860a6cb1878e9580_I20220930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNC0xLTEtMS0xMDgxNjE_35e975ec-ccef-4fbb-8b00-c4e83cd2bdcf">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaffc9253e79f4fcebff3b4c90c35286e_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNC0zLTEtMS0xMDgxNjE_528656de-6a61-4765-97de-d6ad12fa1932">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNS0xLTEtMS0xMDgxNjE_cbda70a8-69b5-4a80-9519-006439fac85e">1,062.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNS0zLTEtMS0xMDgxNjE_e7acc1ec-e4be-453d-a823-4a4f0651d736">849.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Current portion of long-term debt, net of debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNy0xLTEtMS0xMDgxNjE_dfae5401-3980-4ad9-bf77-b8ba8bc3d18c">21.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNy0zLTEtMS0xMDgxNjE_6fa2bb9b-8166-4ef3-ae4f-99fd7c853f7d">31.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfOC0xLTEtMS0xMDgxNjE_c405a5a0-5234-452c-81a8-e9f1ddba3c50">9.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfOC0zLTEtMS0xMDgxNjE_9b0fcb97-c912-4495-a435-960d68a3da68">8.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Non-current portion of debt</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfOS0xLTEtMS0xMDgxNjE_ea3debcc-ec07-4130-9125-9749ed04842b">1,032.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfOS0zLTEtMS0xMDgxNjE_a34b54b9-ca2e-443b-8c60-2946a93b7e7d">809.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021 there was $<ix:nonFraction unitRef="usd" contextRef="i7432986424e74ac09ac1dd272585adcb_I20220930" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNTQ5NzU1ODIwNzI3_4190af41-cc33-4e26-a16d-63fd6d3c6ea6">238.0</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="if50ceba61f3047f1834721079b974236_I20211231" decimals="INF" name="us-gaap:LongTermDebt" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNTQ5NzU1ODMyODI4_11f557ab-1f7f-4259-9a4d-30a5497e8c93">no</ix:nonFraction></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding revolver balance, respectively. The Company classifies debt issuance costs associated with the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revolver</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loan as other current assets and other assets on the Company's consolidated balance sheets. As of September&#160;30, 2022, the Company </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i52ff7e19b291454e8bfdc9447c1f3ea7" continuedAt="i2f2f083d40764dcbbe43fb7829942712"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had $<ix:nonFraction unitRef="usd" contextRef="i685e03fb0a4c4543b949a4d6d792d36a_I20220930" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNTQ5NzU1ODMyODAw_a2b09692-4a39-4cc5-a3b7-14dc63e6da26">4.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5375d3691d1d44bc8c0347410a5bea7e_I20220930" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMjk5_efdc68bc-8a01-4d10-9026-3b3602e3ad77">4.9</ix:nonFraction>&#160;million of debt issuance costs associated with the revolver loan classified as other current assets and other assets, respectively. As of December&#160;31, 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDY2_e5ecf7bb-2e3d-4ab6-ba4f-9361b5c728c9">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDcz_f058688b-745a-4b04-88c4-282d9faa2a5c">1.6</ix:nonFraction> million of debt issuance costs associated with the revolver loan that were classified as other current assets and other assets, respectively.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i08291fa7af0b411b9ad50845378e5f4f_I20200807" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjEw_600e5ec6-f09e-4b69-b19d-2222f0bb6423">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company completed its offering of $<ix:nonFraction unitRef="usd" contextRef="i08291fa7af0b411b9ad50845378e5f4f_I20200807" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNzAz_2259ed44-b97c-4a36-811c-69b6371f990f">450.0</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i08291fa7af0b411b9ad50845378e5f4f_I20200807" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNzM2_4da65499-0226-4895-af35-de31775c2205">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028 (the 2028 Notes) of which the majority of the net proceeds were used to pay down the Revolving Credit Facility (as defined below). Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related Indenture, plus accrued and unpaid interest. Prior to August 15, 2023 the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i4e7c1aaf68b942a4862dd65bfc9fb9b0_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMTM3OQ_b7d77cf9-ebc3-4607-b2f2-82ea66abb998">100</ix:nonFraction>% of the principal amount of the 2028 Notes plus a &#8220;make-whole&#8221; premium and accrued and unpaid interest. Prior to August 15, 2023, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i920e76d8a6b143808c57dd4353d67903_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMTU0MA_245afd0b-516f-4765-8f6e-b76f75e0356d">40</ix:nonFraction>% of the aggregate principal amount of the 2028 Notes using the net cash proceeds of certain equity offerings at the redemption price set forth in the related Indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of <ix:nonFraction unitRef="number" contextRef="if4f8efea66de4544a5582830d8b59691_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMTgzMA_1bfea86c-f7a9-4ece-8df2-87dfbe969fac">101</ix:nonFraction>% of the principal amount of such 2028 Notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative covenants in the Indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on August 7, 2020, the Company entered into a Second Amendment (the &#8220;Credit Agreement Amendment&#8221;) to its senior secured credit agreement, dated October 15, 2018, with multiple lending institutions relating to the Company&#8217;s senior secured credit facilities (the &#8220;Credit Agreement,&#8221; and as amended, the &#8220;Amended Credit Agreement&#8221;), consisting of a senior revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and senior term loan facility (the &#8220;Term Loan Facility,&#8221; and together with the Revolving Credit Facility, the &#8220;Senior Secured Credit Facilities&#8221;).  The Credit Agreement Amendment amended, among other things, the definition of incremental facilities limit, the consolidated net leverage ratio financial covenant by increasing the maximum level, increased the permissible applicable margins based on the Company&#8217;s consolidated net leverage ratio and increased the commitment fee that the Company is required to pay in respect of the average daily unused commitments under the Revolving Credit Facility, depending on the Company&#8217;s consolidated net leverage ratio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement includes (i) a Revolving Credit Facility of $<ix:nonFraction unitRef="usd" contextRef="i6200f8d1ae104ba18d6fdb545b3e9d53_I20200807" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMzM2NQ_d4ccd4be-8847-4220-ab78-40644adea26c">600.0</ix:nonFraction>&#160;million and (ii) a Term Loan Facility with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i71e35fd549cd4231be789d968dfd1543_I20200807" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMzQyNQ_db25392a-db3d-4f61-8587-d4bcba131d8e">450.0</ix:nonFraction>&#160;million. The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as certain requirements involving the Company's net leverage ratio will be maintained on a pro forma basis. Borrowings under the Revolving Credit Facility and the Term Loan Facility bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from <ix:nonFraction unitRef="number" contextRef="i8605ed75b07d49a3b547f97fccb0e405_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMzgzNQ_d5e25100-d83b-4cba-84c9-9d24a281e30a">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i82b05a62bd63445cb568d4c2e2c3d9e0_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMzg0MQ_4d498f57-34fc-46f7-967e-b26dce6a5c44">2.25</ix:nonFraction>% per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="ic84be99323cc4584be4962051ab7756d_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDAwMg_e98fc959-14b4-466c-b732-e036c2f57766">0.50</ix:nonFraction>%, and a eurocurrency rate for an interest period of one month plus <ix:nonFraction unitRef="number" contextRef="ib0b9e211f3b94cda86f8d463e61a3a6c_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDA3MQ_866a4ceb-c5a1-4368-8107-9d610d00a81e">1</ix:nonFraction>% plus a margin ranging from <ix:nonFraction unitRef="number" contextRef="i17b0291bd1dd47a7b7ee65d4fecc6232_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDEwMQ_e6f4e1de-c7c7-40f1-96fe-ccf2efd07548">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i655fab78c8164add9eea8222ce75abaf_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDEwNw_bf0cb1bb-0c3d-4961-a8c8-1665bd8286a5">1.25</ix:nonFraction>%, depending on the Company's consolidated net leverage ratio). The Company is required to make quarterly payments on the last business day of each calendar quarter under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from <ix:nonFraction unitRef="number" contextRef="i1479ba7c4c8141da9c266a76d41c699c_D20200807-20200807" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDQ4Ng_e9129a05-5404-42e8-89e5-d18a88ded49a">0.15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ida101d603b624a549b887226e83027b1_D20200807-20200807" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDQ5Mg_9e0da997-a509-462a-b96b-c75944f2512c">0.35</ix:nonFraction>% per annum, depending on the Company's consolidated net leverage ratio, for the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments on the last business day of each calendar quarter based on an annual percentage equal to <ix:nonFraction unitRef="number" contextRef="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807" decimals="INF" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDg0Mg_6d06204b-05d8-4c1b-9775-a9999f2965d9">2.5</ix:nonFraction>% of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, <ix:nonFraction unitRef="number" contextRef="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807" decimals="INF" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDk2Ng_9792db5d-3ee5-4836-9586-fc99e83791ff">5</ix:nonFraction>% of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and <ix:nonFraction unitRef="number" contextRef="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807" decimals="INF" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNTA4MA_1a8e9cdd-eed6-4b75-815d-2e126b285656">7.5</ix:nonFraction>% of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i2f2f083d40764dcbbe43fb7829942712"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature on October 13, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of $<ix:nonFraction unitRef="usd" contextRef="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807" decimals="-5" name="ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNTc5OA_9bf4b53f-c8bc-4999-a52d-452d3a3ead33">100.0</ix:nonFraction>&#160;million during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights. The financial covenants under the Amended Credit Agreement currently require the quarterly presentation of a minimum consolidated <ix:nonNumeric contextRef="i1eb46693aa644293a59a4421942c528f_D20200807-20200807" name="ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjA5OQ_fc23cd8c-be47-4db1-806b-04437d84379b">12</ix:nonNumeric>-month rolling debt service coverage ratio of <ix:nonFraction unitRef="number" contextRef="i1479ba7c4c8141da9c266a76d41c699c_D20200807-20200807" decimals="INF" name="ebs:DebtInstrumentCovenantDebtServiceCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjE0Nw_f1898d96-99a6-47de-85e9-36459adc2749">2.50</ix:nonFraction> to 1.00, and a maximum consolidated net leverage ratio of <ix:nonFraction unitRef="number" contextRef="ida101d603b624a549b887226e83027b1_D20200807-20200807" decimals="INF" name="ebs:DebtInstrumentCovenantNetLeverageRatioOne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjIwOA_9f0d25de-115e-4ebb-8113-000e318334f1">4.50</ix:nonFraction> to 1.00 (subject to an increase to <ix:nonFraction unitRef="number" contextRef="ida101d603b624a549b887226e83027b1_D20200807-20200807" decimals="INF" name="ebs:DebtInstrumentCovenantNetLeverageRatioTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjI0Ng_84861c91-2517-494e-95ff-fc4b83af0932">5.00</ix:nonFraction> to 1.00 for an applicable four quarter period, at the election of the Company, in connection with a permitted acquisition having an aggregate consideration in excess of $<ix:nonFraction unitRef="usd" contextRef="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807" decimals="-5" name="ebs:DebtInstrumentCovenantConsiderationThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjQxOA_7331b3e2-973a-41fb-a58b-cbac1f05ba86">75.0</ix:nonFraction>&#160;million). Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants.</span></div></ix:continuation><div id="i9bec4b75ff354735b09dcc9c604dfa92_64"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM5MA_263b1dce-38c2-4dfc-a253-6060a070771d" continuedAt="i6b66c50de14a48478e65ace4f67532da" escape="true">Revenue Recognition </ix:nonNumeric></span></div><ix:continuation id="i6b66c50de14a48478e65ace4f67532da" continuedAt="i4c6ee586318b4348b552f6311e9394e2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfMTY0OTI2NzQ3NzYyMA_83999cc4-ff49-48c3-9fd0-714701d38614"><ix:nonFraction unitRef="segment" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfMTY0OTI2NzQ3NzYyMA_ec67a01a-2c1e-4636-9b75-53d42761c544">two</ix:nonFraction></ix:nonFraction> operating segments (Note 14, "Segment information</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM4NA_1e8d70fc-17c4-47fb-9186-cbcaf7318eae" continuedAt="idb5b4cacae5c47e99258f81ab1287b17" escape="true">The Company's revenues disaggregated by the major sources were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="idb5b4cacae5c47e99258f81ab1287b17"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28a266eb53e04df59d47c4a05b3e2244_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi0xLTEtMS0xMDgxNjE_2a51430f-e319-499c-9158-7adcc555b96d">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0c02245efe03492d998177bd87378e02_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi0zLTEtMS0xMDgxNjE_86660dee-84c1-46da-be87-08a660a34421">152.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i52646bb207c64e15902c5f7cebbaa5a9_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi01LTEtMS0xMDgxNjE_f097acfb-dcbb-4244-839d-a32c952d0d23">186.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0a88ddbd25d44236801b5ce80ff820a0_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi03LTEtMS0xMDgxNjE_287ea4a8-2432-429a-b3ba-cccd5236e428">129.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib8ec2984c86b4778b38ae6b4badb7f46_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi05LTEtMS0xMDgxNjE_a83b7ae0-f213-4438-a2b6-85b34f83beef">140.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3c1314a596fa4be2be2dbbc905e0e0ce_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi0xMS0xLTEtMTA4MTYx_85fdbce8-cf0e-4090-93b6-0f3800668942">270.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if8c4a64e596d45aea88a95a509f10f86_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC0xLTEtMS0xMDgxNjE_aa40ac80-3ce4-4781-9a54-94f17be8c15c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iee319a3e184c49c88a65354d45c0fcb5_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC0zLTEtMS0xMDgxNjE_743e8ea5-55fe-4942-b212-7eb42fee0bc3">36.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie3ea905c3a1d48a9a374e41f47cd9e7e_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC01LTEtMS0xMDgxNjE_42c97c2a-01d4-464d-927e-b3e4b0452322">36.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i68059df57d924b6c9a6d571ce4686d06_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC03LTEtMS0xMDgxNjE_8c690d0c-c9d2-4d5e-926b-84d281b6c2ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1a498fe04f304b2bb151292ea1f5194c_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC05LTEtMS0xMDgxNjE_089d58d0-e418-4c75-b077-e421fce23d70">112.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i293e88d455b74b89b6ea596c99361768_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC0xMS0xLTEtMTA4MTYx_208005d4-451a-4cb5-800f-c9f6969e020f">112.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i85d2fdbc895b41fe8983ba64d0d2ffb0_D20220701-20220930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS0xLTEtMS0xMDgxNjE_3e541543-9295-46f5-9f45-7cf9f8c0f31c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i93ce7d6831194524b6acb971a73c8b1a_D20220701-20220930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS0zLTEtMS0xMDgxNjE_b471db51-6958-4f0a-8a2e-e1ebdd02577b">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25e36ed15c584f8abca1aae53e56c499_D20220701-20220930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS01LTEtMS0xMDgxNjE_9bd1090e-dc75-4ebf-b79a-c4a03cc73172">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if6ea4a6a0de647a8a6d921dd7b209282_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS03LTEtMS0xMDgxNjE_e38bb6f7-2ee4-498e-8a2c-6d22c97df2ab">86.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad159380abc745509e18c7cd554939da_D20210701-20210930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS05LTEtMS0xMDgxNjE_7be59673-af50-442a-a665-0607d1ec16c5">15.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5106d154262648b8966552fa34ac668e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS0xMS0xLTEtMTA4MTYx_78e5a8fd-4bb7-42ae-8135-55158cc970c4">71.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total CDMO</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if4317852774f4594bf7d43b26a0b6f3d_D20220701-20220930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi0xLTEtMS0xMDgxNjE_44321538-94da-431a-96ae-0216554aaff9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4d65c5dfe69a49298805ed95c23e4944_D20220701-20220930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi0zLTEtMS0xMDgxNjE_8ea901bd-b511-4870-8670-77557aa1d81d">36.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7c744e01ccc4b70a3f8d3f033d69fc7_D20220701-20220930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi01LTEtMS0xMDgxNjE_a0dab402-c557-49cc-8452-b9a4891959ca">36.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2d79a2aa8e1a4715897d56ad0693e4a1_D20210701-20210930" decimals="-5" sign="-" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi03LTEtMS0xMDgxNjE_e71b66f2-43e3-4178-b604-994a6514c9e6">86.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iff568f9147f143f48975cc8ccf7bb4d9_D20210701-20210930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi05LTEtMS0xMDgxNjE_ecea80af-7ac4-4ea0-8400-a166a298b6b7">127.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iefc13edfdf22466c94aef0c6826da80b_D20210701-20210930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi0xMS0xLTEtMTA4MTYx_65a9e119-0719-4d21-b9b0-da5956a470ad">41.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie21ef4d129104b7a8ae5cd39ae894a3f_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy0xLTEtMS0xMDgxNjE_2dda24d2-7901-43b8-b190-f1405f5bf8f6">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ce67d2e233d4f5786192e1687c3c262_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy0zLTEtMS0xMDgxNjE_1b04aacc-b1a3-44c6-802a-9f4485602fe0">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iee99b848e7d34f24ba7ebd4d2abf4f85_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy01LTEtMS0xMDgxNjE_ab49ffeb-c226-41ec-9098-af2cb2b9e376">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if950b033c22d4b22a7e329ed5dbe41cd_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy03LTEtMS0xMDgxNjE_a186f5b3-906e-4db0-b75a-0cfb8df71e1e">16.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i71c0ec50c43b41b5899fc5e10c1d9ea3_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy05LTEtMS0xMDgxNjE_454f9b38-cad1-4186-899e-6db11fb2c9fd">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5105f0204af64b01a45ffaaf2c96b86e_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy0xMS0xLTEtMTA4MTYx_f5e0a8c0-6229-4331-b2d6-1e0a4057fd7b">16.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifc42b30bb7694aa3bd4d198c2dc52e32_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC0xLTEtMS0xMDgxNjE_6a10a50b-a544-4429-92a6-d41924c7b8e1">49.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if5a6612cb27940cd836298ddf8f13245_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC0zLTEtMS0xMDgxNjE_e30e77ef-921e-4d84-bc65-35c248816ce1">190.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC01LTEtMS0xMDgxNjE_d16a6bf3-2349-4314-a31a-e10385548e4e">240.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if6fe41cba330404f809cbe23888df0e9_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC03LTEtMS0xMDgxNjE_c12db91d-038c-4712-8ed1-0d06a663803a">60.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia96662ac0ab84db9a8a6492b07c4e033_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC05LTEtMS0xMDgxNjE_9dfabd9d-5ec5-4c33-b895-3d1554b07cdc">268.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC0xMS0xLTEtMTA4MTYx_51a7363a-1475-4005-a350-9e99f7fcf672">329.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8e7025c3b25f4602939fc3db062b06cb_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItMS0xLTEtMTA4MTYx_95764707-14ad-4933-9fcd-3deb9e97a180">255.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i59ac47cd04fe4a45ba8a9128f2df0c0c_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItMy0xLTEtMTA4MTYx_f0f68f83-9d08-4e10-8bd5-8037b249158b">405.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if6605ab0b24d4a3a95cd07e88110dd0e_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItNS0xLTEtMTA4MTYx_cfa6fd52-5d3c-499d-82a7-d66a6595c049">660.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib714d01e5ecf4cd28cfdd767aab24593_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItNy0xLTEtMTA4MTYx_41f3765e-33cd-4738-a93f-10480c505291">252.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic74b2084ca8b4016920a9bb39463c71e_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItOS0xLTEtMTA4MTYx_1946bf2a-b208-465a-9a06-b7283fe36aac">337.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3ac0c2ed83d34c43b639039d2831ada9_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItMTEtMS0xLTEwODE2MQ_baa8bc96-82ef-4deb-a24e-7ee9c9925e60">589.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icb1d9ae26ce84cf1851284c7e4edc162_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtMS0xLTEtMTA4MTYx_2c6b693b-a18a-4922-b3b2-a974d1a1109e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0d2c7c6dafc46998c4e95a9750239ee_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtMy0xLTEtMTA4MTYx_dcaec87d-e17f-4bef-b94e-1ca204609541">90.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i94946a3df68a4894a63cc93522fd6ca4_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtNS0xLTEtMTA4MTYx_92919e42-65a5-4a0a-9c0a-2888da670845">90.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad57e6166b6f48cabbffd992ec0bae18_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtNy0xLTEtMTA4MTYx_03de4244-6a6e-41c8-a520-433c50eab372">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a8c2b7b92db42f19333bc4e4af5abf1_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtOS0xLTEtMTA4MTYx_d403faf0-a3c2-43d7-ae70-8078f01c0e59">283.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8e3af1259505476faa37180bca0dbed6_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtMTEtMS0xLTEwODE2MQ_2bdb2ca5-1af4-4f9f-8503-9a6a17a47005">283.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibb131a1d8ee2411bbdf86420dba67a16_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtMS0xLTEtMTA4MTYx_60259537-d62b-4c8b-b864-e67d4e70b037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id5748c1fd8864631b676f49aec67c5f9_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtMy0xLTEtMTA4MTYx_2ce200aa-6c26-4276-98f8-6dca4aa1a6e7">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3ae88a70cad04a6f9c132484c353e5b9_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtNS0xLTEtMTA4MTYx_86d3b11b-9dc4-4eea-ba73-9d45cd25ce63">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id5afd6d5f0de4b5a880e3f897b519fff_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtNy0xLTEtMTA4MTYx_64ef7bda-d982-438b-a81d-eff515fe28d7">81.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i759d3f20525a4e73a29ad36cd1f9ad52_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtOS0xLTEtMTA4MTYx_2c86ae04-ff39-4a75-8651-31d06b3b35e0">50.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30625a73d79a4164a68a490ce85445d6_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtMTEtMS0xLTEwODE2MQ_5cc6df8a-9db3-46ab-90d8-3faf2b815372">132.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total CDMO</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3d296d42d02f4c53851eb8bbaa2f0904_D20220101-20220930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtMS0xLTEtMTA4MTYx_e3c78a91-87c7-4f09-9d14-c7cd2e1e8c70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9444f3dda52346f994f9fa3d1d5f265e_D20220101-20220930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtMy0xLTEtMTA4MTYx_6bdcea6b-cc6b-420d-ab6a-eac360e71be9">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8eff28a2bc3a4e869ed6725ec343457b_D20220101-20220930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtNS0xLTEtMTA4MTYx_fcffcfda-fba0-4577-92d4-d77a4f408f21">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i230926cc93b94f13a0f1ea180f586c99_D20210101-20210930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtNy0xLTEtMTA4MTYx_bfb567b5-2585-4388-bb9f-388f305577c1">81.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifbfcd3defae147349f8488c0ed4ae6b3_D20210101-20210930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtOS0xLTEtMTA4MTYx_50262895-4d4e-4cd5-9547-11afc9c4cc1d">334.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e2dd808a6bb49acaba894087e88aab6_D20210101-20210930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtMTEtMS0xLTEwODE2MQ_312f42bc-a50d-42f2-9d33-b9c4d5b9b5b0">416.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icf3d857066a346c9b7cc2f77fc9cf913_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctMS0xLTEtMTA4MTYx_ab9c9a1d-88b9-422f-a36d-d3b03f76e337">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6f054a91031f430392248a4bca839f9f_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctMy0xLTEtMTA4MTYx_e169df40-0317-4a84-8c1e-c539f3492d15">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icc86efbf51c9459a924cb8855de7d59d_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctNS0xLTEtMTA4MTYx_35f1c9ed-d8f7-49bb-83e3-a2ecb8ce754e">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifb67dea42a90430caaa50cf5bb540f53_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctNy0xLTEtMTA4MTYx_021d0909-c017-46a5-907e-2bbf5ec9e1fd">60.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i15644a22cf32438bb4e89c230573cc53_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctOS0xLTEtMTA4MTYx_47670b40-6218-4fad-95a7-108a4f910ea3">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1dd3f76fb0234ae9898dcecdd750649a_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctMTEtMS0xLTEwODE2MQ_ed96c761-d9dd-45ff-bf8f-c7194ad1b7e1">63.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iee7392a5534e4fed8a494faf3156d30a_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtMS0xLTEtMTA4MTYx_b3730c86-ebc7-4d45-8475-8acd5a5bd735">286.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic7686e78d6544ad4ab6f238d59a463ae_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtMy0xLTEtMTA4MTYx_63f2f16c-6942-48b3-a033-440760ec5261">503.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtNS0xLTEtMTA4MTYx_491701f3-d402-44d1-ab06-b6db0cabee4d">790.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia0599ce5bf334bcd978cd677b9ce3488_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtNy0xLTEtMTA4MTYx_3241feb8-2e0d-4663-956c-c58e89e6d97d">395.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iac249b92a2c34f4786aaa61ef1798afc_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtOS0xLTEtMTA4MTYx_b2fbd5a2-41d4-4d89-bcd1-744e09cafa0f">674.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtMTEtMS0xLTEwODE2MQ_1c1bf3b3-099c-499f-b967-8540683ae8c5">1,069.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/><br/></span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2020, the Company, through its wholly-owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into a manufacturing services agreement with Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, for large-scale drug substance manufacturing of Johnson &amp; Johnson&#8217;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#8220;Product&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, the Company provided to Janssen a notice (the &#8220;Notice&#8221;) of material breach of the Agreement for, among other things, failure by Janssen (i) to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Agreement and (ii) to confirm Janssen&#8217;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Agreement and instead, wind-down the Agreement ahead of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i4c6ee586318b4348b552f6311e9394e2" continuedAt="ic91c7abfbd6146379d476c2309d48760"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#8220;Janssen Notice&#8221;) of the Agreement for asserted material breaches of the Agreement by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices ("cGMP") or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the Company&#8217;s breaches were not curable and that, therefore, termination of the Agreement would be effective as of July 6, 2022. The Company disputes Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result of the Company's alleged failure to perform under the Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process including through mediation and/or arbitration.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, there were no impacts on previously recognized revenue or depreciation related to the conclusion of the Agreement. As of September&#160;30, 2022, the Company has no billed or unbilled net accounts receivable related to the Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has $<ix:nonFraction unitRef="usd" contextRef="if052ae8be962412ca908a8ec55ce01bb_I20220930" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNTQ5NzU1ODQ5NzUz_4f303e3b-1983-4de2-b241-03e68206607d">131.0</ix:nonFraction>&#160;million of raw materials inventory recorded in its condensed consolidated balance sheet as of September&#160;30, 2022, representing materials purchased for the Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of this inventory as of September&#160;30, 2022, concluding that because the Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for any reason, the Company is entitled to payment from Janssen for these raw materials. Therefore, this inventory remains an asset on the condensed consolidated balance sheet as of September&#160;30, 2022. Additionally, the Company has an immaterial amount of non-cancelable orders as of September&#160;30, 2022 which have not been received and Janssen has not reimbursed. The Company also recorded approximately $<ix:nonFraction unitRef="usd" contextRef="if052ae8be962412ca908a8ec55ce01bb_I20220930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNTQ5NzU1ODQ5NzY5_7b85ea79-5b3d-4a49-8227-205bb85de184">13.6</ix:nonFraction>&#160;million to other assets, which relates to termination penalties and certain inventory related items. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BARDA COVID-19 Development Public-Private Partnership</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company announced the issuance of a task order under its existing Center for Innovation in Advanced Development and Manufacturing ("CIADM") agreement with BARDA for COVID-19 vaccine development and manufacturing (the "BARDA COVID-19 Development Public Private Partnership"). The BARDA COVID-19 Development Public Private Partnership is considered a lease and is accounted for under ASC 842. The initial task order had a contract value of up to $<ix:nonFraction unitRef="usd" contextRef="i3f1c052aa974422c8e8de6bf7e629008_I20201231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNDU4Mg_eb8d6a22-f237-4d26-96c8-60918e58ebb1">628.2</ix:nonFraction>&#160;million and included the reservation of manufacturing capacity and accelerated expansion of fill/finish capacity valued at $<ix:nonFraction unitRef="usd" contextRef="i4c15bfbd578f4b02a335a5f53693bd78_I20201231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNDcwMA_eec11a54-753e-4023-84a3-bf5e4fa24ced">542.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1cc548c971bc4ddab945aa7c2daa9c29_I20201231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNDcwNw_6718a735-5f43-43ee-a6a7-06fdd2ff0361">85.5</ix:nonFraction>&#160;million, respectively. Subsequently, the task order was expanded to include incremental capital activities which increased the value to </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i7eb263408fe5444cbc0c106687b0c0bf_I20211031" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNDgzOA_b028a9a4-9300-4757-8c0d-163259cea38d">650.8</ix:nonFraction>&#160;million. On November 1, 2021, the Compa</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ny and BARDA mutually agreed to the completion of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's CIADM contract and associated task orders, including the BARDA COVID-19 Development Public Private Partnership. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="ibb131a1d8ee2411bbdf86420dba67a16_D20220101-20220930" decimals="INF" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfMjE5OTAyMzI5MTcyMQ_5122b35f-1f7e-44bc-bdd8-fbd952f10cfb"><ix:nonFraction unitRef="usd" contextRef="i85d2fdbc895b41fe8983ba64d0d2ffb0_D20220701-20220930" decimals="INF" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfMjE5OTAyMzI5MTcyMQ_fbdddb62-4d2b-44c3-94dc-3bc373b83fef">no</ix:nonFraction></ix:nonFraction>t recognize lease revenues under this arrangement during the three and nine months ended September 30, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company reversed lease revenues of $<ix:nonFraction unitRef="usd" contextRef="if6ea4a6a0de647a8a6d921dd7b209282_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNTIwOQ_e38bb6f7-2ee4-498e-8a2c-6d22c97df2ab">86.0</ix:nonFraction> million and recognized lease revenues of $<ix:nonFraction unitRef="usd" contextRef="id5afd6d5f0de4b5a880e3f897b519fff_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNTIxNg_64ef7bda-d982-438b-a81d-eff515fe28d7">81.9</ix:nonFraction> million, respectively, related to this arrangement.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO operating leases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain multi-year CDMO service arrangements with commercial customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates <ix:nonNumeric contextRef="ib5f414c7b3a34d038d192fa7b90dcfbe_I20220930" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNTcxNQ_4f1ac461-c7d7-41a1-b502-00d9a70beab2">2.5</ix:nonNumeric> years. The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Excluding future amounts related to the Janssen Agreement as discussed above, the Company estimates future operating lease revenues to be $<ix:nonFraction unitRef="usd" contextRef="i44ef3a51186e41038ea49e018725fc47_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjAzMQ_61ec1c7d-d5fd-41da-857f-f9ad817c25a2">0.2</ix:nonFraction>&#160;million in the remainder of 2022, $<ix:nonFraction unitRef="usd" contextRef="i0c28ec30bdcd4241b718857d94f0738f_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjA2MA_1a762904-3274-4f3d-a88c-77522d9d2db6">5.1</ix:nonFraction>&#160;million in 2023, $<ix:nonFraction unitRef="usd" contextRef="i6d0613c15a9a4b2891e92b0cb74673fa_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjA3Mg_47bc7199-92a4-41a0-a633-821d3f7a7f8a">0.9</ix:nonFraction>&#160;million in 2024, $<ix:nonFraction unitRef="usd" contextRef="if50fd0c04e7b433595e1fc59565af1ac_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjA4NA_8aecbece-f5ef-4925-91db-0d422f503ad7">0.9</ix:nonFraction>&#160;million in 2025 and $<ix:nonFraction unitRef="usd" contextRef="ied97412e542e49649f895e9d8fca082b_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjEwNw_e39cfb72-0ec0-48bb-ad3b-8c06148bee34">2.7</ix:nonFraction>&#160;million in years beyon</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="ic91c7abfbd6146379d476c2309d48760"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price allocated to remaining performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company has future contract value on unsatisfied performance obligations of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjMwMg_a553a0b0-0427-49e7-932f-558836e4d7b2">453.9</ix:nonFraction> million associated with all arrangements entered into by the Company. The Company expects to recognize a majority of the $<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjQxOA_a553a0b0-0427-49e7-932f-558836e4d7b2">453.9</ix:nonFraction> million of unsatisfied performance obligations within the next <ix:nonNumeric contextRef="i49ec7f41ed1e466ea8c8265cc217d1c9_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjQ3Ng_4b28a74b-045b-4b49-ac94-bc963aadc2f5">24</ix:nonNumeric> months. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associat</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#8217;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNzQyMQ_37db5a46-01bd-40a3-8543-ca3378828d9c">33.9</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNzQyOA_14121eb1-94a7-45a0-8293-930f915cdd48">21.5</ix:nonFraction> million, respectively, of contract assets</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded within accounts receivable, net on the condensed consolidated balance sheets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the condensed consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM4Mw_75867040-2b35-4bbd-8181-102eeea20966" continuedAt="i36d4d2d1c00145e9ac77d63c89f36a26" escape="true">The following table presents the roll forward of the contract liability balances:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify"><ix:continuation id="i36d4d2d1c00145e9ac77d63c89f36a26"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.884%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjk0OWQ1MjIwNTIxODRhNTliY2M2N2Y5NWJkMjVjMTIwL3RhYmxlcmFuZ2U6OTQ5ZDUyMjA1MjE4NGE1OWJjYzY3Zjk1YmQyNWMxMjBfMS0yLTEtMS0xMDgxNjE_d2825968-d03a-496b-8857-4f9578e0a44b">16.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="ebs:ContractWithCustomerLiabilityAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjk0OWQ1MjIwNTIxODRhNTliY2M2N2Y5NWJkMjVjMTIwL3RhYmxlcmFuZ2U6OTQ5ZDUyMjA1MjE4NGE1OWJjYzY3Zjk1YmQyNWMxMjBfMi0yLTEtMS0xMDgxNjE_56b9d4f5-2cd9-4cf1-af5e-fd0eef305803">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="ebs:ContractWithCustomerLiabilityDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjk0OWQ1MjIwNTIxODRhNTliY2M2N2Y5NWJkMjVjMTIwL3RhYmxlcmFuZ2U6OTQ5ZDUyMjA1MjE4NGE1OWJjYzY3Zjk1YmQyNWMxMjBfMy0yLTEtMS0xMDgxNjE_8116fbd7-e3dc-4918-a8df-3e66567e8ecb">16.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjk0OWQ1MjIwNTIxODRhNTliY2M2N2Y5NWJkMjVjMTIwL3RhYmxlcmFuZ2U6OTQ5ZDUyMjA1MjE4NGE1OWJjYzY3Zjk1YmQyNWMxMjBfNC0yLTEtMS0xMDgxNjE_9cf4f4cc-8369-4bdf-ba92-cc18d63819e5">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the current portion of contract liabilities was $<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODA3OA_023097eb-2ef9-4b77-bbe0-49dd2f469712">24.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODA4NQ_190d407f-17bd-4d76-97da-dfa6d9377352">11.7</ix:nonFraction>&#160;million, respectively, and was included in other current liabilities on the balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></div><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="ebs:ScheduleOfAccountsReceivableNetTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM4OA_3dbace6e-4a30-45d8-8ca3-7792f99e13dc" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Billed, net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMS0yLTEtMS0xMDgxNjE_1700acaa-ab42-4c50-a886-c5308feed94d">119.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMS00LTEtMS0xMDgxNjE_2422676f-2b09-4e86-a407-922bd6a3f222">224.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMi0yLTEtMS0xMDgxNjE_989b6a56-4e22-46b8-862a-f820f73d9df7">72.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMi00LTEtMS0xMDgxNjE_e167deb7-33b1-4561-bdb1-1118b762c7af">49.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMy0yLTEtMS0xMDgxNjE_77a434b9-26fb-44d9-a299-cda54b02c802">191.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMy00LTEtMS0xMDgxNjE_6a961302-5ec6-4fa4-89f9-2ce890d02fe0">274.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the allowances for doubtful accounts was $<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM1NA_f6318cde-59d6-4056-90a9-d97fe1737edd">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM2MQ_b6c785e1-e6c0-4204-99bb-25b04283b876">3.2</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_70"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfNTk5_07ff004b-20f8-4370-8adc-7b5a2af3e52e" continuedAt="i31b48744ab38442a80f86a1e6e15c3f8" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="i31b48744ab38442a80f86a1e6e15c3f8"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated effective annual tax rate as of September&#160;30, 2022 and 2021 for the years ended December 31, 2022 and 2021, excluding the impact of discrete adjustments, was <ix:nonFraction unitRef="number" contextRef="if2e7ce5556ca4a7fb06da82e3898d7b2_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMTg3_c8507dd6-5c62-4508-acd9-7f244f3da1b9">3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3eabe1e8d9c443b4aba12a1f4dfe8104_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMTk0_94c9da9a-1d0e-451f-a565-1553056e1465">24</ix:nonFraction>%, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease in the estimated effective annual tax rate is primarily due to decreased profitability, the impact of certain permanent adjustments, and a valuation allowance charge. The Company recorded discrete tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMjY4_833a7ec2-cb4f-4b75-9110-9d0deefb9b16">10.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMjc1_c0b8ee71-0353-473f-99ca-88939a7a84bb">10.3</ix:nonFraction>&#160;million for the three and nine months ended September&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMzI0_06e60a94-e4b2-4fdf-8aeb-51e4a40a4c2c">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMzMx_3430f977-c03e-452d-b480-652268ec55e1">7.2</ix:nonFraction>&#160;million, for the three and nine months ended September&#160;30, 2021, respectively. The discrete tax benefit in 2022 was primarily due to return to provision adjustments and the benefit of the release of an indemnified uncertain tax position offset by share-based compensation activity. The net discrete benefits in 2021 were primarily due to share-based compensation activity.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> deductible. At each reporting period, the Company considers the scheduled reversal of deferred tax liabilities and assets, available taxes in carryback periods, tax planning strategies and projected future taxable income in making this assessment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company determined that it was more likely than not that deferred tax assets in the U.S. would not be realized due to reductions in estimates </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> future profitability in the U.S. Accordingly, the Company recorded a provision of $<ix:nonFraction unitRef="usd" contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfNDk0NzgwMjMzMTA3OA_72e5333c-e73e-4e84-a178-93225d60fa19">19.2</ix:nonFraction> million associated with the establishment of a valuation allowance on those deferred tax assets.</span></div></ix:continuation><div id="i9bec4b75ff354735b09dcc9c604dfa92_73"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RleHRyZWdpb246MDM1ZDFjMjQ4YmFjNDUzN2FmZTYwMDhhYzI4MjFkNWFfMTMwMw_7f0d82a6-7411-4adb-abc3-93a8b816c017" continuedAt="i8e0c3715bb7a4bcab863cf9e93b5ae04" escape="true">Net income (loss) per share</ix:nonNumeric></span></div><ix:continuation id="i8e0c3715bb7a4bcab863cf9e93b5ae04" continuedAt="i14a26988c9084ec6b389de52773d5e83"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RleHRyZWdpb246MDM1ZDFjMjQ4YmFjNDUzN2FmZTYwMDhhYzI4MjFkNWFfMTMwMA_fd1097a9-091b-4c39-b41a-f3cba8314f77" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net income (loss) per share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.273%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMy0xLTEtMS0xMDgxNjE_2d38d949-533f-40b6-b15f-f3713e508c9a">75.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMy0zLTEtMS0xMDgxNjE_a85819e8-8e18-41d3-ab77-061fe44c9d8a">32.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMy01LTEtMS0xMDgxNjE_0c1fb09a-6ae6-44fa-accf-3d79eed0240b">135.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMy03LTEtMS0xMDgxNjE_b30bdb0f-e594-4200-8308-ba89abf8457b">41.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted-average number of shares&#8212;basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNi0xLTEtMS0xMDgxNjE_04a63ac4-ddcb-46fb-b04d-fb1bad27675c">49.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNi0zLTEtMS0xMDgxNjE_fa28151c-2528-415e-b55c-ac7c11bc7db5">53.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNi01LTEtMS0xMDgxNjE_668ceebc-0faa-4967-a3a4-83dc57066d4c">50.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNi03LTEtMS0xMDgxNjE_cb2c4406-3006-4eb7-8d94-95af548e4c7a">53.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Dilutive securities&#8212;equity awards</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNy0xLTEtMS0xMDgxNjE_73627f6a-0d46-469a-b05c-ad985482e531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNy0zLTEtMS0xMDgxNjE_f6f680f4-ad2d-4cb8-a5ad-8e448cc5f51c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNy01LTEtMS0xMDgxNjE_b9cb315c-143b-4ae6-b609-a18969b8af43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNy03LTEtMS0xMDgxNjE_bf82b902-4cde-4d9e-8193-ebeaa6e7a999">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted-average number of shares&#8212;diluted</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfOC0xLTEtMS0xMDgxNjE_de5566c4-404b-4a02-92f7-1c0d5f75bd0c">49.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfOC0zLTEtMS0xMDgxNjE_6f7ac32e-cb05-40cb-8bef-5b561fe47281">53.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfOC01LTEtMS0xMDgxNjE_3db09b23-3db5-4d61-b52d-91960e691fea">50.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfOC03LTEtMS0xMDgxNjE_5604f6c5-81c1-44db-83b9-cb5372a9f663">54.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss) per share - basic</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTAtMS0xLTEtMTA4MTYx_0899720f-7187-49ac-87ad-48802a69f128">1.52</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTAtMy0xLTEtMTA4MTYx_9f18dbc4-432c-4cb0-83f5-f77c210c1903">0.61</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTAtNS0xLTEtMTA4MTYx_8764a2a5-bc7d-4f36-9242-458b5166a651">2.71</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTAtNy0xLTEtMTA4MTYx_7c2d6d94-d878-464d-9d6d-7bc1de4d6f6b">0.78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss) per share - diluted</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTEtMS0xLTEtMTA4MTYx_1529dd60-b266-4d24-9a1a-859642f79c9b">1.52</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTEtMy0xLTEtMTA4MTYx_fdd5441a-2fac-4746-bdce-4edddcccc5ef">0.61</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTEtNS0xLTEtMTA4MTYx_4d6dad44-41c2-4239-83cc-2b02db325c84">2.71</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTEtNy0xLTEtMTA4MTYx_fcd76b95-bc43-4ff4-b7cf-b753ab1ff37e">0.77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. No adjustment for the potential dilutive effect of dilutive securities is reported for the three and nine months ended September&#160;30, 2022 as the effect would have been anti-dilutive due to the Company's net loss.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i14a26988c9084ec6b389de52773d5e83"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price. <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RleHRyZWdpb246MDM1ZDFjMjQ4YmFjNDUzN2FmZTYwMDhhYzI4MjFkNWFfMTMwMQ_b07ce4c2-87c2-4138-a71f-c684e125c662" continuedAt="i661eeed89b974c59b94ae633556cfd41" escape="true">The following table presents the share-based awards that are not considered in the diluted income (loss) per share calculation generally because the exercise price of the awards was greater than the average per share closing price during the three and nine months ended September&#160;30, 2022 and 2021:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><ix:continuation id="i661eeed89b974c59b94ae633556cfd41"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:39.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Anti-dilutive stock awards</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOjUzZjU2ZWQ2MjNlOTQyNGE5OTQ3NTA2M2I1YmU4ODZmL3RhYmxlcmFuZ2U6NTNmNTZlZDYyM2U5NDI0YTk5NDc1MDYzYjViZTg4NmZfMi0xLTEtMS0xMDgxNjE_699f77ac-66b1-4928-bd11-8974f3d42f20">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOjUzZjU2ZWQ2MjNlOTQyNGE5OTQ3NTA2M2I1YmU4ODZmL3RhYmxlcmFuZ2U6NTNmNTZlZDYyM2U5NDI0YTk5NDc1MDYzYjViZTg4NmZfMi0zLTEtMS0xMDgxNjE_f06daa4d-553a-4b11-93b3-bb7a7333cf85">1.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOjUzZjU2ZWQ2MjNlOTQyNGE5OTQ3NTA2M2I1YmU4ODZmL3RhYmxlcmFuZ2U6NTNmNTZlZDYyM2U5NDI0YTk5NDc1MDYzYjViZTg4NmZfMi01LTEtMS0xMDgxNjE_37932ffa-6ab9-4fe3-80fd-cd01fb2057ad">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOjUzZjU2ZWQ2MjNlOTQyNGE5OTQ3NTA2M2I1YmU4ODZmL3RhYmxlcmFuZ2U6NTNmNTZlZDYyM2U5NDI0YTk5NDc1MDYzYjViZTg4NmZfMi03LTEtMS0xMDgxNjE_8782608b-3a17-48ef-bb96-13feeefd56f8">0.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i9bec4b75ff354735b09dcc9c604dfa92_76"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMTUzOQ_8c07a8bc-d24f-4ff4-b58d-7b5787643222" continuedAt="i8e15eef0f6374f609c8cd742299f76ef" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="i8e15eef0f6374f609c8cd742299f76ef" continuedAt="icbc2165774bd4a68ae768829e14cc478"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchase programs</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2021, the Company announced that its Board of Directors authorized management to repurchase up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ic4d3da6f40f548208c86343dfbb7f66e_I20211111" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfNTQ5NzU1ODE1NDM4_bcf0a8b3-991d-4254-a718-8ef703a45fc9">250.0</ix:nonFraction>&#160;million of Common Stock under a board-approved Share Repurchase Program, of which $<ix:nonFraction unitRef="usd" contextRef="if6a69a9d549d4a7f9e5cca915ff81ac2_D20211111-20220930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMjU1_9e80c821-e2e1-4217-9a19-42b5287dd493">187.9</ix:nonFraction>&#160;million has been utilized to purchase <ix:nonFraction unitRef="shares" contextRef="if6a69a9d549d4a7f9e5cca915ff81ac2_D20211111-20220930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMjg4_fb011bf4-8dc5-44d8-9a67-019e49a28f9b">4.4</ix:nonFraction>&#160;million shares as of September&#160;30, 2022. During the three months ended September&#160;30, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i6c17179d3e4b4293af0a828cab7b1e54_D20220701-20220930" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfNTQ5NzU1ODE1Njcz_4e671748-10a5-42e9-a473-c3fe227f9e62">no</ix:nonFraction> shares repurchased. During the nine months ended September&#160;30, 2022, the Company has utilized $<ix:nonFraction unitRef="usd" contextRef="i8990366d48494f1b8a20b74e61189484_D20220101-20220930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMzU4_558b5ab0-211c-45c2-bb0f-ce64d6a352b1">75.5</ix:nonFraction>&#160;million to purchase <ix:nonFraction unitRef="shares" contextRef="i8990366d48494f1b8a20b74e61189484_D20220101-20220930" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMzgw_c3dec7f6-0acb-4d9d-a297-de493ec24eaf">1.8</ix:nonFraction>&#160;million shares. The Share Repurchase Program does not obligate the Company to acquire any specific number of shares. Repurchased shares will be available for use in connection with the Company's stock plans and for other corporate purposes.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, the Company granted stock options to purchase <ix:nonFraction unitRef="shares" contextRef="i741c417cf3c5438e926f3c181037b75a_D20220101-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfNzIy_0e7af33d-305e-4254-92cd-c4d50f4abd74">0.7</ix:nonFraction>&#160;million shares of common stock and <ix:nonFraction unitRef="shares" contextRef="icec9923b70dd4963ad63bbf6fbe6313b_D20220101-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfNzUy_413d5adc-d05a-446c-b2a5-61db33a774e9">1.5</ix:nonFraction>&#160;million restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Typically, the stock option and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the <ix:nonNumeric contextRef="icec9923b70dd4963ad63bbf6fbe6313b_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMTU0NQ_953cc636-d966-4bc8-9ef5-e94171ed61ee">three-year</ix:nonNumeric> performance period based on the Company's results compared to the performance criteria. <ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMTUzOA_f1650d37-7b8c-4e39-b39e-ab3b5d9a321b" continuedAt="ica6c4028267f4aec84bc8ad7bfd6cb2a" escape="true">Share-based compensation expense was recorded in the following financial statement line items:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="ica6c4028267f4aec84bc8ad7bfd6cb2a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.273%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28b1f195ba044f8fba31c82ade107986_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMi0xLTEtMS0xMDgxNjE_3997e759-e9b4-4a16-8f5a-a075c93f6deb">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76cbbd4bcdbd481f9e12b0c3a5cf4906_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMi0zLTEtMS0xMDgxNjE_d6ab1792-0258-42b7-9fc2-7737d7d6548e">1.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic35e87d35bfd4ff89237fb26b10d3744_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMi01LTEtMS0xMDgxNjE_413bab59-4a65-4296-9238-5b7ed8d4970a">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i598359cdd71c4de1a7ee59cbd115af40_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMi03LTEtMS0xMDgxNjE_d3451414-46eb-4bea-b0b7-01857351099b">4.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iff9ad4afb37944048472b35bed2debf0_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMy0xLTEtMS0xMDgxNjE_5ea8bfd0-0df3-474a-9c79-c5d51d700ada">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic29a7152fbf34b57b22e53b5f6a77694_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMy0zLTEtMS0xMDgxNjE_1bff696e-e2b4-4cfc-adba-701353b3b180">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib20b602b02994e55bb8f5ff08e429097_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMy01LTEtMS0xMDgxNjE_f4a773bc-2a24-4326-afa8-35bb393001a4">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i37dbd3322fa84e95b69930efeffb24f6_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMy03LTEtMS0xMDgxNjE_e7ae48b8-d38e-4cd2-985b-7bf360022af6">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i19613f0852b447be92b4d26268de48b6_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNC0xLTEtMS0xMDgxNjE_0a7f06d3-d583-4de2-b6d5-ab6c4eae3ee9">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibefbe152ae4b4ce4a115b201334e73c7_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNC0zLTEtMS0xMDgxNjE_78528549-c85d-4961-bacf-8e50488aea60">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icd27e1e917ee436d8d215b793434f26a_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNC01LTEtMS0xMDgxNjE_404e5533-f589-481b-ab72-560a606dc7b4">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bff5d9f1c2e45429a4c8237c99b05c8_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNC03LTEtMS0xMDgxNjE_e0160318-7629-40cb-aa2c-08914cbfb0cd">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ica2181992bf34758ae89111c96b05c4a_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNS0xLTEtMS0xMDgxNjE_c19600d3-c11a-4e56-8c38-5ed78b7fab12">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i38e2b94c99ce4c32bf8a4a143327d9e3_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNS0zLTEtMS0xMDgxNjE_f771aa8a-ea84-40eb-8ac6-61c94a65e62e">7.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia02d17b7af424e47932221e5cb92610d_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNS01LTEtMS0xMDgxNjE_edee29bb-32de-4222-b6be-5165888888de">22.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22dbe6000d7d4fb6bb7bafebd2ab2977_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNS03LTEtMS0xMDgxNjE_4526048a-e165-4448-a888-6f10f86dad50">22.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNi0xLTEtMS0xMDgxNjE_f4daf2b1-cd77-4793-9d92-e69662708b8e">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNi0zLTEtMS0xMDgxNjE_7bc61830-33e5-42dd-983c-a9ed32f36f04">10.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNi01LTEtMS0xMDgxNjE_579c55c8-b6ae-4785-9033-c858c109d651">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNi03LTEtMS0xMDgxNjE_17427a8c-ac7c-432f-b693-ce5a085dd27f">32.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="icbc2165774bd4a68ae768829e14cc478" continuedAt="ibca6c991d74b45a9a276f9b5cd4f4b43"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss, net of tax</span></div><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMTU0Ng_9350e633-64d9-4107-afe2-40889998612c" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive loss, net of tax by component:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.254%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Defined Benefit Pension Plan</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, December&#160;31, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9f2c4b48c5bf44b583764343364acd18_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMi0yLTEtMS0xMDgxNjE_9e1bbd39-44bf-4fa8-bfea-1678b46f0def">4.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5e4037d8d3a6449baf24676b5b39d131_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMi00LTEtMS0xMDgxNjE_9b2655b1-4f80-484d-b86a-cf66b2133351">4.5</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i73cb1d2c06c148969484c4bf9e7eb0eb_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMi02LTEtMS0xMDgxNjE_0b41fb08-8724-48e7-8dd8-cc0fdd692958">7.6</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id4698414e7c1401c82d1bdd7bd331f7f_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMi04LTEtMS0xMDgxNjE_5c499fc2-d4fc-4601-bd47-304ec54fceb4">16.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMy00LTEtMS0xMDgxNjE_d025147a-880f-4805-b44a-b27223a446aa">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMy02LTEtMS0xMDgxNjE_db252e39-35c1-492f-9731-cac1c1ff5a93">0.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMy04LTEtMS0xMDgxNjE_c480dc90-650a-40ff-9e3c-41287c7a7599">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNC00LTEtMS0xMDgxNjE_e5f8aade-c9d5-4fdb-aae9-8f48d518e4d8">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNC04LTEtMS0xMDgxNjE_e18cd3d5-d9ce-4cc9-a0e5-f997020a863a">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6b67a9c1ec7349d18cbb84f1528227b8_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNS0yLTEtMS0xMDgxNjE_b8634afc-ff25-4c4d-8dd6-566d76b254a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNS00LTEtMS0xMDgxNjE_d2ae4efa-7e50-49ba-90f1-ad5e290a31e1">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNS02LTEtMS0xMDgxNjE_ab2c4fc3-3e0b-4203-a906-5d85b030a79a">0.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNS04LTEtMS0xMDgxNjE_a4d8109c-e059-4303-ae7a-552ce0260256">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id7b70bf533d44156972098e72400de35_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNi0yLTEtMS0xMDgxNjE_29a78287-01e6-4ebc-b4f7-78ee36292400">4.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2be39dc33a614a138b0a5fa59b102996_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNi00LTEtMS0xMDgxNjE_8df486cc-b3b6-4936-bd91-9f6a932c5296">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iced5a2acfffc465fa00678af5ae50f55_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNi02LTEtMS0xMDgxNjE_4e3aba7f-cb41-41ad-9d8b-490c1741b4db">8.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib32c62eb60fc4dc39b819eb33d2ecd33_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNi04LTEtMS0xMDgxNjE_a5b55a2c-4f90-4330-8380-8be91f7da4bb">5.2</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id7c28ab284a34fd99cbac681f30c7f59_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOC0yLTEtMS0xMDgxNjE_c7451da5-735b-4fef-8bed-60bbf7ff49b9">4.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaac12e2048894448abb1be8d9798b112_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOC00LTEtMS0xMDgxNjE_72d71ea1-4a24-4d04-a57c-071dafa4a951">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i67e98f514b5248989bc8c524e454fe4b_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOC02LTEtMS0xMDgxNjE_ddf2bf28-0dc9-4575-ba61-50e6faf8edc6">6.7</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i215adb10fcbf40a5a7ec2fc2088354e3_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOC04LTEtMS0xMDgxNjE_632e3aa6-c091-4861-9fae-d6b0a08114ff">6.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOS00LTEtMS0xMDgxNjE_2dcb0579-da1d-4f96-a1cf-504607e46daf">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOS02LTEtMS0xMDgxNjE_feb52855-9332-4c71-8c5a-f6e4baced55a">1.3</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOS04LTEtMS0xMDgxNjE_7ee4a978-2375-4561-8317-5d125e0cd270">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTAtNC0xLTEtMTA4MTYx_3f6ea8df-ec04-4053-b3a0-48057576bf2f">0.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTAtOC0xLTEtMTA4MTYx_c9938429-9c69-4731-a22b-61afd64fb2ae">0.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9f38ed14c4bf4de6b87cd4d750fc372c_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTEtMi0xLTEtMTA4MTYx_6b7ae297-6a85-4741-9481-084b622b3fb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTEtNC0xLTEtMTA4MTYx_174afa78-da1d-4e91-a012-98a93a863975">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTEtNi0xLTEtMTA4MTYx_92f4f2b0-7d4f-4c1d-8fbe-3cf8e63a2c3d">1.3</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTEtOC0xLTEtMTA4MTYx_3bec92d5-d767-40e4-81db-c244151f7ee5">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id7b70bf533d44156972098e72400de35_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTItMi0xLTEtMTA4MTYx_bda1f451-8f1d-4f91-afae-1409cc3b0f34">4.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2be39dc33a614a138b0a5fa59b102996_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTItNC0xLTEtMTA4MTYx_e7299448-0eb0-4e7f-9e35-52e80c7dfd47">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iced5a2acfffc465fa00678af5ae50f55_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTItNi0xLTEtMTA4MTYx_3106b705-300d-4da3-908a-e9c2c8af0868">8.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib32c62eb60fc4dc39b819eb33d2ecd33_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTItOC0xLTEtMTA4MTYx_fa5e4ebb-438b-47bd-8b9b-f120913c4d47">5.2</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, December&#160;31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i43143025a48b44c0a71392046d272649_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTQtMi0xLTEtMTA4MTYx_8a7357bf-ddee-455a-9bd5-f3432299c4c8">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9c5ea12368ef4ae3bb23c26ed19c8995_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTQtNC0xLTEtMTA4MTYx_6f825458-f8e8-431a-ae39-68bb8848ec56">11.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i63b169b1e50643f2add731b5b39f04c4_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTQtNi0xLTEtMTA4MTYx_ee3013b6-6658-4e27-9602-41a3f984a13b">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9334dc4e6d884a7cbb7f455bf2f9af61_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTQtOC0xLTEtMTA4MTYx_f43b9d3d-3f56-47cd-8ab4-b532a2f7a795">25.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTUtNC0xLTEtMTA4MTYx_deb8c285-a85b-4d31-bf9a-26b9b686dd5b">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTUtNi0xLTEtMTA4MTYx_cd99077c-0f34-4376-a34d-eae13357c606">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTUtOC0xLTEtMTA4MTYx_45eee84c-e1c8-4bb4-a659-db4bb89a0fee">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTYtNC0xLTEtMTA4MTYx_42b2d1fb-db22-49f3-b2a5-c795ccbc717b">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTYtOC0xLTEtMTA4MTYx_fe421dbe-6f2f-4640-83af-d54f74eb4779">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTctNC0xLTEtMTA4MTYx_ba2a4934-dbcc-4f4b-b28e-df28080ee98e">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTctNi0xLTEtMTA4MTYx_1d119008-65a2-484b-877b-94d4ab1346df">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTctOC0xLTEtMTA4MTYx_d5f61d4f-3f64-4e43-a59a-0d35484035e5">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie4f63f2b44854c31bb36daeefef5eb2a_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTgtMi0xLTEtMTA4MTYx_3fcb112f-97e4-46fb-840c-160bd6f2fbbc"><ix:nonFraction unitRef="usd" contextRef="ia5dd4144da824a99afec23d0225b46ec_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTgtMi0xLTEtMTA4MTYx_91ef1eb0-5a77-4e52-b794-da0674ad6fd5">7.7</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iccb2cd37199e4c108d7c667ed7106280_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTgtNC0xLTEtMTA4MTYx_ee52ce82-7a11-41f8-8d15-57e3312ca8c9">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0020c5f97ae64effb8f68a65a66da7b3_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTgtNi0xLTEtMTA4MTYx_38a42148-86d2-456e-805c-1376b7ee57cb">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i234810222a77469a8d310e47d2fa2f03_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTgtOC0xLTEtMTA4MTYx_60e0080d-6344-4fca-b40d-4ed00d3d796d">23.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, June&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i580d7f5f89514a8d9a9655a5cb84908b_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjAtMi0xLTEtMTA4MTYx_5c5a85eb-94e8-48eb-a98c-9c9635f9b21d">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5938e145ac85492f83e842b212b1e504_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjAtNC0xLTEtMTA4MTYx_f751e77a-1561-4f83-af2d-571c78d79a9c">6.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i563cf1b2420d41c1ba3c84e069d89c8a_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjAtNi0xLTEtMTA4MTYx_19e55076-08c5-4b1c-af46-20876ed61d14">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9e6a2188c167465d9720bcd73f722dcd_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjAtOC0xLTEtMTA4MTYx_a70cc2f6-0312-4667-b0f4-7b94b37fe573">22.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjEtNC0xLTEtMTA4MTYx_6cd593f6-a31f-4ff8-b443-fd6da1644d0d">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjEtNi0xLTEtMTA4MTYx_f15bc7a6-2757-4afd-8d7c-4560e2e0c157">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjEtOC0xLTEtMTA4MTYx_bc5b37c3-031e-4251-96eb-285bd9c30900">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjItNC0xLTEtMTA4MTYx_1d00677c-1a2b-4006-9538-fcf6ce8bb04f">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjItOC0xLTEtMTA4MTYx_c49e70ab-866c-4f7a-81e4-919846913aa9">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifd7dfbc7f90e4bce9bca0903609cb140_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjMtMi0xLTEtMTA4MTYx_298c4409-0c9c-414f-a610-de80dcce8fd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjMtNC0xLTEtMTA4MTYx_2874d438-563e-4552-8022-14a221b9c93f">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjMtNi0xLTEtMTA4MTYx_3d17bda9-d18e-4469-a827-5ced3ba0b070">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjMtOC0xLTEtMTA4MTYx_2efee48b-c4cf-4f96-baff-2622cb396c1e">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie4f63f2b44854c31bb36daeefef5eb2a_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjQtMi0xLTEtMTA4MTYx_b0ce805c-8b25-4db6-86ed-c47b70d79e58">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iccb2cd37199e4c108d7c667ed7106280_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjQtNC0xLTEtMTA4MTYx_cb4de046-4594-446b-91a5-3d1cf08a288b">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0020c5f97ae64effb8f68a65a66da7b3_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjQtNi0xLTEtMTA4MTYx_0e7945bc-e955-4ba5-86b8-e6bf74beece5">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i234810222a77469a8d310e47d2fa2f03_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjQtOC0xLTEtMTA4MTYx_ce2f7e97-2923-402e-b2f8-0663ffef181f">23.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="ibca6c991d74b45a9a276f9b5cd4f4b43"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMTU0Mw_032d0c6f-8620-4657-aa7d-a36c284979aa" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present the tax effects related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="33" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC0xLTEtMS0xMDgxNjE_e10ee30d-d0ff-40e3-bcc0-104673f343eb">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC0zLTEtMS0xMDgxNjE_99c7ac87-45ff-4951-9067-fe6f65058cbe">0.8</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC01LTEtMS0xMDgxNjE_004441f5-47c1-4b99-9235-5a202ecde45b">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC03LTEtMS0xMDgxNjE_8bfba810-cdf7-4423-b07e-568471fc86e6">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC05LTEtMS0xMDgxNjE_92bb5c04-6d69-44a0-8a69-b72a2b585d35">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC0xMS0xLTEtMTA4MTYx_9317f9c4-8881-49a7-8f11-0beaaf9e923c">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS0xLTEtMS0xMDgxNjE_12267fe6-d67e-42e2-b2f3-4f4e2cf45c77">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS0zLTEtMS0xMDgxNjE_30cb41c0-da66-4e00-aee5-4b7603831faa">1.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS01LTEtMS0xMDgxNjE_8e1d835b-1982-4a63-b3a2-f91bcdbb8842">1.3</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS03LTEtMS0xMDgxNjE_1f5d5ebf-a7b0-4d07-b66e-9070fe8a38e4">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS05LTEtMS0xMDgxNjE_6aad4633-fc28-42d9-81f7-87bb05945646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS0xMS0xLTEtMTA4MTYx_1524bf79-cb33-4ee6-9571-4570df02809e">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi0xLTEtMS0xMDgxNjE_af6d0e93-2c4a-42c3-a34e-740e3bd4f112">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi0zLTEtMS0xMDgxNjE_72bf2cca-3d83-40e9-8923-e101479c5cb8">2.2</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi01LTEtMS0xMDgxNjE_96347f54-f2f5-4c5d-9ac4-2967294bbc58">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi03LTEtMS0xMDgxNjE_287b035b-a083-40e3-8900-d72f59f40e49">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi05LTEtMS0xMDgxNjE_9a09e2df-31ec-4c4e-9c9b-26a58a9cd740">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi0xMS0xLTEtMTA4MTYx_7e5eb6b1-45ba-4d2b-8362-9fed4eafddbf">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="33" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC0xLTEtMS0xMDgxNjE_96d32b4f-8264-4e16-bc4d-634d1d9a1cc0">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC0zLTEtMS0xMDgxNjE_da5a0bf8-bcda-4211-b16a-3cc13185f0e0">4.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC01LTEtMS0xMDgxNjE_de822f8d-53ef-4008-a96e-06d662844493">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC03LTEtMS0xMDgxNjE_08fc474a-d028-4933-976c-91eb57184bd5">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC05LTEtMS0xMDgxNjE_52141188-fc53-48c9-a6fd-ecc07aa98796">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC0xMS0xLTEtMTA4MTYx_ba76517d-f932-4c14-a428-b78a324392aa">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS0xLTEtMS0xMDgxNjE_d23c2606-070a-47e0-95f2-38e3f8e252d2">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS0zLTEtMS0xMDgxNjE_bffca51a-447b-4e68-b086-e9b9bdea3be0">2.5</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS01LTEtMS0xMDgxNjE_3b1129c1-245a-4ed4-9ad8-ff70bd26d010">0.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS03LTEtMS0xMDgxNjE_7fb0072f-34a3-47da-8b8f-7b84c31cce60">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS05LTEtMS0xMDgxNjE_78a65b0a-a781-44f2-b9ec-9e4e709e08b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS0xMS0xLTEtMTA4MTYx_d2959959-1664-4bbf-b870-0b9725d09f91">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi0xLTEtMS0xMDgxNjE_3896e4ae-3981-455a-b31f-fcb0d2d2545c">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi0zLTEtMS0xMDgxNjE_54f45c77-1a7d-442a-a50d-0c7a832f513a">6.6</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi01LTEtMS0xMDgxNjE_d92a3cfc-057b-4a0e-941b-d57a66e61c16">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi03LTEtMS0xMDgxNjE_121a5d3d-28e8-4fc9-9286-145c68798245">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi05LTEtMS0xMDgxNjE_c1952fff-64e4-4dbc-879a-5117e275b133">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi0xMS0xLTEtMTA4MTYx_713e100d-0672-4c6f-bf53-d24fa7bb65b4">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9bec4b75ff354735b09dcc9c604dfa92_82"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTg4OA_0a8462d2-3ef9-4253-ba05-002d6a5eb49b" continuedAt="i0748ad4a561a4156b2e4c11b67dd210e" escape="true">Segment Information</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0748ad4a561a4156b2e4c11b67dd210e" continuedAt="i60260d1b257b4d7096a0c73b2cd30b37"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTg4NA_f84d7acc-5bac-41e5-bf34-41a1a29ea5bc" escape="true">The Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. During the first quarter of 2022, the Company revised the reporting that the CODM reviews in order to assess Company performance. The CODM manages the business with a focus on <ix:nonFraction unitRef="segment" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTY0OTI2NzQ0NDc4Mw_83999cc4-ff49-48c3-9fd0-714701d38614"><ix:nonFraction unitRef="segment" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTY0OTI2NzQ0NDc4Mw_ec67a01a-2c1e-4636-9b75-53d42761c544">two</ix:nonFraction></ix:nonFraction> reportable segments: 1) Products segment consisting of the Government - MCM and Commercial business lines and 2) Services segment focused on CDMO. The Company evaluates the performance of these reportable segments based on revenue and adjusted gross margin. Segment revenue includes external customer sales, but it does not include inter-segment services. Adjusted gross margin for each segment is segment revenue less segment cost of sales reduced for significant one-time events. We do not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. The Company has recast the related historical information for consistency.</ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i60260d1b257b4d7096a0c73b2cd30b37"><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTg4Ng_3fe0aee1-4c55-4fd7-ae90-1b3b145c7d1e" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables include segment revenues and a reconciliation of the Company's segment adjusted gross margin to the condensed consolidated statement of operations for each of the Company's reporting segments:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.256%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi0xLTEtMS0xMDgxNjE_2d162cbe-6320-4097-a4a8-08fbebc56007">186.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if7856b9f8f6d49b08fcf4b3d7646741d_D20220701-20220930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi0yLTEtMS0xMDgxNjE_99f6e57f-faaf-4708-993f-2bdd75c6e042">36.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a9d457339c7409eb76312880e7a9ad8_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi0zLTEtMS0xMDgxNjE_70968e20-78fe-49df-be22-84cf5182f91c">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi00LTEtMS0xMDgxNjE_6beeeb03-dc34-41b1-ad31-9eb6f49956dd">240.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi02LTEtMS0xMDgxNjE_4ca65b6f-4059-45bd-bb7b-7cfd934d18b4">270.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib3c3d681b76e40419af6d49da37af710_D20210701-20210930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi03LTEtMS0xMDgxNjE_576f694f-ac17-4605-ac9e-2e7116c8ad3c">41.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ied76f18f442f4ab69a0615274373a47b_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi04LTEtMS0xMDgxNjE_61dcdf4a-7e08-400c-a809-e4cbadd3ba1a">16.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi05LTEtMS0xMDgxNjE_5624700e-d7f7-4969-85b5-6b947bb65c49">329.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1bf31d14f117481daf2044655dd6e7ad_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMy0zLTEtMS0xMDgxNjE_948889bc-792c-4309-9c51-5defdcdb5024">17.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iee99b848e7d34f24ba7ebd4d2abf4f85_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMy00LTEtMS0xMDgxNjE_c3df8e30-c059-4597-932d-3906299f52d5">17.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i16214c20216b4ae9b2e00cb861cc0703_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMy04LTEtMS0xMDgxNjE_38b40244-c0c0-40ed-86b1-c82f54935306">16.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5105f0204af64b01a45ffaaf2c96b86e_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMy05LTEtMS0xMDgxNjE_c7fa5a24-bdf0-43af-a8a1-8fd3471b43ac">16.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i97728d771d6646119c3295cf7509eb03_D20220701-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNC0xLTEtMS0xMDgxNjE_77e84f39-05c5-41bf-8271-47234540729e">85.5</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i52646bb207c64e15902c5f7cebbaa5a9_D20220701-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNC00LTEtMS0xMDgxNjE_06c05f52-7c6b-45d7-b0b5-7c9967ad3529">85.5</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icae6520aeb4c4128b277d196b54c5c64_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNC02LTEtMS0xMDgxNjE_2bd96389-7afb-4e88-a8b9-7de89e4550c1">103.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3c1314a596fa4be2be2dbbc905e0e0ce_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNC05LTEtMS0xMDgxNjE_41f4bb2f-a2f0-4d26-836e-f5cd51149f8b">103.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie6d422d97fbb4e9c9744b614e2bf12b0_D20220701-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNS0yLTEtMS0xMDgxNjE_a371156f-e572-4c25-9d02-319ef0abd78a">63.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie3ea905c3a1d48a9a374e41f47cd9e7e_D20220701-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNS00LTEtMS0xMDgxNjE_e08a7515-a8c7-44ea-a2bc-ff0a146b043b">63.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7460e31e951a480b816dfe2ae15feac6_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNS03LTEtMS0xMDgxNjE_57fcfc30-3bb8-45c5-b99c-dd38b6ec9a05">114.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i293e88d455b74b89b6ea596c99361768_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNS05LTEtMS0xMDgxNjE_cf2a449a-7036-4088-bac9-90f52494e76c">114.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS0xLTEtMS0xMDgxNjE_0386eb6e-aec4-469b-a4bf-ca6fe2b153af">100.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if7856b9f8f6d49b08fcf4b3d7646741d_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS0yLTEtMS0xMDgxNjE_5e23b2fa-4f49-4445-8aba-596aeb5be351">26.7</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a9d457339c7409eb76312880e7a9ad8_D20220701-20220930" decimals="-5" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS0zLTEtMS0xMDgxNjE_4cb4a848-d7e6-47ba-a624-a5374c06f4d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS00LTEtMS0xMDgxNjE_e9191167-e7a8-4f64-a67a-04d1505e8c4f">74.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS02LTEtMS0xMDgxNjE_bb48413f-b651-4290-9d21-a1ba09d4906d">167.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib3c3d681b76e40419af6d49da37af710_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS03LTEtMS0xMDgxNjE_8a584b5d-9c43-4f13-b988-2d5aedc285c3">72.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ied76f18f442f4ab69a0615274373a47b_D20210701-20210930" decimals="-5" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS04LTEtMS0xMDgxNjE_a4405c66-e35d-4db2-96c8-fb1912cd555c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS05LTEtMS0xMDgxNjE_f8b6e66a-1e2a-4af1-8dc0-86f70954a2f5">94.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTAtMS0xLTEtMTA4MTYx_0f354caf-ed91-4bc1-addf-4b73b8d0aab4">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTAtNC0xLTEtMTA4MTYx_0d96a20f-775a-493c-bbf5-1f371dc4e1dd">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTAtNi0xLTEtMTA4MTYx_8e1acc7b-d7d1-4754-aaf8-288af73c4b7d">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTAtOS0xLTEtMTA4MTYx_614543f0-0055-4ffd-87d3-d3c49d16e720">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtMS0xLTEtMTA4MTYx_c707f263-6fd0-4618-ac41-d5fd64beec59">101.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if7856b9f8f6d49b08fcf4b3d7646741d_D20220701-20220930" decimals="-5" sign="-" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtMi0xLTEtMTA4MTYx_4d363ba7-ce7f-4597-bd86-c012443082ea">26.7</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a9d457339c7409eb76312880e7a9ad8_D20220701-20220930" decimals="-5" name="ebs:AdjustedGrossMargin" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtMy0xLTEtMTA4MTYx_18f605c8-f5cb-4ff4-bc49-cb5bdeb298a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtNC0xLTEtMTA4MTYx_234d61c4-8098-4fd0-abb8-79704cc58efc">74.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtNi0xLTEtMTA4MTYx_c31d7e7d-a96d-4033-9d0c-5e6eb1b25507">168.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib3c3d681b76e40419af6d49da37af710_D20210701-20210930" decimals="-5" sign="-" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtNy0xLTEtMTA4MTYx_c9dc0294-f716-461a-ab80-63527f05d926">72.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ied76f18f442f4ab69a0615274373a47b_D20210701-20210930" decimals="-5" name="ebs:AdjustedGrossMargin" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtOC0xLTEtMTA4MTYx_c2f2c2c1-c10c-4613-b5aa-dea33ce11ac1">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtOS0xLTEtMTA4MTYx_38ae4271-184c-44b0-9d62-42e22f821359">95.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Services revenue and Services adjusted gross margin for the three months ended September 30, 2021 includes the impact of the reversal of $<ix:nonFraction unitRef="usd" contextRef="if6ea4a6a0de647a8a6d921dd7b209282_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmJiN2E3ZWVhNDY5NDNhYjkzOTdjYjBmY2NmMTI5MmFfOTU_e38bb6f7-2ee4-498e-8a2c-6d22c97df2ab">86.0</ix:nonFraction> million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi0xLTEtMS0xMDgxNjE_ab19f9b9-6374-4cae-b2e7-b59bbdfb5d9e">660.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i801413427f1f43babdb24055bb4bd90c_D20220101-20220930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi0yLTEtMS0xMDgxNjE_eb4a9a6d-e51c-4729-8520-b3e659480101">95.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id4dc9efc2b614e0dab48fd0fdb3134a0_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi0zLTEtMS0xMDgxNjE_04348b45-fc8f-4688-9b88-08f9d0b0a447">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi00LTEtMS0xMDgxNjE_89473302-1410-4eaf-8edf-475a0178c819">790.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi02LTEtMS0xMDgxNjE_95bb1989-6e86-4dcf-ac52-d01a3b993e3c">589.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0058f71a7708496abfdf19ad817835bb_D20210101-20210930" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi03LTEtMS0xMDgxNjE_9bbb4c86-4a0e-4578-b3cf-4d6f2bdfe4ab">416.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3a9984fa01164445b43977c0e9fc6107_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi04LTEtMS0xMDgxNjE_065f20d2-6746-4765-bc97-b80897212d95">63.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi05LTEtMS0xMDgxNjE_01b02f00-4ae5-4432-a648-91ead8d23d8f">1,069.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia28dc2c9d43e4b13a7778805dc25c68c_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNC0zLTEtMS0xMDgxNjE_145e1f10-d84c-44cd-b9cf-1d27bd8d5d4d">34.3</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icc86efbf51c9459a924cb8855de7d59d_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNC00LTEtMS0xMDgxNjE_8f02af7a-6ebd-4fdd-a64e-817b26653778">34.3</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i32b2a80ee4ec410d9527e186fd40b2bd_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNC04LTEtMS0xMDgxNjE_685d10b8-3353-4d9d-963f-d3d8574bb4d0">63.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1dd3f76fb0234ae9898dcecdd750649a_D20210101-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNC05LTEtMS0xMDgxNjE_a3641b3b-103c-4b33-8e2f-6f34033455f0">63.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1a49e5be45554d6d948e7369dce4055d_D20220101-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNS0xLTEtMS0xMDgxNjE_84b89bf9-3832-4f94-9cd5-d8274d36be87">256.8</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if6605ab0b24d4a3a95cd07e88110dd0e_D20220101-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNS00LTEtMS0xMDgxNjE_65954fc1-acf6-43ad-bbd6-8f87a092ab9f">256.8</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia00293a7076049e7979650ad37c66b83_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNS02LTEtMS0xMDgxNjE_68aed353-0973-4794-b939-2a00f47aa588">237.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3ac0c2ed83d34c43b639039d2831ada9_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNS05LTEtMS0xMDgxNjE_17f6a868-326f-4d15-8f01-221e449b9b13">237.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie24035e19dcb4f0a9e08c4030356556d_D20220101-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNi0yLTEtMS0xMDgxNjE_e77877f0-e19e-4bd3-88ca-03a7716f9282">217.5</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i94946a3df68a4894a63cc93522fd6ca4_D20220101-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNi00LTEtMS0xMDgxNjE_d62b24df-e800-48c2-8d80-ba4991237bdb">217.5</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i03d9a1c9cc0b4c1281e5652109cbc1df_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNi03LTEtMS0xMDgxNjE_fea21cd4-7558-43d2-935f-757da44f2632">307.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8e3af1259505476faa37180bca0dbed6_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNi05LTEtMS0xMDgxNjE_c46f96b2-3a0e-4e7f-ad90-4d83f7e99440">307.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtMS0xLTEtMTA4MTYx_6d0cb131-be1a-4fe3-94e8-32fb97c6936d">403.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i801413427f1f43babdb24055bb4bd90c_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtMi0xLTEtMTA4MTYx_816e9a7d-ccac-4644-9584-27469093ca45">122.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id4dc9efc2b614e0dab48fd0fdb3134a0_D20220101-20220930" decimals="-5" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtMy0xLTEtMTA4MTYx_a8582d7a-ac55-443c-94ef-3044cd8e28af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtNC0xLTEtMTA4MTYx_e9e9e56d-a151-427d-ac73-6dde29d98a53">281.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtNi0xLTEtMTA4MTYx_e69ff9b2-8bd8-4844-8e74-f2199e83ff43">352.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0058f71a7708496abfdf19ad817835bb_D20210101-20210930" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtNy0xLTEtMTA4MTYx_79b71dd3-2261-4bde-81d2-8c5c8dd95834">108.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3a9984fa01164445b43977c0e9fc6107_D20210101-20210930" decimals="-5" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtOC0xLTEtMTA4MTYx_dbe6de92-bfd9-4919-bf83-845c551fa1a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtOS0xLTEtMTA4MTYx_8d823367-c3f0-4c91-b406-4b765cdc32a8">461.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTEtMS0xLTEtMTA4MTYx_2f6db2cc-10cb-405b-87e3-79aa2ba52145">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTEtNC0xLTEtMTA4MTYx_c558b472-a2ba-4525-b196-a9d72078a1d5">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTEtNi0xLTEtMTA4MTYx_f862972f-b50d-4a52-b3aa-92c053444bb0">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTEtOS0xLTEtMTA4MTYx_37231cb4-8216-44b3-87c1-6590ae81ec3e">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItMS0xLTEtMTA4MTYx_08110c9f-eef2-4497-9ce5-69946f8ac2bb">406.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i801413427f1f43babdb24055bb4bd90c_D20220101-20220930" decimals="-5" sign="-" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItMi0xLTEtMTA4MTYx_8d5758de-818e-4445-a0fa-3ff72a93b7dc">122.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id4dc9efc2b614e0dab48fd0fdb3134a0_D20220101-20220930" decimals="-5" name="ebs:AdjustedGrossMargin" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItMy0xLTEtMTA4MTYx_4c2b0960-ae77-4523-bec9-2f7985ddb545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItNC0xLTEtMTA4MTYx_002a2844-6f94-43ce-9cb2-5b1365609367">284.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItNi0xLTEtMTA4MTYx_3b6d7cb3-7b4f-4f49-9fcb-0dc17cf1b0f0">355.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0058f71a7708496abfdf19ad817835bb_D20210101-20210930" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItNy0xLTEtMTA4MTYx_3e9fd946-ea8a-4bd2-899a-44e0bc9fe5a0">108.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3a9984fa01164445b43977c0e9fc6107_D20210101-20210930" decimals="-5" name="ebs:AdjustedGrossMargin" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItOC0xLTEtMTA4MTYx_816b86de-3971-4694-beba-624287cde334">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItOS0xLTEtMTA4MTYx_2d1da0e2-f0aa-4346-8bed-aa8cc5043463">463.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"> Services revenue and Services adjusted gross margin for the nine months ended September 30, 2021 includes the impact of $<ix:nonFraction unitRef="usd" contextRef="id5afd6d5f0de4b5a880e3f897b519fff_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NDhiOTg2YmZjNjUxNDU2Yzg5ODdkYjEyMzZkOTdjY2NfOTU_64ef7bda-d982-438b-a81d-eff515fe28d7">81.9</ix:nonFraction> million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTg4Nw_30199d6b-5a9f-40df-b57c-599ef010e5df" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each segment:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.273%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Depreciation:</span></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfMy0xLTEtMS0xMDgxNjE_87caf461-6734-499c-8c7f-7f2e1ce87484">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfMy0zLTEtMS0xMDgxNjE_549d8cbd-43a8-49d0-8d08-5b1ccd3a0a64">5.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfMy01LTEtMS0xMDgxNjE_feaeba5c-8ae0-4611-b389-6820f22378ba">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfMy03LTEtMS0xMDgxNjE_4269cea5-1dd1-4f98-adfb-968d2ffefa62">20.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if7856b9f8f6d49b08fcf4b3d7646741d_D20220701-20220930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNC0xLTEtMS0xMDgxNjE_30aaaf25-9ec4-48fc-af92-8040ba245382">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib3c3d681b76e40419af6d49da37af710_D20210701-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNC0zLTEtMS0xMDgxNjE_67029964-31b0-4489-9ed2-9dc568aae4b9">8.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i801413427f1f43babdb24055bb4bd90c_D20220101-20220930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNC01LTEtMS0xMDgxNjE_0ffa2978-f403-4af2-98dd-15d1847d1ad2">34.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0058f71a7708496abfdf19ad817835bb_D20210101-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNC03LTEtMS0xMDgxNjE_a6ebcc7e-53f3-4011-9405-0b467bc444fe">21.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a9d457339c7409eb76312880e7a9ad8_D20220701-20220930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNS0xLTEtMS0xMDgxNjE_5b1385f9-feb9-4065-b090-1a9048ce8653">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ied76f18f442f4ab69a0615274373a47b_D20210701-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNS0zLTEtMS0xMDgxNjE_d84e8a6c-31d3-4de8-b216-5423221df6fe">1.0</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id4dc9efc2b614e0dab48fd0fdb3134a0_D20220101-20220930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNS01LTEtMS0xMDgxNjE_e131d2d9-cc6b-43b9-a20f-8d3f238e4181">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3a9984fa01164445b43977c0e9fc6107_D20210101-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNS03LTEtMS0xMDgxNjE_b04d51ff-87a1-4c9e-937c-f2ccd1ed8706">4.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNi0xLTEtMS0xMDgxNjE_b7971f11-da72-4a6f-8675-05b47efd66bc">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNi0zLTEtMS0xMDgxNjE_0268f370-f3b8-4fc6-bba1-24996aadefed">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNi01LTEtMS0xMDgxNjE_83acd299-ec0f-4028-a5e9-fac17628668a">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNi03LTEtMS0xMDgxNjE_ddfa8089-a141-48cb-9d7a-71287b0c1734">46.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its assets on a total company basis, not by operating segment, as the Company's operating assets are shared or commingled. Therefore, the Company's CODM does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_88"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84OC9mcmFnOjQwNmVhZjkxNzQxMTQ1ODBhZjhmMDJmZDQ0OWQzMjQxL3RleHRyZWdpb246NDA2ZWFmOTE3NDExNDU4MGFmOGYwMmZkNDQ5ZDMyNDFfODk2Nw_c6c8b62f-9656-493d-965a-92f790c6520f" continuedAt="i878f337d97324fb6b3c867863294dd29" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i878f337d97324fb6b3c867863294dd29" continuedAt="ia99e773fd32f448fb5914168f0f4b215"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities and shareholder litigation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock, seeking to pursue remedies under the Securities Exchange Act of 1934. These complaints were filed by Palm Tran, Inc. &#8211; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth; and Stephen M. Weiss, respectively. The complaints allege, among other things, that the defendants made false and misleading statements about the Company's manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as "CDMO Manufacturing Capabilities"). These cases were consolidated on December 23, 2021, under the caption </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Emergent BioSolutions Inc. Securities Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:21-cv-00955-PWG (the "Federal Securities Class Action"). The Lead Plaintiffs in the consolidated matter are Nova Scotia Health Employees&#8217; Pension Plan and The City of Fort Lauderdale Police &amp; Firefighters&#8217; Retirement System. The defendants filed a motion to dismiss on May 19, 2022 and the Lead Plaintiff filed an opposition to that motion on July 19, 2022. The defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the consolidated action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, Lincolnshire Police Pension Fund (&#8220;Lincolnshire&#8221;), and on August 16, 2021, Pooja Sayal, filed putative shareholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, the cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-PWG. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022 the Court approved the parties joint stipulation to and stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action. The defendants believe that the allegations in the complaints are without merit and intend to defend the matter vigorously.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, September 16, 2021 and November 12, 2021, putative shareholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp; Police Officers Pension Fund, respectively, in The Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Emergent BioSolutions, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#8217; filed a motion to dismiss the complaint. Ruling on this motion is stayed pursuant to a March 29, 2022 order staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, December 22, 2021 and January 18, 2022, putative shareholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the federal securities laws, each allegation related to the CDMO Manufacturing Capabilities.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings and Discovery, pursuant to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="ia99e773fd32f448fb5914168f0f4b215" continuedAt="i35a3800241b84181a486aa45246c8d77"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which the parties agreed to stay all proceedings until 30 calendar days after a ruling on the defendants&#8217; motion to dismiss the Federal Securities Class Action. The Court approved the Joint Stipulation on March 14, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above actions, the Company has received preliminary inquiries and subpoenas to produce documents related to these matters from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis, Senator Murray of the Committee on Health, Education, Labor and Pensions, the Department of Justice, the SEC, the Maryland Attorney General&#8217;s Office, and the New York Attorney General&#8217;s Office. The Company is producing and has produced documents as required in response and will continue to cooperate with these government inquiries.</span></div><div style="text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ANDA litigation - Teva 2mg</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i35a3800241b84181a486aa45246c8d77">In 2018, Teva Pharmaceuticals Industries Limited and Teva Pharmaceuticals USA (collectively, "Teva") provided a notice to Emergent Devices Inc., a subsidiary of Emergent formerly known as Adapt Pharma Inc. ("EBPA"); Emergent Operations Ireland Limited, a subsidiary of Emergent formerly known as Adapt Pharma Operations Limited ("EIRE"); and Opiant Pharmaceuticals Inc. ("Opiant"). The notice stated that Teva had filed an abbreviated new drug application ("ANDA") with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone HCI) Nasal Spray 2 mg/spray before the expiration of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#174;. Teva&#8217;s notice letter alleged that claims of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#174; were invalid and/or would not be infringed by the activities described in Teva&#8217;s ANDA. Emergent and Opiant filed complaints against Teva in the U.S. District Court for the District of New Jersey alleging infringement of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN. This case was dismissed July 27, 2022.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_91"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes and other financial information included elsewhere in this quarterly report on Form 10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. Some of the information contained in this discussion and analysis or set forth elsewhere in this quarterly report on Form 10-Q, includes information with respect to our plans and strategy for our business and financing, as well as forward-looking statements that involve risks and uncertainties. You should carefully review the "Special Note Regarding Forward-Looking Statements" and "Risk Factors" sections of this quarterly report on Form 10-Q for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_94"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS OVERVIEW</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (the Company or Emergent) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (CDMO) services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following five distinct PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; and acute/emergency care. We have a product portfolio of thirteen products that contribute a substantial portion of our revenue and are sold to government and commercial customers. We also have a product candidate that is procured under special circumstances by the U.S. government (USG), although it is not approved by the U.S. Food and Drug Administration (FDA). Additionally, we have a development pipeline consisting of a diversified mix of both pre-clinical and clinical stage product candidates. Finally, we have a fully-integrated portfolio of CDMO services. Our CDMO service offerings cover development services, drug substance manufacturing and drug product manufacturing and packaging. </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our product revenue comes from the following products and procured product candidates:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government - MCM products</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Anthrax vaccines, including our AV7909 (Anthrax vaccine adsorbed (AVA), adjuvanted) procured product candidate being developed as a next-generation anthrax vaccine for post-exposure prophylaxis and BioThrax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. AV7909 has not been approved by the FDA, but is procured by certain authorized government buyers for their use;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">ACAM2000</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">BAT</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of botulism; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">CNJ-016</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Raxibacumab injection, a fully human monoclonal antibody, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Anthrasil</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">RSDL</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Trobigard</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> atropine sulfate, obidoxime chloride AUTO-INJECTOR, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA, but is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">TEMBEXA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. It has been approved by the FDA for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates; and</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Ebanga&#8482; (ansuvimab-zykl, formerly referred to as mAb114) is a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the United States and Canada, and Ridgeback Biotherapeutics will serve as the global access partner for Ebanga&#8482;.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial products</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">NARCAN</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Vaxchora</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the only single-dose oral vaccine approved by the FDA and EMA for the prevention of cholera; and</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Vivotif</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services - contract development and manufacturing</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our services revenue consists of distinct but interrelated CDMO services</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations. These services, which we refer to as "molecule-to-market" offerings, employ diverse technology platforms (mammalian, microbial, viral and plasma) across a network of nine geographically distinct development and manufacturing sites operated by us for our internal products and pipeline candidates and third party CDMO services. We service both clinical-stage and commercial-stage projects for a variety of third-party customers, including government agencies, innovative pharmaceutical companies, and non-government organizations.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, the Company acquired from Chimerix the exclusive worldwide rights to brincidofovir, including TEMBEXA&#174; and other related assets. TEMBEXA is a medical countermeasure for smallpox approved by the FDA in June 2021.</span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_100"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FINANCIAL OPERATIONS OVERVIEW</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenues from the sale of our marketed products and procured product candidates which include vaccines, therapeutics and devices which have been described above. The USG is the largest purchaser of our MCM products and primarily purchases our products for the SNS, a national repository of medical countermeasures including critical antibiotics, vaccines, chemical antidotes, antitoxins and other critical medical supplies. The USG primarily purchases our products under long-term, firm fixed-price procurement contracts, generally with annual options. Our opioid overdose reversal product, NARCAN&#174; Nasal Spray, and our travel health products, Vivotif and Vaxchora, are sold commercially through wholesalers and distributors, physician-directed or standing order prescriptions at retail pharmacies and to state and local community healthcare agencies, practitioners and hospitals.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also generate revenue from our CDMO services provided at our established development and manufacturing infrastructure, technology platforms and expertise. Our services include a fully integrated molecule-to-market contract development and manufacturing services business offering across development </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services, drug substance and drug product for small to large pharmaceutical and biotechnology industry and government agencies/non-governmental organizations. From time to time, clients require suite reservations at our various manufacturing sites, which may be considered leases depending on the facts and circumstances. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received contracts and grants funding from the USG and other non-governmental organizations to perform research and development activities, particularly related to programs addressing certain CBRNE threats and EIDs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue, operating results and profitability vary quarterly based on the timing of production and deliveries, the timing of manufacturing services performed and the nature of providing large scale bundles of products and services as needs arise. We </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect continued variability in our quarterly financial statements.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cost of product sales and CDMO services</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The primary expenses that we incur to deliver our products consist of fixed and variable costs. We determine the cost of product sales for products sold during a reporting period based on the average manufacturing cost per unit in the period those units were manufactured. Fixed manufacturing costs include facilities, utilities and amortization of intangible assets. Variable manufacturing costs primarily consist of costs for materials and personnel-related expenses for direct and indirect manufacturing support staff, contract manufacturing operations, sales-based royalties, shipping and logistics. In addition to the fixed and variable manufacturing costs described above, the cost of product sales depends on utilization of available manufacturing capacity. For our commercial sales, other associated expenses include sales-based royalties (which include fair value adjustments associated with contingent consideration), shipping and logistics.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CDMO</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The primary expenses that we incur to deliver our CDMO services consist of fixed and variable costs. We operate five facilities that perform manufacturing activities for CDMO services customers. We use the same manufacturing facilities and methods of production for our own products as well as for fulfillment of our CDMO service contracts. Our manufacturing process includes the production of bulk material and performing &#8220;fill/finish&#8221; work for containment and distribution of biological products. For &#8220;fill finish&#8221; customers, we receive work in process inventory to be prepared for distribution. When producing bulk material, we generally procure raw materials, manufacture the product and retain the risk of loss through the manufacturing and review process until delivery.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research and development expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Our research and development expenses consist primarily of:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">personnel-related expenses;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">fees to professional service providers for, among other things, analytical testing, independent monitoring or other administration of our clinical trials and obtaining and evaluating data from our clinical trials and non-clinical studies;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">costs of CDMO services for clinical trial material; and</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">costs of materials and equipment used in clinical trials and research and development.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many cases, we plan to seek funding for development activities from external sources and third parties, such as governments and non-governmental organizations, or through collaborative partnerships. We expect our research and development spending will be dependent upon such factors as the results from our clinical trials, the availability of reimbursement of research and development spending, the number of product candidates under development, the size, structure and duration of any clinical programs that we may initiate, the costs associated with manufacturing and development of our product candidates on a large-scale basis for later stage clinical trials and our ability to use or rely on data generated by government agencies.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Selling, general and administrative expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel-related costs and professional fees in support of our executives, sales and marketing, business development, government affairs, finance, accounting, information technology, legal, human resource functions and other corporate functions. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty in income taxes is accounted for using a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We recognize in our financial statements the impact of a tax position if that position is more likely than not of being sustained on audit, based on the technical merits of the position.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the assumptions and estimates related to the provision for income taxes are critical to the Company&#8217;s results of operations. </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_103"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and exp</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enses. Actual results may differ from these estimates. There have been no significant changes to our critical accounting policies and estimates contained in "Critical Accounting Policies and Estimates" in the Management's Discussion and Analysis, in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.</span></div><div style="margin-bottom:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please see Note 2, "Basis of presentation and principles of consolidation", in Part I item 1, of this Quarterly Report on Form 10-Q. </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_106"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="21" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="21" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$ Change</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">% Change</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$ Change</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Product sales, net:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Nasal naloxone products</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">87.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">133.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(45.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">282.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">313.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(31.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">ACAM2000</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">49.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">80.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(31.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">63.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">80.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(17.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Anthrax vaccines</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">24.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">15.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">223.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">122.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">101.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other product sales</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">40.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(15.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">91.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">73.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total product sales, net</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">186.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">270.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(84.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">660.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">589.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">70.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">112.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(76.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">90.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">283.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(193.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(71.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">71.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">132.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(127.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(96)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">95.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">416.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(320.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">17.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">34.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">63.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(29.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">240.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">329.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(89.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">790.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,069.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(279.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">85.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">103.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(17.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">256.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">237.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">19.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">63.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">114.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(51.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">217.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">307.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(90.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">39.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">49.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(10.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">135.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">151.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(15.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">80.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">82.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">246.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">254.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">14.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">14.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">42.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">44.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">282.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">363.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(81.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">897.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">994.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(96.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(42.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(34.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(107.6)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">75.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(182.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(24.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(25.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(13.4)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(11.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(18.4)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(15.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(21.9)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(10.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(11.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(42.9)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(28.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(14.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(63.9)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(45.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(18.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(150.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">46.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(197.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Income tax benefit (provision)</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(11.8)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">12.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(24.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">14.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">20.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(75.7)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(32.7)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(43.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(135.8)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(177.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM</span></td></tr><tr style="height:8pt"><td colspan="48" style="padding:0 1pt"></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">NM - Not meaningful</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenues</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220930_g2.jpg" alt="ebs-20220930_g2.jpg" style="height:587px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legend</span></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Nasal naloxone products</span></td><td colspan="3" style="background-color:#19415e;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other product sales</span></td></tr><tr><td colspan="3" style="background-color:#f7876d;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">ACAM2000</span></td><td colspan="3" style="background-color:#5e838a;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO</span></td></tr><tr><td colspan="3" style="background-color:#ababaa;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Anthrax vaccines</span></td><td colspan="3" style="background-color:#133146;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product sales, net</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anthrax vaccines</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax vaccine sales increased $8.6 million to $24.2 million for the three months ended September 30, 2022. The increase in sales for the three months ended September 30, 2022 was primarily due to an increase in the number of doses sold as a result of the timing of deliveries to the USG. </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthrax vaccine sales increased $101.3 million to $223.4 million for the nine months ended September 30, 2022. The increase in sales for the nine months ended September 30, 2022 was primarily due to an increase in the number of doses sold as a result of the timing of deliveries to the USG. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price per unit of Anthrax vaccines was largely consistent period over period. Anthrax vaccine product sales are made under annual purchase options exercised by the USG. Fluctuations in revenues result from the timing of the exercise of annual purchase options and the USG purchases and Company delivery of orders that follow. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nasal naloxone products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasal naloxone products sales decreased $45.4 million to $87.9 million for the three months ended September 30, 2022. The decrease in sales for the three months ended September 30, 2022 was driven by a reduction in commercial retail sales following the launch of a generic version of NARCAN Nasal Spray 4mg in December 2021, partially offset by strong growth in unit sales of NARCAN Nasal Spray to U.S. public interest customers, as well as from sales of the authorized generic product licensed to Sandoz which launched in December 2021. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasal naloxone products sales decreased $31.1 million to $282.6 million for the nine months ended September 30, 2022. The decrease in sales for the nine months ended September 30, 2022 was driven by a reduction in commercial retail sales following the launch of a generic version of NARCAN Nasal Spray 4mg in December 2021, partially offset by increase in US public interest, Canadian and authorized generic sales.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ACAM2000</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACAM2000 sales decreased $31.7 million to $49.0 million for the three months ended September 30, 2022. The decrease was due to lower number of units sold to the USG, partially offset by an increased number of units sold to non-US customers at a higher price per unit. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACAM2000 sales decreased $17.3 million to $63.4 million for the nine months ended September 30, 2022. The decrease in sales for the nine months ended September 30, 2022 was due to a lower number of units sold to the USG, partially offset by an increased number of units sold to non-US customers at a higher price per unit. </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other product sales</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales decreased $15.8 million to $25.1 million for the three months ended September 30, 2022. The decrease in sales for the three months ended September 30, 2022 was primarily due to reduced VIG and BAT sales due to timing of deliveries, partially offset by an increase in Anthrasil, RSDL and Vivotif sales. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales increased $18.0 million to $91.1 million for the nine months ended September 30, 2022. The increase in sales for the nine months ended September 30, 2022 was primarily due to increased sales of Vivotif, BAT, and Anthrasil.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CDMO</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO services revenues decreased $76.4 million to $36.2 million for the three months ended September 30, 2022. The decrease in revenues for the three months ended September 30, 2022 is largely due to reduced production activities at the Company's Bayview facility as a result of a halt in manufacturing under the Janssen contract which began in the first quarter 2022 and no activities under the AstraZeneca contract in 2022. The combined services revenues from the Janssen and AstraZeneca contracts decreased $59.1&#160;million during the three months ended September 30, 2022. Additionally, the Company's Camden facility had reduced production. The declines were partially offset by an increase in services revenues earned at the Company's Winnipeg facility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO services revenues decreased $193.0 million to $90.7 million for the nine months ended September 30, 2022. The decrease in revenues for the nine months ended September 30, 2022 is largely due to reduced production activities at the Company's Bayview facility as a result of a halt in manufacturing under the Janssen contract which began in the first quarter 2022 and no activities under the AstraZeneca contract in 2022. The combined services revenues from the Janssen and AstraZeneca contracts decreased $169.6&#160;million during the nine months ended September 30, 2022. Additionally, the Company's Camden facility had reduced production. The decreases were partially offset by an increase in manufacturing activities at the Company's Winnipeg facility mentioned above. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO leases revenues increased $71.2 million to $0.2 million for the three months ended September </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30, 2022. The increase in revenues for the three months ended September 30, 2022 was primarily due to the reversal of $86.0 million during the three months ended September 30, 2021 associated with the completion of our COVID-19 development public-private partnership with BARDA in November 2021, partially offset by reduced lease revenues under the Janssen contract of $15.1&#160;million. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO leases revenues decreased $127.9 million to $4.7 million for the nine months ended September 30, 2022. The decrease in revenues for the nine months ended September 30, 2022 was primarily due to a reduction of $81.9 million associated with the completion of our COVID-19 development public-private partnership with BARDA in November 2021 and reduced lease revenues under the Janssen contract of $46.7&#160;million. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants revenues were consistent for the three months ended September 30, 2022. Contracts and grants revenues decreased $29.3 million to $34.3 million for the nine months ended September 30, 2022. The decrease in revenues for the nine months ended September 30, 2022 was largely due to BARDA's completion of the Center of Innovation and Advanced Development and Manufacturing agreement in November 2021 as well as decreases in development activities associated with various other externally funded research and development projects, most notably the Company's COVID-HIG therapeutic product candidate, as well as decreases in development activities for AV7909. Decreases were partially offset by revenue increases relating to indirect rate adjustments during the quarter.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of product sales</span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220930_g3.jpg" alt="ebs-20220930_g3.jpg" style="height:239px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales </span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">l</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Gross profit margin for Product segment</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales decreased $17.7 million to $85.5 million for the three months ended September 30, 2022. The decrease was primarily due to a decrease in product sales. The decrease in gross profit margin for the Product segment for the three months ended September 30, 2022 was due to lower margin for Nasal naloxone products. Cost of product sales increased $19.8 million to $256.8 million for the nine months ended September 30, 2022. The increase was primarily due to an increase in products sales. The increase in gross profit margin for the Product segment for the nine months ended September 30, 2022 was largely due to a favorable product revenue mix which was weighted more heavily to higher margin products. </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of CDMO</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> s</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ervices</span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220930_g4.jpg" alt="ebs-20220930_g4.jpg" style="height:239px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO services</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">l</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Gross profit margin for Services segment</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#929292;font-family:'Wingdings',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">l</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Not meaningful</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of CDMO services decreased $51.2 million to $63.1 million for the three months ended September 30, 2022. The decrease is primarily due to reduced production activities across our CDMO network in Q3 2022 compared with Q3 2021 resulting in decreased raw materials consumption. These decreases were partially offset by the Company's Camden facility due to additional investments in quality enhancement and improvement initiatives. Cost of CDMO services decreased $90.1 million to $217.5 million for the nine months ended September 30, 2022. The decrease is primarily due to reduced production activities across our CDMO network, as well as a $41.5 million inventory write-off in Q2 2021. The decrease in gross profit margin for the Services segment was also impacted by the completion of the BARDA lease in November 2021.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development expense</span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220930_g5.jpg" alt="ebs-20220930_g5.jpg" style="height:238px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Research and development expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased $10.4 million to $39.2 million for the three months ended September 30, 2022. The decrease was primarily due to a decrease in spending for the Company's COVID therapeutic product candidates along with a number of other developmental activities, partially offset by an increase in costs associated with the Company's Phase 3 study of our chikungunya virus-like particle vaccine candidate. Research and development expense decreased $15.6 million to $135.4 million for the nine months ended September 30, 2022. The decrease was primarily due to a decrease in spending for the Company's COVID therapeutic product candidates along with a number of other developmental activities, partially offset by an increase in costs associated with the Company's Phase 3 study of our chikungunya virus-like particle vaccine candidate.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220930_g6.jpg" alt="ebs-20220930_g6.jpg" style="height:233px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">l</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">SG&amp;A as a percentage of total revenue</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses decreased $1.9 million to $80.2 million for the three months ended September 30, 2022. The decrease was due to lower professional services and marketing expenses partially offset by increased employee costs, primarily due to increased travel. Selling, general and administrative expenses decreased $8.1 million to $246.1 million for the nine months ended September 30, 2022. The decrease was due to lower professional services and marketing expenses partially offset by increased employee costs, primarily due to increased travel costs. Selling, general and administrative costs as a percentage of total revenue increased 8.4% and 7.3% for the three and nine months ended September&#160;30, 2022. The increase was due to a decrease in revenues during the periods, partially offset by a decrease in selling, general and administrative expenses during the periods. </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of intangible assets</span></div><div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"><img src="ebs-20220930_g7.jpg" alt="ebs-20220930_g7.jpg" style="height:233px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amortization expense</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets and the composition of intangible assets amortized during the three and nine months ended September&#160;30, 2022 was consistent with the three and nine months ended September&#160;30, 2021.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other income (expense), net</span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220930_g8.jpg" alt="ebs-20220930_g8.jpg" style="height:233px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#5e838a;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other income (expense), net</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net decreased $11.1 million to an expense of $21.9 million for the three months ended September 30, 2022. The decrease was primarily due to a write-off of a tax indemnity receivable, which is offset in income tax expense (benefit), and unrealized foreign currency losses recorded related to the remeasurement of certain intercompany balances. Interest expense was largely consistent between periods. Other income (expense), net decreased $14.6 million to an expense of $42.9 </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million for the nine months ended September 30, 2022. The decrease was due to a write-off of a tax indemnity receivable, which is offset in income tax expense (benefit), and unrealized foreign currency losses recorded related to the remeasurement of certain intercompany balances. Interest expense was largely consistent between periods.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income tax expense (benefit)</span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220930_g9.jpg" alt="ebs-20220930_g9.jpg" style="height:226px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">l</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Effective tax rate</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated effective annual tax rate as of September&#160;30, 2022 and 2021 for the years ended December 31, 2022 and 2021, excluding the impact of discrete adjustments, was 3% and 24%, respectively. The decrease in the estimated effective annual tax rate is primarily due to decreased profitability, the impact of certain permanent adjustments, and a valuation allowance charge. The Company recorded discrete tax benefits of $10.9 million and $10.3&#160;million for the three and nine months ended September&#160;30, 2022, respectively, and $1.7 million and $7.2&#160;million for the three and nine months ended September&#160;30, 2021, respectively. The discrete tax benefit in 2022 was primarily due to return to provision adjustments and the benefit of the release of an indemnified uncertain tax position offset by share-based compensation activity. The net discrete benefits in 2021 were primarily due to share-based compensation activity.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit decreased $24.6 million to an income tax expense of $11.8 million for the three months ended September 30, 2022. The decrease in tax benefit was due to a lower estimated effective annual tax rate. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit increased $20.0 million from an income tax expense of $5.3 million to an income tax benefit of $14.7 million for the nine months ended September 30, 2022. The increase in income tax </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefit is largely due to the increase in net loss before income taxes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. At each reporting period, the Company considers the scheduled reversal of deferred tax liabilities and assets, available taxes in carryback periods, tax planning strategies and projected future taxable income in making this assessment.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company determined that it was more likely than not that deferred tax assets in the U.S. would not be realized due to reductions in estimates of future profitability in the U.S. Accordingly, the Company recorded a provision of $19.2 million associated with the establishment of a valuation allowance on those deferred tax assets.</span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_112"></div></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Change %</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Financial assets:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">240.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">576.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Borrowings:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Debt, current portion</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">21.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Debt, net of current portion</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,032.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">809.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total borrowings</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,053.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">841.0&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Working capital:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Current assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,118.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,272.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">268.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">373.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(28)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total working capital</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">850.1&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">898.3&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Sources of liquidity</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operating and capital expenditures through cash on hand, cash from operations, debt financing and contracts and grants development funding. We also obtain financing from the sale of our common stock upon exercise of stock options. We have operated profitably for each of the last five annual fiscal years through the period ended December&#160;31, 2021. As of September&#160;30, 2022, we had unrestricted cash and cash equivalents of $240.9 million and capacity under our revolving credit facility of $360.7&#160;million.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Going Concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, there is $238.0&#160;million outstanding on the revolver loan and $371.3&#160;million on the term loan that matures in October 2023, which is within one year of the date that the consolidated financial statements are issued for the quarter ended September&#160;30, 2022. The Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation considered the potential mitigating effect of management&#8217;s plans that have not been fully implemented. Management may evaluate the mitigating effect of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern. The Company's plan to alleviate the substantial doubt includes amending its existing revolver loan and term loan that are due October 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company is in the process of and expects to replace the current credit facility before it matures, management cannot make the assumption that it is probable that the Company will be able to obtain such debt refinancing on commercially reasonable terms or at all until the new credit facility is in place. The Company is currently working with its lenders and expects to refinance the credit facility with revised terms and conditions. The extent to which the Company will be able to affect such refinancing, replacement or maturity extension on terms that are favorable or at all is dependent on a number of uncertain factors, including then-prevailing credit and other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, disruptions or volatility caused by factors such as COVID-19, regional conflicts, inflation, and supply chain disruptions. In addition, rising interest rates could limit our ability to refinance our existing credit facility when it matures or cause us to pay higher interest rates upon refinancing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the replacement of the Company&#8217;s current debt facility is conditional upon the execution of agreements with new or existing third parties, which are considered outside of the Company&#8217;s control, until such time as they are completed, the refinancing cannot be considered to be probable to occur as of the date of this report. The Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating activities</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(126.9)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(335.9)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(178.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">128.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(31.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:9pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(335.3)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(217.5)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating activities</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $126.9 million for the nine months ended September 30, 2022 was due to a net income excluding non-cash items of $46.8&#160;million offset by negative working capital changes of $173.7&#160;million due to increases in inventory and an increase in payments for our contingent consideration and other accrued expenses, partially offset by collections on receivables.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $7.9 million for the nine months ended September 30, 2021 was due to net income excluding non-cash items of $266.0&#160;million offset by negative working capital changes of $273.9&#160;million due to increases in receivables, the accumulation of inventory and prepaid expenses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $119.0 million from cash used in operating activities of $7.9 million to cash used in operating activities of $126.9 million is due to a decrease in net income excluding non-cash items of $219.2&#160;million partially offset by an increase in working capital changes of $100.2&#160;million.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities relates to purchases of property, plant and equipment as well as asset acquisitions and was $335.9 million and $178.3 million for the nine months ended September 30, 2022 and 2021, respectively. The cash used in investing activities increased during the nine months ended September 30, 2022 largely due the acquisition of TEMBEXA&#174; during the three months ended September 30, 2022. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing activities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $128.1 million for the nine months ended September 30, 2022 was primarily due proceeds from our revolving credit facility of $238.0&#160;million, partially offset by repurchases of stock of $81.9 million and payments on debt of $25.3&#160;million.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities of $31.0 million for the nine months ended September 30, 2021 was primarily due to payments on debt of $27.5&#160;million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $159.1 million of cash provided by financing activities is largely due proceeds from our revolving credit facility of $238.0 million, partially offset by an increase in cash used for repurchases of stock of $81.9 million.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding requirements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to fund our anticipated operating expenses, capital expenditures and debt service requirements from the following sources:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">existing cash and cash equivalents;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">net proceeds from the sale of our products and CDMO services;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">development contracts and grants funding; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">our Senior Secured Credit Facilities and any other lines of credit we may establish from time to time.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous risks and uncertainties associated with product sales, delivery of CDMO services and the development and commercialization of our product candidates. We may seek additional external financing to provide additional financial flexibility. Our future capital requirements will depend on many factors, including (but not limited to):</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the level, timing and cost of product sales and cost of contract development and manufacturing services;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the payment obligations under our indebtedness;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the scope, progress, results and costs of our development activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs;</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the extent to which we repurchase additional shares of our common stock under our current share repurchase program; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the costs of commercialization activities, including product marketing, sales and distribution.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans or collaboration and licensing arrangements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds by issuing equity securities, our stockholders may experience dilution. Public or bank debt financing, if available, may involve agreements that include covenants, like those contained in our Senior Unsecured Notes due 2028 and the Senior Secured Credit Facilities, which could limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities, buying back shares or declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions, including market volatility and adverse impacts on financial markets may make it more difficult to obtain financing on attractive terms, or at all. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Unused credit capacity</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available room under the revolving credit facility for the periods ended September&#160;30, 2022 and December&#160;31, 2021 was:</span></div><div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total Capacity</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Outstanding Letters of Credit</span></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Outstanding Indebtedness on Revolving Credit Facility</span></div></td><td colspan="3" style="background-color:#19415e;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Unused Capacity</span></td></tr><tr><td colspan="3" style="background-color:#19415e;border-left:0.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;border-right:0.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$600.0</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">238.0</span></td><td colspan="3" style="border-right:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$360.7</span></td></tr><tr><td colspan="3" style="background-color:#19415e;border-left:0.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#19415e;border-right:0.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$600.0</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-right:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$597.7</span></td></tr></table></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_115"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET&#160;RISK</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of additional risks arising from our operations, see &#8220;Item&#160;1A-Risk Factors&#8221; of this Quarterly Report on Form 10-Q. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have interest rate and foreign currency market risk. Because of the short-term maturities of our cash and cash equivalents, we believe that an increase in market rates would likely not have a significant impact on the realized value of our investments.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest rate risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have debt with a mix of fixed and variable rates of interest. Floating rate debt carries interest based generally on the eurocurrency rate, as defined in our Amended Credit Agreement, plus an applicable margin. We manage the impact of interest rate changes on our variable debt through derivative interest rate swap arrangements. Increases in interest rates could result in an increase in interest payments for debt that we have not hedged through our interest rate swap arrangements. See Note 9, "Debt", in Part I, item 1, of this Quarterly Report on Form 10-Q. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assessed our exposure to changes in interest rates by analyzing the sensitivity to our operating results assuming various changes in market interest</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> rates. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A hypothetical increase of one percentage point in the eurocurrency rate as of September&#160;30, 2022 would increase our interest expense by approximately $2.6&#160;million annually.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency exchange rate risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exposure to foreign currency exchange rate fluctuations worldwide and primarily with respect to the Euro, Canadian dollar, Swiss franc and British pound. We manage our foreign currency exchange rate risk primarily by either entering into foreign currency hedging transactions or incurring operating expenses in the local currency in the countries in which we operate, to the extent practical. We currently do not hedge all of our foreign currency exchange exposure and the movement of foreign currency exchange rates could have an adverse or positive impact on our results of operations.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div id="i9bec4b75ff354735b09dcc9c604dfa92_118"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September&#160;30, 2022. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September&#160;30, 2022, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in internal control over financial reporting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during the three months ended September&#160;30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_121"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATIO</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N</span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_124"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 15, "Commitments and contingencies" in Part I, item 1, of this Quarterly Report on Form 10-Q. </span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_127"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risk factors and other information included in this Quarterly Report on Form 10-Q should be carefully considered. The occurrence of any of the following risks or of unknown risks and uncertainties may adversely affect our business, operating results and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of government contracting risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Reduced demand for and/or funding for procurement of AV7909 and/or BioThrax or ACAM2000 and discontinuation of funding of our other USG procurement and development contracts.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Inability to receive FDA licensure of AV7909 and realize the full value of our contract for development and procurement of AV7909.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of manufacturing risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our inability to maintain quality and manufacturing compliance at our manufacturing facilities has hindered and could continue to hinder our ability to produce products and product candidates for our CDMO customers.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Disruption at, damage to or destruction of our development and/or manufacturing facilities and supply chain disruption, including lower availability of plasma, may impede our ability to manufacture our products, as well as deliver our CDMO services.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our operations, including our use of hazardous materials, chemicals, bacteria and viruses expose us to significant potential liabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of product development and commercialization risks that could impact our business, financial condition, operating results and cash flows, including:</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The product candidates we are working on for our CDMO customers may not be safe or effective and we may be unable to manufacture sufficient quantities to meet demand.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Clinical trials of product candidates are expensive and time-consuming, and their outcome is uncertain.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We may fail to capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to numerous factors, the COVID-19 coronavirus pandemic could have a material adverse impact on our business, results of operations and financial performance, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Changes in government priorities resulting from the pandemic and continuing supply chain shortages could impact our overall business.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">COVID-19 may impede our workers ability to work and may result in reduced production of products or services.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The evolving nature of COVID-19 and related vaccines and treatments and resulting changes in demand for such product candidates may impact sales of related services offered by our CDMO business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of regulatory and compliance risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Failure to comply with complex laws and regulations pertaining to government contracts and resources required for responding to related government inquiries.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Conditions associated with approvals and ongoing regulation of products may limit how and the extent to which we manufacture and market them.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Failure to comply with various health care laws could result in substantial penalties.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Failure to comply with obligations under USG pricing programs may require reimbursement for underpayments and the payment of substantial penalties, sanctions and fines.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The extent to which we may be able to lawfully offer to sell and sell unapproved products in many jurisdictions may be unclear or </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ambiguous and such activities may subject us to regulatory enforcement actions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of competitive and political risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Development and commercialization of pharmaceutical products are subject to evolving private and public sector competition.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">NARCAN is currently subject to generic competition and may be subject to additional branded and generic competition and generic products rather than branded products are often dispensed where a generic version is available.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Biologic products may be affected by the approval and entry of follow-on biologics, or biosimilars in the United States and other jurisdictions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to our intellectual property that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Challenges in defense or enforcement of our intellectual property rights including against current or potential infringers.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Potential discrepancies or challenges with respect to third party licenses, including our failure to comply with obligations under such licenses.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Potential loss of proprietary information and know-how, which carries the risk of reducing the value of our technology and products.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Entry of competing generic drugs upon patent expiry or with patents no longer in force.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to reliance on third parties that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The loss of sole-source suppliers or an increase in the price of inventory.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">If third parties upon which we rely to conduct many of our clinical trials and other work do not perform as contractually required or as expected, we may not be able to obtain regulatory approval for or commercialize our product candidates or honor customer obligations.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of legal and reputational risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Unfavorable results of legal proceedings and government investigations could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our work on PHTs has exposed us to criticism and may expose us to further criticism, from the media, government personnel and others, which could further harm our reputation, negatively affect our share price, operations, and our ability to attract and retain talent.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The potential for cyber security incidents to harm our ability to operate our business effectively in light of our heightened risk profile.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Inherent product liability exposure due to our unique business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of financial risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our ability to maintain sufficient cash flow from our operations to pay our substantial debt, both now and in the future.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our ability to obtain additional funding and be able to raise capital when needed.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our ability to comply with the covenants under our Senior Secured Credit Facilities and other debt agreements and to refinance the Senior Secured Credit Facilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to our strategic acquisitions and collaborations that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our strategy of generating growth through acquisitions may be unsuccessful.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our failure to successfully integrate acquired businesses and/or assets into our operations and our ability to realize the benefits of such acquisitions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks associated with our common stock, including, but not limited to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our business or our share price could be negatively affected as a result of the actions of shareholders.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The price of our common stock has been and remains subject to extreme volatility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factors below contain more detailed descriptions of the risks identified above as well as additional risks that may materially harm our business, financial condition or results of cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT CONTRACTING RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently derive a substantial portion of our revenue from USG procurement of AV7909 and ACAM2000 and have historically derived a substantial portion of our revenue from USG procurement of BioThrax. If the USG&#8217;s demand for and/or funding for procurement of AV7909 and/or BioThrax or ACAM2000 is substantially reduced, our business, financial condition, operating results and cash flows would be materially harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive a substantial portion of our current and expected future revenues from USG procurement of AV7909. As AV7909 is a product candidate, there is a higher level of risk that we may encounter challenges causing delays or an inability to deliver AV7909 than with BioThrax, an approved product, which may have a material effect on our ability to generate and recognize revenue.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The success of our business and our future operating results are significantly dependent on anticipated funding for the procurement of our anthrax vaccines and the terms of such procurement by the USG, including the price per dose, the number of doses and the timing of deliveries. We have no certainty that funding will be made available for the procurement of our anthrax vaccines. If priorities for the SNS change generally, or as a result of the conclusion of the USG&#8217;s audit of the Strategic National Stockpile ("SNS"), or with respect to the level of procurement of our anthrax vaccines, funding to procure future doses of AV7909 or BioThrax may be delayed, limited or not available, BARDA may never complete the anticipated full transition to stockpiling AV7909 in support of anthrax preparedness, and our future business, financial condition, operating results and cash flows could be materially harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we currently derive a substantial portion of our revenues from sales of ACAM2000 to the USG. If priorities for the SNS change with respect to ACAM2000 or the USG decides not to exercise additional options under our ACAM2000 contract, our future business, financial condition, operating results and cash flows would be materially harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not receive FDA licensure of AV7909 in a timely manner or at all. Delays in our ability to achieve a </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">favorable outcome from the FDA, or lack of approval from the FDA, could prevent us from realizing the full potential value of our BARDA contract for the advanced development and procurement of AV7909.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with us, the Centers for Disease Control and Prevention (the "CDC") filed with the FDA a pre-Emergency Use Authorization ("EUA") submission package related to AV7909, which enables FDA review of data in anticipation of a request for an EUA. Following this submission, BARDA began procuring AV7909, exercising its first contract option in July 2019 to procure 10 million doses of AV7909 and its second contract option in July 2020 and, most recently, funded another procurement commitment in October 2021 for inclusion of additional doses into the SNS in support of anthrax preparedness.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we completed the rolling submission of a Biologics License Application ("BLA") filing with the FDA related to AV7909 and the application has been accepted for review. There can be no guarantee that our submission will be approved by the FDA. The FDA may decide that our initial data are insufficient and require additional pre-clinical, clinical or other studies. If we are unsuccessful in obtaining FDA licensure, in a timely manner or at all, we may not be able to realize the full potential value of the contract, which could have a material adverse effect on our future business, financial condition, operating results and cash flows. Furthermore, prior to FDA licensure, if we obtain an EUA, the EUA could be terminated if the emergency determination underlying the EUA terminates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our USG procurement and development contracts require ongoing funding decisions by the USG. Any reduction or discontinuation of funding of any of these contracts could cause our business, financial condition, operating results and cash flows to suffer materially.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USG is the principal customer for our Medical Countermeasures ("MCMs") and the primary source of funds for the development of most of our product candidates in our development pipeline, most notably our AV7909 procured product candidate. We anticipate that the USG will also be a principal customer for any MCMs that we successfully develop from within our existing product development pipeline, as well as those we acquire in the future. Additionally, a significant portion of our revenue comes from USG development contracts and grants. Over its lifetime, a USG procurement or development program, such as for AV909 under our development and procurement contract with BARDA, may be implemented through the award of many different individual contracts and subcontracts. The funding for such government programs is subject to Congressional appropriations, </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally made on a fiscal year basis, even for programs designed to continue for several years. These appropriations can be subject to a number of undertainties, including political considerations, changes in priorities due to global pandemics, the results of elections and stringent budgetary constraints.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our government-funded development contracts typically give the USG the right, exercisable in its sole discretion, to extend these contracts for successive option periods following a base period of performance. The value of the services to be performed during these option periods may constitute the majority of the total value of the underlying contract. For example, the September 2016 contract award from BARDA for the development and delivery to the SNS of AV7909 for post-exposure prophylaxis of anthrax disease consisted of a five-year base period of performance and includes options for the delivery of additional doses of AV7909 to the SNS and options for an additional clinical study and post-marketing commitments. This contract was extended in September 2021 through 2025, and provides for additional procurement of AV7909 for the SNS over 18 months. In addition, the September 2019 contract award from the USG for the supply of ACAM2000 to the SNS included a one-year base period of performance and includes nine options for additional years of performance, the first two of which were exercised by the USG. If levels of government expenditures and authorizations for public health countermeasure preparedness decrease or shift to programs in areas where we do not offer products or are not developing product candidates, or if the USG otherwise declines to exercise its options under our existing contracts, our revenues would suffer, as well as our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">There can be no assurance that we will be able to secure follow-on product procurement contracts with the USG upon the expiration of any of our existing procurement contracts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue is substantially dependent upon product procurement contracts with the USG and foreign governments for our MCMs. Upon the expiration of a procurement contract, we may not be able to negotiate a follow-on procurement contract for the particular product on similar terms. For example, in November 2019, the BARDA procurement contract for raxibacumab that we acquired in our 2017 acquisition of the product from GlaxoSmithKline LLC was completed. We intend to negotiate a follow-on procurement contract for raxibacumab and other follow-on procurement contracts for most of our MCMs upon the expiration of a related procurement contract, but </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there can be no assurance that we will be successful obtaining any follow-on contracts. Even if we are successful in negotiating a follow-on procurement contract, it may be for a lower product volume, over a shorter period of performance or be on less favorable pricing or other terms. An inability to secure follow-on procurement contracts for our approved products and product candidates procured under special circumstances could materially and adversely affect our revenues, and our business, financial condition, operating results and cash flows could be harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The government contracting process is typically a competitive bidding process and involves unique risks and requirements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business involves government contracts and grants, which may be awarded through competitive bidding. Competitive bidding for government contracts presents many risks and requirements, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the possibility that we may be ineligible to respond to a request for proposal;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the commitment of substantial time and attention of management and key employees to the preparation of bids and proposals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the need to accurately estimate the resources and cost structure that will be required to perform any contract that we might be awarded;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the submission by third parties of protests to our responses to requests for proposal that could result in delays or withdrawals of those requests for proposal; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">in the event our competitors protest or challenge contract or grant awards made to us through competitive bidding, the potential that we may incur expenses or delays, and that any such protest or challenge could result in the resubmission of bids based on modified specifications, or in the termination, reduction or modification of the awarded contract.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USG may choose not to award us future contracts for either the development of our new product candidates or the procurement of our existing MCM products and may instead award such contracts to our competitors. If we are unable to secure particular contracts, we may not be able to operate in the market for products that are provided under those contracts. Additionally, if we are unable to consistently win new contract awards over an extended period, or if we fail to anticipate all of the costs or resources that we will be required to secure and, if applicable, perform </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under such contract awards, our growth strategy and our business, financial condition and operating results and cash flows could be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The amounts we are paid under our fixed price government procurement contracts are based on estimates we have made of the time, resources and expenses required for us to perform under those contracts. If our actual costs exceed our estimates, we may not be able to earn an adequate return or may incur a loss under these contracts, which could harm our operating results and materially reduce our net income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current procurement contracts with the U.S. Department of Health and Human Services ("HHS") and the U.S. Department of Defense ("DoD") are typically fixed price contracts. We expect that any future procurement contracts we successfully secure with the USG would likely also be fixed price contracts. Under a fixed price contract, we are required to deliver our products at a fixed price regardless of the actual costs we incur. Estimating costs that are related to performance in accordance with contract specifications is difficult, particularly where the period of performance is over several years and when factoring in higher levels of inflation. Our failure to anticipate technical problems, estimate costs accurately or control costs during performance of a fixed price contract could reduce the profitability of such a contract or cause a loss, which could harm our operating results and materially reduce our net income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unfavorable provisions in government contracts, some of which may be customary, may subject our business to material limitations, restrictions and uncertainties and may have a material adverse impact on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government contracts customarily contain provisions that give the USG substantial rights and remedies, many of which are not typically found in commercial contracts, including provisions that allow the USG to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">terminate existing contracts, in whole or in part, for any or no reason;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">unilaterally reduce or modify contracts or subcontracts;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">decline, in whole or in part, to exercise an option to purchase product under a procurement contract or to fund additional development under a development contract;</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">decline to renew a procurement contract;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">claim certain rights to facilities or to products, including intellectual property, developed under the contract;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require repayment of contract funds spent on construction of facilities in the event of contract default;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">take actions that result in a longer development timeline than expected;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">direct the course of a development program in a manner not chosen by the government contractor;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">suspend or debar the contractor from doing business with the government or a specific government agency;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pursue civil or criminal remedies under acts such as the False Claims Act and False Statements Act; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">control or prohibit the export of products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, government contracts contain provisions permitting unilateral termination or modification, in whole or in part, at the USG&#8217;s convenience. Under general principles of government contracting law, if the USG terminates a contract for convenience, the government contractor may recover only its incurred or committed costs, settlement expenses and profit on work completed prior to the termination. If the USG terminates a contract for default, the government contractor is entitled to recover costs incurred and associated profits on accepted items only and may be liable for excess costs incurred by the government in procuring undelivered items from another source. All of our development and procurement contracts with the USG are terminable at the USG's convenience with these potential consequences.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our USG contracts grant the USG the right to use technologies developed by us under the government contract or the right to share data related to our technologies, for or on behalf of the USG. Under our USG contracts, we may not be able to limit third parties, including our competitors, from accessing certain of these technology or data rights, including intellectual property, in providing products and services to the USG.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An inability to maintain manufacturing compliance at our manufacturing facilities could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts periodic inspections of our manufacturing facilities for compliance with cGMP requirements relating to quality control. For example, on August 10, 2022, the FDA issued a warning letter to the Company with respect to its Camden manufacturing facility in Baltimore, Maryland. The warning letter cited two areas of deficiencies: (i) systems for cleaning and maintenance of equipment to prevent contamination of drug product, specifically related to particulates from the metal trays, and (ii) processes and practices surrounding aseptic processing. In addition, the FDA recommended the Company review and assess its Quality Management System and engage a consultant with respect to Current Good Manufacturing Practices. The Company has retained a third party for additional review of the facility and to provide additional oversight of processes for product release. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's failure to regain or maintain compliance with cGMP standards at our manufacturing facilities has hindered and could continue to hinder our ability to continue manufacturing for CDMO customers, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disruption at, damage to or destruction of our manufacturing facilities could impede our ability to manufacture anthrax vaccines, ACAM2000 or our other products or product candidates, as well as impact the delivery of CDMO services, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any interruptions in our manufacturing operations could result in our inability to produce products and product candidates for delivery to satisfy the demands of our customers in a timely manner, which would reduce our revenues and materially harm our business, financial condition, operating results and cash flows. A number of factors could cause interruptions, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">equipment malfunctions or failures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">technology malfunctions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">cyber-attacks;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">ongoing supply chain interruptions from the COVID-19 pandemic, including lower available plasma levels caused by the pandemic (which has the potential to impact our plasma-based products);</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">work stoppages or slowdowns due to the potential resurgence of new COVID-19 variants;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">civil unrest and protests, including by animal rights activists;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">injunctions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to or destruction of one or more facilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">FDA facility inspection findings/recommendations; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">product contamination or tampering.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providers of MCMs could be subject to an increased risk of terrorist activities. The USG has designated both our Lansing, Michigan and our Bayview bulk manufacturing facility in Baltimore, Maryland as facilities requiring additional security. Although we continually evaluate and update security measures, there can be no assurance that any additional security measures would protect these facilities from terrorist efforts determined to disrupt our manufacturing activities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors listed above could also cause disruptions at our other facilities. We do not have any redundant manufacturing facilities for any of our products. Accordingly, any damage to, or disruption or destruction of one or more of our facilities could impede our ability to manufacture our products, our product candidates and our ability to provide manufacturing and development services for external customers, result in losses and delays, including delays in the performance of our contractual obligations or delays in our clinical trials, any of which could be costly to us and materially harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Problems may arise during the production of our products and product candidates, as well as those we produce for our CDMO customers, due to the complexity of the processes involved in their development, manufacturing and shipment. Significant delays in product manufacturing or development and our ability to ramp up production to meet the needs of our customers could cause delays in recognizing revenues, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our products and product candidates are biologics. Manufacturing biologics, especially in large quantities, is complex. The products must be made consistently and in compliance with a clearly-defined manufacturing process. Problems during manufacturing may arise for a variety of reasons, including problems with raw materials, equipment </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">malfunction and failure to follow specific protocols and procedures. Slight deviations anywhere in the manufacturing process, including obtaining materials, maintaining master seed or cell banks and preventing genetic drift, seed or cell growth, fermentation, contamination including from particulates among other things, filtration, filling, labeling, packaging, storage and shipping, potency and stability issues and other quality control testing, may result in lot failures or manufacturing shut-downs, delays in the release of lots, product recalls, spoilage or regulatory action. Such deviations may require us to revise manufacturing processes or change manufacturers. In addition, we are contractually required to ship our biologic products at a prescribed temperature range and variations from that temperature range could result in loss of product and could significantly and adversely impact our revenues, which would harm our business, financial condition, operating results and cash flows. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our equipment ages, it will need to be replaced, which has the potential to result in similar consequences. Success rates can also vary dramatically at different stages of the manufacturing process, which can reduce yields and increase costs. From time to time, we may experience deviations in the manufacturing process that may take significant time and resources to resolve and, if unresolved, may affect manufacturing output and could cause us to fail to satisfy customer orders or contractual commitments, lead to a termination of one or more of our contracts, lead to delays in our clinical trials, result in litigation or regulatory action against us, including the issuance of Forms FDA 483, warning letters and other restrictions on the marketing or manufacturing of a product, or cause the FDA to cease releasing product until the deviations are explained and corrected, any of which could be costly to us, damage our reputation and negatively impact our business. For example, in April 2021, we temporarily stopped manufacturing bulk drug substance material for Johnson &amp; Johnson&#8217;s COVID-19 vaccine at our Baltimore Bayview facility after issues were identified in a viral vaccine drug substance batch.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if changes are made to the manufacturing process, we may be required to provide the FDA with pre-clinical and clinical data showing the comparable identity, strength, quality, purity or potency of any impacted products before and after the changes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may not be able to ramp up our manufacturing processes to meet the rapidly changing demand or specifications of our customers on the desired timeframe, if at all. For example, we have not previously had to ramp our organization for a commercial launch of any product or manufacture any </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product for our CDMO customers at the pace required to address treatments related to COVID-19 and doing so in a pandemic environment with an urgent, critical global need creates unique manufacturing challenges, challenges related to distribution channels, and the need to establish teams of people with the relevant skills. Our inability to ramp up manufacturing to meet the demand or specifications of our customers or the inability to timely obtain regulatory authorization to produce the products or product candidates of our customers could also harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products and product candidates procured by the USG and other customers require us to perform tests for and meet certain potency and lot release standards prescribed by the FDA and other agencies, which may not be met on a timely basis or at all.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and product candidates procured by the USG and other customers require us to perform tests for and meet certain potency and lot release standards prescribed by the FDA and other agencies, which may not be met on a timely basis or at all. We are unable to sell any products and product candidates that fail to satisfy such testing specifications. For example, we must provide the FDA with the results of certain tests, including potency tests, before certain lots are released for sale. Potency testing of each applicable lot is performed against qualified control lots that we maintain. We continually monitor the status of such reference lots for FDA compliance and periodically produce and qualify a new reference lot to replace the existing reference lot. If we are unable to satisfy USG requirements for the release of our products or product candidates, our ability to supply such products and product candidates to authorized buyers would be impaired until such time as we become able to meet such requirements, which could materially harm our future business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operations, including our use of hazardous materials, chemicals, bacteria and viruses, require us to comply with regulatory requirements and expose us to significant potential liabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve the use of hazardous materials, including chemicals, bacteria and viruses, and may produce dangerous waste products. Accordingly, we, along with the third parties that conduct clinical trials and manufacture our products and product candidates on our behalf, are subject to federal, state, local and foreign laws and regulations that govern the use, manufacture, distribution, storage, handling, exposure, disposal and recordkeeping with respect to these materials. Under the Federal Select </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agent Program, pursuant to the Public Health Security and Bioterrorism Preparedness and Response Act, we are required to register with and be inspected by the CDC and the Animal and Plant Health Inspection Service if we have in our possession, or if we use or transfer, select biological agents or toxins that could pose a threat to public health and safety, to animal or plant health or to animal or plant products. This legislation requires stringent safeguards and security measures for these select agents and toxins, including controlled access and the screening of entities and personnel and establishes a comprehensive national database of registered entities. We are also subject to a variety of environmental and occupational health and safety laws. Compliance with current or future laws and regulations in this area can require significant costs and we could be subject to substantial fines and penalties in the event of noncompliance. In addition, the risk of contamination or injury from these materials cannot be completely eliminated. In such event, we could be held liable for substantial civil damages or costs associated with the cleanup of hazardous materials. From time to time, we have been involved in remediation activities and may be so involved in the future. Any related cost or liability might not be fully covered by insurance, could exceed our resources and could have a material adverse effect on our business, financial condition, operating results and cash flows. In addition to complying with environmental and occupational health and safety laws, we must comply with special regulations relating to biosafety administered by the CDC, HHS, U.S. Department of Agriculture and the DoD, as well as regulatory authorities in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCT DEVELOPMENT AND COMMERCIALIZATION RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 product candidates we are manufacturing for our CDMO customers may not be safe or effective and even if they are, we may be unable to manufacture sufficient quantities to meet demand.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are providing CDMO services for the development and/or manufacture of multiple therapeutic product candidates. There can be no assurance that any of these product candidates will be safe or effective. There can also be no assurance that any of these product candidates will be authorized for emergency use or approved by the FDA or any other health regulatory authority. Even if these product candidates are safe and/or effective and receive authorization or approval by a health regulatory authority, the manufacturing processes for our CDMO COVID-19 programs are under development and are complex. There can be no assurance that we will be able to produce any significant quantity of these </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates in a timely basis or at all, or negotiate further commitments under our existing CDMO contracts, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our growth depends on our success in developing and commercializing our product candidates. If we are unable to commercialize these product candidates, or experience significant delays or unanticipated costs in doing so, our business would be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested significant efforts and financial resources in the development of our vaccines, therapeutics and medical device product candidates and the acquisition of additional product candidates. In addition to our product sales, our ability to generate revenue is dependent on a number of factors, including the success of our development programs, the USG's interest in providing development funding for or procuring certain of our product candidates, and the commercial viability of our acquired or developed product candidates. The commercial success of our product candidates can depend on many factors, including accomplishing the following in an economical manner:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">successful development, formulation and cGMP scale-up of manufacturing that meets FDA and/or foreign regulatory requirements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">successful program partnering;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">successful completion of clinical or non-clinical development;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">receipt of marketing approvals from the FDA and equivalent foreign regulatory authorities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">establishment of commercial manufacturing processes and product supply arrangements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">training of a commercial sales force for the product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">successful registration and maintenance of relevant patent and/or other proprietary protection;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">competitive pricing and market access; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">acceptance of the product by potential government and other customers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trials of product candidates are expensive and time-consuming, and their outcome is uncertain. We must invest substantial amounts of time and financial resources in these trials, which may not yield viable </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">products. Failure to obtain regulatory approval for product candidates, particularly in the United States, could materially and adversely affect our financial resources, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval of our product candidates, we and our collaborative partners, where applicable, must conduct pre-clinical studies and clinical trials to establish proof of concept and demonstrate the safety and efficacy of our product candidates. Pre-clinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. Success in pre-clinical testing or early clinical trials does not ensure that later clinical trials will be successful, and interim results of such trials do not necessarily predict final results. An unexpected result in one or more of our preclinical studies or clinical trials can occur at any stage of testing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience unforeseen events or issues during, or as a result of, pre-clinical testing, clinical trials or animal efficacy studies. These issues and events, which could delay or prevent our ability to receive regulatory approval for a product candidate, include, among others:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our inability to manufacture sufficient quantities for use in trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the unavailability or variability in the number and types of subjects for each study;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety issues or inconclusive or incomplete testing, trial or study results;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">drug immunogenicity;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lack of efficacy of product candidates during the trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government or regulatory restrictions or delays; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">greater than anticipated costs of trials.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical and clinical testing for certain of our MCM product candidates may face additional difficulties and uncertainties because they cannot ethically or feasibly be tested in human subjects. We therefore expect to rely on the Animal Rule to obtain regulatory approval for some of our MCM product candidates. The Animal Rule permits, for certain limited diseases and circumstances, the use of animal efficacy studies, together with human clinical safety and immunogenicity trials, to support an application for marketing approval. For a product approved under the Animal Rule, certain additional post-marketing </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements apply. For example, to the extent feasible and ethical, applicants must conduct post-marketing studies, such as field studies, to verify and describe the drug's clinical benefit and to assess its safety when used as indicated. It is possible that results from the animal efficacy studies used to support approval under the Animal Rule may not be predictive of the actual efficacy of our product candidates in humans.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of certain MCM product candidates, the Secretary of HHS can contract to purchase MCMs for the SNS under Project BioShield under specific circumstances. Under PAHPRA, the USG may also, at its discretion, purchase critical biodefense products for the SNS prior to FDA approval after the filing of a pre-EUA application with the FDA.  If our MCM product candidates are not procured or funded under Project BioShield, or do not qualify for EUA, they generally will have to be fully approved by the FDA through traditional regulatory mechanisms prior to sale and distribution in the United States.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our product development strategy and, as a result, may modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product candidates or may delay or halt the development of various product candidates. We may change or refocus our existing product development, commercialization and manufacturing activities based on government funding decisions and other factors. This could require changes in our facilities and our personnel. Any product development changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates or choose candidates for which government development funds are not available. Our decisions to allocate our R&amp;D, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources from better business opportunities. Similarly, our decisions to delay or terminate product development programs could also cause us to miss valuable opportunities.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GLOBAL PANDEMIC RISK</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 pandemic could have a material adverse impact on our business, results of operations and financial performance.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, operations and financial condition and results have been and may continue to be impacted by the COVID-19 pandemic to varying degrees. The pandemic has presented a number of risks and challenges for our business, including, among others, prior government-mandated work-from-home or shelter-in-place orders; manufacturing disruptions and delays, including at our Baltimore Bayview facility, supply chain interruptions or delays, including challenges related to reliance on third-party suppliers; disruptions to pipeline development and clinical trials and decreased product demand for our travel health vaccines due to the significant reduction in international travel. Additional travel restrictions and other governmental measures may result in further disruptions or continued delays in delivery of supplies by our third-party contractors and suppliers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face uncertainties related to our efforts and those of our collaborative partners to develop a potential treatment or vaccine for COVID-19, including uncertainties related to pre-clinical or clinical trials, the risk that such development programs may not be successful, commercially viable, or that EUA or regulatory approval will not be received from regulatory authorities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trading price of our common stock, and that of other biopharmaceutical companies, has been highly volatile due to the COVID-19 pandemic, especially as a result of investor concerns and uncertainty related to the impact of the pandemic on the economies of countries worldwide. These broad market and industry fluctuations, as well as general economic, political and market conditions, may negatively impact the market price of shares of our common stock.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic and new variants of COVID-19 may further negatively impact our business, affect the supply chain, disrupt key clinical trials, divert government funding away from our primary procured products and product candidates due to changes in government priorities and potential delays in the delivery of products to our customers will depend on future developments, which are highly uncertain. The ultimate geographic spread of COVID-19 and new variants of the disease, the duration of the pandemic, further travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease cannot be predicted with certainty.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The continually evolving nature of the COVID-19 pandemic and the resulting public health response, including the changing demand for various COVID-19 vaccines and treatments from both patients and governments around the world, may affect the demand for COVID-19 product candidates manufactured by our CDMO business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our CDMO business, we provide services for a variety of product candidates intended for the prevention or treatment of COVID-19 and its symptoms and effects. These services include product development and drug product fill and finish services.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the COVID-19-related product candidates we develop and manufacture have yet to receive full regulatory approval from any regulatory authority, although some are being offered and sold pursuant to an EUA from the FDA or the equivalent authorization from non-U.S. regulatory authorities. Should the facilities producing these product candidates be denied an EUA or one or more of these COVID-19-related product candidates be denied an EUA (or equivalent) or be denied full regulatory approval by the FDA or other major non-U.S. regulatory authority, the demand for such product candidates could decrease significantly and therefore decrease customer orders for additional CDMO services for such product candidates. Additionally, the need for continued manufacture and supply of vaccines (including &#8220;booster&#8221; doses) and therapies to address the COVID-19 pandemic, including new and developing variants of COVID-19, is highly uncertain and subject to various political, economic, regulatory and other factors that are outside of our control. For example, in the first quarter of 2022, Johnson and Johnson suspended its COVID-19 vaccine sales guidance due to global supply surplus and demand uncertainty. Should the United States or other major regions worldwide determine that additional manufacturing of COVID-19 vaccines, boosters, or therapies is no longer necessary, or necessary to a lesser degree, it could adversely affect our revenue and financial condition and our ability to grow our CDMO business in the near term. In addition, highly-public political and social debates relating to the need for, efficacy of, or side effects related to one or more specific COVID-19 vaccines could contribute to changes in public perception of COVID-19 vaccines manufactured by us, which could decrease demand for a COVID-19 related product candidate we develop or manufacture (in whole or in part).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The impact of working remotely may increase our cybersecurity risk profile and potentially impact productivity.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the significant areas of impact of COVID-19 on our business has been a shift in company policy to hybrid work arrangements. We have recently implemented a hybrid work model through which our administrative workforce may choose a mixture of in-office and remote work, continue to work entirely on a remote basis or return to the office full time. Although we have allowed all employees to return to the office, a significant number of administrative employees have chosen to continue to work remotely either on a part-time or full-time basis. Working remotely could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations. In addition, our on-site staff conducting R&amp;D may not be able to access our laboratories if government-mandated lockdowns return, due to a resurgence in COVID-19 variants and new state and local restrictions.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGULATORY AND COMPLIANCE RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">There are a number of complex laws and regulations that pertain to government contracts and compliance with those laws and regulations require significant time and cost, which could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a manufacturer and supplier of MCMs to the USG addressing PHTs, we must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts. These laws and regulations govern how we transact business with our government clients and, in some instances, impose additional costs and related obligations on our operations. Our status as a USG contractor means that we are subject to various statutes and regulations, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the Federal Acquisition Regulation ("FAR") and agency-specific regulations supplemental to FAR, which comprehensively regulate the award, formation, administration and performance of government contracts;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the Defense Federal Acquisition Regulations ("DFARs") and agency-specific regulations supplemental to DFARs, which comprehensively regulate the award, formation, administration and performance of DoD government contracts;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the Department of State Acquisition Regulation which regulates the relationship between a Department of State organization and a contractor or potential contractor;</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act, the False Claims Act and the Foreign Corrupt Practices Act (the "FCPA");</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">export and import control laws and regulations, including but not limited to International Traffic in Arms Regulations; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to government investigations of compliance with government acquisition regulations. USG agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. Even though we take significant precautions to identify, prevent and deter fraud, misconduct and non-compliance, we face the risk that our personnel or outside partners may engage in misconduct, fraud or improper activities. If we are audited or investigated and such audit or investigation were to uncover improper or illegal activities, we could be subject to civil and criminal fines and penalties, administrative sanctions, including suspension or debarment from government contracting, and suffer significant reputational harm. The loss of our status as an eligible government contractor or significant fines or penalties associated with contract non-compliance or resulting from investigations could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our long-term success depends, in part, upon our ability to develop, receive regulatory approval for and commercialize product candidates we develop or acquire and, if we are not successful, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with them are subject to extensive FDA regulation and oversight, as well as oversight by other regulatory agencies in the United States and by comparable foreign regulatory authorities. This includes, but is not limited to, laws and regulations governing product development, including testing, manufacturing, record keeping, storage and approval, as well as advertising and promotion. In limited circumstances, governments may procure products that have not obtained regulatory approval. In all other </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances, failure to obtain regulatory approval for a product candidate will prevent us from selling and commercializing the product candidate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, to obtain approval from the FDA to market and sell any of our future drug, biologic, or vaccine products, we will be required to submit a New Drug Application ("NDA") or BLA to the FDA. Ordinarily, the FDA will require a company to support an NDA or BLA with substantial evidence of the product candidate&#8217;s effectiveness, safety, purity and potency in treating the targeted indication based on data derived from adequate and well-controlled clinical trials, including Phase 3 trials conducted in patients with the disease or condition being targeted. Once an NDA or BLA is submitted, the FDA has substantial discretion and may refuse to accept any application or may decide that our data are insufficient to support approval and require additional pre-clinical, clinical or other studies.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, many of our MCM product candidates, for example, may take advantage of a different regulatory approval pathway under the FDA&#8217;s &#8220;Animal Rule.&#8221; Under the Animal Rule, efficacy must be demonstrated, in part, by utilizing animal models rather than testing in humans. We cannot guarantee that the FDA will permit us to proceed with licensure of any of our MCM product candidates under the Animal Rule. Even if we are able to proceed under the Animal Rule, product development can take a considerable amount of time, and the FDA may decide that our data are insufficient to support approval and require additional pre-clinical, clinical or other studies, refuse to approve our products, or place restrictions on our ability to commercialize those products. Furthermore, products approved under the Animal Rule are subject to certain additional post-marketing requirements. We cannot guarantee that we will be able to meet this regulatory requirement even if one or more of our product candidates are approved under the Animal Rule.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining these regulatory approvals is expensive, often takes many years if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidate involved. Changes in the regulatory approval process may cause delays in the approval or rejection of an application. There is a high rate of failure inherent in this process, and potential products that appear promising at early stages of development may fail for a number of reasons, and positive results from pre-clinical studies may not be predictive of similar results in human clinical trials. Similarly, promising results from earlier clinical trials of a product candidate may not be replicated in later clinical trials.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to successfully develop future product candidates may materially adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unapproved and investigational stage products are also subject to the FDA's laws and regulations governing advertising and promotion, which prohibit the promotion of both unapproved products and unapproved uses of approved products. There is some risk that the FDA could conclude that our communications relating to unapproved products or unapproved uses of approved products constitute the promotion of an unapproved product or product use in violation of FDA laws and regulations.&#160;There is also a risk that a regulatory authority in another country could take a similar position under that country's laws and regulations and conclude that we have violated the laws and regulations related to product development, approval, or promotion in that country.&#160;Therefore, there is a risk that we could be subject to enforcement actions if found to be in violation of such laws or regulations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Even if we or our collaborators obtain marketing approvals for our product candidates, the conditions of approvals and ongoing regulation of our products may limit how we manufacture, market and sell our products, which could materially impair our ability to generate revenue.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once approval has been granted, an approved product and its manufacturer and marketer remain subject to ongoing review and extensive regulation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators must therefore comply with post-approval regulatory requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to FDA-regulated products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to sell any products we develop for indications or uses for which they are not approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and our collaborators are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market and sell any products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we or our collaborators obtain marketing approval could be </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we or our collaborators obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are subject to post marketing requirements ("PMRs"), which we are required to conduct, and post marketing commitments ("PMCs"), which we have agreed to conduct. The FDA has the authority to take action against sponsors who fail to meet the obligations of a PMR, including civil monetary penalties and/or misbranding charges.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other agencies, including the U.S. Department of Justice ("DOJ") and the HHS Office of Inspector General ("OIG"), closely regulate and monitor the pre-approval and post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA, DOJ, and OIG impose stringent restrictions on manufacturers&#8217; communications regarding unapproved products and unapproved uses of approved products and if we market unapproved products or market our approved products for unapproved indications, we may be subject to enforcement action. Violations of the Federal Food, Drug, and Cosmetics Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturing partners or manufacturing processes, or failure to comply with regulatory requirements, may result in various penalties and sanctions. For all FDA-regulated products, if the FDA finds that a manufacturer has failed to comply with applicable laws and regulations, or that a product is ineffective or poses an unreasonable health risk, it can institute or seek a wide variety of enforcement actions and remedies, including but not limited to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">restrictions on the labeling or marketing of a product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">restrictions on distribution or use of a product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">warning letters or untitled letters;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">refusal to approve pending applications or supplements to approved applications that are submitted;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fines, restitution or disgorgement of profits or revenues; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">refusal to permit the import or export of our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">product seizure; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU and other legal and regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions. Non-compliance with similar requirements in other foreign jurisdictions can also result in enforcement actions and significant penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and may affect the prices we, or our collaborators, may obtain.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other health care reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we, or any collaborators, may receive for any approved products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the "ACA"), passed in 2010 and substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry. However, some provisions of the ACA have yet to be fully implemented and certain provisions have been subject to legal and political challenges, as well as efforts by the last Presidential administration to repeal or replace certain aspects of the ACA. On January 28, 2021, however, the President issued an executive order to strengthen implementation of the ACA. Concurrently, Congress considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA, such as removing penalties as of January 1, 2019 for not complying with the ACA&#8217;s individual mandate to carry health insurance, delaying the implementation of certain ACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, the current Presidential administration issued an executive order initiating a special enrollment period during 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare. It is unclear how healthcare reform measures enacted by Congress or implemented by the current Presidential administration or other challenges to the ACA, if any, will impact the ACA or our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACA was enacted that may negatively impact us. On August 2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031 under the Coronavirus Aid, Relief and Economic Security Act, or CARES Act. These Medicare sequester reductions were suspended through the end of March 2022, and a 1% sequester cut was in effect from April 2022 through June 2022, with the full 2% cut resuming thereafter.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there has been recent heightened federal governmental scrutiny over the manner in which manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries and has been proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, the last Presidential administration released a &#8220;Blueprint&#8221;, or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program ("SIP"), to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on July 9, 2021, the President signed an Executive Order that focuses on, among other things, the price of pharmaceuticals. The Order directed HHS to create a plan within 45 days to combat "excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging." On September 9, 2021, HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a) make pharmaceutical prices more affordable and equitable for all consumers; (b) improve and promote competition throughout the prescription pharmaceutical industry; and (c) foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers and wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we fail to comply with foreign, federal, state and local health care laws, including fraud and abuse and health information privacy and security laws, and antitrust laws, we could face substantial&#160;penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, certain of our products are reimbursed under federal and state health care programs such as Medicaid, Medicare, TriCare, and/or state pharmaceutical assistance programs. Many foreign countries have similar laws. Federal and state laws designed to prevent fraud and abuse under these programs prohibit pharmaceutical companies from offering valuable items or services to customers or </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential customers to induce them to buy, prescribe, or recommend our product (the so-called &#8220;anti-kickback&#8221; laws). Exceptions are provided for discounts and certain other arrangements if specified requirements are met. Other federal and state laws, and similar foreign laws, not only prohibit us from submitting any false information to government reimbursement programs but also prohibit us, our employees, or any third party acting on our behalf from doing anything to cause, assist, or encourage our customers to submit false claims for payment to these programs. We are also subject to various federal, state and foreign antitrust and competition laws that prohibit certain activities that may have an impact against potential competitors. Violations of the various fraud and abuse and antitrust laws may result in severe penalties against the responsible employees and us, including jail sentences, large fines, and the exclusion of our products from reimbursement under federal and state programs. Some of the laws that may affect our ability to operate include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the federal Anti-Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay remuneration, directly or indirectly, overtly or covertly, to induce, or in return for, either the referral of an individual, or the purchase, lease, prescribing or recommendation of an item, good, facility or service reimbursable by a federally funded health care program, such as the Medicare or Medicaid program. The term &#8220;remuneration&#8221; has been interpreted broadly and may constrain our marketing practices, educational programs, pricing policies and relationships with health care providers or other entities, among other activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal health care program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability, including mandatory treble damages and significant per-claim penalties.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), which imposes criminal and civil liability for, </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statement, in connection with the delivery of, or payment for, health care benefits, items or services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">HIPAA, as amended by HITECH, and their respective implementing regulations mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common health care transactions, as well as standards relating to the privacy, security and transmission of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA's security standards directly applicable to &#8220;business associates,&#8221; or independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the Physician Payments Sunshine Act and its implementing regulations require certain manufacturers of drugs, biologics, medical devices and medical supplies for which payment is available under Medicare, Medicaid or the Centers for Medicare &amp; Medicaid Services ("CMS") to report certain payments and transfers of value made to U.S. physicians, other healthcare providers and teaching hospitals, and ownership or investment interests held by physicians, other healthcare providers and their immediate family members; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state and foreign laws governing the privacy and security of health information in certain circumstances, </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; state, local and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, obtain pharmaceutical agent licensure, and/or otherwise restrict payments that may be made to health care providers and entities; and state, local and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to health care providers or entities, or marketing expenditures.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under the federal Anti-Kickback Statute, it is possible that some of our business activities could be subject to challenges under one or more of such laws. Moreover, recent health care reform legislation has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal health care fraud statutes, so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or otherwise, we may be subject to penalties, including civil and criminal penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from funded health care programs and the curtailment or restructuring of our operations. Any such penalties could adversely affect our financial results. We continue to improve our corporate compliance program designed to ensure that our development, marketing, and sales of existing and future products and product candidates are in compliance with all applicable laws and regulations, but we cannot guarantee that this program will protect us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from government funded health care programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If a third party fails to comply with applicable laws and regulations while acting on our behalf, we may also be subject to criminal, civil, and administrative penalties, including those listed above.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States government, state governments and private payors regularly investigate the pricing and competitive practices of pharmaceutical companies and biotechnology companies, and many file actions alleging that inaccurate reporting of prices has improperly inflated reimbursement rates. We may also be subject to investigations related to our pricing practices. Regardless of merit or eventual outcome, these types of investigations and related litigation can result in:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Diversion of management time and attention;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Significant legal fees and payment of damages or penalties;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Limitations on our ability to continue certain operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Decreased product demand; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Injury to our reputation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, an adverse outcome, or the imposition of penalties or sanctions for failing to comply with the fraud and abuse and antitrust laws, could adversely affect us and may have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we fail to comply with our obligations under U.S. governmental pricing programs, we could&#160;be required to reimburse government programs for underpayments and could pay penalties, sanctions and fines.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of regulations and coverage expansion by various governmental agencies relating to the Medicaid rebate program will continue to increase our costs and the complexity of compliance and will be time-consuming. Changes to the definition of average </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturer price ("AMP"), and the Medicaid rebate amount under the ACA and CMS and the issuance of final regulations implementing those changes has affected and could further affect our 340B &#8220;ceiling price&#8221; calculations. Because we participate in the Medicaid rebate program, we are required to report average sales price ("ASP"), information to CMS for certain categories of drugs that are paid for under Part B of the Medicare program. Future statutory or regulatory changes or CMS binding guidance could affect the ASP calculations for our products and the resulting Medicare payment rate and could negatively impact our results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary among products and programs, involve complex calculations and are often subject to interpretation by us, governmental or regulatory agencies and the courts. The Medicaid rebate amount is computed each quarter based on our submission to CMS of our current AMP and &#8220;best price&#8221; for the quarter. If we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due. Any such revisions could have the impact of increasing or decreasing our rebate liability for prior quarters, depending on the direction of the revision. Such restatements and recalculations would increase our costs for complying with the laws and regulations governing the Medicaid rebate program. Price recalculations also may affect the &#8220;ceiling price&#8221; at which we are required to offer our products to certain covered entities, such as safety-net providers, under the 340B/Public Health Service ("PHS") drug pricing program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we are found to have made a misrepresentation in the reporting of ASP, we are subject to civil monetary penalties for each such price misrepresentation and for each day in which such price misrepresentation was applied. If we are found to have knowingly submitted false AMP or &#8220;best price&#8221; information to the government, we may be liable for civil monetary penalties per item of false information. Any refusal of a request for information or knowing provision of false information in connection with an AMP survey verification would also subject us to civil monetary penalties. In addition, our failure to submit monthly/quarterly AMP or &#8220;best price&#8221; information on a timely basis could result in a civil monetary penalty per day for each day the information is late beyond the due date. Such failure could also be grounds for CMS to terminate our Medicaid drug rebate agreement, under which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, no </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal payments would be available under Medicaid or Medicare Part B for our covered outpatient drugs. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot assure that our submissions will not be found by CMS to be incomplete or incorrect.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for our products to be reimbursed by the primary federal governmental programs, we must report certain pricing data to the USG. Compliance with reporting and other requirements of these federal programs is a pre-condition to: (i)&#160;the availability of federal funds to pay for our products under Medicaid and Medicare Part B; and (ii)&#160;procurement of our products by the Department of Veterans Affairs ("DVA"), and by covered entities under the 340B/PHS program. The pricing data reported are used as the basis for establishing Federal Supply Schedule ("FSS"), and 340B/PHS program contract pricing and payment and rebate rates under the Medicare Part B and Medicaid programs, respectively. Pharmaceutical companies have been prosecuted under federal and state false claims laws for submitting inaccurate and/or incomplete pricing information to the government that resulted in increased payments made by these programs. Although we maintain and follow strict procedures to ensure the maximum possible integrity for our federal pricing calculations, the process for making the required calculations is complex, involves some subjective judgments and the risk of errors always exists, which creates the potential for exposure under the false claims laws. If we become subject to investigations or other inquiries concerning our compliance with price reporting laws and regulations, and our methodologies for calculating federal prices are found to include flaws or to have been incorrectly applied, we could be required to pay or be subject to additional reimbursements, penalties, sanctions or fines, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, we also must participate in the DVA FSS pricing program. To participate, we are required to enter into an&#160;FSS contract with the DVA, under which we must make our innovator &#8220;covered drugs&#8221; available to the &#8220;Big Four&#8221; federal agencies-the DVA, the DoD, the PHS (including the Indian Health Service), and the Coast Guard-at pricing that is capped under a statutory federal ceiling price ("FCP") formula set forth in Section&#160;603 of the Veterans Health Care Act of 1992 ("VHCA"). The FCP is based on a weighted average </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">wholesale price known as the Non-Federal Average Manufacturer Price ("Non-FAMP"), which manufacturers are required to report on a quarterly and annual basis to the DVA. Under the VHCA, knowingly providing false information in connection with a Non-FAMP filing can subject us to significant penalties for each item of false information. If we overcharge the government in connection with our FSS contract or Section&#160;703 Agreement, whether due to a misstated FCP or otherwise, we are required to disclose the error and refund the difference to the government. The failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government&#160;investigation or enforcement action, can be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">From time to time, we sell unapproved MCMs to government entities under certain circumstances. While this is permissible in some cases, the extent to which we may be able to lawfully offer to sell and sell unapproved products in many jurisdictions may be unclear or ambiguous. Such sales could subject us to regulatory enforcement action, product liability and reputational risk.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain circumstances, MCMs may be procured by government entities prior to approval by the FDA or other regulatory authorities, a practice which we follow in connection with certain MCMs, including AV7909 and TROBIGARD, in the United States. In the United States, Project BioShield permits the Secretary of HHS to contract to purchase MCMs for the SNS prior to FDA approval of the relevant MCM in specified circumstances. Project BioShield and the PAHPRA also allow the FDA Commissioner to authorize the emergency use of medical products that have not yet been approved by the FDA under an EUA. An EUA terminates when the emergency determination underlying the EUA terminates. An EUA is not a long-term alternative to obtaining FDA approval, licensure, or clearance for a product. Absent an applicable exception, our MCM product candidates generally will have to be approved by the FDA or other regulatory authorities in the relevant country through traditional pathways before we can sell those products to governments. Additionally, the laws in certain jurisdictions regarding the ability of government entities to purchase unapproved product candidates are ambiguous, and the permissibility of exporting unapproved products from the United States and importing them to foreign countries may be unclear. Nevertheless, government bodies, such as U.S. federal </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entities other than HHS, state and local governments within the United States, and foreign governments have sought and may further seek to procure our MCM product candidates that are not yet approved. If so, we would expect to assess the permissibility and liability implications of supplying our product candidates to such entities on a case-by-case basis, which presents certain challenges, both in the case of U.S. and foreign governments, and particularly under emergency conditions. In addition, agencies or branches of one country&#8217;s government may take different positions regarding the permissibility of such sales than another country&#8217;s government or even other agencies or branches of the same government. If local enforcement authorities disagree with our conclusion that such activities are permissible, they may take enforcement action against us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the sale of unapproved products also could give rise to product liability claims for which we may not be able to obtain indemnification or insurance coverage. For example, liability protections applicable to claims arising under U.S. law and resulting from the use of certain unlicensed or unauthorized products, such as a declaration issued under the PREP Act, may lead plaintiffs to assert that their claims are not barred under the PREP Act.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of the permissibility and liability risks, in the event a user of one or more of our products suffers an adverse event, we may be subject to additional reputational risk if the product has not been approved by the FDA or the corresponding regulatory authority of another country, particularly because we will not have approved labeling regarding the safety or efficacy of those products. In addition, legislatures and other governmental bodies that have oversight responsibility for procuring agencies may raise concerns after the fact, even if procurement was permissible at the time, which could result in negative publicity, reputational risk and harm to our business prospects.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that our communications with governments about our unapproved products, such as in the procurement context, could be considered promotion of an unapproved product or unapproved use of an approved product. Therefore, there is a risk that we could be subject to enforcement actions if found to be in violation of such laws or regulations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Even after regulatory approval is received, if we fail to comply with regulatory requirements, or if we experience unanticipated problems with our approved products, they could be subject to restrictions, penalties or withdrawal from the market.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any vaccine, therapeutic product or medical device for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to the continual requirements of and review by the FDA and other regulatory bodies. Our approved products are subject to these requirements and ongoing review. These requirements include submissions of safety and other post-marketing information and reports, plasma donor testing, registration requirements, cGMP, requirements relating to potency and stability, quality control, quality assurance, restrictions on advertising and promotion, import and export restrictions and recordkeeping requirements. In addition, various state laws require that companies that manufacture and/or distribute drug products within the state obtain and maintain a manufacturer or distributor license, as appropriate. Because of the breadth of these laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government regulators enforce cGMP and other requirements through periodic unannounced inspections of manufacturing facilities. The FDA is authorized to inspect domestic and foreign manufacturing facilities without prior notice at reasonable times and in a reasonable manner. Health Canada may conduct similar inspections of our domestic and foreign facilities where products offered and sold in Canada are produced, or related formulation and filling operations are conducted. The FDA, Health Canada and other foreign regulatory agencies conduct periodic inspections of our facilities. Following several of these inspections, regulatory authorities have issued inspectional observations, some of which were significant, but all of which are being, or have been, addressed through corrective actions. If, in connection with any future inspection, regulatory authorities find that we are not in substantial compliance with all applicable requirements, or if they are not satisfied with the corrective actions we take, our regulators may undertake enforcement action against us, which may include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">warning letters and other communications;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">product seizure or withdrawal of the product from the market;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">restrictions on the marketing or manufacturing of a product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">suspension or withdrawal of regulatory approvals or refusal to approve pending applications or supplements to approved applications;</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fines or disgorgement of profits or revenue; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar action may be taken against us should we fail to comply with regulatory requirements, or later discover previously unknown problems with our products or manufacturing processes. For instance, our products are tested regularly to determine if they satisfy potency and stability requirements for their required shelf lives. Failure to meet potency, stability or other specification requirements could result in delays in distributions, recalls or other consequences. Even if regulatory approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or sold or to the conditions of approval. Regulatory approval may also contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. If we experience any of these post-approval events, our business, financial condition, operating results and cash flows could be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, companies may not promote unapproved products or unapproved uses of approved products (i.e. &#8220;off-label&#8221; uses or uses that are not described in the product&#8217;s approved labeling and that differ from the uses approved by the applicable regulatory agencies). A company that is found to have improperly promoted an unapproved product or unapproved use of an approved product may be subject to significant liability, including civil and administrative remedies (such as entering into corporate integrity agreements with the USG), as well as criminal sanctions. If our employees or agents engage in marketing of an unapproved product or the unapproved use of an approved product, we could be subject to civil or criminal investigations and monetary and injunctive penalties, which could adversely impact our ability to conduct business in certain markets, negatively affect our business, financial condition, operating results and cash flows, and damage our reputation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failure to obtain or maintain regulatory approval in international jurisdictions could prevent us from marketing our products abroad and could limit the growth of our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently sell certain of our products outside the United States and intend to expand the countries in which we sell our products and have received market authorization under the mutual recognition procedure to sell BioThrax in France, Italy, the Netherlands, Poland, and the United Kingdom. To market or sell our </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products in foreign jurisdictions under normal circumstances, we generally need to obtain separate regulatory approvals and comply with numerous and varying requirements or use alternative &#8220;emergency use&#8221; or other exemptions from general approval and import requirements. Approval by the FDA in the United States or the mutual recognition procedure in the European member states does not ensure approval by all foreign regulatory authorities. The approval procedures in foreign jurisdictions can vary widely and can involve additional clinical trials and data review beyond that required by the FDA or under the mutual recognition procedure. There is also a risk that a regulatory authority in another country could conclude that we have violated the rules and regulations related to product development, approval or promotion in that country. Therefore, there is a risk that we could be subject to a foreign enforcement action if found to be in violation of such laws and regulations. We and our collaborators may not be able to obtain foreign regulatory approvals on a timely basis, if at all, and we may be unable to successfully commercialize our products in desired jurisdictions internationally if no alternate procurement pathway is identified for authorized government customers in a particular jurisdiction. We have limited experience in preparing, filing and prosecuting the applications necessary to gain foreign regulatory approvals and expect to rely on third-party contract research organizations and consultants to assist us in this process. Our reliance on third parties can introduce additional uncertainty into the process.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency (the MHRA), became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to European Union rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended). or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law of the body of European Union law instruments governing medicinal products that pre-existed prior to the United Kingdom's withdrawal from the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain products outside of </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the United States and require us to develop and implement costly compliance programs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our commercialization activities outside of the United States, we are subject to an increased risk of, and must dedicate additional resources towards avoiding inadvertently conducting activities in a manner that violates the FCPA, the U.K. Bribery Act, Canada's Corruption of Foreign Public Officials Act, and other similar foreign laws, which prohibit corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the Company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including the United States, also have various lobbying laws and regulations governing the conduct of individuals and companies who interact with government officials. These laws and regulations typically include certain restrictions and disclosure obligations. If we, our employees, or third parties acting on our behalf do not comply with these laws and regulations, we may be subject to civil and criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including the United States, restrict the export or import of products to or from certain countries through, for example, bans, sanction programs, and boycotts. Such restrictions may preclude us from supplying products in certain countries, which could limit our growth potential. Furthermore, if we, or third parties acting on our behalf, do not comply with these restrictions, we may be subject to civil and criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we continue to expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITIVE AND POLITICAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development and commercialization of pharmaceutical products, including for PHT preparedness, are routinely subject to evolving private and public sector competition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new biopharmaceutical and medical technology products is highly competitive and subject to rapid technological advances. We face and will continue to face future competition from other companies and governments, universities and other non-profit research organizations in respect of our products, any products that we acquire, our current product candidates and any products we may seek to develop or commercialize in the future. The market for products can be subject to development of safer, more effective, more convenient or less costly products. The market for products can also depend on what resources can be devoted to marketing or selling products, or how companies are positioned to adapt more quickly to new technologies, respond to scientific advances or patient preferences and needs, initiate or withstand substantial price competition and/or procure third-party licensing and collaborative arrangements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of companies with products or product candidates addressing PHT preparedness that are competing with us for both USG procurement and development resources. Factors to consider include competitors' financial, technical, marketing and selling resources as well as potential leverage that their intellectual property estates may offer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in demand for our products or reduction or loss of development funding for our products or product candidates in favor of a competing </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product could lead to a loss of market share for our products and cause reduced revenues, margins and levels of profitability for us, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our biologic products may face risks of competition from biosimilar manufacturers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biological products and product candidates, which we refer to as &#8220;Biologic Products&#8221;, can be affected by the approval and entry of &#8220;biosimilars&#8221; in the United States and other jurisdictions. Biosimilar drugs are &#8220;highly similar&#8221;, but close enough in duplication, to accomplish the same therapeutic and clinical result. Biologic Products in our current pipeline include AV7909, BioThrax, and ACAM2000. If a biosimilar version of one of our Biologic Products were approved, it could have a material adverse effect on the sales and gross profits of the affected Biologic Product and could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NARCAN&#174; (naloxone HCI) Nasal Spray is currently subject to generic competition and may be subject to additional branded and generic competition in the future.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN currently faces generic competition. In 2016, Teva filed an ANDA seeking regulatory approval to market a generic version of NARCAN. In patent litigation related to Teva&#8217;s ANDA filing, a trial Court decided in favor of Teva, and this decision was subsequently affirmed by the Court of Appeals for the Federal Circuit.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2021, Teva commenced the launch of its generic naloxone nasal spray. NARCAN may face additional generic competition from other parties, including from Perrigo UK FINCO Limited Partnership (Perrigo), who filed their own ANDA in 2018. Emergent settled with Perrigo on February 12, 2020 providing for a license effective upon the Teva litigation decision.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of generic versions of NARCAN at prices lower than our branded product or the version provided at no cost by Teva, have the potential to erode our sales and could impact our product revenue related to NARCAN. For example, certain U.S. state laws allow for, and in some instances in the absence of specific instructions from the prescribing physician, mandate the dispensing of generic products rather than branded products where a generic version is available. In addition, in January 2019, the FDA released new proposed template Drug Facts Labels to assist sponsors of investigational naloxone nasal sprays and </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">auto-injectors seeking approval from the FDA for over-the-counter naloxone products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN may also face branded competition.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on April 30, 2021, the FDA approved Kloxxado</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a branded product developed by Hikma Pharmaceuticals, Inc. which delivers a higher dose naloxone nasal spray.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Orexo AB and Harm Reduction Therapeutics both have development programs for novel naloxone nasal spray formulations intended for use in opioid overdose reversal.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional branded competition may correspond to other injectable naloxone, auto-injectors and improvised nasal kits including Amphastar Pharmaceuticals, Inc.'s naloxone injection product and Kal&#233;o's EVZIO</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCI injection) Auto-Injector.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Political or social factors may delay or impair our ability to market and sell our products and may require us to spend significant management time and financial resources to address these issues.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products developed to counter the potential impact of PHTs are subject to changing political and social environments. The political responses and social awareness of the risks of these threats on military personnel or civilians and the level of emphasis placed on such risks by the USG may vary over time. If the threat of terrorism were to decline, then the public perception of the risk on public health and safety may be reduced. This perception, as well as political or social pressures, could delay or cause resistance to bringing our products in development to market or limit pricing or purchases of our products, any of which could negatively affect our revenues and our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, substantial delays or cancellations of purchases could result from protests or challenges from third parties. Lawsuits brought against us by third parties or activists, even if not successful, could require us to spend significant management time and financial resources defending the related litigation and could potentially damage the public's perception of us and our products. Any publicity campaigns or other negative publicity may adversely affect the degree of market acceptance of our MCMs and thereby limit the demand for our products, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to obtain orphan drug exclusivity for product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven years in the United States.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for the FDA to grant orphan drug exclusivity to one of our products, the agency must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA or such authorities conclude that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Protection of our intellectual property rights is an important tool for sustaining our business and the failure to do so could impact our financial condition, operating results, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek to protect intellectual property rights related to our Company's assets, including patent rights, trademark rights, trade secrets and proprietary confidential information, through defense and enforcement of existing rights and pursuit of protection on new and arising innovations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining, maintaining and defending our intellectual property rights in the United States and other countries remains a critical component of the development and commercialization of our Company's assets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the risks associated with procurement, maintenance and enforcement of intellectual property </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights include changes in patent laws or administrative patent office rules, evolving criteria and eligibility of obtaining patent protection on particular subject matter, the validity and enforceability of our intellectual property rights, the potential scope of coverage of our intellectual property rights, and/or the availability or strength of legal remedies in a particular country to defend and enforce intellectual property rights.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks include associated costs, such as costs of patent prosecution and maintenance and costs associated with post-grant challenges. For example, such costs include </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes review</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proceedings in the United States and oppositions in Europe, as well as costs associated with litigating and enforcing patent and trademark rights.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional risks include limitations on our extent or ability to procure, maintain or defend intellectual property rights associated with in-licensed or acquired intellectual property, where, for example, third parties may have the first right to maintain or defend intellectual property rights in which we have an interest, or may pursue strategies that are divergent to the interest of our Company.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third-party claims of patent infringement could impact our business, financial condition, operating results, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Claims by third parties of alleged patent infringement could delay or affect the development and commercialization of our products and product candidates. Such challenges, while ongoing, could be costly, requiring and utilizing company resources. Such challenges, if successful, may impact marketing or launch of products, or require ongoing license and/or royalty fees associated with potential settlement agreements. These may have the potential to materially harm our business, financial condition, operating results, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intellectual property licenses with third parties carry risks of challenges, which may be costly and time consuming and could impact the commercialization of our products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of license agreements and expect to enter into additional license agreements in the future. Such license agreements or collaboration arrangements can be subject to challenges if interests or expectations under such license agreements diverge. Such challenges may be costly, risk time and resources, and could delay or impact development, commercialization or launch of our products.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential loss of proprietary information and know-how generally carries the risk of reducing the value of our technology and products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented proprietary technology, processes, and know-how, particularly as to our proprietary manufacturing processes. These types of confidential information and trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants, and third parties, as well as confidentiality policies and audits, although these may not always be successful in protecting our trade secrets and confidential information.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One or more of our products could be subject to early competition from generic drugs and biosimilars.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our products is approved as a drug product under the provisions of the FDCA, which may render it susceptible to potential competition from generic manufacturers via the Hatch-Waxman Act and ANDA process. Other of our products may be susceptible to challenges by entry of biosimilars through the route established under the Biologics Price Competition and Innovation Action of 2009.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we intend to vigorously enforce our intellectual property rights, there can be no assurance that we will prevail in our enforcement or defense of our patent rights. Our existing patents could be invalidated, found unenforceable, or found not to cover a generic form of our product.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO RELIANCE ON THIRD PARTIES </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The loss of any of our non-exclusive, sole-source or single source suppliers, a shortage of related supplies or an increase in the price of inventory supplied to us could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase certain supplies used in our manufacturing processes from non-exclusive or single sources due to quality considerations, costs or constraints resulting from regulatory requirements. We depend on certain single-source suppliers for key materials and services necessary to manufacture the majority of our products and certain product candidates. For example, we rely on a single-source supplier to provide us with Alhydrogel in sufficient quantities to meet our needs to manufacture AV7909 and BioThrax and the specialty plasma in our hyperimmune specialty plasma products and certain ingredients for ACAM2000. We also rely on single-source suppliers for the materials necessary to produce NARCAN, such as the naloxone active </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmaceutical ingredient and other excipients, along with the vial, stopper and device.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where a particular single-source supply relationship is terminated, we may not be able to establish additional or replacement suppliers for certain components or materials quickly. This is largely due to the FDA approval system, which mandates validation of materials prior to use in our products and product candidates, and the complex nature of manufacturing processes. In addition, we may lose a sole-source supplier due to, among other things, the impact of COVID-19 on such supplier, the acquisition of a supplier by a competitor (which may cause the supplier to stop selling its products to us) or the bankruptcy of such a supplier, which may cause the supplier to cease operations. Any reduction or interruption by a sole-source supplier of the supply of materials or key components used in the manufacturing of our products or product candidates, a reduction in quality or an increase in the price of those materials or components could adversely affect us. If we are unable to locate or establish alternative suppliers, our ability to manufacture our products and product candidates could be adversely affected and could harm our revenues, cause us to fail to satisfy contractual commitments, lead to a termination of one or more of our contracts or lead to delays in our clinical trials, any of which could be costly to us and otherwise materially harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend on third parties to conduct many of our clinical and non-clinical trials. If these third parties do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or commercialize our product candidates and, as a result, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on third parties, such as independent clinical investigators, contract research organizations and other third-party service providers to conduct the clinical and non-clinical trials of our product candidates and expect to continue to do so. We rely heavily on these third parties for successful execution of our clinical and non-clinical trials, but do not exercise day-to-day control over their activities. Our reliance on these service providers does not relieve us of our regulatory responsibilities, including ensuring that our trials are conducted in accordance with good clinical practice regulations and the plan and protocols contained in the relevant regulatory application. In addition, these organizations may not complete these activities on our anticipated or desired timeframe. We also may experience unexpected cost increases that are beyond our control. Problems with the timeliness or </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quality of the work of a contract research organization or other third party may lead us to seek to terminate the relationship and use an alternative service provider, which may prove difficult, costly and result in a delay of our trials. Any delay in or inability to complete our trials could delay or prevent the development, approval and commercialization of our product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, government entities and non-governmental organizations ("NGOs") conduct studies of our product candidates, and we may seek to rely on these studies in applying for marketing approval for certain of our product candidates. These government entities and NGOs have no obligation or commitment to us to conduct or complete any of these studies or clinical trials and may choose to discontinue these development efforts at any time. Furthermore, government entities depend on annual Congressional appropriations to fund their development efforts, which may not be approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain any necessary third-party services on acceptable terms or if these service providers do not successfully carry out their contractual duties or meet expected deadlines, our efforts to obtain regulatory approvals for our product candidates may be delayed or prevented.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL AND REPUTATIONAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our financial condition and operating results could be adversely impacted by unfavorable results of legal proceedings or government investigations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various claims, legal proceedings and government investigations that have not yet been fully resolved, including shareholder derivative and putative class action lawsuits, and new matters may arise in the future. In addition, agreements entered into by us sometimes include indemnification provisions which can subject us to costs and damages in the event of a claim against an indemnified third party. The number of claims, legal proceedings and government investigations involving us, and the alleged magnitude of such claims, proceedings and government investigations, has generally increased over time and may continue to increase. Certain of these actions include, and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other actions adverse to us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, multiple purported class action lawsuits have been filed against us and certain of our current and former senior officers in the United States District Court for the District of Maryland seeking unspecified damages on behalf of a putative class of </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">persons who purchased or otherwise acquired shares of our common stock during various date ranges. The complaints allege, among other things, that we made materially false and misleading statements regarding our procedures and quality controls relating to vaccine production, in violation of federal securities laws. As another example, multiple shareholder derivative lawsuits were filed in The Court of Chancery of the State of Delaware and the United States District Court for the District of Maryland on behalf of the Company against certain current and former officers and directors for breach of fiduciary duties, waste of corporate assets, unjust enrichment and insider trading, each allegation related to the Company&#8217;s capabilities to manufacture COVID-19 vaccine bulk drug substance. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have received inquiries and subpoenas to produce documents from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis, Senator Murray of the Committee on Health, Education, Labor and Pensions, the Financial Industry Regulatory Authority, the Department of Justice), the SEC, the Maryland Attorney General&#8217;s Office, and the New York Attorney General&#8217;s Office. We are producing and have produced documents as required in response and will continue to cooperate with these government inquiries.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of merit, litigation can be both time-consuming and disruptive to our operations and cause significant expense and diversion of management&#8217;s attention. The outcome of litigation or government investigations is also inherently uncertain. If one or more legal matters were resolved against us or an indemnified third party in a reporting period for amounts above management&#8217;s expectations, our financial condition and operating results for that reporting period could be materially adversely affected. Further, such an outcome could result in significant compensatory, punitive or trebled monetary damages, disgorgement of revenue or profits, remedial corporate measures or injunctive relief against us and could require us to change our business practices or limit our ability to offer certain products and services, all of which could materially adversely affect our financial condition and operating results. While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> rely significantly on information technology systems and any failure, inadequacy, interruption or </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">security lapse of that technology, including any cyber security incidents, could harm our ability to operate our business effectively or result in data leakage of proprietary and confidential business and employee information.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. We also have contracted with the USG and pharmaceutical companies, which has raised our security profile, and heightened potential risks that malicious actors may seek to disrupt our systems or misappropriate our information. The size and complexity of our computer systems make them potentially vulnerable to interruption, invasion, computer viruses, destruction, malicious intrusion and additional related disruptions, which may result in the impairment of production and key business processes. Our systems are also potentially vulnerable to data security breaches through employee error, phishing scams and malfeasance, which may expose sensitive data to unauthorized persons. No system of protection is adequate to protect against all such threats, even if they are deemed to be industry standard, and there can be no assurance that we will be able to repel any such attacks. Data security breaches could lead to the loss of trade secrets or other intellectual property or the public exposure of personal information, including sensitive personal information, of our employees, clinical trial patients, customers and others. Responding to any such threats may also be expensive and time-consuming.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant business disruption or a breach in security resulting in misappropriation, theft or sabotage with respect to proprietary and confidential business and employee information could result in significant financial losses, legal, business or reputational harm to us, compromise our business prospects and our commitments to the USG or other customers, any of which could materially and adversely affect our business, financial condition and operating results.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our work on PHTs has exposed us to criticism and may expose us to further criticism, from the media, government personnel, and others, that can negatively affect our share price, reputation, operations, and our ability to attract and retain talent and secure new customer contracts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our work on PHTs, including manufacturing issues at our Baltimore Bayview facility, has exposed us to criticism and may expose us to additional potential criticism, from the media, government personnel, and others. In addition, our work on PHTs has exposed us </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to governmental inquiries and investigations, including by Congress and other government agencies. For example, a joint panel of the U.S. House of Representatives launched an investigation into, among other things, the cause of the previously mentioned cross-contamination issues identified in a viral vaccine drug substance batch at the Baltimore Bayview facility. Such criticism can be particularly acute during a public health emergency like the COVID-19 pandemic. The unfavorable media coverage and increased government scrutiny, including the Congressional inquiry, could further harm our reputation, distract management&#8217;s attention from our operations, and impact our ability to attract and retain talent and result in further declines to our share price. We have already incurred significant legal costs to respond to government inquiries and are likely to incur additional costs. Any adverse actions by government authorities may result in significant civil or criminal fines or penalties, all of which could adversely impact our financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face product liability exposure, which could cause us to incur substantial liabilities and negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the sale of our products, any other products that we successfully acquire or develop and the testing of our product candidates in clinical trials.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One measure of protection against such lawsuits is coverage under the PREP Act, which was signed into law in December 2005. The PREP Act creates liability protection for manufacturers of biodefense countermeasures when the Secretary of HHS issues a declaration for their manufacture, administration or use. A PREP Act declaration is meant to provide liability protection from all claims under federal or state law for loss arising out of the administration or use of a covered countermeasure under a government contract. The Secretary of HHS has issued PREP Act declarations identifying certain of our products, namely BioThrax, ACAM2000, raxibacumab, Anthrasil, BAT and VIGIV, as covered countermeasures, which expire on December 31, 2022. Manufacturers are not entitled to protection under the PREP Act in cases of willful misconduct or for cases brought in non-U.S. tribunals or under non-U.S. law. We cannot predict whether the Secretary of HHS will renew the declarations when they expire, whether Congress will fund the relevant PREP Act compensation programs, or whether the necessary prerequisites for immunity would be triggered with respect to our products or product candidates.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, BioThrax and RSDL have been certified as anti-terrorism products under the SAFETY Act and applications for continued coverage under the SAFETY Act are currently pending. The SAFETY Act creates product liability limitations for qualifying anti-terrorism technologies for claims arising from or related to an act of terrorism. Although we have been entitled to the benefits of the SAFETY Act for BioThrax and RSDL, such benefits may not be renewed and even if they are renewed, the SAFETY Act may not provide adequate protection from claims made against us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against future claims that our products or product candidates caused injuries and if we are not entitled to indemnity by the USG, or the USG does not honor its obligations to us under the PREP Act or SAFETY Act, where applicable, or if the liability protections under the PREP Act and SAFETY Act, if applicable, are not adequate to cover all claims, we may incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">decreased demand or withdrawal of a product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">injury to our reputation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">costs to defend the related litigation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">loss of revenue; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an inability to commercialize products that we may develop.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. Further product liability insurance may be difficult and expensive to obtain. We may not be able to maintain insurance coverage at a reasonable cost and we may not be able to obtain insurance coverage that will be adequate to satisfy all potential liabilities. For example, we may not have sufficient insurance against potential liabilities associated with a possible large-scale deployment of BioThrax as a countermeasure to a bioterrorism threat. We rely on PREP Act protection for BioThrax, raxibacumab, ACAM2000, Anthrasil, BAT and VIGIV, and possible continuation of SAFETY Act protection for BioThrax and RSDL in addition to our insurance coverage to help mitigate our product liability exposure for these products. Additionally, potential product liability claims related to our commercial products, including NARCAN, Vivotif and Vaxchora, may be made by patients, health care providers or others who sell or consume these products. Such claims may </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be made even with respect to those products that possess regulatory approval for commercial sale. Claims or losses in excess of our product liability insurance coverage could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have incurred significant indebtedness in connection with our acquisitions and servicing our debt requires a significant amount of cash. We may not have sufficient cash flow from our operations to pay our substantial debt.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled payments of the principal of, to pay interest on or to further refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing can have significant adverse consequences for our business, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requiring us to dedicate a substantial portion of cash flows from operations to payment on our debt, which would reduce available funds for other corporate initiatives;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasing the amount of interest that we have to pay on debt with variable interest rates, if market rates of interest increase, to the extent we are unable to offset such risk through our hedging instruments;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">subjecting us, as under our Senior Secured Credit Facilities and the indenture governing the 3.875% Senior Unsecured Notes due 2028 (the "Senior Unsecured Notes"), to restrictive covenants that reduce our ability to take certain corporate actions, acquire companies, products or technology, or obtain further debt financing; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requiring us to pledge our assets as collateral, which could limit our ability to obtain additional debt financing; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limiting our flexibility in planning for, or reacting to, general adverse economic and industry conditions; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">placing us at a competitive disadvantage compared to our competitors that have less debt, better debt servicing options or stronger debt servicing capacity.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient funds or be able to obtain additional financing to pay the amounts due under our indebtedness. In addition, failure to comply with the covenants under our Senior Secured Credit Facilities and other debt agreements, including the maintenance of a specified consolidated net leverage ratio and debt service coverage ratio under our Senior Secured Credit Facilities, could result in an event of default under those agreements. An event of default could result in the acceleration of amounts due under a particular debt agreement and a cross default and acceleration under other debt agreements, and we may not have sufficient funds to pay or be able to obtain additional financing to make any accelerated payments. Under these circumstances, our lenders could seek to enforce security interests in our assets securing our indebtedness.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as of September 30, 2022, there was $238.0 million outstanding under the Revolving Credit Facility and $371.3 million outstanding under the Term Loan Facility that matures in October 2023, which is within one year of the date that the consolidated financial statements are issued for the quarter ended September 30, 2022. The Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern as a result. Any delay in or inability to refinance these Senior Secured Credit Facilities on favorable terms, or at all, could adversely affect our results of operations and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current indebtedness restricts and any additional debt financing may restrict the operation of our business and limit the cash available for investment in our&#160;business operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities include a </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$450&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Term Loan Facility which had an outstanding principal balance of $371.3 million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the ability </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to borrow up to $600&#160;million under our Revolving Credit Facility, of which we had $238 million in borrowings as of September&#160;30, 2022. On August 7, 2020, we completed an offering of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$450 million aggregate principal amount of Senior Unsecured Notes, of which $353 million of the net proceeds were used to pay down our Revolving Credit Facility. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing can have significant adverse consequences for our business, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the level, timing and cost of product sales and CDMO services;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the payment obligations under our indebtedness;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the scope, progress, results and costs of our development activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the extent to which we repurchase additional shares of common stock under our current share repurchase program; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the costs of commercialization activities, including product marketing, sales and distribution.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our hedging program is subject to counterparty default risk.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our interest rate risk in part by entering into interest rate swaps with a number of counterparties to swap a portion of our indebtedness that is based on variable interest rates to a fixed rate. As a result, we are subject to the risk that the counterparty to one or more of these contracts defaults on its performance under the contract. During an economic downturn, the counterparty's financial condition may deteriorate rapidly and with little notice and we may be unable to take action to protect our exposure. In the event of a counterparty default, we could incur losses, which may harm our business and financial condition. In the event that one or more of our counterparties becomes insolvent or files for bankruptcy, our ability to eventually recover any losses suffered as a result of that counterparty's default may be limited by the liquidity of the counterparty.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may require significant additional funding and be unable to raise capital when&#160;needed or on acceptable terms, which would harm our ability to grow our business, and our results of operations and financial condition. In addition, any capital we raise may result in dilution to our current shareholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans or collaboration and licensing arrangements. In August 2021, we filed an automatic shelf registration statement, which immediately became effective under SEC rules. For so long as we continue to satisfy the requirements to be deemed a &#8220;well-known seasoned issuer&#8221; under SEC rules (which </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include, among other things, the timely filing of our reports under the Exchange Act and maintenance of at least $700 million of public float or issuing an aggregate amount of $1 billion of non-convertible securities, other than common stock, in registered offerings for cash during the past three years), this shelf registration statement, effective until August 9, 2024, allows us to issue an unrestricted amount of equity, debt and certain other types of securities through one or more future primary or secondary offerings. If we do not file a new shelf registration statement prior to the expiration of our automatic shelf registration statement (whether by lapse of time or due to us no longer qualifying as a "well-known seasoned issuer"), the existing shelf registration statement will expire, and we will not be able to publicly raise capital or issue debt until a new registration statement is filed and becomes effective. There can be no assurance that we will be eligible to file an automatically effective shelf registration statement at a future date when we may need to raise funds publicly.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds by issuing equity securities, our shareholders may experience dilution. Debt financing, if available, may involve agreements that include covenants, like those contained in our Senior Secured Credit Facilities and the indenture governing the Senior Unsecured Notes, limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities or declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us. Our Senior Secured Credit Facilities as well as the indenture governing the Senior Unsecured Notes restrict our ability to incur additional indebtedness.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions may make it difficult to obtain financing on attractive terms, or at all. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not maintain profitability in future periods or on a consistent basis.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have been profitable on an annual basis since becoming a public company, we have not been profitable for every quarter during that time. Our profitability has been substantially dependent on product sales, which historically have fluctuated significantly from quarter to quarter, and we expect that they will continue to fluctuate significantly based primarily on the timing of our fulfillment of orders from </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the USG. We may not be able to achieve profitability on a quarterly basis or sustain or increase profitability on an annual basis.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The expansion of our international operations increases our risk of exposure to credit losses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our business activities with foreign governments in certain countries that have experienced deterioration in credit and economic conditions or otherwise, our exposure to uncollectible accounts will rise. Global economic conditions and liquidity issues in certain countries have resulted and may continue to result in delays in the collection of accounts receivable and may result in credit losses. Future governmental actions and customer specific actions may require us to re-evaluate the collectability of our accounts receivable and we may potentially incur credit losses that materially impact our operating results.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A substantial portion of our indebtedness bears interest at variable interest rates based on LIBOR and certain of our financial contracts are also indexed to LIBOR. Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness and may otherwise adversely affect our financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the Financial Conduct Authority, the authority that regulates the London Inter-bank Offered Rate ("LIBOR") announced that it intended to stop compelling banks to submit rates for the calculation of LIBOR after 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the International Exchange ("ICE") Benchmark Association, which administrates LIBOR, ceased (i) entering into new contracts that use LIBOR as a reference rate and (ii) publication of two LIBOR rates (one-week and two-month) and announced that the remaining LIBOR rates (overnight, one-month, three-month, six-month and 12-month) will be retired on June 30, 2023. It is unclear if LIBOR will cease to exist at that time or if new methods of calculating LIBOR will be established such that it continues to exist after 2023. We have certain financial contracts, including the amended credit agreement related to our Senior Secured Credit Facilities and our interest rate swaps, that are indexed to LIBOR. Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness. Any transition process may involve, among other things, increased volatility or illiquidity in markets for instruments that rely on LIBOR, reductions in the value of certain instruments or the effectiveness of related </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions such as hedges, increased borrowing costs, uncertainty under applicable documentation, or difficult and costly consent processes. The transition away from LIBOR may result in increased expenses, may impair our ability to refinance our indebtedness or hedge our exposure to floating rate instruments, or may result in difficulties, complications or delays in connection with future financing efforts, any of which could adversely affect our financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO STRATEGIC ACQUISITIONS AND COLLABORATIONS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our strategy of generating growth through acquisitions may not be successful.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes growing our business through acquisition and in-licensing transactions. For example, in September 2022, we completed the acquisition from Chimerix, Inc. of its exclusive worldwide rights to brincidofovir, including TEMBEXA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and related assets. We may not be successful in identifying, effectively evaluating, structuring, acquiring or in-licensing, and developing and commercializing additional products on favorable terms, or at all. Competition for attractive product opportunities is intense and may require us to devote substantial resources, both managerial and financial, to an acquisition opportunity. A number of more established companies are also pursuing strategies to acquire or in-license products in the biopharmaceutical field. These companies may have a competitive advantage over us due to their size, cash resources, cost of capital, effective tax rate and greater clinical development and commercialization capabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition efforts can consume significant management attention and require substantial expenditures, which could detract from our other programs. In addition, we may devote significant resources to potential acquisitions that are never completed. Even if we are successful in acquiring a company or product, it may not result in a successfully developed or commercialized product or, even if an acquired product is commercialized, competing products or technologies could render a product noncompetitive, uneconomical or obsolete. Moreover, the cost of acquiring other companies or in-licensing products could be substantial, and in order to acquire companies or new products, we may need to incur substantial debt or issue dilutive securities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in our efforts to acquire other companies or products or in-license and develop additional products, or if we acquire or in-license unproductive assets, it could have a material adverse effect on the growth of our business, and we could be </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compelled to record significant impairment charges to write-down the carrying value of our acquired intangible assets, which could materially harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our failure to successfully integrate acquired businesses and/or assets into our operations could adversely affect our ability to realize the benefits of such acquisitions and, therefore, to grow our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to integrate any acquired business successfully or operate any acquired business profitably. In addition, cost synergies, if achieved at all, may be less than we expect, or may take greater time to achieve than we anticipate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issues that could delay or prevent successful integration or cost synergies of an acquired business or products include, among others:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">retaining existing customers and attracting new customers;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">retaining key employees;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diversion of management attention and resources;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">conforming internal controls, policies and procedures, business cultures and compensation programs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidating corporate and administrative infrastructures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">successfully executing technology transfers and obtaining required regulatory approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidating sales and marketing operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">identifying and eliminating redundant and underperforming operations and assets;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">assumption of known and unknown liabilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">coordinating geographically dispersed organizations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">managing tax costs or inefficiencies associated with integrating operations; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">risks associated with intellectual property rights related to an acquisition or collaboration.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully integrate pending and future acquisitions with our existing businesses, or operate any acquired business profitably, we may not obtain the advantages that the acquisitions were intended to create, which may materially adversely </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affect the growth of our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business or our share price could be negatively affected as a result of the actions of shareholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, some shareholders have placed increasing pressure on publicly traded companies in our industry and others to effect changes to corporate governance practices, executive compensation practices, social and environmental practices and to undertake certain corporate actions. This may be true even if they only hold a minority of shares. In addition, many institutional investors are increasingly focused on ESG factors. These investors may be seeking enhanced ESG disclosures or to implement policies adverse to our business. There can be no assurances that shareholders will not publicly advocate for us to make corporate governance changes or engage in certain corporate actions. Responding to challenges from shareholders, such as proxy contests, media campaigns or other public or private means, could be costly and time consuming and could have an adverse effect on our reputation and divert the attention and resources of management and our board, which could have an adverse effect on our business and operational results. Any such shareholder actions or requests, or the mere public presence of shareholders with a reputation for taking such actions among our shareholder base, could also cause the market price of our common stock to experience periods of significant volatility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and by-laws and under Delaware law may discourage acquisition proposals, delay a change in control or prevent transactions that shareholders may consider favorable.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and by-laws may discourage, delay or prevent a merger, acquisition or other changes in control that shareholders may consider favorable, including transactions in which shareholders might otherwise receive a premium for their shares. These provisions may also prevent or frustrate attempts by our shareholders to replace or remove our management.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the classification of our directors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations on changing the size of our Board of Directors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations on the removal of directors;</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations on filling vacancies on the Board of Directors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">advance notice requirements for shareholder nominations of candidates for election to the Board of Directors and other proposals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability of shareholders to act by written consent;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability of shareholders to call special meetings; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the ability of our Board of Directors to designate the terms of and issue a new series of preferred stock without shareholder approval.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative vote of a majority of our Board of Directors or the holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal the above provisions of our certificate of incorporation or by-laws. The affirmative vote of either a majority of the directors present at a meeting of our Board of Directors or holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal our by-laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to Section 203 of the Delaware General Corporation Law ("Section 203"). In general and subject to certain exceptions, Section 203 prohibits a publicly-held corporation from engaging in a business combination with an interested shareholder, generally a person which, together with its affiliates, owns or within the last three years has owned 15% or more of the corporation's voting stock, for a period of three years after the date of the transaction in which the person became an interested shareholder, unless the business combination is approved in a prescribed manner. Accordingly, Section 203 may discourage, delay or prevent a change in control of us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Board of Directors may implement a new shareholder rights plan without shareholder approval, which could prevent a change in control of us in instances in which some shareholders may believe a change in control is in their best interests.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors may implement a shareholder rights plan without shareholder approval. We previously implemented a shareholder rights plan, which expired on November 14, 2016. Under our prior shareholder rights plan, we issued to each of our shareholders one preferred stock purchase right for each outstanding share of our common stock. Each right, when exercisable, would have entitled its holder </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to purchase from us a unit consisting of one one-thousandth of a share of series A junior participating preferred stock at a purchase price of $150 in cash, subject to adjustments. Our shareholder rights plan was intended to protect shareholders in the event of an unfair or coercive offer to acquire us and to provide our Board of Directors with adequate time to evaluate unsolicited offers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors may implement a new shareholder rights plan, which may have anti-takeover effects, potentially preventing a change in control of us in instances in which some shareholders may believe a change in control is in their best interests. This could cause substantial dilution to a person or group that attempts to acquire us on terms that our Board of Directors does not believe are in our best interests or those of our shareholders and may discourage, delay or prevent a merger or acquisition that shareholders may consider favorable, including transactions in which shareholders might otherwise receive a premium for their shares.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our stock price is volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been, and is likely to continue to be, volatile. The market price of our common stock could fluctuate significantly for many reasons, including in response to the risks described in this &#8220;Risk Factors&#8221; section, or for reasons unrelated to our operations, such as reports by industry analysts, investor perceptions or negative announcements by our customers, competitors or suppliers regarding their own performance, as we</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ll as industry conditions and general financial, economic and political instability. From November 15, 2006, when our common stock first began trading on the New York Stock Exchange, through November&#160;1, 2022, our common stock has traded as high as $137.61 per share and as low as $4.17 per share. Due to fears associated with current world events, current historically high levels of inflation and the possible resurgence of COVID-19, the stock market has been </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experiencing extreme volatility and the market for biopharmaceutical companies has generally experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock may be influenced by many factors, including, among others:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">contracts, decisions and procurement policies by the USG affecting our anthrax vaccines and our other products and product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">CDMO contracts related to COVID-19 with collaboration partners;</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the success of competitive products or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">results of clinical and non-clinical trials of our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">announcements of acquisitions, financings or other transactions by us;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">litigation or legal proceedings;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">public concern as to the safety of our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">termination or delay of a development program;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">variations in our product revenue and profitability; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because we currently do not pay dividends, investors will benefit from an investment in our common stock only if it appreciates in value.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not pay dividends on our common stock. Our Senior Secured Credit Facilities and the indenture governing our Senior Unsecured Notes limit and any future debt agreements that we enter into may limit our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our shareholders based on current expectations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future issuances of our common stock or securities convertible into common stock could result in dilution of our shareholders and could cause our share price to decline.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations or for general corporate purposes. To the extent we raise additional capital by issuing equity securities or securities convertible or exchangeable into common stock, our shareholders may experience substantial dilution. We may sell common stock, and we may sell convertible or exchangeable securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell such common stock, convertible or exchangeable securities or other equity securities in subsequent transactions, existing shareholders may be materially diluted.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accuracy of our financial reporting depends on the effectiveness of our internal control over financial reporting. A material weakness in our internal control over financial reporting could have an adverse effect on our business and financial results and our ability to meet our reporting obligations could be negatively affected, each of which could negatively affect the trading price of our common stock.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements and may not prevent or detect misstatements. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Failure to maintain effective internal control over financial reporting, or lapses in disclosure controls and procedures, could impact our financial information and disclosures, require significant resources to remediate, and expose us to legal or regulatory proceedings.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review and update our internal controls and disclosure controls and procedures. In addition, we are required under the Sarbanes-Oxley Act of 2002 to report annually on our internal control over financial reporting.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our system of internal controls, however well-designed, can provide only reasonable, not absolute, assurances that the objectives of the system are met. If we, or our independent registered public accounting firm, determine that our internal controls over financial reporting, or the internal controls of other companies we may acquire, are not effective, or we discover areas that need improvement in the future, these shortcomings could have an adverse effect on our business and financial reporting, and the trading price of our common stock could be negatively affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our success is dependent on our continued ability to attract, motivate and retain key personnel, and any failure to attract or retain key personnel may negatively affect our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the specialized scientific nature of our business, our ability to develop products and to compete with our current and future competitors largely depends upon our ability to attract, retain and motivate highly qualified managerial and key scientific and technical personnel (including quality and manufacturing personnel). If we are unable to retain the services of one or more of the principal members </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of senior management or other key employees, our ability to implement our business strategy could be materially harmed. We face intense competition for qualified employees from biopharmaceutical companies, research organizations and academic institutions. Attracting, retaining or replacing these personnel on acceptable terms may be difficult and time-consuming given the high demand in our industry for similar personnel. We believe part of being able to attract, motivate and retain personnel is our ability to offer a competitive compensation package, including equity incentive awards. If we cannot offer a competitive compensation package to attract and retain the qualified personnel necessary for the continued development of our business, we may not be able to maintain our operations or grow our business.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_130"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent sales of unregistered securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of proceeds</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of equity securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_133"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_136"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_139"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.&#160;&#160;&#160;&#160;</span></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_142"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits hereto.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_145"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="a311-kramercert93022.htm">Certification of the Chief Executive Officer, pursuant to Exchange Act Rule 13a-14(a).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="a312-lindhalcert93022.htm">Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1 #</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="a321-kramercert93022.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2 #</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline" href="a322-lindhalcert93022.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial information related to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2022, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statement of Changes in Stockholders' Equity; and (vi) the related Notes to the Condensed Consolidated Financial Statements.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101.<br/></span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i9bec4b75ff354735b09dcc9c604dfa92_148"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.195%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">By: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ROBERT G. KRAMER</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Robert G. Kramer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Date: November 8, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">By: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%;text-decoration:underline">/s/RICHARD S. LINDAHL</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Richard S. Lindahl</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Executive Vice President, Chief Financial Officer and Treasurer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Date: November 8, 2022</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a311-kramercert93022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0e614fa84740496abad3037612b6de6b_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert G. Kramer, certify that&#58;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Emergent BioSolutions Inc.&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; November&#160;8, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47;ROBERT G. KRAMER</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Robert G. Kramer</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></div><div style="height:69.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a312-lindhalcert93022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib13f6dec5ff04a309b16323fccaedf2c_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard S. Lindahl, certify that&#58;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Emergent BioSolutions Inc.&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;November&#160;8, 2022</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47;RICHARD S. LINDAHL</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard S. Lindahl</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a321-kramercert93022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4767e9eb5f414d91b0f85365acdf3235_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form&#160;10-Q&#160;of Emergent BioSolutions Inc. (the &#34;Company&#34;) for the period ended&#160;September&#160;30, 2022&#160;as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned, Robert G. Kramer, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-indent:-13.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;November&#160;8, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47;ROBERT G. KRAMER</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert G. Kramer</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a322-lindhalcert93022.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ife71721c9c0c469e9986d05327197338_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 32.2</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In connection with the Quarterly Report on Form 10-Q of Emergent BioSolutions Inc. (the &#34;Company&#34;) for the period ended&#160;September&#160;30, 2022&#160;as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned, Richard S. Lindahl, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58; </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58;&#160;November&#160;8, 2022</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;RICHARD S. LINDAHL</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Richard S. Lindahl</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ebs-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e49bcad1-b3a3-4429-b549-b7280da8936a,g:b60fc6ff-4763-459f-a134-feb07b4a5302-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ebs="http://emergentbiosolutions.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://emergentbiosolutions.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://emergentbiosolutions.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical">
        <link:definition>0000008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Business" roleURI="http://emergentbiosolutions.com/role/Business">
        <link:definition>0000009 - Disclosure - Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpresentationandprinciplesofconsolidation" roleURI="http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation">
        <link:definition>0000010 - Disclosure - Basis of presentation and principles of consolidation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventoriesnet" roleURI="http://emergentbiosolutions.com/role/Inventoriesnet">
        <link:definition>0000011 - Disclosure - Inventories, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipmentnet" roleURI="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet">
        <link:definition>0000012 - Disclosure - Property, plant and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://emergentbiosolutions.com/role/Leases">
        <link:definition>0000013 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassets" roleURI="http://emergentbiosolutions.com/role/Intangibleassets">
        <link:definition>0000014 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurements" roleURI="http://emergentbiosolutions.com/role/Fairvaluemeasurements">
        <link:definition>0000015 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Derivativeinstrumentsandhedgingactivities" roleURI="http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities">
        <link:definition>0000016 - Disclosure - Derivative instruments and hedging activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://emergentbiosolutions.com/role/Debt">
        <link:definition>0000017 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://emergentbiosolutions.com/role/RevenueRecognition">
        <link:definition>0000018 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://emergentbiosolutions.com/role/Incometaxes">
        <link:definition>0000019 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomelosspershare" roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershare">
        <link:definition>0000020 - Disclosure - Net Income (loss) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://emergentbiosolutions.com/role/Equity">
        <link:definition>0000021 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://emergentbiosolutions.com/role/SegmentInformation">
        <link:definition>0000022 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://emergentbiosolutions.com/role/CommitmentsandContingencies">
        <link:definition>0000023 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandprinciplesofconsolidationPolicies" roleURI="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies">
        <link:definition>0000024 - Disclosure - Basis of presentation and principles of consolidation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetTables" roleURI="http://emergentbiosolutions.com/role/InventoriesnetTables">
        <link:definition>0000025 - Disclosure - Inventories, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentnetTables" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables">
        <link:definition>0000026 - Disclosure - Property, plant and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://emergentbiosolutions.com/role/LeasesTables">
        <link:definition>0000027 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsTables" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsTables">
        <link:definition>0000028 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsTables" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables">
        <link:definition>0000029 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesTables" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables">
        <link:definition>0000030 - Disclosure - Derivative instruments and hedging activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://emergentbiosolutions.com/role/DebtTables">
        <link:definition>0000031 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionTables">
        <link:definition>0000032 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomelosspershareTables" roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershareTables">
        <link:definition>0000033 - Disclosure - Net Income (loss) per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://emergentbiosolutions.com/role/EquityTables">
        <link:definition>0000034 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://emergentbiosolutions.com/role/SegmentInformationTables">
        <link:definition>0000035 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessDetails" roleURI="http://emergentbiosolutions.com/role/BusinessDetails">
        <link:definition>0000036 - Disclosure - Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandprinciplesofconsolidationDetails" roleURI="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails">
        <link:definition>0000037 - Disclosure - Basis of presentation and principles of consolidation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetScheduleofInventoryDetails" roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails">
        <link:definition>0000038 - Disclosure - Inventories, net - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>0000039 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails">
        <link:definition>0000040 - Disclosure - Property, plant and equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>0000041 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>0000042 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails">
        <link:definition>0000043 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails">
        <link:definition>0000044 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails">
        <link:definition>0000045 - Disclosure - Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails">
        <link:definition>0000046 - Disclosure - Intangible assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsGoodwillRollForwardDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails">
        <link:definition>0000047 - Disclosure - Intangible assets - Goodwill Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails">
        <link:definition>0000048 - Disclosure - Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsContingentConsiderationRollForwardDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails">
        <link:definition>0000049 - Disclosure - Fair value measurements - Contingent Consideration Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsAdditionalInformationDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails">
        <link:definition>0000050 - Disclosure - Fair value measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails">
        <link:definition>0000051 - Disclosure - Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails">
        <link:definition>0000052 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails">
        <link:definition>0000053 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails">
        <link:definition>0000054 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails">
        <link:definition>0000055 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleDetails" roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails">
        <link:definition>0000056 - Disclosure - Debt - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails">
        <link:definition>0000057 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>0000058 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>0000059 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionPerformanceObligationsDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails">
        <link:definition>0000060 - Disclosure - Revenue Recognition - Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionPerformanceObligationsDetails_1" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails_1">
        <link:definition>0000060 - Disclosure - Revenue Recognition - Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionRemainingPerformanceObligationDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails">
        <link:definition>0000061 - Disclosure - Revenue Recognition - Remaining Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionRemainingPerformanceObligationDetails_1" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails_1">
        <link:definition>0000061 - Disclosure - Revenue Recognition - Remaining Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractLiabilitiesDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails">
        <link:definition>0000062 - Disclosure - Revenue Recognition - Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionAccountsReceivableDetails" roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails">
        <link:definition>0000063 - Disclosure - Revenue Recognition - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesDetails" roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails">
        <link:definition>0000064 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomelosspershareDetails" roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershareDetails">
        <link:definition>0000065 - Disclosure - Net Income (loss) per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/EquityNarrativeDetails">
        <link:definition>0000066 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofStockbasedCompensationExpenseDetails" roleURI="http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>0000067 - Disclosure - Equity - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityChangesinAccumulatedOtherComprehensiveLossDetails" roleURI="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails">
        <link:definition>0000068 - Disclosure - Equity - Changes in Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" roleURI="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails">
        <link:definition>0000069 - Disclosure - Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails">
        <link:definition>0000070 - Disclosure - Segment Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails">
        <link:definition>0000071 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>0000072 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ebs_ProductsSegmentMember" abstract="true" name="ProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_AssetAcquisitionTreatmentVolumeThreshold" abstract="false" name="AssetAcquisitionTreatmentVolumeThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_ContractsAndGrantsMember" abstract="true" name="ContractsAndGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ContractWithCustomerLiabilityDeductions" abstract="false" name="ContractWithCustomerLiabilityDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantConsiderationThreshold" abstract="false" name="DebtInstrumentCovenantConsiderationThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_OperatingLeaseRightOfUseAssetRemoval" abstract="false" name="OperatingLeaseRightOfUseAssetRemoval" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" abstract="false" name="AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_ChimerixAssetAcquisitionMember" abstract="true" name="ChimerixAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" abstract="false" name="CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_AdjustedGrossMargin" abstract="false" name="AdjustedGrossMargin" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_OtherLongTermDebtFacilityMember" abstract="true" name="OtherLongTermDebtFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioRollingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" abstract="false" name="AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_MilestonePaymentsMember" abstract="true" name="MilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AcceleratedExpansionOfFillFinishCapacityMember" abstract="true" name="AcceleratedExpansionOfFillFinishCapacityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ServicesSegmentMember" abstract="true" name="ServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioOne" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_ContractWithCustomerLiabilityAdditions" abstract="false" name="ContractWithCustomerLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" abstract="false" name="AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_NumberOfRevenueGeneratingProducts" abstract="false" name="NumberOfRevenueGeneratingProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" abstract="false" name="PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioTwo" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" abstract="false" name="DebtInstrumentCovenantDebtServiceCoverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_OperatingLeaseLeaseIncomeReversal" abstract="false" name="OperatingLeaseLeaseIncomeReversal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ReservationOfManufacturingCapacityMember" abstract="true" name="ReservationOfManufacturingCapacityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_NumberOfBusinessLines" abstract="false" name="NumberOfBusinessLines" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" abstract="false" name="PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" abstract="false" name="OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ebs_ContractDevelopmentAndManufacturingLeasesMember" abstract="true" name="ContractDevelopmentAndManufacturingLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ContractDevelopmentAndManufacturingMember" abstract="true" name="ContractDevelopmentAndManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_BARDAMember" abstract="true" name="BARDAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_NumberOfCategoriesOfPublicHealthThreats" abstract="false" name="NumberOfCategoriesOfPublicHealthThreats" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_ChangeinContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeinContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_RockvilleManufacturingFacilityMember" abstract="true" name="RockvilleManufacturingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_JansenPharmaceuticalsIncMember" abstract="true" name="JansenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" abstract="false" name="PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_MeasurementInputProbabilityofPaymentMember" abstract="true" name="MeasurementInputProbabilityofPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ScheduleOfAccountsReceivableNetTableTextBlock" abstract="false" name="ScheduleOfAccountsReceivableNetTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ebs_SeniorUnsecuredNotesDueAugust2028Member" abstract="true" name="SeniorUnsecuredNotesDueAugust2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ebs-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e49bcad1-b3a3-4429-b549-b7280da8936a,g:b60fc6ff-4763-459f-a134-feb07b4a5302-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bbf76f89-ed57-4a4a-aef1-7dc5f42cfac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6bf76b29-2100-4c8e-b57c-c4812b617889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bbf76f89-ed57-4a4a-aef1-7dc5f42cfac0" xlink:to="loc_us-gaap_AccountsPayableCurrent_6bf76b29-2100-4c8e-b57c-c4812b617889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8cd2437e-db12-49cb-8c1a-5839e70bf2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bbf76f89-ed57-4a4a-aef1-7dc5f42cfac0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8cd2437e-db12-49cb-8c1a-5839e70bf2ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7905674d-c707-476c-adbf-875e0e9f1ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bbf76f89-ed57-4a4a-aef1-7dc5f42cfac0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7905674d-c707-476c-adbf-875e0e9f1ce1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_54862e79-0591-445e-8f0e-1428c661c5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bbf76f89-ed57-4a4a-aef1-7dc5f42cfac0" xlink:to="loc_us-gaap_NotesPayableCurrent_54862e79-0591-445e-8f0e-1428c661c5a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_16adb4c6-30d5-4a8c-833d-ca010b6df427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bbf76f89-ed57-4a4a-aef1-7dc5f42cfac0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_16adb4c6-30d5-4a8c-833d-ca010b6df427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c1198e7b-67bd-4f7e-b2b3-0883872652fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_288b7b9a-0fe9-4327-a0ca-de0ddc4cc467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c1198e7b-67bd-4f7e-b2b3-0883872652fc" xlink:to="loc_us-gaap_PreferredStockValue_288b7b9a-0fe9-4327-a0ca-de0ddc4cc467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7357296d-0601-4b6b-889c-20bea8571b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c1198e7b-67bd-4f7e-b2b3-0883872652fc" xlink:to="loc_us-gaap_CommonStockValue_7357296d-0601-4b6b-889c-20bea8571b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e27f4dfb-0682-4889-b888-b1e0a6cf71b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c1198e7b-67bd-4f7e-b2b3-0883872652fc" xlink:to="loc_us-gaap_TreasuryStockValue_e27f4dfb-0682-4889-b888-b1e0a6cf71b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7b7b9c24-516f-4dba-8689-62e4a04899ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c1198e7b-67bd-4f7e-b2b3-0883872652fc" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7b7b9c24-516f-4dba-8689-62e4a04899ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56195421-6bc1-4801-a389-cf6d56f98411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c1198e7b-67bd-4f7e-b2b3-0883872652fc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56195421-6bc1-4801-a389-cf6d56f98411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_90853586-08c0-41c5-8e4e-ab735b93e62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c1198e7b-67bd-4f7e-b2b3-0883872652fc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_90853586-08c0-41c5-8e4e-ab735b93e62e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9aa5195-d4ee-47ab-8269-1dd33f1f691d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_03a7df85-7219-4916-b8c7-7fbc33aefc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9aa5195-d4ee-47ab-8269-1dd33f1f691d" xlink:to="loc_us-gaap_StockholdersEquity_03a7df85-7219-4916-b8c7-7fbc33aefc0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ba8d632-ba94-47e2-bbc1-35d417053cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9aa5195-d4ee-47ab-8269-1dd33f1f691d" xlink:to="loc_us-gaap_Liabilities_5ba8d632-ba94-47e2-bbc1-35d417053cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5b2d0374-7306-4ab3-8af6-677c6e4a7664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3c83d4fc-69b9-4e22-98e3-8c3b06735d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b2d0374-7306-4ab3-8af6-677c6e4a7664" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3c83d4fc-69b9-4e22-98e3-8c3b06735d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_1401d07a-9861-41c0-8a16-f869c6a9bf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b2d0374-7306-4ab3-8af6-677c6e4a7664" xlink:to="loc_us-gaap_RestrictedCashCurrent_1401d07a-9861-41c0-8a16-f869c6a9bf15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7bb00f8c-8a27-46c2-afc1-2039ac8320c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b2d0374-7306-4ab3-8af6-677c6e4a7664" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7bb00f8c-8a27-46c2-afc1-2039ac8320c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a8ef1848-edee-4143-8bc9-14eb21fd6ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b2d0374-7306-4ab3-8af6-677c6e4a7664" xlink:to="loc_us-gaap_InventoryNet_a8ef1848-edee-4143-8bc9-14eb21fd6ca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02fb79f2-e78c-4d34-8077-11768b35776b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b2d0374-7306-4ab3-8af6-677c6e4a7664" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_02fb79f2-e78c-4d34-8077-11768b35776b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_029e2320-49a1-4a81-89b0-f8824dd4c2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_28b26a19-0ab3-4a17-a466-5163afcffc91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_029e2320-49a1-4a81-89b0-f8824dd4c2a0" xlink:to="loc_us-gaap_AssetsCurrent_28b26a19-0ab3-4a17-a466-5163afcffc91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6e42b9aa-fc63-444d-a072-fef08619cf53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_029e2320-49a1-4a81-89b0-f8824dd4c2a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6e42b9aa-fc63-444d-a072-fef08619cf53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b04ea141-c6d2-440d-9bed-8bc7274378db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_029e2320-49a1-4a81-89b0-f8824dd4c2a0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b04ea141-c6d2-440d-9bed-8bc7274378db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9a728f94-b582-4222-9e68-960a4d2510b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_029e2320-49a1-4a81-89b0-f8824dd4c2a0" xlink:to="loc_us-gaap_Goodwill_9a728f94-b582-4222-9e68-960a4d2510b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fd1c6ee1-ff63-4a1d-9f51-1be2bb24b222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_029e2320-49a1-4a81-89b0-f8824dd4c2a0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fd1c6ee1-ff63-4a1d-9f51-1be2bb24b222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3bb890d7-3a27-4d5b-9d3c-babe925c599b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ed72cc2c-65b2-4ae4-a3d8-4badd364d21d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3bb890d7-3a27-4d5b-9d3c-babe925c599b" xlink:to="loc_us-gaap_LiabilitiesCurrent_ed72cc2c-65b2-4ae4-a3d8-4badd364d21d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3a1edfe5-4860-46f8-ae98-2d5fbafb500b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3bb890d7-3a27-4d5b-9d3c-babe925c599b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3a1edfe5-4860-46f8-ae98-2d5fbafb500b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_93b09ff2-039a-4fa7-acbc-d273b7a73fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3bb890d7-3a27-4d5b-9d3c-babe925c599b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_93b09ff2-039a-4fa7-acbc-d273b7a73fae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_515dbf99-606a-41d6-866d-3f18d4f49bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3bb890d7-3a27-4d5b-9d3c-babe925c599b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_515dbf99-606a-41d6-866d-3f18d4f49bca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_e7acb00e-b354-49ba-af72-8f880c997d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_49c75849-9760-480e-a564-56950726fa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_e7acb00e-b354-49ba-af72-8f880c997d33" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_49c75849-9760-480e-a564-56950726fa4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e2627d4e-97ad-4f58-a8ba-02bed7ab316c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_e7acb00e-b354-49ba-af72-8f880c997d33" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e2627d4e-97ad-4f58-a8ba-02bed7ab316c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23f85478-d85d-4823-922f-38a8c1c3a974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_e7acb00e-b354-49ba-af72-8f880c997d33" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_23f85478-d85d-4823-922f-38a8c1c3a974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0b6bed91-8e99-4a42-8252-740a490b1896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_e7acb00e-b354-49ba-af72-8f880c997d33" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0b6bed91-8e99-4a42-8252-740a490b1896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f1187fdd-83d8-4c51-933a-18d29365ca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a295726a-25ad-4658-a964-d5fc55805f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f1187fdd-83d8-4c51-933a-18d29365ca0a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a295726a-25ad-4658-a964-d5fc55805f31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_17e09e97-8683-4565-a15d-0f7cfdada642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f1187fdd-83d8-4c51-933a-18d29365ca0a" xlink:to="loc_us-gaap_OperatingIncomeLoss_17e09e97-8683-4565-a15d-0f7cfdada642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_54fdc22a-3929-4a7d-a51b-9edd2ff0ec5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_66bc17fe-042a-4398-bb12-7a5381100332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_54fdc22a-3929-4a7d-a51b-9edd2ff0ec5c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_66bc17fe-042a-4398-bb12-7a5381100332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_23f94e45-984e-4b73-b84b-419039a44760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_54fdc22a-3929-4a7d-a51b-9edd2ff0ec5c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_23f94e45-984e-4b73-b84b-419039a44760" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7ef12b9b-3059-438f-8b07-8617743e3097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_2a3ddc62-9016-4e76-a6e6-c20ddab7ec47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_7ef12b9b-3059-438f-8b07-8617743e3097" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_2a3ddc62-9016-4e76-a6e6-c20ddab7ec47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_71ae8c99-5317-4d7e-b139-9e069e631cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_7ef12b9b-3059-438f-8b07-8617743e3097" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_71ae8c99-5317-4d7e-b139-9e069e631cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_92765393-f410-4a8c-90ad-a2d2ef219ba7" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_a475b95f-fbcf-4de8-bfc2-a54a070053b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_92765393-f410-4a8c-90ad-a2d2ef219ba7" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_a475b95f-fbcf-4de8-bfc2-a54a070053b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_087b01c2-7dff-4b36-aea4-5d5259226a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_92765393-f410-4a8c-90ad-a2d2ef219ba7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_087b01c2-7dff-4b36-aea4-5d5259226a4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a325bd0d-7b29-4b70-beab-8ecc8d74df22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ae950c6a-681b-481e-821b-67a4910a4e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a325bd0d-7b29-4b70-beab-8ecc8d74df22" xlink:to="loc_us-gaap_InterestExpense_ae950c6a-681b-481e-821b-67a4910a4e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_53c1b2c1-76a8-4765-bb78-e06624d79002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a325bd0d-7b29-4b70-beab-8ecc8d74df22" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_53c1b2c1-76a8-4765-bb78-e06624d79002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_89afabde-d3e0-474d-ae80-578d1462e7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0f75f886-76c9-404a-a987-1269053a7586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_89afabde-d3e0-474d-ae80-578d1462e7b7" xlink:to="loc_us-gaap_Revenues_0f75f886-76c9-404a-a987-1269053a7586" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_21932b25-b182-472f-bfdb-34e4bb0b4835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_89afabde-d3e0-474d-ae80-578d1462e7b7" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_21932b25-b182-472f-bfdb-34e4bb0b4835" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_098d5415-c198-4198-9bf5-7176eede9aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_92a8bbf3-7cb3-4a4b-9922-9a5bfb45e5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_098d5415-c198-4198-9bf5-7176eede9aa4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_92a8bbf3-7cb3-4a4b-9922-9a5bfb45e5bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8e05c90b-410e-4693-968b-06f16c31dea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_098d5415-c198-4198-9bf5-7176eede9aa4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8e05c90b-410e-4693-968b-06f16c31dea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_765a8e70-dd86-4680-9d6e-b01cb5b76187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d065b0d8-ee69-48bd-bb77-09b9ff800d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_765a8e70-dd86-4680-9d6e-b01cb5b76187" xlink:to="loc_us-gaap_NetIncomeLoss_d065b0d8-ee69-48bd-bb77-09b9ff800d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e396b41e-641e-4ddc-81ab-ff18da45e492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_765a8e70-dd86-4680-9d6e-b01cb5b76187" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e396b41e-641e-4ddc-81ab-ff18da45e492" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a253905e-153a-44a1-988d-5fa9c5320756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_768ce53e-c7bd-44c3-bbdd-205b9f3d7188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a253905e-153a-44a1-988d-5fa9c5320756" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_768ce53e-c7bd-44c3-bbdd-205b9f3d7188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4ad80738-4702-4024-9ec6-0e7c559cff89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a253905e-153a-44a1-988d-5fa9c5320756" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4ad80738-4702-4024-9ec6-0e7c559cff89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_066e687e-7c07-4c82-b865-4b2d92cf3e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a253905e-153a-44a1-988d-5fa9c5320756" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_066e687e-7c07-4c82-b865-4b2d92cf3e8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_155a8a69-0bc2-4743-9e1f-684fb7a68353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a253905e-153a-44a1-988d-5fa9c5320756" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_155a8a69-0bc2-4743-9e1f-684fb7a68353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_37da8bba-1372-413d-83c9-4d2efc650dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a253905e-153a-44a1-988d-5fa9c5320756" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_37da8bba-1372-413d-83c9-4d2efc650dc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4fb8480c-526f-4b21-933b-4f7046b43253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a253905e-153a-44a1-988d-5fa9c5320756" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4fb8480c-526f-4b21-933b-4f7046b43253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_0d886968-8d60-4f03-83b9-feb4cb1b8b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a253905e-153a-44a1-988d-5fa9c5320756" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_0d886968-8d60-4f03-83b9-feb4cb1b8b61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62119bee-9c4a-4e6c-ad5b-4b60dc81d992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_23b9c43d-8b94-4fb7-b7ba-11e31aa69fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62119bee-9c4a-4e6c-ad5b-4b60dc81d992" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_23b9c43d-8b94-4fb7-b7ba-11e31aa69fa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfe8c89f-f79e-454e-909b-04088ecc3ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62119bee-9c4a-4e6c-ad5b-4b60dc81d992" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfe8c89f-f79e-454e-909b-04088ecc3ab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_132bdad1-bed1-4750-b87b-b5eada6a7e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62119bee-9c4a-4e6c-ad5b-4b60dc81d992" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_132bdad1-bed1-4750-b87b-b5eada6a7e7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e04adcd-324f-431d-87c5-6a6c015efe8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_62119bee-9c4a-4e6c-ad5b-4b60dc81d992" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e04adcd-324f-431d-87c5-6a6c015efe8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_26ac183b-d9ed-40ef-999e-7cb115ae1c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_ShareBasedCompensation_26ac183b-d9ed-40ef-999e-7cb115ae1c2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeReversal_4f13c025-55e2-473c-ad99-32f8acbb1d1f" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseLeaseIncomeReversal"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeReversal_4f13c025-55e2-473c-ad99-32f8acbb1d1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c2010b5d-9279-49e1-bdbb-56158846e9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c2010b5d-9279-49e1-bdbb-56158846e9e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_635ee2ef-ffcb-4948-918e-86010693ffe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_635ee2ef-ffcb-4948-918e-86010693ffe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13338ce8-112c-4811-9348-49634e9caae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13338ce8-112c-4811-9348-49634e9caae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ee84cedc-a948-430c-9e4e-c7813caf34c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ee84cedc-a948-430c-9e4e-c7813caf34c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0147cd66-017f-45f9-994b-221be9828340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0147cd66-017f-45f9-994b-221be9828340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_551424d3-9250-40a7-9a89-902e9d7744b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_551424d3-9250-40a7-9a89-902e9d7744b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_514c9fb8-9dac-42f7-b37a-f58c69c636e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_514c9fb8-9dac-42f7-b37a-f58c69c636e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_92a88c9e-abb5-4bd9-8e56-8b8d80ed1e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_92a88c9e-abb5-4bd9-8e56-8b8d80ed1e9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a0fcf195-7510-4d58-9559-fb41eddd6db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a0fcf195-7510-4d58-9559-fb41eddd6db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ab8b92e2-d4b6-4dd1-8ff7-e2e91f0af547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ab8b92e2-d4b6-4dd1-8ff7-e2e91f0af547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5f3cc5db-2935-4d5c-9aed-874a2802ced2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5f3cc5db-2935-4d5c-9aed-874a2802ced2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6536fb39-f1b0-411f-b25c-95a26a6b8dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_NetIncomeLoss_6536fb39-f1b0-411f-b25c-95a26a6b8dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4037f426-4ce3-44cf-ac07-10627545b8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac513b27-d645-4fa2-b4e7-9871f3ba7edb" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4037f426-4ce3-44cf-ac07-10627545b8e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad619af6-0998-42a5-9645-abae23dcbf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b847a5bc-1737-442a-8d3b-c0774d561492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad619af6-0998-42a5-9645-abae23dcbf7b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b847a5bc-1737-442a-8d3b-c0774d561492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_60335116-6b77-4065-b81f-b3e6bce5f7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ad619af6-0998-42a5-9645-abae23dcbf7b" xlink:to="loc_us-gaap_RestrictedCashCurrent_60335116-6b77-4065-b81f-b3e6bce5f7c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2611bf97-40ac-4390-b8aa-f428c2c82f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_a9bbe3f2-52b7-4107-806b-ed94d5cb0db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2611bf97-40ac-4390-b8aa-f428c2c82f45" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_a9bbe3f2-52b7-4107-806b-ed94d5cb0db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cffbb66d-3267-4b37-8986-dbf7fd5e36c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2611bf97-40ac-4390-b8aa-f428c2c82f45" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cffbb66d-3267-4b37-8986-dbf7fd5e36c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#InventoriesnetScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8ff6bd6a-ab16-4681-a151-3172473b8f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_60448047-3e3f-4662-af1c-621c30f28884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_8ff6bd6a-ab16-4681-a151-3172473b8f34" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_60448047-3e3f-4662-af1c-621c30f28884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_452357ba-b1bc-44d6-a616-92584308a9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_8ff6bd6a-ab16-4681-a151-3172473b8f34" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_452357ba-b1bc-44d6-a616-92584308a9de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_edc35bf7-cf10-4de0-81a9-7bd29689216e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_8ff6bd6a-ab16-4681-a151-3172473b8f34" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_edc35bf7-cf10-4de0-81a9-7bd29689216e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4d15e97b-256e-4427-b228-a9bd3457a627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_682f7bc8-4cb3-4fbb-abb2-d86a3eb462ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4d15e97b-256e-4427-b228-a9bd3457a627" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_682f7bc8-4cb3-4fbb-abb2-d86a3eb462ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e798b3b4-a6b9-4220-a852-9e67977efc71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4d15e97b-256e-4427-b228-a9bd3457a627" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e798b3b4-a6b9-4220-a852-9e67977efc71" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c41a7e5d-c65a-436d-85c4-c8f4049f4a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c0349dc8-64fc-4f3c-8c41-d983fcf94b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c41a7e5d-c65a-436d-85c4-c8f4049f4a75" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c0349dc8-64fc-4f3c-8c41-d983fcf94b1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_d0ff76bb-5b5d-4359-b015-23fd6dfb3591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c41a7e5d-c65a-436d-85c4-c8f4049f4a75" xlink:to="loc_us-gaap_OperatingLeaseExpense_d0ff76bb-5b5d-4359-b015-23fd6dfb3591" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b98cb6e6-5e6e-4928-bf32-e3154d29b22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14c5c34e-6cf9-45b0-a458-f2b7e555e912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b98cb6e6-5e6e-4928-bf32-e3154d29b22a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_14c5c34e-6cf9-45b0-a458-f2b7e555e912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a73b4fe3-092b-4793-a8d1-81ec7d896a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b98cb6e6-5e6e-4928-bf32-e3154d29b22a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a73b4fe3-092b-4793-a8d1-81ec7d896a9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6f6fe629-61db-4b16-81b2-9f75d2d11425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f4de620a-24dc-4d7e-8121-4e9c53ee5516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6f6fe629-61db-4b16-81b2-9f75d2d11425" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f4de620a-24dc-4d7e-8121-4e9c53ee5516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3e9194b4-712e-48ec-9cfe-931e5b8cdfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6f6fe629-61db-4b16-81b2-9f75d2d11425" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3e9194b4-712e-48ec-9cfe-931e5b8cdfd1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_68103e6f-52ba-4685-93bb-9b24cc36bac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e79a87ac-3d94-4a19-b0fd-5a26acf594d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_68103e6f-52ba-4685-93bb-9b24cc36bac0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e79a87ac-3d94-4a19-b0fd-5a26acf594d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_56973948-ae23-4f0b-a181-3abd3fa66f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_68103e6f-52ba-4685-93bb-9b24cc36bac0" xlink:to="loc_us-gaap_DerivativeAssets_56973948-ae23-4f0b-a181-3abd3fa66f57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_9c781ba6-704a-4333-9d55-2462b732ae20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3468f8d3-0b9a-46d6-abaa-6342f9016417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_9c781ba6-704a-4333-9d55-2462b732ae20" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3468f8d3-0b9a-46d6-abaa-6342f9016417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_22af5a66-d2e3-4176-8d08-adddfaa900f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_9c781ba6-704a-4333-9d55-2462b732ae20" xlink:to="loc_us-gaap_DerivativeLiabilities_22af5a66-d2e3-4176-8d08-adddfaa900f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_145493ef-30ac-4ef7-b72c-a18c57a368fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_9e03e42f-29fa-4b80-93b3-7c4b29b7d013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_145493ef-30ac-4ef7-b72c-a18c57a368fa" xlink:to="loc_us-gaap_BilledContractReceivables_9e03e42f-29fa-4b80-93b3-7c4b29b7d013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_d946e272-b144-4eca-b3f4-ac4fbd09741a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_145493ef-30ac-4ef7-b72c-a18c57a368fa" xlink:to="loc_us-gaap_UnbilledContractsReceivable_d946e272-b144-4eca-b3f4-ac4fbd09741a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershareDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#NetIncomelosspershareDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/NetIncomelosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a877adfe-ed4e-4c13-87d3-0184c9099ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_594a4a9a-3227-473b-b1df-780603c6b0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a877adfe-ed4e-4c13-87d3-0184c9099ead" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_594a4a9a-3227-473b-b1df-780603c6b0ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_91bd90cf-5be1-4cf3-8784-d6bc47e88bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a877adfe-ed4e-4c13-87d3-0184c9099ead" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_91bd90cf-5be1-4cf3-8784-d6bc47e88bcc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#EquityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_da5853db-a547-49a9-be6f-aeaf24316478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_9cc7d0d2-fa54-4570-ab6a-2986f43de072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_da5853db-a547-49a9-be6f-aeaf24316478" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_9cc7d0d2-fa54-4570-ab6a-2986f43de072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_7522c29e-69d2-41c1-858b-25ed4f256377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_da5853db-a547-49a9-be6f-aeaf24316478" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_7522c29e-69d2-41c1-858b-25ed4f256377" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_712d7fc6-e94c-462d-b57c-7a11a60c03ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_eaf4a6b4-18e1-4d91-b009-d5e28be1563a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_712d7fc6-e94c-462d-b57c-7a11a60c03ed" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_eaf4a6b4-18e1-4d91-b009-d5e28be1563a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_e2fe6a5d-14be-4818-be23-a1bf178284c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_712d7fc6-e94c-462d-b57c-7a11a60c03ed" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_e2fe6a5d-14be-4818-be23-a1bf178284c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_0d56b32c-4f15-439c-88c7-4bf3b3a5e818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7392558b-22ae-42e2-a392-2b2abdbddfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_0d56b32c-4f15-439c-88c7-4bf3b3a5e818" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7392558b-22ae-42e2-a392-2b2abdbddfe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e94375dd-908d-42e4-aa99-6ca158d2ef35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_0d56b32c-4f15-439c-88c7-4bf3b3a5e818" xlink:to="loc_us-gaap_Revenues_e94375dd-908d-42e4-aa99-6ca158d2ef35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_bcc119b5-76ed-44b4-86dd-fffc5bf20b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_0d56b32c-4f15-439c-88c7-4bf3b3a5e818" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_bcc119b5-76ed-44b4-86dd-fffc5bf20b54" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ebs-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e49bcad1-b3a3-4429-b549-b7280da8936a,g:b60fc6ff-4763-459f-a134-feb07b4a5302-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="idc54c4b8fbf44c3ab33adebaeba292b1_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3a527db-78b0-4e34-8b0d-b3e514103b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3a527db-78b0-4e34-8b0d-b3e514103b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_daaf4bfa-f1d8-474a-9148-4e0a9ac6502b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_daaf4bfa-f1d8-474a-9148-4e0a9ac6502b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_6d1f9237-5455-4b5c-9656-533c8c2c83fb" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_6d1f9237-5455-4b5c-9656-533c8c2c83fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f6f05f22-3a95-4751-93c4-2b9d2bf52f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:to="loc_us-gaap_Revenues_f6f05f22-3a95-4751-93c4-2b9d2bf52f17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_dc17f199-0d8f-43b3-96ea-ce37a0287498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_dc17f199-0d8f-43b3-96ea-ce37a0287498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_dc67fac1-1906-42cb-82af-6de0b3aa2a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_dc67fac1-1906-42cb-82af-6de0b3aa2a6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1bd3cd77-6b4d-4b70-bfbd-a4fedc26bf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1bd3cd77-6b4d-4b70-bfbd-a4fedc26bf7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_89e22a73-2217-461c-83b3-517504b16793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_89e22a73-2217-461c-83b3-517504b16793" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_9fa342ea-e421-4872-a076-cc1188f49095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_9fa342ea-e421-4872-a076-cc1188f49095" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9bc0f79a-5e3f-4313-b9b2-7c67a7727f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_OperatingIncomeLoss_9bc0f79a-5e3f-4313-b9b2-7c67a7727f40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4ab14647-ee25-4e26-a6df-0c49b6e765db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4ab14647-ee25-4e26-a6df-0c49b6e765db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_741e73a9-bacf-4502-af2f-ce705ff7cb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4ab14647-ee25-4e26-a6df-0c49b6e765db" xlink:to="loc_us-gaap_InterestExpense_741e73a9-bacf-4502-af2f-ce705ff7cb12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_36f719bd-de62-4c46-8fbd-fcbeeb78562b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4ab14647-ee25-4e26-a6df-0c49b6e765db" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_36f719bd-de62-4c46-8fbd-fcbeeb78562b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_df1635ec-765c-486a-b4e0-cc74613e99d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4ab14647-ee25-4e26-a6df-0c49b6e765db" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_df1635ec-765c-486a-b4e0-cc74613e99d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a536aba-aca6-4116-b69f-b8c1afd4c408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a536aba-aca6-4116-b69f-b8c1afd4c408" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c2333d66-880c-4120-a9ca-5d94d4250171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c2333d66-880c-4120-a9ca-5d94d4250171" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_441f9571-c22a-48f3-958a-2757f506a8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_NetIncomeLoss_441f9571-c22a-48f3-958a-2757f506a8aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_94a19fbc-bf3d-4e1e-b3dd-fce13505410f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_94a19fbc-bf3d-4e1e-b3dd-fce13505410f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_800aa1d0-d9bf-46ff-ab67-e7fb336b2b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_94a19fbc-bf3d-4e1e-b3dd-fce13505410f" xlink:to="loc_us-gaap_EarningsPerShareBasic_800aa1d0-d9bf-46ff-ab67-e7fb336b2b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_08dd9af3-0b2f-4a50-adb9-08624e0923cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_94a19fbc-bf3d-4e1e-b3dd-fce13505410f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_08dd9af3-0b2f-4a50-adb9-08624e0923cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_261715ed-d875-4d22-8c57-267263673fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_261715ed-d875-4d22-8c57-267263673fdb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ebbfd9a-0095-4c96-8506-3f881bbce6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_261715ed-d875-4d22-8c57-267263673fdb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ebbfd9a-0095-4c96-8506-3f881bbce6cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_139de832-ff86-4887-800d-cbdead61237b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_261715ed-d875-4d22-8c57-267263673fdb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_139de832-ff86-4887-800d-cbdead61237b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cc9b095a-8ca1-4e3b-a707-3393f3a2c5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_StatementTable_cc9b095a-8ca1-4e3b-a707-3393f3a2c5f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_285fa0c0-10cf-4923-b67c-021e359fe6ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cc9b095a-8ca1-4e3b-a707-3393f3a2c5f7" xlink:to="loc_srt_ProductOrServiceAxis_285fa0c0-10cf-4923-b67c-021e359fe6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_285fa0c0-10cf-4923-b67c-021e359fe6ca_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_285fa0c0-10cf-4923-b67c-021e359fe6ca" xlink:to="loc_srt_ProductsAndServicesDomain_285fa0c0-10cf-4923-b67c-021e359fe6ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d21546b0-ff58-4400-a41f-34a036a346c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_285fa0c0-10cf-4923-b67c-021e359fe6ca" xlink:to="loc_srt_ProductsAndServicesDomain_d21546b0-ff58-4400-a41f-34a036a346c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c31fd5ea-f21b-47f7-b096-1a3fbb7960e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d21546b0-ff58-4400-a41f-34a036a346c1" xlink:to="loc_us-gaap_ProductMember_c31fd5ea-f21b-47f7-b096-1a3fbb7960e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_19fc2a88-4f6f-45b8-aaf0-8482c433f824" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d21546b0-ff58-4400-a41f-34a036a346c1" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_19fc2a88-4f6f-45b8-aaf0-8482c433f824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1dc055f9-ece7-4d33-9230-495bab15197d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_19fc2a88-4f6f-45b8-aaf0-8482c433f824" xlink:to="loc_us-gaap_ServiceMember_1dc055f9-ece7-4d33-9230-495bab15197d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_c5d1096b-aff0-47e9-90fa-16ef39c29a30" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_19fc2a88-4f6f-45b8-aaf0-8482c433f824" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_c5d1096b-aff0-47e9-90fa-16ef39c29a30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_dd706c65-1a2f-4692-a766-040e1c112f11" xlink:href="ebs-20220930.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d21546b0-ff58-4400-a41f-34a036a346c1" xlink:to="loc_ebs_ContractsAndGrantsMember_dd706c65-1a2f-4692-a766-040e1c112f11" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended" id="ifdd90bb58782474ebf6247e0479d753b_CondensedConsolidatedStatementsofChangesinStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b8a3d055-1a3d-4123-a129-802a0e844471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b8a3d055-1a3d-4123-a129-802a0e844471" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fec1c488-b2e7-44ba-af21-e8c07823c0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fec1c488-b2e7-44ba-af21-e8c07823c0ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ef6fc29c-1d5e-4555-9229-7dfc0c9c0a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_StockholdersEquity_ef6fc29c-1d5e-4555-9229-7dfc0c9c0a03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_62b54905-1095-44d6-8aa0-564f0a499bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_TreasuryStockCommonShares_62b54905-1095-44d6-8aa0-564f0a499bbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7c6021d6-28fb-4365-be13-7eac91269454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7c6021d6-28fb-4365-be13-7eac91269454" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_718e12dd-a419-488d-8ff6-83e2650dc736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_718e12dd-a419-488d-8ff6-83e2650dc736" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6488b1c1-eefb-4e7b-871e-ba179ab84f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_NetIncomeLoss_6488b1c1-eefb-4e7b-871e-ba179ab84f99" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_1414da38-a590-4e9c-a871-97370c243ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_1414da38-a590-4e9c-a871-97370c243ea9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_4d2ee8d5-82cb-4eef-bb78-b71c3d4b0ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_4d2ee8d5-82cb-4eef-bb78-b71c3d4b0ffd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_88c68af3-2830-4a07-8042-1be4cb6136dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_88c68af3-2830-4a07-8042-1be4cb6136dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7272577d-5671-46bd-bbe0-afde4c6ea23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_4365f811-6905-4033-8e95-ac8f5eab7b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_954d4f73-ce0c-4378-8559-5cc26cab21d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4f3e544e-2213-4290-9ae6-df4b499d87fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b8a3d055-1a3d-4123-a129-802a0e844471" xlink:to="loc_us-gaap_StatementTable_4f3e544e-2213-4290-9ae6-df4b499d87fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d8e6499d-6a57-4ddd-a896-2d4a6d31f502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4f3e544e-2213-4290-9ae6-df4b499d87fe" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d8e6499d-6a57-4ddd-a896-2d4a6d31f502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d8e6499d-6a57-4ddd-a896-2d4a6d31f502_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8e6499d-6a57-4ddd-a896-2d4a6d31f502" xlink:to="loc_us-gaap_EquityComponentDomain_d8e6499d-6a57-4ddd-a896-2d4a6d31f502_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8e6499d-6a57-4ddd-a896-2d4a6d31f502" xlink:to="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_76c3564d-bd8f-4248-99ad-635f49644aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:to="loc_us-gaap_CommonStockMember_76c3564d-bd8f-4248-99ad-635f49644aeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_67c84a77-f5d8-4b97-b2ae-964a93cd9387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_67c84a77-f5d8-4b97-b2ae-964a93cd9387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dfe7c2ff-d180-4917-875d-496227f9373b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dfe7c2ff-d180-4917-875d-496227f9373b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0d191963-110e-495f-a5fa-a0f66f979fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0d191963-110e-495f-a5fa-a0f66f979fb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6213bf20-247d-4f2a-9b94-3aa09c839404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:to="loc_us-gaap_RetainedEarningsMember_6213bf20-247d-4f2a-9b94-3aa09c839404" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#BusinessDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="extended" id="i63a3e986fe5f4d94993028ad26042ccf_BusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_efb8924a-4f98-42f5-a8b6-d0097dc1f73e" xlink:href="ebs-20220930.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_efb8924a-4f98-42f5-a8b6-d0097dc1f73e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts_c407b90f-265e-42eb-83f2-7065c08422f6" xlink:href="ebs-20220930.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_NumberOfRevenueGeneratingProducts_c407b90f-265e-42eb-83f2-7065c08422f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductCandidates_08e605aa-2e22-4fc7-ab1f-1285fda38c72" xlink:href="ebs-20220930.xsd#ebs_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_NumberOfProductCandidates_08e605aa-2e22-4fc7-ab1f-1285fda38c72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfBusinessLines_2d2dbdb9-1292-49e3-ad4d-833bc63be5c2" xlink:href="ebs-20220930.xsd#ebs_NumberOfBusinessLines"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_NumberOfBusinessLines_2d2dbdb9-1292-49e3-ad4d-833bc63be5c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a5679677-834d-427f-828c-adf8624d9f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a5679677-834d-427f-828c-adf8624d9f6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_952af7c2-8d48-488f-a574-1e7136d73f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_952af7c2-8d48-488f-a574-1e7136d73f6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_deb87e9e-dfcc-4df8-90c7-ef312f6f4794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_deb87e9e-dfcc-4df8-90c7-ef312f6f4794" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_2a54c419-5dc7-4740-8455-6ab77044ed4e" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_2a54c419-5dc7-4740-8455-6ab77044ed4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionTreatmentVolumeThreshold_729bd640-7b60-4788-b6a4-750635106b10" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionTreatmentVolumeThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_AssetAcquisitionTreatmentVolumeThreshold_729bd640-7b60-4788-b6a4-750635106b10" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_2c2f0323-f040-4daa-bb85-2257335b444a" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_2c2f0323-f040-4daa-bb85-2257335b444a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_38ee37e4-6fae-4e73-a417-11f179503714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_us-gaap_AssetAcquisitionTable_38ee37e4-6fae-4e73-a417-11f179503714" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_69442078-7777-4f00-b176-a6af34117ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_38ee37e4-6fae-4e73-a417-11f179503714" xlink:to="loc_us-gaap_AssetAcquisitionAxis_69442078-7777-4f00-b176-a6af34117ec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_69442078-7777-4f00-b176-a6af34117ec3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_69442078-7777-4f00-b176-a6af34117ec3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_69442078-7777-4f00-b176-a6af34117ec3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b4610072-93d0-4ea3-a4ab-0ea47c20998e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_69442078-7777-4f00-b176-a6af34117ec3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b4610072-93d0-4ea3-a4ab-0ea47c20998e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixAssetAcquisitionMember_af712bbc-7c54-4f82-a418-073694ce91dd" xlink:href="ebs-20220930.xsd#ebs_ChimerixAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b4610072-93d0-4ea3-a4ab-0ea47c20998e" xlink:to="loc_ebs_ChimerixAssetAcquisitionMember_af712bbc-7c54-4f82-a418-073694ce91dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_da7e0bf6-6999-493b-ac7a-b01cdc83867f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_38ee37e4-6fae-4e73-a417-11f179503714" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_da7e0bf6-6999-493b-ac7a-b01cdc83867f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_da7e0bf6-6999-493b-ac7a-b01cdc83867f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_da7e0bf6-6999-493b-ac7a-b01cdc83867f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_da7e0bf6-6999-493b-ac7a-b01cdc83867f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0fa5304f-b99b-4a85-ac13-f85dc95ac6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_da7e0bf6-6999-493b-ac7a-b01cdc83867f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0fa5304f-b99b-4a85-ac13-f85dc95ac6fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentsMember_faba06e1-aa89-4f35-ae0b-812941691274" xlink:href="ebs-20220930.xsd#ebs_MilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0fa5304f-b99b-4a85-ac13-f85dc95ac6fa" xlink:to="loc_ebs_MilestonePaymentsMember_faba06e1-aa89-4f35-ae0b-812941691274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RegulatoryMilestonesMember_84b724db-45ec-4eda-9c8a-bd21f5a171f2" xlink:href="ebs-20220930.xsd#ebs_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0fa5304f-b99b-4a85-ac13-f85dc95ac6fa" xlink:to="loc_ebs_RegulatoryMilestonesMember_84b724db-45ec-4eda-9c8a-bd21f5a171f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#BasisofpresentationandprinciplesofconsolidationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails" xlink:type="extended" id="i0e5f674fb76843bca2576b1cb8501407_BasisofpresentationandprinciplesofconsolidationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8900a402-f8a1-4e2e-9900-f342bea970e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_db965c81-0c4e-4762-8b27-a80957c0325f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8900a402-f8a1-4e2e-9900-f342bea970e2" xlink:to="loc_us-gaap_LongTermDebt_db965c81-0c4e-4762-8b27-a80957c0325f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e81a28c2-7b72-4419-97a1-3e21f618e6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8900a402-f8a1-4e2e-9900-f342bea970e2" xlink:to="loc_us-gaap_NumberOfReportableSegments_e81a28c2-7b72-4419-97a1-3e21f618e6f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b44d8f90-5801-42a9-a314-c7fee5baad9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8900a402-f8a1-4e2e-9900-f342bea970e2" xlink:to="loc_us-gaap_DebtInstrumentTable_b44d8f90-5801-42a9-a314-c7fee5baad9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ad4bbb77-e068-420c-9aa7-c0e1fa672abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b44d8f90-5801-42a9-a314-c7fee5baad9e" xlink:to="loc_us-gaap_CreditFacilityAxis_ad4bbb77-e068-420c-9aa7-c0e1fa672abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ad4bbb77-e068-420c-9aa7-c0e1fa672abf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ad4bbb77-e068-420c-9aa7-c0e1fa672abf" xlink:to="loc_us-gaap_CreditFacilityDomain_ad4bbb77-e068-420c-9aa7-c0e1fa672abf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_139c73ae-7fcb-4313-b656-6964f61d2579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ad4bbb77-e068-420c-9aa7-c0e1fa672abf" xlink:to="loc_us-gaap_CreditFacilityDomain_139c73ae-7fcb-4313-b656-6964f61d2579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_00c536d5-f83e-4139-a465-9d216f39477d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_139c73ae-7fcb-4313-b656-6964f61d2579" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_00c536d5-f83e-4139-a465-9d216f39477d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e30ee17e-c118-48d2-ac60-90a9cb96bf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b44d8f90-5801-42a9-a314-c7fee5baad9e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e30ee17e-c118-48d2-ac60-90a9cb96bf1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e30ee17e-c118-48d2-ac60-90a9cb96bf1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e30ee17e-c118-48d2-ac60-90a9cb96bf1b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e30ee17e-c118-48d2-ac60-90a9cb96bf1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9752d76b-c563-4cde-9deb-50ec6dc9249d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e30ee17e-c118-48d2-ac60-90a9cb96bf1b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9752d76b-c563-4cde-9deb-50ec6dc9249d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_cc380e20-38da-4d5d-b880-f7b22ab31e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9752d76b-c563-4cde-9deb-50ec6dc9249d" xlink:to="loc_us-gaap_LineOfCreditMember_cc380e20-38da-4d5d-b880-f7b22ab31e7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_6752d237-7820-4c88-806a-ed01af5e8fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9752d76b-c563-4cde-9deb-50ec6dc9249d" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_6752d237-7820-4c88-806a-ed01af5e8fae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#InventoriesnetScheduleofInventoryDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="extended" id="i66b14596f7ad4f0b9f4227923aa51aae_InventoriesnetScheduleofInventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_b625c64b-c77b-4790-a9c0-a2b99a2ec93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_b625c64b-c77b-4790-a9c0-a2b99a2ec93c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4519a786-8b9b-4904-91a8-2908e03e056b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4519a786-8b9b-4904-91a8-2908e03e056b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7a5cb4d7-1d38-4e8a-8de2-1cab0ee21ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7a5cb4d7-1d38-4e8a-8de2-1cab0ee21ce6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_88c678ef-cd6d-463b-b02b-9403301b0372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:to="loc_us-gaap_InventoryNet_88c678ef-cd6d-463b-b02b-9403301b0372" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0e203748-f891-408a-862b-3cf037dfcd2e" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:to="loc_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0e203748-f891-408a-862b-3cf037dfcd2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_d69c3f3e-6c1e-4cca-8f62-fbbec264c39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:to="loc_us-gaap_InventoryCurrentTable_d69c3f3e-6c1e-4cca-8f62-fbbec264c39a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_41d5669a-920d-48a0-bfae-5d408edef6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_d69c3f3e-6c1e-4cca-8f62-fbbec264c39a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_41d5669a-920d-48a0-bfae-5d408edef6ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_41d5669a-920d-48a0-bfae-5d408edef6ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_41d5669a-920d-48a0-bfae-5d408edef6ad" xlink:to="loc_us-gaap_AssetAcquisitionDomain_41d5669a-920d-48a0-bfae-5d408edef6ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_43a10d79-4d3a-4469-bce4-881ec6edcfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_41d5669a-920d-48a0-bfae-5d408edef6ad" xlink:to="loc_us-gaap_AssetAcquisitionDomain_43a10d79-4d3a-4469-bce4-881ec6edcfc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixAssetAcquisitionMember_4442b710-d602-4cd0-8905-8b1068832909" xlink:href="ebs-20220930.xsd#ebs_ChimerixAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_43a10d79-4d3a-4469-bce4-881ec6edcfc1" xlink:to="loc_ebs_ChimerixAssetAcquisitionMember_4442b710-d602-4cd0-8905-8b1068832909" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i652ff060f61644e0b9ab8763f0fe2f80_PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d19a0c89-c1f1-4edc-951c-10ffa8695a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bc238177-bd72-4454-b158-22089f45b376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d19a0c89-c1f1-4edc-951c-10ffa8695a57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bc238177-bd72-4454-b158-22089f45b376" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bcbcc890-7d44-4a02-bbf8-227373c4f539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bc238177-bd72-4454-b158-22089f45b376" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bcbcc890-7d44-4a02-bbf8-227373c4f539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_96df4cb6-6518-461d-b27e-9d21fa8caf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bc238177-bd72-4454-b158-22089f45b376" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_96df4cb6-6518-461d-b27e-9d21fa8caf1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f5e6e349-31f3-4a88-849e-a6bdabb74083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bc238177-bd72-4454-b158-22089f45b376" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f5e6e349-31f3-4a88-849e-a6bdabb74083" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e935cd1f-bb1c-4dbd-bff9-2cdc218e92e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d19a0c89-c1f1-4edc-951c-10ffa8695a57" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e935cd1f-bb1c-4dbd-bff9-2cdc218e92e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_557d7982-8a21-416f-a89d-c57cf7f91255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e935cd1f-bb1c-4dbd-bff9-2cdc218e92e7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_557d7982-8a21-416f-a89d-c57cf7f91255" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_557d7982-8a21-416f-a89d-c57cf7f91255_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_557d7982-8a21-416f-a89d-c57cf7f91255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_557d7982-8a21-416f-a89d-c57cf7f91255_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_557d7982-8a21-416f-a89d-c57cf7f91255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_6a1f5f3a-7ec1-4fe4-974f-26268885b5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_6a1f5f3a-7ec1-4fe4-974f-26268885b5c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_03f2da86-5593-4bf9-9823-738698865a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_03f2da86-5593-4bf9-9823-738698865a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_faf7dcfd-cac4-45ab-ba35-4977565cf336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_faf7dcfd-cac4-45ab-ba35-4977565cf336" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_17849764-4134-4f22-8079-b7c6f8d7f55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_17849764-4134-4f22-8079-b7c6f8d7f55c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_36fda13a-86d1-444f-9a29-7339dfe86d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:to="loc_us-gaap_ConstructionInProgressMember_36fda13a-86d1-444f-9a29-7339dfe86d70" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#PropertyplantandequipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="extended" id="i32e6b1f1cf054e6daa1e5aee1e573ca8_PropertyplantandequipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_df6d2a88-1d62-4ce1-8669-9bd5c047bf87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3698b52b-b8af-4fb7-9ffc-d31509918260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_df6d2a88-1d62-4ce1-8669-9bd5c047bf87" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3698b52b-b8af-4fb7-9ffc-d31509918260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6346fe0d-82ab-42e6-9652-e98acd7e8a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_df6d2a88-1d62-4ce1-8669-9bd5c047bf87" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6346fe0d-82ab-42e6-9652-e98acd7e8a43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dba6147e-5d0d-4180-aeac-a4e7bee6f8a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6346fe0d-82ab-42e6-9652-e98acd7e8a43" xlink:to="loc_srt_MajorCustomersAxis_dba6147e-5d0d-4180-aeac-a4e7bee6f8a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_dba6147e-5d0d-4180-aeac-a4e7bee6f8a7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_dba6147e-5d0d-4180-aeac-a4e7bee6f8a7" xlink:to="loc_srt_NameOfMajorCustomerDomain_dba6147e-5d0d-4180-aeac-a4e7bee6f8a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3bec2369-d6d4-4ef5-ba25-5184137011f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_dba6147e-5d0d-4180-aeac-a4e7bee6f8a7" xlink:to="loc_srt_NameOfMajorCustomerDomain_3bec2369-d6d4-4ef5-ba25-5184137011f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_72bfaee5-0d98-43f3-aa78-cb7f3a2b8e89" xlink:href="ebs-20220930.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3bec2369-d6d4-4ef5-ba25-5184137011f2" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_72bfaee5-0d98-43f3-aa78-cb7f3a2b8e89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d00fd157-58ef-4a3f-b505-74197c61c2cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6346fe0d-82ab-42e6-9652-e98acd7e8a43" xlink:to="loc_srt_ProductOrServiceAxis_d00fd157-58ef-4a3f-b505-74197c61c2cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d00fd157-58ef-4a3f-b505-74197c61c2cc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d00fd157-58ef-4a3f-b505-74197c61c2cc" xlink:to="loc_srt_ProductsAndServicesDomain_d00fd157-58ef-4a3f-b505-74197c61c2cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2ff3465e-7d51-48cc-8609-0a8fb39f10fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d00fd157-58ef-4a3f-b505-74197c61c2cc" xlink:to="loc_srt_ProductsAndServicesDomain_2ff3465e-7d51-48cc-8609-0a8fb39f10fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_bd5ae794-182e-44f6-99fd-09d837e29a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ff3465e-7d51-48cc-8609-0a8fb39f10fa" xlink:to="loc_us-gaap_ServiceMember_bd5ae794-182e-44f6-99fd-09d837e29a86" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i15cd60d5f8af4ca7986e402d92789ba7_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_760c41e5-77c5-41a3-9ec5-f9a48918a6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseRightOfUseAssetRemoval_c4672225-249c-4ce5-90b0-cc4fea3e4504" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseRightOfUseAssetRemoval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_760c41e5-77c5-41a3-9ec5-f9a48918a6d5" xlink:to="loc_ebs_OperatingLeaseRightOfUseAssetRemoval_c4672225-249c-4ce5-90b0-cc4fea3e4504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ecc6e117-9533-4a39-837a-cf31faf32578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_760c41e5-77c5-41a3-9ec5-f9a48918a6d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ecc6e117-9533-4a39-837a-cf31faf32578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3f3c04f7-6425-4b77-a114-656fc1fa4f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_760c41e5-77c5-41a3-9ec5-f9a48918a6d5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3f3c04f7-6425-4b77-a114-656fc1fa4f70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_895d4495-3877-4e75-9834-636214f88aab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3f3c04f7-6425-4b77-a114-656fc1fa4f70" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_895d4495-3877-4e75-9834-636214f88aab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_895d4495-3877-4e75-9834-636214f88aab_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_895d4495-3877-4e75-9834-636214f88aab" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_895d4495-3877-4e75-9834-636214f88aab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_71975733-4b36-4c3a-8d3f-a358c7e6511f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_895d4495-3877-4e75-9834-636214f88aab" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_71975733-4b36-4c3a-8d3f-a358c7e6511f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RockvilleManufacturingFacilityMember_73d25fb6-4716-4062-9150-952784b02063" xlink:href="ebs-20220930.xsd#ebs_RockvilleManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_71975733-4b36-4c3a-8d3f-a358c7e6511f" xlink:to="loc_ebs_RockvilleManufacturingFacilityMember_73d25fb6-4716-4062-9150-952784b02063" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended" id="i0d8a2dc20263451583ab6e8b543c5364_IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7e5cb1dd-a2d7-4040-95d0-bdbab2d889a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7e5cb1dd-a2d7-4040-95d0-bdbab2d889a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_500359a5-7fb7-477b-8533-1b5749e333f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_500359a5-7fb7-477b-8533-1b5749e333f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ce1cecfb-e109-4faa-908b-3c262fe63323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ce1cecfb-e109-4faa-908b-3c262fe63323" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_34b78068-0b21-401d-b632-4f3593f280d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_34b78068-0b21-401d-b632-4f3593f280d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7639d1d8-ff77-4bdb-8972-64a38eed5d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7639d1d8-ff77-4bdb-8972-64a38eed5d27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e2461e71-1453-456a-9105-0d6e4a2da9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e2461e71-1453-456a-9105-0d6e4a2da9fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5255466-1c24-4341-88b2-34c161ae5ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e2461e71-1453-456a-9105-0d6e4a2da9fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5255466-1c24-4341-88b2-34c161ae5ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5255466-1c24-4341-88b2-34c161ae5ac7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5255466-1c24-4341-88b2-34c161ae5ac7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d5255466-1c24-4341-88b2-34c161ae5ac7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4d15035-22de-4677-8bae-ca490afae763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5255466-1c24-4341-88b2-34c161ae5ac7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4d15035-22de-4677-8bae-ca490afae763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_38e4f3bf-9b50-4b90-a693-b121d30e839c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4d15035-22de-4677-8bae-ca490afae763" xlink:to="loc_us-gaap_ProductMember_38e4f3bf-9b50-4b90-a693-b121d30e839c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_3c6315c6-902c-478f-97c1-533769ccdbff" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4d15035-22de-4677-8bae-ca490afae763" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_3c6315c6-902c-478f-97c1-533769ccdbff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_16b8ab4b-76d8-4bf0-a07b-89495972f62f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e2461e71-1453-456a-9105-0d6e4a2da9fc" xlink:to="loc_srt_RangeAxis_16b8ab4b-76d8-4bf0-a07b-89495972f62f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_16b8ab4b-76d8-4bf0-a07b-89495972f62f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_16b8ab4b-76d8-4bf0-a07b-89495972f62f" xlink:to="loc_srt_RangeMember_16b8ab4b-76d8-4bf0-a07b-89495972f62f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_342cec81-7e34-42b0-9bea-5f0c391f9107" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16b8ab4b-76d8-4bf0-a07b-89495972f62f" xlink:to="loc_srt_RangeMember_342cec81-7e34-42b0-9bea-5f0c391f9107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a10d1c92-6db1-4112-a35a-4b2897a8157f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_342cec81-7e34-42b0-9bea-5f0c391f9107" xlink:to="loc_srt_MinimumMember_a10d1c92-6db1-4112-a35a-4b2897a8157f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_36370b57-6b71-4028-895a-4b5abce1cd1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_342cec81-7e34-42b0-9bea-5f0c391f9107" xlink:to="loc_srt_MaximumMember_36370b57-6b71-4028-895a-4b5abce1cd1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_188403a0-bfaa-4b87-84ae-7c45b5fea4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e2461e71-1453-456a-9105-0d6e4a2da9fc" xlink:to="loc_us-gaap_AssetAcquisitionAxis_188403a0-bfaa-4b87-84ae-7c45b5fea4f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_188403a0-bfaa-4b87-84ae-7c45b5fea4f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_188403a0-bfaa-4b87-84ae-7c45b5fea4f1" xlink:to="loc_us-gaap_AssetAcquisitionDomain_188403a0-bfaa-4b87-84ae-7c45b5fea4f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_5faa1c4d-0f71-46d3-b39b-f05598f992e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_188403a0-bfaa-4b87-84ae-7c45b5fea4f1" xlink:to="loc_us-gaap_AssetAcquisitionDomain_5faa1c4d-0f71-46d3-b39b-f05598f992e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixAssetAcquisitionMember_4bc322cb-ce05-49c2-aa36-97ab46803e99" xlink:href="ebs-20220930.xsd#ebs_ChimerixAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_5faa1c4d-0f71-46d3-b39b-f05598f992e3" xlink:to="loc_ebs_ChimerixAssetAcquisitionMember_4bc322cb-ce05-49c2-aa36-97ab46803e99" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended" id="i9aace7bc14874c54b5cf2e9f6ad962bb_FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_372b02cc-0719-4537-9bd3-86aaa82f754f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_372b02cc-0719-4537-9bd3-86aaa82f754f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6202c04d-1816-4c37-a11e-12448b3738f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_DerivativeAssets_6202c04d-1816-4c37-a11e-12448b3738f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_eef96ec1-26a6-4c42-8966-ae72c2f1c386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_eef96ec1-26a6-4c42-8966-ae72c2f1c386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b52ba336-8a43-40f4-8748-5a51afe7c919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b52ba336-8a43-40f4-8748-5a51afe7c919" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5beb1145-b649-4fae-8bbd-751b3b487f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_DerivativeLiabilities_5beb1145-b649-4fae-8bbd-751b3b487f39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c5e91d95-f415-4f57-8289-1477ecb99c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_c5e91d95-f415-4f57-8289-1477ecb99c29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8dda82a-e1c7-44c8-a459-ca1ff7625a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8dda82a-e1c7-44c8-a459-ca1ff7625a11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_d3869da5-ca7e-4341-9aae-6da044c55613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8dda82a-e1c7-44c8-a459-ca1ff7625a11" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_d3869da5-ca7e-4341-9aae-6da044c55613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d3869da5-ca7e-4341-9aae-6da044c55613_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_d3869da5-ca7e-4341-9aae-6da044c55613" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d3869da5-ca7e-4341-9aae-6da044c55613_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_544c5e48-b0dd-4ce3-952e-d1a77841c80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_d3869da5-ca7e-4341-9aae-6da044c55613" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_544c5e48-b0dd-4ce3-952e-d1a77841c80e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ff8c3b45-aa04-4157-83b2-bd2ec6d2a4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_544c5e48-b0dd-4ce3-952e-d1a77841c80e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ff8c3b45-aa04-4157-83b2-bd2ec6d2a4f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_746a9e4e-66ba-446b-8625-e6df70680221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_544c5e48-b0dd-4ce3-952e-d1a77841c80e" xlink:to="loc_us-gaap_BankTimeDepositsMember_746a9e4e-66ba-446b-8625-e6df70680221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fbbc4a13-5e44-4c74-916f-576ee38ed9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8dda82a-e1c7-44c8-a459-ca1ff7625a11" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fbbc4a13-5e44-4c74-916f-576ee38ed9e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbbc4a13-5e44-4c74-916f-576ee38ed9e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fbbc4a13-5e44-4c74-916f-576ee38ed9e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fbbc4a13-5e44-4c74-916f-576ee38ed9e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a91bc5b-6624-469f-b4b0-e1ba85b2d50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fbbc4a13-5e44-4c74-916f-576ee38ed9e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a91bc5b-6624-469f-b4b0-e1ba85b2d50b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ec51be62-571a-43cc-b26c-d042be6a97ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a91bc5b-6624-469f-b4b0-e1ba85b2d50b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ec51be62-571a-43cc-b26c-d042be6a97ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d68b980f-1964-48ca-970c-1a45dbc6f9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a91bc5b-6624-469f-b4b0-e1ba85b2d50b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d68b980f-1964-48ca-970c-1a45dbc6f9ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4e01ff9f-f90d-4a2f-9037-aa29d7efb2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a91bc5b-6624-469f-b4b0-e1ba85b2d50b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4e01ff9f-f90d-4a2f-9037-aa29d7efb2a4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#FairvaluemeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="extended" id="ie4e0ffd49e6f4552ab3fcb206b22c0bb_FairvaluemeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_82f2d125-8507-4373-882d-4011ff856d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_06ccfd22-df64-4749-bcae-942b05efd2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82f2d125-8507-4373-882d-4011ff856d03" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_06ccfd22-df64-4749-bcae-942b05efd2c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52f5c02e-25c5-4bda-b9a1-e9ebd6600f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82f2d125-8507-4373-882d-4011ff856d03" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52f5c02e-25c5-4bda-b9a1-e9ebd6600f93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_6baf2c88-f741-4ce3-b311-74f69c79d2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82f2d125-8507-4373-882d-4011ff856d03" xlink:to="loc_us-gaap_LongTermDebtFairValue_6baf2c88-f741-4ce3-b311-74f69c79d2b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1a918200-ee1b-44b0-a55b-a1356d645ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82f2d125-8507-4373-882d-4011ff856d03" xlink:to="loc_us-gaap_DebtInstrumentTable_1a918200-ee1b-44b0-a55b-a1356d645ba8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_066ad1b7-e04e-4b89-85d4-86a642eb4674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1a918200-ee1b-44b0-a55b-a1356d645ba8" xlink:to="loc_us-gaap_DebtInstrumentAxis_066ad1b7-e04e-4b89-85d4-86a642eb4674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_066ad1b7-e04e-4b89-85d4-86a642eb4674_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_066ad1b7-e04e-4b89-85d4-86a642eb4674" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_066ad1b7-e04e-4b89-85d4-86a642eb4674_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a6ad4e8d-0214-4f3b-80b4-9c66f643707e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_066ad1b7-e04e-4b89-85d4-86a642eb4674" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a6ad4e8d-0214-4f3b-80b4-9c66f643707e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_36aac126-29a9-4e9e-8ac3-fb5d46449e63" xlink:href="ebs-20220930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a6ad4e8d-0214-4f3b-80b4-9c66f643707e" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_36aac126-29a9-4e9e-8ac3-fb5d46449e63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8c03a145-e967-4662-b4b5-1e8797fb5776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1a918200-ee1b-44b0-a55b-a1356d645ba8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8c03a145-e967-4662-b4b5-1e8797fb5776" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8c03a145-e967-4662-b4b5-1e8797fb5776_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8c03a145-e967-4662-b4b5-1e8797fb5776" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8c03a145-e967-4662-b4b5-1e8797fb5776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_721d76c0-06ab-47ee-835d-1636934f1f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8c03a145-e967-4662-b4b5-1e8797fb5776" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_721d76c0-06ab-47ee-835d-1636934f1f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_649cb5b9-36d0-48a3-abfb-2811f439cd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_721d76c0-06ab-47ee-835d-1636934f1f05" xlink:to="loc_us-gaap_SeniorNotesMember_649cb5b9-36d0-48a3-abfb-2811f439cd7b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="extended" id="i6510af6c0db8480a9a79f634f5327199_FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ddf70656-7b93-4a11-b46f-1668df8bf988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c2d475c3-dad9-45fa-b0d1-940b9bba9c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ddf70656-7b93-4a11-b46f-1668df8bf988" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c2d475c3-dad9-45fa-b0d1-940b9bba9c85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d7a07ce8-e6f7-4b9c-9df9-68f1f9c198a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ddf70656-7b93-4a11-b46f-1668df8bf988" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d7a07ce8-e6f7-4b9c-9df9-68f1f9c198a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ddf70656-7b93-4a11-b46f-1668df8bf988" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_58fddd59-5a87-46b1-9149-b1c3228d987e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:to="loc_us-gaap_ValuationTechniqueAxis_58fddd59-5a87-46b1-9149-b1c3228d987e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_58fddd59-5a87-46b1-9149-b1c3228d987e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_58fddd59-5a87-46b1-9149-b1c3228d987e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_58fddd59-5a87-46b1-9149-b1c3228d987e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f23ffa88-a328-4536-948d-aa553cbac100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_58fddd59-5a87-46b1-9149-b1c3228d987e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f23ffa88-a328-4536-948d-aa553cbac100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_0cc20048-8881-4821-b472-754a4b2932fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_f23ffa88-a328-4536-948d-aa553cbac100" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_0cc20048-8881-4821-b472-754a4b2932fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14b001eb-f2e6-47db-b1eb-2768d3b0a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14b001eb-f2e6-47db-b1eb-2768d3b0a0f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14b001eb-f2e6-47db-b1eb-2768d3b0a0f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14b001eb-f2e6-47db-b1eb-2768d3b0a0f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14b001eb-f2e6-47db-b1eb-2768d3b0a0f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1aa0cc80-4cf5-4546-b922-a57d91c31b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14b001eb-f2e6-47db-b1eb-2768d3b0a0f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1aa0cc80-4cf5-4546-b922-a57d91c31b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_92e55f4a-529d-4ede-a27b-44ef6df86c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1aa0cc80-4cf5-4546-b922-a57d91c31b87" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_92e55f4a-529d-4ede-a27b-44ef6df86c73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efe281d-146a-43c7-b0df-49a21ed3bf96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efe281d-146a-43c7-b0df-49a21ed3bf96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5efe281d-146a-43c7-b0df-49a21ed3bf96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efe281d-146a-43c7-b0df-49a21ed3bf96" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5efe281d-146a-43c7-b0df-49a21ed3bf96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e84a4f58-48b8-4dcd-a205-1412cae49c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efe281d-146a-43c7-b0df-49a21ed3bf96" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e84a4f58-48b8-4dcd-a205-1412cae49c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2971ba8a-e690-417c-b118-ae975a179988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e84a4f58-48b8-4dcd-a205-1412cae49c62" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2971ba8a-e690-417c-b118-ae975a179988" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f0a2c2cc-d281-4a4f-9aa4-52eab6770c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f0a2c2cc-d281-4a4f-9aa4-52eab6770c91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f0a2c2cc-d281-4a4f-9aa4-52eab6770c91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f0a2c2cc-d281-4a4f-9aa4-52eab6770c91" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f0a2c2cc-d281-4a4f-9aa4-52eab6770c91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_da636734-4c58-4baa-b887-adafeb582ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f0a2c2cc-d281-4a4f-9aa4-52eab6770c91" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_da636734-4c58-4baa-b887-adafeb582ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d1ac3a27-fb48-428e-9d5d-8d3c73e968ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_da636734-4c58-4baa-b887-adafeb582ee2" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d1ac3a27-fb48-428e-9d5d-8d3c73e968ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityofPaymentMember_3c3a2192-c753-4c10-bbb7-de8b2833af0b" xlink:href="ebs-20220930.xsd#ebs_MeasurementInputProbabilityofPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_da636734-4c58-4baa-b887-adafeb582ee2" xlink:to="loc_ebs_MeasurementInputProbabilityofPaymentMember_3c3a2192-c753-4c10-bbb7-de8b2833af0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4f418976-51f7-4c59-9d8d-8949a85e87de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:to="loc_srt_RangeAxis_4f418976-51f7-4c59-9d8d-8949a85e87de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4f418976-51f7-4c59-9d8d-8949a85e87de_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4f418976-51f7-4c59-9d8d-8949a85e87de" xlink:to="loc_srt_RangeMember_4f418976-51f7-4c59-9d8d-8949a85e87de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8aafed9c-ce50-4d1b-90f3-f3bad373147d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4f418976-51f7-4c59-9d8d-8949a85e87de" xlink:to="loc_srt_RangeMember_8aafed9c-ce50-4d1b-90f3-f3bad373147d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2519676b-9931-4889-8011-442a9f37fb76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8aafed9c-ce50-4d1b-90f3-f3bad373147d" xlink:to="loc_srt_MinimumMember_2519676b-9931-4889-8011-442a9f37fb76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_320b523e-0f57-4def-ac91-76048b7fe994" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8aafed9c-ce50-4d1b-90f3-f3bad373147d" xlink:to="loc_srt_MaximumMember_320b523e-0f57-4def-ac91-76048b7fe994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_78d1545b-e48e-4918-9594-b32736442325" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8aafed9c-ce50-4d1b-90f3-f3bad373147d" xlink:to="loc_srt_WeightedAverageMember_78d1545b-e48e-4918-9594-b32736442325" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="extended" id="i867d8709e4594172b9575b9a71a995ba_DerivativeinstrumentsandhedgingactivitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4806de49-be31-4620-9df4-20413644d92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_d0f4014e-852f-4839-a880-251898def207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4806de49-be31-4620-9df4-20413644d92c" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_d0f4014e-852f-4839-a880-251898def207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3260ba4e-3fec-4426-a223-6c2714b6d9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4806de49-be31-4620-9df4-20413644d92c" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3260ba4e-3fec-4426-a223-6c2714b6d9b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1ba0bfe1-685f-4fc0-93db-acd4a2a84386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3260ba4e-3fec-4426-a223-6c2714b6d9b1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1ba0bfe1-685f-4fc0-93db-acd4a2a84386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1ba0bfe1-685f-4fc0-93db-acd4a2a84386_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1ba0bfe1-685f-4fc0-93db-acd4a2a84386" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1ba0bfe1-685f-4fc0-93db-acd4a2a84386_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_89d65656-2d67-423f-8364-dbb6ab99b064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1ba0bfe1-685f-4fc0-93db-acd4a2a84386" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_89d65656-2d67-423f-8364-dbb6ab99b064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5b6849bb-6766-4518-b47b-530b6b7e67fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_89d65656-2d67-423f-8364-dbb6ab99b064" xlink:to="loc_us-gaap_InterestRateSwapMember_5b6849bb-6766-4518-b47b-530b6b7e67fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="extended" id="if1c92bea6e8e474cb1d7ba66e3fecfda_DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7ffe8103-fb5b-4428-86d0-941fdd9aa89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_e32fcf6d-d7a2-4ec6-a048-9d1cda38fdac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7ffe8103-fb5b-4428-86d0-941fdd9aa89b" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_e32fcf6d-d7a2-4ec6-a048-9d1cda38fdac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_65dd1f76-a980-47df-b293-8425c940b780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7ffe8103-fb5b-4428-86d0-941fdd9aa89b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_65dd1f76-a980-47df-b293-8425c940b780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1620109f-6b14-4f92-8f84-b7195c66b323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7ffe8103-fb5b-4428-86d0-941fdd9aa89b" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1620109f-6b14-4f92-8f84-b7195c66b323" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e69d6fc7-22f6-4861-8df9-8703e41e94c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1620109f-6b14-4f92-8f84-b7195c66b323" xlink:to="loc_us-gaap_HedgingDesignationAxis_e69d6fc7-22f6-4861-8df9-8703e41e94c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e69d6fc7-22f6-4861-8df9-8703e41e94c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_e69d6fc7-22f6-4861-8df9-8703e41e94c6" xlink:to="loc_us-gaap_HedgingDesignationDomain_e69d6fc7-22f6-4861-8df9-8703e41e94c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9fa27e3e-ec04-43e2-bb78-24f5e633c09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_e69d6fc7-22f6-4861-8df9-8703e41e94c6" xlink:to="loc_us-gaap_HedgingDesignationDomain_9fa27e3e-ec04-43e2-bb78-24f5e633c09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e652037-d408-4c0d-9ae1-72818995372c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_9fa27e3e-ec04-43e2-bb78-24f5e633c09d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e652037-d408-4c0d-9ae1-72818995372c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8dd645b9-0d3e-427a-a2c6-0cf249913513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1620109f-6b14-4f92-8f84-b7195c66b323" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8dd645b9-0d3e-427a-a2c6-0cf249913513" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8dd645b9-0d3e-427a-a2c6-0cf249913513_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8dd645b9-0d3e-427a-a2c6-0cf249913513" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8dd645b9-0d3e-427a-a2c6-0cf249913513_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ac46804d-66d7-4a13-b7c8-10834f77948b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8dd645b9-0d3e-427a-a2c6-0cf249913513" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ac46804d-66d7-4a13-b7c8-10834f77948b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f34a8999-cf5b-493a-a472-f43d0c70d80c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ac46804d-66d7-4a13-b7c8-10834f77948b" xlink:to="loc_us-gaap_InterestRateSwapMember_f34a8999-cf5b-493a-a472-f43d0c70d80c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="extended" id="ia92de7e7a1394b13a0493d589777c86e_DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0311ed9a-72ff-4b44-b213-266fbb8e7fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_4e077133-673d-4965-a687-be93cb62e6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0311ed9a-72ff-4b44-b213-266fbb8e7fb6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_4e077133-673d-4965-a687-be93cb62e6e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a43d81ae-35ea-4845-aa8f-fc6867e9097c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0311ed9a-72ff-4b44-b213-266fbb8e7fb6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a43d81ae-35ea-4845-aa8f-fc6867e9097c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2dd979dc-2a1f-4183-bbcc-c7c4a5ec7e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0311ed9a-72ff-4b44-b213-266fbb8e7fb6" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2dd979dc-2a1f-4183-bbcc-c7c4a5ec7e46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_137a08fc-85ba-4b5a-bbe5-7fd93d277273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2dd979dc-2a1f-4183-bbcc-c7c4a5ec7e46" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_137a08fc-85ba-4b5a-bbe5-7fd93d277273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_137a08fc-85ba-4b5a-bbe5-7fd93d277273_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_137a08fc-85ba-4b5a-bbe5-7fd93d277273" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_137a08fc-85ba-4b5a-bbe5-7fd93d277273_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fa676828-0bfb-4119-918b-b3a1100005b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_137a08fc-85ba-4b5a-bbe5-7fd93d277273" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fa676828-0bfb-4119-918b-b3a1100005b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_6f374ca7-298d-4b11-a3e3-f60c2ffbc4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa676828-0bfb-4119-918b-b3a1100005b7" xlink:to="loc_us-gaap_InterestRateSwapMember_6f374ca7-298d-4b11-a3e3-f60c2ffbc4bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_573f5234-722e-4a12-981c-a63e2b964108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2dd979dc-2a1f-4183-bbcc-c7c4a5ec7e46" xlink:to="loc_us-gaap_HedgingDesignationAxis_573f5234-722e-4a12-981c-a63e2b964108" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_573f5234-722e-4a12-981c-a63e2b964108_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_573f5234-722e-4a12-981c-a63e2b964108" xlink:to="loc_us-gaap_HedgingDesignationDomain_573f5234-722e-4a12-981c-a63e2b964108_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d5eeac5d-b774-452a-ba0d-a284fd1ec333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_573f5234-722e-4a12-981c-a63e2b964108" xlink:to="loc_us-gaap_HedgingDesignationDomain_d5eeac5d-b774-452a-ba0d-a284fd1ec333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_bb32820c-093b-4a73-ac2a-8ccc764906ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d5eeac5d-b774-452a-ba0d-a284fd1ec333" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_bb32820c-093b-4a73-ac2a-8ccc764906ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ecdca4a8-63e6-4fa7-b43d-f1841eb4f643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2dd979dc-2a1f-4183-bbcc-c7c4a5ec7e46" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ecdca4a8-63e6-4fa7-b43d-f1841eb4f643" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ecdca4a8-63e6-4fa7-b43d-f1841eb4f643_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ecdca4a8-63e6-4fa7-b43d-f1841eb4f643" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ecdca4a8-63e6-4fa7-b43d-f1841eb4f643_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ecdca4a8-63e6-4fa7-b43d-f1841eb4f643" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_c1fadf54-2d3b-4c38-a402-a528c4350387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_c1fadf54-2d3b-4c38-a402-a528c4350387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_b809c511-5ef5-4db7-8b03-8052b8aacec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:to="loc_us-gaap_OtherAssetsMember_b809c511-5ef5-4db7-8b03-8052b8aacec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_d343f4dd-3524-4a7e-bd9f-c104b26a406d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_d343f4dd-3524-4a7e-bd9f-c104b26a406d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_2f60eb6f-34d3-41b8-b84c-da2daed4676f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:to="loc_us-gaap_OtherLiabilitiesMember_2f60eb6f-34d3-41b8-b84c-da2daed4676f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="extended" id="i39bcdc113a2e4f54bedd365bbd9dd48a_DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ad5890c8-2d58-422d-8546-ed4f1310510b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_cc7e085d-2c61-4ff4-aa55-7b2f10bb0920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ad5890c8-2d58-422d-8546-ed4f1310510b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_cc7e085d-2c61-4ff4-aa55-7b2f10bb0920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9466276c-e4a9-4e24-ac83-0b2f256fa016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ad5890c8-2d58-422d-8546-ed4f1310510b" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9466276c-e4a9-4e24-ac83-0b2f256fa016" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_98fae3f2-a3ad-41a1-aad1-07f200b6d320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9466276c-e4a9-4e24-ac83-0b2f256fa016" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_98fae3f2-a3ad-41a1-aad1-07f200b6d320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_98fae3f2-a3ad-41a1-aad1-07f200b6d320_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_98fae3f2-a3ad-41a1-aad1-07f200b6d320" xlink:to="loc_us-gaap_HedgingRelationshipDomain_98fae3f2-a3ad-41a1-aad1-07f200b6d320_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5ed6f7d3-00ac-443a-9870-c32a32d1d828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_98fae3f2-a3ad-41a1-aad1-07f200b6d320" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5ed6f7d3-00ac-443a-9870-c32a32d1d828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_10508c2b-629a-43cd-926b-4ccf2469ec18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_5ed6f7d3-00ac-443a-9870-c32a32d1d828" xlink:to="loc_us-gaap_CashFlowHedgingMember_10508c2b-629a-43cd-926b-4ccf2469ec18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e13388eb-7616-4852-9bdf-dcc76644c18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9466276c-e4a9-4e24-ac83-0b2f256fa016" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e13388eb-7616-4852-9bdf-dcc76644c18e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e13388eb-7616-4852-9bdf-dcc76644c18e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e13388eb-7616-4852-9bdf-dcc76644c18e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e13388eb-7616-4852-9bdf-dcc76644c18e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8ef23938-5476-4304-b21c-d6eb26f77340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e13388eb-7616-4852-9bdf-dcc76644c18e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8ef23938-5476-4304-b21c-d6eb26f77340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_004480e6-ae22-42b1-8f7b-d0848c7d4a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8ef23938-5476-4304-b21c-d6eb26f77340" xlink:to="loc_us-gaap_InterestExpenseMember_004480e6-ae22-42b1-8f7b-d0848c7d4a63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2fac3950-93a6-4832-a16f-f55037292dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9466276c-e4a9-4e24-ac83-0b2f256fa016" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2fac3950-93a6-4832-a16f-f55037292dec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2fac3950-93a6-4832-a16f-f55037292dec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2fac3950-93a6-4832-a16f-f55037292dec" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2fac3950-93a6-4832-a16f-f55037292dec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c881de21-038b-4a3a-902a-ab77f105d168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2fac3950-93a6-4832-a16f-f55037292dec" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c881de21-038b-4a3a-902a-ab77f105d168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_10d2d50b-67e6-46cf-8703-aa8b5dcecb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c881de21-038b-4a3a-902a-ab77f105d168" xlink:to="loc_us-gaap_InterestRateSwapMember_10d2d50b-67e6-46cf-8703-aa8b5dcecb7f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DebtScheduleDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended" id="i3ead8be0f8fd4b85b8b18caa9577e254_DebtScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_99f14029-dca5-47fa-866f-9721cbfaee55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_99f14029-dca5-47fa-866f-9721cbfaee55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f770a084-ad27-4ab3-9555-5016921c1fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:to="loc_us-gaap_LongTermDebt_f770a084-ad27-4ab3-9555-5016921c1fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_cef3b16b-2c36-43f5-9c81-601e21132b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:to="loc_us-gaap_LongTermDebtCurrent_cef3b16b-2c36-43f5-9c81-601e21132b1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_05e08af5-e637-4ba5-abed-39b2ac1aeadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_05e08af5-e637-4ba5-abed-39b2ac1aeadd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d3e86ba8-008b-4c24-92a0-ad611d6e0db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d3e86ba8-008b-4c24-92a0-ad611d6e0db0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5857f2d4-33a6-47e6-a711-de33af5f6fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:to="loc_us-gaap_DebtInstrumentTable_5857f2d4-33a6-47e6-a711-de33af5f6fa5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c223de28-9ff3-4df9-a02f-79aa39738d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5857f2d4-33a6-47e6-a711-de33af5f6fa5" xlink:to="loc_us-gaap_DebtInstrumentAxis_c223de28-9ff3-4df9-a02f-79aa39738d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c223de28-9ff3-4df9-a02f-79aa39738d61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c223de28-9ff3-4df9-a02f-79aa39738d61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c223de28-9ff3-4df9-a02f-79aa39738d61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4edd46bb-5b9f-4959-8025-6e53a94ff4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c223de28-9ff3-4df9-a02f-79aa39738d61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4edd46bb-5b9f-4959-8025-6e53a94ff4c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_bb27597d-b108-4b46-b2a9-8559b36aa19e" xlink:href="ebs-20220930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4edd46bb-5b9f-4959-8025-6e53a94ff4c1" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_bb27597d-b108-4b46-b2a9-8559b36aa19e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_7a2ead7a-ad62-4fa3-afdc-8a6174891ba3" xlink:href="ebs-20220930.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4edd46bb-5b9f-4959-8025-6e53a94ff4c1" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_7a2ead7a-ad62-4fa3-afdc-8a6174891ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dd8775ef-edc3-45a9-bdb3-0b702d1dc3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5857f2d4-33a6-47e6-a711-de33af5f6fa5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dd8775ef-edc3-45a9-bdb3-0b702d1dc3e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dd8775ef-edc3-45a9-bdb3-0b702d1dc3e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dd8775ef-edc3-45a9-bdb3-0b702d1dc3e0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dd8775ef-edc3-45a9-bdb3-0b702d1dc3e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cafcdca6-d254-4b4e-b3de-53ab01dacadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dd8775ef-edc3-45a9-bdb3-0b702d1dc3e0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cafcdca6-d254-4b4e-b3de-53ab01dacadf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_989e5466-93fc-4ed6-90f4-02a52106b68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cafcdca6-d254-4b4e-b3de-53ab01dacadf" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_989e5466-93fc-4ed6-90f4-02a52106b68a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ec064262-5c3f-4286-8bdb-0d96a1935d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cafcdca6-d254-4b4e-b3de-53ab01dacadf" xlink:to="loc_us-gaap_SeniorNotesMember_ec064262-5c3f-4286-8bdb-0d96a1935d39" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended" id="ia14af6022fad404c8a2e98060fd4d5ba_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ed48d06e-9f58-41de-a6f8-00ab3313120b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_LongTermDebt_ed48d06e-9f58-41de-a6f8-00ab3313120b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_ea844e22-b5ef-4ea6-8a7c-d5cc70c6090f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_ea844e22-b5ef-4ea6-8a7c-d5cc70c6090f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_b7474405-edae-4620-a9dc-5a626e37c1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_b7474405-edae-4620-a9dc-5a626e37c1bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4cb9331c-d243-4e6e-8c5c-b6508a4d9a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4cb9331c-d243-4e6e-8c5c-b6508a4d9a99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d68db37b-49a4-4bef-94f0-ed14698bdbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d68db37b-49a4-4bef-94f0-ed14698bdbe4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0ed4798d-67f5-47ad-b87a-4df6752c6eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0ed4798d-67f5-47ad-b87a-4df6752c6eef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e1c48c56-dcd1-4b27-87c1-45bd8ca0dd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e1c48c56-dcd1-4b27-87c1-45bd8ca0dd5b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_cb835ea1-49f6-4f2c-be85-f504b25ae5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_cb835ea1-49f6-4f2c-be85-f504b25ae5e1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_1c2939bc-2bb1-4b9c-a4cb-e695949f9f2e" xlink:href="ebs-20220930.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_1c2939bc-2bb1-4b9c-a4cb-e695949f9f2e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_3bcb8182-5420-47de-b034-088155dad0fa" xlink:href="ebs-20220930.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_3bcb8182-5420-47de-b034-088155dad0fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_e4bd5782-8bed-482c-856b-3afbed102177" xlink:href="ebs-20220930.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_e4bd5782-8bed-482c-856b-3afbed102177" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_27b84105-77d9-43bb-b7af-98df450ea5de" xlink:href="ebs-20220930.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_27b84105-77d9-43bb-b7af-98df450ea5de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_2eaf7a20-2466-4cbe-950c-11207c412ccf" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_2eaf7a20-2466-4cbe-950c-11207c412ccf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_61407a79-4a39-463f-8d67-e88acb7562dc" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_61407a79-4a39-463f-8d67-e88acb7562dc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_db3519c4-bb66-4aee-9fa2-0488ddeb8961" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_db3519c4-bb66-4aee-9fa2-0488ddeb8961" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_2c9caa74-c7ce-409e-8ece-618b441d8a50" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_2c9caa74-c7ce-409e-8ece-618b441d8a50" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_a4713b9b-c6ec-44bb-aadd-0cdece915354" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_a4713b9b-c6ec-44bb-aadd-0cdece915354" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_112bd997-2af6-4dc5-bcfa-77202b8d2100" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_112bd997-2af6-4dc5-bcfa-77202b8d2100" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1f150462-8f60-442f-bdbc-5f146342e988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_CreditFacilityAxis_1f150462-8f60-442f-bdbc-5f146342e988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1f150462-8f60-442f-bdbc-5f146342e988_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1f150462-8f60-442f-bdbc-5f146342e988" xlink:to="loc_us-gaap_CreditFacilityDomain_1f150462-8f60-442f-bdbc-5f146342e988_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_94cde685-0afd-4b98-b8a7-edebaa52b9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1f150462-8f60-442f-bdbc-5f146342e988" xlink:to="loc_us-gaap_CreditFacilityDomain_94cde685-0afd-4b98-b8a7-edebaa52b9bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_16dd146b-086a-4975-8a06-c9a673cda53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_94cde685-0afd-4b98-b8a7-edebaa52b9bb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_16dd146b-086a-4975-8a06-c9a673cda53f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember_735f2cef-dd23-48de-ada7-5073c90af190" xlink:href="ebs-20220930.xsd#ebs_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_94cde685-0afd-4b98-b8a7-edebaa52b9bb" xlink:to="loc_ebs_TermLoanFacilityMember_735f2cef-dd23-48de-ada7-5073c90af190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3d58cf8d-4f2a-449e-ab66-6a4d00a53209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_DebtInstrumentAxis_3d58cf8d-4f2a-449e-ab66-6a4d00a53209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3d58cf8d-4f2a-449e-ab66-6a4d00a53209_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d58cf8d-4f2a-449e-ab66-6a4d00a53209" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3d58cf8d-4f2a-449e-ab66-6a4d00a53209_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14e0f563-948f-49ec-a5de-59707e30890c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d58cf8d-4f2a-449e-ab66-6a4d00a53209" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14e0f563-948f-49ec-a5de-59707e30890c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_3bbd1103-8663-49df-8523-2fb366441fd7" xlink:href="ebs-20220930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14e0f563-948f-49ec-a5de-59707e30890c" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_3bbd1103-8663-49df-8523-2fb366441fd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember_11f03a65-9904-4dc9-b1b7-6c114fab32d5" xlink:href="ebs-20220930.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14e0f563-948f-49ec-a5de-59707e30890c" xlink:to="loc_ebs_AmendedCreditAgreementMember_11f03a65-9904-4dc9-b1b7-6c114fab32d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7dfc8ca7-a3d7-495b-9f14-db71b586b86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_VariableRateAxis_7dfc8ca7-a3d7-495b-9f14-db71b586b86a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7dfc8ca7-a3d7-495b-9f14-db71b586b86a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_7dfc8ca7-a3d7-495b-9f14-db71b586b86a" xlink:to="loc_us-gaap_VariableRateDomain_7dfc8ca7-a3d7-495b-9f14-db71b586b86a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3cabe759-556b-469d-a121-136ddb403d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_7dfc8ca7-a3d7-495b-9f14-db71b586b86a" xlink:to="loc_us-gaap_VariableRateDomain_3cabe759-556b-469d-a121-136ddb403d01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_1df0c6d2-a16f-444b-bf6b-131c8db3e9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3cabe759-556b-469d-a121-136ddb403d01" xlink:to="loc_us-gaap_EurodollarMember_1df0c6d2-a16f-444b-bf6b-131c8db3e9f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e32bcb7e-200a-4e8e-b129-6522f085aacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3cabe759-556b-469d-a121-136ddb403d01" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e32bcb7e-200a-4e8e-b129-6522f085aacf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_80e7bf0f-576f-40a4-bfb3-f05f4e9c86bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3cabe759-556b-469d-a121-136ddb403d01" xlink:to="loc_us-gaap_BaseRateMember_80e7bf0f-576f-40a4-bfb3-f05f4e9c86bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd072f8a-be1a-4051-aa98-01f3dfcea661" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_srt_RangeAxis_fd072f8a-be1a-4051-aa98-01f3dfcea661" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd072f8a-be1a-4051-aa98-01f3dfcea661_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fd072f8a-be1a-4051-aa98-01f3dfcea661" xlink:to="loc_srt_RangeMember_fd072f8a-be1a-4051-aa98-01f3dfcea661_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab95b888-fa7d-41e4-a530-ab1a775ca1f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fd072f8a-be1a-4051-aa98-01f3dfcea661" xlink:to="loc_srt_RangeMember_ab95b888-fa7d-41e4-a530-ab1a775ca1f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc605a50-8278-4cc5-895e-a749564486dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab95b888-fa7d-41e4-a530-ab1a775ca1f7" xlink:to="loc_srt_MinimumMember_bc605a50-8278-4cc5-895e-a749564486dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_356faae8-5b6b-4fea-a600-14339b4a17e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab95b888-fa7d-41e4-a530-ab1a775ca1f7" xlink:to="loc_srt_MaximumMember_356faae8-5b6b-4fea-a600-14339b4a17e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dae9b5ad-70a5-45b1-a21a-5623a6be9fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dae9b5ad-70a5-45b1-a21a-5623a6be9fa3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dae9b5ad-70a5-45b1-a21a-5623a6be9fa3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dae9b5ad-70a5-45b1-a21a-5623a6be9fa3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dae9b5ad-70a5-45b1-a21a-5623a6be9fa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_249cf34f-f061-4ccd-9723-247146ac1c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dae9b5ad-70a5-45b1-a21a-5623a6be9fa3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_249cf34f-f061-4ccd-9723-247146ac1c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6ec95106-6a04-4a56-84af-ca36e0c956bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_249cf34f-f061-4ccd-9723-247146ac1c96" xlink:to="loc_us-gaap_LineOfCreditMember_6ec95106-6a04-4a56-84af-ca36e0c956bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a8e16f01-f7a4-486e-9423-5d292ab53e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_249cf34f-f061-4ccd-9723-247146ac1c96" xlink:to="loc_us-gaap_SeniorNotesMember_a8e16f01-f7a4-486e-9423-5d292ab53e81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7b742d13-69a3-4f26-bcd9-258f82e627f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7b742d13-69a3-4f26-bcd9-258f82e627f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7b742d13-69a3-4f26-bcd9-258f82e627f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7b742d13-69a3-4f26-bcd9-258f82e627f5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7b742d13-69a3-4f26-bcd9-258f82e627f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_eb8f0cc5-ea43-487f-8f6c-f55585e7cd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7b742d13-69a3-4f26-bcd9-258f82e627f5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_eb8f0cc5-ea43-487f-8f6c-f55585e7cd3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_cbffd1f3-14cd-4a19-a1ff-569186e760dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eb8f0cc5-ea43-487f-8f6c-f55585e7cd3e" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_cbffd1f3-14cd-4a19-a1ff-569186e760dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_4b9a0037-ada8-411b-82f2-a61a180a4332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eb8f0cc5-ea43-487f-8f6c-f55585e7cd3e" xlink:to="loc_us-gaap_OtherAssetsMember_4b9a0037-ada8-411b-82f2-a61a180a4332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_995464b5-9596-4c96-b297-9e520ef75e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_995464b5-9596-4c96-b297-9e520ef75e1d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_995464b5-9596-4c96-b297-9e520ef75e1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_995464b5-9596-4c96-b297-9e520ef75e1d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_995464b5-9596-4c96-b297-9e520ef75e1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8bdc65b4-5899-422d-b4a4-a06f9699201d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_995464b5-9596-4c96-b297-9e520ef75e1d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8bdc65b4-5899-422d-b4a4-a06f9699201d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_19202e7d-450f-4023-b297-7c3593ffb3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8bdc65b4-5899-422d-b4a4-a06f9699201d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_19202e7d-450f-4023-b297-7c3593ffb3c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_a9fed60f-911a-463f-aaa9-0a7e1c16f900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8bdc65b4-5899-422d-b4a4-a06f9699201d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_a9fed60f-911a-463f-aaa9-0a7e1c16f900" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" id="iaea8042e4c6947a9b8e666defa0d51dd_RevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_29d30e63-9d39-4244-815e-d4fe765d22a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_29d30e63-9d39-4244-815e-d4fe765d22a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5cebc428-2c7e-4c66-aef7-89395d72531e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5cebc428-2c7e-4c66-aef7-89395d72531e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_87dfbd8e-a7f7-4eb9-adf9-cce659db8b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_87dfbd8e-a7f7-4eb9-adf9-cce659db8b63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1688e16e-0605-49f3-a9c0-36460c909b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1688e16e-0605-49f3-a9c0-36460c909b32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_51733b3b-dcc1-4a34-b548-726687962b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_51733b3b-dcc1-4a34-b548-726687962b44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_32d66256-e357-467a-9572-4c1d7f6f1979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_32d66256-e357-467a-9572-4c1d7f6f1979" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ec5b83a4-871c-43c6-90ba-386aa4a5746d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ec5b83a4-871c-43c6-90ba-386aa4a5746d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_87d3de4a-5748-49be-b792-a0d68221968a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_87d3de4a-5748-49be-b792-a0d68221968a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_4ced0a3a-7979-4922-95bd-25c0ec55a09c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_4ced0a3a-7979-4922-95bd-25c0ec55a09c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8497b55d-6694-4d3e-b517-b079f7528d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8497b55d-6694-4d3e-b517-b079f7528d5a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8329d88e-fb5d-4c4f-874d-bc297ce3a868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8329d88e-fb5d-4c4f-874d-bc297ce3a868" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_2c4032b2-5999-4aad-8e7c-fae7eeb7c317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:to="loc_us-gaap_LeaseContractualTermAxis_2c4032b2-5999-4aad-8e7c-fae7eeb7c317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_2c4032b2-5999-4aad-8e7c-fae7eeb7c317_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2c4032b2-5999-4aad-8e7c-fae7eeb7c317" xlink:to="loc_us-gaap_LeaseContractualTermDomain_2c4032b2-5999-4aad-8e7c-fae7eeb7c317_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_7849924f-e6c4-445a-9ac6-e34638f35083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2c4032b2-5999-4aad-8e7c-fae7eeb7c317" xlink:to="loc_us-gaap_LeaseContractualTermDomain_7849924f-e6c4-445a-9ac6-e34638f35083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ReservationOfManufacturingCapacityMember_2c67a026-db71-4098-ba61-30351ccba484" xlink:href="ebs-20220930.xsd#ebs_ReservationOfManufacturingCapacityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_7849924f-e6c4-445a-9ac6-e34638f35083" xlink:to="loc_ebs_ReservationOfManufacturingCapacityMember_2c67a026-db71-4098-ba61-30351ccba484" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_ee1dd669-8a6b-42b7-a156-30a321cf37d5" xlink:href="ebs-20220930.xsd#ebs_AcceleratedExpansionOfFillFinishCapacityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_7849924f-e6c4-445a-9ac6-e34638f35083" xlink:to="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_ee1dd669-8a6b-42b7-a156-30a321cf37d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c9a5c75d-cc09-4461-905e-f9dfd22e0b24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:to="loc_srt_StatementGeographicalAxis_c9a5c75d-cc09-4461-905e-f9dfd22e0b24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c9a5c75d-cc09-4461-905e-f9dfd22e0b24_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c9a5c75d-cc09-4461-905e-f9dfd22e0b24" xlink:to="loc_srt_SegmentGeographicalDomain_c9a5c75d-cc09-4461-905e-f9dfd22e0b24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b70ea3f8-8796-49f5-8b65-4ceed336a35a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c9a5c75d-cc09-4461-905e-f9dfd22e0b24" xlink:to="loc_srt_SegmentGeographicalDomain_b70ea3f8-8796-49f5-8b65-4ceed336a35a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c379e1fe-661f-44c4-87a8-f44bc582f121" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b70ea3f8-8796-49f5-8b65-4ceed336a35a" xlink:to="loc_country_US_c379e1fe-661f-44c4-87a8-f44bc582f121" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_8c945140-100a-4c50-a819-4c99c0cb1fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b70ea3f8-8796-49f5-8b65-4ceed336a35a" xlink:to="loc_us-gaap_NonUsMember_8c945140-100a-4c50-a819-4c99c0cb1fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d7ff8769-7c2e-48e4-a03d-bb7d32878078" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:to="loc_srt_MajorCustomersAxis_d7ff8769-7c2e-48e4-a03d-bb7d32878078" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d7ff8769-7c2e-48e4-a03d-bb7d32878078_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_d7ff8769-7c2e-48e4-a03d-bb7d32878078" xlink:to="loc_srt_NameOfMajorCustomerDomain_d7ff8769-7c2e-48e4-a03d-bb7d32878078_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5090c1e1-f9da-481c-a3a4-35dbbab1b8eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_d7ff8769-7c2e-48e4-a03d-bb7d32878078" xlink:to="loc_srt_NameOfMajorCustomerDomain_5090c1e1-f9da-481c-a3a4-35dbbab1b8eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_588c06be-6e92-4f42-a1db-a760f8a7e88a" xlink:href="ebs-20220930.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5090c1e1-f9da-481c-a3a4-35dbbab1b8eb" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_588c06be-6e92-4f42-a1db-a760f8a7e88a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember_34e03a7d-56fe-4c57-a505-fad85da6d221" xlink:href="ebs-20220930.xsd#ebs_BARDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5090c1e1-f9da-481c-a3a4-35dbbab1b8eb" xlink:to="loc_ebs_BARDAMember_34e03a7d-56fe-4c57-a505-fad85da6d221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0e5a3889-e06f-42de-a466-8b91bdbd904a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:to="loc_srt_ProductOrServiceAxis_0e5a3889-e06f-42de-a466-8b91bdbd904a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0e5a3889-e06f-42de-a466-8b91bdbd904a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0e5a3889-e06f-42de-a466-8b91bdbd904a" xlink:to="loc_srt_ProductsAndServicesDomain_0e5a3889-e06f-42de-a466-8b91bdbd904a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ba0b41f7-ff34-4343-a1bb-5c961970ed80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0e5a3889-e06f-42de-a466-8b91bdbd904a" xlink:to="loc_srt_ProductsAndServicesDomain_ba0b41f7-ff34-4343-a1bb-5c961970ed80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_7ab18189-332a-4291-a096-271404fcc46b" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ba0b41f7-ff34-4343-a1bb-5c961970ed80" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_7ab18189-332a-4291-a096-271404fcc46b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1d9e5403-360a-47a0-97ab-f90654c292fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ba0b41f7-ff34-4343-a1bb-5c961970ed80" xlink:to="loc_us-gaap_ServiceMember_1d9e5403-360a-47a0-97ab-f90654c292fe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="ie4f92e86ba4d46b5af75842c5e19daa2_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a63d7d62-3df9-409c-9e19-61486ade7a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a63d7d62-3df9-409c-9e19-61486ade7a12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_4daee79f-e037-45ba-bbf1-e72a7a2f2037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_4daee79f-e037-45ba-bbf1-e72a7a2f2037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_09f010a8-5bc8-4bf5-80c1-f9b515fd4d53" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_09f010a8-5bc8-4bf5-80c1-f9b515fd4d53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_deb07b99-48ed-4d62-a6c7-4a6a842b99c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:to="loc_us-gaap_Revenues_deb07b99-48ed-4d62-a6c7-4a6a842b99c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6fbaddf3-628f-4dd8-a949-6400f3c7e7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6fbaddf3-628f-4dd8-a949-6400f3c7e7e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_96d0eed3-739e-4384-8c3c-cfac5151230f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fbaddf3-628f-4dd8-a949-6400f3c7e7e6" xlink:to="loc_srt_ProductOrServiceAxis_96d0eed3-739e-4384-8c3c-cfac5151230f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96d0eed3-739e-4384-8c3c-cfac5151230f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_96d0eed3-739e-4384-8c3c-cfac5151230f" xlink:to="loc_srt_ProductsAndServicesDomain_96d0eed3-739e-4384-8c3c-cfac5151230f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_12465499-9d5b-41f4-8f9f-bae411d5385f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_96d0eed3-739e-4384-8c3c-cfac5151230f" xlink:to="loc_srt_ProductsAndServicesDomain_12465499-9d5b-41f4-8f9f-bae411d5385f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_61082696-a5ea-4450-9c17-d98b908d02b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_12465499-9d5b-41f4-8f9f-bae411d5385f" xlink:to="loc_us-gaap_ProductMember_61082696-a5ea-4450-9c17-d98b908d02b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_174e94b2-fbfb-4dbc-9576-24702eba7b0f" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_12465499-9d5b-41f4-8f9f-bae411d5385f" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_174e94b2-fbfb-4dbc-9576-24702eba7b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ecbb62d2-7643-4f6c-a80e-bac82d8e78bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_174e94b2-fbfb-4dbc-9576-24702eba7b0f" xlink:to="loc_us-gaap_ServiceMember_ecbb62d2-7643-4f6c-a80e-bac82d8e78bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_e7a00f4f-c29b-42e2-a43f-452940f472b9" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_174e94b2-fbfb-4dbc-9576-24702eba7b0f" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_e7a00f4f-c29b-42e2-a43f-452940f472b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_2f03ae14-97de-41ed-9c7d-78b0f9584e00" xlink:href="ebs-20220930.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_12465499-9d5b-41f4-8f9f-bae411d5385f" xlink:to="loc_ebs_ContractsAndGrantsMember_2f03ae14-97de-41ed-9c7d-78b0f9584e00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ec5d457a-565e-49e4-bf58-10a9542f29c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fbaddf3-628f-4dd8-a949-6400f3c7e7e6" xlink:to="loc_srt_StatementGeographicalAxis_ec5d457a-565e-49e4-bf58-10a9542f29c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ec5d457a-565e-49e4-bf58-10a9542f29c1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ec5d457a-565e-49e4-bf58-10a9542f29c1" xlink:to="loc_srt_SegmentGeographicalDomain_ec5d457a-565e-49e4-bf58-10a9542f29c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2b3f4582-fcb1-4940-8ff7-86c1e2a57a34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ec5d457a-565e-49e4-bf58-10a9542f29c1" xlink:to="loc_srt_SegmentGeographicalDomain_2b3f4582-fcb1-4940-8ff7-86c1e2a57a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a9e64b13-e6f8-4265-a6e2-c4c7513674a2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2b3f4582-fcb1-4940-8ff7-86c1e2a57a34" xlink:to="loc_country_US_a9e64b13-e6f8-4265-a6e2-c4c7513674a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_6adf28f5-7670-4980-b3cb-a35d6e18f6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2b3f4582-fcb1-4940-8ff7-86c1e2a57a34" xlink:to="loc_us-gaap_NonUsMember_6adf28f5-7670-4980-b3cb-a35d6e18f6ac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails" xlink:type="extended" id="ib8db713517334f4497a81a0521817be0_RevenueRecognitionPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_88f90e8b-7258-4041-8387-97840d79434f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_88f90e8b-7258-4041-8387-97840d79434f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1a41b894-9090-4e15-8d32-dbd53b5cdc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1a41b894-9090-4e15-8d32-dbd53b5cdc3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_a12d4ba1-4d24-4199-a3e8-852b1289c17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_a12d4ba1-4d24-4199-a3e8-852b1289c17d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_96c6e025-27bc-4230-9b07-e75e5e91a7be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:to="loc_srt_ProductOrServiceAxis_96c6e025-27bc-4230-9b07-e75e5e91a7be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96c6e025-27bc-4230-9b07-e75e5e91a7be_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_96c6e025-27bc-4230-9b07-e75e5e91a7be" xlink:to="loc_srt_ProductsAndServicesDomain_96c6e025-27bc-4230-9b07-e75e5e91a7be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b979d64-b8d6-423a-9963-d3dbd5a615ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_96c6e025-27bc-4230-9b07-e75e5e91a7be" xlink:to="loc_srt_ProductsAndServicesDomain_2b979d64-b8d6-423a-9963-d3dbd5a615ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_26c98f8c-17cb-4e8b-89c1-590a4da0f20d" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b979d64-b8d6-423a-9963-d3dbd5a615ee" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_26c98f8c-17cb-4e8b-89c1-590a4da0f20d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails_1" xlink:type="extended" id="i2e122f13fe2840df888daaeb3b1bad64_RevenueRecognitionPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_88f90e8b-7258-4041-8387-97840d79434f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_88f90e8b-7258-4041-8387-97840d79434f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1a41b894-9090-4e15-8d32-dbd53b5cdc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1a41b894-9090-4e15-8d32-dbd53b5cdc3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_96c6e025-27bc-4230-9b07-e75e5e91a7be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:to="loc_srt_ProductOrServiceAxis_96c6e025-27bc-4230-9b07-e75e5e91a7be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96c6e025-27bc-4230-9b07-e75e5e91a7be_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_96c6e025-27bc-4230-9b07-e75e5e91a7be" xlink:to="loc_srt_ProductsAndServicesDomain_96c6e025-27bc-4230-9b07-e75e5e91a7be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b979d64-b8d6-423a-9963-d3dbd5a615ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_96c6e025-27bc-4230-9b07-e75e5e91a7be" xlink:to="loc_srt_ProductsAndServicesDomain_2b979d64-b8d6-423a-9963-d3dbd5a615ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_26c98f8c-17cb-4e8b-89c1-590a4da0f20d" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b979d64-b8d6-423a-9963-d3dbd5a615ee" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_26c98f8c-17cb-4e8b-89c1-590a4da0f20d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionRemainingPerformanceObligationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails" xlink:type="extended" id="ic377199d44d843daa00d2c8587ef8ef8_RevenueRecognitionRemainingPerformanceObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_db650f9e-4f8c-4aaf-b7cc-2fd3b8732174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_351c8942-e80a-4e52-8391-2ee02f54ce9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_db650f9e-4f8c-4aaf-b7cc-2fd3b8732174" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_351c8942-e80a-4e52-8391-2ee02f54ce9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ccc820ea-3be1-4bfb-9960-045259b1b5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_db650f9e-4f8c-4aaf-b7cc-2fd3b8732174" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ccc820ea-3be1-4bfb-9960-045259b1b5ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_68891dc0-52ea-4079-ac43-ff6881cfabbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ccc820ea-3be1-4bfb-9960-045259b1b5ee" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_68891dc0-52ea-4079-ac43-ff6881cfabbf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionRemainingPerformanceObligationDetails_1"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails_1" xlink:type="extended" id="i5aa9e0e97ae94528811cc5faeee09182_RevenueRecognitionRemainingPerformanceObligationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_db650f9e-4f8c-4aaf-b7cc-2fd3b8732174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_351c8942-e80a-4e52-8391-2ee02f54ce9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_db650f9e-4f8c-4aaf-b7cc-2fd3b8732174" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_351c8942-e80a-4e52-8391-2ee02f54ce9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ccc820ea-3be1-4bfb-9960-045259b1b5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_db650f9e-4f8c-4aaf-b7cc-2fd3b8732174" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ccc820ea-3be1-4bfb-9960-045259b1b5ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#IncometaxesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="extended" id="ie7d727be047441f1bf3af13d8ae95d39_IncometaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesLineItems_1df410ab-4ba7-4479-ab97-3055ad200957" xlink:href="ebs-20220930.xsd#ebs_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a69d219-1b13-46dd-896b-5f75faf9e655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_IncomeTaxesLineItems_1df410ab-4ba7-4479-ab97-3055ad200957" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a69d219-1b13-46dd-896b-5f75faf9e655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b199a8a1-eba5-438c-8fa9-e8808b2c4131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_IncomeTaxesLineItems_1df410ab-4ba7-4479-ab97-3055ad200957" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b199a8a1-eba5-438c-8fa9-e8808b2c4131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9bff9163-eaed-4876-b097-ff1d6ada4417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_IncomeTaxesLineItems_1df410ab-4ba7-4479-ab97-3055ad200957" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9bff9163-eaed-4876-b097-ff1d6ada4417" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesTable_5d09fe4e-50e3-4cc5-b8fd-3c53f0aab320" xlink:href="ebs-20220930.xsd#ebs_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ebs_IncomeTaxesLineItems_1df410ab-4ba7-4479-ab97-3055ad200957" xlink:to="loc_ebs_IncomeTaxesTable_5d09fe4e-50e3-4cc5-b8fd-3c53f0aab320" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_79923490-a55e-414c-8f15-bac1284dadb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ebs_IncomeTaxesTable_5d09fe4e-50e3-4cc5-b8fd-3c53f0aab320" xlink:to="loc_srt_StatementScenarioAxis_79923490-a55e-414c-8f15-bac1284dadb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_79923490-a55e-414c-8f15-bac1284dadb8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_79923490-a55e-414c-8f15-bac1284dadb8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_79923490-a55e-414c-8f15-bac1284dadb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_936f35fb-5e04-49b5-9da5-16d6504ad44a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_79923490-a55e-414c-8f15-bac1284dadb8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_936f35fb-5e04-49b5-9da5-16d6504ad44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_00f99c05-e4bd-4bbe-9eae-8e817b1168e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_936f35fb-5e04-49b5-9da5-16d6504ad44a" xlink:to="loc_srt_ScenarioForecastMember_00f99c05-e4bd-4bbe-9eae-8e817b1168e7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#EquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/EquityNarrativeDetails" xlink:type="extended" id="i644c76a016774d528a825b533078e691_EquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_06eff3fd-d504-4397-83f0-70704e0566bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_06eff3fd-d504-4397-83f0-70704e0566bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_4e6730ee-1808-412b-b026-37e2634ed79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_4e6730ee-1808-412b-b026-37e2634ed79e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_1ab1aba6-0704-4fa6-a187-9163b26dfae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_1ab1aba6-0704-4fa6-a187-9163b26dfae2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7672f774-5f91-4d1d-99eb-d0b55518eef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7672f774-5f91-4d1d-99eb-d0b55518eef6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c108699c-b977-4e10-9cdd-c67fa5032232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c108699c-b977-4e10-9cdd-c67fa5032232" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_08fbedc0-d1b0-482d-8f35-e69c357cd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_08fbedc0-d1b0-482d-8f35-e69c357cd26b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_238966b1-deb6-47fd-9134-ae84aef441b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_238966b1-deb6-47fd-9134-ae84aef441b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49d3e07e-eb4a-4725-b934-cccba49860dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49d3e07e-eb4a-4725-b934-cccba49860dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d1c5ccbe-118a-4a19-965a-3265ab7b916a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49d3e07e-eb4a-4725-b934-cccba49860dc" xlink:to="loc_us-gaap_VestingAxis_d1c5ccbe-118a-4a19-965a-3265ab7b916a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d1c5ccbe-118a-4a19-965a-3265ab7b916a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_d1c5ccbe-118a-4a19-965a-3265ab7b916a" xlink:to="loc_us-gaap_VestingDomain_d1c5ccbe-118a-4a19-965a-3265ab7b916a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_4a826428-a449-4983-8a3f-e113b7c442ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_d1c5ccbe-118a-4a19-965a-3265ab7b916a" xlink:to="loc_us-gaap_VestingDomain_4a826428-a449-4983-8a3f-e113b7c442ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_15b0dabf-019d-4345-ba21-063545c3c198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_4a826428-a449-4983-8a3f-e113b7c442ee" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_15b0dabf-019d-4345-ba21-063545c3c198" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_209f7c75-964d-4374-bbb1-107e450d29de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_4a826428-a449-4983-8a3f-e113b7c442ee" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_209f7c75-964d-4374-bbb1-107e450d29de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_37f28707-d9a7-464a-8384-81997056c0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_4a826428-a449-4983-8a3f-e113b7c442ee" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_37f28707-d9a7-464a-8384-81997056c0ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da6f51b8-4075-463b-9d00-430696ba0341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49d3e07e-eb4a-4725-b934-cccba49860dc" xlink:to="loc_us-gaap_AwardTypeAxis_da6f51b8-4075-463b-9d00-430696ba0341" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da6f51b8-4075-463b-9d00-430696ba0341_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_da6f51b8-4075-463b-9d00-430696ba0341" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da6f51b8-4075-463b-9d00-430696ba0341_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e05ecd10-837f-4ed2-bf3b-d89c26b183cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_da6f51b8-4075-463b-9d00-430696ba0341" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e05ecd10-837f-4ed2-bf3b-d89c26b183cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3477b6e8-b0d3-408f-8e34-5bda4707d31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e05ecd10-837f-4ed2-bf3b-d89c26b183cb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3477b6e8-b0d3-408f-8e34-5bda4707d31a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_62764654-2ccf-4a65-bb63-4c355536255b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e05ecd10-837f-4ed2-bf3b-d89c26b183cb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_62764654-2ccf-4a65-bb63-4c355536255b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a9cc15db-8622-4728-b9af-63350617d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49d3e07e-eb4a-4725-b934-cccba49860dc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a9cc15db-8622-4728-b9af-63350617d59e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a9cc15db-8622-4728-b9af-63350617d59e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a9cc15db-8622-4728-b9af-63350617d59e" xlink:to="loc_us-gaap_EquityComponentDomain_a9cc15db-8622-4728-b9af-63350617d59e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b43e611d-895c-4147-9d44-e5acfd483710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a9cc15db-8622-4728-b9af-63350617d59e" xlink:to="loc_us-gaap_EquityComponentDomain_b43e611d-895c-4147-9d44-e5acfd483710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_14c22a9b-d00f-4a1a-adb8-21c19602ba1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b43e611d-895c-4147-9d44-e5acfd483710" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_14c22a9b-d00f-4a1a-adb8-21c19602ba1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_a8681f1a-9fa3-46e0-9588-6b8793633fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b43e611d-895c-4147-9d44-e5acfd483710" xlink:to="loc_us-gaap_TreasuryStockCommonMember_a8681f1a-9fa3-46e0-9588-6b8793633fd1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#EquityScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i6812cc656b974921be424f07d4f2395c_EquityScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d442f909-47ca-42b1-aa08-4b6e04ac6649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_078a74f9-fcd8-4b87-b0a7-52a665865be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d442f909-47ca-42b1-aa08-4b6e04ac6649" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_078a74f9-fcd8-4b87-b0a7-52a665865be5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5bed1544-dda5-4d3f-940d-5ee939c68c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d442f909-47ca-42b1-aa08-4b6e04ac6649" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5bed1544-dda5-4d3f-940d-5ee939c68c35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d440e81a-5475-4368-802c-7649a7158988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5bed1544-dda5-4d3f-940d-5ee939c68c35" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d440e81a-5475-4368-802c-7649a7158988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d440e81a-5475-4368-802c-7649a7158988_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d440e81a-5475-4368-802c-7649a7158988" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d440e81a-5475-4368-802c-7649a7158988_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_82dfef9b-a897-40f1-9114-d92bed1dc549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d440e81a-5475-4368-802c-7649a7158988" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_82dfef9b-a897-40f1-9114-d92bed1dc549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_e0224850-2e6e-4be9-af7f-c6ae377f198c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82dfef9b-a897-40f1-9114-d92bed1dc549" xlink:to="loc_us-gaap_CostOfSalesMember_e0224850-2e6e-4be9-af7f-c6ae377f198c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b2f5ef55-f203-47b6-b3fb-6ec30823d0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82dfef9b-a897-40f1-9114-d92bed1dc549" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b2f5ef55-f203-47b6-b3fb-6ec30823d0b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7bf9dcd9-6854-4693-a5d0-b7479af23ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82dfef9b-a897-40f1-9114-d92bed1dc549" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7bf9dcd9-6854-4693-a5d0-b7479af23ebd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d13dc910-35a9-4bcc-9f17-4b270c538ec3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5bed1544-dda5-4d3f-940d-5ee939c68c35" xlink:to="loc_srt_ProductOrServiceAxis_d13dc910-35a9-4bcc-9f17-4b270c538ec3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d13dc910-35a9-4bcc-9f17-4b270c538ec3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d13dc910-35a9-4bcc-9f17-4b270c538ec3" xlink:to="loc_srt_ProductsAndServicesDomain_d13dc910-35a9-4bcc-9f17-4b270c538ec3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_671048f8-afeb-4c33-80e0-5fdd3b7765d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d13dc910-35a9-4bcc-9f17-4b270c538ec3" xlink:to="loc_srt_ProductsAndServicesDomain_671048f8-afeb-4c33-80e0-5fdd3b7765d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d3f02177-4620-44df-af1e-e304ece600fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_671048f8-afeb-4c33-80e0-5fdd3b7765d5" xlink:to="loc_us-gaap_ProductMember_d3f02177-4620-44df-af1e-e304ece600fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2ef35792-c4b4-4d3d-a9fe-4607768099ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_671048f8-afeb-4c33-80e0-5fdd3b7765d5" xlink:to="loc_us-gaap_ServiceMember_2ef35792-c4b4-4d3d-a9fe-4607768099ef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#EquityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="ie735aa1b8ae04ad49a2c21e605d87777_EquityChangesinAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_df737b5b-73c7-47db-b329-92335f6a2e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_df737b5b-73c7-47db-b329-92335f6a2e0a" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a987ecad-74db-403d-b314-5cce9a9302db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:to="loc_us-gaap_StockholdersEquity_a987ecad-74db-403d-b314-5cce9a9302db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_a1a65737-6c4e-428c-9ef1-dd0fe47b7b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_a1a65737-6c4e-428c-9ef1-dd0fe47b7b69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_f338daf7-3a15-4ff1-8cd4-57df6373201b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_f338daf7-3a15-4ff1-8cd4-57df6373201b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6668b4ff-5d73-4456-bfdb-f514020e42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6668b4ff-5d73-4456-bfdb-f514020e42ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b85b92f1-5c3f-4a8a-a1a9-7f90268b15bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5f42ac6b-8e0c-49cb-8cd7-af48e9796ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_df737b5b-73c7-47db-b329-92335f6a2e0a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5f42ac6b-8e0c-49cb-8cd7-af48e9796ad5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7f6fcd88-77e6-48b8-ab99-e0b13a71ed96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5f42ac6b-8e0c-49cb-8cd7-af48e9796ad5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7f6fcd88-77e6-48b8-ab99-e0b13a71ed96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7f6fcd88-77e6-48b8-ab99-e0b13a71ed96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7f6fcd88-77e6-48b8-ab99-e0b13a71ed96" xlink:to="loc_us-gaap_EquityComponentDomain_7f6fcd88-77e6-48b8-ab99-e0b13a71ed96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0753b0c5-3956-4b7d-ab57-fe5d0d7361e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7f6fcd88-77e6-48b8-ab99-e0b13a71ed96" xlink:to="loc_us-gaap_EquityComponentDomain_0753b0c5-3956-4b7d-ab57-fe5d0d7361e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d9d5da-8640-427b-8c02-06f0683f78ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0753b0c5-3956-4b7d-ab57-fe5d0d7361e1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d9d5da-8640-427b-8c02-06f0683f78ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_0f2470dc-6330-48fd-a3d4-0cab2434dd65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d9d5da-8640-427b-8c02-06f0683f78ff" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_0f2470dc-6330-48fd-a3d4-0cab2434dd65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e75c4e06-d3ac-4a0a-bcd1-323238accb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d9d5da-8640-427b-8c02-06f0683f78ff" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e75c4e06-d3ac-4a0a-bcd1-323238accb75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f7348fb6-f96a-4273-8586-5f27522064e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d9d5da-8640-427b-8c02-06f0683f78ff" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f7348fb6-f96a-4273-8586-5f27522064e2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended" id="i07c9da1f9e69403ebe48543ef3e76ed2_EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0a907c53-2fe3-45d0-a9b3-55f8cc70bd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_3d7a7925-bb21-46b9-a507-9c90fb9ae8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0a907c53-2fe3-45d0-a9b3-55f8cc70bd8d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_3d7a7925-bb21-46b9-a507-9c90fb9ae8d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_53b0656b-9477-46a1-81f1-9b4beed5a4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0a907c53-2fe3-45d0-a9b3-55f8cc70bd8d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_53b0656b-9477-46a1-81f1-9b4beed5a4ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fbd6c938-63c4-4ce1-96fc-cbe200075270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0a907c53-2fe3-45d0-a9b3-55f8cc70bd8d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fbd6c938-63c4-4ce1-96fc-cbe200075270" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_926522fa-5241-4a07-9b9f-442c3e44349f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0a907c53-2fe3-45d0-a9b3-55f8cc70bd8d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_926522fa-5241-4a07-9b9f-442c3e44349f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0a4d1ba0-41ee-46d4-aa09-a346c2dc8e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_926522fa-5241-4a07-9b9f-442c3e44349f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0a4d1ba0-41ee-46d4-aa09-a346c2dc8e4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0a4d1ba0-41ee-46d4-aa09-a346c2dc8e4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a4d1ba0-41ee-46d4-aa09-a346c2dc8e4c" xlink:to="loc_us-gaap_EquityComponentDomain_0a4d1ba0-41ee-46d4-aa09-a346c2dc8e4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a18b617-422b-47f2-816b-1688798562f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a4d1ba0-41ee-46d4-aa09-a346c2dc8e4c" xlink:to="loc_us-gaap_EquityComponentDomain_1a18b617-422b-47f2-816b-1688798562f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_f4253274-3efa-4262-9e3e-3363c295d66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1a18b617-422b-47f2-816b-1688798562f2" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_f4253274-3efa-4262-9e3e-3363c295d66f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_b80e7419-7631-40a1-ac3a-c3988c60b627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1a18b617-422b-47f2-816b-1688798562f2" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_b80e7419-7631-40a1-ac3a-c3988c60b627" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended" id="i7868d4e697354a9cbb00b93815ccfdaa_SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d74a654f-a329-440f-97d0-aa827590003d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d74a654f-a329-440f-97d0-aa827590003d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3794d313-1be5-400b-b654-ae8428c9e77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_Revenues_3794d313-1be5-400b-b654-ae8428c9e77c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3ee4c20f-53a9-4278-802a-02e389dabad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3ee4c20f-53a9-4278-802a-02e389dabad5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_500a8376-44b1-4ccb-b983-926c9f75b908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_GrossProfit_500a8376-44b1-4ccb-b983-926c9f75b908" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_316ed9c1-0fda-4d59-b267-c411d1448c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_316ed9c1-0fda-4d59-b267-c411d1448c7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin_925e28c9-dae4-4351-b059-aea17ff01e29" xlink:href="ebs-20220930.xsd#ebs_AdjustedGrossMargin"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_ebs_AdjustedGrossMargin_925e28c9-dae4-4351-b059-aea17ff01e29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_91c61ac1-be3f-432e-952f-57f781349c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_91c61ac1-be3f-432e-952f-57f781349c97" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_4f967e90-b6d0-4a9b-b1d9-7353c4a8b905" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_4f967e90-b6d0-4a9b-b1d9-7353c4a8b905" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_afbcd64a-7d9f-4a40-ba6f-3ca9d6a90333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_afbcd64a-7d9f-4a40-ba6f-3ca9d6a90333" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5635c0a6-58cd-478e-9b1f-be80b388d06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_afbcd64a-7d9f-4a40-ba6f-3ca9d6a90333" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5635c0a6-58cd-478e-9b1f-be80b388d06c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5635c0a6-58cd-478e-9b1f-be80b388d06c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5635c0a6-58cd-478e-9b1f-be80b388d06c" xlink:to="loc_us-gaap_SegmentDomain_5635c0a6-58cd-478e-9b1f-be80b388d06c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a8166038-591f-4f22-ba36-ae37e14d01db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5635c0a6-58cd-478e-9b1f-be80b388d06c" xlink:to="loc_us-gaap_SegmentDomain_a8166038-591f-4f22-ba36-ae37e14d01db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_5ac6262f-5494-4d73-a003-b6900c8806bf" xlink:href="ebs-20220930.xsd#ebs_ProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a8166038-591f-4f22-ba36-ae37e14d01db" xlink:to="loc_ebs_ProductsSegmentMember_5ac6262f-5494-4d73-a003-b6900c8806bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_abd1c6b7-47d9-4cab-8ec6-8b5923dd57b8" xlink:href="ebs-20220930.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a8166038-591f-4f22-ba36-ae37e14d01db" xlink:to="loc_ebs_ServicesSegmentMember_abd1c6b7-47d9-4cab-8ec6-8b5923dd57b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e693d656-f3ef-4319-9773-9fabb2032578" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_afbcd64a-7d9f-4a40-ba6f-3ca9d6a90333" xlink:to="loc_srt_ProductOrServiceAxis_e693d656-f3ef-4319-9773-9fabb2032578" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e693d656-f3ef-4319-9773-9fabb2032578_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e693d656-f3ef-4319-9773-9fabb2032578" xlink:to="loc_srt_ProductsAndServicesDomain_e693d656-f3ef-4319-9773-9fabb2032578_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_515a3266-493b-44c1-a6f8-9b3176146f77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e693d656-f3ef-4319-9773-9fabb2032578" xlink:to="loc_srt_ProductsAndServicesDomain_515a3266-493b-44c1-a6f8-9b3176146f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_7e3487e6-2ad3-4e25-93c9-be42b848a22f" xlink:href="ebs-20220930.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_515a3266-493b-44c1-a6f8-9b3176146f77" xlink:to="loc_ebs_ContractsAndGrantsMember_7e3487e6-2ad3-4e25-93c9-be42b848a22f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e2e93fe1-1358-4d2e-898f-5e5261acc5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_515a3266-493b-44c1-a6f8-9b3176146f77" xlink:to="loc_us-gaap_ProductMember_e2e93fe1-1358-4d2e-898f-5e5261acc5f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2211cf4e-3ec1-4f38-9160-c08d98092319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_515a3266-493b-44c1-a6f8-9b3176146f77" xlink:to="loc_us-gaap_ServiceMember_2211cf4e-3ec1-4f38-9160-c08d98092319" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d444df62-56d8-4c86-9a94-d0aac6cb91d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_afbcd64a-7d9f-4a40-ba6f-3ca9d6a90333" xlink:to="loc_srt_ConsolidationItemsAxis_d444df62-56d8-4c86-9a94-d0aac6cb91d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d444df62-56d8-4c86-9a94-d0aac6cb91d2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_d444df62-56d8-4c86-9a94-d0aac6cb91d2" xlink:to="loc_srt_ConsolidationItemsDomain_d444df62-56d8-4c86-9a94-d0aac6cb91d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8ce40cba-a075-4310-a3fe-808493d3d15a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_d444df62-56d8-4c86-9a94-d0aac6cb91d2" xlink:to="loc_srt_ConsolidationItemsDomain_8ce40cba-a075-4310-a3fe-808493d3d15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_b0170212-a065-4b37-b649-5459da3df68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8ce40cba-a075-4310-a3fe-808493d3d15a" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_b0170212-a065-4b37-b649-5459da3df68b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended" id="i297ab44ab82e4e7c9fcbe279f1590a18_SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ce1faa01-c55d-4e4c-8d25-6d50277b0a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract_7a7d589e-70a2-4f9e-bb1c-d5100310c3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ce1faa01-c55d-4e4c-8d25-6d50277b0a59" xlink:to="loc_us-gaap_DepreciationAbstract_7a7d589e-70a2-4f9e-bb1c-d5100310c3ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a281b3bc-785c-4e71-81bc-856b1c80da92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DepreciationAbstract_7a7d589e-70a2-4f9e-bb1c-d5100310c3ad" xlink:to="loc_us-gaap_Depreciation_a281b3bc-785c-4e71-81bc-856b1c80da92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_431332db-a6b8-44d9-843a-08e7f88f719e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ce1faa01-c55d-4e4c-8d25-6d50277b0a59" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_431332db-a6b8-44d9-843a-08e7f88f719e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8a0adeda-ca63-4f77-b96e-41a1caba274b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_431332db-a6b8-44d9-843a-08e7f88f719e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8a0adeda-ca63-4f77-b96e-41a1caba274b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a0adeda-ca63-4f77-b96e-41a1caba274b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a0adeda-ca63-4f77-b96e-41a1caba274b" xlink:to="loc_us-gaap_SegmentDomain_8a0adeda-ca63-4f77-b96e-41a1caba274b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_19ae7c3d-a178-4d54-9c28-bc8357b25f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a0adeda-ca63-4f77-b96e-41a1caba274b" xlink:to="loc_us-gaap_SegmentDomain_19ae7c3d-a178-4d54-9c28-bc8357b25f7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_7d392be1-1748-45c7-8d93-a13c56c70d02" xlink:href="ebs-20220930.xsd#ebs_ProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_19ae7c3d-a178-4d54-9c28-bc8357b25f7f" xlink:to="loc_ebs_ProductsSegmentMember_7d392be1-1748-45c7-8d93-a13c56c70d02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_0ebe4157-86b8-4d92-90ae-0029f0688c9f" xlink:href="ebs-20220930.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_19ae7c3d-a178-4d54-9c28-bc8357b25f7f" xlink:to="loc_ebs_ServicesSegmentMember_0ebe4157-86b8-4d92-90ae-0029f0688c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_989d5717-c8a6-4a03-a273-250fd7ccbbd8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_431332db-a6b8-44d9-843a-08e7f88f719e" xlink:to="loc_srt_ConsolidationItemsAxis_989d5717-c8a6-4a03-a273-250fd7ccbbd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_989d5717-c8a6-4a03-a273-250fd7ccbbd8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_989d5717-c8a6-4a03-a273-250fd7ccbbd8" xlink:to="loc_srt_ConsolidationItemsDomain_989d5717-c8a6-4a03-a273-250fd7ccbbd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_acd02374-f32f-44ee-8207-84e82a4758e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_989d5717-c8a6-4a03-a273-250fd7ccbbd8" xlink:to="loc_srt_ConsolidationItemsDomain_acd02374-f32f-44ee-8207-84e82a4758e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_8a1eb6e7-3b60-4384-afb5-de1d4db3eb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_acd02374-f32f-44ee-8207-84e82a4758e1" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_8a1eb6e7-3b60-4384-afb5-de1d4db3eb1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ebs-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e49bcad1-b3a3-4429-b549-b7280da8936a,g:b60fc6ff-4763-459f-a134-feb07b4a5302-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9f68f39a-6c9e-4f9b-8b10-5fcf42ccc27e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ServicesSegmentMember_12bb547a-2d5d-4853-a052-53b18ac1a78f_terseLabel_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_ebs_ServicesSegmentMember_label_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Segment [Member]</link:label>
    <link:label id="lab_ebs_ServicesSegmentMember_documentation_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember" xlink:href="ebs-20220930.xsd#ebs_ServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ServicesSegmentMember" xlink:to="lab_ebs_ServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c2503e79-6ee4-49fe-bc56-5074e2e40bf6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_ab61c88d-87bc-422b-ac4a-ad29b131a80e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_8bc453f9-1d8f-44a3-90e1-35a61d9ec774_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_cabdab33-4cd6-471a-9b50-320db4648f6e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted cash flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cf563fca-3f72-47e6-9969-7e05fa619ec7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_53520ca1-9328-4295-9634-ac7554ac9cd1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeReversal_ed59a22d-3c63-499e-9c1e-e1b2e7741289_terseLabel_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeReversal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment for prior period lease receivables (Note 10)</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeReversal_label_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income Reversal</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeReversal_documentation_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeReversal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income Reversal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeReversal" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseLeaseIncomeReversal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeReversal" xlink:to="lab_ebs_OperatingLeaseLeaseIncomeReversal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2d8dd139-5633-4749-8db8-8392a3ec4e4b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_23046b82-3ccc-4224-9616-02d7c712b107_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, consideration transferred, contingent consideration</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_648f37f0-e9c1-4da1-a809-902624b472b4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ee8f1716-9e95-4be0-bf24-0cdfa827cad4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a4055963-154f-4d6a-b086-f3d2a70ff4fc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_cf576f5d-fcb6-498c-b659-56a61eff42f3_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9791e259-9146-41e3-8efa-8180a7250196_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b05b3128-f309-449b-940f-1b35e4c44787_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_b7e8cd3e-51f1-4281-b736-049d984baa4d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5018e82d-82f9-43ab-a235-9399297b1eb7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_01a414a2-f9e4-4de6-9022-c65aabe5d3e2_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_2f9da628-15d3-4b74-8581-bb599bfbca8e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_9c13a8cd-d412-445d-a00d-c8a14854c31c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_c7298fd6-f9ff-4ed3-9937-beecd333d218_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_b5e6f47f-5cc3-4e74-be0f-482d462bac5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_5801dbc5-c594-4858-8957-5e1c4c3aa2fb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_68fde09e-c3ce-48e2-89d1-e3455431d374_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ab690277-66b1-4b81-9364-6ca07cd4d76a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ea2e8067-1c1f-4c02-a1e9-2321be796a67_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_9681b5a6-0bfd-41e7-a743-ab0e8fc6fd63_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_b7dfb0b3-ca6f-494f-a115-a15747d418f3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_30695205-07fb-4c73-9d51-b99a27de9048_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_45e6100d-e433-472d-bea3-8696e8b67190_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_0f5435a0-af21-47e4-8529-a3ce597aed52_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84b7a468-80d5-42a4-a02a-af706f21c415_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_135a3d1d-7dfc-4294-b814-f436f2dcd8e1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_f81a5ea2-8e48-44e3-ae88-babd780f2a85_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_a6b5c2df-3038-4153-b046-fed711a1ba65_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_4463078c-7df3-40b1-972e-b5317cf0e95f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_339b68e0-d441-4f43-8ac9-cc13d7c4c95f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractsAndGrantsMember_d33f1d2b-d8e3-49d1-87d8-2c5a5ef4768d_terseLabel_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracts and grants</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_label_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracts and Grants [Member]</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_documentation_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember" xlink:href="ebs-20220930.xsd#ebs_ContractsAndGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractsAndGrantsMember" xlink:to="lab_ebs_ContractsAndGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_3bb000ab-e6ba-4850-a08d-64bf4122cdfc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ff97a427-663e-4468-9cba-fd6b0675f944_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_45c68826-2b54-4360-9cc9-bb17df74619c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_211e9ca6-c12c-4840-b845-ca4a59e98b9e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Instruments</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_094804f6-c190-481a-9939-4ab572b46b24_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_592ea000-1f8b-4650-89af-3bd124cc018a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4d3ca5c2-df28-4c8d-9823-8a0a2fceae4b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAbstract_6b090405-a640-47b2-941a-5e7174bdc433_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation:</link:label>
    <link:label id="lab_us-gaap_DepreciationAbstract_label_en-US" xlink:label="lab_us-gaap_DepreciationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAbstract" xlink:to="lab_us-gaap_DepreciationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_5edf0d9c-b999-403a-b13a-549f9b843de8_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_767a1c6c-dc0f-4846-a3c0-d59a79e13315_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_63e33ce4-2bb8-4430-a120-d07096a43bd1_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_6b44d519-f267-4a86-b52e-326aeae303b1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8d73856b-17e2-4b81-9267-48599936db11_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_e7494b0d-235d-4d23-8b08-aaf1e9e13b2a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f652c1d1-90f9-41fd-9347-3ae793ee366b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f7e0ee75-d3ef-4c99-9a0a-2799f42a53fc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7337a8ad-7f81-480a-9b66-ab8a718b8d90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d90fd58e-84d0-4395-bb34-4e9551f7a2e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4e0fde38-0997-4000-b94e-d8720faa597f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_e08536a8-9db0-4382-a3a1-7dbadd790c41_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d82794b3-3158-4270-a792-3ca23076cd3c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2e707bff-1ce2-49ca-9a90-55aeabfe09e4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_478a0060-0be5-4a46-ade6-5f047ea8e11d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0246c653-2326-4a18-b33c-468e70edaca7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_06840ae8-1e23-4024-af0a-bf9f54be3cc9_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_3d107dff-fbb3-4947-9098-7fe38857f288_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_ae31b406-27ee-4028-9f9c-df956d36e6bc_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_49007168-2f3c-4f3b-97dc-11f501c6b5e9_verboseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, consolidated debt service coverage ratio, minimum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:to="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_94146ac2-6f4d-4dbd-81de-6ca8df7d7a1b_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_acce28a9-d5eb-49fd-91ab-b926a47be6e3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_51f2e133-d6b8-4e5f-a9ca-eebf2aef3a43_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_94ae2112-dee8-4408-908c-f13ede722dbe_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_17588335-8c5f-48d9-9c5b-65f0ac30810e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20b16e0-be09-4768-880a-d670f8d2dfe6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_bd9a3107-5b18-4f23-a225-af0ed77227a7_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_a16005d5-6c1c-450d-8b20-7120cc23e5eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Loss Reclassified from Accumulated OCL into Income (Loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15c8bb98-e1c8-48f8-a383-3756ed72e605_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b9a17310-d789-43a3-b072-cd6c5eedb461_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c06aeb30-4096-40bb-9e09-2db73abf8c38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_BARDAMember_73176386-b916-42ac-ab7e-6c2d9da6aac7_terseLabel_en-US" xlink:label="lab_ebs_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA</link:label>
    <link:label id="lab_ebs_BARDAMember_label_en-US" xlink:label="lab_ebs_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA [Member]</link:label>
    <link:label id="lab_ebs_BARDAMember_documentation_en-US" xlink:label="lab_ebs_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember" xlink:href="ebs-20220930.xsd#ebs_BARDAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BARDAMember" xlink:to="lab_ebs_BARDAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_e06c33fd-df5d-401e-b55c-5124775de1eb_terseLabel_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_label_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_documentation_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember" xlink:href="ebs-20220930.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OtherLongTermDebtFacilityMember" xlink:to="lab_ebs_OtherLongTermDebtFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_0685bb15-70da-41ed-9378-7107bdc704bb_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured credit agreement - Revolver loan due 2023</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_76acefb4-2043-43a5-8ab1-d1c9a56f2f3a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d9630be6-3560-4a52-bc09-84a68b8d32e8_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_69c2ccce-0125-41f3-909f-3f4853ca1272_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5f666828-9c9e-4076-997b-818c2c471ed6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_3604af70-e229-414d-bcd3-168a7f1200aa_terseLabel_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of revenue generating products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_label_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Revenue Generating Products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_documentation_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to the number of revenue generating products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts" xlink:href="ebs-20220930.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfRevenueGeneratingProducts" xlink:to="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_da9f59fc-5ff8-4299-9a4e-8fff80ab88e3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_d347b6cb-8910-4afa-a448-0c83daad5688_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1e82c314-6319-445b-b97f-0404badc6a52_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_1aac923c-0be4-4c5d-a5c0-99bb10b60c36_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_bb8cf004-95e4-4ffb-a1ae-a96362a9955f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_bc3e62f9-1903-4a44-995e-5303c301cf30_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_2dd5c97c-ebd2-4d5a-a585-ddf44fbb46af_terseLabel_en-US" xlink:label="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, domestic royalty percentage</link:label>
    <link:label id="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_label_en-US" xlink:label="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Domestic Gross Profit Royalty Percentage</link:label>
    <link:label id="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_documentation_en-US" xlink:label="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Domestic Gross Profit Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:to="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e7abddef-8c8c-434e-8885-d29442a42ae8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_eebd5a1a-5a30-464b-adbf-98f7663aa5eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_c217b5fe-8ba7-4c26-8493-60b346701258_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_7c93f9a8-be5f-4f68-ba80-e13ef43e6c50_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, consideration threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Consideration Threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Consideration Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:to="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_4d76c701-60e2-4fa9-ab36-917cec328d52_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_beab0ea9-647d-4960-b6b6-7a7eaad49de1_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_fc73841c-5508-4417-b2ad-f849c9ffa279_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rollforward of Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_73f99185-6dd7-4bff-81f0-2ed5ce56681e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_031c6468-fff2-4c3a-acc7-040b298c1b7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d73aac2f-bae1-435b-8663-f24a82cd20a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a2a6894e-e00a-49e5-841b-61ba0764de74_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_6147bbc1-6c9e-42d9-85cc-0ba854dc5a4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3d7a3fb2-b680-4e7e-a8cc-3c4dd0b76edc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ed465e76-c302-4a10-95df-c2b352df7c91_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_0f4c0119-37f3-44d5-88f0-6ff5f40bd8ba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_7bc85d1b-d95e-467d-852b-3a5fdf073e2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_cb96f0b3-cfc3-4c13-b839-2202a33c31af_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ChimerixAssetAcquisitionMember_77513233-39f4-4bee-91f1-ead646dcaaba_terseLabel_en-US" xlink:label="lab_ebs_ChimerixAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chimerix Asset Acquisition</link:label>
    <link:label id="lab_ebs_ChimerixAssetAcquisitionMember_label_en-US" xlink:label="lab_ebs_ChimerixAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chimerix Asset Acquisition [Member]</link:label>
    <link:label id="lab_ebs_ChimerixAssetAcquisitionMember_documentation_en-US" xlink:label="lab_ebs_ChimerixAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chimerix Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixAssetAcquisitionMember" xlink:href="ebs-20220930.xsd#ebs_ChimerixAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChimerixAssetAcquisitionMember" xlink:to="lab_ebs_ChimerixAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8d1301c7-478b-45a4-983f-3e0c2dfdf2f4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_b7b0fd1d-6e68-491f-87ca-5e555cc8efb8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Expense</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_1c705ac8-c523-4640-8565-ee5bfd62a066_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_6be59241-7e49-4c76-9c7a-cc149b885a9d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_d0983b38-f1d8-4b43-9d04-ef46147f392d_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a3509df0-ebd7-45da-b5d2-1bc89b38f23e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_30187b32-7ffb-40f5-9c11-d25ea02392b9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f3005bff-3bed-451f-8917-bec54f15d47d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_073dfcc5-1a34-41df-ad0a-ba87e0ad4260_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_9fe6558d-b3de-4f6f-bf2d-a4d2a395e00e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_19113735-7632-421e-8886-71d28144392d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_9fbec502-6352-4420-b7ab-5f323a3a40a9_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_37e3e471-ea35-442d-9baf-690c34875e79_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b43191f3-3147-4bc0-96f4-7a9e31355540_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e24122c1-ce48-4c2d-8a30-f4d9455e3b22_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_f2650784-e7bc-4b73-af49-c9407991d005_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6aab7162-6550-4e8e-bc1c-a497f0139dbe_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_06e41e0b-d80e-4779-a20b-a0651f35bc37_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6e3b6647-b7d3-4a1b-bd79-ea3bb6312530_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability removal</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3454f023-edb4-4273-8d32-fa1c9f839baa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b187887d-63af-4ee4-8ab3-a1244fd7cd88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_459647f8-0265-4b61-ad2f-f6939223e546_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3d11ded7-c54f-4483-b193-2f822973313f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OperatingLeaseRightOfUseAssetRemoval_3c680ae7-7d17-47f7-9999-a9fb5c9250ec_terseLabel_en-US" xlink:label="lab_ebs_OperatingLeaseRightOfUseAssetRemoval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset removal</link:label>
    <link:label id="lab_ebs_OperatingLeaseRightOfUseAssetRemoval_label_en-US" xlink:label="lab_ebs_OperatingLeaseRightOfUseAssetRemoval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Removal</link:label>
    <link:label id="lab_ebs_OperatingLeaseRightOfUseAssetRemoval_documentation_en-US" xlink:label="lab_ebs_OperatingLeaseRightOfUseAssetRemoval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Removal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseRightOfUseAssetRemoval" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseRightOfUseAssetRemoval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OperatingLeaseRightOfUseAssetRemoval" xlink:to="lab_ebs_OperatingLeaseRightOfUseAssetRemoval" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AdjustedGrossMargin_9ca5bc1d-bd3d-4fbe-893d-8bd90c49c2ab_terseLabel_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted gross margin</link:label>
    <link:label id="lab_ebs_AdjustedGrossMargin_label_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Gross Margin</link:label>
    <link:label id="lab_ebs_AdjustedGrossMargin_documentation_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Gross Margin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin" xlink:href="ebs-20220930.xsd#ebs_AdjustedGrossMargin"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AdjustedGrossMargin" xlink:to="lab_ebs_AdjustedGrossMargin" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_18e04eac-95d4-40aa-ab5e-f175064bd842_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_19ef4e94-3926-4e1c-bc0b-412497bc02d7_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_8d00266e-9474-4a4c-af0b-7f71f3911f1c_terseLabel_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable, Net</link:label>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_label_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_documentation_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:href="ebs-20220930.xsd#ebs_ScheduleOfAccountsReceivableNetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:to="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f596ea52-09cb-401a-b945-17957d4994b0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfBusinessLines_490b9ca9-20f3-4bfa-bc06-314f8dcc9118_terseLabel_en-US" xlink:label="lab_ebs_NumberOfBusinessLines" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business lines</link:label>
    <link:label id="lab_ebs_NumberOfBusinessLines_label_en-US" xlink:label="lab_ebs_NumberOfBusinessLines" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Business Lines</link:label>
    <link:label id="lab_ebs_NumberOfBusinessLines_documentation_en-US" xlink:label="lab_ebs_NumberOfBusinessLines" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Business Lines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfBusinessLines" xlink:href="ebs-20220930.xsd#ebs_NumberOfBusinessLines"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfBusinessLines" xlink:to="lab_ebs_NumberOfBusinessLines" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_e9f2e844-fc9f-4ea9-b30b-0ab1226d3a9b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MeasurementInputProbabilityofPaymentMember_39ef54d0-8a55-4634-b418-669d3b8431a5_terseLabel_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityofPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of payment</link:label>
    <link:label id="lab_ebs_MeasurementInputProbabilityofPaymentMember_label_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityofPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability of Payment [Member]</link:label>
    <link:label id="lab_ebs_MeasurementInputProbabilityofPaymentMember_documentation_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityofPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability of Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityofPaymentMember" xlink:href="ebs-20220930.xsd#ebs_MeasurementInputProbabilityofPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MeasurementInputProbabilityofPaymentMember" xlink:to="lab_ebs_MeasurementInputProbabilityofPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_7510337b-0155-4806-bd85-a1caaa0593ac_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3ea3a422-3f1f-447b-bcff-31078b5d265f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c8cc1bd2-2dc6-41a0-b7ed-c65a2e380b5b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_08b540cc-0530-4984-bd47-0a6796be2c53_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e5575a5c-851d-4741-9f6e-9069e3c96a44_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3f3fa044-83c2-4727-a57e-81e851c713cf_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d05a1c38-c1ec-438d-98e7-980780e32d4d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ProductsSegmentMember_b94cc562-6dd0-40ab-a074-6dfeb87a71c1_terseLabel_en-US" xlink:label="lab_ebs_ProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products</link:label>
    <link:label id="lab_ebs_ProductsSegmentMember_label_en-US" xlink:label="lab_ebs_ProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Segment [Member]</link:label>
    <link:label id="lab_ebs_ProductsSegmentMember_documentation_en-US" xlink:label="lab_ebs_ProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember" xlink:href="ebs-20220930.xsd#ebs_ProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ProductsSegmentMember" xlink:to="lab_ebs_ProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_22897e0d-d139-4f04-8ca4-fb70594110e7_terseLabel_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CDMO</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_c7e6803c-fb94-4233-9651-9c651bf01d48_verboseLabel_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDMO</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_label_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Development And Manufacturing [Member]</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_documentation_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue earned during the period arising from manufacturing sale under the terms of a contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember" xlink:to="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_95a26fe4-a3f4-4acb-b23d-ae6fe5ce2486_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e38b6f20-45d0-47ed-83d5-74c5ef645766_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b2d2eb64-3981-40a3-8222-505d8c27ad3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_b293a2c1-0e40-4099-a35e-c65f52ff5974_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, raw materials, net of reserves</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_3a5e48ed-73b4-4c83-a147-69e91f2c4400_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58a9e10c-0874-48b9-bcd9-5e0f2d1c74f0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a33ad415-c99b-499f-992f-17875eefee57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_a776d64a-49ec-40a1-b39f-e3972b07bddb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a1763237-bb5f-412b-8a08-38b030095361_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c183c558-dc11-404d-867c-4f1ed1113bb0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f87a6cdf-d667-40a0-aac6-d8c64273428a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_add9457f-5ee6-4d3a-bef0-6ac7baa64602_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember" xlink:to="lab_us-gaap_OtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_f85062e1-98db-415b-86fb-684e610b1806_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfProductCandidates_c3d56189-ae23-4f8a-b187-cf216693d38e_terseLabel_en-US" xlink:label="lab_ebs_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates</link:label>
    <link:label id="lab_ebs_NumberOfProductCandidates_label_en-US" xlink:label="lab_ebs_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:label id="lab_ebs_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_ebs_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductCandidates" xlink:href="ebs-20220930.xsd#ebs_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfProductCandidates" xlink:to="lab_ebs_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_28a4ac1a-3782-4218-b8d7-d6c7122997fb_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_3fc1ab09-2c47-4e49-8659-9368bf54f42f_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_b951c1a1-c074-4278-9b8e-704eb0963635_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ebb7ce4e-1150-4c2f-9d6f-6ea390bdd851_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9bcd1e52-4c24-4419-aed9-2af9480900ec_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_6552db19-6e19-4681-ac53-e1c7f5008137_terseLabel_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of categories of public health threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_label_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Categories Of Public Health Threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_documentation_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to the number of categories of public health threats.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:href="ebs-20220930.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:to="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_54946607-33ed-45fc-967f-dd22cbcbd356_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_34f72ba3-7ac0-4444-9794-25982830c1a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_70f54d34-ddd9-4fb5-b27f-22906ed2563c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4f05f0a8-34d8-4d24-bbbd-84c420143b7b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective annual tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5aef28fe-870a-4f5f-95fc-25d3c6f67759_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_99d84fcd-717a-474c-951d-5ec9c0e7bc6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ab2b84cf-bad7-4fd9-aa54-5334ab7a879a_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b335266c-2b62-4d08-b90e-6797a163182e_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_de789b42-ba05-4dc4-911c-bbfb1783a1a4_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_7c1ff2df-d3da-4d0f-aa18-0bcfe0315303_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_94f006fc-6c39-4dae-a784-c31b4e836b3f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on hedging activities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_b2d5a785-42b9-4444-9126-76f1f0b563d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_628bbe04-dde9-4d43-91ca-83c1bef30bbd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_65b58c79-90d6-46d2-a954-fbe0e6d46270_terseLabel_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jansen Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jansen Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jansen Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember" xlink:href="ebs-20220930.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_JansenPharmaceuticalsIncMember" xlink:to="lab_ebs_JansenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_5531076e-b4ef-4308-a112-16347a7e5cf3_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_21358e68-494a-41cc-ac5d-c71b8e508fd5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_c22622bb-965f-4be9-a80c-bd4e933dd3b1_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_4c9cbca7-f5b5-4c0f-b93c-96b0ff2ef3ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_8e4f9dd4-5aa6-4635-8303-46390f542c79_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_be5cdfab-d6e3-4cb7-962a-b13bf8b05807_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a985573a-9a62-4a01-812f-ece612d15481_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1638760b-76b2-4885-aace-0d8c3af0e9c0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_a0094019-dc97-4558-b134-03feb76507ea_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_370010c5-6481-422a-9648-bb9e35bbac92_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_3deab415-0b91-473c-bf27-70bd6351b923_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9e14e537-aa0a-48c3-8675-e37496574cab_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b02bd687-9779-40f6-9681-a370f3a69d97_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_719a5f52-def4-46dc-a364-cc7d2f1e320d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_8aae4e43-1f9d-4636-80b2-02e43ce5af88_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments and hedging activities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_ebaa6596-0d79-4b55-9099-a8f1739f7c60_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_0cd806c2-145b-4954-a44d-30f2f1d24ffa_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_bd8c2ba2-bbad-40db-832e-77f7f128b798_terseLabel_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:href="ebs-20220930.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:to="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_63c804fc-6b64-4779-8235-40e2358d0ed7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_433a48a0-77f8-4565-a097-314738bad0c8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b2b544ee-4760-4521-a0b4-332e9eab654f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3535a336-df5d-4c38-9bca-263b6e93f7e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d7176b88-bf76-4e76-92ac-5a880dbeff45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0f50ef79-1948-4cd4-8866-3371690b370f_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market accounts</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d37e4277-7f09-4389-aff9-2729af989329_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_d2d5116f-9659-482e-bc82-515df7e5e4bd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_5f96aa4d-3cc5-47da-b26c-d8cfc18935a0_terseLabel_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferral of revenue</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_label_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Additions</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_documentation_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityAdditions" xlink:href="ebs-20220930.xsd#ebs_ContractWithCustomerLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractWithCustomerLiabilityAdditions" xlink:to="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_f45a60bd-487d-4b90-adf7-b80023df88fb_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_36c02ec8-d33e-4114-b9fc-67a25ccaa96a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$0.001 Par Value Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c53b5be8-85a6-4d45-97d4-aab02c37233b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8d8a9b55-bc9c-4687-bc57-790691a596fb_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_89d43de4-86a1-4061-a375-f88015c99715_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_34e4dd0f-edbc-4d63-96eb-11f604bf4ecb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation activity</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_a07e8871-d1af-4b2d-955b-1b4ea9f5e1f8_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_9bda1ac9-b067-4321-a7ef-1fe2c39236db_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_5c431502-f863-4449-b277-a223c2b47bab_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_5be2b57f-82da-47f6-b5fc-458b10c4a472_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_961b127e-6258-402b-96d2-41758e0206f2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_685d546b-1109-4a66-b8f0-72f4f1196eb3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1ea314ea-7d20-4163-b126-b9a2e779f62f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_57458c50-9f69-4ee0-ab3c-187394e093da_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember_fda387dc-bdc6-4d25-98a7-216ffa916a4a_terseLabel_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember_label_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Development And Manufacturing, Leases [Member]</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember_documentation_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Development And Manufacturing, Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:to="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_27967f12-b704-41df-aa27-a1a0c780ca48_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3540b830-2b35-4c5d-8b87-94fb6dda4ba4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1544ddbb-f84e-44cd-baee-997e3a35791a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_28a084be-3d6a-49d3-b50d-d7f8605225a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0d01a403-2a1a-4389-9f17-1d64d4e29a23_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_4f8c3987-ef4a-4ec7-9830-3ce3aaa3763c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_38daf491-cf99-4a16-8156-ef36cf133a96_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payments</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_9a285c0f-2f07-4e2f-92b1-e76d5a7cfee9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, asset, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fdf94ad0-1842-4861-a3fa-2278bc143762_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_365feb8a-80b4-400d-b637-2a69a3ee52f8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_750948f8-554e-42ee-931f-b19a1105b929_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f594c3d-89cf-40af-9ccf-12aa5f890736_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_dcdfebab-0e1e-4693-8c43-6b0997015f91_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_c3e2032e-6271-4438-975e-774f5374d0c4_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3ef88462-dbd3-47c1-a69c-ef8b552fe9dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_c12cb923-7eb3-4681-861f-fa5ec5ab4943_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ccaf218f-20c4-4077-a58e-768ed419dbb4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_c3f53984-61c0-456d-8c61-0988bb6efca1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d45aa597-90c0-4786-b843-976c02e577c4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_51dd0467-56d5-4b27-8d36-1c7e79ef655a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fc1ea128-2d62-4a8b-936d-79bdeb91316b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, liability, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d6b97120-a41f-474a-818e-15e682e2117a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9ed7af15-588b-4fdf-a05c-57837deb434e_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_19b33338-868d-4fff-8ab4-99ab10c8d310_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7364c634-cb67-43e4-a018-db25655174be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_1db59d85-26ac-47d7-bcf6-dbe1aa6259ce_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_308d1ee8-64a2-4b38-9be0-9ca9a70ea6b6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_43fbd1fe-67a8-4beb-83b8-91b6a76cd079_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_00d3a13c-328f-4ff6-badc-7b246e6366fe_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_23beaf37-93e4-40fe-817f-9f501ec6dbc0_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_bd5c626c-2e75-4293-a82d-24b1398706d4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_a297fffb-5522-46c7-bf08-b872104aa82e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_7d171720-5252-4dcf-a716-9f143dd21c94_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_b04e7f1b-9264-4aac-a7e0-4e046aac1764_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_bf7de5fa-9e5d-48eb-9cb0-81a0aefd2a60_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4c81cb5d-85f5-4420-866d-566eabf62a02_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fcfe8bec-e07b-4375-a72d-e12dfd9ddc53_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember_7c13785a-7fba-4e9c-8614-5be79002053a_terseLabel_en-US" xlink:label="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Expansion Of Fill/Finish Capacity</link:label>
    <link:label id="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember_label_en-US" xlink:label="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Expansion Of Fill/Finish Capacity [Member]</link:label>
    <link:label id="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember_documentation_en-US" xlink:label="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Expansion Of Fill/Finish Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:href="ebs-20220930.xsd#ebs_AcceleratedExpansionOfFillFinishCapacityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:to="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_499471ec-c559-4bdf-a42b-9787a5e4f321_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_ffb3aaa2-206d-4431-998f-bfc953abbc8e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire productive assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_bf99bcf3-ff67-4772-9d20-76fc5fd364cd_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_19ec0487-d1d0-4097-8e0c-7df889479e10_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ee60b209-300d-4fd0-8fbd-0b8e79158476_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7e309e8b-8893-43c7-81b1-83fefc95cf08_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_6f927d3a-4a07-4496-a9bd-b7bcb926e0a8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_949390b3-f2e2-4b2a-bcee-be810a94590e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently issued accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_7bf00a31-69a7-4d03-9df3-664e0b4f0521_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2d4f7d79-9d38-4f65-9fa9-c94d0f3f39fe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4e638282-a154-42e8-a401-75521285aa94_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9f1dd735-af13-4227-939c-6eec6de34534_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_39daf0b2-46c8-4f39-ac43-91d84e063eee_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_89cd4bdf-e0c4-46cc-a5e5-bd7203372c83_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_2897de0b-2aac-4dd8-b307-af9e22c22645_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_03526dd1-8e56-416d-891b-d65720196a88_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_cf1016d9-31ed-43a5-ab2b-66efabfe6525_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_Goodwill_69943eca-c627-412d-ad21-1e75a1d3efe4_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, September&#160;30, 2022</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_d10697cd-6d14-45d6-8348-4c2052bf66a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1e9ef40e-09e6-405d-ab49-169b248e2b52_terseLabel_en-US" xlink:label="lab_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, inventory acquired</link:label>
    <link:label id="lab_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:label id="lab_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_documentation_en-US" xlink:label="lab_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_b601fe4d-e092-494e-a18b-863ba9072869_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_47140054-006c-43c1-acee-e26b41f5826f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9270ae32-abe1-4b47-aaf3-e3a16b6c801e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_c7011865-3d31-4fbf-b675-34ade15d722f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_066e7c07-ddfc-40c8-af0f-df36d82f5be4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during period, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_8614f155-1d64-418f-a6c1-5bb6858e0c62_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, current, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_f98d4a56-d1ea-4f5a-bdce-fd28370e03b2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_a096fd0c-5894-4b65-9424-6d6b074bfaf9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease revenue</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income, Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ac124aae-6225-49ff-aff0-d3f1d3e403c3_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_84c70535-a77a-4159-b8d4-ef91cd8c72dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b5c72e41-400d-4a35-b7cb-0b91483e3235_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ff81ed06-0e35-4da2-8782-d4a3635f125e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (provision)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_d941131f-32d1-438d-a6d9-95249add5f00_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7d38afa4-62e0-4363-9ab4-717f85da52f0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0bc8fa71-ec01-4c5e-8ebc-43aa1cc6ff94_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_07d858bf-0ec5-4d51-8490-53e4b5f0281f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_55fb55e9-182a-42c4-af5a-14931877ec9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c978b3ec-fe74-47ab-8fc2-330f892e8631_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1475aa90-176a-42e3-8ef1-3537ca8f012d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d01cb041-de50-4ee9-b9d5-bbcd7c694da7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_263ad9bd-7d65-4fe7-9fd4-b60746c54b58_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f73303b0-c6f8-4cfc-a9ee-5293b8e216d1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods and services sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f12e9224-d429-421e-8ada-151f711cf35c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods and services sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10c9653b-691d-4b08-90fd-ac70327453fc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4579a946-dd80-4e07-a723-aeb5ecd28141_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares-diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_288607e0-93f1-4152-9857-44cdc7ce96de_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_abb784ff-b6a5-483c-9441-8f4f53c07532_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation &amp; amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_93fe99c9-e0cc-4ac0-a1be-0a7e8a1c9c77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityDeductions_afec5ffe-c541-4f2d-bd26-03876a000756_negatedTerseLabel_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityDeductions_label_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deductions</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityDeductions_documentation_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityDeductions" xlink:href="ebs-20220930.xsd#ebs_ContractWithCustomerLiabilityDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractWithCustomerLiabilityDeductions" xlink:to="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledContractReceivables_ac0ade8c-c2c6-4d67-8fa3-eb9ba3ed9398_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed, net</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables" xlink:to="lab_us-gaap_BilledContractReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_6c2e89cf-4a8d-4ec9-85e9-aaf9a97460c4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_474f9139-8dca-4a24-869b-a613bf80a9b8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_fbca205b-c490-488f-b2d9-43c36245c907_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, current portion</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_025eea6b-f973-4a84-9cd4-adf1e5cc68ed_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings, building improvements and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_35cb111f-9a81-4fac-954c-c4ba2a3eb6ce_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a3e763db-576d-453f-8fd4-7eee459a937a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200.0 shares authorized, 55.5 and 55.1 shares issued; 49.9 and 51.3 shares outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_fd5e4ab0-1939-4487-af3b-5496074602cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_3136e856-277e-4e93-afc5-867aba860e76_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_f54979d1-9fda-43bd-a949-caa15270ac91_terseLabel_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Leases Supplemental Balance Sheets</link:label>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="ebs-20220930.xsd#ebs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d107da67-4dd4-4cc4-8749-5a3e2feceabc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_989ccd7a-1f30-450d-9bd2-5239c35162ba_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred losses from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_6f019159-0024-4288-a7da-0b01d97da8f3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0cc27cba-c946-4dcb-aeaf-b7abe073bdd6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetAcquisitionTreatmentVolumeThreshold_4da91e8a-7260-44c0-9ace-8e0d12756a81_terseLabel_en-US" xlink:label="lab_ebs_AssetAcquisitionTreatmentVolumeThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, treatment volume threshold</link:label>
    <link:label id="lab_ebs_AssetAcquisitionTreatmentVolumeThreshold_label_en-US" xlink:label="lab_ebs_AssetAcquisitionTreatmentVolumeThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Treatment Volume Threshold</link:label>
    <link:label id="lab_ebs_AssetAcquisitionTreatmentVolumeThreshold_documentation_en-US" xlink:label="lab_ebs_AssetAcquisitionTreatmentVolumeThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Treatment Volume Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionTreatmentVolumeThreshold" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionTreatmentVolumeThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetAcquisitionTreatmentVolumeThreshold" xlink:to="lab_ebs_AssetAcquisitionTreatmentVolumeThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5e887499-9d6a-412b-a30e-a1b7306f9028_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1ed8abf0-5ee3-4586-954e-2b50e52ed314_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8dc05e5-4571-4e3a-a498-a62dd677c503_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6ddaec56-819b-4a7d-878d-93bafe66c9a1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2b962ba7-65a6-4302-9f3d-931a95c80d4d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fb4fab06-20e3-4672-8ff8-c92b08d0d5bd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impaired, accumulated impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_51a8903b-c333-469f-9bd1-ae79f78da9d1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f39de75c-d416-4db8-80df-1d5ff6296e8e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_89f5e914-6418-424e-ac4b-c8a56e498e29_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_c1013d20-edf0-4279-8ca2-52ea66721b6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discrete tax expense (benefits)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_481495e4-207b-4469-acfe-3456dc1cae69_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_31c2c88a-059f-40af-8502-1d16a3ea2300_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment unpaid at period end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d7171edc-279c-4726-9c9a-b0d84c60679c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_e9c0d684-36ad-4c2f-9c2f-5544979b9ea9_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_629fd421-7f0a-4237-bf7d-abf7ca9d9f98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6a369b48-2fa6-47b4-9f13-8d12f04eb873_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_9c84d93a-49f1-478e-ba5b-9dba727e4fdc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f7899c18-b3dd-4c34-8953-81a2be89128f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_552a8caf-64af-4f26-8ebd-287846957551_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_1cc43920-1e3f-4931-b86b-0ca29d71af42_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c10f03b3-c1b8-42f2-83de-8693d4fe8f4c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_43d7b1e7-e0bb-4d74-8ca3-8cf43040fa7f_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio adjustment period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_faf187e4-352d-4dda-b605-771bf280df80_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from share-based compensation activity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_16cc2f2c-d875-4708-bcf2-779f54dd6148_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_c9376d63-b8a2-4adb-839e-526aaa3165fa_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c52f11d7-bd92-4364-b78e-d5eec5915441_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b0e68aa3-6c66-44c1-b9e9-3e7787a08c60_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_f55aa6f4-a787-4c2a-8564-f743c836ee05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_56982343-be58-40d7-bcfc-df10c7c977da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_fdbf429f-342d-412e-8ec0-03e3a7f8280f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_ee8fa1b1-4799-4f79-b802-1f76a1733ee2_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original principal amount required to repay in the first two years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay in First Two Years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in the first two years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:href="ebs-20220930.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1a099a31-aca8-4e5a-953a-d91e36e78fb8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_5ae6d4b2-8abd-4c2f-ac71-e448e5a093fc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8c9e28d8-350f-454e-873e-0653758f1acd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_c3a7a4eb-04d8-4e9f-908d-2b1734571419_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_79b973fc-d98c-4b66-8e1f-1b086222f592_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_00bec321-4934-4237-96a9-77e964a04b62_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8de7f239-6937-45d7-ba6e-8f9994a9b2d0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6645d75d-136f-41f6-ad48-abfd4a238e92_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9a4f8cf3-5294-4304-a77e-fc2d1ccdf037_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_43ec061e-0294-4927-904b-244dcf246b06_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 5.6 and 3.8 common shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_5e993bf0-5d62-4b4c-a7c4-cb7b02aae053_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_2e14e2d8-7764-443a-acb0-e52c07640907_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_80586098-aebf-4322-88f8-f1c9bcad25cc_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_d53a60ea-6a1d-4d47-bdd0-372c9a90421b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_c23b9268-7347-4c29-b8b6-a51c2ff4f7d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_06516faa-d86a-4ca8-a7c6-2a4f604cb95c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f9da5774-1724-4e66-9110-761ab539cfb2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ec4978-cb09-4579-a8fe-550b61a9588d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5c6d4e5e-4faa-4ae2-b87e-42fc2c893fe2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_841fc415-1d30-4282-9f3d-86326c234bde_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_89a8f3e9-6e93-457c-9b6e-9c7d9c961c68_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ReservationOfManufacturingCapacityMember_95720781-ec0e-4e32-b9dc-3303e143e98c_terseLabel_en-US" xlink:label="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reservation Of Manufacturing Capacity</link:label>
    <link:label id="lab_ebs_ReservationOfManufacturingCapacityMember_label_en-US" xlink:label="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reservation Of Manufacturing Capacity [Member]</link:label>
    <link:label id="lab_ebs_ReservationOfManufacturingCapacityMember_documentation_en-US" xlink:label="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reservation Of Manufacturing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ReservationOfManufacturingCapacityMember" xlink:href="ebs-20220930.xsd#ebs_ReservationOfManufacturingCapacityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ReservationOfManufacturingCapacityMember" xlink:to="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_534e0ae6-5cae-4507-9ebc-a6cae17bf153_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0174cb1b-37aa-462b-866e-d8ae429ae18d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d9207342-3de4-4408-beba-6ca1da0e3633_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_d2356632-3fb3-4d72-aa06-b0758b61b946_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RegulatoryMilestonesMember_fb8def65-fbd1-448d-b693-5493a2d2f20a_terseLabel_en-US" xlink:label="lab_ebs_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_ebs_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_ebs_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_ebs_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_ebs_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RegulatoryMilestonesMember" xlink:href="ebs-20220930.xsd#ebs_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RegulatoryMilestonesMember" xlink:to="lab_ebs_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_1123d4c3-8b0a-48d8-911a-27a457e76ee7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0e268777-2324-4d28-9161-dfdd9bf5b327_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4271f81b-e986-4cc5-a543-523014628ee4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7027a850-5c44-4088-bf64-b8c9c9e93ec4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_881bc84c-8d1f-48c3-bd64-5ade4e7cb239_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_9f118552-3d6b-4773-a345-b00869e6ab1d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_adaaa8d5-038a-47d5-ac30-9499b22d2b18_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8c92b8e6-787a-472c-8dd9-0b5181cfd4a1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1a44ce9c-21ee-4dd4-ad44-76a00a1cdc5a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and principles of consolidation</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_2717aba5-8d7b-4083-9f61-8a42c5d57f9b_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51c466f1-f8ab-41f5-b96f-7c342608450c_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_23aeeb29-7b16-41d7-b6e7-0b89c28aa964_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f4b69632-a73f-4934-ab7d-62565e5f4ead_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c298cd48-240b-40f6-8f64-06ffefda3843_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d16de886-1e74-4c2a-8894-95857fe7537a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2d788e0f-d746-4fc0-a59f-835c895ad6f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_56f58e84-0d90-482a-8724-e3fd25b6dd6d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_18f31148-ca6b-422e-b9c8-7489b2a1490e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation activity (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_67d0c3df-1214-4f00-aaa9-4802942fc758_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_221e3737-4063-42b6-afe2-9e8d7af9263d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1c7de50c-1f50-403f-973f-92adc5fb540f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_637a171a-4ec5-4767-8da9-dfab8a79517d_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, payments to be received</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_97fd6777-5b07-461d-85f2-0be88dd47c83_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8aefea54-1ac4-44de-b297-954ee351c3a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2e30a961-ff8d-4b86-b304-17e29e1c307f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per common share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_62cbc7d3-6d04-4a64-ba9a-11301e37c5f7_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_1388c86a-8e3f-468a-bcb8-a092d5767061_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_02d5bd42-5dc6-425d-b445-7800d4600366_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_8de31eff-b790-44fd-9205-a233835b21a4_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_b29089e9-d0f6-4294-8063-2227a0c1fbf3_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MilestonePaymentsMember_3a89124f-80dd-4fca-8b54-936d4e0e676d_terseLabel_en-US" xlink:label="lab_ebs_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_ebs_MilestonePaymentsMember_label_en-US" xlink:label="lab_ebs_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments [Member]</link:label>
    <link:label id="lab_ebs_MilestonePaymentsMember_documentation_en-US" xlink:label="lab_ebs_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentsMember" xlink:href="ebs-20220930.xsd#ebs_MilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MilestonePaymentsMember" xlink:to="lab_ebs_MilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ffd9f6d7-fef7-4f34-b8bd-11733aacc08c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a988d9d0-3c2a-493b-aa89-d8c78e616535_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bb0e715d-6b4e-4a8e-ba1c-052e06923be0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares-basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_137dd289-c046-401e-9429-8feee787f17a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_IncomeTaxesLineItems_c08befc4-3d5c-4a1d-a50a-589cd573d162_terseLabel_en-US" xlink:label="lab_ebs_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_ebs_IncomeTaxesLineItems_label_en-US" xlink:label="lab_ebs_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_ebs_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_ebs_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesLineItems" xlink:href="ebs-20220930.xsd#ebs_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_IncomeTaxesLineItems" xlink:to="lab_ebs_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_39d6e6e2-a2dc-4fb1-92ed-1ded838d910f_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_d14140a7-c9e4-4f93-b5ae-87c29509cab2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on term loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Medium-term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:to="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_13ca42f2-1518-498e-bd01-6715c56be402_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_06dcd93f-23eb-4291-ac26-060ce42850bd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_fa8dd0b3-e53f-4bb6-96d4-22021e4443c1_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_87c7c2e6-6c2d-468d-be4c-be75ec07a017_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_804f6739-e7fb-407a-bb78-8145329b7e4b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_db30d409-618e-4312-888b-29f51a24c8c5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_718ce812-490a-462c-9c42-7464f6af3490_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_db27114f-d572-41e0-a4c4-9fb60ad0953e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_339e0b05-fc0d-440a-b0ac-a167c03768d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_626e8bdf-cdd2-4bff-91e2-35119441c0b5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_df4d536b-62a0-4a8c-ae58-32d54c16d00f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_96514b5b-ca0f-4315-a0f5-fc2fea6e4c75_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b2e4c917-4ac7-4bb6-86d2-6fb00a53167f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_037f3059-1fc1-48bb-8a10-2367d9ba1092_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_00f6f18d-85a1-4706-ae43-281955eb060e_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_cd92b475-bfc4-4fc0-94d3-18275d265e97_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plan</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_94efa7fb-4022-4ab3-9a9b-25639a9e085d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_70014d6d-efc0-49ca-a8a0-78e148432791_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio, maximum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, One</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_ca25a838-fff3-4e21-af0d-a43b2a75d55d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_TermLoanFacilityMember_4fdcb635-5973-4081-a945-fb4b6b15b114_verboseLabel_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_label_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan dated December 2013.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember" xlink:href="ebs-20220930.xsd#ebs_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TermLoanFacilityMember" xlink:to="lab_ebs_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_a6f55504-d1b7-4c60-a49d-1c5d34b5b508_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original principal amount required to repay during the third year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay During the Third Year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in the third year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:href="ebs-20220930.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_69d7dfba-70c6-4b30-ac33-2d7fe54482e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon the occurrence of a change in control</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_0e7f58cf-adbb-47b8-833b-63ad609bce54_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_26be8332-4485-4738-b44a-8ca2ecaea2ac_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid for share-based compensation activity</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_97d8e55d-920b-463c-8f76-fbbe0d3a30cc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_209028f3-dcb3-4682-93ce-388aa0785aba_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_4860c7c1-7a9d-4a99-b83b-6d817d53e33f_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurocurrency</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_b8fa803b-86eb-4de1-8485-4986ec682be9_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_e26ce8cf-42e1-4c46-9d8b-6df6bdfb3e87_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f4038290-a9ec-4fbe-9036-73fa257aa598_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_4d0626d8-acb7-454b-9b83-c31b0e825d97_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio, adjustment</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Two</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d22e77f7-f5b4-451d-9105-53a5a64e5871_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities-equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_d194098c-8915-4668-a9cf-793a6d040d32_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_135477f2-0839-481d-a5b5-a15b95cef86d_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Government</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b543ee7-88b5-4550-99ca-aae48ddbc1af_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3521f996-2885-4178-b954-ae9792419aa6_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3dfa43de-5df5-4874-9b04-a4b70f48ab54_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8369d84d-7e29-4c50-8f84-beffb3fd51f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_a7b7f612-07dd-4c3f-8ffc-bbe2537c0650_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_74e9833e-ff38-4be3-9ab7-528d4cdcfe71_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to August 15, 2023</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_fd91067e-92b4-43be-8481-c0808c7e1df6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_c81bb24b-fbb3-4f93-b4ad-ca6eb6e9254a_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d3e0893-9fb5-4497-a644-0d88a8ef79db_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_14a7d6f9-64ee-447b-bd86-70ea549b7c91_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d401d208-6398-494f-b2e2-6ecf1c8f67b7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1372c44c-842c-478e-87ad-15aeb00610ae_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_029c3612-b30b-4132-b8f5-c83f5a88ea43_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c2a9beba-add5-4da0-91a1-126ffa114349_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b68d714a-2934-4814-974c-9f5334cb07f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_d79ddb5e-43bc-4489-bf97-aa4693d6ffa1_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4e2a0ab2-b223-41a9-853a-9c7e12a48b12_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_53ae4fce-113f-480c-8fed-6401ea611e38_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_825db2eb-8eb3-4102-ad73-ed5907f5c0da_terseLabel_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Senior Unsecured Notes due 2028</link:label>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_label_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due August 2028 [Member]</link:label>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_documentation_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due August 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:href="ebs-20220930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:to="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_b802a6cd-a503-447f-88f8-01f19fc08303_totalLabel_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CDMO</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_866dd936-6ba8-464c-a116-da4c7561cada_terseLabel_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_documentation_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_b05aec84-7996-4240-9a69-e92b25949527_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ace2526a-1f91-4bb3-9560-93d9770bd08d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_6be3a370-9c48-4743-8609-d60f55c7ac3e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_cd0fdbbd-62f7-4025-90ac-5725a56dad1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RockvilleManufacturingFacilityMember_bb4ebebb-74fa-4c7f-9ffc-a1af73afbfe3_terseLabel_en-US" xlink:label="lab_ebs_RockvilleManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville Manufacturing Facility</link:label>
    <link:label id="lab_ebs_RockvilleManufacturingFacilityMember_label_en-US" xlink:label="lab_ebs_RockvilleManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville Manufacturing Facility [Member]</link:label>
    <link:label id="lab_ebs_RockvilleManufacturingFacilityMember_documentation_en-US" xlink:label="lab_ebs_RockvilleManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rockville Manufacturing Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RockvilleManufacturingFacilityMember" xlink:href="ebs-20220930.xsd#ebs_RockvilleManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RockvilleManufacturingFacilityMember" xlink:to="lab_ebs_RockvilleManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_ba8d275f-e26f-4d03-bad9-53e1f1012c2e_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_c2f4af5c-2d94-4f8b-aed1-02d0f8e52bb0_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original principal amount required to repay remaining year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay Remaining Years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in remaining years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:href="ebs-20220930.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_30012301-6b46-4626-bfbf-c11b661d7391_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_36da510b-3b61-4431-a6f1-009e5ecb1809_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_fd4a7708-2f57-4d70-bcc6-5f4c8f161991_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_8a2342a1-1a28-4ae1-befe-43479ed17d3a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9b36a8f6-0c64-427a-b79b-7ec1e9f2d287_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_aab5a4de-af88-4336-8199-accc9488a979_verboseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_19467e6a-2608-408c-806e-1a10600579c2_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a6dc7e99-76dd-4127-aaab-512c5c970020_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_6ff5246f-289d-47ce-be13-ee73b5955789_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d834f3e4-5094-42ae-9c62-8069dff50daf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_c51d7a44-5a73-4c43-8fca-67aaa5d3a8a0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_61b70a44-f2b8-4ec2-b577-c9196f6157af_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_7c98b80e-dc7f-44aa-bec6-54b2752fb49c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash and cash equivalents and restricted cash at September&#160;30, 2022 and December&#160;31, 2021:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a067198a-c422-4418-8fed-a7db4de858b9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_af274069-c747-4a4f-b8f5-8973bf2ec6d5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_119f45f1-5e38-4a30-8703-7d20ac3c5284_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_7dd7f0f2-bdfb-46fa-b7cd-d2afa961c5f3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_011e5756-a0ff-4efa-92eb-9d86ec222d10_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_482738bf-fcdf-47da-b7bf-fdfab1a15f74_terseLabel_en-US" xlink:label="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, international royalty percentage</link:label>
    <link:label id="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_label_en-US" xlink:label="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, International Gross Profit Royalty Percentage</link:label>
    <link:label id="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_documentation_en-US" xlink:label="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, International Gross Profit Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:to="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_aca7d9b3-5e64-4a8b-ab1a-4076a234637e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_e5e3a2d6-3a59-440b-b26c-0ab51d087569_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0bba1a8d-7082-49fd-bbda-c6d7f72f6a47_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c619802a-e301-42de-bb36-212935fcd32f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_40163453-a50e-4925-b8c6-5cf5ea14804d_terseLabel_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended credit agreement dated October 15, 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember" xlink:href="ebs-20220930.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AmendedCreditAgreementMember" xlink:to="lab_ebs_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_9bfabbe2-d0be-4dfe-a28c-3c826765edaf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_280cfac8-c5fa-41d3-8259-c405c77521cf_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_27272437-8550-4a24-8569-e6edee733710_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2ea46049-f180-4516-9ba9-1194f8b52724_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5248fe1b-4c4d-4840-b4e1-1da7335ae383_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22dbb157-9580-44a4-a4dd-87b143d89fb0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_IncomeTaxesTable_9c5ad33f-9af0-4134-a3ea-d14b15cf35ba_terseLabel_en-US" xlink:label="lab_ebs_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_ebs_IncomeTaxesTable_label_en-US" xlink:label="lab_ebs_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_ebs_IncomeTaxesTable_documentation_en-US" xlink:label="lab_ebs_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesTable" xlink:href="ebs-20220930.xsd#ebs_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_IncomeTaxesTable" xlink:to="lab_ebs_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_dc62e581-c485-4da8-81a8-0a22cc855be4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_9eb5cd55-bd19-4016-82fd-310128124cef_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_77ee83ed-86d6-4613-ae1b-445211884b26_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4d96d6fe-ecf7-4e05-8475-3be6439d9062_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_fa0f8986-18f7-49aa-b8e3-081810ab2b89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_42441f20-4ed2-428a-87d1-caf31b424f4d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_fd76ef81-b24b-4530-9244-0722b49640db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_579d2c52-c675-4446-b538-0152c680b122_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_be45285d-3079-4243-8ded-a4fc34035b75_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows provided by (used in) financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_c4517274-bda0-4392-a881-908e7298e8a2_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio rolling period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_80f51832-d09e-475f-9aa5-52cfd8c86470_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental information on non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4eb98db8-1f7f-4876-9d63-4b427179a7d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_b55806f9-b85e-4eba-80da-103c660c465e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e58418ba-e58c-41bb-bc25-a40829ac9a42_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c9f686ac-c8ed-4838-a656-3fd6d857af42_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_37f099af-a06a-4f90-928c-a5694d23cd0b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_115537b9-edcd-45b5-9508-0bb29427a40f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_8ff0da57-0d02-4cb3-bbec-56011bd8963b_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_51969bff-a2ee-43f1-96f1-669cbb5248e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Income per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_10510b1a-c828-4fd4-9a59-046f6bf1ce87_terseLabel_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right</link:label>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_label_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Proceeds Excess Amount from Dispositions of Property or Casualty Events Subject to Certain Reinvestment Right</link:label>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_documentation_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:href="ebs-20220930.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:to="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_906d618a-62f8-49cf-a563-f86199acd4fd_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_a2ab94db-7639-4f4f-a924-9e781d2e2b90_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ebs-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e49bcad1-b3a3-4429-b549-b7280da8936a,g:b60fc6ff-4763-459f-a134-feb07b4a5302-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPage" xlink:type="simple" xlink:href="ebs-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f963888c-4b42-4b37-b925-09cf21798d84" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_DocumentType_f963888c-4b42-4b37-b925-09cf21798d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e1b9b08c-dc2b-4523-afab-1322ee51a979" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_DocumentQuarterlyReport_e1b9b08c-dc2b-4523-afab-1322ee51a979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_21361d03-4064-48ad-bd9c-fe76b0f3b8b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_DocumentPeriodEndDate_21361d03-4064-48ad-bd9c-fe76b0f3b8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ca1560ac-70d6-49cc-8dd9-8e5d1c44db64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_DocumentTransitionReport_ca1560ac-70d6-49cc-8dd9-8e5d1c44db64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f3e01d91-a754-45a1-aa9f-5c1244121b65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityFileNumber_f3e01d91-a754-45a1-aa9f-5c1244121b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a2cf07e6-f66e-4077-81c2-b6ae9b753de6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityRegistrantName_a2cf07e6-f66e-4077-81c2-b6ae9b753de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_af6bdc1b-72e9-45e5-ab08-8e8c96ceef7e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityIncorporationStateCountryCode_af6bdc1b-72e9-45e5-ab08-8e8c96ceef7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0ef84cb3-04d4-47e9-bf10-e73afccc0dfd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityTaxIdentificationNumber_0ef84cb3-04d4-47e9-bf10-e73afccc0dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d2d1f668-d691-4724-8d14-c5fed372d511" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityAddressAddressLine1_d2d1f668-d691-4724-8d14-c5fed372d511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e5eb2e7d-bf22-41d8-836b-92e4e522dccc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityAddressCityOrTown_e5eb2e7d-bf22-41d8-836b-92e4e522dccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e3876150-a53e-4088-aa20-633dd6e0e27c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityAddressStateOrProvince_e3876150-a53e-4088-aa20-633dd6e0e27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f29753f3-94ab-4b8b-a9f9-4a0b35686a71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityAddressPostalZipCode_f29753f3-94ab-4b8b-a9f9-4a0b35686a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c8af9757-0879-44e2-976a-d15d253b385f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_CityAreaCode_c8af9757-0879-44e2-976a-d15d253b385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_407f6e62-08d4-4ece-b4c6-569cd1c805a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_LocalPhoneNumber_407f6e62-08d4-4ece-b4c6-569cd1c805a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d0699b69-7112-4060-9b13-29459358accb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_Security12bTitle_d0699b69-7112-4060-9b13-29459358accb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_eda35a41-b039-47e3-bedc-21d5de228661" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_TradingSymbol_eda35a41-b039-47e3-bedc-21d5de228661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_88f37255-a923-427c-bd83-1761885614c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_SecurityExchangeName_88f37255-a923-427c-bd83-1761885614c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0e55865a-0d83-48f4-9b9d-b7652ed89fc4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityCurrentReportingStatus_0e55865a-0d83-48f4-9b9d-b7652ed89fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_bfdf1cb5-8d26-40b6-9f9d-03cf1b5c2e23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityInteractiveDataCurrent_bfdf1cb5-8d26-40b6-9f9d-03cf1b5c2e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4984e59c-9600-489f-a0db-4c01b403033b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityFilerCategory_4984e59c-9600-489f-a0db-4c01b403033b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_474d5d3d-99be-4c24-99f6-9b502faddfdd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntitySmallBusiness_474d5d3d-99be-4c24-99f6-9b502faddfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f648925c-0060-46cc-aa50-1b1c1a6357be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityEmergingGrowthCompany_f648925c-0060-46cc-aa50-1b1c1a6357be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a3afe886-3ded-4f85-96f5-a4eab453f957" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityShellCompany_a3afe886-3ded-4f85-96f5-a4eab453f957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f0d58bba-1a6e-49a8-86e1-78e85bad2b5d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f0d58bba-1a6e-49a8-86e1-78e85bad2b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a886ab1b-ad14-4e3c-8b7e-47993ddf2a12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_EntityCentralIndexKey_a886ab1b-ad14-4e3c-8b7e-47993ddf2a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cbb6ca08-6085-4b74-bfc6-dadc4493ab64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_CurrentFiscalYearEndDate_cbb6ca08-6085-4b74-bfc6-dadc4493ab64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_339748c0-bb75-439d-a158-90f5981ed8b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_AmendmentFlag_339748c0-bb75-439d-a158-90f5981ed8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a3c858d3-e8e9-4d8f-8e20-09a37caf4a23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_DocumentFiscalYearFocus_a3c858d3-e8e9-4d8f-8e20-09a37caf4a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_88b1f14b-178f-41e1-9bcb-711cbfc2bf88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4cd2f73e-fd33-4730-ab1f-f696330c2685" xlink:to="loc_dei_DocumentFiscalPeriodFocus_88b1f14b-178f-41e1-9bcb-711cbfc2bf88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c571b686-98a3-4daa-b9a1-1432fd36145e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_970bb730-73c5-4aa1-b72c-6f6c90f2fdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c571b686-98a3-4daa-b9a1-1432fd36145e" xlink:to="loc_us-gaap_AssetsAbstract_970bb730-73c5-4aa1-b72c-6f6c90f2fdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_76670914-59fa-4e38-854e-abdfcf5ad858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_970bb730-73c5-4aa1-b72c-6f6c90f2fdfc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_76670914-59fa-4e38-854e-abdfcf5ad858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c85c2a5b-3f8b-47e9-987a-ea8146ce36bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76670914-59fa-4e38-854e-abdfcf5ad858" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c85c2a5b-3f8b-47e9-987a-ea8146ce36bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_471c49d6-673b-4923-a483-7876bd91065f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76670914-59fa-4e38-854e-abdfcf5ad858" xlink:to="loc_us-gaap_RestrictedCashCurrent_471c49d6-673b-4923-a483-7876bd91065f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_376d6a92-a8d7-4d15-b5e9-27f2310487d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76670914-59fa-4e38-854e-abdfcf5ad858" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_376d6a92-a8d7-4d15-b5e9-27f2310487d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cc6a8890-6a8d-431c-9c9a-59d023a0ddeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76670914-59fa-4e38-854e-abdfcf5ad858" xlink:to="loc_us-gaap_InventoryNet_cc6a8890-6a8d-431c-9c9a-59d023a0ddeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_265e7459-0c8d-4127-827a-c5b829bc46de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76670914-59fa-4e38-854e-abdfcf5ad858" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_265e7459-0c8d-4127-827a-c5b829bc46de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_41d5f0bb-5062-4ec5-aae9-75dd9d41f6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76670914-59fa-4e38-854e-abdfcf5ad858" xlink:to="loc_us-gaap_AssetsCurrent_41d5f0bb-5062-4ec5-aae9-75dd9d41f6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b8568885-5289-4307-b12f-34e5562c3851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_970bb730-73c5-4aa1-b72c-6f6c90f2fdfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b8568885-5289-4307-b12f-34e5562c3851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_01569074-62c6-49af-b69a-a7426bf6c423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_970bb730-73c5-4aa1-b72c-6f6c90f2fdfc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_01569074-62c6-49af-b69a-a7426bf6c423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ab6e7e31-cf45-46de-8a40-9d1c9093f181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_970bb730-73c5-4aa1-b72c-6f6c90f2fdfc" xlink:to="loc_us-gaap_Goodwill_ab6e7e31-cf45-46de-8a40-9d1c9093f181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_66e5feb4-47e3-4d6e-8205-7e7a37c99171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_970bb730-73c5-4aa1-b72c-6f6c90f2fdfc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_66e5feb4-47e3-4d6e-8205-7e7a37c99171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_27862f50-e4d1-4bf9-9aa6-4b13b8a02d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_970bb730-73c5-4aa1-b72c-6f6c90f2fdfc" xlink:to="loc_us-gaap_Assets_27862f50-e4d1-4bf9-9aa6-4b13b8a02d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5331d825-b144-45f1-968e-6c0c28646023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c571b686-98a3-4daa-b9a1-1432fd36145e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5331d825-b144-45f1-968e-6c0c28646023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c6ae2a4c-e2e1-47f9-8808-e2718d736f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5331d825-b144-45f1-968e-6c0c28646023" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c6ae2a4c-e2e1-47f9-8808-e2718d736f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2e680e23-2016-4eaf-9bc8-9adcfce9cbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6ae2a4c-e2e1-47f9-8808-e2718d736f99" xlink:to="loc_us-gaap_AccountsPayableCurrent_2e680e23-2016-4eaf-9bc8-9adcfce9cbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_514121b6-c592-4b41-839d-12d4844b1eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6ae2a4c-e2e1-47f9-8808-e2718d736f99" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_514121b6-c592-4b41-839d-12d4844b1eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8d14f454-00bd-4b09-a1a0-b655edf5e106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6ae2a4c-e2e1-47f9-8808-e2718d736f99" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8d14f454-00bd-4b09-a1a0-b655edf5e106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_9e700dbd-266e-4744-aace-816d6bcd090c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6ae2a4c-e2e1-47f9-8808-e2718d736f99" xlink:to="loc_us-gaap_NotesPayableCurrent_9e700dbd-266e-4744-aace-816d6bcd090c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7b2c97fe-4fbb-4508-9487-09e7da7e8449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6ae2a4c-e2e1-47f9-8808-e2718d736f99" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_7b2c97fe-4fbb-4508-9487-09e7da7e8449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e991b040-3f38-47eb-90b1-31765e66ce8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c6ae2a4c-e2e1-47f9-8808-e2718d736f99" xlink:to="loc_us-gaap_LiabilitiesCurrent_e991b040-3f38-47eb-90b1-31765e66ce8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f8a40aec-d756-447c-b470-9970b6b83961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5331d825-b144-45f1-968e-6c0c28646023" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f8a40aec-d756-447c-b470-9970b6b83961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c0039d25-bd1c-4bf4-98d5-f9d98d84744d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5331d825-b144-45f1-968e-6c0c28646023" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c0039d25-bd1c-4bf4-98d5-f9d98d84744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_499b6c7c-c772-40f2-ab0a-be39760c5062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5331d825-b144-45f1-968e-6c0c28646023" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_499b6c7c-c772-40f2-ab0a-be39760c5062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b83c814f-5ceb-44e0-b7cf-d0fbbe44daf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5331d825-b144-45f1-968e-6c0c28646023" xlink:to="loc_us-gaap_Liabilities_b83c814f-5ceb-44e0-b7cf-d0fbbe44daf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0d324d5a-36b1-4567-a8c7-a291a5aeba83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5331d825-b144-45f1-968e-6c0c28646023" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0d324d5a-36b1-4567-a8c7-a291a5aeba83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_848e6ec2-89f0-4c97-b737-3f606df87cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0d324d5a-36b1-4567-a8c7-a291a5aeba83" xlink:to="loc_us-gaap_PreferredStockValue_848e6ec2-89f0-4c97-b737-3f606df87cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_43fa0ec7-1d04-4bc7-8da8-741b09fb3869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0d324d5a-36b1-4567-a8c7-a291a5aeba83" xlink:to="loc_us-gaap_CommonStockValue_43fa0ec7-1d04-4bc7-8da8-741b09fb3869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_48e2c8af-ab75-4531-bbdd-c5d40a9aa4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0d324d5a-36b1-4567-a8c7-a291a5aeba83" xlink:to="loc_us-gaap_TreasuryStockValue_48e2c8af-ab75-4531-bbdd-c5d40a9aa4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_63c8564b-b00a-484d-841b-32d0c1a25177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0d324d5a-36b1-4567-a8c7-a291a5aeba83" xlink:to="loc_us-gaap_AdditionalPaidInCapital_63c8564b-b00a-484d-841b-32d0c1a25177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_db84b022-9af3-489d-b8ed-20f43ba65bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0d324d5a-36b1-4567-a8c7-a291a5aeba83" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_db84b022-9af3-489d-b8ed-20f43ba65bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ff1e77fc-f31a-4559-83ba-8ee99dd6ea92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0d324d5a-36b1-4567-a8c7-a291a5aeba83" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ff1e77fc-f31a-4559-83ba-8ee99dd6ea92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ba7ce591-7dcd-4c1f-9847-d3552ca5b370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0d324d5a-36b1-4567-a8c7-a291a5aeba83" xlink:to="loc_us-gaap_StockholdersEquity_ba7ce591-7dcd-4c1f-9847-d3552ca5b370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_296997f2-d8a6-40d9-a824-fbcd71ada617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5331d825-b144-45f1-968e-6c0c28646023" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_296997f2-d8a6-40d9-a824-fbcd71ada617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4d35444d-f06c-44dd-b1eb-99aee3d39af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd4cb830-830f-49d5-bb33-bb118cc5715b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4d35444d-f06c-44dd-b1eb-99aee3d39af4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd4cb830-830f-49d5-bb33-bb118cc5715b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_038763e2-f1e5-42a9-b449-c50d656f3b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd4cb830-830f-49d5-bb33-bb118cc5715b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_038763e2-f1e5-42a9-b449-c50d656f3b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_65252b42-ddba-4108-ab36-2150becf28de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_038763e2-f1e5-42a9-b449-c50d656f3b61" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_65252b42-ddba-4108-ab36-2150becf28de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3b1b13b5-e87a-4a70-8753-d481097bd5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_038763e2-f1e5-42a9-b449-c50d656f3b61" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3b1b13b5-e87a-4a70-8753-d481097bd5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_504241f5-0a65-4d1f-8813-c34fc40ffb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_038763e2-f1e5-42a9-b449-c50d656f3b61" xlink:to="loc_us-gaap_PreferredStockSharesIssued_504241f5-0a65-4d1f-8813-c34fc40ffb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1cd9f353-c38d-4103-b646-1dad2f48bd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_038763e2-f1e5-42a9-b449-c50d656f3b61" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1cd9f353-c38d-4103-b646-1dad2f48bd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9253cf6e-139c-433f-a75a-a98622b32f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_038763e2-f1e5-42a9-b449-c50d656f3b61" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9253cf6e-139c-433f-a75a-a98622b32f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7f33cbfd-ba2f-4352-9a49-2e9fea78d1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_038763e2-f1e5-42a9-b449-c50d656f3b61" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7f33cbfd-ba2f-4352-9a49-2e9fea78d1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_336784aa-4c8c-45d9-a269-b7e4b215ae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_038763e2-f1e5-42a9-b449-c50d656f3b61" xlink:to="loc_us-gaap_CommonStockSharesIssued_336784aa-4c8c-45d9-a269-b7e4b215ae8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ec20e31c-8f11-4182-8a91-cf028bb17b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_038763e2-f1e5-42a9-b449-c50d656f3b61" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ec20e31c-8f11-4182-8a91-cf028bb17b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_bd813926-aeb6-470f-b192-a05c826ab49e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_038763e2-f1e5-42a9-b449-c50d656f3b61" xlink:to="loc_us-gaap_TreasuryStockShares_bd813926-aeb6-470f-b192-a05c826ab49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_32ea8d75-3543-42c5-90b2-49be00490b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cc9b095a-8ca1-4e3b-a707-3393f3a2c5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32ea8d75-3543-42c5-90b2-49be00490b9d" xlink:to="loc_us-gaap_StatementTable_cc9b095a-8ca1-4e3b-a707-3393f3a2c5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_285fa0c0-10cf-4923-b67c-021e359fe6ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc9b095a-8ca1-4e3b-a707-3393f3a2c5f7" xlink:to="loc_srt_ProductOrServiceAxis_285fa0c0-10cf-4923-b67c-021e359fe6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d21546b0-ff58-4400-a41f-34a036a346c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_285fa0c0-10cf-4923-b67c-021e359fe6ca" xlink:to="loc_srt_ProductsAndServicesDomain_d21546b0-ff58-4400-a41f-34a036a346c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c31fd5ea-f21b-47f7-b096-1a3fbb7960e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d21546b0-ff58-4400-a41f-34a036a346c1" xlink:to="loc_us-gaap_ProductMember_c31fd5ea-f21b-47f7-b096-1a3fbb7960e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_19fc2a88-4f6f-45b8-aaf0-8482c433f824" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d21546b0-ff58-4400-a41f-34a036a346c1" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_19fc2a88-4f6f-45b8-aaf0-8482c433f824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1dc055f9-ece7-4d33-9230-495bab15197d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_19fc2a88-4f6f-45b8-aaf0-8482c433f824" xlink:to="loc_us-gaap_ServiceMember_1dc055f9-ece7-4d33-9230-495bab15197d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_c5d1096b-aff0-47e9-90fa-16ef39c29a30" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_19fc2a88-4f6f-45b8-aaf0-8482c433f824" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_c5d1096b-aff0-47e9-90fa-16ef39c29a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_dd706c65-1a2f-4692-a766-040e1c112f11" xlink:href="ebs-20220930.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d21546b0-ff58-4400-a41f-34a036a346c1" xlink:to="loc_ebs_ContractsAndGrantsMember_dd706c65-1a2f-4692-a766-040e1c112f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc9b095a-8ca1-4e3b-a707-3393f3a2c5f7" xlink:to="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3a527db-78b0-4e34-8b0d-b3e514103b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3a527db-78b0-4e34-8b0d-b3e514103b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_daaf4bfa-f1d8-474a-9148-4e0a9ac6502b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_daaf4bfa-f1d8-474a-9148-4e0a9ac6502b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_6d1f9237-5455-4b5c-9656-533c8c2c83fb" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_6d1f9237-5455-4b5c-9656-533c8c2c83fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f6f05f22-3a95-4751-93c4-2b9d2bf52f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_4f45dd03-7567-43f3-97c3-ac0504767b01" xlink:to="loc_us-gaap_Revenues_f6f05f22-3a95-4751-93c4-2b9d2bf52f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_dc17f199-0d8f-43b3-96ea-ce37a0287498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_dc17f199-0d8f-43b3-96ea-ce37a0287498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_dc67fac1-1906-42cb-82af-6de0b3aa2a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_dc67fac1-1906-42cb-82af-6de0b3aa2a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1bd3cd77-6b4d-4b70-bfbd-a4fedc26bf7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1bd3cd77-6b4d-4b70-bfbd-a4fedc26bf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_89e22a73-2217-461c-83b3-517504b16793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_89e22a73-2217-461c-83b3-517504b16793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_9fa342ea-e421-4872-a076-cc1188f49095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_427d5216-8bfe-4817-908a-6c1a4d8cb5be" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_9fa342ea-e421-4872-a076-cc1188f49095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9bc0f79a-5e3f-4313-b9b2-7c67a7727f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_OperatingIncomeLoss_9bc0f79a-5e3f-4313-b9b2-7c67a7727f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4ab14647-ee25-4e26-a6df-0c49b6e765db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4ab14647-ee25-4e26-a6df-0c49b6e765db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_741e73a9-bacf-4502-af2f-ce705ff7cb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4ab14647-ee25-4e26-a6df-0c49b6e765db" xlink:to="loc_us-gaap_InterestExpense_741e73a9-bacf-4502-af2f-ce705ff7cb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_36f719bd-de62-4c46-8fbd-fcbeeb78562b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4ab14647-ee25-4e26-a6df-0c49b6e765db" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_36f719bd-de62-4c46-8fbd-fcbeeb78562b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_df1635ec-765c-486a-b4e0-cc74613e99d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4ab14647-ee25-4e26-a6df-0c49b6e765db" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_df1635ec-765c-486a-b4e0-cc74613e99d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a536aba-aca6-4116-b69f-b8c1afd4c408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a536aba-aca6-4116-b69f-b8c1afd4c408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c2333d66-880c-4120-a9ca-5d94d4250171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c2333d66-880c-4120-a9ca-5d94d4250171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_441f9571-c22a-48f3-958a-2757f506a8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_NetIncomeLoss_441f9571-c22a-48f3-958a-2757f506a8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_94a19fbc-bf3d-4e1e-b3dd-fce13505410f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_94a19fbc-bf3d-4e1e-b3dd-fce13505410f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_800aa1d0-d9bf-46ff-ab67-e7fb336b2b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_94a19fbc-bf3d-4e1e-b3dd-fce13505410f" xlink:to="loc_us-gaap_EarningsPerShareBasic_800aa1d0-d9bf-46ff-ab67-e7fb336b2b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_08dd9af3-0b2f-4a50-adb9-08624e0923cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_94a19fbc-bf3d-4e1e-b3dd-fce13505410f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_08dd9af3-0b2f-4a50-adb9-08624e0923cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_261715ed-d875-4d22-8c57-267263673fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_23f40570-1ebf-4c1f-bba3-ea92bb93814f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_261715ed-d875-4d22-8c57-267263673fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ebbfd9a-0095-4c96-8506-3f881bbce6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_261715ed-d875-4d22-8c57-267263673fdb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ebbfd9a-0095-4c96-8506-3f881bbce6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_139de832-ff86-4887-800d-cbdead61237b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_261715ed-d875-4d22-8c57-267263673fdb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_139de832-ff86-4887-800d-cbdead61237b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3d994990-6ee9-4142-a419-cc7e600a355d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cc21319a-e2d1-487a-ac6d-4cd3acebee2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3d994990-6ee9-4142-a419-cc7e600a355d" xlink:to="loc_us-gaap_NetIncomeLoss_cc21319a-e2d1-487a-ac6d-4cd3acebee2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_799e520e-7669-417f-bd59-c4b18cac6252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3d994990-6ee9-4142-a419-cc7e600a355d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_799e520e-7669-417f-bd59-c4b18cac6252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9535fc17-9263-4ec0-a022-6891f3f591b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_799e520e-7669-417f-bd59-c4b18cac6252" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9535fc17-9263-4ec0-a022-6891f3f591b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3cf2cdf0-398b-4128-a8ac-4de93d1a412a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_799e520e-7669-417f-bd59-c4b18cac6252" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3cf2cdf0-398b-4128-a8ac-4de93d1a412a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fb053ec2-314c-4e32-ac5b-06933e1a84ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_799e520e-7669-417f-bd59-c4b18cac6252" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fb053ec2-314c-4e32-ac5b-06933e1a84ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e5e98ac1-7989-4d5c-ab09-d54661bdabfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3d994990-6ee9-4142-a419-cc7e600a355d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e5e98ac1-7989-4d5c-ab09-d54661bdabfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e899bb88-ad46-42c5-8a3f-3bd2e1fb521e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2ae297c5-8518-4437-b0c6-22bd1b4bee83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e899bb88-ad46-42c5-8a3f-3bd2e1fb521e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2ae297c5-8518-4437-b0c6-22bd1b4bee83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_372ab74a-562a-4d68-825a-b361189cfb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2ae297c5-8518-4437-b0c6-22bd1b4bee83" xlink:to="loc_us-gaap_NetIncomeLoss_372ab74a-562a-4d68-825a-b361189cfb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef43cc7f-1ece-46f7-95f3-7739b8b55fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2ae297c5-8518-4437-b0c6-22bd1b4bee83" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef43cc7f-1ece-46f7-95f3-7739b8b55fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_48bcce6e-ff17-4da5-8c77-6d1d63cd6e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef43cc7f-1ece-46f7-95f3-7739b8b55fb4" xlink:to="loc_us-gaap_ShareBasedCompensation_48bcce6e-ff17-4da5-8c77-6d1d63cd6e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1f3341a0-3abb-4863-b37b-87048d6f891e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef43cc7f-1ece-46f7-95f3-7739b8b55fb4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1f3341a0-3abb-4863-b37b-87048d6f891e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeReversal_a463c78e-dbb6-42b5-84a7-fa1b57bb338e" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseLeaseIncomeReversal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef43cc7f-1ece-46f7-95f3-7739b8b55fb4" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeReversal_a463c78e-dbb6-42b5-84a7-fa1b57bb338e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fa125213-17df-42fc-9bdf-cdeea302752e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef43cc7f-1ece-46f7-95f3-7739b8b55fb4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fa125213-17df-42fc-9bdf-cdeea302752e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7a979706-0c31-476b-bf31-b19125d3d7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef43cc7f-1ece-46f7-95f3-7739b8b55fb4" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7a979706-0c31-476b-bf31-b19125d3d7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0ff93fb5-dbb3-451b-ad23-1dcbb5af86e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef43cc7f-1ece-46f7-95f3-7739b8b55fb4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0ff93fb5-dbb3-451b-ad23-1dcbb5af86e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_dddbb4b6-8500-4616-b423-ecdfa91b640e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef43cc7f-1ece-46f7-95f3-7739b8b55fb4" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_dddbb4b6-8500-4616-b423-ecdfa91b640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e697e6eb-2a36-4055-a274-5b96009eea07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef43cc7f-1ece-46f7-95f3-7739b8b55fb4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e697e6eb-2a36-4055-a274-5b96009eea07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5ea67af8-952a-418d-821c-fdf8298aa182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e697e6eb-2a36-4055-a274-5b96009eea07" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5ea67af8-952a-418d-821c-fdf8298aa182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d40daa52-521a-4591-ba13-2154ae4ebb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e697e6eb-2a36-4055-a274-5b96009eea07" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d40daa52-521a-4591-ba13-2154ae4ebb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_18040d70-8a05-43d3-82ed-702de50e04d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e697e6eb-2a36-4055-a274-5b96009eea07" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_18040d70-8a05-43d3-82ed-702de50e04d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_380a32fb-ea3a-4c42-bb05-30f6248c4493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e697e6eb-2a36-4055-a274-5b96009eea07" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_380a32fb-ea3a-4c42-bb05-30f6248c4493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ff072b9c-1fec-4369-bc51-43b90b4e40ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e697e6eb-2a36-4055-a274-5b96009eea07" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ff072b9c-1fec-4369-bc51-43b90b4e40ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_5ca9193a-60c1-4b47-9a79-b40f51ca5f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e697e6eb-2a36-4055-a274-5b96009eea07" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_5ca9193a-60c1-4b47-9a79-b40f51ca5f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c4bde4ea-de98-410a-a12e-ac91a06de940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e697e6eb-2a36-4055-a274-5b96009eea07" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c4bde4ea-de98-410a-a12e-ac91a06de940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71d5eccd-4f6e-4bfc-8c1c-142410895f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2ae297c5-8518-4437-b0c6-22bd1b4bee83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71d5eccd-4f6e-4bfc-8c1c-142410895f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c1a31c22-3c20-4b2a-b5bc-8e3960c32c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e899bb88-ad46-42c5-8a3f-3bd2e1fb521e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c1a31c22-3c20-4b2a-b5bc-8e3960c32c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_caa411db-def7-4523-b3e7-421379852f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c1a31c22-3c20-4b2a-b5bc-8e3960c32c2a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_caa411db-def7-4523-b3e7-421379852f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_3d45ef12-6f27-4ad7-a877-e93e34919a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c1a31c22-3c20-4b2a-b5bc-8e3960c32c2a" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_3d45ef12-6f27-4ad7-a877-e93e34919a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aabacd6b-319a-4b36-a307-dc78d54ccf81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c1a31c22-3c20-4b2a-b5bc-8e3960c32c2a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aabacd6b-319a-4b36-a307-dc78d54ccf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_425979a5-de30-43cb-944f-2997c68df502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e899bb88-ad46-42c5-8a3f-3bd2e1fb521e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_425979a5-de30-43cb-944f-2997c68df502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5a3dc353-dff8-472f-b774-c34e4cbfadac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_425979a5-de30-43cb-944f-2997c68df502" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5a3dc353-dff8-472f-b774-c34e4cbfadac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_351c82a8-ba03-4caf-8d4f-27c77cb1221b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_425979a5-de30-43cb-944f-2997c68df502" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_351c82a8-ba03-4caf-8d4f-27c77cb1221b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_a123d389-391d-4c76-9d09-d6d2ce53af56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_425979a5-de30-43cb-944f-2997c68df502" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_a123d389-391d-4c76-9d09-d6d2ce53af56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_ab1aef43-a8cc-4f38-b6a3-b30831c882e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_425979a5-de30-43cb-944f-2997c68df502" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_ab1aef43-a8cc-4f38-b6a3-b30831c882e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5bf0e165-ba2c-4b6d-8511-1ef38d1d3602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_425979a5-de30-43cb-944f-2997c68df502" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5bf0e165-ba2c-4b6d-8511-1ef38d1d3602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_acdaf400-5e25-4470-8474-aaff5e09daf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_425979a5-de30-43cb-944f-2997c68df502" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_acdaf400-5e25-4470-8474-aaff5e09daf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_2a631855-e116-45e9-8ed0-ab6450e1eff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_425979a5-de30-43cb-944f-2997c68df502" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_2a631855-e116-45e9-8ed0-ab6450e1eff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4649c06c-e7a5-46a7-9137-a46979c259cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_425979a5-de30-43cb-944f-2997c68df502" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4649c06c-e7a5-46a7-9137-a46979c259cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_74204824-ad0e-4640-a410-93ba79d89944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e899bb88-ad46-42c5-8a3f-3bd2e1fb521e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_74204824-ad0e-4640-a410-93ba79d89944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b4a81816-4586-4e5b-bd9c-f34cb30dd7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e899bb88-ad46-42c5-8a3f-3bd2e1fb521e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b4a81816-4586-4e5b-bd9c-f34cb30dd7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_67ae61da-de95-43e9-92a2-3fdf4bca8bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e899bb88-ad46-42c5-8a3f-3bd2e1fb521e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_67ae61da-de95-43e9-92a2-3fdf4bca8bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f5b608f-822f-49b6-b61c-51a4d48bf98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e899bb88-ad46-42c5-8a3f-3bd2e1fb521e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f5b608f-822f-49b6-b61c-51a4d48bf98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ed97630-8f21-47bb-b047-ce1ac2f0f52e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e899bb88-ad46-42c5-8a3f-3bd2e1fb521e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ed97630-8f21-47bb-b047-ce1ac2f0f52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ba9e37d8-02c8-408d-ac78-0c4d74d985ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ed97630-8f21-47bb-b047-ce1ac2f0f52e" xlink:to="loc_us-gaap_InterestPaidNet_ba9e37d8-02c8-408d-ac78-0c4d74d985ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_21dda7f8-08de-4cf4-bfcd-5321f75782d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ed97630-8f21-47bb-b047-ce1ac2f0f52e" xlink:to="loc_us-gaap_IncomeTaxesPaid_21dda7f8-08de-4cf4-bfcd-5321f75782d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a3c404bd-3ee7-4d53-9922-a4dc3aa7a134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e899bb88-ad46-42c5-8a3f-3bd2e1fb521e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a3c404bd-3ee7-4d53-9922-a4dc3aa7a134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6393fc3-6d91-4800-8c83-88a0786ca40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a3c404bd-3ee7-4d53-9922-a4dc3aa7a134" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c6393fc3-6d91-4800-8c83-88a0786ca40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_7446bc23-e6d3-4819-b162-ba1001260ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e899bb88-ad46-42c5-8a3f-3bd2e1fb521e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_7446bc23-e6d3-4819-b162-ba1001260ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b81fb208-d6ec-4c50-bd9c-4ac68c81203e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_7446bc23-e6d3-4819-b162-ba1001260ec3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b81fb208-d6ec-4c50-bd9c-4ac68c81203e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_c8ab0d3d-507b-41f1-bee0-ac7aebc2fa30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_7446bc23-e6d3-4819-b162-ba1001260ec3" xlink:to="loc_us-gaap_RestrictedCashCurrent_c8ab0d3d-507b-41f1-bee0-ac7aebc2fa30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf91f748-1d56-4985-9c2e-2262464b012e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_7446bc23-e6d3-4819-b162-ba1001260ec3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf91f748-1d56-4985-9c2e-2262464b012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_146a51b8-5a0c-4a5b-a47b-231af53f43db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4f3e544e-2213-4290-9ae6-df4b499d87fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_146a51b8-5a0c-4a5b-a47b-231af53f43db" xlink:to="loc_us-gaap_StatementTable_4f3e544e-2213-4290-9ae6-df4b499d87fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d8e6499d-6a57-4ddd-a896-2d4a6d31f502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4f3e544e-2213-4290-9ae6-df4b499d87fe" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d8e6499d-6a57-4ddd-a896-2d4a6d31f502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d8e6499d-6a57-4ddd-a896-2d4a6d31f502" xlink:to="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_76c3564d-bd8f-4248-99ad-635f49644aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:to="loc_us-gaap_CommonStockMember_76c3564d-bd8f-4248-99ad-635f49644aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_67c84a77-f5d8-4b97-b2ae-964a93cd9387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_67c84a77-f5d8-4b97-b2ae-964a93cd9387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_dfe7c2ff-d180-4917-875d-496227f9373b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_dfe7c2ff-d180-4917-875d-496227f9373b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0d191963-110e-495f-a5fa-a0f66f979fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0d191963-110e-495f-a5fa-a0f66f979fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6213bf20-247d-4f2a-9b94-3aa09c839404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_05f42423-b0f1-4d75-86f2-77578bae7dd6" xlink:to="loc_us-gaap_RetainedEarningsMember_6213bf20-247d-4f2a-9b94-3aa09c839404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b8a3d055-1a3d-4123-a129-802a0e844471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4f3e544e-2213-4290-9ae6-df4b499d87fe" xlink:to="loc_us-gaap_StatementLineItems_b8a3d055-1a3d-4123-a129-802a0e844471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b8a3d055-1a3d-4123-a129-802a0e844471" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fec1c488-b2e7-44ba-af21-e8c07823c0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fec1c488-b2e7-44ba-af21-e8c07823c0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ef6fc29c-1d5e-4555-9229-7dfc0c9c0a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_StockholdersEquity_ef6fc29c-1d5e-4555-9229-7dfc0c9c0a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_62b54905-1095-44d6-8aa0-564f0a499bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_TreasuryStockCommonShares_62b54905-1095-44d6-8aa0-564f0a499bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7c6021d6-28fb-4365-be13-7eac91269454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7c6021d6-28fb-4365-be13-7eac91269454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_718e12dd-a419-488d-8ff6-83e2650dc736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_718e12dd-a419-488d-8ff6-83e2650dc736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6488b1c1-eefb-4e7b-871e-ba179ab84f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_NetIncomeLoss_6488b1c1-eefb-4e7b-871e-ba179ab84f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_1414da38-a590-4e9c-a871-97370c243ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_1414da38-a590-4e9c-a871-97370c243ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_4d2ee8d5-82cb-4eef-bb78-b71c3d4b0ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_4d2ee8d5-82cb-4eef-bb78-b71c3d4b0ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_88c68af3-2830-4a07-8042-1be4cb6136dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_88c68af3-2830-4a07-8042-1be4cb6136dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7272577d-5671-46bd-bbe0-afde4c6ea23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7272577d-5671-46bd-bbe0-afde4c6ea23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_4365f811-6905-4033-8e95-ac8f5eab7b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_TreasuryStockCommonShares_4365f811-6905-4033-8e95-ac8f5eab7b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_954d4f73-ce0c-4378-8559-5cc26cab21d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9c26d2d3-587f-432f-9821-89ad1e01de57" xlink:to="loc_us-gaap_StockholdersEquity_954d4f73-ce0c-4378-8559-5cc26cab21d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ebs-20220930.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_cc10c75a-8157-4a91-8506-76a8be9510f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9a3885e5-19c4-4453-9f60-67524740989d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_cc10c75a-8157-4a91-8506-76a8be9510f2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9a3885e5-19c4-4453-9f60-67524740989d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Business" xlink:type="simple" xlink:href="ebs-20220930.xsd#Business"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Business" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2694221b-ebcb-49af-b41f-e04214a7c8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f010f241-403d-4a2a-8632-47dcf397a500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2694221b-ebcb-49af-b41f-e04214a7c8aa" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f010f241-403d-4a2a-8632-47dcf397a500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation" xlink:type="simple" xlink:href="ebs-20220930.xsd#Basisofpresentationandprinciplesofconsolidation"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6e5bdc8f-5661-4637-b1db-2e2d73b3e022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6be09308-fa4b-49ee-9f68-05287521f091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e5bdc8f-5661-4637-b1db-2e2d73b3e022" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6be09308-fa4b-49ee-9f68-05287521f091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Inventoriesnet" xlink:type="simple" xlink:href="ebs-20220930.xsd#Inventoriesnet"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Inventoriesnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e4d79b66-c8d8-479f-8b86-e6d6fee5a5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_32a13fe9-c05e-4010-8bc9-41025f115bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e4d79b66-c8d8-479f-8b86-e6d6fee5a5fa" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_32a13fe9-c05e-4010-8bc9-41025f115bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet" xlink:type="simple" xlink:href="ebs-20220930.xsd#Propertyplantandequipmentnet"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_17c07a10-3dcd-4028-9df3-1d5b0d935cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_daafb001-5a53-4490-a75c-92c287d3b591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_17c07a10-3dcd-4028-9df3-1d5b0d935cff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_daafb001-5a53-4490-a75c-92c287d3b591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Leases" xlink:type="simple" xlink:href="ebs-20220930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_656af62a-61e4-483d-998c-cd025f558d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_bbe2e555-1f1a-4942-924d-497bd2982f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_656af62a-61e4-483d-998c-cd025f558d8a" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_bbe2e555-1f1a-4942-924d-497bd2982f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Intangibleassets" xlink:type="simple" xlink:href="ebs-20220930.xsd#Intangibleassets"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Intangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6d4aea3c-c49b-4b5f-b77a-a087a56733c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b9e65efb-1c3d-48d1-be44-049432db0fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6d4aea3c-c49b-4b5f-b77a-a087a56733c0" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b9e65efb-1c3d-48d1-be44-049432db0fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Fairvaluemeasurements" xlink:type="simple" xlink:href="ebs-20220930.xsd#Fairvaluemeasurements"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Fairvaluemeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9044ff1d-dc50-4fdb-8105-6b1b3b659f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1ba9b938-a3a1-446f-bce2-328823477a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9044ff1d-dc50-4fdb-8105-6b1b3b659f3e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1ba9b938-a3a1-446f-bce2-328823477a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities" xlink:type="simple" xlink:href="ebs-20220930.xsd#Derivativeinstrumentsandhedgingactivities"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cbe4faf4-0dc5-4655-9d85-260d3c5dd402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_38d53ab2-c737-4185-a3bf-7298a23d270e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_cbe4faf4-0dc5-4655-9d85-260d3c5dd402" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_38d53ab2-c737-4185-a3bf-7298a23d270e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Debt" xlink:type="simple" xlink:href="ebs-20220930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_111403a0-145e-4835-abf8-8988f1f7e2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_61da7827-2696-44df-a668-bcdd0461a4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_111403a0-145e-4835-abf8-8988f1f7e2d1" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_61da7827-2696-44df-a668-bcdd0461a4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61a00c11-941c-44d1-b32b-c5aad757a5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_74150edd-d8af-47f8-87af-958fa71cdbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61a00c11-941c-44d1-b32b-c5aad757a5fe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_74150edd-d8af-47f8-87af-958fa71cdbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Incometaxes" xlink:type="simple" xlink:href="ebs-20220930.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b9471d6b-32e8-42a6-ad7f-b07b6c6f787d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_af0ae08f-efce-407b-9a05-60153b5c9d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b9471d6b-32e8-42a6-ad7f-b07b6c6f787d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_af0ae08f-efce-407b-9a05-60153b5c9d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershare" xlink:type="simple" xlink:href="ebs-20220930.xsd#NetIncomelosspershare"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NetIncomelosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f16468b7-367e-4f51-9d9b-96bf83ea26a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f2a2787d-93ae-4293-9e25-0c708ad559ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f16468b7-367e-4f51-9d9b-96bf83ea26a4" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f2a2787d-93ae-4293-9e25-0c708ad559ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Equity" xlink:type="simple" xlink:href="ebs-20220930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6f9ec6d3-5318-4c3d-86f2-61953672c70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ea3c7c58-e805-45ad-9a8e-493a15f4d1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6f9ec6d3-5318-4c3d-86f2-61953672c70f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ea3c7c58-e805-45ad-9a8e-493a15f4d1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformation" xlink:type="simple" xlink:href="ebs-20220930.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_68bcf461-b031-4f3f-9ba1-456980d8d674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_27331ff5-5d2a-4e98-bbc7-22baa2f20643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_68bcf461-b031-4f3f-9ba1-456980d8d674" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_27331ff5-5d2a-4e98-bbc7-22baa2f20643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ebs-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a314649-348d-4250-be43-e908f5a8e566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_9cd9886c-64de-4a8e-b4d5-87c546b35ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1a314649-348d-4250-be43-e908f5a8e566" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_9cd9886c-64de-4a8e-b4d5-87c546b35ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies" xlink:type="simple" xlink:href="ebs-20220930.xsd#BasisofpresentationandprinciplesofconsolidationPolicies"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_175cdfa5-7c5e-4e95-95f2-23b648137334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f6497f94-a362-431f-a4cb-81286b65170f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_175cdfa5-7c5e-4e95-95f2-23b648137334" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f6497f94-a362-431f-a4cb-81286b65170f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_03fda638-b6e9-4d05-9ff6-31f85b44f176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_175cdfa5-7c5e-4e95-95f2-23b648137334" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_03fda638-b6e9-4d05-9ff6-31f85b44f176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55c65425-aebd-4785-b262-04a925aa53ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_175cdfa5-7c5e-4e95-95f2-23b648137334" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55c65425-aebd-4785-b262-04a925aa53ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_1e4d8419-108c-4674-b132-0c4cc0b6c749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_175cdfa5-7c5e-4e95-95f2-23b648137334" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_1e4d8419-108c-4674-b132-0c4cc0b6c749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8a8669a2-7cd1-4682-b5c5-e34fba8c62c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_175cdfa5-7c5e-4e95-95f2-23b648137334" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8a8669a2-7cd1-4682-b5c5-e34fba8c62c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetTables" xlink:type="simple" xlink:href="ebs-20220930.xsd#InventoriesnetTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8098da09-dd5d-4925-a966-5aa6504540d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_31a0a3a2-af90-4972-b0a9-a8d45a708040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8098da09-dd5d-4925-a966-5aa6504540d8" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_31a0a3a2-af90-4972-b0a9-a8d45a708040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables" xlink:type="simple" xlink:href="ebs-20220930.xsd#PropertyplantandequipmentnetTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_0c6efe3d-aa73-4d9e-bbe7-cea10471f1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f3de189d-4d95-4668-9498-4a19bf255724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_0c6efe3d-aa73-4d9e-bbe7-cea10471f1e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f3de189d-4d95-4668-9498-4a19bf255724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="simple" xlink:href="ebs-20220930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_19df859d-6cf6-443b-8757-0c7479b638f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_a32d25e0-a82a-48d7-9dca-de6a6cc48db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19df859d-6cf6-443b-8757-0c7479b638f7" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_a32d25e0-a82a-48d7-9dca-de6a6cc48db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_72b15e4a-81f2-4845-a91c-aeb5ad806981" xlink:href="ebs-20220930.xsd#ebs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19df859d-6cf6-443b-8757-0c7479b638f7" xlink:to="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_72b15e4a-81f2-4845-a91c-aeb5ad806981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsTables" xlink:type="simple" xlink:href="ebs-20220930.xsd#IntangibleassetsTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_129a3fb3-72fd-4821-ab1e-891ae70ca558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ca5e2ac2-ab2f-4f13-8f42-3c7a22103ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_129a3fb3-72fd-4821-ab1e-891ae70ca558" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ca5e2ac2-ab2f-4f13-8f42-3c7a22103ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_c01ff55d-ee4d-4484-a077-842d8b46ae47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_129a3fb3-72fd-4821-ab1e-891ae70ca558" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_c01ff55d-ee4d-4484-a077-842d8b46ae47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_8ef85b09-374e-4409-9908-1b0d794ed1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_129a3fb3-72fd-4821-ab1e-891ae70ca558" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_8ef85b09-374e-4409-9908-1b0d794ed1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables" xlink:type="simple" xlink:href="ebs-20220930.xsd#FairvaluemeasurementsTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e2387c31-1463-47b9-a600-5a8eed61c7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_38a773e4-84b6-4c3a-8b50-904e2a70ca25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e2387c31-1463-47b9-a600-5a8eed61c7c5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_38a773e4-84b6-4c3a-8b50-904e2a70ca25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c68b9dd3-2604-494d-83ac-3ba0d388cc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e2387c31-1463-47b9-a600-5a8eed61c7c5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c68b9dd3-2604-494d-83ac-3ba0d388cc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ae24686e-7778-46a6-97c9-351dfe3ff773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e2387c31-1463-47b9-a600-5a8eed61c7c5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ae24686e-7778-46a6-97c9-351dfe3ff773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables" xlink:type="simple" xlink:href="ebs-20220930.xsd#DerivativeinstrumentsandhedgingactivitiesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c9d4c50f-84ec-460d-8403-b426e8b720b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_a72798cc-3797-43ea-9eb2-c2b24c6d760f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c9d4c50f-84ec-460d-8403-b426e8b720b9" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_a72798cc-3797-43ea-9eb2-c2b24c6d760f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_a9c7f195-e8dd-4183-9245-b7ea06d9ed2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c9d4c50f-84ec-460d-8403-b426e8b720b9" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_a9c7f195-e8dd-4183-9245-b7ea06d9ed2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_b0e456ac-76df-4c98-8d1a-3cf788149470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c9d4c50f-84ec-460d-8403-b426e8b720b9" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_b0e456ac-76df-4c98-8d1a-3cf788149470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTables" xlink:type="simple" xlink:href="ebs-20220930.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_78222fd1-4534-4b2b-b878-5e88a6be6bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_d3532c3e-d2b8-42f5-8fcf-5afddfdf65c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_78222fd1-4534-4b2b-b878-5e88a6be6bb1" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_d3532c3e-d2b8-42f5-8fcf-5afddfdf65c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_99b77c00-b054-443c-a4f5-81d2bafd1f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1d6b00e4-44dd-496e-97f3-db8a35a77928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_99b77c00-b054-443c-a4f5-81d2bafd1f6c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1d6b00e4-44dd-496e-97f3-db8a35a77928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_bda55250-d984-413c-a47b-376c5a0862ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_99b77c00-b054-443c-a4f5-81d2bafd1f6c" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_bda55250-d984-413c-a47b-376c5a0862ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_1d29c262-0795-40d0-a94e-588222d662d7" xlink:href="ebs-20220930.xsd#ebs_ScheduleOfAccountsReceivableNetTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_99b77c00-b054-443c-a4f5-81d2bafd1f6c" xlink:to="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_1d29c262-0795-40d0-a94e-588222d662d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershareTables" xlink:type="simple" xlink:href="ebs-20220930.xsd#NetIncomelosspershareTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NetIncomelosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_08a11096-8d45-4f32-8090-3d4d72c20b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ae957afe-56ad-4abd-a52e-f2f948480a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08a11096-8d45-4f32-8090-3d4d72c20b0a" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ae957afe-56ad-4abd-a52e-f2f948480a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3498fd86-569a-4041-a3bd-0b854ee8f599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_08a11096-8d45-4f32-8090-3d4d72c20b0a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3498fd86-569a-4041-a3bd-0b854ee8f599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityTables" xlink:type="simple" xlink:href="ebs-20220930.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_3dec4f3c-153f-41a5-b4ce-b2232c017898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b1a451af-3900-4ec0-a86a-c6321e10c2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3dec4f3c-153f-41a5-b4ce-b2232c017898" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b1a451af-3900-4ec0-a86a-c6321e10c2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_afc326a9-d71b-4947-9eb1-c4bd3420fa34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3dec4f3c-153f-41a5-b4ce-b2232c017898" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_afc326a9-d71b-4947-9eb1-c4bd3420fa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_ed206250-1f5f-46b5-8e3c-a5110afe0693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3dec4f3c-153f-41a5-b4ce-b2232c017898" xlink:to="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_ed206250-1f5f-46b5-8e3c-a5110afe0693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="ebs-20220930.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d2e4aa5f-ba09-40d3-b632-2a7f035f7e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_82714718-a094-48e5-8269-97d28b2f19c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2e4aa5f-ba09-40d3-b632-2a7f035f7e6a" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_82714718-a094-48e5-8269-97d28b2f19c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_cd74c465-47b2-4157-a685-cb8c83b4b95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2e4aa5f-ba09-40d3-b632-2a7f035f7e6a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_cd74c465-47b2-4157-a685-cb8c83b4b95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#BusinessDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3140c82-d13a-4c17-bfcd-6af89578ae01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_38ee37e4-6fae-4e73-a417-11f179503714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3140c82-d13a-4c17-bfcd-6af89578ae01" xlink:to="loc_us-gaap_AssetAcquisitionTable_38ee37e4-6fae-4e73-a417-11f179503714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_69442078-7777-4f00-b176-a6af34117ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_38ee37e4-6fae-4e73-a417-11f179503714" xlink:to="loc_us-gaap_AssetAcquisitionAxis_69442078-7777-4f00-b176-a6af34117ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b4610072-93d0-4ea3-a4ab-0ea47c20998e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_69442078-7777-4f00-b176-a6af34117ec3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b4610072-93d0-4ea3-a4ab-0ea47c20998e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixAssetAcquisitionMember_af712bbc-7c54-4f82-a418-073694ce91dd" xlink:href="ebs-20220930.xsd#ebs_ChimerixAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b4610072-93d0-4ea3-a4ab-0ea47c20998e" xlink:to="loc_ebs_ChimerixAssetAcquisitionMember_af712bbc-7c54-4f82-a418-073694ce91dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_da7e0bf6-6999-493b-ac7a-b01cdc83867f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_38ee37e4-6fae-4e73-a417-11f179503714" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_da7e0bf6-6999-493b-ac7a-b01cdc83867f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0fa5304f-b99b-4a85-ac13-f85dc95ac6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_da7e0bf6-6999-493b-ac7a-b01cdc83867f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0fa5304f-b99b-4a85-ac13-f85dc95ac6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentsMember_faba06e1-aa89-4f35-ae0b-812941691274" xlink:href="ebs-20220930.xsd#ebs_MilestonePaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0fa5304f-b99b-4a85-ac13-f85dc95ac6fa" xlink:to="loc_ebs_MilestonePaymentsMember_faba06e1-aa89-4f35-ae0b-812941691274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RegulatoryMilestonesMember_84b724db-45ec-4eda-9c8a-bd21f5a171f2" xlink:href="ebs-20220930.xsd#ebs_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0fa5304f-b99b-4a85-ac13-f85dc95ac6fa" xlink:to="loc_ebs_RegulatoryMilestonesMember_84b724db-45ec-4eda-9c8a-bd21f5a171f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_38ee37e4-6fae-4e73-a417-11f179503714" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_efb8924a-4f98-42f5-a8b6-d0097dc1f73e" xlink:href="ebs-20220930.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_efb8924a-4f98-42f5-a8b6-d0097dc1f73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts_c407b90f-265e-42eb-83f2-7065c08422f6" xlink:href="ebs-20220930.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_NumberOfRevenueGeneratingProducts_c407b90f-265e-42eb-83f2-7065c08422f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductCandidates_08e605aa-2e22-4fc7-ab1f-1285fda38c72" xlink:href="ebs-20220930.xsd#ebs_NumberOfProductCandidates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_NumberOfProductCandidates_08e605aa-2e22-4fc7-ab1f-1285fda38c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfBusinessLines_2d2dbdb9-1292-49e3-ad4d-833bc63be5c2" xlink:href="ebs-20220930.xsd#ebs_NumberOfBusinessLines"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_NumberOfBusinessLines_2d2dbdb9-1292-49e3-ad4d-833bc63be5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a5679677-834d-427f-828c-adf8624d9f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a5679677-834d-427f-828c-adf8624d9f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_952af7c2-8d48-488f-a574-1e7136d73f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_952af7c2-8d48-488f-a574-1e7136d73f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_deb87e9e-dfcc-4df8-90c7-ef312f6f4794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_deb87e9e-dfcc-4df8-90c7-ef312f6f4794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_2a54c419-5dc7-4740-8455-6ab77044ed4e" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_2a54c419-5dc7-4740-8455-6ab77044ed4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionTreatmentVolumeThreshold_729bd640-7b60-4788-b6a4-750635106b10" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionTreatmentVolumeThreshold"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_AssetAcquisitionTreatmentVolumeThreshold_729bd640-7b60-4788-b6a4-750635106b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_2c2f0323-f040-4daa-bb85-2257335b444a" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_05d31285-37d4-4a42-a0c3-071d351c331a" xlink:to="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_2c2f0323-f040-4daa-bb85-2257335b444a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#BasisofpresentationandprinciplesofconsolidationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d517861-ff9c-430c-afac-787f1fb39be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b44d8f90-5801-42a9-a314-c7fee5baad9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d517861-ff9c-430c-afac-787f1fb39be7" xlink:to="loc_us-gaap_DebtInstrumentTable_b44d8f90-5801-42a9-a314-c7fee5baad9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ad4bbb77-e068-420c-9aa7-c0e1fa672abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b44d8f90-5801-42a9-a314-c7fee5baad9e" xlink:to="loc_us-gaap_CreditFacilityAxis_ad4bbb77-e068-420c-9aa7-c0e1fa672abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_139c73ae-7fcb-4313-b656-6964f61d2579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ad4bbb77-e068-420c-9aa7-c0e1fa672abf" xlink:to="loc_us-gaap_CreditFacilityDomain_139c73ae-7fcb-4313-b656-6964f61d2579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_00c536d5-f83e-4139-a465-9d216f39477d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_139c73ae-7fcb-4313-b656-6964f61d2579" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_00c536d5-f83e-4139-a465-9d216f39477d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e30ee17e-c118-48d2-ac60-90a9cb96bf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b44d8f90-5801-42a9-a314-c7fee5baad9e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e30ee17e-c118-48d2-ac60-90a9cb96bf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9752d76b-c563-4cde-9deb-50ec6dc9249d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e30ee17e-c118-48d2-ac60-90a9cb96bf1b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9752d76b-c563-4cde-9deb-50ec6dc9249d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_cc380e20-38da-4d5d-b880-f7b22ab31e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9752d76b-c563-4cde-9deb-50ec6dc9249d" xlink:to="loc_us-gaap_LineOfCreditMember_cc380e20-38da-4d5d-b880-f7b22ab31e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_6752d237-7820-4c88-806a-ed01af5e8fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9752d76b-c563-4cde-9deb-50ec6dc9249d" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_6752d237-7820-4c88-806a-ed01af5e8fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8900a402-f8a1-4e2e-9900-f342bea970e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b44d8f90-5801-42a9-a314-c7fee5baad9e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8900a402-f8a1-4e2e-9900-f342bea970e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_db965c81-0c4e-4762-8b27-a80957c0325f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8900a402-f8a1-4e2e-9900-f342bea970e2" xlink:to="loc_us-gaap_LongTermDebt_db965c81-0c4e-4762-8b27-a80957c0325f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e81a28c2-7b72-4419-97a1-3e21f618e6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8900a402-f8a1-4e2e-9900-f342bea970e2" xlink:to="loc_us-gaap_NumberOfReportableSegments_e81a28c2-7b72-4419-97a1-3e21f618e6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#InventoriesnetScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_cfe0a8a3-0914-4c40-a125-030a1ba40672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_d69c3f3e-6c1e-4cca-8f62-fbbec264c39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_cfe0a8a3-0914-4c40-a125-030a1ba40672" xlink:to="loc_us-gaap_InventoryCurrentTable_d69c3f3e-6c1e-4cca-8f62-fbbec264c39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_41d5669a-920d-48a0-bfae-5d408edef6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_d69c3f3e-6c1e-4cca-8f62-fbbec264c39a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_41d5669a-920d-48a0-bfae-5d408edef6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_43a10d79-4d3a-4469-bce4-881ec6edcfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_41d5669a-920d-48a0-bfae-5d408edef6ad" xlink:to="loc_us-gaap_AssetAcquisitionDomain_43a10d79-4d3a-4469-bce4-881ec6edcfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixAssetAcquisitionMember_4442b710-d602-4cd0-8905-8b1068832909" xlink:href="ebs-20220930.xsd#ebs_ChimerixAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_43a10d79-4d3a-4469-bce4-881ec6edcfc1" xlink:to="loc_ebs_ChimerixAssetAcquisitionMember_4442b710-d602-4cd0-8905-8b1068832909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_d69c3f3e-6c1e-4cca-8f62-fbbec264c39a" xlink:to="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_b625c64b-c77b-4790-a9c0-a2b99a2ec93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_b625c64b-c77b-4790-a9c0-a2b99a2ec93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4519a786-8b9b-4904-91a8-2908e03e056b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4519a786-8b9b-4904-91a8-2908e03e056b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7a5cb4d7-1d38-4e8a-8de2-1cab0ee21ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7a5cb4d7-1d38-4e8a-8de2-1cab0ee21ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_88c678ef-cd6d-463b-b02b-9403301b0372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:to="loc_us-gaap_InventoryNet_88c678ef-cd6d-463b-b02b-9403301b0372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0e203748-f891-408a-862b-3cf037dfcd2e" xlink:href="ebs-20220930.xsd#ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_e8a888bb-cb0a-4a56-802c-3894d75cd970" xlink:to="loc_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0e203748-f891-408a-862b-3cf037dfcd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_c5958474-b978-4116-994f-70d5561a9348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e935cd1f-bb1c-4dbd-bff9-2cdc218e92e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_c5958474-b978-4116-994f-70d5561a9348" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e935cd1f-bb1c-4dbd-bff9-2cdc218e92e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_557d7982-8a21-416f-a89d-c57cf7f91255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e935cd1f-bb1c-4dbd-bff9-2cdc218e92e7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_557d7982-8a21-416f-a89d-c57cf7f91255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_557d7982-8a21-416f-a89d-c57cf7f91255" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_6a1f5f3a-7ec1-4fe4-974f-26268885b5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_6a1f5f3a-7ec1-4fe4-974f-26268885b5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_03f2da86-5593-4bf9-9823-738698865a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_03f2da86-5593-4bf9-9823-738698865a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_faf7dcfd-cac4-45ab-ba35-4977565cf336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_faf7dcfd-cac4-45ab-ba35-4977565cf336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_17849764-4134-4f22-8079-b7c6f8d7f55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_17849764-4134-4f22-8079-b7c6f8d7f55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_36fda13a-86d1-444f-9a29-7339dfe86d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5203cbb9-8e13-45c1-ac25-066ee0f7a906" xlink:to="loc_us-gaap_ConstructionInProgressMember_36fda13a-86d1-444f-9a29-7339dfe86d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d19a0c89-c1f1-4edc-951c-10ffa8695a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e935cd1f-bb1c-4dbd-bff9-2cdc218e92e7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d19a0c89-c1f1-4edc-951c-10ffa8695a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bc238177-bd72-4454-b158-22089f45b376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d19a0c89-c1f1-4edc-951c-10ffa8695a57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bc238177-bd72-4454-b158-22089f45b376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bcbcc890-7d44-4a02-bbf8-227373c4f539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bc238177-bd72-4454-b158-22089f45b376" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bcbcc890-7d44-4a02-bbf8-227373c4f539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_96df4cb6-6518-461d-b27e-9d21fa8caf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bc238177-bd72-4454-b158-22089f45b376" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_96df4cb6-6518-461d-b27e-9d21fa8caf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f5e6e349-31f3-4a88-849e-a6bdabb74083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bc238177-bd72-4454-b158-22089f45b376" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f5e6e349-31f3-4a88-849e-a6bdabb74083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#PropertyplantandequipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6fc7f527-bebc-46cf-a45e-7c9c2771b7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6346fe0d-82ab-42e6-9652-e98acd7e8a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6fc7f527-bebc-46cf-a45e-7c9c2771b7c5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6346fe0d-82ab-42e6-9652-e98acd7e8a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dba6147e-5d0d-4180-aeac-a4e7bee6f8a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6346fe0d-82ab-42e6-9652-e98acd7e8a43" xlink:to="loc_srt_MajorCustomersAxis_dba6147e-5d0d-4180-aeac-a4e7bee6f8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3bec2369-d6d4-4ef5-ba25-5184137011f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_dba6147e-5d0d-4180-aeac-a4e7bee6f8a7" xlink:to="loc_srt_NameOfMajorCustomerDomain_3bec2369-d6d4-4ef5-ba25-5184137011f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_72bfaee5-0d98-43f3-aa78-cb7f3a2b8e89" xlink:href="ebs-20220930.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3bec2369-d6d4-4ef5-ba25-5184137011f2" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_72bfaee5-0d98-43f3-aa78-cb7f3a2b8e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d00fd157-58ef-4a3f-b505-74197c61c2cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6346fe0d-82ab-42e6-9652-e98acd7e8a43" xlink:to="loc_srt_ProductOrServiceAxis_d00fd157-58ef-4a3f-b505-74197c61c2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2ff3465e-7d51-48cc-8609-0a8fb39f10fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d00fd157-58ef-4a3f-b505-74197c61c2cc" xlink:to="loc_srt_ProductsAndServicesDomain_2ff3465e-7d51-48cc-8609-0a8fb39f10fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_bd5ae794-182e-44f6-99fd-09d837e29a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ff3465e-7d51-48cc-8609-0a8fb39f10fa" xlink:to="loc_us-gaap_ServiceMember_bd5ae794-182e-44f6-99fd-09d837e29a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_df6d2a88-1d62-4ce1-8669-9bd5c047bf87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6346fe0d-82ab-42e6-9652-e98acd7e8a43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_df6d2a88-1d62-4ce1-8669-9bd5c047bf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3698b52b-b8af-4fb7-9ffc-d31509918260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_df6d2a88-1d62-4ce1-8669-9bd5c047bf87" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3698b52b-b8af-4fb7-9ffc-d31509918260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9c300d7c-2ea9-4733-8fd3-3dc6b33a75da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_6f206df1-9e15-4b23-afa5-6f31ba98e214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c300d7c-2ea9-4733-8fd3-3dc6b33a75da" xlink:to="loc_us-gaap_LeaseCostAbstract_6f206df1-9e15-4b23-afa5-6f31ba98e214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f3655d6c-cf8e-4d1a-b327-fca96c604be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_6f206df1-9e15-4b23-afa5-6f31ba98e214" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f3655d6c-cf8e-4d1a-b327-fca96c604be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_4c3a862e-7d0b-436c-849e-75a372bfa311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_6f206df1-9e15-4b23-afa5-6f31ba98e214" xlink:to="loc_us-gaap_OperatingLeaseExpense_4c3a862e-7d0b-436c-849e-75a372bfa311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_277bac1f-c817-403e-9d73-631e40758967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_6f206df1-9e15-4b23-afa5-6f31ba98e214" xlink:to="loc_us-gaap_LeaseCost_277bac1f-c817-403e-9d73-631e40758967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2273df97-d461-496d-8967-963f5aab76dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59b38253-31b7-4494-bcae-40b49afa18cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2273df97-d461-496d-8967-963f5aab76dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59b38253-31b7-4494-bcae-40b49afa18cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c450b606-9945-44f4-a1fe-96d01e6ec021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59b38253-31b7-4494-bcae-40b49afa18cf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_c450b606-9945-44f4-a1fe-96d01e6ec021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c3996179-8426-4d8a-9e16-04e905ba51bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59b38253-31b7-4494-bcae-40b49afa18cf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c3996179-8426-4d8a-9e16-04e905ba51bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ebb196bf-7b39-406a-8d47-1c8ba11cb7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59b38253-31b7-4494-bcae-40b49afa18cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ebb196bf-7b39-406a-8d47-1c8ba11cb7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3287a81b-861e-438e-88ea-5e83b2d05a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59b38253-31b7-4494-bcae-40b49afa18cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3287a81b-861e-438e-88ea-5e83b2d05a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_c6b7e9c5-cea9-43af-b267-4bf124accae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59b38253-31b7-4494-bcae-40b49afa18cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_c6b7e9c5-cea9-43af-b267-4bf124accae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_71746d8e-7673-4c2d-8bd7-321143cb5d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59b38253-31b7-4494-bcae-40b49afa18cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_71746d8e-7673-4c2d-8bd7-321143cb5d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d8538e57-16c3-44df-86f2-7b72dab76f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59b38253-31b7-4494-bcae-40b49afa18cf" xlink:to="loc_us-gaap_OperatingLeaseLiability_d8538e57-16c3-44df-86f2-7b72dab76f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_33c5bff6-f3e0-418e-a8bb-b9ddf3e255b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2273df97-d461-496d-8967-963f5aab76dc" xlink:to="loc_us-gaap_LeaseCostAbstract_33c5bff6-f3e0-418e-a8bb-b9ddf3e255b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_84e7a757-026b-4e2e-8b6c-07234bce67ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_33c5bff6-f3e0-418e-a8bb-b9ddf3e255b1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_84e7a757-026b-4e2e-8b6c-07234bce67ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_05051565-4b00-4a7e-a59d-8415ac6fca98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_33c5bff6-f3e0-418e-a8bb-b9ddf3e255b1" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_05051565-4b00-4a7e-a59d-8415ac6fca98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a148dd26-d588-44d3-9d21-9f7c7417f25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3f3c04f7-6425-4b77-a114-656fc1fa4f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a148dd26-d588-44d3-9d21-9f7c7417f25e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3f3c04f7-6425-4b77-a114-656fc1fa4f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_895d4495-3877-4e75-9834-636214f88aab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3f3c04f7-6425-4b77-a114-656fc1fa4f70" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_895d4495-3877-4e75-9834-636214f88aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_71975733-4b36-4c3a-8d3f-a358c7e6511f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_895d4495-3877-4e75-9834-636214f88aab" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_71975733-4b36-4c3a-8d3f-a358c7e6511f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RockvilleManufacturingFacilityMember_73d25fb6-4716-4062-9150-952784b02063" xlink:href="ebs-20220930.xsd#ebs_RockvilleManufacturingFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_71975733-4b36-4c3a-8d3f-a358c7e6511f" xlink:to="loc_ebs_RockvilleManufacturingFacilityMember_73d25fb6-4716-4062-9150-952784b02063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_760c41e5-77c5-41a3-9ec5-f9a48918a6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3f3c04f7-6425-4b77-a114-656fc1fa4f70" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_760c41e5-77c5-41a3-9ec5-f9a48918a6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseRightOfUseAssetRemoval_c4672225-249c-4ce5-90b0-cc4fea3e4504" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseRightOfUseAssetRemoval"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_760c41e5-77c5-41a3-9ec5-f9a48918a6d5" xlink:to="loc_ebs_OperatingLeaseRightOfUseAssetRemoval_c4672225-249c-4ce5-90b0-cc4fea3e4504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ecc6e117-9533-4a39-837a-cf31faf32578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_760c41e5-77c5-41a3-9ec5-f9a48918a6d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ecc6e117-9533-4a39-837a-cf31faf32578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_645666fc-d6dc-469d-92cb-ee226780f6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e2461e71-1453-456a-9105-0d6e4a2da9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_645666fc-d6dc-469d-92cb-ee226780f6da" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e2461e71-1453-456a-9105-0d6e4a2da9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5255466-1c24-4341-88b2-34c161ae5ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e2461e71-1453-456a-9105-0d6e4a2da9fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5255466-1c24-4341-88b2-34c161ae5ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4d15035-22de-4677-8bae-ca490afae763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d5255466-1c24-4341-88b2-34c161ae5ac7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4d15035-22de-4677-8bae-ca490afae763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_38e4f3bf-9b50-4b90-a693-b121d30e839c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4d15035-22de-4677-8bae-ca490afae763" xlink:to="loc_us-gaap_ProductMember_38e4f3bf-9b50-4b90-a693-b121d30e839c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_3c6315c6-902c-478f-97c1-533769ccdbff" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4d15035-22de-4677-8bae-ca490afae763" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_3c6315c6-902c-478f-97c1-533769ccdbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_16b8ab4b-76d8-4bf0-a07b-89495972f62f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e2461e71-1453-456a-9105-0d6e4a2da9fc" xlink:to="loc_srt_RangeAxis_16b8ab4b-76d8-4bf0-a07b-89495972f62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_342cec81-7e34-42b0-9bea-5f0c391f9107" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_16b8ab4b-76d8-4bf0-a07b-89495972f62f" xlink:to="loc_srt_RangeMember_342cec81-7e34-42b0-9bea-5f0c391f9107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a10d1c92-6db1-4112-a35a-4b2897a8157f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_342cec81-7e34-42b0-9bea-5f0c391f9107" xlink:to="loc_srt_MinimumMember_a10d1c92-6db1-4112-a35a-4b2897a8157f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_36370b57-6b71-4028-895a-4b5abce1cd1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_342cec81-7e34-42b0-9bea-5f0c391f9107" xlink:to="loc_srt_MaximumMember_36370b57-6b71-4028-895a-4b5abce1cd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_188403a0-bfaa-4b87-84ae-7c45b5fea4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e2461e71-1453-456a-9105-0d6e4a2da9fc" xlink:to="loc_us-gaap_AssetAcquisitionAxis_188403a0-bfaa-4b87-84ae-7c45b5fea4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_5faa1c4d-0f71-46d3-b39b-f05598f992e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_188403a0-bfaa-4b87-84ae-7c45b5fea4f1" xlink:to="loc_us-gaap_AssetAcquisitionDomain_5faa1c4d-0f71-46d3-b39b-f05598f992e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixAssetAcquisitionMember_4bc322cb-ce05-49c2-aa36-97ab46803e99" xlink:href="ebs-20220930.xsd#ebs_ChimerixAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_5faa1c4d-0f71-46d3-b39b-f05598f992e3" xlink:to="loc_ebs_ChimerixAssetAcquisitionMember_4bc322cb-ce05-49c2-aa36-97ab46803e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e2461e71-1453-456a-9105-0d6e4a2da9fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7e5cb1dd-a2d7-4040-95d0-bdbab2d889a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7e5cb1dd-a2d7-4040-95d0-bdbab2d889a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_500359a5-7fb7-477b-8533-1b5749e333f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_500359a5-7fb7-477b-8533-1b5749e333f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ce1cecfb-e109-4faa-908b-3c262fe63323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ce1cecfb-e109-4faa-908b-3c262fe63323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_34b78068-0b21-401d-b632-4f3593f280d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_34b78068-0b21-401d-b632-4f3593f280d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7639d1d8-ff77-4bdb-8972-64a38eed5d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_09ba351a-f8dc-4e24-801c-a509974f3de0" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_7639d1d8-ff77-4bdb-8972-64a38eed5d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5f610693-9a66-4181-ab03-51d30e1b0903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9e76f15d-390a-4887-8445-a1ea5744a7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5f610693-9a66-4181-ab03-51d30e1b0903" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9e76f15d-390a-4887-8445-a1ea5744a7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#IntangibleassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50066b8c-ae61-4c52-a8c0-fc80799815b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_3743f94f-8d0c-4e0f-808d-d58c494cbd05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50066b8c-ae61-4c52-a8c0-fc80799815b1" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_3743f94f-8d0c-4e0f-808d-d58c494cbd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_915a5638-981f-4a79-8443-97c1af1086e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50066b8c-ae61-4c52-a8c0-fc80799815b1" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_915a5638-981f-4a79-8443-97c1af1086e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cc1d11dd-f43b-411c-abb2-028d5da70fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50066b8c-ae61-4c52-a8c0-fc80799815b1" xlink:to="loc_us-gaap_Goodwill_cc1d11dd-f43b-411c-abb2-028d5da70fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#IntangibleassetsGoodwillRollForwardDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_879a012b-4b2d-4868-b920-b1ebef805192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_e9d3c246-4ddd-48c4-b442-061821464e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_879a012b-4b2d-4868-b920-b1ebef805192" xlink:to="loc_us-gaap_GoodwillRollForward_e9d3c246-4ddd-48c4-b442-061821464e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_09e07410-38b7-4703-8c1b-d4131d6df259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e9d3c246-4ddd-48c4-b442-061821464e71" xlink:to="loc_us-gaap_Goodwill_09e07410-38b7-4703-8c1b-d4131d6df259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_61618002-8bd4-46bf-9798-392d7d1513fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e9d3c246-4ddd-48c4-b442-061821464e71" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_61618002-8bd4-46bf-9798-392d7d1513fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_80b6879f-7d92-4848-9107-fdaf60b8cb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e9d3c246-4ddd-48c4-b442-061821464e71" xlink:to="loc_us-gaap_Goodwill_80b6879f-7d92-4848-9107-fdaf60b8cb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d07af50c-7978-4773-89a1-98776f284798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8dda82a-e1c7-44c8-a459-ca1ff7625a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d07af50c-7978-4773-89a1-98776f284798" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8dda82a-e1c7-44c8-a459-ca1ff7625a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_d3869da5-ca7e-4341-9aae-6da044c55613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8dda82a-e1c7-44c8-a459-ca1ff7625a11" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_d3869da5-ca7e-4341-9aae-6da044c55613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_544c5e48-b0dd-4ce3-952e-d1a77841c80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_d3869da5-ca7e-4341-9aae-6da044c55613" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_544c5e48-b0dd-4ce3-952e-d1a77841c80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ff8c3b45-aa04-4157-83b2-bd2ec6d2a4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_544c5e48-b0dd-4ce3-952e-d1a77841c80e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ff8c3b45-aa04-4157-83b2-bd2ec6d2a4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_746a9e4e-66ba-446b-8625-e6df70680221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_544c5e48-b0dd-4ce3-952e-d1a77841c80e" xlink:to="loc_us-gaap_BankTimeDepositsMember_746a9e4e-66ba-446b-8625-e6df70680221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fbbc4a13-5e44-4c74-916f-576ee38ed9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8dda82a-e1c7-44c8-a459-ca1ff7625a11" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fbbc4a13-5e44-4c74-916f-576ee38ed9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a91bc5b-6624-469f-b4b0-e1ba85b2d50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fbbc4a13-5e44-4c74-916f-576ee38ed9e8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a91bc5b-6624-469f-b4b0-e1ba85b2d50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ec51be62-571a-43cc-b26c-d042be6a97ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a91bc5b-6624-469f-b4b0-e1ba85b2d50b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ec51be62-571a-43cc-b26c-d042be6a97ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d68b980f-1964-48ca-970c-1a45dbc6f9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a91bc5b-6624-469f-b4b0-e1ba85b2d50b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d68b980f-1964-48ca-970c-1a45dbc6f9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4e01ff9f-f90d-4a2f-9037-aa29d7efb2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a91bc5b-6624-469f-b4b0-e1ba85b2d50b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4e01ff9f-f90d-4a2f-9037-aa29d7efb2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8dda82a-e1c7-44c8-a459-ca1ff7625a11" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_372b02cc-0719-4537-9bd3-86aaa82f754f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_372b02cc-0719-4537-9bd3-86aaa82f754f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6202c04d-1816-4c37-a11e-12448b3738f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_DerivativeAssets_6202c04d-1816-4c37-a11e-12448b3738f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_eef96ec1-26a6-4c42-8966-ae72c2f1c386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_eef96ec1-26a6-4c42-8966-ae72c2f1c386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b52ba336-8a43-40f4-8748-5a51afe7c919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b52ba336-8a43-40f4-8748-5a51afe7c919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5beb1145-b649-4fae-8bbd-751b3b487f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_DerivativeLiabilities_5beb1145-b649-4fae-8bbd-751b3b487f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c5e91d95-f415-4f57-8289-1477ecb99c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11653715-e9a6-4d02-8a09-4e431427cadd" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_c5e91d95-f415-4f57-8289-1477ecb99c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#FairvaluemeasurementsContingentConsiderationRollForwardDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_05d3bcc4-b82d-4b61-a2c5-d4e3aee085f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e79e939c-1fb6-4aab-8bfc-9a2863e99af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_05d3bcc4-b82d-4b61-a2c5-d4e3aee085f5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e79e939c-1fb6-4aab-8bfc-9a2863e99af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f9487679-7fab-4638-a2dc-6fad20a748a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e79e939c-1fb6-4aab-8bfc-9a2863e99af6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f9487679-7fab-4638-a2dc-6fad20a748a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_25c4ba9d-154d-4aec-8449-74cd7622a7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e79e939c-1fb6-4aab-8bfc-9a2863e99af6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_25c4ba9d-154d-4aec-8449-74cd7622a7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ce7fc6c7-c87e-45af-a517-8445a75e2142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e79e939c-1fb6-4aab-8bfc-9a2863e99af6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_ce7fc6c7-c87e-45af-a517-8445a75e2142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_123bb08a-4997-4ae1-945f-43f087d47a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e79e939c-1fb6-4aab-8bfc-9a2863e99af6" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_123bb08a-4997-4ae1-945f-43f087d47a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#FairvaluemeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4e560394-19d1-4941-9d0b-d974661447c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1a918200-ee1b-44b0-a55b-a1356d645ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4e560394-19d1-4941-9d0b-d974661447c1" xlink:to="loc_us-gaap_DebtInstrumentTable_1a918200-ee1b-44b0-a55b-a1356d645ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_066ad1b7-e04e-4b89-85d4-86a642eb4674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1a918200-ee1b-44b0-a55b-a1356d645ba8" xlink:to="loc_us-gaap_DebtInstrumentAxis_066ad1b7-e04e-4b89-85d4-86a642eb4674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a6ad4e8d-0214-4f3b-80b4-9c66f643707e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_066ad1b7-e04e-4b89-85d4-86a642eb4674" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a6ad4e8d-0214-4f3b-80b4-9c66f643707e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_36aac126-29a9-4e9e-8ac3-fb5d46449e63" xlink:href="ebs-20220930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a6ad4e8d-0214-4f3b-80b4-9c66f643707e" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_36aac126-29a9-4e9e-8ac3-fb5d46449e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8c03a145-e967-4662-b4b5-1e8797fb5776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1a918200-ee1b-44b0-a55b-a1356d645ba8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8c03a145-e967-4662-b4b5-1e8797fb5776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_721d76c0-06ab-47ee-835d-1636934f1f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8c03a145-e967-4662-b4b5-1e8797fb5776" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_721d76c0-06ab-47ee-835d-1636934f1f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_649cb5b9-36d0-48a3-abfb-2811f439cd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_721d76c0-06ab-47ee-835d-1636934f1f05" xlink:to="loc_us-gaap_SeniorNotesMember_649cb5b9-36d0-48a3-abfb-2811f439cd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_82f2d125-8507-4373-882d-4011ff856d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1a918200-ee1b-44b0-a55b-a1356d645ba8" xlink:to="loc_us-gaap_DebtInstrumentLineItems_82f2d125-8507-4373-882d-4011ff856d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_06ccfd22-df64-4749-bcae-942b05efd2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82f2d125-8507-4373-882d-4011ff856d03" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_06ccfd22-df64-4749-bcae-942b05efd2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52f5c02e-25c5-4bda-b9a1-e9ebd6600f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82f2d125-8507-4373-882d-4011ff856d03" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52f5c02e-25c5-4bda-b9a1-e9ebd6600f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_6baf2c88-f741-4ce3-b311-74f69c79d2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82f2d125-8507-4373-882d-4011ff856d03" xlink:to="loc_us-gaap_LongTermDebtFairValue_6baf2c88-f741-4ce3-b311-74f69c79d2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4819a92a-0b01-4b87-b729-345df8b216be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4819a92a-0b01-4b87-b729-345df8b216be" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_58fddd59-5a87-46b1-9149-b1c3228d987e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:to="loc_us-gaap_ValuationTechniqueAxis_58fddd59-5a87-46b1-9149-b1c3228d987e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f23ffa88-a328-4536-948d-aa553cbac100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_58fddd59-5a87-46b1-9149-b1c3228d987e" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f23ffa88-a328-4536-948d-aa553cbac100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_0cc20048-8881-4821-b472-754a4b2932fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_f23ffa88-a328-4536-948d-aa553cbac100" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_0cc20048-8881-4821-b472-754a4b2932fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14b001eb-f2e6-47db-b1eb-2768d3b0a0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14b001eb-f2e6-47db-b1eb-2768d3b0a0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1aa0cc80-4cf5-4546-b922-a57d91c31b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_14b001eb-f2e6-47db-b1eb-2768d3b0a0f8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1aa0cc80-4cf5-4546-b922-a57d91c31b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_92e55f4a-529d-4ede-a27b-44ef6df86c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1aa0cc80-4cf5-4546-b922-a57d91c31b87" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_92e55f4a-529d-4ede-a27b-44ef6df86c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efe281d-146a-43c7-b0df-49a21ed3bf96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efe281d-146a-43c7-b0df-49a21ed3bf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e84a4f58-48b8-4dcd-a205-1412cae49c62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5efe281d-146a-43c7-b0df-49a21ed3bf96" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e84a4f58-48b8-4dcd-a205-1412cae49c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2971ba8a-e690-417c-b118-ae975a179988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e84a4f58-48b8-4dcd-a205-1412cae49c62" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2971ba8a-e690-417c-b118-ae975a179988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f0a2c2cc-d281-4a4f-9aa4-52eab6770c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f0a2c2cc-d281-4a4f-9aa4-52eab6770c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_da636734-4c58-4baa-b887-adafeb582ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f0a2c2cc-d281-4a4f-9aa4-52eab6770c91" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_da636734-4c58-4baa-b887-adafeb582ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d1ac3a27-fb48-428e-9d5d-8d3c73e968ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_da636734-4c58-4baa-b887-adafeb582ee2" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d1ac3a27-fb48-428e-9d5d-8d3c73e968ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityofPaymentMember_3c3a2192-c753-4c10-bbb7-de8b2833af0b" xlink:href="ebs-20220930.xsd#ebs_MeasurementInputProbabilityofPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_da636734-4c58-4baa-b887-adafeb582ee2" xlink:to="loc_ebs_MeasurementInputProbabilityofPaymentMember_3c3a2192-c753-4c10-bbb7-de8b2833af0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4f418976-51f7-4c59-9d8d-8949a85e87de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:to="loc_srt_RangeAxis_4f418976-51f7-4c59-9d8d-8949a85e87de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8aafed9c-ce50-4d1b-90f3-f3bad373147d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4f418976-51f7-4c59-9d8d-8949a85e87de" xlink:to="loc_srt_RangeMember_8aafed9c-ce50-4d1b-90f3-f3bad373147d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2519676b-9931-4889-8011-442a9f37fb76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8aafed9c-ce50-4d1b-90f3-f3bad373147d" xlink:to="loc_srt_MinimumMember_2519676b-9931-4889-8011-442a9f37fb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_320b523e-0f57-4def-ac91-76048b7fe994" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8aafed9c-ce50-4d1b-90f3-f3bad373147d" xlink:to="loc_srt_MaximumMember_320b523e-0f57-4def-ac91-76048b7fe994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_78d1545b-e48e-4918-9594-b32736442325" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8aafed9c-ce50-4d1b-90f3-f3bad373147d" xlink:to="loc_srt_WeightedAverageMember_78d1545b-e48e-4918-9594-b32736442325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ddf70656-7b93-4a11-b46f-1668df8bf988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9ca9aec3-2fa2-4167-ab76-94107ec94d08" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ddf70656-7b93-4a11-b46f-1668df8bf988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c2d475c3-dad9-45fa-b0d1-940b9bba9c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ddf70656-7b93-4a11-b46f-1668df8bf988" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c2d475c3-dad9-45fa-b0d1-940b9bba9c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d7a07ce8-e6f7-4b9c-9df9-68f1f9c198a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ddf70656-7b93-4a11-b46f-1668df8bf988" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d7a07ce8-e6f7-4b9c-9df9-68f1f9c198a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5cdd578b-d568-4053-8a14-7ae74c347c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3260ba4e-3fec-4426-a223-6c2714b6d9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5cdd578b-d568-4053-8a14-7ae74c347c9c" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3260ba4e-3fec-4426-a223-6c2714b6d9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1ba0bfe1-685f-4fc0-93db-acd4a2a84386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3260ba4e-3fec-4426-a223-6c2714b6d9b1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1ba0bfe1-685f-4fc0-93db-acd4a2a84386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_89d65656-2d67-423f-8364-dbb6ab99b064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1ba0bfe1-685f-4fc0-93db-acd4a2a84386" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_89d65656-2d67-423f-8364-dbb6ab99b064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5b6849bb-6766-4518-b47b-530b6b7e67fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_89d65656-2d67-423f-8364-dbb6ab99b064" xlink:to="loc_us-gaap_InterestRateSwapMember_5b6849bb-6766-4518-b47b-530b6b7e67fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4806de49-be31-4620-9df4-20413644d92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_3260ba4e-3fec-4426-a223-6c2714b6d9b1" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4806de49-be31-4620-9df4-20413644d92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_d0f4014e-852f-4839-a880-251898def207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4806de49-be31-4620-9df4-20413644d92c" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_d0f4014e-852f-4839-a880-251898def207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_87996aca-7454-47b0-8bb3-02a4cca563f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1620109f-6b14-4f92-8f84-b7195c66b323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_87996aca-7454-47b0-8bb3-02a4cca563f8" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1620109f-6b14-4f92-8f84-b7195c66b323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e69d6fc7-22f6-4861-8df9-8703e41e94c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1620109f-6b14-4f92-8f84-b7195c66b323" xlink:to="loc_us-gaap_HedgingDesignationAxis_e69d6fc7-22f6-4861-8df9-8703e41e94c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9fa27e3e-ec04-43e2-bb78-24f5e633c09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_e69d6fc7-22f6-4861-8df9-8703e41e94c6" xlink:to="loc_us-gaap_HedgingDesignationDomain_9fa27e3e-ec04-43e2-bb78-24f5e633c09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e652037-d408-4c0d-9ae1-72818995372c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_9fa27e3e-ec04-43e2-bb78-24f5e633c09d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e652037-d408-4c0d-9ae1-72818995372c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8dd645b9-0d3e-427a-a2c6-0cf249913513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1620109f-6b14-4f92-8f84-b7195c66b323" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8dd645b9-0d3e-427a-a2c6-0cf249913513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ac46804d-66d7-4a13-b7c8-10834f77948b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8dd645b9-0d3e-427a-a2c6-0cf249913513" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ac46804d-66d7-4a13-b7c8-10834f77948b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_f34a8999-cf5b-493a-a472-f43d0c70d80c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ac46804d-66d7-4a13-b7c8-10834f77948b" xlink:to="loc_us-gaap_InterestRateSwapMember_f34a8999-cf5b-493a-a472-f43d0c70d80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7ffe8103-fb5b-4428-86d0-941fdd9aa89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1620109f-6b14-4f92-8f84-b7195c66b323" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7ffe8103-fb5b-4428-86d0-941fdd9aa89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_e32fcf6d-d7a2-4ec6-a048-9d1cda38fdac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7ffe8103-fb5b-4428-86d0-941fdd9aa89b" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_e32fcf6d-d7a2-4ec6-a048-9d1cda38fdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_65dd1f76-a980-47df-b293-8425c940b780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_7ffe8103-fb5b-4428-86d0-941fdd9aa89b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_65dd1f76-a980-47df-b293-8425c940b780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a3e443cc-7852-4c05-a0f1-05e3a2fce74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2dd979dc-2a1f-4183-bbcc-c7c4a5ec7e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a3e443cc-7852-4c05-a0f1-05e3a2fce74b" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2dd979dc-2a1f-4183-bbcc-c7c4a5ec7e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_137a08fc-85ba-4b5a-bbe5-7fd93d277273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2dd979dc-2a1f-4183-bbcc-c7c4a5ec7e46" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_137a08fc-85ba-4b5a-bbe5-7fd93d277273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fa676828-0bfb-4119-918b-b3a1100005b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_137a08fc-85ba-4b5a-bbe5-7fd93d277273" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fa676828-0bfb-4119-918b-b3a1100005b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_6f374ca7-298d-4b11-a3e3-f60c2ffbc4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa676828-0bfb-4119-918b-b3a1100005b7" xlink:to="loc_us-gaap_InterestRateSwapMember_6f374ca7-298d-4b11-a3e3-f60c2ffbc4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_573f5234-722e-4a12-981c-a63e2b964108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2dd979dc-2a1f-4183-bbcc-c7c4a5ec7e46" xlink:to="loc_us-gaap_HedgingDesignationAxis_573f5234-722e-4a12-981c-a63e2b964108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d5eeac5d-b774-452a-ba0d-a284fd1ec333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_573f5234-722e-4a12-981c-a63e2b964108" xlink:to="loc_us-gaap_HedgingDesignationDomain_d5eeac5d-b774-452a-ba0d-a284fd1ec333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_bb32820c-093b-4a73-ac2a-8ccc764906ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d5eeac5d-b774-452a-ba0d-a284fd1ec333" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_bb32820c-093b-4a73-ac2a-8ccc764906ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ecdca4a8-63e6-4fa7-b43d-f1841eb4f643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2dd979dc-2a1f-4183-bbcc-c7c4a5ec7e46" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ecdca4a8-63e6-4fa7-b43d-f1841eb4f643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ecdca4a8-63e6-4fa7-b43d-f1841eb4f643" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_c1fadf54-2d3b-4c38-a402-a528c4350387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_c1fadf54-2d3b-4c38-a402-a528c4350387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_b809c511-5ef5-4db7-8b03-8052b8aacec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:to="loc_us-gaap_OtherAssetsMember_b809c511-5ef5-4db7-8b03-8052b8aacec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_d343f4dd-3524-4a7e-bd9f-c104b26a406d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_d343f4dd-3524-4a7e-bd9f-c104b26a406d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_2f60eb6f-34d3-41b8-b84c-da2daed4676f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_22f37866-622a-4aa3-890d-d58ed077df40" xlink:to="loc_us-gaap_OtherLiabilitiesMember_2f60eb6f-34d3-41b8-b84c-da2daed4676f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0311ed9a-72ff-4b44-b213-266fbb8e7fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2dd979dc-2a1f-4183-bbcc-c7c4a5ec7e46" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_0311ed9a-72ff-4b44-b213-266fbb8e7fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_4e077133-673d-4965-a687-be93cb62e6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0311ed9a-72ff-4b44-b213-266fbb8e7fb6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_4e077133-673d-4965-a687-be93cb62e6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a43d81ae-35ea-4845-aa8f-fc6867e9097c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0311ed9a-72ff-4b44-b213-266fbb8e7fb6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a43d81ae-35ea-4845-aa8f-fc6867e9097c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a003c295-34b2-4241-8d23-04f1f61fa822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9466276c-e4a9-4e24-ac83-0b2f256fa016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a003c295-34b2-4241-8d23-04f1f61fa822" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9466276c-e4a9-4e24-ac83-0b2f256fa016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_98fae3f2-a3ad-41a1-aad1-07f200b6d320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9466276c-e4a9-4e24-ac83-0b2f256fa016" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_98fae3f2-a3ad-41a1-aad1-07f200b6d320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5ed6f7d3-00ac-443a-9870-c32a32d1d828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_98fae3f2-a3ad-41a1-aad1-07f200b6d320" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5ed6f7d3-00ac-443a-9870-c32a32d1d828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_10508c2b-629a-43cd-926b-4ccf2469ec18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_5ed6f7d3-00ac-443a-9870-c32a32d1d828" xlink:to="loc_us-gaap_CashFlowHedgingMember_10508c2b-629a-43cd-926b-4ccf2469ec18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e13388eb-7616-4852-9bdf-dcc76644c18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9466276c-e4a9-4e24-ac83-0b2f256fa016" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e13388eb-7616-4852-9bdf-dcc76644c18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8ef23938-5476-4304-b21c-d6eb26f77340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e13388eb-7616-4852-9bdf-dcc76644c18e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8ef23938-5476-4304-b21c-d6eb26f77340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_004480e6-ae22-42b1-8f7b-d0848c7d4a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8ef23938-5476-4304-b21c-d6eb26f77340" xlink:to="loc_us-gaap_InterestExpenseMember_004480e6-ae22-42b1-8f7b-d0848c7d4a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2fac3950-93a6-4832-a16f-f55037292dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9466276c-e4a9-4e24-ac83-0b2f256fa016" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2fac3950-93a6-4832-a16f-f55037292dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c881de21-038b-4a3a-902a-ab77f105d168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2fac3950-93a6-4832-a16f-f55037292dec" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c881de21-038b-4a3a-902a-ab77f105d168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_10d2d50b-67e6-46cf-8703-aa8b5dcecb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c881de21-038b-4a3a-902a-ab77f105d168" xlink:to="loc_us-gaap_InterestRateSwapMember_10d2d50b-67e6-46cf-8703-aa8b5dcecb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ad5890c8-2d58-422d-8546-ed4f1310510b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_9466276c-e4a9-4e24-ac83-0b2f256fa016" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ad5890c8-2d58-422d-8546-ed4f1310510b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_cc7e085d-2c61-4ff4-aa55-7b2f10bb0920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ad5890c8-2d58-422d-8546-ed4f1310510b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_cc7e085d-2c61-4ff4-aa55-7b2f10bb0920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DebtScheduleDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_33f47a08-61d9-4c01-8b67-9d8bd0edc681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5857f2d4-33a6-47e6-a711-de33af5f6fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_33f47a08-61d9-4c01-8b67-9d8bd0edc681" xlink:to="loc_us-gaap_DebtInstrumentTable_5857f2d4-33a6-47e6-a711-de33af5f6fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c223de28-9ff3-4df9-a02f-79aa39738d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5857f2d4-33a6-47e6-a711-de33af5f6fa5" xlink:to="loc_us-gaap_DebtInstrumentAxis_c223de28-9ff3-4df9-a02f-79aa39738d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4edd46bb-5b9f-4959-8025-6e53a94ff4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c223de28-9ff3-4df9-a02f-79aa39738d61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4edd46bb-5b9f-4959-8025-6e53a94ff4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_bb27597d-b108-4b46-b2a9-8559b36aa19e" xlink:href="ebs-20220930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4edd46bb-5b9f-4959-8025-6e53a94ff4c1" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_bb27597d-b108-4b46-b2a9-8559b36aa19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_7a2ead7a-ad62-4fa3-afdc-8a6174891ba3" xlink:href="ebs-20220930.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4edd46bb-5b9f-4959-8025-6e53a94ff4c1" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_7a2ead7a-ad62-4fa3-afdc-8a6174891ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dd8775ef-edc3-45a9-bdb3-0b702d1dc3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5857f2d4-33a6-47e6-a711-de33af5f6fa5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dd8775ef-edc3-45a9-bdb3-0b702d1dc3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cafcdca6-d254-4b4e-b3de-53ab01dacadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dd8775ef-edc3-45a9-bdb3-0b702d1dc3e0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cafcdca6-d254-4b4e-b3de-53ab01dacadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_989e5466-93fc-4ed6-90f4-02a52106b68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cafcdca6-d254-4b4e-b3de-53ab01dacadf" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_989e5466-93fc-4ed6-90f4-02a52106b68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ec064262-5c3f-4286-8bdb-0d96a1935d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cafcdca6-d254-4b4e-b3de-53ab01dacadf" xlink:to="loc_us-gaap_SeniorNotesMember_ec064262-5c3f-4286-8bdb-0d96a1935d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5857f2d4-33a6-47e6-a711-de33af5f6fa5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_99f14029-dca5-47fa-866f-9721cbfaee55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_99f14029-dca5-47fa-866f-9721cbfaee55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f770a084-ad27-4ab3-9555-5016921c1fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:to="loc_us-gaap_LongTermDebt_f770a084-ad27-4ab3-9555-5016921c1fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_cef3b16b-2c36-43f5-9c81-601e21132b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:to="loc_us-gaap_LongTermDebtCurrent_cef3b16b-2c36-43f5-9c81-601e21132b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_05e08af5-e637-4ba5-abed-39b2ac1aeadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_05e08af5-e637-4ba5-abed-39b2ac1aeadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d3e86ba8-008b-4c24-92a0-ad611d6e0db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e7e0bcf-d0b9-44ac-bbfc-fc583439ce43" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d3e86ba8-008b-4c24-92a0-ad611d6e0db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a412aaaf-82d1-4002-827c-84cb1c4c8d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a412aaaf-82d1-4002-827c-84cb1c4c8d2d" xlink:to="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1f150462-8f60-442f-bdbc-5f146342e988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_CreditFacilityAxis_1f150462-8f60-442f-bdbc-5f146342e988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_94cde685-0afd-4b98-b8a7-edebaa52b9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1f150462-8f60-442f-bdbc-5f146342e988" xlink:to="loc_us-gaap_CreditFacilityDomain_94cde685-0afd-4b98-b8a7-edebaa52b9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_16dd146b-086a-4975-8a06-c9a673cda53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_94cde685-0afd-4b98-b8a7-edebaa52b9bb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_16dd146b-086a-4975-8a06-c9a673cda53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember_735f2cef-dd23-48de-ada7-5073c90af190" xlink:href="ebs-20220930.xsd#ebs_TermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_94cde685-0afd-4b98-b8a7-edebaa52b9bb" xlink:to="loc_ebs_TermLoanFacilityMember_735f2cef-dd23-48de-ada7-5073c90af190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3d58cf8d-4f2a-449e-ab66-6a4d00a53209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_DebtInstrumentAxis_3d58cf8d-4f2a-449e-ab66-6a4d00a53209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14e0f563-948f-49ec-a5de-59707e30890c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3d58cf8d-4f2a-449e-ab66-6a4d00a53209" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14e0f563-948f-49ec-a5de-59707e30890c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_3bbd1103-8663-49df-8523-2fb366441fd7" xlink:href="ebs-20220930.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14e0f563-948f-49ec-a5de-59707e30890c" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_3bbd1103-8663-49df-8523-2fb366441fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember_11f03a65-9904-4dc9-b1b7-6c114fab32d5" xlink:href="ebs-20220930.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14e0f563-948f-49ec-a5de-59707e30890c" xlink:to="loc_ebs_AmendedCreditAgreementMember_11f03a65-9904-4dc9-b1b7-6c114fab32d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7dfc8ca7-a3d7-495b-9f14-db71b586b86a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_VariableRateAxis_7dfc8ca7-a3d7-495b-9f14-db71b586b86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3cabe759-556b-469d-a121-136ddb403d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_7dfc8ca7-a3d7-495b-9f14-db71b586b86a" xlink:to="loc_us-gaap_VariableRateDomain_3cabe759-556b-469d-a121-136ddb403d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_1df0c6d2-a16f-444b-bf6b-131c8db3e9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3cabe759-556b-469d-a121-136ddb403d01" xlink:to="loc_us-gaap_EurodollarMember_1df0c6d2-a16f-444b-bf6b-131c8db3e9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e32bcb7e-200a-4e8e-b129-6522f085aacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3cabe759-556b-469d-a121-136ddb403d01" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e32bcb7e-200a-4e8e-b129-6522f085aacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_80e7bf0f-576f-40a4-bfb3-f05f4e9c86bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3cabe759-556b-469d-a121-136ddb403d01" xlink:to="loc_us-gaap_BaseRateMember_80e7bf0f-576f-40a4-bfb3-f05f4e9c86bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd072f8a-be1a-4051-aa98-01f3dfcea661" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_srt_RangeAxis_fd072f8a-be1a-4051-aa98-01f3dfcea661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab95b888-fa7d-41e4-a530-ab1a775ca1f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fd072f8a-be1a-4051-aa98-01f3dfcea661" xlink:to="loc_srt_RangeMember_ab95b888-fa7d-41e4-a530-ab1a775ca1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc605a50-8278-4cc5-895e-a749564486dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab95b888-fa7d-41e4-a530-ab1a775ca1f7" xlink:to="loc_srt_MinimumMember_bc605a50-8278-4cc5-895e-a749564486dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_356faae8-5b6b-4fea-a600-14339b4a17e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab95b888-fa7d-41e4-a530-ab1a775ca1f7" xlink:to="loc_srt_MaximumMember_356faae8-5b6b-4fea-a600-14339b4a17e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dae9b5ad-70a5-45b1-a21a-5623a6be9fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dae9b5ad-70a5-45b1-a21a-5623a6be9fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_249cf34f-f061-4ccd-9723-247146ac1c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dae9b5ad-70a5-45b1-a21a-5623a6be9fa3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_249cf34f-f061-4ccd-9723-247146ac1c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6ec95106-6a04-4a56-84af-ca36e0c956bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_249cf34f-f061-4ccd-9723-247146ac1c96" xlink:to="loc_us-gaap_LineOfCreditMember_6ec95106-6a04-4a56-84af-ca36e0c956bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a8e16f01-f7a4-486e-9423-5d292ab53e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_249cf34f-f061-4ccd-9723-247146ac1c96" xlink:to="loc_us-gaap_SeniorNotesMember_a8e16f01-f7a4-486e-9423-5d292ab53e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7b742d13-69a3-4f26-bcd9-258f82e627f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7b742d13-69a3-4f26-bcd9-258f82e627f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_eb8f0cc5-ea43-487f-8f6c-f55585e7cd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7b742d13-69a3-4f26-bcd9-258f82e627f5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_eb8f0cc5-ea43-487f-8f6c-f55585e7cd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_cbffd1f3-14cd-4a19-a1ff-569186e760dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eb8f0cc5-ea43-487f-8f6c-f55585e7cd3e" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_cbffd1f3-14cd-4a19-a1ff-569186e760dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_4b9a0037-ada8-411b-82f2-a61a180a4332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eb8f0cc5-ea43-487f-8f6c-f55585e7cd3e" xlink:to="loc_us-gaap_OtherAssetsMember_4b9a0037-ada8-411b-82f2-a61a180a4332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_995464b5-9596-4c96-b297-9e520ef75e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_995464b5-9596-4c96-b297-9e520ef75e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8bdc65b4-5899-422d-b4a4-a06f9699201d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_995464b5-9596-4c96-b297-9e520ef75e1d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8bdc65b4-5899-422d-b4a4-a06f9699201d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_19202e7d-450f-4023-b297-7c3593ffb3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8bdc65b4-5899-422d-b4a4-a06f9699201d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_19202e7d-450f-4023-b297-7c3593ffb3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_a9fed60f-911a-463f-aaa9-0a7e1c16f900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8bdc65b4-5899-422d-b4a4-a06f9699201d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_a9fed60f-911a-463f-aaa9-0a7e1c16f900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ab827eb-26f4-4d59-ab67-542fdc092ccb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ed48d06e-9f58-41de-a6f8-00ab3313120b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_LongTermDebt_ed48d06e-9f58-41de-a6f8-00ab3313120b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_ea844e22-b5ef-4ea6-8a7c-d5cc70c6090f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_ea844e22-b5ef-4ea6-8a7c-d5cc70c6090f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_b7474405-edae-4620-a9dc-5a626e37c1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_b7474405-edae-4620-a9dc-5a626e37c1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4cb9331c-d243-4e6e-8c5c-b6508a4d9a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4cb9331c-d243-4e6e-8c5c-b6508a4d9a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d68db37b-49a4-4bef-94f0-ed14698bdbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d68db37b-49a4-4bef-94f0-ed14698bdbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0ed4798d-67f5-47ad-b87a-4df6752c6eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0ed4798d-67f5-47ad-b87a-4df6752c6eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e1c48c56-dcd1-4b27-87c1-45bd8ca0dd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e1c48c56-dcd1-4b27-87c1-45bd8ca0dd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_cb835ea1-49f6-4f2c-be85-f504b25ae5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_cb835ea1-49f6-4f2c-be85-f504b25ae5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_1c2939bc-2bb1-4b9c-a4cb-e695949f9f2e" xlink:href="ebs-20220930.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_1c2939bc-2bb1-4b9c-a4cb-e695949f9f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_3bcb8182-5420-47de-b034-088155dad0fa" xlink:href="ebs-20220930.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_3bcb8182-5420-47de-b034-088155dad0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_e4bd5782-8bed-482c-856b-3afbed102177" xlink:href="ebs-20220930.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_e4bd5782-8bed-482c-856b-3afbed102177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_27b84105-77d9-43bb-b7af-98df450ea5de" xlink:href="ebs-20220930.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_27b84105-77d9-43bb-b7af-98df450ea5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_2eaf7a20-2466-4cbe-950c-11207c412ccf" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_2eaf7a20-2466-4cbe-950c-11207c412ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_61407a79-4a39-463f-8d67-e88acb7562dc" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_61407a79-4a39-463f-8d67-e88acb7562dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_db3519c4-bb66-4aee-9fa2-0488ddeb8961" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_db3519c4-bb66-4aee-9fa2-0488ddeb8961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_2c9caa74-c7ce-409e-8ece-618b441d8a50" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_2c9caa74-c7ce-409e-8ece-618b441d8a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_a4713b9b-c6ec-44bb-aadd-0cdece915354" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_a4713b9b-c6ec-44bb-aadd-0cdece915354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_112bd997-2af6-4dc5-bcfa-77202b8d2100" xlink:href="ebs-20220930.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f4883816-130b-4aa5-be3e-8d47198f6c1c" xlink:to="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_112bd997-2af6-4dc5-bcfa-77202b8d2100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_52bd1617-0ae3-4db5-ae53-4c7034371afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_52bd1617-0ae3-4db5-ae53-4c7034371afe" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_2c4032b2-5999-4aad-8e7c-fae7eeb7c317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:to="loc_us-gaap_LeaseContractualTermAxis_2c4032b2-5999-4aad-8e7c-fae7eeb7c317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_7849924f-e6c4-445a-9ac6-e34638f35083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2c4032b2-5999-4aad-8e7c-fae7eeb7c317" xlink:to="loc_us-gaap_LeaseContractualTermDomain_7849924f-e6c4-445a-9ac6-e34638f35083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ReservationOfManufacturingCapacityMember_2c67a026-db71-4098-ba61-30351ccba484" xlink:href="ebs-20220930.xsd#ebs_ReservationOfManufacturingCapacityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_7849924f-e6c4-445a-9ac6-e34638f35083" xlink:to="loc_ebs_ReservationOfManufacturingCapacityMember_2c67a026-db71-4098-ba61-30351ccba484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_ee1dd669-8a6b-42b7-a156-30a321cf37d5" xlink:href="ebs-20220930.xsd#ebs_AcceleratedExpansionOfFillFinishCapacityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_7849924f-e6c4-445a-9ac6-e34638f35083" xlink:to="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_ee1dd669-8a6b-42b7-a156-30a321cf37d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c9a5c75d-cc09-4461-905e-f9dfd22e0b24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:to="loc_srt_StatementGeographicalAxis_c9a5c75d-cc09-4461-905e-f9dfd22e0b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b70ea3f8-8796-49f5-8b65-4ceed336a35a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c9a5c75d-cc09-4461-905e-f9dfd22e0b24" xlink:to="loc_srt_SegmentGeographicalDomain_b70ea3f8-8796-49f5-8b65-4ceed336a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c379e1fe-661f-44c4-87a8-f44bc582f121" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b70ea3f8-8796-49f5-8b65-4ceed336a35a" xlink:to="loc_country_US_c379e1fe-661f-44c4-87a8-f44bc582f121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_8c945140-100a-4c50-a819-4c99c0cb1fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b70ea3f8-8796-49f5-8b65-4ceed336a35a" xlink:to="loc_us-gaap_NonUsMember_8c945140-100a-4c50-a819-4c99c0cb1fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d7ff8769-7c2e-48e4-a03d-bb7d32878078" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:to="loc_srt_MajorCustomersAxis_d7ff8769-7c2e-48e4-a03d-bb7d32878078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5090c1e1-f9da-481c-a3a4-35dbbab1b8eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_d7ff8769-7c2e-48e4-a03d-bb7d32878078" xlink:to="loc_srt_NameOfMajorCustomerDomain_5090c1e1-f9da-481c-a3a4-35dbbab1b8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_588c06be-6e92-4f42-a1db-a760f8a7e88a" xlink:href="ebs-20220930.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5090c1e1-f9da-481c-a3a4-35dbbab1b8eb" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_588c06be-6e92-4f42-a1db-a760f8a7e88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember_34e03a7d-56fe-4c57-a505-fad85da6d221" xlink:href="ebs-20220930.xsd#ebs_BARDAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5090c1e1-f9da-481c-a3a4-35dbbab1b8eb" xlink:to="loc_ebs_BARDAMember_34e03a7d-56fe-4c57-a505-fad85da6d221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0e5a3889-e06f-42de-a466-8b91bdbd904a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:to="loc_srt_ProductOrServiceAxis_0e5a3889-e06f-42de-a466-8b91bdbd904a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ba0b41f7-ff34-4343-a1bb-5c961970ed80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0e5a3889-e06f-42de-a466-8b91bdbd904a" xlink:to="loc_srt_ProductsAndServicesDomain_ba0b41f7-ff34-4343-a1bb-5c961970ed80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_7ab18189-332a-4291-a096-271404fcc46b" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ba0b41f7-ff34-4343-a1bb-5c961970ed80" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_7ab18189-332a-4291-a096-271404fcc46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1d9e5403-360a-47a0-97ab-f90654c292fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ba0b41f7-ff34-4343-a1bb-5c961970ed80" xlink:to="loc_us-gaap_ServiceMember_1d9e5403-360a-47a0-97ab-f90654c292fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d76895b9-cc1d-4ad7-b161-5bf07d0f77f4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_29d30e63-9d39-4244-815e-d4fe765d22a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_NumberOfOperatingSegments_29d30e63-9d39-4244-815e-d4fe765d22a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5cebc428-2c7e-4c66-aef7-89395d72531e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5cebc428-2c7e-4c66-aef7-89395d72531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_87dfbd8e-a7f7-4eb9-adf9-cce659db8b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_87dfbd8e-a7f7-4eb9-adf9-cce659db8b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1688e16e-0605-49f3-a9c0-36460c909b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1688e16e-0605-49f3-a9c0-36460c909b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_51733b3b-dcc1-4a34-b548-726687962b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_51733b3b-dcc1-4a34-b548-726687962b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_32d66256-e357-467a-9572-4c1d7f6f1979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_32d66256-e357-467a-9572-4c1d7f6f1979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ec5b83a4-871c-43c6-90ba-386aa4a5746d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ec5b83a4-871c-43c6-90ba-386aa4a5746d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_87d3de4a-5748-49be-b792-a0d68221968a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_87d3de4a-5748-49be-b792-a0d68221968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_4ced0a3a-7979-4922-95bd-25c0ec55a09c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_4ced0a3a-7979-4922-95bd-25c0ec55a09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8497b55d-6694-4d3e-b517-b079f7528d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8497b55d-6694-4d3e-b517-b079f7528d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8329d88e-fb5d-4c4f-874d-bc297ce3a868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_955cd15c-55cb-47bb-b0ec-1b870258c5f5" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_8329d88e-fb5d-4c4f-874d-bc297ce3a868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e02e6435-e23c-445d-860a-8ddee645ce65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6fbaddf3-628f-4dd8-a949-6400f3c7e7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e02e6435-e23c-445d-860a-8ddee645ce65" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6fbaddf3-628f-4dd8-a949-6400f3c7e7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_96d0eed3-739e-4384-8c3c-cfac5151230f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fbaddf3-628f-4dd8-a949-6400f3c7e7e6" xlink:to="loc_srt_ProductOrServiceAxis_96d0eed3-739e-4384-8c3c-cfac5151230f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_12465499-9d5b-41f4-8f9f-bae411d5385f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_96d0eed3-739e-4384-8c3c-cfac5151230f" xlink:to="loc_srt_ProductsAndServicesDomain_12465499-9d5b-41f4-8f9f-bae411d5385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_61082696-a5ea-4450-9c17-d98b908d02b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_12465499-9d5b-41f4-8f9f-bae411d5385f" xlink:to="loc_us-gaap_ProductMember_61082696-a5ea-4450-9c17-d98b908d02b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_174e94b2-fbfb-4dbc-9576-24702eba7b0f" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_12465499-9d5b-41f4-8f9f-bae411d5385f" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_174e94b2-fbfb-4dbc-9576-24702eba7b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ecbb62d2-7643-4f6c-a80e-bac82d8e78bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_174e94b2-fbfb-4dbc-9576-24702eba7b0f" xlink:to="loc_us-gaap_ServiceMember_ecbb62d2-7643-4f6c-a80e-bac82d8e78bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_e7a00f4f-c29b-42e2-a43f-452940f472b9" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_174e94b2-fbfb-4dbc-9576-24702eba7b0f" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_e7a00f4f-c29b-42e2-a43f-452940f472b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_2f03ae14-97de-41ed-9c7d-78b0f9584e00" xlink:href="ebs-20220930.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_12465499-9d5b-41f4-8f9f-bae411d5385f" xlink:to="loc_ebs_ContractsAndGrantsMember_2f03ae14-97de-41ed-9c7d-78b0f9584e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ec5d457a-565e-49e4-bf58-10a9542f29c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fbaddf3-628f-4dd8-a949-6400f3c7e7e6" xlink:to="loc_srt_StatementGeographicalAxis_ec5d457a-565e-49e4-bf58-10a9542f29c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2b3f4582-fcb1-4940-8ff7-86c1e2a57a34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ec5d457a-565e-49e4-bf58-10a9542f29c1" xlink:to="loc_srt_SegmentGeographicalDomain_2b3f4582-fcb1-4940-8ff7-86c1e2a57a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a9e64b13-e6f8-4265-a6e2-c4c7513674a2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2b3f4582-fcb1-4940-8ff7-86c1e2a57a34" xlink:to="loc_country_US_a9e64b13-e6f8-4265-a6e2-c4c7513674a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_6adf28f5-7670-4980-b3cb-a35d6e18f6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2b3f4582-fcb1-4940-8ff7-86c1e2a57a34" xlink:to="loc_us-gaap_NonUsMember_6adf28f5-7670-4980-b3cb-a35d6e18f6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6fbaddf3-628f-4dd8-a949-6400f3c7e7e6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a63d7d62-3df9-409c-9e19-61486ade7a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a63d7d62-3df9-409c-9e19-61486ade7a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_4daee79f-e037-45ba-bbf1-e72a7a2f2037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_4daee79f-e037-45ba-bbf1-e72a7a2f2037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_09f010a8-5bc8-4bf5-80c1-f9b515fd4d53" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_09f010a8-5bc8-4bf5-80c1-f9b515fd4d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_deb07b99-48ed-4d62-a6c7-4a6a842b99c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_68581670-fb44-4fd3-8e03-d855ea5b7597" xlink:to="loc_us-gaap_Revenues_deb07b99-48ed-4d62-a6c7-4a6a842b99c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_504aaab3-53b6-4047-9bb2-e884a1e340c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_504aaab3-53b6-4047-9bb2-e884a1e340c6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_a12d4ba1-4d24-4199-a3e8-852b1289c17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_a12d4ba1-4d24-4199-a3e8-852b1289c17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_96c6e025-27bc-4230-9b07-e75e5e91a7be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:to="loc_srt_ProductOrServiceAxis_96c6e025-27bc-4230-9b07-e75e5e91a7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b979d64-b8d6-423a-9963-d3dbd5a615ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_96c6e025-27bc-4230-9b07-e75e5e91a7be" xlink:to="loc_srt_ProductsAndServicesDomain_2b979d64-b8d6-423a-9963-d3dbd5a615ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_26c98f8c-17cb-4e8b-89c1-590a4da0f20d" xlink:href="ebs-20220930.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2b979d64-b8d6-423a-9963-d3dbd5a615ee" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_26c98f8c-17cb-4e8b-89c1-590a4da0f20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2a884685-4f93-4130-a844-0191a80134c9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_88f90e8b-7258-4041-8387-97840d79434f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_88f90e8b-7258-4041-8387-97840d79434f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1a41b894-9090-4e15-8d32-dbd53b5cdc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_f7f38a13-be40-415b-a0c9-2679ff9adccd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1a41b894-9090-4e15-8d32-dbd53b5cdc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionRemainingPerformanceObligationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_de1d04c8-f6fe-4720-a3fa-f7abab5318ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ccc820ea-3be1-4bfb-9960-045259b1b5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_de1d04c8-f6fe-4720-a3fa-f7abab5318ce" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ccc820ea-3be1-4bfb-9960-045259b1b5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_68891dc0-52ea-4079-ac43-ff6881cfabbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ccc820ea-3be1-4bfb-9960-045259b1b5ee" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_68891dc0-52ea-4079-ac43-ff6881cfabbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_db650f9e-4f8c-4aaf-b7cc-2fd3b8732174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ccc820ea-3be1-4bfb-9960-045259b1b5ee" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_db650f9e-4f8c-4aaf-b7cc-2fd3b8732174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_351c8942-e80a-4e52-8391-2ee02f54ce9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_db650f9e-4f8c-4aaf-b7cc-2fd3b8732174" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_351c8942-e80a-4e52-8391-2ee02f54ce9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionRemainingPerformanceObligationDetails_1"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d644633b-dd52-4146-a30a-e52b2b1f38b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_25b456dc-bb94-4fef-90d8-c728f3e69dd9" xlink:href="ebs-20220930.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d644633b-dd52-4146-a30a-e52b2b1f38b4" xlink:to="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_25b456dc-bb94-4fef-90d8-c728f3e69dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8ef25c54-fb36-444e-a15b-0183f1c4c52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_25b456dc-bb94-4fef-90d8-c728f3e69dd9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8ef25c54-fb36-444e-a15b-0183f1c4c52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityAdditions_3fb42602-54e9-4206-91e1-632f2663fdbe" xlink:href="ebs-20220930.xsd#ebs_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_25b456dc-bb94-4fef-90d8-c728f3e69dd9" xlink:to="loc_ebs_ContractWithCustomerLiabilityAdditions_3fb42602-54e9-4206-91e1-632f2663fdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityDeductions_5a6560bb-4c66-4089-a3dc-c5c6a03f3874" xlink:href="ebs-20220930.xsd#ebs_ContractWithCustomerLiabilityDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_25b456dc-bb94-4fef-90d8-c728f3e69dd9" xlink:to="loc_ebs_ContractWithCustomerLiabilityDeductions_5a6560bb-4c66-4089-a3dc-c5c6a03f3874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_15560115-f00c-4aa5-844f-81e097dd44e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_25b456dc-bb94-4fef-90d8-c728f3e69dd9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_15560115-f00c-4aa5-844f-81e097dd44e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#RevenueRecognitionAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6781a590-0a32-41fe-9346-ff3a4e7439ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_a9fc2716-c508-47b2-96c9-87d82605deea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6781a590-0a32-41fe-9346-ff3a4e7439ee" xlink:to="loc_us-gaap_BilledContractReceivables_a9fc2716-c508-47b2-96c9-87d82605deea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_59906fe2-2307-4d03-9346-8eb8bbc732dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6781a590-0a32-41fe-9346-ff3a4e7439ee" xlink:to="loc_us-gaap_UnbilledContractsReceivable_59906fe2-2307-4d03-9346-8eb8bbc732dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_85ae93c0-35d9-4dde-aa8d-0deeeb6038cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6781a590-0a32-41fe-9346-ff3a4e7439ee" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_85ae93c0-35d9-4dde-aa8d-0deeeb6038cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#IncometaxesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_967b7d75-08dc-4984-b56d-d87c5bf166ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesTable_5d09fe4e-50e3-4cc5-b8fd-3c53f0aab320" xlink:href="ebs-20220930.xsd#ebs_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_967b7d75-08dc-4984-b56d-d87c5bf166ac" xlink:to="loc_ebs_IncomeTaxesTable_5d09fe4e-50e3-4cc5-b8fd-3c53f0aab320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_79923490-a55e-414c-8f15-bac1284dadb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesTable_5d09fe4e-50e3-4cc5-b8fd-3c53f0aab320" xlink:to="loc_srt_StatementScenarioAxis_79923490-a55e-414c-8f15-bac1284dadb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_936f35fb-5e04-49b5-9da5-16d6504ad44a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_79923490-a55e-414c-8f15-bac1284dadb8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_936f35fb-5e04-49b5-9da5-16d6504ad44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_00f99c05-e4bd-4bbe-9eae-8e817b1168e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_936f35fb-5e04-49b5-9da5-16d6504ad44a" xlink:to="loc_srt_ScenarioForecastMember_00f99c05-e4bd-4bbe-9eae-8e817b1168e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesLineItems_1df410ab-4ba7-4479-ab97-3055ad200957" xlink:href="ebs-20220930.xsd#ebs_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesTable_5d09fe4e-50e3-4cc5-b8fd-3c53f0aab320" xlink:to="loc_ebs_IncomeTaxesLineItems_1df410ab-4ba7-4479-ab97-3055ad200957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a69d219-1b13-46dd-896b-5f75faf9e655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesLineItems_1df410ab-4ba7-4479-ab97-3055ad200957" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a69d219-1b13-46dd-896b-5f75faf9e655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b199a8a1-eba5-438c-8fa9-e8808b2c4131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesLineItems_1df410ab-4ba7-4479-ab97-3055ad200957" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b199a8a1-eba5-438c-8fa9-e8808b2c4131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9bff9163-eaed-4876-b097-ff1d6ada4417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesLineItems_1df410ab-4ba7-4479-ab97-3055ad200957" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9bff9163-eaed-4876-b097-ff1d6ada4417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershareDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#NetIncomelosspershareDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NetIncomelosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4f3a85b6-fb8c-45ae-80f3-dcbfdd72c8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_dd4cf70c-1fe0-4a25-b7b0-1680d826d6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4f3a85b6-fb8c-45ae-80f3-dcbfdd72c8e8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_dd4cf70c-1fe0-4a25-b7b0-1680d826d6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_75aad412-e0d9-4aeb-a133-645738b05e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_dd4cf70c-1fe0-4a25-b7b0-1680d826d6c3" xlink:to="loc_us-gaap_NetIncomeLoss_75aad412-e0d9-4aeb-a133-645738b05e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1e3ef4d5-2a5b-4188-bfad-a2237151a708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4f3a85b6-fb8c-45ae-80f3-dcbfdd72c8e8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1e3ef4d5-2a5b-4188-bfad-a2237151a708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ed52f567-889e-44b7-bfbf-043cd3515c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1e3ef4d5-2a5b-4188-bfad-a2237151a708" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ed52f567-889e-44b7-bfbf-043cd3515c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2432ef29-2dc4-4777-aa97-655b9d45f490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1e3ef4d5-2a5b-4188-bfad-a2237151a708" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2432ef29-2dc4-4777-aa97-655b9d45f490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a54aa8dc-86d7-4046-835f-103403e054d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1e3ef4d5-2a5b-4188-bfad-a2237151a708" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a54aa8dc-86d7-4046-835f-103403e054d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0c8b8bf8-dc6c-4e45-94ea-8cee2516fcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4f3a85b6-fb8c-45ae-80f3-dcbfdd72c8e8" xlink:to="loc_us-gaap_EarningsPerShareBasic_0c8b8bf8-dc6c-4e45-94ea-8cee2516fcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b07ed309-8b97-4d93-9ec1-01e9f07dfea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4f3a85b6-fb8c-45ae-80f3-dcbfdd72c8e8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b07ed309-8b97-4d93-9ec1-01e9f07dfea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_99f1ca92-db6f-4a48-a7b6-a82a151ebbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4f3a85b6-fb8c-45ae-80f3-dcbfdd72c8e8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_99f1ca92-db6f-4a48-a7b6-a82a151ebbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#EquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_38cb6c30-6631-440b-ac82-b960bb23c0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49d3e07e-eb4a-4725-b934-cccba49860dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_38cb6c30-6631-440b-ac82-b960bb23c0c0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49d3e07e-eb4a-4725-b934-cccba49860dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d1c5ccbe-118a-4a19-965a-3265ab7b916a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49d3e07e-eb4a-4725-b934-cccba49860dc" xlink:to="loc_us-gaap_VestingAxis_d1c5ccbe-118a-4a19-965a-3265ab7b916a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_4a826428-a449-4983-8a3f-e113b7c442ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_d1c5ccbe-118a-4a19-965a-3265ab7b916a" xlink:to="loc_us-gaap_VestingDomain_4a826428-a449-4983-8a3f-e113b7c442ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_15b0dabf-019d-4345-ba21-063545c3c198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_4a826428-a449-4983-8a3f-e113b7c442ee" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_15b0dabf-019d-4345-ba21-063545c3c198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_209f7c75-964d-4374-bbb1-107e450d29de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_4a826428-a449-4983-8a3f-e113b7c442ee" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_209f7c75-964d-4374-bbb1-107e450d29de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_37f28707-d9a7-464a-8384-81997056c0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_4a826428-a449-4983-8a3f-e113b7c442ee" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_37f28707-d9a7-464a-8384-81997056c0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da6f51b8-4075-463b-9d00-430696ba0341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49d3e07e-eb4a-4725-b934-cccba49860dc" xlink:to="loc_us-gaap_AwardTypeAxis_da6f51b8-4075-463b-9d00-430696ba0341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e05ecd10-837f-4ed2-bf3b-d89c26b183cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_da6f51b8-4075-463b-9d00-430696ba0341" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e05ecd10-837f-4ed2-bf3b-d89c26b183cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3477b6e8-b0d3-408f-8e34-5bda4707d31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e05ecd10-837f-4ed2-bf3b-d89c26b183cb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3477b6e8-b0d3-408f-8e34-5bda4707d31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_62764654-2ccf-4a65-bb63-4c355536255b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e05ecd10-837f-4ed2-bf3b-d89c26b183cb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_62764654-2ccf-4a65-bb63-4c355536255b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a9cc15db-8622-4728-b9af-63350617d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49d3e07e-eb4a-4725-b934-cccba49860dc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a9cc15db-8622-4728-b9af-63350617d59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b43e611d-895c-4147-9d44-e5acfd483710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a9cc15db-8622-4728-b9af-63350617d59e" xlink:to="loc_us-gaap_EquityComponentDomain_b43e611d-895c-4147-9d44-e5acfd483710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_14c22a9b-d00f-4a1a-adb8-21c19602ba1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b43e611d-895c-4147-9d44-e5acfd483710" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_14c22a9b-d00f-4a1a-adb8-21c19602ba1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_a8681f1a-9fa3-46e0-9588-6b8793633fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b43e611d-895c-4147-9d44-e5acfd483710" xlink:to="loc_us-gaap_TreasuryStockCommonMember_a8681f1a-9fa3-46e0-9588-6b8793633fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49d3e07e-eb4a-4725-b934-cccba49860dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_06eff3fd-d504-4397-83f0-70704e0566bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_06eff3fd-d504-4397-83f0-70704e0566bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_4e6730ee-1808-412b-b026-37e2634ed79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_4e6730ee-1808-412b-b026-37e2634ed79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_1ab1aba6-0704-4fa6-a187-9163b26dfae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_1ab1aba6-0704-4fa6-a187-9163b26dfae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7672f774-5f91-4d1d-99eb-d0b55518eef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_7672f774-5f91-4d1d-99eb-d0b55518eef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c108699c-b977-4e10-9cdd-c67fa5032232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c108699c-b977-4e10-9cdd-c67fa5032232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_08fbedc0-d1b0-482d-8f35-e69c357cd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_08fbedc0-d1b0-482d-8f35-e69c357cd26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_238966b1-deb6-47fd-9134-ae84aef441b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02b48805-a994-4305-b305-5840dda1ec6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_238966b1-deb6-47fd-9134-ae84aef441b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#EquityScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_b50276a0-8dff-482e-960c-01b5930693f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5bed1544-dda5-4d3f-940d-5ee939c68c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b50276a0-8dff-482e-960c-01b5930693f9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5bed1544-dda5-4d3f-940d-5ee939c68c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d440e81a-5475-4368-802c-7649a7158988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5bed1544-dda5-4d3f-940d-5ee939c68c35" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d440e81a-5475-4368-802c-7649a7158988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_82dfef9b-a897-40f1-9114-d92bed1dc549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d440e81a-5475-4368-802c-7649a7158988" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_82dfef9b-a897-40f1-9114-d92bed1dc549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_e0224850-2e6e-4be9-af7f-c6ae377f198c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82dfef9b-a897-40f1-9114-d92bed1dc549" xlink:to="loc_us-gaap_CostOfSalesMember_e0224850-2e6e-4be9-af7f-c6ae377f198c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b2f5ef55-f203-47b6-b3fb-6ec30823d0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82dfef9b-a897-40f1-9114-d92bed1dc549" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b2f5ef55-f203-47b6-b3fb-6ec30823d0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7bf9dcd9-6854-4693-a5d0-b7479af23ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_82dfef9b-a897-40f1-9114-d92bed1dc549" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7bf9dcd9-6854-4693-a5d0-b7479af23ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d13dc910-35a9-4bcc-9f17-4b270c538ec3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5bed1544-dda5-4d3f-940d-5ee939c68c35" xlink:to="loc_srt_ProductOrServiceAxis_d13dc910-35a9-4bcc-9f17-4b270c538ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_671048f8-afeb-4c33-80e0-5fdd3b7765d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d13dc910-35a9-4bcc-9f17-4b270c538ec3" xlink:to="loc_srt_ProductsAndServicesDomain_671048f8-afeb-4c33-80e0-5fdd3b7765d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d3f02177-4620-44df-af1e-e304ece600fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_671048f8-afeb-4c33-80e0-5fdd3b7765d5" xlink:to="loc_us-gaap_ProductMember_d3f02177-4620-44df-af1e-e304ece600fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2ef35792-c4b4-4d3d-a9fe-4607768099ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_671048f8-afeb-4c33-80e0-5fdd3b7765d5" xlink:to="loc_us-gaap_ServiceMember_2ef35792-c4b4-4d3d-a9fe-4607768099ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d442f909-47ca-42b1-aa08-4b6e04ac6649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5bed1544-dda5-4d3f-940d-5ee939c68c35" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d442f909-47ca-42b1-aa08-4b6e04ac6649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_078a74f9-fcd8-4b87-b0a7-52a665865be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d442f909-47ca-42b1-aa08-4b6e04ac6649" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_078a74f9-fcd8-4b87-b0a7-52a665865be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#EquityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_c249ea6b-5e1d-4ff3-a44e-38b144116285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5f42ac6b-8e0c-49cb-8cd7-af48e9796ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c249ea6b-5e1d-4ff3-a44e-38b144116285" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5f42ac6b-8e0c-49cb-8cd7-af48e9796ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7f6fcd88-77e6-48b8-ab99-e0b13a71ed96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5f42ac6b-8e0c-49cb-8cd7-af48e9796ad5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7f6fcd88-77e6-48b8-ab99-e0b13a71ed96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0753b0c5-3956-4b7d-ab57-fe5d0d7361e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7f6fcd88-77e6-48b8-ab99-e0b13a71ed96" xlink:to="loc_us-gaap_EquityComponentDomain_0753b0c5-3956-4b7d-ab57-fe5d0d7361e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d9d5da-8640-427b-8c02-06f0683f78ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0753b0c5-3956-4b7d-ab57-fe5d0d7361e1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d9d5da-8640-427b-8c02-06f0683f78ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_0f2470dc-6330-48fd-a3d4-0cab2434dd65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d9d5da-8640-427b-8c02-06f0683f78ff" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_0f2470dc-6330-48fd-a3d4-0cab2434dd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e75c4e06-d3ac-4a0a-bcd1-323238accb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d9d5da-8640-427b-8c02-06f0683f78ff" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e75c4e06-d3ac-4a0a-bcd1-323238accb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f7348fb6-f96a-4273-8586-5f27522064e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_99d9d5da-8640-427b-8c02-06f0683f78ff" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f7348fb6-f96a-4273-8586-5f27522064e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_df737b5b-73c7-47db-b329-92335f6a2e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5f42ac6b-8e0c-49cb-8cd7-af48e9796ad5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_df737b5b-73c7-47db-b329-92335f6a2e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_df737b5b-73c7-47db-b329-92335f6a2e0a" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a987ecad-74db-403d-b314-5cce9a9302db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:to="loc_us-gaap_StockholdersEquity_a987ecad-74db-403d-b314-5cce9a9302db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_a1a65737-6c4e-428c-9ef1-dd0fe47b7b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_a1a65737-6c4e-428c-9ef1-dd0fe47b7b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_f338daf7-3a15-4ff1-8cd4-57df6373201b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_f338daf7-3a15-4ff1-8cd4-57df6373201b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6668b4ff-5d73-4456-bfdb-f514020e42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6668b4ff-5d73-4456-bfdb-f514020e42ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b85b92f1-5c3f-4a8a-a1a9-7f90268b15bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_86ae54a3-da61-4953-b45d-0126fd5a74c9" xlink:to="loc_us-gaap_StockholdersEquity_b85b92f1-5c3f-4a8a-a1a9-7f90268b15bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ee1e7213-2e31-4277-948e-10709ed8649c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_926522fa-5241-4a07-9b9f-442c3e44349f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ee1e7213-2e31-4277-948e-10709ed8649c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_926522fa-5241-4a07-9b9f-442c3e44349f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0a4d1ba0-41ee-46d4-aa09-a346c2dc8e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_926522fa-5241-4a07-9b9f-442c3e44349f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0a4d1ba0-41ee-46d4-aa09-a346c2dc8e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a18b617-422b-47f2-816b-1688798562f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a4d1ba0-41ee-46d4-aa09-a346c2dc8e4c" xlink:to="loc_us-gaap_EquityComponentDomain_1a18b617-422b-47f2-816b-1688798562f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_f4253274-3efa-4262-9e3e-3363c295d66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1a18b617-422b-47f2-816b-1688798562f2" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_f4253274-3efa-4262-9e3e-3363c295d66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_b80e7419-7631-40a1-ac3a-c3988c60b627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1a18b617-422b-47f2-816b-1688798562f2" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_b80e7419-7631-40a1-ac3a-c3988c60b627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0a907c53-2fe3-45d0-a9b3-55f8cc70bd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_926522fa-5241-4a07-9b9f-442c3e44349f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0a907c53-2fe3-45d0-a9b3-55f8cc70bd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_3d7a7925-bb21-46b9-a507-9c90fb9ae8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0a907c53-2fe3-45d0-a9b3-55f8cc70bd8d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_3d7a7925-bb21-46b9-a507-9c90fb9ae8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_53b0656b-9477-46a1-81f1-9b4beed5a4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0a907c53-2fe3-45d0-a9b3-55f8cc70bd8d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_53b0656b-9477-46a1-81f1-9b4beed5a4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fbd6c938-63c4-4ce1-96fc-cbe200075270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0a907c53-2fe3-45d0-a9b3-55f8cc70bd8d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fbd6c938-63c4-4ce1-96fc-cbe200075270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ce964458-18c9-480e-8d5f-c96c332cba48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_039f3c4d-e34d-4a4c-90b8-8db74712857f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ce964458-18c9-480e-8d5f-c96c332cba48" xlink:to="loc_us-gaap_NumberOfReportableSegments_039f3c4d-e34d-4a4c-90b8-8db74712857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e3005609-d605-449f-8698-0eaff780f42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_afbcd64a-7d9f-4a40-ba6f-3ca9d6a90333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e3005609-d605-449f-8698-0eaff780f42f" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_afbcd64a-7d9f-4a40-ba6f-3ca9d6a90333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5635c0a6-58cd-478e-9b1f-be80b388d06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_afbcd64a-7d9f-4a40-ba6f-3ca9d6a90333" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5635c0a6-58cd-478e-9b1f-be80b388d06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a8166038-591f-4f22-ba36-ae37e14d01db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5635c0a6-58cd-478e-9b1f-be80b388d06c" xlink:to="loc_us-gaap_SegmentDomain_a8166038-591f-4f22-ba36-ae37e14d01db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_5ac6262f-5494-4d73-a003-b6900c8806bf" xlink:href="ebs-20220930.xsd#ebs_ProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a8166038-591f-4f22-ba36-ae37e14d01db" xlink:to="loc_ebs_ProductsSegmentMember_5ac6262f-5494-4d73-a003-b6900c8806bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_abd1c6b7-47d9-4cab-8ec6-8b5923dd57b8" xlink:href="ebs-20220930.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a8166038-591f-4f22-ba36-ae37e14d01db" xlink:to="loc_ebs_ServicesSegmentMember_abd1c6b7-47d9-4cab-8ec6-8b5923dd57b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e693d656-f3ef-4319-9773-9fabb2032578" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_afbcd64a-7d9f-4a40-ba6f-3ca9d6a90333" xlink:to="loc_srt_ProductOrServiceAxis_e693d656-f3ef-4319-9773-9fabb2032578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_515a3266-493b-44c1-a6f8-9b3176146f77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e693d656-f3ef-4319-9773-9fabb2032578" xlink:to="loc_srt_ProductsAndServicesDomain_515a3266-493b-44c1-a6f8-9b3176146f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_7e3487e6-2ad3-4e25-93c9-be42b848a22f" xlink:href="ebs-20220930.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_515a3266-493b-44c1-a6f8-9b3176146f77" xlink:to="loc_ebs_ContractsAndGrantsMember_7e3487e6-2ad3-4e25-93c9-be42b848a22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e2e93fe1-1358-4d2e-898f-5e5261acc5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_515a3266-493b-44c1-a6f8-9b3176146f77" xlink:to="loc_us-gaap_ProductMember_e2e93fe1-1358-4d2e-898f-5e5261acc5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2211cf4e-3ec1-4f38-9160-c08d98092319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_515a3266-493b-44c1-a6f8-9b3176146f77" xlink:to="loc_us-gaap_ServiceMember_2211cf4e-3ec1-4f38-9160-c08d98092319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d444df62-56d8-4c86-9a94-d0aac6cb91d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_afbcd64a-7d9f-4a40-ba6f-3ca9d6a90333" xlink:to="loc_srt_ConsolidationItemsAxis_d444df62-56d8-4c86-9a94-d0aac6cb91d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8ce40cba-a075-4310-a3fe-808493d3d15a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_d444df62-56d8-4c86-9a94-d0aac6cb91d2" xlink:to="loc_srt_ConsolidationItemsDomain_8ce40cba-a075-4310-a3fe-808493d3d15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_b0170212-a065-4b37-b649-5459da3df68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8ce40cba-a075-4310-a3fe-808493d3d15a" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_b0170212-a065-4b37-b649-5459da3df68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_afbcd64a-7d9f-4a40-ba6f-3ca9d6a90333" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d74a654f-a329-440f-97d0-aa827590003d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d74a654f-a329-440f-97d0-aa827590003d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3794d313-1be5-400b-b654-ae8428c9e77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_Revenues_3794d313-1be5-400b-b654-ae8428c9e77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3ee4c20f-53a9-4278-802a-02e389dabad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3ee4c20f-53a9-4278-802a-02e389dabad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_500a8376-44b1-4ccb-b983-926c9f75b908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_GrossProfit_500a8376-44b1-4ccb-b983-926c9f75b908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_316ed9c1-0fda-4d59-b267-c411d1448c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_316ed9c1-0fda-4d59-b267-c411d1448c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin_925e28c9-dae4-4351-b059-aea17ff01e29" xlink:href="ebs-20220930.xsd#ebs_AdjustedGrossMargin"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_ebs_AdjustedGrossMargin_925e28c9-dae4-4351-b059-aea17ff01e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_91c61ac1-be3f-432e-952f-57f781349c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_91c61ac1-be3f-432e-952f-57f781349c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_4f967e90-b6d0-4a9b-b1d9-7353c4a8b905" xlink:href="ebs-20220930.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1ec34e63-00e1-4841-a809-d16a57246738" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_4f967e90-b6d0-4a9b-b1d9-7353c4a8b905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="ebs-20220930.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9df602c6-0eae-427a-b013-a6c01d78ae7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_431332db-a6b8-44d9-843a-08e7f88f719e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9df602c6-0eae-427a-b013-a6c01d78ae7f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_431332db-a6b8-44d9-843a-08e7f88f719e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8a0adeda-ca63-4f77-b96e-41a1caba274b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_431332db-a6b8-44d9-843a-08e7f88f719e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8a0adeda-ca63-4f77-b96e-41a1caba274b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_19ae7c3d-a178-4d54-9c28-bc8357b25f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8a0adeda-ca63-4f77-b96e-41a1caba274b" xlink:to="loc_us-gaap_SegmentDomain_19ae7c3d-a178-4d54-9c28-bc8357b25f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_7d392be1-1748-45c7-8d93-a13c56c70d02" xlink:href="ebs-20220930.xsd#ebs_ProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_19ae7c3d-a178-4d54-9c28-bc8357b25f7f" xlink:to="loc_ebs_ProductsSegmentMember_7d392be1-1748-45c7-8d93-a13c56c70d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_0ebe4157-86b8-4d92-90ae-0029f0688c9f" xlink:href="ebs-20220930.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_19ae7c3d-a178-4d54-9c28-bc8357b25f7f" xlink:to="loc_ebs_ServicesSegmentMember_0ebe4157-86b8-4d92-90ae-0029f0688c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_989d5717-c8a6-4a03-a273-250fd7ccbbd8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_431332db-a6b8-44d9-843a-08e7f88f719e" xlink:to="loc_srt_ConsolidationItemsAxis_989d5717-c8a6-4a03-a273-250fd7ccbbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_acd02374-f32f-44ee-8207-84e82a4758e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_989d5717-c8a6-4a03-a273-250fd7ccbbd8" xlink:to="loc_srt_ConsolidationItemsDomain_acd02374-f32f-44ee-8207-84e82a4758e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_8a1eb6e7-3b60-4384-afb5-de1d4db3eb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_acd02374-f32f-44ee-8207-84e82a4758e1" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_8a1eb6e7-3b60-4384-afb5-de1d4db3eb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ce1faa01-c55d-4e4c-8d25-6d50277b0a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_431332db-a6b8-44d9-843a-08e7f88f719e" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_ce1faa01-c55d-4e4c-8d25-6d50277b0a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract_7a7d589e-70a2-4f9e-bb1c-d5100310c3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ce1faa01-c55d-4e4c-8d25-6d50277b0a59" xlink:to="loc_us-gaap_DepreciationAbstract_7a7d589e-70a2-4f9e-bb1c-d5100310c3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a281b3bc-785c-4e71-81bc-856b1c80da92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DepreciationAbstract_7a7d589e-70a2-4f9e-bb1c-d5100310c3ad" xlink:to="loc_us-gaap_Depreciation_a281b3bc-785c-4e71-81bc-856b1c80da92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ebs-20220930_g1.jpg
<TEXT>
begin 644 ebs-20220930_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M &22I"I>1@BCJS$ #MR3P* &PSQW"[X761<XRC!AGTR"1F@"6@ H * "@ H
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MT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_\<H
M/^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_
M\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\
M@7!_\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@">V\3Z1>RK
M!;7UG-*YPL<=Q"[L<9PJJY8G )X'2@#<H * "@ H * "@ H * "@ H * "@#
M.U#6+'2=OV^Y@M/,SL\^6.+?MQNV[V7=MW+G&<9&>HH S?\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
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M_A,="_Z"-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\
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M_BJ #^U;+_GXA_[^I_\ %4 ']JV7_/Q#_P!_4_\ BJ #^U;+_GXA_P"_J?\
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MT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_\<H
M/^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_
M\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\
M@7!_\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C
M8?\ @7!_\<H /^$QT+_H(V'_ (%P?_'* 'Q^+=%E81QZA9.[D*JK=0$DDX
M#Y))X ')- '04 % !0 4 % !0 4 % $4T\=LAEF98XUY9G(50/<D@#\30!A'
MQ?H:D@ZC8@C@@W4&0?\ OY0!JV6IVFI*6LYX;E1U,,B2 ?4H2* +M !0 4 ?
ME;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?8G[-O_()OO^OM?_1*4T!]'4P"@ H * "@ H * "@ H *
M/,OC)_R*.H_[D/\ Z4PTF!\C_#'XB3^ K_+[I-.N2!<PCDCL)8P<#S$],@.N
M5.#M94,^^[&^@U*".[M'6:"90\<B'*LI&00?Z=0>#@U0BU0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'AWQA^)X\(VYTK3'!U2Y3EA@_9HV&-Y])6_Y9*1P/WAX
M"!T!X)\"6+^+868DL8;DDDY))C.23W)[FD,^[*H04 % !0 4 % !0 4 % !0
M 4 % !0!\9_M'_\ (=M/^O!?_1\]2QGSS0(* "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79O_14
ME S]#:H04 % !0 4 % !0 4 % !0 4 % 'RM^TS_ ,PG_M^_]LZ3 ^5J0!0
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MWQ-X=VI%=M=0KC]U=CSUPO10S$2HN.,)(HQCT& 9[QX:_:)TZ]VPZY;O8N<
MS19FASW8K@2H/91,?>G<1[WI.M6.NP"ZTV>*ZA/\<3A@#UVM@Y5O56 8=P*8
M&G0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY
M_P"1LG_ZX6__ *+%2,\;H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0![)\!O^1L@_ZX7'_HLT#/NZJ$% !0 4
M % !0 4 % !0 4 % !0!\V?&C_D*6_\ UZC_ -&RUX6,^-?X?U9]GE'\&?\
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M9^T;_P C';?]@V+_ -*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5=3PRGD?0@FA&O0!^5M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!]B?LV_P#()OO^OM?_ $2E- ?1U, H
M * "@ H * "@ H * "@#S+XR?\BCJ/\ N0_^E,-)@?GU2 ]W^#?Q0/A6X&CZ
MF_\ Q++A_D=CQ:RL?OY_YXN?]8,@(?W@Q\^XV&?;2L' 92"",@CD$'H0>X-4
M(6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M 4 % !0 4 % !0 4 % !0 4 % !0  XY% 'JGA/XQ>(/"I6(S&^M%X\BY)?
MZ8CE_P!:F!]T;C&/^>9H&?5/@OXOZ)XP*V^\V-ZW'V><@;SZ0R\))[+\DA[1
MX&:8CU6F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H ]D^ W_(V0?]<+C_ -%F@9]W50@H * "@ H
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M315(SR.@04 % !0 4 % !0!]<_LU?\>6H_\ 7>#_ - >FAGTS3$% !0 4 %
M!0 4 % !0!\6?M&_\C';?]@V+_TINZE@> 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;?AK_D+67_ %]V
M_P#Z.2@9^F]4(* "@ H * "@#Y=^/WCV2WQX8L'*%T$EZRD@[6YC@^C+B23'
M52B]"P*8S6^#/PJATRWB\0:O&)+R=1);1. 5MXSRDA4\><XPRG_EFI&,.6V@
M$&N_M"_V)J-UIO\ 9?F_8KF:W\S[9MW^3(T>_;]E;;NVYV[FQG&3UHN(RO\
MAIC_ *A/_D]_]QT7 V]$_:-TV]F$6IV<M@C''FI*+A5SW<>7$X7U*JY]C1<#
MTCQMX'TSXCZ<K IYYC#VEXF"0&&Y/F'WX7SEEY&#N7#8- 'RO\/?%-[\,/$#
MZ;J>8[9YOL][$3\J,#M6X7J#LR&W+D20DXSE"%L,^[001D<@U0C\K:D H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#[$_9M_Y!-]_P!?:_\ HE*: ^CJ8!0 4 % !0 4 % !0 4 % 'F7QD_
MY%'4?]R'_P!*8:3 _/JD 4 ?5'P1^*6/+\,ZQ)Q]VQG<\^UL['_R 2>/]5G'
MEJ&AGU53$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!ROC+Q?9>"M.?4KXYQ\L40.'FE()6-
M>#C.,LV"$4%B#@ @'YZ^)?$E[XKOY-3U!]\LIX49V1H/NQQ@D[44=!U)RS$L
M23(S!H$>R? ;_D;(/^N%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % '
MQG^T?_R';3_KP7_T?/4L9\\T""@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H ]%^$O\ R-FF_P#79O\ T5)0,_0V
MJ$% !0 4 % !0 4 % !0 4 % !0!\K?M,_\ ,)_[?O\ VSI,#Y6I % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %  #CD4 >\_
M#[XX7_API9:T7O[ 84.3NN(1_LLQ'FH/[CG(  1U VD&?8VC:U9:_:I?:=*E
MQ;R#Y70]^ZL.JL/XE8!AW%4(TZ "@ H * "@ H * "@ H * "@ H * "@ H
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M /A'X\_\C9/_ -<+?_T6*D9XW0(* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#V3X#?\C9!_P!<+C_T6:!GW=5"
M"@ H * "@ H * "@ H * "@ H ^;/C1_R%+?_KU'_HV6O"QGQK_#^K/L\H_@
MS_Q_^VQ/':\T^C"@#3TG5[K0[E+RR<QRQG\&'=6'1E;H0?T(!JX2=-J4'9HP
MJTH5X.G45XO\/-=F?5W@WQK:^+(/EQ%=QC][!GD=MZ9^]&2?JI.UNQ;Z&C65
M9=I+=?JO+\CX+%X.>$EKK3?PR_1]G^>Z\NTKK/-"@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!EZUK-KX?LY=1OW$5O;KN=C^051W9F(55'+,0!UH _/OQ_XZN_'>HM
M>3YCMH\K;09^6*,GOS@R/@&5NY  PBJ!(SA:!!0![)\!O^1L@_ZX7'_HLT#/
MNZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/-
M@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /1?A+_R-FF_]=F_]%24#/T-JA!0 4 % !0 4 % !0 4 % !0 4 ?
M*W[3/_,)_P"W[_VSI,#Y6I % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 =KX(\>:CX%N_M-BVZ%R//MV)\J91ZC^%P,
M[) -RYQRI96!GWIX0\8:?XTL5O\ 3FR/NR1-@20OW2103CU5@2K#E3UQ0CJ:
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H AN;F*RB:>X=8
MHHU+.[L%55'4LQP !ZF@#Y,^(WQWENR^F^&&:&'E7O<%9'['[.#S&O\ TT($
MAX*B/&6D9\T.[2,7<EF8DDDY))Y))/))/4T"&T % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0![?\.?C/?>$REAJF^^TT84 G,UN.
MG[IF/SH!_P LG( P-C)R&!GVAHVM66OVJ7VG2I<6\@^5T/?NK#JK#^)6 8=Q
M5"-.@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /A'X\_\C9/_ -<+
M?_T6*D9XW0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M3=U+ \ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%8]2M@!<PCC/831CO&_<=8WRIX*,[ ].I@% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $-Q<16D33SLL44
M2EW=R%55499F)P  .23P!0!\(?%?XER>.+S[-:%DTNU8^2AX,K\@SN.N2,B-
M3]Q.P9FJ1GD5 @H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H *
M"@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Z+\)?^1LTW_KL
MW_HJ2@9^AM4(* "@ H * "@ H * "@ H * "@#Y6_:9_YA/_ &_?^V=)@?*U
M( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H ZWP7XQO?!&H)J%D<K]V:$DA)H^Z-CN.J-@E&P<$9!!GZ#^&?$EGXK
ML(M3T]]\4HY4XWQN/O1R#^%U/4=""&4E64FA&]0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!DZYKMEX;LWU#4I5@MXARQY))Z*JC)9V/"JH)/T
MS0!\,?$?XJ7WCJ4P1YM=,C;,=N#RY'22<CAW[J@^2/@ %LNTC/*J!!0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 =KX(\>
M:CX%N_M%BVZ%R//MV)\N91ZC^%P,[) -R]]REE(,^\?!OC/3_&UD+[3GY7"S
M0M_K(7(SM<=P>=CCY7 .#D,!0CK* "@ H * "@ H * "@ H * "@ H * "@
MH * "@#X1^//_(V3_P#7"W_]%BI&>-T""@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@
M9]W50@H * "@ H * "@ H * "@ H * /FSXT?\A2W_Z]1_Z-EKPL9\:_P_JS
M[/*/X,_\?_ML3QVO-/HPH * "@">WN)+.19X&:.6-@R.IPRL.001T---IW6C
M1$HJ:<))--6:>S1].> OB''XB5;&^(COU'!X5)P.Z]A)CED'!P63C*K[U#$*
MI[D])_@_^#Y?<?$8W /#-U:6M+\8^3\NS^3[OU*O0/#"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /@GXY?\ (W7G^Y;?^DT52,\CH$%
M!0 4 % !0 4 ?7/[-7_'EJ/_ %W@_P#0'IH9],TQ!0 4 % !0 4 % !0 4 ?
M%G[1O_(QVW_8-B_]*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M='P Z$' .5%".NH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MS%55F !\">/O']]X\O3<7),5K$2+>V!RD2GN>FZ5N-\A&3]U0J!5$C.#H$%
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MJ?%T??U\_P _7?XS'9>Z-ZV'5X;RCUCYKO'\O3;V*O4/G0H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /@GXY?\ (W7G^Y;?^DT52,\CH$%
M!0 4 % !0 4 ?7/[-7_'EJ/_ %W@_P#0'IH9],TQ!0 4 % !0 4 % !0 4 ?
M%G[1O_(QVW_8-B_]*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * /L'X >.CJ-LWAN]?,UFN^U+'EH,_-%GN86(*CD^6V  L5-
M?2-, H * "@ H * "@ H * "@ H * "@ H * "@#,UC6+30+.74+^00V]NNY
MV/Y  #EF8D*JCEF( Y- 'Y__ !"\?W?CV_-Q-F*TBRMM;YRL:GJS8X:5\ NW
MT4':JU(S@*!!0 4 % !0 4 % !0 4 % !0 4 % %NUL+F].VVBDF/I&C.?R4
M&@9TL/P]\23XV:7?\]-UM*@_-E7CWZ4 6O\ A67BC_H&7?\ W[- %>;X=^)8
M/O:7?'']VVE?K_N*W_UJ .8NM/N;$[;F&6 ^DB,A]>C =N: *E @H * "@ H
M * "@ H * "@ H * "@#IO"7BN^\&Z@FI:>V&7Y9(S]R:,D%HY!W5L<'JK .
MI# &@9^@_A+Q79>,=.CU.P/RO\LD9^_%( "T;^ZY&#T92&'!%4(Z6@ H * "
M@ H * "@ H * "@ H * "@ H * /A'X\_P#(V3_]<+?_ -%BI&>-T""@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH ]D^ W_ "-D'_7"X_\ 19H&?=U4(* "@ H * "@ H * "@ H * "@#YL^-'
M_(4M_P#KU'_HV6O"QGQK_#^K/L\H_@S_ ,?_ +;$\=KS3Z,* "@ H * "@!0
M<<C@B@1[_P##_P")?F;-+UE\-]V*Y=OO>B3$]^RR$_-P'Y^8^QA\3M3JOTD_
MR?\ G]Y\GCLOM>OAEIO*"6WG'R[KITTT7NM>N?+!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!\$_'+_D;KS_<MO\ TFBJ1GD= @H * "@ H *
M "@#ZY_9J_X\M1_Z[P?^@/30SZ9IB"@ H * "@ H * "@ H ^+/VC?\ D8[;
M_L&Q?^E-W4L#P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(C<<46 ^NM"T*R\-V<>G:;&(+>(<*.I)ZL['EG8\LQY/T %4(UZ /RMJ0"@
MH * "@ H * "@#[@^&O@+P_JGANPN[RPMIYY8B7D>,%F/F.,D]S@ 4QG<_\
M"LO"_P#T#+3_ +]"@0?\*R\+_P#0,M/^_0H /^%9>%_^@9:?]^A0 ?\ "LO"
M_P#T#+3_ +]"@ _X5EX7_P"@9:?]^A0 ?\*R\+_] RT_[]"@ _X5EX7_ .@9
M:?\ ?H4 '_"LO"__ $#+3_OT* #_ (5EX7_Z!EI_WZ% !_PK+PO_ - RT_[]
M"@ _X5EX7_Z!EI_WZ% !_P *R\+_ /0,M/\ OT* #_A67A?_ *!EI_WZ% !_
MPK+PO_T#+3_OT* #_A67A?\ Z!EI_P!^A0 ?\*R\+_\ 0,M/^_0H /\ A67A
M?_H&6G_?H4 '_"LO"_\ T#+3_OT* #_A67A?_H&6G_?H4 '_  K+PO\ ] RT
M_P"_0H /^%9>%_\ H&6G_?H4 '_"LO"__0,M/^_0H Z'1O#^G>'HVATNWBM(
MY&WNL2[0S8QD^^!BF!L4 % !0 4 % !0 4 % !0 4 >9?&3_ )%'4?\ <A_]
M*8:3 _/JD 4 % !0 4 % 'K/PJ^),O@6]\FY+/I=TP$Z<GRF. )XU_O*,"10
M,R(,<LJ8!GWG;7,5Y$EQ;LLD4JJZ.IRK*PRK ]P0<BJ$34 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!XM\7OB<G@RU_
ML_3V#:K<J=N,'[-&>/-8?WSTA4C!(+M\JA70'PS)(TK&1R6=R69B<DDG)))Y
M))Y)/4T@&4 % !0 4 % 'LGP&_Y&R#_KA<?^BS0,^[JH04 % !0 4 % !0 4
M % !0 4 % !0!\9_M'_\AVT_Z\%_]'SU+&?/- @H * "@ H * "@#W;X#>']
M.\0ZE=PZG;Q7<<=LKHLJA@K>:HR/0X.*!GU'_P *R\+_ /0,M/\ OT*8@_X5
MEX7_ .@9:?\ ?H4 '_"LO"__ $#+3_OT* #_ (5EX7_Z!EI_WZ% !_PK+PO_
M - RT_[]"@ _X5EX7_Z!EI_WZ% !_P *R\+_ /0,M/\ OT* #_A67A?_ *!E
MI_WZ% !_PK+PO_T#+3_OT* #_A67A?\ Z!EI_P!^A0 ?\*R\+_\ 0,M/^_0H
M /\ A67A?_H&6G_?H4 '_"LO"_\ T#+3_OT* #_A67A?_H&6G_?H4 '_  K+
MPO\ ] RT_P"_0H /^%9>%_\ H&6G_?H4 '_"LO"__0,M/^_0H /^%9>%_P#H
M&6G_ 'Z% !_PK+PO_P! RT_[]"@ _P"%9>%_^@9:?]^A0 ?\*R\+_P#0,M/^
M_0H /^%9>%_^@9:?]^A0!;T_P%X?TJ=+NSL+:">(Y21(P&4X(R#V."13 ZZ@
M H * "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@
MH * /4_@WI%GK?B2&TU"%+F!HIR8Y!N4E8R5./4'D4#/L;_A67A?_H&6G_?H
M4Q!_PK+PO_T#+3_OT* #_A67A?\ Z!EI_P!^A0 ?\*R\+_\ 0,M/^_0H /\
MA67A?_H&6G_?H4 '_"LO"_\ T#+3_OT* #_A67A?_H&6G_?H4 '_  K+PO\
M] RT_P"_0H /^%9>%_\ H&6G_?H4 '_"LO"__0,M/^_0H /^%9>%_P#H&6G_
M 'Z% %>?X4^%;CA]-MQQCY-\?_H#+S[]:+ <KJ?P"\+WV3;I<6+8X\F9F&?4
MB<3<9Z@$>@Q18#QWQ-^SSJVFJTVCS1ZC&O/E,/)G[GY06:-\?]=$8GA4-*PS
MP.\LY].F>VNHW@FB.UXY%*.I'9E8 @_44"*U !0 4 % !0 4 % !0!L>'];G
M\-ZA;ZI:'$MK(L@&<!@.&0X_A=2R-_LL:!GZ4:/JL&N64&HVAW0W4:RH>X##
M.#CHRG*L.S CM5"-*@ H * "@ H * "@ H * "@ H * "@ H ;)(L2EW(5%!
M9F8@  #)))X  Y)/ % 'PA\6_B5)XUO?L=FQ72K1SY0&1YT@RIG<?0D1 _=0
MD\,["I&>/4""@ H * "@ H * "@ H * "@#MO#'P\UWQ<0VFVKF$G!N)/W<
M]?WC8#XSRL8=O]F@9[_X?_9OMX@)-<O'E;O%:J$0'T\V0,S#Z11GWIV$>Q:1
M\,?#.AX-KI]NS #YYE-PV1W!G,FT_P"[M]L#BBP'<11)"HCC4(B\!5   ] !
MP/PI@/H * "@!KQK*I1P&5A@@@$$>A!X(H X76/ACX9UL'[3I]NK$'YX%^SO
MD]R83'N(Z_/N'J".*5@/'/$/[-\#@R:%>-&W:*[&Y3])HE#*!Z&*0^]%@/GS
MQ-X"UOP@W_$TM7CBS@3+B2$YZ#S4RH)[*Q5_]FD,X^@04 % !0 4 % !0 4
M% !0 4 >A?#CQ[<> ]2%PNY[*<JEW"/XT!X=02!YL>2R$XSED)"N30,_06PO
MX-3MX[RT=9H)T#QNO1E89!'<>X(!!R" 015"+= !0 4 % !0 4 % !0 4 %
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M!EI_WZ% !_PK+PO_ - RT_[]"@ _X5EX7_Z!EI_WZ% !_P *R\+_ /0,M/\
MOT* #_A67A?_ *!EI_WZ% !_PK+PO_T#+3_OT* )(?AQX:MI%FBTZU22-@ZL
M(QE64Y4CW! (I@=K0 4 % !0 4 % !0 4 1RPI.ACE571N"K ,I'N#D'\: ,
M)O"&AL<MIUB2>I-K 3_Z+H U;+3;735*6<,5LIQE8HTC!QTR$ '';TH N4 %
M !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?_1DE- >B4P"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MV_\ (6OO^O1?_1JT(9]AU0@H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^5OVF?^83_ -OW_MG2
M8'RM2 * "@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@9]W50@H * "@ H * "@
MH * "@ H * "@ H X/QQ\.]+\=0;+Q/*ND&(KJ,#S8_0'IYD>>3&QQR2I5CN
MI ?"?B_P??\ @J^;3]17!^]%*N?+F3/#H2!]&4_,IX(Z90SE:!!0 4 % !0
M4 % !0!]@?LZ^*#=V-QH,S9>S;SX 2<^3*<2*!V5)3N^LU- ?25, H * "@
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M * "@ H * "@ H * "@#Z/\ @1\0SI=P/#>H/_HMTV;5F/$4[=8L]DF/W1G
MEZ#]XQ AGV'5""@ H * "@ H * "@ H * "@ H * "@#X1^//_(V3_\ 7"W_
M /18J1GC= @H * "@ H * "@#ZP_9H_U.J?[]I_*XIH9]14Q!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!\V?&C_D*6_\ UZC_ -&RUX6,^-?X?U9]GE'\&?\ C_\ ;8GCM>:?
M1A0 4 % !0 4 % !0 4 >M^ /B,^A%=.U(E['HC\EX,]!ZM%ZKU7.5X&T^C0
MQ'L_<G\'XK_@>7W'S^.P"KWK4-*G5;*7^4O/KU[GTM#,DZ++$P=' 964@JRD
M9!!'!!'((KW4TU=;'Q33BW&2LUHT]TR2F(* "@ H * "@ H * "@ H * "@
MH * "@ H * /@GXY?\C=>?[EM_Z315(SR.@04 % !0 4 % !0!]<_LU?\>6H
M_P#7>#_T!Z:&?3-,04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % 'SC^TE_R";'_K[;_T2])@?'=( H * "@ H * "@#U7X)_\CCI_P#V]?\
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M@SZ\TW3;72+=+.QB2W@B&$CC4*H'T'4GJS'+,<EB22:H1=H * "@ H * "@
MH * "@ H * "@ H Q=>\/6'B:U:QU.%+B%^S#YD/9XW&&1QV92#C(Z$@@'Q;
M\1_@]?>#"]]9;KS2\Y\P#]Y #T$RC^$=!*H"G^((2 9V&>,T""@ H * "@ H
M * "@#LO"'@/5_&LWE:9"3$I DN),I!'T^\^#EL'.Q TA'(7&30,^P_ GP=T
MCP<$N9P+_4%P?/E4;(V_Z81'(3'9VW29&0R@[:=A'KM, H * "@ H * "@ H
M * "@ H * "@ H ^$?CS_P C9/\ ]<+?_P!%BI&>-T""@ H * "@ H * /K#
M]FC_ %.J?[]I_*XIH9]14Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\Y_&FWE%_;7&UO*-OL
M#X.W>)'8KGINVD''7'->'C$^>+Z<MK^=V?8Y1)>SG"ZYN:]NMK)7]+GBU>8?
M2A0 4 % !0 4 % !0 4 % 'I?@3X@3>&7%I=[IK!SRO5H2>KQ_[/=H^AZKAL
M[NZAB'1?++6'Y>:_R/%QN!CB5[2G:-5?=+R?GV?WZ;?45I=PW\*7%LZRQ2#<
MCJ<@CV/Z$=000<$5[\6I)2B[I['PTHRIR<)IJ2T:>Z+%40% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?!/QR_Y&Z\_W+;_ -)HJD9Y'0(* "@ H * "@ H
M ^N?V:O^/+4?^N\'_H#TT,^F:8@H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /G']I+_ )!-C_U]M_Z)>DP/CND 4 % !0 4 % !0!ZK\$_^
M1QT__MZ_]([B@#[]J@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#\K:D H * "@ H * "@ H _0[X2_\BGIO_7 _P#HR2F@
M/1*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 >9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 %
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M * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[9TF!\K4@"@ H * "@ H
M* /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H * "@ H * "@ H * "@
M H ^6_VB/!X9(?$MLN&4K;W6!U!_U,IP.QS$S$Y.8E' I,#Y1I % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /RMJ0"@ H *
M"@ H * "@#]#OA+_ ,BGIO\ UP/_ *,DIH#T2F 4 % !0 4 % !0 4 % !0
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M&?/- @H * "@ H * "@#Z/\ V;?^0M??]>B_^C5H0S[#JA!0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!\K?M,_\PG_ +?O_;.DP/E:D 4 % !0 4 % !0![)\!O^1L@_ZX7'_H
MLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 87B?1(_$>E76ER@$7
M4+HN>BOC,;_\ D"N/=><CB@#\S9(VB8QN-K(2I!Z@@X(_ U(#* "@ H * "@
M H * /NKX":B;[PM'$?^7.XG@'T)$X_+S\?3%- >T4P"@ H * "@ H * "@
MH * "@#R/XS^,#X4T)XK=MMYJ)-O"1U1"/WT@X_A0[ 005>1&'0T@/@FD 4
M% !0 4 % !0 4 % 'V'\&?A0-(2/Q#K,?^FN-UK X_U"$<2NI_Y;,"=JG_5+
M@G]X?W;0SZ/IB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /DKXS
M_"867F>(]$3]R27O+9!_J^I:XC _Y9D\RH/]63O7]WN$:&?,5(04 % 'L?@3
MX,:MXNVW5T#IVGMR)9%_>2#K^YB)!(.1B1]J8.5WD%:!GV%X3\$:3X+@\C2X
M0C,,23/AIY>_SR8!QGD(H5 >0HJA'6T % !0 4 % !0 4 % !0 4 % !0 4
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M * "@ H * "@ H * "@ H * "@#YQ_:2_P"038_]?;?^B7I,#X[I % !0 4
M% !0 4 >J_!/_D<=/_[>O_2.XH ^_:H H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _*VI * "@ H * "@ H * /T.^$O_(I
MZ;_UP/\ Z,DIH#T2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_TIAI,#\^J0!0
M4 % !0 4 % !0 4 % '1>%?$][X/U"/4]/;$D?#(<[)8R1NBD (RC8'N&"LN
M&4$ S]"_"7BJS\8Z='J=@?E?Y9(S]^*0 ;HW]USP>C*0PX(JA'2T % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?'_QK^*?]J._AW1Y/]%C8K=S(
M?]<ZGF%"/^62$'>>1(PP/D7,DC/FV@04 % !0 4 % !0 4 % !0![)\!O^1L
M@_ZX7'_HLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7
M_P!'SU+&?/- @H * "@ H * "@#Z/_9M_P"0M??]>B_^C5H0S[#JA!0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!\K?M,_\PG_M^_\ ;.DP/E:D 4 % !0 4 % !0![)\!O^1L@
M_P"N%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^<WQ,T
M[^RO$^I6^ H^U/*H' "SXG4 <8&V08 X Z<5(SAJ!!0 4 % !0 4 % 'UM^S
M3=%[34K;/$<UO(![R)*I[=_*'?MT'=H#Z<I@% !0 4 % !0 4 % !0 4 % '
MP)\9?%1\3^(9EB;=:Z?FUAP<J2A/FN,<'?)N 8?>14YXJ1GE% @H * "@ H
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M-'^IU3_?M/Y7%-#/J*F(* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H CFA2X1HI5#HX*LK
M%64C!!!X((X(-)I-6>PTW%J479K5-;IGS/X^^'+Z"6U#30TEB>73JT&3^;1>
MC<E>C_WCX-?#NE[\-8?E_P #S^_N_M<#CU7M1K653H]E/_*7EUZ=CR:O//H
MH * "@ H * "@ H * "@#H_#/B>[\+70N;0Y4\21,3LD7T([$?PL.5/J"0=J
M=25&7-'YKHSBQ&&ABH<E3?I);I_Y=UU/K/PYXDL_$UJ+JS;D8$D9^_$Q'W6'
MY[6'RL!D'J!]'3J1JQYH_-=4? XC#SPL_9U%Z/I)=U^JW1OUL<@4 % !0 4
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M: ]$I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!YE\9/\ D4=1_P!R'_TIAI,#\^J0!0 4 % !0 4
M% !0 4 % !0!W_P[\>W7@+41<QYDM)BJW4 /$B \,H/ ECR3&W'4H3M=J!GZ
M!Z5JEMK=I%?V+B:WN%#QNO0@\$'N&4@JRGE6!4@$$50C0H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /G'XU?%+^QXW\/:/)_IDJXNID/,",/\ 5H0>
M)G'WC_RS0\?.P*(9\=TA!0 4 % !0 4 % !0 4 % !0![)\!O^1L@_ZX7'_H
MLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&
M?/- @H * "@ H * "@#Z/_9M_P"0M??]>B_^C5H0S[#JA!0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!\K?M,_\PG_M^_\ ;.DP/E:D 4 % !0 4 % !0![)\!O^1L@_P"N%Q_Z
M+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\+_'VT^S>*I),$
M?:;:WEZ8SA3#D>O^JQD8Y!'4$F1GBM @H * "@ H * "@#Z8_9KN"M]J,&3A
MX(7QV^21UR?<>9QQT+=.[0'UU3 * "@ H * "@ H * "@ H XGXB^)/^$4T"
M[U!&VS"/RX/7SI?DC(]2A/F$?W4-(#\Y"23D\DT@$H * "@ H * "@ H ZOP
M3X4G\9ZM#I4&560[II ,^5"O,C^F0.%!(#.RKGF@9^C6FZ;;Z/:Q6-F@B@MT
M6.-!T"J,#ZD]68\LQ+$DDFJ$7: "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H S=7T>TUZTDT_48EGMI@ \;$@'!##!4AE(8 AE(((!!% $F
MFZ9:Z/;I9V$4=M!$,+'&H51[X'4GJS'+,>6))S0!>H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /A'X\_P#(V3_]<+?_ -%BI&>-T""@ H *
M "@ H * /K#]FC_4ZI_OVG\KBFAGU%3$% !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ",
MH<%6 96!!!&00>"".X/<4;Z,:=M5N?.WQ ^&S6._5-(0M!RTMNHR8NY>,#K'
MU++UCZC*9V>)B,-RWJ4]NJ[>:\OR]-OK\#F'/:AB':6T9/[7D_/L^OKOXI7E
MGTP4 % !0 4 % !0 4 % !0!M:%KUWX<NEO+)]C#AE/W)%SDHX[J?S!Y4@@&
MM83E2?-!Z_GY,YJU"&)@Z=5:='U3[KS_ *9]8^%/%MIXKMO.@/ES)_K8"070
M^O;<A_A<#!Z'# @?0TJT:RNM'U7;_@>9\#B<+/"2Y9ZQ?PRZ/_)]U^AU5=)P
M!0 4 % !0 4 % !0 4 % !0 4 ?!/QR_Y&Z\_P!RV_\ 2:*I&>1T""@ H *
M"@ H * /KG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#YQ_:2_Y!-C_U]M_Z)>DP/CND 4 % !0 4 % !0!Z
MK\$_^1QT_P#[>O\ TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@#]#OA+_ ,BGIO\
MUP/_ *,DIH#T2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_ -*8:3 _/JD 4 %
M!0 4 % !0 4 % !0 4 % 'LOPC^)K^"KO[#?,S:5=-\XZ^1(>!,@_NG $JCD
MJ P!90K S[JBE2=%EB8.C@,K*0RLK#(92,@@@@@C@CD50A] !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 >/?%GXFQ^"+3[)9%7U6Z4^4O!\A#QY[KZ_\\E88
M9@2051E* ^$YIGN)&FE8O)(Q9V8Y9F8Y+$GDDDY)/4T@(J "@ H * "@ H *
M "@ H * "@#V3X#?\C9!_P!<+C_T6:!GW=5""@ H * "@ H * "@ H * "@
MH * /C/]H_\ Y#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4 ?1_[-O\ R%K[
M_KT7_P!&K0AGV'5""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#Y6_:9_YA/_;]_P"V=)@?*U(
MH * "@ H * "@#V3X#?\C9!_UPN/_19H&?=U4(* "@ H * "@ H * "@ H *
M "@ H * "@ H * /B_\ :."CQ!:D'YCI\8(]A<7.#^))_*I8'S[0 4 % !0
M4 % !0!]'_LV_P#(6OO^O1?_ $:M"&?8=4(* "@ H * "@ H * "@ H ^4?V
MD?$!,EEH<9.%#7<HSP2Q:*'\5 F//9@:3 ^6Z0!0 4 % !0 4 % !0!]P_ O
MP6/#VCC5+A<7FI@2<CE+?K$GMYG^M;U#1@C*4T![C3 * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /A'X\_P#(V3_]<+?_ -%BI&>-T""@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _*VI *
M"@ H * "@ H * /T.^$O_(IZ;_UP/_HR2F@/1*8!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?&3_
M )%'4?\ <A_]*8:3 _/JD 4 % !0 4 % !0 4 % !0 4 % !0!]*?!/XI?V8
MZ>'-8DQ:R';:3.>(7)XA<G_EFY/R$G$;?*?D;* SZ^JA!0 4 % !0 4 % !0
M 4 % !0 4 % !0!P?Q"\>6O@+3C=2XDNI<K;09P9'[DXY$:9!=N.R@[F6D!^
M?>L:O=:]=RZA?R&:XN&+NQ]3T '154855&%50%  %(9FT""@ H * "@ H *
M"@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@9]W50@H * "@ H * "@ H * "@ H
M * "@#XS_:/_ .0[:?\ 7@O_ */GJ6,^>:!!0 4 % !0 4 % 'T?^S;_ ,A:
M^_Z]%_\ 1JT(9]AU0@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H ^5OVF?^83_V_?\ MG28'RM2
M * "@ H * "@ H ]D^ W_(V0?]<+C_T6:!GW=5""@ H * "@ H * "@ H *
M"@ H * "@ H * "@#X?_ &@[L7/B<1C'^C6<$1Q[M+-S[XE'3MCOFI \-H *
M "@ H * "@ H ^D_V;(B=2OY.RVT:X_WI,_IL_6A#/K^J$% !0 4 % !0 4
M% !0 4 ?G7\3]:_M[Q+?W0.Z-)C!'CIL@Q"I'LVPO]6-2,X&@04 % !0 4 %
M !0!VGP^\,'Q=KEKIC F%G\R<CC$$?SR<\X+ ;%./ONM S]'$18U"( JJ
M,  <  #@ #@ =*H0Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^
M$?CS_P C9/\ ]<+?_P!%BI&>-T""@ H * "@ H * /K#]FC_ %.J?[]I_*XI
MH9]14Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M'CA0 4 % !0 4 % !0 4 % 'P3\<O^1NO/\ <MO_ $FBJ1GD= @H * "@ H
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M % !0 4 % !0 4 % !0 4 % !0!YE\9/^11U'_<A_P#2F&DP/SZI % !0 4
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M H ^N?V<?#@@M+O79 -]PXM83SD1QX>4CMM=R@Z]8CT[M ?3-, H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /A'X\_\C9/_ -<+?_T6*D9XW0(*
M "@ H * "@ H ^L/V:/]3JG^_:?RN*:&?45,04 % !0 4 % !0 4 % !0 4
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MWK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /RMJ0"@ H * "@ H * "@#[0^'7Q/\-:)X=L;"^O5AN((BLB&
M*=BI+N<96)E/!!X)IC.U_P"%R>$?^@BG_?FY_P#C-%Q!_P +D\(_]!%/^_-S
M_P#&:+@'_"Y/"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3P
MC_T$4_[\W/\ \9HN ?\ "Y/"/_013_OS<_\ QFBX!_PN3PC_ -!%/^_-S_\
M&:+@'_"Y/"/_ $$4_P"_-S_\9HN ?\+D\(_]!%/^_-S_ /&:+@'_  N3PC_T
M$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\ OS<__&:+
M@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/"/\ T$4_
M[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\ \9HN ?\
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MN%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_ ,AVT_Z\%_\
M1\]2QGSS0(* "@ H * "@ H ]N^!WBK2_"FHW<^KSBUCEMPB,5D;+"16QB-'
M(X!.2 />@9]+_P#"Y/"/_013_OS<_P#QFG<0?\+D\(_]!%/^_-S_ /&:+@'_
M  N3PC_T$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\
MOS<__&:+@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/
M"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\
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M7.I$@2JAC@!_BGD!6( =]I.]A_<1CVI ?G S%B23DGDD]2:0"4 % !0 4 %
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M  N3PC_T$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\
MOS<__&:+@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/
M"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\
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M@ H * "@ H ^<?VDO^038_\ 7VW_ *)>DP/CND 4 % !0 4 % !0!ZK\$_\
MD<=/_P"WK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /1?A+_ ,C9IO\ UV;_ -%24#/T-JA!0 4
M% !0 4 % !0 4 % !0 4 % 'F7QD_P"11U'_ '(?_2F&DP/SZI % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!IZ-K%UH%Y%J-@YAN+=@R,/R((/#*PRK*>&4D
M'@T#/T&^'_CFU\=Z<+R#$=Q%M2Y@SS%(1U'.3&^"8V/4 @_,K ,1W-, H *
M"@ H * "@ H ;)(L2EW(5%!9F8@  #)))X  Y)/ % 'PY\8/B<WC"Y.FZ<Y&
ME6S<$<?:9%X\UAU\M3D1*>H_>, S!4D9XE0(* "@ H * "@ H * "@ H * "
M@ H * "@#V3X#?\ (V0?]<+C_P!%F@9]W50@H * "@ H * "@ H * "@ H *
M "@#XS_:/_Y#MI_UX+_Z/GJ6,^>:!!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z,_#+_D5],_Z](OY4P.YI@% !0
M4 % !0 4 % !0 4 % !0 4 % 'RM^TS_ ,PG_M^_]LZ3 ^5J0!0 4 % !0 4
M % 'LGP&_P"1L@_ZX7'_ *+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'Q+\=?'*^(M272+-MUGII8,RG*R7)X=N#@K$/W:G^\92"0PJ1G@] @H
M * "@ H * "@ H _2/P!I!T+P_86+ J\=M&S@C!$D@\V08]I'8?X4P.OI@%
M!0 4 % !0 4 % !0!\Z?M(7IBT>SM!_RVNS(?I%$XQ^<H/3L.1W3 ^.*0!0
M4 % !0 4 % '1^#],&LZU8V#?<N+N!'_ -PR+O\ R3<:!GZ7U0@H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#X1^//_(V3_\ 7"W_ /18J1GC
M= @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#]./#7_ "";+_KTM_\ T4E4!M4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'QG^T?_P AVT_Z\%_]'SU+&?/- @H LV=Y/I\R75K(\,T3!DD1BK*PZ%2,
M$&@#[;^%GQ<@\8(NFZF4M]50 #HJ70 Y>,=%EX)>(<?Q1_+N5&![=3 * "@
MH Y?Q3X3M/%5MY%R-LJ F&8#YHV/Y;D/\2'@CD88!ASU:4:RL]^C[?\  \CN
MPV)GA)\T-8OXH]&OT?9_IH?)_B#P]>>&KIK2]7:1DHXSLD7^\C8&1ZCJIX8
MU\[4IRI/EDO\GYH^^H5X8F"J4GZKK%]FOZOT,*LCJ"@ H * "@ H * "@ H
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M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >B_"7_D;--_Z[-_Z
M*DH&?H;5""@ H * "@ H * "@ H * "@ H * /,OC)_R*.H_[D/_ *4PTF!^
M?5( H * "@ H * "@ H * "@ H * "@ H * "@#JO!OBZ\\%:BFI6)SCY98B
M<)-$2"T;=<9QE6P2K ,.F"#/T*\,^)+/Q781:GI[[XI1RIQOC<?>CD'\+J>H
MZ$$,I*LI-"-Z@ H * "@ H * "@#Y)^-OQ2^UL_AK1W_ '*$K>S(2/,8<&W0
MC_EFO/FGD.WR#"JV^1GS'0(* "@ H * "@ H * "@ H * "@ H * "@ H ]D
M^ W_ "-D'_7"X_\ 19H&?=U4(* "@ H * "@ H * "@ H * "@ H ^,_VC_^
M0[:?]>"_^CYZEC/GF@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!^C/PR_Y%?3/^O2+^5,#N:8!0 4 % !0 4 % !0
M 4 % !0 4 % !0!\K?M,_P#,)_[?O_;.DP/E:D 4 % !0 4 % !0![)\!O\
MD;(/^N%Q_P"BS0,^[JH04 % !0 4 % !0 4 % !0 4 % !0 4 % '@WQC^**
M>&+=M&TMP=3N$Q(ZGFUC8?>..DSJ?W8R"@/F''R;D!\3$YY-( H * "@ H *
M "@ H Z_P%H)\2Z]9:<5+1RSJTH'_/&/]Y+ST'[M6 )[D#DG% S](ZH04 %
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M !N@ _X6UXL_Z"4W_?,7_P ;H ^Y/ ]U<WV@Z?=7SF6XGM(99'.,L9$#AC@
M9(89P.M4(ZF@ H * "@ H * "@ H * "@#X1^//_ "-D_P#UPM__ $6*D9XW
M0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H _3CPU_R";+_ *]+?_T4E4!M4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'QG^T?\ \AVT_P"O!?\ T?/4L9\\T""@ H DAF>W=98F:.2-@RLI*LK Y#*1
M@@@\@CD&@#[(^$_QB37PFC:ZXCU #;#<,0J7..BMT"SXZ?PRGIAR%9@?0U,
MH * "@#$\0>'K3Q):FTO5W#DHXX>-L8#H>Q]1T8<,"*QJ4XU5RR^3ZKT.JA7
MGAI^TI.W==&NS_K3H?)WBKPG=^%+GR;@;X7)\F8#"R ?GM<9&Y"<@]"5(8_.
MU:4J+M+;H^C_ *ZH^]PV*ABX\T-)+XH]4_U79_KH<M6!WA0 4 % !0 4 % !
M0 4 % 'M7P_^))T_9IFKL6M_NQ3L<F+T20]X_1NJ=#E/N>IA\3R6IU/AZ/MZ
M^7Y>FWS..R_GO7PZ][>45]KS7GW77UW^BE8. RD,K $$'((/0@CJ#V->WOJC
MY!JVCW%H$% !0 4 % 'P3\<O^1NO/]RV_P#2:*I&>1T""@ H * "@ H * /K
MG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@#YQ_:2_P"038_]?;?^B7I,#X[I % !0 4 % !0 4 >J_!/_D<=
M/_[>O_2.XH ^_:H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H _*VI * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H ]%^$O_ "-FF_\ 79O_ $5)0,_0VJ$% !0 4 %
M!0 4 % !0 4 % !0 4 >9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'I7PS^(=QX"OP[;I-/N"%N80>W02QCH)(^O^VN4
M)&0RFPS[]L+^WU2WCO+-UF@G0/&Z]&5AD'U'N" 0<@@$$50BW0 4 % !0 4
M?/?QH^*/_"/Q-H.DOC4)E_?RJ>;:-AG:I'2:13P>L:'<,,R,J ^,:0!0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0![)\!O^1L@_ZX7'_HLT#/NZJ$% !0
M 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/- @H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]&?A
ME_R*^F?]>D7\J8'<TP"@ H * "@ H * "@ H * "@ H * "@#Y6_:9_YA/\
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MKD#W,I!/X[1^52QGS=0(* "@ H * "@ H ]Z_9UB63Q),S=8]/F9?J9[9/\
MT%C_ #H0'VQ5 % !0 4 % !0 4 % !0 4 ?,W[2O_'EIW_7>?_T!*3&?(U(0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z5>!T,
M?A[2T/5=.LP?J+>,50'44 % !0 4 % !0 4 % !0 4 ?"/QY_P"1LG_ZX6__
M *+%2,\;H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 ?IQX:_Y!-E_UZ6__HI*H#:H * "@ H * "@ H * "@ H *
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MD@(W5K?GMW:+U3JO5.ZMZ%#$.E[D]8?^D_\  \ON\_ QV 5>]6BDJG5;*?\
ME+SZ]>Z^F89H[A%EA97C<!E92"I!Z$$<$?2O>335UL?%-.+<9)IK=/1HDIDA
M0 4 % 'Q=\?/">H6FL2:^4WV%V(4$B9/END2Q[)1CY2Q3*'E6!QG<"*D9\_4
M""@ H * "@ H * /KG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#YQ_:2_Y!-C_U]M_Z)>DP/CND 4 % !0
M4 % !0!ZK\$_^1QT_P#[>O\ TCN* /OVJ * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /1?A+_R-FF_]=F_]%24#
M/T-JA!0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_ -*8:3 _/JD
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M\D(#URSD N0 9X?0(* "@ H * "@ H ]D^ W_(V0?]<+C_T6:!GW=5""@ H
M* "@ H * "@ H * "@ H * /C/\ :/\ ^0[:?]>"_P#H^>I8SYYH$% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?HS\
M,O\ D5],_P"O2+^5,#N:8!0 4 % !0 4 % !0 4 % !0 4 % !0!\K?M,_\
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M - 2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!^F'@\8T/3@?^?&U_P#1$=4!T5 !0 4 % !0 4 % !0 4 % 'PC\>?\
MD;)_^N%O_P"BQ4C/&Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % 'Z<>&O^039?]>EO_Z*2J VJ "@ H * "@ H *
M"@ H * "@ H * "@#XS_ &C_ /D.VG_7@O\ Z/GJ6,^>:!!0 4 % !0 4 ?3
M'PF^,QTX1Z'XADS; !+>[<DM%V6*8\YB[))UCX5LQX,8,^N58. RD$$9!'((
M/0@]P:H0M !0 4 5KRSAU"%[:Y19895*NC#((/\ (CJ",$$ @@@&IE%23C)7
M3Z%PG*G)3@VI)W370^7/'7P_F\,.;JUW36#GANKQ$_PR8'3LK]#T;#8W?/U\
M.Z+YHZP[]O7_ #/N<%CHXE>SG[M5=.DO./GW7W:;>;5Q'M!0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 ?./[27_()L?\ K[;_ -$O28'QW2 * "@
MH * "@ H ]5^"?\ R..G_P#;U_Z1W% 'W[5 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y6U(!0 4 % !0 4 % !0 4 %
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M^-<UN[\17LNHZA(9;B=MS$]!Z*H_A1!A44<*H I#,J@04 % !0 4 % !0 4
M.1&D8(@+,Q   R23P  .22>@H ^X_@_\,5\'VHU+44!U6Z3D$?\ 'M&W/E+_
M --&&#*W&#^['"L78'%?M+_ZG2_]^[_E;T,9\GTA!0 4 % !0 4 % 'LGP&_
MY&R#_KA<?^BS0,^[JH04 % !0 4 % !0 4 % !0 4 % !0!\9_M'_P#(=M/^
MO!?_ $?/4L9\\T""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /T9^&7_(KZ9_UZ1?RI@=S3 * "@ H * "@ H * "@
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M_P"/+3O^N\__ * E)C/D:D(* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#].?#BE-*LU8$$6MN"#P01$F01ZU0&S0 4 % !0 4 %
M!0 4 % !0!\(_'G_ )&R?_KA;_\ HL5(SQN@04 % !0 4 % !0 4 % !0 4
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M(X- 'QQ\6/@X^@&36="0R6!)::W4%FMNY9>I:#U[Q#KE,LLC/GB@04 % !0
M4 ?7/[-7_'EJ/_7>#_T!Z:&?3-,04 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?
M_(XZ?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0!^5M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!Z+\)?^1LTW_KLW_HJ2@9^AM4(* "@ H *
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M7GC;47U&\.T?=AB!.R&(?=1<]_XG;JSDG@8 D9R5 @H * "@ H * "@ H *
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M &_?^V=)@?*U( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /0/AQX%G\=ZHMJH9+.';)=RC^"//"*3QYDI!5!R
M1\SX*HU S]";*SATZ".TMD$4,"+'&B]%10 H'T [\^O-4(LT % !0 4 % !0
M 4 % !0 4 % 'S!^TM;EK?3+C'$<ERF>>LBPL!Z<^6??CCO28'R92 * "@ H
M * "@ H ]'^$>H#3?%>G2GI),T!_[;QO"/R9P?P[]*!GZ%U0@H * "@ H *
M"@ H * "@#YF_:5_X\M._P"N\_\ Z E)C/D:D(* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#]0]*_P"/*W_ZXQ?^@+5 7Z "@ H
M* "@ H * "@ H * /A'X\_\ (V3_ /7"W_\ 18J1GC= @H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]./#7_()LO\
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M0@H * "@#ZY_9J_X\M1_Z[P?^@/30SZ9IB"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H ^<?VDO^038_]?;?^B7I,#X[I % !0 4 % !0 4
M>J_!/_D<=/\ ^WK_ -([B@#[]J@"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#\K:D H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79O_14E S]#:H04
M % !0 4 % !0 4 % !0 4 % !0!YE\9/^11U'_<A_P#2F&DP/SZI % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH _1GX9?\BOIG_7I%_*F!W-, H * "@ H * "@ H * "@ H * "@ H ^5OVF
M?^83_P!OW_MG28'RM2 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * -[PUX;O?%=_'IFG)OFE/).0D:#[TDC ':BCJ
M<9)PJ@L0"#/T(\%^#[/P3IJ:;9C)'S32D8::4@;G;T'&$7G:@"Y)R36PCK*
M"@ H * "@ H * "@ H * "@ H \)_:&LOM/AI)@.;:\A<GC(5DEB(SUP6=,@
M8R0">E)@?$=( H * "@ H * "@"[IMZ^F74-Y$2)+:6.92."&C<.I!['(% S
M]/K2YCO88[F$[HYD61#ZJZAE/X@BJ$3T % !0 4 % !0 4 % !0!\S?M*_\
M'EIW_7>?_P! 2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % #D4NP5>K$ ?4\4 ?J7;PK;1)"F2L:J@SUPH &<8&<#G@50$M
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M=( H * "@ H * "@#U7X)_\ (XZ?_P!O7_I'<4 ??M4 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4
M % 'VO\ #CX<>'-8\.6-[>V,4UQ-$6DD8R L?,<9.' Z #@4QG;_ /"I?"?_
M $#8/SD_^.46$'_"I?"?_0-@_.3_ ..46 /^%2^$_P#H&P?G)_\ '*+ '_"I
M?"?_ $#8/SD_^.46 /\ A4OA/_H&P?G)_P#'*+ '_"I?"?\ T#8/SD_^.46
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MD]N=:TM/^)E;)^\1>MS$HZ8[S1@?N\<NN8_F(C 0'Q000<'@BD E !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!Z3\,_A]/X\U#RSNBL+<AKJ8#H.T2'
MIYDF,#^XNYR#@*P,^_K"PM]+MX[.SC6&"!0D<:C"JHZ ?U)R2<DDDDU0BW0
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M_P#'*+ =S86$&EV\=G:((8(%"1HN<*HZ 9)/'N:8%N@ H * "@ H * "@ H
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M)[>5CRO?_4-%^.:: ]5I@% !0 4 % !0 4 % !0!\S?M*_\ 'EIW_7>?_P!
M2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &
M]X6LO[2UBQL_^>]W;Q_0/*BDG@\ ')X/':@9^FE4(* "@ H * "@ H * "@
MH * /A'X\_\ (V3_ /7"W_\ 18J1GC= @H * "@ H * "@#Z-^ _A#2/%$6H
M-JULEV8&MQ&7+#:'$V[&UEZ[5ZYZ4(9] _\ "I?"?_0-@_.3_P".4["#_A4O
MA/\ Z!L'YR?_ !RBP!_PJ7PG_P! V#\Y/_CE%@#_ (5+X3_Z!L'YR?\ QRBP
M!_PJ7PG_ - V#\Y/_CE%@#_A4OA/_H&P?G)_\<HL ?\ "I?"?_0-@_.3_P".
M46 /^%2^$_\ H&P?G)_\<HL ?\*E\)_] V#\Y/\ XY18 _X5+X3_ .@;!^<G
M_P <HL ?\*E\)_\ 0-@_.3_XY18 _P"%2^$_^@;!^<G_ ,<HL ?\*E\)_P#0
M-@_.3_XY18 _X5+X3_Z!L'YR?_'*+ '_  J7PG_T#8/SD_\ CE%@#_A4OA/_
M *!L'YR?_'*+ '_"I?"?_0-@_.3_ ..46 /^%2^$_P#H&P?G)_\ '*+ '_"I
M?"?_ $#8/SD_^.46 /\ A4OA/_H&P?G)_P#'*+ =_! EK&D,0"1Q*J(HZ*J@
M!0/8  4P): "@ H * "@ H * "@ H * "@ H * "@#XS_:/_ .0[:?\ 7@O_
M */GJ6,^>:!!0 4 % !0 4 % 'T-^S?_ ,AV[_Z\&_\ 1\%"&?9E4(* "@ H
M * "@ H * /*?'OPZCU\-?Z<%BO@,LO19\#H>RR=@_ ;H_9E\ZOAE4]^GI+J
MN_\ P?Z9[V"Q[P]J5:[I='UA_FNZZ=.S^9IX)+61H9E:.1"596!#*1U!!Y!K
MPFFM'HT?;1DI)2BTT]4ULR&D4% !0 4 % !0 4 % !0!L:'KEWX>NEO+)]DB
M\$'E74]4=>,J?S!P00P!&D)RIOF@[/\ /R9S5J,,1!TZJNOQ3[I]'_3T/K'P
MEXOM/%EOYD'[N>,#SH2?F0GN/[R$_=8?0@'BOHJ-:-976C6Z_KH?!8K"SPDN
M66L7\,NC_P GW1UE=)YX4 % !0!X#\5_@]'XE#ZQHJK%J2@M)$ %2Z[D]@L_
M7YCQ(<!R#\](9\8W%O):2-!.C12QL4='!5E93@JRG!!!X((R#2$0T ?7/[-7
M_'EJ/_7>#_T!Z:&?3-,04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?_(XZ?_V]
M?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?\ T9)30'HE, H
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M *-6A#/L.J$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'RM^TS_P PG_M^_P#;.DP/E:D 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'J?@
M'X3ZIXW=9R#9Z=GYKF13\X!P1 AP96R""V1&N#EMP"D&?;?A?PGIO@ZS%CI<
M7EIP7<_-)*X&-\KX&YCZ !5Z(JKQ5".DH * "@ H * "@ H * "@ H * "@
MH * (YH4N(VAE 9)%*LIZ%6&"#[$'% 'YAZSILFC7UQI\O#VL\D+?6-RN?H<
M9![CFI&9M @H * "@ H * "@#Z%_9Y\3#3=6FT:8XCU&/='GM/"&8#DC&^(R
M9ZDLB"A#/LVJ$% !0 4 % !0 4 % !0!Y'\6OA]>^/[>UAL98(&M9)'8S%P"
M'50-NQ'Y&.<XI >'_P##-^N_\_=A_P!]3_\ QBE88?\ #-^N_P#/W8?]]3__
M !BBP!_PS?KO_/W8?]]3_P#QBBP!_P ,WZ[_ ,_=A_WU/_\ &*+ '_#-^N_\
M_=A_WU/_ /&*+ '_  S?KO\ S]V'_?4__P 8HL ?\,WZ[_S]V'_?4_\ \8HL
M ?\ #-^N_P#/W8?]]3__ !BBP!_PS?KO_/W8?]]3_P#QBBP!_P ,WZ[_ ,_=
MA_WU/_\ &*+ '_#-^N_\_=A_WU/_ /&*+ '_  S?KO\ S]V'_?4__P 8HL ?
M\,WZ[_S]V'_?4_\ \8HL ?\ #-^N_P#/W8?]]3__ !BBP!_PS?KO_/W8?]]3
M_P#QBBP'B?B/1'\-ZC/I<LD<\EJ_EN\6[86 !8+O56^4DJ<J/F!QD8) ,6@0
M4 % !0 4 % !0!ZA\&M._M+Q98J?NP-).WMY43LG_D38/Q_"@9^@54(* "@
MH * "@ H * "@ H * /A'X\_\C9/_P!<+?\ ]%BI&>-T""@ H * "@ H * /
MK#]FC_4ZI_OVG\KBFAGU%3$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MO3>TOT?9_@^G9=S78>6% !0 4 >,?%'X2V_C2,W^GA+?5D'WNB7( P(Y<='
M "2XR/N/E=I1 ?#]_87&ESO:7D;03PL5>-QAE8=B/U!'!&""0<T@/J[]FK_C
MRU'_ *[P?^@/30SZ9IB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H ^<?VDO^038_P#7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_ .1QT_\
M[>O_ $CN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /RMJ0"@ H * "@ H * "@#]#OA+_P BGIO_ %P/_HR2F@/1
M*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 >9?&3_D4=1_W(?_ $IAI,#\^J0!0 4 % !0 4 % $]K
M_KH_]]?YBD,_4NK$% !0 4 -DC652C@,C JRL 001@@@\$$<$'@B@#X6^+WP
MS;P7=_;[!2=*NG.SJ?L\AR?)8GG:>3$Q))4%6)9<M.PSQB@04 % !0 4 % !
M0 4 % !0 4 % !0 4 7]+TRYUFZBL;*-IKBX<)&B]23[] !U9B0JJ"S$ $T
M?H%\.? 5MX"TX6R8DO)]KW4V/ON!PB]_*CR0@/7+.0"Q >P'H-, H * "@#Y
M=_:7_P!3I?\ OW?\K>DQGR?2$% !0 4 % !0 4 >R? ;_D;(/^N%Q_Z+- S[
MNJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_R';3_KP7_T?/4L9\\T""@
MH * "@ H * /H_\ 9M_Y"U]_UZ+_ .C5H0S[#JA!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\
MK?M,_P#,)_[?O_;.DP/E:D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!U7AKP3K'BZ3R]*MI)ESAI2-D*>N^5L(#CG:"7/\*D
M\4#/JCP3\ ].T0K=ZXRZC=+R(@"+5#_ND!IC[R!4YP8B0#3L(]^1%C4(@"JH
M   P !P  .  . !TI@.H * "@ H * "@ H * "@ H * "@ H * "@ H ^%_C
MSH7]D^)6ND&(M1B2<8& '4>5(/\ >)02-_UTJ1GBM @H * "@ H * "@"[IN
MH3:3=0WULVR:VD26-O1D8,/PR.1W'% 'Z4>&=>@\3Z9;ZK;?ZNZC#;<YV/TD
MC/NCAD)[D9'!J@-V@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H Q_$&LP^'M.N-3N/]7:1/(1G&XJ/E0>[MA%]V% 'YGWMY+J%Q+=W
M#%YKB1Y9&/5G=BS'\6)-2!5H * "@ H * "@ H ^E?V;=)\W4+[4R.+>!(%)
M_O3/O./<+#@GKAL=":$!]>U0!0 4 % !0 4 % !0 4 % !0!\(_'G_D;)_\
MKA;_ /HL5(SQN@04 % !0 4 % !0!]8?LT?ZG5/]^T_E<4T,^HJ8@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M % !0 4 % !0 4 % !0!\X_M)?\ ()L?^OMO_1+TF!\=T@"@ H * "@ H *
M/5?@G_R..G_]O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_
M -&24T!Z)3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?GU2 * "@ H *
M "@ H GM?]='_OK_ #%(9^I=6(* "@ H * ,[5M*MM<M)=/OD$MO<(4=#W!Y
M!'HRD!E8<JP# @@&@#\^OB%X$NO >HFTES):RY>UGQQ)'GH<<"2/(61>W# ;
M'4F=AG!T""@ H * "@ H * "@ H * "@ H <JER%4$L2  !DDGH .Y/84 ?<
M7P>^&*^#[8:GJ* ZI=(.#_R[1-SY0_Z:-QYK=O\ 5J<!B[ ]NI@% !0 4 %
M'R[^TO\ ZG2_]^[_ )6])C/D^D(* "@ H * "@ H ]D^ W_(V0?]<+C_ -%F
M@9]W50@H * "@ H * "@ H * "@ H * "@#XS_:/_P"0[:?]>"_^CYZEC/GF
M@04 % !0 4 % !0!]'_LV_\ (6OO^O1?_1JT(9]AU0@H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MQGO@9Q^63^9H 6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* /G']I+_D$V/_7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_Y''3_ /MZ_P#2
M.XH ^_:H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _*VI * "@ H * "@ H * /T.^$O\ R*>F_P#7 _\ HR2F@/1*8!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 >9?&3_D4=1_W(?\ TIAI,#\^J0!0 4 % !0 4 % $]K_ *Z/
M_?7^8I#/U+JQ!0 4 % !0 4 <IXS\(6?C739--O!@GYH90!NAE ^5U_DZ\;D
M)7(R" #\]/$?AZ\\*W\NF:@NR:!L9'W74_=D0\91QRIP#V8!@0)&8= @H *
M"@ H * "@ H * "@ H ^K?@?\+_+$?B?5X_F.&L86'0=KEP>Y_Y8 ]!^]QS&
MP:&?4M,04 % !0 4 % 'R[^TO_J=+_W[O^5O28SY/I""@ H * "@ H * /9/
M@-_R-D'_ %PN/_19H&?=U4(* "@ H * "@ H * "@ H * "@ H ^,_VC_P#D
M.VG_ %X+_P"CYZEC/GF@04 % !0 4 % !0!]'_LV_P#(6OO^O1?_ $:M"&?8
M=4(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@ H *
M/9/@-_R-D'_7"X_]%F@9]W50@H * "@ H * "@#,UK1[;Q!93:;?+YEO<H4=
M>A]0RGLRL R'LP![4 ?G3XR\*77@S4Y=+N^?+.Z*3&%EB;[DB_4<, 3M<,N2
M5J1G+4""@ H * "@ H * "@#V+X0?$9O!5_]DO6/]EWK 2YY$,GW5G ]!PLH
M'+)AL,T:@@S[N1UD4,A#*P!!!R"#R""."".AJA#J "@ H * "@ H * "@ H
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M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^,_VC_\
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M_E\U_=\NGIM[57JGS04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!\X_M)?\@FQ_P"OMO\ T2])@?'=( H * "@ H * "@#U7X)
M_P#(XZ?_ -O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_T9
M)30'HE, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /,OC)_R*.H_P"Y#_Z4PTF!^?5( H * "@ H *
M"@">U_UT?^^O\Q2&?J75B"@ H * "@ H * /+OBC\.H?'=AF$+'J5J";:0X&
M[N8)#_<<]"?]6_S#@N&0'P-=VDUA,]M<HT4T+,DB.,,C*<,K ]"",4@*] !0
M 4 % !0 4 % !0 4 >[?!OX8'Q5<#5]30_V9;/\ *C#BZE4_<YZPH?\ 6'D,
M1Y0S\Y4&?;:J%  & . !T JA"T % !0 4 % !0!\N_M+_P"ITO\ W[O^5O28
MSY/I""@ H * "@ H * /9/@-_P C9!_UPN/_ $6:!GW=5""@ H * "@ H *
M"@ H * "@ H * /C/]H__D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?1_P"S
M;_R%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[9TF!
M\K4@"@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H *
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M 009^AGA[Q!9^)[&+4]/<203+G_:1A]Z-Q_"Z'AA^()4@FA&U0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 R65($:65@B("S,Q"JJJ,EF)P  !
MDD\ <F@#X.^+GQ&;QO?BWM"1IEFS"$=/-?HT[#@\CB,'[J9. SN*D9Y#0(*
M"@ H * "@ H * /H?]GGPQ_:&JRZW,O[K3T*1'L9Y@5XXYV1;\]""\9H0S[+
MJA!0 4 % !0 4 % !0 4 % !0 4 ?"/QY_Y&R?\ ZX6__HL5(SQN@04 % !0
M 4 % !0!]8?LT?ZG5/\ ?M/Y7%-#/J*F(* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /C/]H_\
MY#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4 ?0W[-_\ R';O_KP;_P!'P4(9
M]F50@H * "@ H * "@ H * "@ H * "@"AJ>EVVL6[V=X@EAD'*GL>S*>JL.
MH88(J)04URR5T:TZDZ,E4INTEU_1]UY'RKXT\#7/A.7>N9K)SB.;'W2<_NY,
M='&.#]UQR,'*K\]6H.B^\>C_ $?G^9]Y@\;'%JS]VHMX]_->7XK\7P=<AZH4
M % !0 4 % !0 4 % "T >[_#_P")>S9I>M/\OW8;EST]$F)[=ED)XX#\?,/6
MP^)M:G5>G27Z/_/[SY7'9?O7PR\Y07YQ_5?=V/?0<\BO9/DPH * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /G']I+_ )!-C_U]M_Z)
M>DP/CND 4 % !0 4 % !0!ZK\$_^1QT__MZ_]([B@#[]J@"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\K:D H * "@ H *
M "@ H _0[X2_\BGIO_7 _P#HR2F@/1*8!0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?&3_D4=1_W(
M?_2F&DP/SZI % !0 4 % !0 4 3VO^NC_P!]?YBD,_4NK$% !0 4 % !0 4
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MP"@ H * "@ H * "@ H * "@ H ^$?CS_P C9/\ ]<+?_P!%BI&>-T""@ H
M* "@ H * /K#]FC_ %.J?[]I_*XIH9]14Q!0 4 % !0 4 % !0 4 % !0 4
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M0>001P01R".M>WOJCXYJVCT:'4Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'SC^TE_R";'_ *^V_P#1+TF!\=T@"@ H * "@ H * /5
M?@G_ ,CCI_\ V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M5O28SY/I""@ H * "@ H * /9/@-_P C9!_UPN/_ $6:!GW=5""@ H * "@
MH * "@ H * "@ H * /C/]H__D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?1
M_P"S;_R%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[
M9TF!\K4@"@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@
MH * "@""ZM8KZ%[:X1989D:.1&&59&!5E(]""0: /SW^)?@67P)JC6P#-93[
MI+24\[H\\HQZ&2+(5^F05? #BI&>>4""@ H * "@ H * "@#IO"/BF[\&ZE%
MJED?FC.V2,G"RQ-C?$_LP&0<':P5Q\RB@9^B7A[7[3Q/80ZG8-O@G7(S]Y&'
M#1N.SHV58<C(R"5()H1M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '
MS+^T#X&^U0KXFLU_>0!8KP*/O19Q',<#),9/EN3D[&3HL9I,#Y'I % !0 4
M% !0 4 % !0!Z#X!^(NH> KKS+<^=9R$>?:LQ"..,LG7RY0!A7 /HRLO% S[
MJ\*>+]-\96@O=,D#@8$D;8$L+'^&1,G:>#@\JP!*L15".GH * "@ H * "@
MH * "@ H * "@ H * "@"O=W<-A"]S<NL,,2EGD=@JJHZEF. !0!\;?%/XRR
M>) ^D:&6AT[[LLW*R7..J@<%(3_=/SR#[VU24,C/GZ@04 % !0 4 % !0 4
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MO9^_3^'JNW_ _(^SP.8*K:C7=JG26REZ]I?@_70\>KS3Z(* "@ H * "@ H
M* "@ H ]4\!?$23P\5L;\M)8$_*>KP$]U[F//+)VR63G*MWT,0Z7N3UA^7IY
M>7W>?@XW +$7JT;*KUZ*7KV?9_)]U].6]Q'=1K-"RR1R*&5E.593R"".H->^
MFFKK9GQ,HN#<9*S6C3W3):9(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?_(XZ
M?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?\ T9)30'HE
M, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /,OC)_R*.H_[D/\ Z4PTF!^?5( H * "@ H * "@">U_
MUT?^^O\ ,4AGZEU8@H * "@ H * "@ H * (Y8DG1HI55XW4JRL RLK##*RG
M((()!!&".#0!\(_%KX:/X(O/M=FI;2KISY3<GR7.6,#DY/0$Q,3ET!!)9&-3
ML,\?H$% !0 4 7M,TVYUBZBL;*-IKB=PD:+U)/Z  9+,<!5!8D $T ?H%\./
M -MX"TX6Z[9+R?#W4X'WGQPBGKY4>2$'&3N<@%B ]@/0J8!0 4 % !0 4 %
M!0 4 ?+O[2_^ITO_ '[O^5O28SY/I""@ H * "@ H * /9/@-_R-D'_7"X_]
M%F@9]W50@H * "@ H * "@ H * "@ H * "@#XS_ &C_ /D.VG_7@O\ Z/GJ
M6,^>:!!0 4 % !0 4 % 'T?^S;_R%K[_ *]%_P#1JT(9]AU0@H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H ^5OVF?\ F$_]OW_MG28'RM2 * "@ H * "@ H ]D^ W_ "-D'_7"
MX_\ 19H&?=U4(* "@ H * "@ H * "@ H XOQ[X,M_'&E2:=-A)A^\MY2/\
M53 ':3CG8V2L@'52<?,%(0'YWZGIMQH]U+8WB&*XMW:.1#V93@\C@@]589#
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MOXF:KXZDVW#?9[)6S':1D^6,=&D/!ED _B8 #G8B9(*&>=4""@ H * "@ H
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M'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_ -&24T!Z)3 * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?GU2 * "@ H * "@ H GM?]='_OK_
M #%(9^I=6(* "@ H * "@ H * "@ H R]:T:U\064NG7Z"6WN%*NO?U#*>S*
M0&5NS 'M0!^>_CWP1=^!-2:QN,O ^7MI\866+. >,@.O21,Y4X(RK*QD9Q-
M@H <JER%4$L2  !DDGH .Y/84 ?<7P>^&*^#[8:GJ* ZI=(.#_R[1-SY0_Z:
M-QYK=O\ 5J<!B[ ]NI@% !0 4 % !0 4 % !0 4 ?+O[2_\ J=+_ -^[_E;T
MF,^3Z0@H * "@ H * "@#V3X#?\ (V0?]<+C_P!%F@9]W50@H * "@ H * "
M@ H * "@ H * "@#XS_:/_Y#MI_UX+_Z/GJ6,^>:!!0 4 % !0 4 % 'T?\
MLV_\A:^_Z]%_]&K0AGV'5""@ H * "@ H * "@ H * "@ H * "@ H * "@
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M!F[JFU?E)D6F@/?J8!0 4 % !0 4 % !0 4 % !0 4 % !0!\(_'G_D;)_\
MKA;_ /HL5(SQN@04 % !0 4 % !0!]8?LT?ZG5/]^T_E<4T,^HJ8@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?0W[-__
M "';O_KP;_T?!0AGV95""@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M *"E_P#^!,O_ ,50 ?\ "P_$O_04O_\ P)E_^*H /^%A^)?^@I?_ /@3+_\
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M9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 3VO^NC_P!]?YBD,_4NK$%
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M4+R>"64AXY)Y&1AY;G#*6((R >>XH ^YJH04 % !0 4 % !0 4 % !0 4 %
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M,^@*,!TYZTK@>3Z[\1O$7B/*WU].T;<&*-A#$1Z&.((K?\"#'OG- SB:!!0
M4 % !0 4 % !0 4 % !0 4 ?0GP4^&)U^==>U6/_ $"W?,$;CBXF4_>(/WH8
MB.<_+(_R?,JR+0,^SJH04 % !0 4 % !0 4 % !0 4 % !0 4 % 'PC\>?\
MD;)_^N%O_P"BQ4C/&Z!!0 4 % !0 4 % &UI/B/4]!#C3+JXLQ+M+B"5X]^W
M.W=M(SC<<9Z9/K0,U_\ A8?B7_H*7_\ X$R__%4 '_"P_$O_ $%+_P#\"9?_
M (J@ _X6'XE_Z"E__P"!,O\ \50 ?\+#\2_]!2__ / F7_XJ@ _X6'XE_P"@
MI?\ _@3+_P#%4 '_  L/Q+_T%+__ ,"9?_BJ #_A8?B7_H*7_P#X$R__ !5
M!_PL/Q+_ -!2_P#_  )E_P#BJ #_ (6'XE_Z"E__ .!,O_Q5 !_PL/Q+_P!!
M2_\ _ F7_P"*H /^%A^)?^@I?_\ @3+_ /%4 '_"P_$O_04O_P#P)E_^*H /
M^%A^)?\ H*7_ /X$R_\ Q5 !_P +#\2_]!2__P# F7_XJ@ _X6'XE_Z"E_\
M^!,O_P 50 ?\+#\2_P#04O\ _P "9?\ XJ@ _P"%A^)?^@I?_P#@3+_\50 ?
M\+#\2_\ 04O_ /P)E_\ BJ #_A8?B7_H*7__ ($R_P#Q5 !_PL/Q+_T%+_\
M\"9?_BJ #_A8?B7_ *"E_P#^!,O_ ,50 ?\ "P_$O_04O_\ P)E_^*H ]6^#
M'B_6M8\2PVM_?75S T,Y,<LTCH2L9()5F(R#R/2@#[+JA!0 4 % !0 4 % !
M0 4 % !0 4 ?&?[1_P#R';3_ *\%_P#1\]2QGSS0(* "@ H * "@ H ^AOV;
M_P#D.W?_ %X-_P"CX*$,^S*H04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M-&5./W<;#][D89AY7/S[4,^U54*  , < #H!5"%H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H ]D^ W_(V0?]<+C_ -%F@9]W50@H * "@ H
M* "@ H * "@ H * /C/]H_\ Y#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4
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M H * "@ H * "@ H * "@ H ^<?VDO\ D$V/_7VW_HEZ3 ^.Z0!0 4 % !0
M4 % 'JOP3_Y''3_^WK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /L3]FW_D$WW_7VO_HE
M*: ^CJ8!0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_TIAI,#\^J0!0 4 %
M!0 4 % $]K_KH_\ ?7^8I#/U+JQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!\N_M+_ .ITO_?N_P"5O28SY/I""@ H * "
M@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H * "@ H * "@ H
M^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 % !0 4 % !0 4 % !0
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M&2QXMYCPLH[!'X27T 5\_(0QL,^Y 01D<@U0@H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /GOXL?!U?$6_6=#41ZA]Z: 85+GU=>@2?U)^67OA\LR
M^-IH9+9VAF5HY$)5D8%65@<$,#@@@\$'D4@(J "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /8OA?\ "FY\;3+>W@:W
MTF-OFDZ/.5ZQPY[=GDQM7D#+\ &?<>G:=;:1;1V5E&L%O H2.-!A54?J23DL
MQ)9F)9B6)-4(NT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY_Y&R?
M_KA;_P#HL5(SQN@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % 'LGP&_P"1L@_ZX7'_ *+- S[NJA!0 4 % !0
M4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/- @H * "@ H * "@#Z
M&_9O_P"0[=_]>#?^CX*$,^S*H04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % '(>+O!MIXL@V2XBN8Q^ZG RR]]K#C<A/52>"25(.<\M:C&LM
M=)+9_IZ'HX7%SPDKQU@_BCT?FNS\_O/E#6M$N_#]RUG>H8Y%Y!_A=<D!T/\
M$IQP?P(!! ^>G"5-\LU9_P!:H^]HUH8B"J4G=?BGV:Z,R*S.@* "@ H * /H
MCX*?\>MY_P!=8_\ T!J]G!;3]5^I\?F_QT_\+_-'MM>L?,A0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?./[27_ "";'_K[;_T2])@?'=(
MH * "@ H * "@#U7X)_\CCI__;U_Z1W% 'W[5 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y6U(!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'V)^S;_R"
M;[_K[7_T2E- ?1U, H * "@ H * "@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?
MGU2 * "@ H * "@ H GM?]='_OK_ #%(9^I=6(* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /EW]I?\ U.E_[]W_ "MZ3&?)
M](04 % !0 4 % !0![)\!O\ D;(/^N%Q_P"BS0,^[JH04 % !0 4 % !0 4
M% !0 4 % !0!\9_M'_\ (=M/^O!?_1\]2QGSS0(* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79
MO_14E S]#:H04 % !0 4 % !0 4 % !0 4 % 'RM^TS_ ,PG_M^_]LZ3 ^5J
M0!0 4 % !0 4 % 'LGP&_P"1L@_ZX7'_ *+- S[NJA!0 4 % !0 4 % !0 4
M % !0 4 % !0!\M?'?X;[PWBC3$Y 'VZ-1U &!<@#T&%FQVVR$<2-28SY2I"
M"@ H * "@ H * "@ H ^R/@9\1_[9MQX=U)\WEJG^C.QYF@4?ZOGK)"!QSEH
MN<?NW8M ?15, H * "@ H * "@ H * "@ H * "@ H * "@ H * /(?B3\);
M+QNAO+;;::HJ_+,!A)L#A)P!D\?*LH!=1@'>JA @/B/7= OO#5V]AJ<+6\\?
M\+=&'9T8?*Z'LRD@\C.012&8] @H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H ^C_ (9?!";53'JOB)&@M,AX[0Y668=09>C1
M1'^[Q(XS]Q2K,6&?7MO;Q6D200(L442A$1 %55485548  '  X JA$U !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0!\(_'G_ )&R?_KA;_\ HL5(SQN@
M04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % 'LGP&_Y&R#_KA<?^BS0,^[JH04 % !0 4 % !0 4 % !0 4 % 'Q
MG^T?_P AVT_Z\%_]'SU+&?/- @H * "@ H * "@#Z&_9O_Y#MW_UX-_Z/@H0
MS[,JA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '.^)?#
M%GXHM3;7:X89,4J@;XF]5/H>-R'AAUP0I&%6E&JN66_1]5_75'9A\1/"SYZ;
MTZQZ27G^CZ?>?)WB3PS>>%[DVUVO!R8Y%^Y(H.-RGL>FY3\RY&>""?G:E.5)
M\LOD^C/OL/B(8J'/3>V\>L7Y_H]F<[6)V!0 4 % 'T1\%/\ CUO/^NL?_H#5
M[."VGZK]3X_-_CI_X7^:/;:]8^9"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H ^<?VDO^038_P#7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_
M .1QT_\ [>O_ $CN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@H * "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@
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M?8_P[^"UAX2*7^I%;[4EPRDC]Q W_3)6^^X/25QD$ HJ$9+L(]OI@% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY_P"1LG_ZX6__ *+%2,\;
MH$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MKV<%M/U7ZGQ^;_'3_P +_-'MM>L?,A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?./[27_()L?^OMO_ $2])@?'=( H * "@ H * "@#U7X
M)_\ (XZ?_P!O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?8G[-O_ "";[_K[7_T2E- ?
M1U, H * "@ H * "@ H * "@#S+XR?\ (HZC_N0_^E,-)@?GU2 * "@ H *
M"@ H GM?]='_ +Z_S%(9^I=6(* "@ H * "@ H * "@ H * "@ H * "@ H
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M^P\-6PLM+@2VA7G:@Y8_WG8Y9V/=G).,#. !5"-B@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H ^$?CS_ ,C9/_UPM_\ T6*D9XW0(* "@ H
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M'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?E;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?8G[-O_()OO^OM?_1*4T!]'4P"@ H * "@ H *
M "@ H * /,OC)_R*.H_[D/\ Z4PTF!^?5( H * "@ H * "@">U_UT?^^O\
M,4AGZEU8@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M % !0 4 % !0 4 % 'QG^T?_ ,AVT_Z\%_\ 1\]2QGSS0(* "@ H * "@ H
M^AOV;_\ D.W?_7@W_H^"A#/LRJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 07-M%>Q-;W"+)%("KHPRK ]014M*2Y9*Z?0J,
MG!J<&TUJFMT?,?CSX=R^'6:]L0TM@QR>[09/"MW*<X5^WW7YPS>#7P[I>]#6
M'Y>OEY_?Y_;X+'K$)4JME5Z=I^:[/NOFNR\MK@/=/HCX*?\ 'K>?]=8__0&K
MV<%M/U7ZGQ^;_'3_ ,+_ #1[;7K'S(4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'SC^TE_R";'_ *^V_P#1+TF!\=T@"@ H * "@ H * /5
M?@G_ ,CCI_\ V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!\C_\,U7O_01A_P"_#_\ Q=*PP_X9JO?^@C#_
M -^'_P#BZ+ '_#-5[_T$8?\ OP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-
M5[_T$8?^_#__ !=%@#_AFJ]_Z",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718
M_P"&:KW_ *",/_?A_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\
MWX?_ .+HL ?\,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7
MO_01A_[\/_\ %T6 /^&:KW_H(P_]^'_^+HL ?\,U7O\ T$8?^_#_ /Q=%@#_
M (9JO?\ H(P_]^'_ /BZ+ '_  S5>_\ 01A_[\/_ /%T6 /^&:KW_H(P_P#?
MA_\ XNBP!_PS5>_]!&'_ +\/_P#%T6 /^&:KW_H(P_\ ?A__ (NBP!_PS5>_
M]!&'_OP__P 718 _X9JO?^@C#_WX?_XNBP!_PS5>_P#01A_[\/\ _%T6 /\
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M_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\ %T6
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M^"USX*UB/5I;R.X6..1/+6)E)\Q2N<ER.,YZ46 ^@:8@H * "@ H * "@ H
M* "@ H * "@ H * "@ H \)^(OP4A\97XU2PG2QGD7%P&C+K*PX60!67:^/E
M?J& 4\-N+*P'GO\ PS5>_P#01A_[\/\ _%T6&'_#-5[_ -!&'_OP_P#\718
M_P"&:KW_ *",/_?A_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\
MWX?_ .+HL ?\,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7
MO_01A_[\/_\ %T6 /^&:KT?\Q&'_ +\/_P#'*+ ?37AFPO\ 2].AL]4G6]N8
M%V&=5*F15X0N&+$OMP';/SD;CR33$;U !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'G?B'X4^&_$F7N;-(9F_P"6UM^X?/J0G[MS[R(]
M*P'BNN?LVR*2^BWRL,G;%=H5(';,T0(8]O\ 4(._M18#R75OA#XJT?)>PDG0
M=&MBL^?HD9:0?B@I#//KJSGL7\NYCD@<?PR(R-^3 &@"M0(* "@ H * "@ H
M ?'$\S!(U+L>@4$D_0#F@#M]*^&7B;6"!;:=<@-R&F3[.F/7=.8U(^A.>V21
M0,]3T7]G'5;G#ZI=P6:GDI$&GD'L?]5&#[J[@=>>E%A'L6@_ SPSHVUYXGU"
M5>=UR^4S[1($C(]G#_4T[ >N6UK#91B"VC2&).%2-51%^BJ !^ I@3T % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\_?$+X+7/C
M76)-6BO([=9(XT\MHF8CRU"YR' YQGI2L,XC_AFJ]_Z",/\ WX?_ .+HL ?\
M,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\
M%T6 /^&:KW_H(P_]^'_^+HL ?\,U7O\ T$8?^_#_ /Q=%@#_ (9JO?\ H(P_
M]^'_ /BZ+ '_  S5>_\ 01A_[\/_ /%T6 /^&:KW_H(P_P#?A_\ XNBP!_PS
M5>_]!&'_ +\/_P#%T6 /^&:KW_H(P_\ ?A__ (NBP!_PS5>_]!&'_OP__P 7
M18 _X9JO?^@C#_WX?_XNBP!_PS5>_P#01A_[\/\ _%T6 /\ AFJ]_P"@C#_W
MX?\ ^+HL ?\ #-5[_P!!&'_OP_\ \718 _X9JO?^@C#_ -^'_P#BZ+ '_#-5
M[_T$8?\ OP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-5[_T$8?^_#__ !=%
M@#_AFJ]_Z",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718 _P"&:KW_ *",/_?A
M_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\ WX?_ .+HL ?\,U7O
M_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\ %T6
M/^&:KW_H(P_]^'_^+HL ?\,U7O\ T$8?^_#_ /Q=%@.W^'OP6N?!6L1ZM+>1
MW"QQR)Y:Q,I/F*5SDN1QG/2BP'T#3$% !0 4 % !0 4 % !0 4 % !0!XA\3
MOA+<>/\ 4(;Z&ZCM1!;B$J\;.21)(^[(88'SXQCM2 \V_P"&:KW_ *",/_?A
M_P#XNBPP_P"&:KW_ *",/_?A_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ
M]_Z",/\ WX?_ .+HL ?\,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+
MHL ?\,U7O_01A_[\/_\ %T6 ])^&/PEN/A_J$U]-=1W0FMS"%2-D()DC?=DL
M>/DQC'>@1[?3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * &NBRJ4<!E8$,I (((P00>""."#P12WT8TVG=:-;'SEX_^&S:9
MOU/25+6O+2PCDP^K(.IB[D=8QSROW?$KX;DO.G\/5=O^!^1]C@<P52U#$.T]
MHR_F\GVE^?KOT7P4_P"/6\_ZZQ_^@-6V"VGZK]3CS?XZ?^%_FCVVO6/F0H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /,OB?X E^(%G!:0SI
M:FWF,I9T+@@H5P &7!YSFD!XI_PS5>_]!&'_ +\/_P#%T6&'_#-5[_T$8?\
MOP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-5[_T$8?^_#__ !=%@#_AFJ]_
MZ",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718 _P"&:KW_ *",/_?A_P#XNBP'
M7>!/@?<^#];MM9EO8ITMO-S&L3*6\R"6(88N0,&3=TY Q181]%4P"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H Q-)T&TT6:X>R3RA=,LCH/N
M!AN!*+CY0>I . ?N@#BL84XTW)PTYK-KIUV.JK6G6C!5'?D32?6VF[Z_GW-N
MMCE"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
+* "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ebs-20220930_g2.jpg
<TEXT>
begin 644 ebs-20220930_g2.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
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M_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H **** "BBB@ HHHH
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MC_B(N_ZL[_\ ,A?_ 'OK\RZ*/]9<[_Y^_P#DL?\ (/\ B'7!O_0+_P"3U/\
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M )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H **** "BBB@
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M->UU^TX#_<:7^&/Y(_CK.O\ D<XG_KY/_P!*84445UGF!1110 4444 %%%%
M'X@_\'O/_)K/P/\ ^R@:C_Z0BBC_ (/>?^36?@?_ -E U'_TA%% 'G__  :;
M?\I3/VN_^WC_ -/D]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1110
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MG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_P>\_\ )K/P/_[*!J/_ *0BB@#S_P#X--O^4IG[7?\ V\?^GR>OW^K\ ?\
M@TV_Y2F?M=_]O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXW_P""
MZ?\ R8I-_P!C=IW_ +5K[(KXW_X+I_\ )BDW_8W:=_[5KS,Y_P"156_PL^CX
M0_Y*C!_]?(_F?B_1117X\?UJ%%%% !1110 4444 %%%% '[^_P#!.+_DQ7X6
M_P#8H6W\C7M=>*?\$XO^3%?A;_V*%M_(U[77[3@/]QI?X8_DC^.LZ_Y'.)_Z
M^3_]*84445UGF!1110 4444 %%%% 'X@_P#![S_R:S\#_P#LH&H_^D(HH_X/
M>?\ DUGX'_\ 90-1_P#2$44 >?\ _!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\
MP:;?\I3/VN_^WC_T^3U^_P!0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7QO_P73_Y,4F_[&[3O_:M?9%?&_P#P73_Y,4F_[&[3O_:M>9G/
M_(JK?X6?1\(?\E1@_P#KY'\S\7Z***_'C^M0HHHH **** "BBB@ HHHH _?W
M_@G%_P F*_"W_L4+;^1KVNO%/^"<7_)BOPM_[%"V_D:]KK]IP'^XTO\ #'\D
M?QUG7_(YQ/\ U\G_ .E,****ZSS HHHH **** "BBB@#\0?^#WG_ )-9^!__
M &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O'_I\
MGK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_P>\_\ )K/P/_[*!J/_ *0BB@#S_P#X--O^4IG[7?\ V\?^GR>OW^K\ ?\
M@TV_Y2F?M=_]O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXW_P""
MZ?\ R8I-_P!C=IW_ +5K[(KXW_X+I_\ )BDW_8W:=_[5KS,Y_P"156_PL^CX
M0_Y*C!_]?(_F?B_1117X\?UJ%%%% !1110 4444 %%%% '[^_P#!.+_DQ7X6
M_P#8H6W\C7M=>*?\$XO^3%?A;_V*%M_(U[77[3@/]QI?X8_DC^.LZ_Y'.)_Z
M^3_]*84445UGF!1110 4444 %%%% 'X@_P#![S_R:S\#_P#LH&H_^D(HH_X/
M>?\ DUGX'_\ 90-1_P#2$44 >?\ _!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\
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M#4?_ $A%% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\
MT^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU[77BG_!.+_DQ7X6_P#8H6W\C7M=?M. _P!QI?X8_DC^.LZ_Y'.)_P"OD_\
MTIA11176>8%%%% !1110 4444 ?B#_P>\_\ )K/P/_[*!J/_ *0BBC_@]Y_Y
M-9^!_P#V4#4?_2$44 >?_P#!IM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]
MKO\ [>/_ $^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9G/_ "*JW^%GT?"'_)48/_KY'\S\7Z***_'C^M0HHHH **** "BBB@ HHHH
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M7[?@-<#2_P ,?R1_&>=Z9UB?^OD__2F%%%%=9Y84444 %%%% !1110!^(/\
MP>\_\FL_ _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\ TA%% 'G_ /P:;?\
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M!_\ V4#4?_2$44 >?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\
MMX_]/D]?O]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "OR=_X.%?^2\> ?^Q1F_\
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M]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\
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M]>"/^QOTW_TJCK2C_&CZHY\7_NE3_"_R/Z.J***_<#^+PHHHH *\+_X*'_\
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M^3U^_P!7X _\&FW_ "E,_:[_ .WC_P!/D]?O]0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7Y._\ !PK_ ,EX\ _]BC-_Z5/7ZQ5^3O\
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MUX(_[&_3?_2J.E1_C1]45B_]TJ?X7^1_1U1117[@?Q>%%%% !7S-_P %9O\
MDTN3_L9++^4E?3-?,W_!6;_DTN3_ +&2R_E)0!^8%%%% !1110 4444 %%%%
M !1110!^PW[$G_)I?@#_ +%N#^1KU*O+?V)/^32_ '_8MP?R->I4 %%%% !1
M110 4444 %%%% 'X@_\ ![S_ ,FL_ __ +*!J/\ Z0BBC_@]Y_Y-9^!__90-
M1_\ 2$44 >?_ /!IM_RE,_:[_P"WC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3
MY/7[_4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^3O\
MP<*_\EX\ _\ 8HS?^E3U^L5?D[_P<*_\EX\ _P#8HS?^E3U\]Q1_R)I^L?S1
M]]X9_P#)74O\,_\ TEGY\U]!? +X)_&OX1>'M-_:<TOX,^)M8UJX1IOAS9V/
MAVXN8XY1E5U:8HA 2)OF@0\R2JKG]W&1)\^UW]C^U=^U)IEE#INF_M)^/[>W
MMXEBM[>#QC?(D2*,*JJ)<*    . !7YKA:E&E/FJ7NMK6T??7\/,_HG,J&,Q
M-%4Z/+9_%S7U7;3OU\M.MUW'[(?PPOW_ &S=,\)?%W3]1M]?TX7FI6^CSWLE
MK=WFKPV<EU:6CR(RR12R3K$I *R;B4^5SQUA^)OCK]I']E[XO7GQWL+#3H?#
M&IV>LZ+?Z3H4&DHVNSW2P/9S16T<:7<CP-.P,H>:/R68,%+AOF?4M?UW6-<G
M\3ZOK5W=:E<W37-SJ%S<L\\L[-N:5I&)9G+$DL3DGG-:GC/XK_%+XCPV]M\0
M_B5K^O1V>?LD>M:S/=+!D8.P2LVWIVK:EBX4J3@D[/F^=U97_P .Z\^VYR8C
M*JN)Q4*TFKI0UMK%QDY2Y/*?PO5:;\RT.Y_9W_9M\7?$C3KKXN:K\-_$6L^$
M-"NECNK;0=,FFGU>ZQN6PA,:-LW#F28C;#&<\NT<<F9^T+9_'KQ;\67\7?&C
MP)J6E>(/%DBS:?I-UICVTGD!OL\$4%NXWK"HC$,8Q@B+ )VFLOPC^T1^T!X
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M &-^F_\ I5'7)1_C1]4>IB_]TJ?X7^1_1U1117[@?Q>%%%% !7S-_P %9O\
MDTN3_L9++^4E?3-?,W_!6;_DTN3_ +&2R_E)0!^8%%%% !1110 4444 %%%%
M !1110!^PW[$G_)I?@#_ +%N#^1KU*O+?V)/^32_ '_8MP?R->I4 %%%% !1
M110 4444 %%%% 'X@_\ ![S_ ,FL_ __ +*!J/\ Z0BBC_@]Y_Y-9^!__90-
M1_\ 2$44 >?_ /!IM_RE,_:[_P"WC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3
MY/7[_4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^3O\
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M4 ><T45UOA7X/>)O$_PN\4?%U(I(-(\,K:I)</ 2EQ<3W$<2PJV0,A69R1G
M4 @;@: .2HHHH _8;]B3_DTOP!_V+<'\C7J5>6_L2?\ )I?@#_L6X/Y&O4J
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MPXX=O,894J:H_!_X\:U\'?$6I^*[3P5X=UZ^U2VD@FF\26,EQY:2;A+L"2(
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MFW_*4S]KO_MX_P#3Y/7[_4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5^3O\ P<*_\EX\ _\ 8HS?^E3U^L5?D[_P<*_\EX\ _P#8HS?^
ME3U\]Q1_R)I^L?S1]]X9_P#)74O\,_\ TEGY\T445^6']-!1110 4444 %%%
M% !77?L_?\EZ\$?]C?IO_I5'7(UUW[/W_)>O!'_8WZ;_ .E4=:4?XT?5'/B_
M]TJ?X7^1_1U1117[@?Q>%%%% !7S-_P5F_Y-+D_[&2R_E)7TS7S-_P %9O\
MDTN3_L9++^4E 'Y@4444 %%%% !1110 4444 %%%% '[#?L2?\FE^ /^Q;@_
MD:]2KRW]B3_DTOP!_P!BW!_(UZE0 4444 %%%% !1110 4444 ?B#_P>\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?D[_P<*_\
M)>/ /_8HS?\ I4]?K%7Y._\ !PK_ ,EX\ _]BC-_Z5/7SW%'_(FGZQ_-'WWA
MG_R5U+_#/_TEGY\T445^6']-!1110 4444 %%%% !77?L_?\EZ\$?]C?IO\
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MS/4:*\N_X;0_9I_Z*3_Y1[S_ .,T?\-H?LT_]%)_\H]Y_P#&:/J&._Y]2_\
M 7_D'U_ _P#/V/\ X$O\S]U_V)/^32_ '_8MP?R->I5X]_P3^\2:+XP_8M^&
MOBCPY>_:+&^\*V\MK/Y;)O0@X.U@"/Q KV&N5IQ=GN=2:DKK8****0PHHHH
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M_P"E3U\]Q1_R)I^L?S1]]X9_\E=2_P ,_P#TEGY\T445^6']-!1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?D[_P '"O\ R7CP#_V*,W_I4]?K
M%7P;_P %;/@_\.OB1\4_"NH>-/#OVV:V\/R1PO\ :YH]JF=CC$;J#SZU\[Q4
MU')9OSC^:/T#PQBY<7TDOY9_^DL_(FBOL/\ X98^ _\ T(G_ )5+K_X[1_PR
MQ\!_^A$_\JEU_P#':_*/:Q/Z>]A,^/**^P_^&6/@/_T(G_E4NO\ X[1_PRQ\
M!_\ H1/_ "J77_QVCVL0]A,^/**^P_\ AECX#_\ 0B?^52Z_^.T?\,L? ?\
MZ$3_ ,JEU_\ ':/:Q#V$SX\HK[#_ .&6/@/_ -")_P"52Z_^.T?\,L? ?_H1
M/_*I=?\ QVCVL0]A,^/*Z[]G[_DO7@C_ +&_3?\ TJCKZ5_X98^ _P#T(G_E
M4NO_ ([70?"C]F7X(:;\4O#6HV7@G9-;^(+.2)_[2N3M99T(.#)@\CO6M"K'
MVT?5?F<^+H3^J5/\+_(_86BBBOW0_BD**** "OS]_P"#ES_E&A/_ -CYI/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J
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M4 %%%% !1110 5\9?\%-/^2C^'/^P(__ *.:OLVOC+_@II_R4?PY_P!@1_\
MT<U?-<6_\B2?K'\T?H?A=_R6-+_#/_TEGS14EI=W-A=17UE</%-#(LD,L;89
M&!R&!'0@\U'17Y(FTS^I&DU9G8ZC\;/$E\=4OK?1-)LM4UNW>'6-9LK9TN+M
M'_UH(+F./?\ QF-$+9.3@G/.:+K2:2TB7.C6=_!+CS+:\5]I(S@AHV1U(R>C
M#.><U1HK:=>M4DI2=[?T_OZ]^IS4L%A:%-PIQLG;:_3;7=6Z6VZ6-GQ=XYUC
MQA'865Y#;VMCI5L8-,TZRC*PVR%BS;0269F8EF9BS,3R3@89XN\87GC*YLKF
M]TK3K0V.FPV4:Z=9K"LBQ@@.X'WI#GEN_'I6314RK59WN][7^6WW%4\+AZ7+
MR12Y;V^>_P WNWNWJ;/AGQQK'A31];T/38;=H=>T];.],R$LL8E24%"",'<@
MY.>,\5C445,IRE%)O1;?F:0I4Z<Y2BK.3N_-V2_))!6W\-?^2BZ!_P!ANU_]
M'+6)6W\-?^2BZ!_V&[7_ -'+5T/X\?5?F9XS_=*G^%_D?J31117[V?P^%%%%
M !7RC_P66_Y,SE_[&BP_]J5]75\H_P#!9;_DS.7_ +&BP_\ :E;X;^/'U.+,
M?]QJ>C/R5HHHKZ$^ "BBB@ HHHH **** "BBB@#]NOV!O^3,_AQ_V*]O_6O7
MJ\A_8&_Y,S^''_8KV_\ 6O7J^;J_Q9>K/T7#?[M#T7Y!11169N%%%% !1110
M 4444 ?B#_P>\_\ )K/P/_[*!J/_ *0BBC_@]Y_Y-9^!_P#V4#4?_2$44 >?
M_P#!IM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&7_!33_DH_AS_L
M"/\ ^CFK[-K\\/\ @LQ_R5WPA_V+<G_I0U>;FV7?VI@98?FY;VUM?9WVNCZ+
MA;/O]6LXAC_9^TY5)<M^7=6WL_R/*J*\+HKY'_47_J(_\D_^V/U+_B-/_4!_
MY5_^YGNE%>%T4?ZB_P#41_Y)_P#;!_Q&G_J _P#*O_W,]THKPNBC_47_ *B/
M_)/_ +8/^(T_]0'_ )5_^YGNE%>%T4?ZB_\ 41_Y)_\ ;!_Q&G_J _\ *O\
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MK/P/_P"R@:C_ .D(HH_X/>?^36?@?_V4#4?_ $A%% 'G_P#P:;?\I3/VN_\
MMX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK/P/_P"R@:C_ .D(HH_X/>?^36?@?_V4#4?_ $A%% 'G_P#P:;?\I3/VN_\
MMX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK/P/_P"R@:C_ .D(HH_X/>?^36?@?_V4#4?_ $A%% 'G_P#P:;?\I3/VN_\
MMX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK/P/_P"R@:C_ .D(HH_X/>?^36?@?_V4#4?_ $A%% 'G_P#P:;?\I3/VN_\
MMX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK/P/_P"R@:C_ .D(HH_X/>?^36?@?_V4#4?_ $A%% 'G_P#P:;?\I3/VN_\
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M\A_8&_Y,S^''_8KV_P#6O7J^;J_Q9>K/T7#?[M#T7Y!11169N%%%% !1110
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M^)]0_P"#4/\ 8]7XK^#K70?CK\5H?A)H7A2\TS7OAW<>/KEAJDLLUM*5615
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MHHKZ$^ "BBB@ HHHH **** "BBB@#]NOV!O^3,_AQ_V*]O\ UKUZO(?V!O\
MDS/X<?\ 8KV_]:]>KYNK_%EZL_1<-_NT/1?D%%%%9FX4444 %%%% !1110!^
M(/\ P>\_\FL_ _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\ TA%% 'G_ /P:
M;?\ *4S]KO\ [>/_ $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\ 4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%?D%^VO_ ,%1OVZ_A'^UAX^^&GP]^.7]GZ)HOB.>UTRR_P"$9TR7R8EQA=\M
MLSM]68GWKS<SS3#Y52C4JIM-VTM^K1]#PYPUC^)\3.AA91BXKF?,VE:Z712[
MGZ^T5^&/_#XO_@H[_P!'%_\ EHZ/_P#(E'_#XO\ X*._]'%_^6CH_P#\B5XO
M^N.6?R3^Z/\ \D?8?\0EXC_Y^TO_  *?_P K/W.HK\,?^'Q?_!1W_HXO_P M
M'1__ )$H_P"'Q?\ P4=_Z.+_ /+1T?\ ^1*/]<<L_DG]T?\ Y(/^(2\1_P#/
MVE_X%/\ ^5G[G45^&/\ P^+_ ."CO_1Q?_EHZ/\ _(E'_#XO_@H[_P!'%_\
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M** "BBB@ HHHH **** "BBB@ HHHH *_ /\ X*/_ /)]?Q2_[&ZY_I7[^5^
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MH **** "BBB@ HHHH **9%<VT[O'!<([1-ME5'!*'&<'T.*?0 4444 %%%%
M!1110 4444 %%%% !1110 5^ ?\ P4?_ .3Z_BE_V-US_2OW\K\ _P#@H_\
M\GU_%+_L;KG^E?'\9?[E3_Q?HS]9\(O^1SB/^O?_ +<CQ.BBBOSL_?PHHHH
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M*9^UW_V\?^GR>OW^H **** "BBB@ HHHH **** "OBO_ (.!/VV/V@?V _\
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M[?\ K7KU?-U?XLO5GZ+AO]VAZ+\@HHHK,W"BBB@ HHHH **** /Q!_X/>?\
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M=2O&K)MN+NET3LXW^YM=M7I?4*^R?^"%?_)]47_8H:C_ #BKXVK[)_X(5_\
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M@OC[_L;XO_25*^AX6_Y'$/27Y'P/B9_R2-7_ !0_]*1^@M%%%?J9_,H4444
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M^3U^_P!7X _\&FW_ "E,_:[_ .WC_P!/D]?O]0 4444 %%%% !1110 4444
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M*** "BBB@ HHHH *^R?^"%?_ "?5%_V*&H_SBKXVK[)_X(5_\GU1?]BAJ/\
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M"_X5!Y7VWQAID'F_\)!NV;[J-=V/LXSC.<9%?%M=Y^RQ_P G._#C_L?-'_\
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M )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H **** "BBB@
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MN?Z5^_E?C=^W%^Q[_P )O^US\0?%O_"Q/LO]H>)9YOL_]D;_ "\XXW><,_7
MKX[C.2C@J=_YOT9^M^$,92SG$6_Y]_\ MR/BBBOH+_AA/_JJ?_E#_P#M]'_#
M"?\ U5/_ ,H?_P!OK\Y]I#N?T#[*IV/GVBOH+_AA/_JJ?_E#_P#M]'_#"?\
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MB@ HHHH *]T_X)X_\G$)_P!@2Z_]DKPNO=/^">/_ "<0G_8$NO\ V2O4R/\
MY&]#_$OS/F>,_P#DE,;_ ->Y?D?>%%%%?MA_'H4444 %?AM_P=8_\G.?"_\
M[$.?_P!+9*_<FOR _P"#D#]G?_A<W[07P\U?_A,/[-^Q^#9H?+_L_P [?F[=
MLY\Q<=>E>KDM2%+'QE)V5G^1X^?)O+9)=U^9^,5%?07_  PG_P!53_\ *'_]
MOH_X83_ZJG_Y0_\ [?7VGU["_P WX/\ R/@O9S['S[17T%_PPG_U5/\ \H?_
M -OH_P"&$_\ JJ?_ )0__M]'U["_S?@_\@]G/L?/M%?07_#"?_54_P#RA_\
MV^C_ (83_P"JI_\ E#_^WT?7L+_-^#_R#V<^Q\^T5]!?\,)_]53_ /*'_P#;
MZ/\ AA/_ *JG_P"4/_[?1]>PO\WX/_(/9S['S[7>?LL?\G._#C_L?-'_ /2V
M&O1O^&$_^JI_^4/_ .WUV7[.G[$O]C?M!^!-8_X69YGV3QEI<WE_V+C?MNXF
MQGSCC..M14QV%<'[W3L_\BZ5.?M(Z=4?TT4445^<GZD%%%% !7RC_P %EO\
MDS.7_L:+#_VI7U=7RC_P66_Y,SE_[&BP_P#:E;X;^/'U.+,?]QJ>C/R5HHHK
MZ$^ "BBB@ HHHH **** "BBB@#]NOV!O^3,_AQ_V*]O_ %KUZO(?V!O^3,_A
MQ_V*]O\ UKUZOFZO\67JS]%PW^[0]%^04445F;A1110 4444 %%%% 'X@_\
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M\@)17)>(_B1JWA/7KOPSKOA2.*]L9VANHHM424)(IPR[HPRD@\'!.""*I?\
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MRC_P66_Y,SE_[&BP_P#:E?5U?*/_  66_P"3,Y?^QHL/_:E;X;^/'U.+,?\
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M4E_QJ_['R[_F*_J1K^6[_@KE_P I+_C5_P!CY=_S%?1\-_[U/_#^J/FN)O\
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M3;_E*9^UW_V\?^GR>OW^K\ ?^#3;_E*9^UW_ -O'_I\GK]_J "BBB@ HHHH
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M['R[_F*^CX;_ -ZG_A_5'S7$W^ZP_P 7Z,^=*]?_ &5?VJM(_9JM/%FE:_\
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M ,9KZ3V=3LSX"S/3Z*\P_P"&R_V;?^BC_P#E'O/_ (S1_P -E_LV_P#11_\
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M .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H ****
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M9M%U2[DM++7--U2UU&Q>Z10SVQN+.66))U4@F%F$@')7%>>U]?)X<TCX<_\
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M!1110 4444 %%%% 'X@_\'O/_)K/P/\ ^R@:C_Z0BBC_ (/>?^36?@?_ -E
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M&0FI<R^]_P"1^2__  4Q_P"4C?Q\_P"RS^)__3K<U9_9C_XM)\ /BK^T[/\
MNKXZ2G@3P;(>&_M#5XY5O9D[D1Z7#?1,1]UKV$YY /ZW_&__ (-U?B)\?OBU
MXA^-7C:W^#L.N>*=7N-4UM]-N_$D<4]Y/*TLTP1KI@A9W8[5PHSP!4.K_P#!
MN;\3M:^%6B?!BXOOA+'H&@:O?ZI9VL%UX@5I+R[2WCFFE;[1F1O+M8$7/"JG
M &YB<UF^&]E&%GTOMT^9;R;%>UE.ZZVW_P C\'Z^Q/V6?V,/'OC7]DBY^(WP
M;^*WPNLO$_CZ>[TG47\4_$W2])N]$T6)_+E@2*YF202WCAE=P !;1[ SK=2J
MOZ2_"_\ X-W/B+\)=-\4:7X=TOX&W<?B[PW-HFHOK=CK-\\%O*RLTELTTK&V
MF!0;98\.O8YP1R7_ !"[:]_SV^%G_@Q\0_\ Q^JJ9S0FK)-?)/\ 5"IY+B(.
M[:?S:_1GQ#_P7*^ 7B[X3_'KP5XM\0>(O#%Y;ZI\+?#&FV\.B>);:]GCEL=$
ML(97DCB<M'$[',4C +*N60D#-?$-?O?\=?\ @WO^,/[1?C*T\=_$S4?A%-J%
MEX>TW18'M)_$$*BTL;6.UMP5%QRPBB0%NYR>]<9_Q"[:]_SV^%G_ (,?$/\
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M/_Q^C_B%VU[_ )[?"S_P8^(?_C]>Y_;>$_EE]R_S/!_L/%_S1^]_Y'Y-Z?\
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M/L.BOCS_ (4Q_P %J/\ H\;X6?\ A('_ .1Z/^%,?\%J/^CQOA9_X2!_^1Z
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M?"S_ ,&/B'_X_1_Q"[:]_P ]OA9_X,?$/_Q^C^V\+_++[E_F']AXO^:/WO\
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ML*BTS5=,UJQCU/1M1@N[:4$Q7%M,LB/@X.&4D'D$?A0!/1110 4444 %%%%
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M:GJ6E?%+PSH%FUSJ$OA?4X#!/?6T"_-,UJ'FD,:Y8^8K<+&[  ]!^//_  1
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M^W7%\48--^$EC;W=ROC36;:2TM[FUMYVMVN(DD42LCS(T<0V!YCM\M6$D98
M_/\ _P""D_\ P3&_9U_8(U3X$?M0_P#!.KP?J/@GXVO\>?#OAVSU"P\0WMS<
M>,[?4)W^WVNI&>9S=AX8Y9Y99,MLCD+-@G'ZS5^6OPN_X+1?\$J?B_\ %NV_
M;A_:0_;$\+6VHZ#97-K\'_AA;">^OO#MK< )->30V\;^=K%X@6,I'N%M"PMT
M)9[EY?U#TN]DU'3+?4)M.GM'G@21[2Z"^;"64$H^UF7<,X."1D'!/6@">BBB
M@ HHHH *YKXN?!SX5?'SX?ZE\*OC5\/=(\4>'-7MG@U'1M;L4N()D="ARK X
M.UCAAAAG((-=+10!^/'_  3F^)7PU_X-^?VM?BO_ ,$P?VJ=9L/#_P +=?BO
MOB/\#_B;J4*H=0TV.$M=Z5<S*,S7,"0G8OWV:.3:/](@0_5'[-G_  3?^ _[
M5WC#Q3_P4#_;[_8X\$:UXU^*?V=] \&>.O!UEJ/_  B/AV!2+"UEBN(W4:C*
MC&XNI,;EDF\@'9 -W@7_  <^^./@1X<U']D*?Q_XF\-6NLZ1^U-X?O[@ZE<0
MBXL]$7<U],V[YDMMRVID)PA*QYZ"OU)N?&G@ZS\+-XYO/%FF1:(EOY[ZQ)?Q
MK:K%_P ]#*3L"_[6<4 ?C]_P;Z_\$ZOV"?VE/V,OCA_POC]C3X8^*;F+]HCQ
MAHEGJFK^"+&6^L=/2*S$=O;71B\ZV2/>YC$3IY98E-IYJ;_@VO\ ^"<W[ O[
M4G_!&SPIXJ_:&_8S^&?B[7-6UW7K:^\2ZUX+LY=5>)-0E1 +[R_M*%% "E9
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MG=WKW/\ XB\?^"R7_0Z_#_\ \(2'_P"+HHH /^(O'_@LE_T.OP__ /"$A_\
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M#_\ \(2'_P"+HHH /^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\
M_P (2'_XNBB@ _XB\?\ @LE_T.OP_P#_  A(?_BZ/^(O'_@LE_T.OP__ /"$
MA_\ BZ** #_B+Q_X+)?]#K\/_P#PA(?_ (NC_B+Q_P""R7_0Z_#_ /\ "$A_
M^+HHH /^(O'_ (+)?]#K\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (NB
MB@ _XB\?^"R7_0Z_#_\ \(2'_P"+H_XB\?\ @LE_T.OP_P#_  A(?_BZ** #
M_B+Q_P""R7_0Z_#_ /\ "$A_^+H_XB\?^"R7_0Z_#_\ \(2'_P"+HHH /^(O
M'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XNBB@ _XB\?\
M@LE_T.OP_P#_  A(?_BZ/^(O'_@LE_T.OP__ /"$A_\ BZ** #_B+Q_X+)?]
M#K\/_P#PA(?_ (NC_B+Q_P""R7_0Z_#_ /\ "$A_^+HHH /^(O'_ (+)?]#K
M\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (NBB@ _XB\?^"R7_0Z_#_\
M\(2'_P"+H_XB\?\ @LE_T.OP_P#_  A(?_BZ** #_B+Q_P""R7_0Z_#_ /\
M"$A_^+H_XB\?^"R7_0Z_#_\ \(2'_P"+HHH /^(O'_@LE_T.OP__ /"$A_\
MBZ/^(O'_ (+)?]#K\/\ _P (2'_XNBB@ _XB\?\ @LE_T.OP_P#_  A(?_BZ
M/^(O'_@LE_T.OP__ /"$A_\ BZ** #_B+Q_X+)?]#K\/_P#PA(?_ (NC_B+Q
M_P""R7_0Z_#_ /\ "$A_^+HHH /^(O'_ (+)?]#K\/\ _P (2'_XNC_B+Q_X
M+)?]#K\/_P#PA(?_ (NBB@ _XB\?^"R7_0Z_#_\ \(2'_P"+H_XB\?\ @LE_
MT.OP_P#_  A(?_BZ** #_B+Q_P""R7_0Z_#_ /\ "$A_^+H_XB\?^"R7_0Z_
M#_\ \(2'_P"+HHH /^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\
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M'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XNBB@ _XB\?\
M@LE_T.OP_P#_  A(?_BZ/^(O'_@LE_T.OP__ /"$A_\ BZ** #_B+Q_X+)?]
M#K\/_P#PA(?_ (NC_B+Q_P""R7_0Z_#_ /\ "$A_^+HHH /^(O'_ (+)?]#K
M\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (NBB@ _XB\?^"R7_0Z_#_\
M\(2'_P"+H_XB\?\ @LE_T.OP_P#_  A(?_BZ** #_B+Q_P""R7_0Z_#_ /\
M"$A_^+H_XB\?^"R7_0Z_#_\ \(2'_P"+HHH /^(O'_@LE_T.OP__ /"$A_\
MBZ/^(O'_ (+)?]#K\/\ _P (2'_XNBB@ _XB\?\ @LE_T.OP_P#_  A(?_BZ
M/^(O'_@LE_T.OP__ /"$A_\ BZ** #_B+Q_X+)?]#K\/_P#PA(?_ (NC_B+Q
M_P""R7_0Z_#_ /\ "$A_^+HHH ^=/^"BW_!:C]N+_@J1X+\.> OVK]>\-WFG
<^%=4EU#25T/P\EDZS21^6Q9E8[AM[4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ebs-20220930_g3.jpg
<TEXT>
begin 644 ebs-20220930_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
MW@*( P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ ^/?V'_V'_P!N3_@KK^W)\=_A1\*/V[O$'@C_ (0CQ!J%^[ZM
MX@U.6*6)]3FA6*-891MVX^F.*^P/^(3;_@J9_P!)=O\ RH:Y_P#'J/\ @TV_
MY2F?M=_]O'_I\GK]_J /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_T
MEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O
M_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH
M:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?
M_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZ
MOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_
MJ* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@
M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@#\0?^#WG_DUGX'_]E U'_P!(111_P>\_\FL_ _\
M[*!J/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?
M)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME?AC11_KCF?\D/NE_P#)!_Q"7AS_ )^U?_ H?_*S]SO^'Q?_  3B_P"CB_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\UGCS_ )'C
M6?\ L+7'_HUJ_I3K^:SQY_R/&L_]A:X_]&M7P_&GP4/^WO\ VT_:/![^+C?2
MG_[>95%%%?!G[@%%%% !1110 4444 %%%% '[<_\$4O^4?7A?_L+:I_Z62U]
M7U\H?\$4O^4?7A?_ +"VJ?\ I9+7U?7['E'_ "*Z'^"/Y'\C<5?\E-C/^OL_
M_2F%%%%>B> %?B/_ ,%K?^4@OBC_ +!.E_\ I'%7[<5^(_\ P6M_Y2"^*/\
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MGK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_FL\>?
M\CQK/_86N/\ T:U?TIU_-9X\_P"1XUG_ +"UQ_Z-:OA^-/@H?]O?^VG[1X/?
MQ<;Z4_\ V\RJ***^#/W **** "BBB@ HHHH **** /VY_P""*7_*/KPO_P!A
M;5/_ $LEKZOKY0_X(I?\H^O"_P#V%M4_]+):^KZ_8\H_Y%=#_!'\C^1N*O\
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M_P#V4#4?_2$44 >?_P#!IM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\
M[>/_ $^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?S6>//^1XUG_L+7'_HUJ_I3K^:SQY_R/&L_]A:X_P#1K5\/QI\%#_M[_P!M
M/VCP>_BXWTI_^WF51117P9^X!1110 4444 %%%% !1110!^W/_!%+_E'UX7_
M .PMJG_I9+7U?7RA_P $4O\ E'UX7_["VJ?^EDM?5]?L>4?\BNA_@C^1_(W%
M7_)38S_K[/\ ]*84445Z)X 5^(__  6M_P"4@OBC_L$Z7_Z1Q5^W%?B/_P %
MK?\ E(+XH_[!.E_^D<5?*\7_ /(KC_C7Y,_3O"?_ )*6?_7J7_I4#Y/HHHK\
MU/Z*"BBB@ HHHH **** "BBB@#]'_P#@W=_Y'CXH_P#8)TO_ -&W-?J37Y;?
M\&[O_(\?%'_L$Z7_ .C;FOU)K]5X8_Y$M/\ [>_]*9_,/B1_R6&(](?^D1"B
MBBO?/A0HHHH **** "BBB@#\0?\ @]Y_Y-9^!_\ V4#4?_2$44?\'O/_ ":S
M\#_^R@:C_P"D(HH \_\ ^#3;_E*9^UW_ -O'_I\GK]_J_ '_ (--O^4IG[7?
M_;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MOYK/'G_(\:S_ -A:X_\ 1K5_2G7\UGCS_D>-9_["UQ_Z-:OA^-/@H?\ ;W_M
MI^T>#W\7&^E/_P!O,JBBBO@S]P"BBB@ HHHH **** "BBB@#]N?^"*7_ "CZ
M\+_]A;5/_2R6OJ^OE#_@BE_RCZ\+_P#86U3_ -+):^KZ_8\H_P"170_P1_(_
MD;BK_DIL9_U]G_Z4PHHHKT3P K\1_P#@M;_RD%\4?]@G2_\ TCBK]N*_$?\
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M_P#1K5\/QI\%#_M[_P!M/VCP>_BXWTI_^WF51117P9^X!1110 4444 %%%%
M!1110!^W/_!%+_E'UX7_ .PMJG_I9+7U?7RA_P $4O\ E'UX7_["VJ?^EDM?
M5]?L>4?\BNA_@C^1_(W%7_)38S_K[/\ ]*84445Z)X 5^(__  6M_P"4@OBC
M_L$Z7_Z1Q5^W%?B/_P %K?\ E(+XH_[!.E_^D<5?*\7_ /(KC_C7Y,_3O"?_
M )*6?_7J7_I4#Y/HHHK\U/Z*"BBB@ HHHH **** "BBB@#]'_P#@W=_Y'CXH
M_P#8)TO_ -&W-?J37Y;?\&[O_(\?%'_L$Z7_ .C;FOU)K]5X8_Y$M/\ [>_]
M*9_,/B1_R6&(](?^D1"BBBO?/A0HHHH **** "BBB@#\0?\ @]Y_Y-9^!_\
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M<R",AB,9X!'U% 'Q7_P;=VEKI_\ P1L^%5A8VR0P0:SXPCAAB4*J(OBS6 %
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M]N+0/B)I$6AO9Z#X7\(?#U= M8;J26-GN[AA/*]PZI'Y:*2$42R'!8@CZ2H
M**** "BBB@ K^:SQY_R/&L_]A:X_]&M7]*=?S6>//^1XUG_L+7'_ *-:OA^-
M/@H?]O?^VG[1X/?Q<;Z4_P#V\RJ***^#/W **** "BBB@ HHHH **** /VY_
MX(I?\H^O"_\ V%M4_P#2R6OJ^OE#_@BE_P H^O"__86U3_TLEKZOK]CRC_D5
MT/\ !'\C^1N*O^2FQG_7V?\ Z4PHHHKT3P K\1_^"UO_ "D%\4?]@G2__2.*
MOVXK\1_^"UO_ "D%\4?]@G2__2.*OE>+_P#D5Q_QK\F?IWA/_P E+/\ Z]2_
M]*@?)]%%%?FI_104444 %%%% !1110 4444 ?H__ ,&[O_(\?%'_ +!.E_\
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M3P?H/Q$\&7_A?^U-<U_7/#OA'58#%<:%HU_J]W=V%G)&>8F6WFC;RSRGF;"
M5( !]@T444 %%%% !1110 45Y[^U9\>/^&8_V?/$WQV_X17^V_\ A';2.?\
MLK[=]F^T;YHXL>;L?9C?G.T],=\U\&_\1%W_ %9W_P"9"_\ O?7FXS-\OR^H
MJ>(GRMJ^S>GR3/H<HX5S[/</*O@://%/E;YH+6R=O>DGLT?II17YE_\ $1=_
MU9W_ .9"_P#O?1_Q$7?]6=_^9"_^]]<G^LN2?\_?_)9?Y'J_\0ZXR_Z!?_)Z
M?_R9^FE%?F7_ ,1%W_5G?_F0O_O?1_Q$7?\ 5G?_ )D+_P"]]'^LN2?\_?\
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M(@%%%%?)'ZH%%%% !1110 4444 %%%% ']*?@/\ Y$?1O^P3;_\ HI:U:RO
M?_(CZ-_V";?_ -%+6K7[E#X$?Q75_BR]6%%%%49A7\UGCS_D>-9_["UQ_P"C
M6K^E.OYK/'G_ "/&L_\ 86N/_1K5\/QI\%#_ +>_]M/VCP>_BXWTI_\ MYE4
M445\&?N 4444 %%%% !1110 4444 ?MS_P $4O\ E'UX7_["VJ?^EDM?5]?*
M'_!%+_E'UX7_ .PMJG_I9+7U?7['E'_(KH?X(_D?R-Q5_P E-C/^OL__ $IA
M1117HG@!7XC_ /!:W_E(+XH_[!.E_P#I'%7[<5^(_P#P6M_Y2"^*/^P3I?\
MZ1Q5\KQ?_P BN/\ C7Y,_3O"?_DI9_\ 7J7_ *5 ^3Z***_-3^B@HHHH ***
M* "BBB@ HHHH _1__@W=_P"1X^*/_8)TO_T;<U^I-?EM_P &[O\ R/'Q1_[!
M.E_^C;FOU)K]5X8_Y$M/_M[_ -*9_,/B1_R6&(](?^D1"BBBO?/A0HHHH **
M** "BBB@#\0?^#WG_DUGX'_]E U'_P!(111_P>\_\FL_ _\ [*!J/_I"** /
M/_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH
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M.,?^1A#_  ?JS^A/"3_D05O^OK_](@%%%%?)'ZH%%%% !1110 4444 %%%%
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M'%7[<5^(_P#P6M_Y2"^*/^P3I?\ Z1Q5\KQ?_P BN/\ C7Y,_3O"?_DI9_\
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M/_!Q%_R(_P +O^PMJG_HJVK\M:_4K_@XB_Y$?X7?]A;5/_15M7Y:U^5<3_\
M(ZJ?]N_^DH_I[PW_ .2/P_K/_P!+D%%%%> ?='&_M"?$R7X._!?Q%\2+:)7N
M--L";17&5\]V6.+([C>ZY'IFORI\0>(-;\5ZW=>)/$FJ37M_>S-+=7=PY9Y7
M/4DU^JW[0GPSE^,7P7\1?#>VE5+C4K BT9SA?/1EDBR>PWHN3Z9K\J?$'A_6
M_"FMW7AOQ)I<UE?V4S17=I<)M>)P>017Z!P;]7]A5M\=]>_+;3\;GX3XN_7O
MKN&O?V/*[=N>[O\ /EY;?.W4/#WB'6_">MVOB3PWJDUE?V4RRVEW;OM>)QT(
M/^<U^JW[/?Q,E^,7P7\._$BYB5+C4K &[5!A?/1FCEP.PWHV!Z8K\J?#_A_6
M_%>MVOAOPWI<U[?WLRQ6EI;IN>5R> !7ZK?L]_#.7X._!?P[\-[F57N--L +
MMD.5\]V:27![C>[8/IBEQE]7]A2O\=]._+;7\;!X1?7OKN)M?V/*K]N>ZM\^
M7FO\K]#LJ***^ /W8*^A?^"4_P#RD%^&G_86N/\ TCGKYZKZ%_X)3_\ *07X
M:?\ 86N/_2.>NS+O^1A1_P <?S1Y'$'_ "(<7_UZJ?\ I#/WCHHHK]H/X^"B
MBB@#Y[_X*L?\H^OB7_V";?\ ]+(*_!NOWD_X*L?\H^OB7_V";?\ ]+(*_!NO
MSCC'_D80_P 'ZL_H3PD_Y$%;_KZ__2(!1117R1^J!7Y5?M+?!+Q!\"/BQJ?A
M'5;"1+*2YDFT6[*_)<VK,2C*>A(!"L.S ^U?JK6+XZ^'/@3XFZ,?#_Q \)V.
MKVF[<L5[ 'V-_>0]4;W4@U[629N\IKN3C>,MUUTV:/CN,N%(<58&$(SY*E-M
MQ;U6NZ?D[+7I8_(6OT)_X)N_!+Q!\+OA/?\ B[Q7826E[XIN8IHK29=KI:QJ
MPB9@>06,DC8_NE?6O0?!O['W[-/@+64\0>&?A)IR7<3[XI;N26Z\MAT91,[A
M2.Q !%>E5Z6=\20S'#>PHQ:B]V[7TZ:7ZGSW!GA[6X?S#Z]C*D93BFHJ-[*Z
MLVVTG>UU:W4****^3/U(**** /Z4_ ?_ "(^C?\ 8)M__12UJUE> _\ D1]&
M_P"P3;_^BEK5K]RA\"/XKJ_Q9>K"BBBJ,PK^:SQY_P CQK/_ &%KC_T:U?TI
MU_-9X\_Y'C6?^PM<?^C6KX?C3X*'_;W_ +:?M'@]_%QOI3_]O,JBBBO@S]P"
MO@__ (*;_!+Q!HGQ-3XV:?823:1K5M##?W"+D6UU&@C57] T:IM/<JP],_>%
M5]4TK2]<TZ;2-:TV"\M+B,I<6MU"LD<JGJK*P(8>QKTLJS&>5XQ5HJZV:[IG
MSW$_#]'B7*98.<N5W4HO>TE>VG56;3]3\<Z^I/\ @F1\$O$&M_$U_C9J%A)#
MI&BVTT-A<.N!<W4B&-E3U"QL^X]BRCUQ]-_\,0_LJ_VO_;?_  IO3_.W[MGV
MF?R<_P#7+S/+Q[;<5Z;I>E:7H>G0Z1HNFP6=I;QA+>UM85CCB4=%55 "CV%?
M1YKQ52Q6#E1H0:<E9MVVZVLWN?GW#/ACB<LS:&,QU6,E3?-%1OJULVVE:SUL
MK^I8HHHKXH_8@HHHH _;G_@BE_RCZ\+_ /86U3_TLEKZOKY0_P""*7_*/KPO
M_P!A;5/_ $LEKZOK]CRC_D5T/\$?R/Y&XJ_Y*;&?]?9_^E,****]$\ *_$?_
M (+6_P#*07Q1_P!@G2__ $CBK]N*_$?_ (+6_P#*07Q1_P!@G2__ $CBKY7B
M_P#Y%<?\:_)GZ=X3_P#)2S_Z]2_]*@?)]%%%?FI_105\H?\ !5KP;K.J^ ?"
M_C:RA=[/1]0N(+[8,^7]H6/8Y]!F$KGU<#O7U?5+Q'X<T+Q=H5WX9\3:5#?:
M??0F*[M+A-R2(>H(_KU!Y%=N6XQX#'0Q%K\K_!JS_!GC<0Y2L]R:M@>;EYUH
M^S335_*Z5_(_'BMOX;^#=9^(7C[1_!/A^%WO-3U"*"'8/NY89<^@498GL 37
MV5XR_P""4O@#5=9>]\$_%#4='LW?=]BN]/6[\O\ V5?S(SCTW;CZDUZK^SI^
MQQ\*OV<Y'UG0Q<:IK<T1CDUC4 N]$/58E Q&#WZL>A;'%??8GBO+8X9RHMRF
MUHK-6?GT^ZY^&9;X8<0U,QC#%Q4*2>LN9.Z_NI:W?2Z1ZU1117YH?T8%%%%
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MK2,D@385" (2'R:[/5?'E_K\NB>'O S>7?:Q;0ZA=3RQAO[/T\X+2,#QO?\
MU<:GJQ9L$1L*Y[XH_"SP?HVC:[J5SKVMQ:5XAO%DU3PIILL(CUB\DVQB%"T9
MD0SD(KA'56Y)P"Y./X&T;Q]K/Q+\3>#QXYET.\TW3K"[U:\TFT@D:YO+E93'
M$OGQN!:V\<2QHBA2Q+LQR3GLY,/5I>TC9*/=?X5K9:V;\[W71NWE*MF&%Q2H
M5'*3G9.S3N[SDW&[2CS16BNK).VJCS>TU]"_\$I_^4@OPT_["UQ_Z1SU\F_
MOQYJGQ+^%.D^,=<MX8[ZX26*]%N"(VEAF>%W0')"LT98#)P&')KZR_X)3_\
M*07X:?\ 86N/_2.>N?!4Y4LUIPENII?=)'H9Q7IXKAG$5J?PRHS:]'!M'[QT
M445^R'\B!1110!\]_P#!5C_E'U\2_P#L$V__ *605^#=?O)_P58_Y1]?$O\
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M6X\+Q7WAQM>DCUWQ0VH%;N\F\\6TM\MMY946RR+L5?-W+#&,#"@'VJO([CX
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M_P#HO6@_]_G_ /B:_6C^6#U>BO*/^&Y_V1_^B]:#_P!_G_\ B:/^&Y_V1_\
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M_P"&6_C)_P! [0?_  M-*_\ DFC_ (9;^,G_ $#M!_\ "TTK_P"2:/[+S/\
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MT+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\
M\36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\ $UNT4 87
M_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_PJ[X9_\
M1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.]"_\%$/_
M ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$/_Q-'_"K
MOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+
M_P %$/\ \36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\
M$UNT4 87_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_
MPJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.
M]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$
M/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[
MX9_]$[T+_P %$/\ \36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0
MO_!1#_\ $UNT4 87_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q
M-;M% &%_PJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\
M*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$
M[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\
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M?)1FCD=2P3)#<D\4 ?I)X=U5M<\/V.MO"(S>6<4YC#9V[T#8SWQFKE9'P_\
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M [N6S\4>*M3^(%KH,5_?P#-U8Z5!+')+?/"<Q22@!1/')"@D="*]7_X)O?\
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MC]GC5O GB30_$>N7K?:]?TG4+:[BO=3N+R/RI-/O)SE5G"L'5.5.,C%?;-%
M!1110 4444 %%%% !1110 4444 ?B#_P>\_\FL_ _P#[*!J/_I"**/\ @]Y_
MY-9^!_\ V4#4?_2$44 >?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/V
MN_\ MX_]/D]?O]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^(/_  >\_P#)K/P/
M_P"R@:C_ .D(HH_X/>?^36?@?_V4#4?_ $A%% 'G_P#P:;?\I3/VN_\ MX_]
M/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'X@_\'O/_)K/P/\ ^R@:C_Z0BBC_ (/>?^36?@?_ -E U'_TA%% 'G__
M  :;?\I3/VN_^WC_ -/D]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\
M_A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?
M_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_
M *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P
M62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%
MX_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@
M_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?
M45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ !=
M']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_
M /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A
M"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A
M_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z
M'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %
MDO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$
M7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='
M_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0
M_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A
M"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7
MX?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z
M'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\
M!9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$
M7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*
M#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U
M%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T
M ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__
M != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^
M$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?
M_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\
MH=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P
M62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C
M_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q
M='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__
M !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\
M_A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?
M_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_
M *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P
M62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%
MX_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@
M_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?H!
M_P 'O/\ R:S\#_\ LH&H_P#I"**_'3_@HM_P6H_;B_X*D>"_#G@+]J_7O#=Y
<I_A75)=0TE=#\/)9.LTD?EL696.X;>U% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ebs-20220930_g4.jpg
<TEXT>
begin 644 ebs-20220930_g4.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB
M@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%'_![
MS_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4
MIG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZRNYUP\\-E:16R.PR<%EB!(]30!V-%%% !1110 4444 %%%% !1110!^(/\
MP>\_\FL_ _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\ TA%% 'G_ /P:;?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]Y_Y-9^!_P#V4#4?_2$44 >?_P#!IM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\
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M_P 'O/\ R:S\#_\ LH&H_P#I"** //\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\
M?^#3;_E*9^UW_P!O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *Y#X^_$_P"''P8^"_B7XI?&!8SX5T729;CQ$9H4DC%GC$I=
M9"%9 A)8'C:#UZ5U]<S\9?A!\/?C_P#"O7_@I\6- 75?#/B?3)-/UW3'E9%N
M[608DB8J0P#+D'!!P30!^-O[:G_!.;X@?\$N/VE/B7^V?_P1=^+,?PN3P?\
M!]?B#XY^&.I,;SPYXCL8KN[-W;QQ2-B "&W:1$&<%BL+6^5(_6+X ?M2>'?B
M9^Q/X)_;,^*B6G@G2_$7PUTWQ;KR:O=B*#1HKBQCNI5DD?&$C#D;FQD#.!TK
MPF3_ ((9_L7W?Q5'B'5Y?&E_X C\-6FE0_"+4?B-KUQH&;>ZDN$#V\M^T<MF
M"Z[;!D-LK*6V'<0/:_VQ/V%OV?OVZ?A!9? CX]Z?KK>%;'4K>^CTKPUXGO-(
M226 ?N1(;.2,R)&V'6-LJKHC ;D4@ \[^"WPZNOCS^TI;_\ !23X_P"EOX=T
M[2=#D\-_ OPQX@3[-<:5IU_/$+G5KN.7!@O]1=;:*.W.'AMXXHW FFFC3ZEK
MY"^#_P#P0[_8&^"GQ;\-_&OPUHGC[4]:\):HNI:&GBGXIZUJMI!=HK".8VUU
M<O$[H6W*64[656'(%?5WBC05\4:!=: ^KW]@+J/8;S2[HPW$7(.4D'*GMD>M
M 'Q=_P &Z?\ RB<\$_\ 8Y>-?_4KU:O7/^"G?Q$\7>$_V4-1^&?PNU5[/QM\
M6=7LOA]X*NHOOVM]JTGV>2\7_KTM#=WI_P!FS;K74_L;_L4?!+]A#X7M\%_V
M>V\0VWA=;R:[M=)USQ)<ZDEK--+)-.T37+NZ>9+*[L-V"S$XR23UWC?X(_#O
MXB_$?P9\5?%^DRW>K_#^]O;SPLQNY%BM+FZM'M)9S$#M>3[/+-&K,"46:3&-
MQH T?AE\.O"/P@^&_A_X3> -*6QT+POHEII.BV2=+>TMH5AAC'^ZB*/PKSO]
ML+PM^QK\9/@;:^"OVR;OPUJ/P^\0^)M)MH;+7]6\K3]6U%KR,V%NQ5U$^ZY$
M16(DJ[* P(!%>JZ_H6E>*-"O?#.NV@N+'4;22UO("Y7S(I%*.N5((RI(R"#S
M7D'@3_@GA^Q]\.?V/+#]@GPU\((A\*]+C9;#PY=:K=S/ YO&OA,ET\IN(YEN
MG,Z3+()(W"E&7:N #Y5^.'[//P1_X)^_\%-?V5]1_84^&FB_#VX^+'B'7/"_
MQ$\!^";!-/TSQ%HEOI,MW]OGLH L7G64T<3BX"!\3E79E;%?HI7D/PD_8?\
M@/\ "'XJO\=[6#Q'XE\;C1SI%GXL\=>+;[6[ZPTXN':TM7O)7%M&S ,_E!6E
M(!D9R!CUZ@ HHHH **** "OQ'_X+6_\ *07Q1_V"=+_](XJ_;BOQ'_X+6_\
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M /*S]SJ*_#'_ (?%_P#!1W_HXO\ \M'1_P#Y$H_X?%_\%'?^CB__ "T='_\
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M -A:X_\ 1K5\/QI\%#_M[_VT_:/![^+C?2G_ .WF51117P9^X!1110 4444
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M_P!+):^KZ_8\H_Y%=#_!'\C^1N*O^2FQG_7V?_I3"BBBO1/ "OQ'_P""UO\
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M68@ #))[4 +17._#SXM?#CXKZ=>ZO\._%MKJMKI^MW6CW<]ON"K>VSE)H06
MWE6!Y7*G&02.:Z*@ HJ.VNK6\C,UI<QRH)'0M&X8!E8JRY'<,"".Q!':EN;F
MVLK:2\O+A(884+RRRN%5% R6)/  '.: 'T4 @C(-1W-U:V<7G7=S'$F0-\CA
M1DG &3[T 2445%?W]CI=G)J.IWL5M;PH6FGGD"(BCJ2QX ]S0!+13+>XM[NW
M2ZM9TEBE0/')&P974C(((X(([T^@ HHHH **** "OYK/'G_(\:S_ -A:X_\
M1K5_2G7\UGCS_D>-9_["UQ_Z-:OA^-/@H?\ ;W_MI^T>#W\7&^E/_P!O,JBB
MBO@S]P"BBB@ HHHH **** "BBB@#]N?^"*7_ "CZ\+_]A;5/_2R6OJ^OE#_@
MBE_RCZ\+_P#86U3_ -+):^KZ_8\H_P"170_P1_(_D;BK_DIL9_U]G_Z4PHHH
MKT3P K\1_P#@M;_RD%\4?]@G2_\ TCBK]N*_$?\ X+6_\I!?%'_8)TO_ -(X
MJ^5XO_Y%<?\ &OR9^G>$_P#R4L_^O4O_ $J!\GT445^:G]%!1110 4444 %%
M%% !1110!^C_ /P;N_\ (\?%'_L$Z7_Z-N:_4FORV_X-W?\ D>/BC_V"=+_]
M&W-?J37ZKPQ_R):?_;W_ *4S^8?$C_DL,1Z0_P#2(A1117OGPH4444 %%%%
M!1110!^(/_![S_R:S\#_ /LH&H_^D(HH_P"#WG_DUGX'_P#90-1_](110!Y_
M_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110
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M*'_;W_MI^T>#W\7&^E/_ -O,JBBBO@S]P"BBB@ HHHH **** "BBB@#]N?\
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MCDGNNQ^FE%?F7_Q$7?\ 5G?_ )D+_P"]]'_$1=_U9W_YD+_[WUS_ .LN2?\
M/W_R67^1W?\ $.N,O^@7_P GI_\ R9^FE%?F7_Q$7?\ 5G?_ )D+_P"]]'_$
M1=_U9W_YD+_[WT?ZRY)_S]_\EE_D'_$.N,O^@7_R>G_\F?II17YE_P#$1=_U
M9W_YD+_[WT?\1%W_ %9W_P"9"_\ O?1_K+DG_/W_ ,EE_D'_ !#KC+_H%_\
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M-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\
M3Y/7[_4 %%%% !1110 4444 %%%% 'YP_P#!Q%_R(_PN_P"PMJG_ **MJ_+6
MOU*_X.(O^1'^%W_86U3_ -%6U?EK7Y5Q/_R.JG_;O_I*/Z>\-_\ DC\/ZS_]
M+D%%%%> ?=!1110 4444 %%%% !7T+_P2G_Y2"_#3_L+7'_I'/7SU7T+_P $
MI_\ E(+\-/\ L+7'_I'/79EW_(PH_P"./YH\CB#_ )$.+_Z]5/\ TAG[QT44
M5^T'\?!1110!\]_\%6/^4?7Q+_[!-O\ ^ED%?@W7[R?\%6/^4?7Q+_[!-O\
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MH_\ I"**/^#WG_DUGX'_ /90-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\
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M2^/'_2+/Q'_X?3P;_P#+"@#Z2_X*L?\ */KXE_\ 8)M__2R"OP;K]!_VPO\
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M )84?\*X_;<_Z,[C_P##O^%?_EA7S7^KV<_\^7]Z_P S]$_U]X1_Z"E]TO\
MY$LT56_X5Q^VY_T9W'_X=_PK_P#+"C_A7'[;G_1G<?\ X=_PK_\ +"C_ %>S
MG_GR_O7^8?Z^\(_]!2^Z7_R)_2YX#_Y$?1O^P3;_ /HI:U:_-SP[_P %O_CW
MHOA^QT:7_@EQXA=K2SBA9U^.?@W#%4"Y'_$P]JN_\/TOCQ_TBS\1_P#A]/!O
M_P L*_68JT4C^6:C3J-KN?HM17YT_P##]+X\?](L_$?_ (?3P;_\L*/^'Z7Q
MX_Z19^(__#Z>#?\ Y851!^BU?S6>//\ D>-9_P"PM<?^C6K]/?\ A^E\>/\
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M_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_PJ[X9_\
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M&C:EX>ED:VAOM+NA;6[RP)-&T$B2V\$D;[1M(8,</]KOX2?%3X5_\%%?A/\
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M'M/_  2[^'NO?$SP3+_P4N^-CV]W\0_C]H.G:Q90Q2&6'PKX4DC^T:3H-LS
M86.*83W#@+YUU/*Q!"QX^8OVO?\ E:[_ &3O^R&^(O\ TFUR@#I?BS_P5]_X
M*1?!;]O;X<?\$\?&_P#P3E^&:>+OBIIMU>^$->MOCS=R:/,EM!/-.LDO]A">
M-E$##!AY+I@D$D=S\?/^"L/[4?[ 5WI7C3_@H[^P1:^'/A7J&H066I?%CX3?
M$-_%%EX>FF<)&=0M)M.LKF*$L0/-17&2%4,[*K>0?\%'?^5EC]A+_L6?%O\
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MS>'/ =W+9^*/%6I_$"UT&*_OX!FZL=*@ECDEOGA.8I)0 HGCDA02.A%>K_\
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MB&VC%]XFNT"A%D2UN88K>(;EBDN+R12"8\'_  =X?\HO_#'_ &7+P]_Z(OJ
M.L_X*._\%;?^"E/_  3"^ D7[27QZ_X)S?##6?"W]LP:;>7'@WX]7=Q+92S!
MO*:2.XT* E&9=N4WD$C( .:]1^)7[:'_  5?^"OPX;XS^*_^"87@GQGX>M+0
M7FK:7\+/CC<7^N16FT.\L%G>:):K=.JY/DI+O;&%!/!\5_X.Z/\ E#-XC_['
MK0?_ $I-?I+X)_Y$S2/^P7;_ /HM: /./V(OVVOV?_\ @H1^SKHO[3O[-?B>
M74?#NL%XI(+R#R;S3;N,@36=U%D^5-&2,@$J05=69&5CY_\ \%/O^"ANK_\
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MTB:&(N;;3;.#,ALM/MP[". .Y+/)+(\DLLDC?J710!R/P%O?C%JGP8\,ZO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\
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MA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\
M_P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (2'_XNC_B+Q_X+)?]#K\/
M_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K
M\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (2'_XNC_B+Q_X+)?]
M#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)
M?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (2'_XNC_B+Q_X
M+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_
M (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (2'_XNC_B
M+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\ BZ/^
M(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (2'_X
MNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\
MBZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (
M2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$
MA_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\
M_P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__
M /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K
M\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.
MOP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)
M?]#K\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@L
ME_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_
M (+)?]#K\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O
M'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#] /\ @]Y_
MY-9^!_\ V4#4?_2$45^.G_!1;_@M1^W%_P %2/!?ASP%^U?KWAN\T_PKJDNH
6:2NA^'DLG6:2/RV+,K'<-O:B@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ebs-20220930_g5.jpg
<TEXT>
begin 644 ebs-20220930_g5.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
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M*!J/_I"** //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\
MI\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)67ASQ1<ZEJ.KWMMX5U*-;Z_66SMX[7;;W.V.",R[3--ND?Y<>Q_\%UO%_\
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M=I&F;/)M(8K"YA1GN[J_9#<S0@[UR #N/>_L=? +XUZK^WA\:_V_/BU\/)_
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MKO\ [>/_ $^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%?-5__ ,%??^"=FF7TVFWW[0VR>WE:*9/^$2U<[64D$9%I@\CM6%?%
M8;#6]M-1OM=I7^\[<'EN8YBY+"49U.7?EBY6OM>R=KGTK17S+_P^+_X)Q?\
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MQ?\ Y:.L?_(E']J99_S_ (?^!1_S#_5KB/\ Z JO_@N?^1]-45\R_P##XO\
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MB_\ Y%<?\:_)GZ=X3_\ )2S_ .O4O_2H'R?1117YJ?T4%%%% !1110 4444
M%%%% 'Z/_P#!N[_R/'Q1_P"P3I?_ *-N:_4FORV_X-W?^1X^*/\ V"=+_P#1
MMS7ZDU^J\,?\B6G_ -O?^E,_F'Q(_P"2PQ'I#_TB(4445[Y\*%%%% !1110
M4444 ?B#_P 'O/\ R:S\#_\ LH&H_P#I"**/^#WG_DUGX'_]E U'_P!(110!
MY_\ \&FW_*4S]KO_ +>/_3Y/7[_5^ /_  :;?\I3/VN_^WC_ -/D]?O]0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\UGCS_ )'C6?\
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M8S_K[/\ ]*84445Z)X 5^(__  6M_P"4@OBC_L$Z7_Z1Q5^W%?B/_P %K?\
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MM'@]_%QOI3_]O,JBBBO@S]P"BBB@ HHHH **** "BBB@#]N?^"*7_*/KPO\
M]A;5/_2R6OJ^OE#_ ((I?\H^O"__ &%M4_\ 2R6OJ^OV/*/^170_P1_(_D;B
MK_DIL9_U]G_Z4PHHHKT3P K\1_\ @M;_ ,I!?%'_ &"=+_\ 2.*OVXK\1_\
M@M;_ ,I!?%'_ &"=+_\ 2.*OE>+_ /D5Q_QK\F?IWA/_ ,E+/_KU+_TJ!\GT
M445^:G]%!1110 4444 %%%% !1110!^C_P#P;N_\CQ\4?^P3I?\ Z-N:_4FO
MRV_X-W?^1X^*/_8)TO\ ]&W-?J37ZKPQ_P B6G_V]_Z4S^8?$C_DL,1Z0_\
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M/^1XUG_L+7'_ *-:OA^-/@H?]O?^VG[1X/?Q<;Z4_P#V\RJ***^#/W ****
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M^6OT/_9$^)OBCXU_LG?##XR^.+:.#6O%OP[T36M8AB3:L=U=6$,\J@#H \C
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MC25&BE0,K AE89!'H:AL],TW3]/32;#3X(+6./9';0Q*L:K_ '0H& /:IZ*
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M^-;7P,?#_P &=1T+1=2AAC@TRXUK29;RRM(UPO-O#/ T@51@()8^@^85T%%
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M@G2__2.*OE>+_P#D5Q_QK\F?IWA/_P E+/\ Z]2_]*@?)]%%%?FI_104444
M%%%% !1110 4444 ?H__ ,&[O_(\?%'_ +!.E_\ HVYK]2:_+;_@W=_Y'CXH
M_P#8)TO_ -&W-?J37ZKPQ_R):?\ V]_Z4S^8?$C_ )+#$>D/_2(A1117OGPH
M4444 %%%% !1110!^(/_  >\_P#)K/P/_P"R@:C_ .D(HH_X/>?^36?@?_V4
M#4?_ $A%% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\
MT^3U^_U !1110 4444 %%%% !1110!\X?\%$?^"@G_# ^A^%M:_X5)_PE?\
MPDMW=0>5_;WV#[-Y*QMG/D2[\^9TP,8[YKY:_P"(B[_JSO\ \R%_][ZUO^#B
M+_D1_A=_V%M4_P#15M7Y:U^?Y[G>:8/,YT:-2T5;2T7ND^J9^[\$\&<-9OPW
M1Q6+H<U23E=\TUM)I:*26R['Z:?\1%W_ %9W_P"9"_\ O?1_Q$7?]6=_^9"_
M^]]?F717D?ZRYW_S]_\ )8_Y'U?_ !#K@W_H%_\ )ZG_ ,F?II_Q$7?]6=_^
M9"_^]]'_ !$7?]6=_P#F0O\ [WU^9=%'^LN=_P#/W_R6/^0?\0ZX-_Z!?_)Z
MG_R9^FG_ !$7?]6=_P#F0O\ [WT?\1%W_5G?_F0O_O?7YET4?ZRYW_S]_P#)
M8_Y!_P 0ZX-_Z!?_ ">I_P#)GZ:?\1%W_5G?_F0O_O?1_P 1%W_5G?\ YD+_
M .]]?F711_K+G?\ S]_\EC_D'_$.N#?^@7_R>I_\F?II_P 1%W_5G?\ YD+_
M .]]>A?LI_\ !;;_ (:<_:#\,_ G_AF7^Q/^$BNY(/[5_P"$S^T_9]D,DN?*
M^QIOSLQC<.N>V*_(FOH7_@E/_P I!?AI_P!A:X_](YZZ<%Q#G%;&4Z<ZMTY)
M/W8[-KR/.SC@'A+"Y1B*U+#6E&$VGSU-&HMIZRMOW/WCHHHK]./YN"BBB@#Y
M[_X*L?\ */KXE_\ 8)M__2R"OP;K]Y/^"K'_ "CZ^)?_ &";?_TL@K\&Z_..
M,?\ D80_P?JS^A/"3_D05O\ KZ__ $B 4445\D?J@4444 %%%% !1110 444
M4 ?TI^ _^1'T;_L$V_\ Z*6M6LKP'_R(^C?]@FW_ /12UJU^Y0^!'\5U?XLO
M5A1115&85_-9X\_Y'C6?^PM<?^C6K^E.OYK/'G_(\:S_ -A:X_\ 1K5\/QI\
M%#_M[_VT_:/![^+C?2G_ .WF51117P9^X!1110 4444 %%%% !1110!^W/\
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MR/&L_P#86N/_ $:U?#\:?!0_[>_]M/VCP>_BXWTI_P#MYE4445\&?N 4444
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M *62U]7U\H?\$4O^4?7A?_L+:I_Z62U]7U^QY1_R*Z'^"/Y'\C<5?\E-C/\
MK[/_ -*84445Z)X 5^(__!:W_E(+XH_[!.E_^D<5?MQ7XC_\%K?^4@OBC_L$
MZ7_Z1Q5\KQ?_ ,BN/^-?DS].\)_^2EG_ ->I?^E0/D^BBBOS4_HH**** "BB
MB@ HHHH **** /T?_P"#=W_D>/BC_P!@G2__ $;<U^I-?EM_P;N_\CQ\4?\
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MW-?J37Y;?\&[O_(\?%'_ +!.E_\ HVYK]2:_5>&/^1+3_P"WO_2F?S#XD?\
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MO"<Y-/573;:=G9_>>Z45X7_PUA\;/^C'_'?_ (%6W_Q5'_#6'QL_Z,?\=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\
M![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@
MTV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH *_.'X!?M7_M?_\
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M]I?2Z4K 7%Y8:CI%E:F.2)"7*2QN@56?#[?+?B_^"CO_ "LL?L)?]BSXM_\
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MFRP:'XGU#0/[5BTNX886X-H9H1<%,Y"-(JD@;MPRI^ ?@S_P2/\ ^"N_[/\
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M\/R?!">_M0+I+B.>2Y<Z[&\SE)\#;Y:CRU(7[V6?M#_\$@/VDOV^K[1_!O\
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M>OW^K\ ?^#3;_E*9^UW_ -O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH
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M ']WM%?PA?\ #6'[4W_1ROQ _P#"ROO_ ([1_P -8?M3?]'*_$#_ ,+*^_\
MCM ']WM%?PA?\-8?M3?]'*_$#_PLK[_X[1_PUA^U-_T<K\0/_"ROO_CM ']W
MM%?PA?\ #6'[4W_1ROQ _P#"ROO_ ([1_P -8?M3?]'*_$#_ ,+*^_\ CM '
M]WM%?PA?\-8?M3?]'*_$#_PLK[_X[1_PUA^U-_T<K\0/_"ROO_CM ']WM%?P
MA?\ #6'[4W_1ROQ _P#"ROO_ ([1_P -8?M3?]'*_$#_ ,+*^_\ CM ']WM%
M?PA?\-8?M3?]'*_$#_PLK[_X[1_PUA^U-_T<K\0/_"ROO_CM ']WM%?PA?\
M#6'[4W_1ROQ _P#"ROO_ ([1_P -8?M3?]'*_$#_ ,+*^_\ CM ']WM%?PA?
M\-8?M3?]'*_$#_PLK[_X[1_PUA^U-_T<K\0/_"ROO_CM ']WM%?PA?\ #6'[
M4W_1ROQ _P#"ROO_ ([1_P -8?M3?]'*_$#_ ,+*^_\ CM ']WM%?PA?\-8?
MM3?]'*_$#_PLK[_X[1_PUA^U-_T<K\0/_"ROO_CM ']WM%?PA?\ #6'[4W_1
MROQ _P#"ROO_ ([1_P -8?M3?]'*_$#_ ,+*^_\ CM ']WM%?PA?\-8?M3?]
M'*_$#_PLK[_X[1_PUA^U-_T<K\0/_"ROO_CM ']WM%?PA?\ #6'[4W_1ROQ
M_P#"ROO_ ([1_P -8?M3?]'*_$#_ ,+*^_\ CM ']WM%?PA?\-8?M3?]'*_$
M#_PLK[_X[1_PUA^U-_T<K\0/_"ROO_CM ']WM%?PA?\ #6'[4W_1ROQ _P#"
MROO_ ([1_P -8?M3?]'*_$#_ ,+*^_\ CM ']WM%?PA?\-8?M3?]'*_$#_PL
MK[_X[1_PUA^U-_T<K\0/_"ROO_CM ']WM%?PA?\ #6'[4W_1ROQ _P#"ROO_
M ([1_P -8?M3?]'*_$#_ ,+*^_\ CM ']WM%?PA?\-8?M3?]'*_$#_PLK[_X
M[1_PUA^U-_T<K\0/_"ROO_CM ']WM%?PA?\ #6'[4W_1ROQ _P#"ROO_ ([1
M_P -8?M3?]'*_$#_ ,+*^_\ CM ']WM%?PA?\-8?M3?]'*_$#_PLK[_X[1_P
MUA^U-_T<K\0/_"ROO_CM ']WM%?PA?\ #6'[4W_1ROQ _P#"ROO_ ([1_P -
M8?M3?]'*_$#_ ,+*^_\ CM ']WM%?PA?\-8?M3?]'*_$#_PLK[_X[1_PUA^U
M-_T<K\0/_"ROO_CM ']WM%?PA?\ #6'[4W_1ROQ _P#"ROO_ ([1_P -8?M3
M?]'*_$#_ ,+*^_\ CM ']WM%?PA?\-8?M3?]'*_$#_PLK[_X[1_PUA^U-_T<
MK\0/_"ROO_CM ']WM%?PA?\ #6'[4W_1ROQ _P#"ROO_ ([1_P -8?M3?]'*
M_$#_ ,+*^_\ CM ']WM%?PA?\-8?M3?]'*_$#_PLK[_X[1_PUA^U-_T<K\0/
M_"ROO_CM ']WM%?PA?\ #6'[4W_1ROQ _P#"ROO_ ([1_P -8?M3?]'*_$#_
M ,+*^_\ CM ']WM%?PA?\-8?M3?]'*_$#_PLK[_X[1_PUA^U-_T<K\0/_"RO
MO_CM ']WM%?PA?\ #6'[4W_1ROQ _P#"ROO_ ([1_P -8?M3?]'*_$#_ ,+*
M^_\ CM ']WM%?PA?\-8?M3?]'*_$#_PLK[_X[1_PUA^U-_T<K\0/_"ROO_CM
M '[_ /\ P>\_\FL_ _\ [*!J/_I"**_GE\;_ !C^+OQ-M8+'XD?%3Q)XA@M9
7#);0ZYKEQ=I"Y&"RB5V"DCC(HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ebs-20220930_g6.jpg
<TEXT>
begin 644 ebs-20220930_g6.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
MB$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-
MO^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@
MJ9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?
M])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27
M;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\
MJ&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AK
MG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\
M>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_
M?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^H
MH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /
MP!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?
M^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$
MV_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^
M"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9
M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#GO&_Q7^'?PWU30-%\;^*K;3[OQ1K*:5H%M*&+WMXR/(L2A
M0<?+&YW'"C !()&=^.6*8%H95<!BI*MG!!P1]0:_!NP^(W[(VN_MX^)/V3?^
M"M_P5TFW^.>K?M1S:A:^,?B9I22V&N>!I8KR/38--OYQML[2(>0J0(T:LY1@
M6F$@C_7+]D']DO7?V0?V3=1_9Q^''CJ1Y[;6_%%WX0UK6;F74GLXM0U2]O+$
M7#S'S+DPI<Q(VYB7\HY8YS0![6FM:/)JKZ%'JULU]'$)9+-9U,JH3@.4SD+G
MOC%3S316\33SRJB(I9W=L!0.I)/05^2/_!8?_@E1^S=^QW^QW_PVA^QWI_B+
M1?VF/"?C30)?!OQ(C\27=UK_ (OUR^U6ULY+>],DA6]:Y$\C-'M"C&U56+?&
M?K'_ (+C^,+WPY_P2K^(WA^]CNS?>-+;2_"<MMHEC/=SR+JFH6ME=B&&%7EF
M*VTUP^Q%9V5" ">* /K*V\1^'KR=;:SUZRED<X2..Z1F;Z 'FKM? /\ P37^
M$G_!#KPG^TG=1_L8?LP0?#CXP:;X>DN8]&\;> ]:T'71I4K"-[NTM]9C1WA8
MX1IH <!BK$!\-]6_M4?'+7_A%X2T[PM\+M)M=6^(OC;4/[&^'^BW9;R9+QD9
MY+RYV_,MG:Q*]S.P()2/RT)EEB5@#TV*ZM9Y9(8+F-WB($J*X)0D9 ([<5)7
MYY?\$9OA3%\$OVW?VVOAH/%FIZ_<6'Q'\+2:EK^LS;[K5+V;P[!/=7<N/E5I
M9Y99-B (F_:BJBJH_0#Q+!K]UX<U"V\*:A;VFJ264JZ;=7<!EBAN"A$;N@(+
MJ&P2H(R 1D4 2#6M';5CH*ZM;&^6'SFLA.OFB/.-^S.=N>,XQ5FOR3_X+$?\
M$HOV9/V4/V'M6_;5_9O3Q-I?[2G@SQ!HVH>%?BW%XBN[CQ%XG\076IVMJ8[G
M=(5NFNFG9?)5 B9"HJQJ8S^K_AI]>D\.:?)XIAACU-K*(ZC';',:S[!Y@4_W
M0V<>U %VBBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!__90-1_\ 2$44
M?\'O/_)K/P/_ .R@:C_Z0BB@#S__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^
M4IG[7?\ V\?^GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KR?\ ;M_:(US]DC]C'XH_M.^&?"(U[4? ?@;4M;L=(;=LN9K>W>1!
M(5^81 @%R.0@8CI7K%<A\??B?\./@Q\%_$OQ2^,"QGPKHNDRW'B(S0I)&+/&
M)2ZR$*R!"2P/&T'KTH _+CP)>?MS_'SPQJG[6G[&O_!3K4_&_P 1=:_9>M?$
MUI"W@_0[K0KR_:ZO6?1;>T@M%GLS%*ABCW323I-GS_-&8Q^E7[0[_M':G\'[
M3PM^S9J&G:3XQ\0W-O8#Q7K>GB[MO#<+(SW&HO:[D^TR(D;)%#D*T\L(?$>\
MC\D_VU/^"<WQ _X)<?M*?$O]L_\ X(N_%F/X7)X/^#Z_$'QS\,=28WGASQ'8
MQ7=V;NWCBD;$ $-NTB(,X+%86M\J1^L7P _:D\._$S]B?P3^V9\5$M/!.E^(
MOAKIOBW7DU>[$4&C17%C'=2K)(^,)&'(W-C(&<#I0!\>^!OB1_P4-_8 _P""
MG_P=_9+_ &B_VN9OCY\-/VAM.U^/1M4UOPA8:5K'A;5]*LA>RG-BB)-;2QE1
M@CY=QP$\O,OW/\>_C9X4_9Z^%>I_%/Q=;W5U%9"*'3])TZ,27FK7TTBPVMA;
M(2/,N)YWCAC7(!>09(&2/"_@M\.KKX\_M*6__!23X_Z6_AW3M)T.3PW\"_#'
MB!/LUQI6G7\\0N=6NXY<&"_U%UMHH[<X>&WCBC<":::-. _;)^)G[>GAC]NC
M2O%'@7_@F=XF^,GP^\"Z#%<^!;G1/B'HFEVXUZY26.[OYXKZ99'FAMV%M!\H
M6,7%VV7,J>4 7O\ @E#^T#^V#\6OCW^T[\,_VP/'^GZMJ/@#XAZ3:Z/I.D6,
M,5GH$5YI$%])I\$B1K)<QPO,8A/*2\GE[R%W;1T/[5'[='CFZ_:PTO\ X)\_
MLG^(?#.E^,CI<&L?$GX@>+ LNG^"=+G8K;1);F2,7FJ795S;VQ<*J(9I Z#:
MWS5_P1K_ &A_VGO'?_!2[]J_2_B)^PKK_@RS\3>/],OO%NHWOC/2[M?"=Y#H
M%LD%C,D$A:Z>=%6020Y1 X#$$&NF_P"";/[)/[.OQ[_;-_;?^,O[3/P;\-^+
M_'EQ\?[GPM+;^,-$@OWM/#,.E6#:>L:3JWEQ3Q2MD@ 2+#&#D(, 'Z%?#[PK
MK7@OPK;^'_$/Q$UGQ5>19,^N:]%:)<W!)SEELX((5 [!(U%7/%'B+3?!_AK4
M?%NLK=M9Z78S7=VMAI\UW.8HT+MY<$"/+,^%.V.-6=CA54D@'X^_X(@^*/$U
MY\ OBK\*;G7[[5O"?PP_:*\8>#/AAJ.H7;W,DGANRND^RQ"=R6F2!Y)[9')/
MR6RJ#A0!]DZ?J%AJUE'J.EWT-S;S+NAGMY0Z./4,."/I0!\5?\$_O^"D'B_]
MN'_@HM^T)\,M/\&>+_#/@'X:^$_"=OX7TCQKX4N-&O;ZYN9=5DN=4-M=Q1W,
M4<RK!'&L@&8[9'VHSL*^VZ^'_P!DK_E.I^V!_P!DY^&O_I/JE?<% !1110 4
M444 %%%% 'Y-_MR_M8?\$N/^"DWP?\&_!_\ ;H\4> _#^J:!\<K_ $7QAH_B
M[5$T2_T[3K9M4MFU"SGN'246LOD6TOGPNT99DC<[@4KU3_@@-J?C/]GG_@G#
MXVUC]H'XO:G<?"/P=\2O$;_!WQQX_E:VEF^'UKY8LK^4S!3';MLN)8]P4"-E
MV@1^6*^YOB'\$/A-\5_[ 'Q#\"6.J#PMKD>L:"DZ$+:7J(Z+* I ;Y9'^5LJ
M202"0".EOK"QU.SDT[4K**XMYD*303QAT=3U!4\$>QH _+G0/^"U/_!)S]IC
MXU:?^TY^T7^VKX.T;PE\.]1N)_A+\/KYYY+E[T*\#^([^!(F/VDQM(EG;8+6
M\4KRN//F$=M]R_'']L[P;\$?V9_#_P"UAK7PU\47WAC5+G19-1$%A&ESX?T_
M4)(D?4KV.1QY,%M'-YEP02T:*Y(PK$>C?\*F^%?_ $33P_\ ^":#_P"(KH
M!M &,=* /@3]I/Q]\/?VN_\ @JQ^RG9_LG>+=)\7ZC\+;WQ'XE^(GB_PI?QW
MMIH&@W>DO:1V5S<PEHP][.\7EP;BY6 R;0JAJ[O]J+]A_P#X*!_$3]KNZ_:>
M_9<_X* ^&OA];2>#K;P_8:%XA^#\7B!].A69I[DP327D0B^T2^4TNU S_9H
MS,(HPOUIH?AWP_X9M&L/#>A6>GP/*TKPV-JD2,[?>8A  2>YZFKE 'Y9?\$?
M/A)^W#X8_P""IO[6%W\8/VPM \4V6B>,M#@^(=G9?#2+3V\37LOAV!K.YA=;
ME_L"P1E$:-1()2A8E=V!]V^#/V\OV5_'/C_XP?#?2OBE#;:A\!C;'XISZO93
M65IHB3VTERDK7,Z)$\8BAE9G1B%V') ()]9MM,TVRNKB]L].@BFNF#74T4*J
MTS 8!<@98@<#/:DN-)TJ[AN;>ZTRWECO%VWD<D*LLXV[<."/F&T <]N* /R]
MT_\ X+3_ /!)W]J3XW:?^T#^T)^VMX-T;P/\-=9FNOA9X#U"2=KF^U.,/#_P
MD=_"D;$.JM(MC:X+1+(UQ(/.DCCM?TL^%WQ#T7XN?#;0/BIX:L[ZWTWQ)H]M
MJ>FQ:G:F"X%O/&LL1DB/S1L4924;#+G# $$!O_"IOA7_ -$T\/\ _@F@_P#B
M*WT1(T$<:!54850, #TH 6BBB@ HHHH **** "BBB@ HHHH _$'_ (/>?^36
M?@?_ -E U'_TA%%'_![S_P FL_ __LH&H_\ I"** //_ /@TV_Y2F?M=_P#;
MQ_Z?)Z_?ZOP!_P"#3;_E*9^UW_V\?^GR>OW^H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KF?C+\(/A[\?_A7K_P4^+&@+JOAGQ/IDFGZ
M[ICRLBW=K(,21,5(8!ER#@@X)KIJ* /C.3_@AG^Q?=_%4>(=7E\:7_@"/PU:
M:5#\(M1^(VO7&@9M[J2X0/;RW[1RV8+KML&0VRLI;8=Q ]K_ &Q/V%OV?OVZ
M?A!9? CX]Z?KK>%;'4K>^CTKPUXGO-(226 ?N1(;.2,R)&V'6-LJKHC ;D4C
MV&B@#Y"^#_\ P0[_ &!O@I\6_#?QK\-:)X^U/6O"6J+J6AIXI^*>M:K:07:*
MPCF-M=7+Q.Z%MREE.UE5AR!7U[110!P'PG_9E^#_ ,%/B9\0OB[\/- GM-=^
M*.MVVK>,[F6_EE6[NK>U2UB=4=BL0$,:+M0 $C)Y-<S\5_V#OV?OBS\3M0^-
M$\?BGPQXKUK2HM+\1Z]X \;:EH-QK=E%N$4-X;&>(7!C#,L<K RQ*Q6.1 2*
M]EHH XWX<?L]_!;X0?!.T_9S^&'P[T_0O!-CI4NG6OA_3E:.)+>7=YHR#O9G
M+NSR%B[N[.S%B35']EG]E[X)?L7_  %\/_LS_LY^$7T'P9X7BG31M*DU">[:
M$37$EQ*3+<.\CEI9I&^9CC=@8  'H%% 'BGPT_8*^"'PG_:>\4?M@>%-9\8-
MXX\:VEK:^*KR^\774]MJ5O;(R6T3VSL856)6;9L52NYCGYFS[7110 4444 %
M%%% !117XC_\%K?^4@OBC_L$Z7_Z1Q5Y6<9G_96%5;DYKM*U[='Y/L?3\)\.
M?ZT9G+">U]G:+E?EYMFE:UX]][G[<45_,O17S7^NO_3C_P F_P#M3]%_X@[_
M -1W_E+_ .Z']-%%?S+T4?ZZ_P#3C_R;_P"U#_B#O_4=_P"4O_NA_3117\R]
M%'^NO_3C_P F_P#M0_X@[_U'?^4O_NA_3117\R]%'^NO_3C_ ,F_^U#_ (@[
M_P!1W_E+_P"Z']-%%?S+T4?ZZ_\ 3C_R;_[4/^(._P#4=_Y2_P#NA_3117Y;
M?\&[O_(\?%'_ +!.E_\ HVYK]2:^JRS'?VE@HXCEY;WTO?9M;V1^8<29+_J]
MG%3 >TY^3E]ZW+>\4]KOO;<****] \(**** "BBB@ HHHH _$'_@]Y_Y-9^!
M_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V
M\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M._\ 1Q?_ ):.C_\ R)1_P^+_ ."CO_1Q?_EHZ/\ _(E?,M%']J9G_P _Y_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !1110 4444 ?H__P &[O\ R/'Q1_[!.E_^C;FOU)K\MO\ @W=_Y'CXH_\
M8)TO_P!&W-?J37ZKPQ_R):?_ &]_Z4S^8?$C_DL,1Z0_](B%%%%>^?"A1110
M 4444 %%%% 'X@_\'O/_ ":S\#_^R@:C_P"D(HH_X/>?^36?@?\ ]E U'_TA
M%% 'G_\ P:;?\I3/VN_^WC_T^3U^_P!7X _\&FW_ "E,_:[_ .WC_P!/D]?O
M]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\UGCS_D>-
M9_["UQ_Z-:OZ4Z_FL\>?\CQK/_86N/\ T:U?#\:?!0_[>_\ ;3]H\'OXN-]*
M?_MYE4445\&?N 4444 %%%% !1110 4444 ?MS_P12_Y1]>%_P#L+:I_Z62U
M]7U\H?\ !%+_ )1]>%_^PMJG_I9+7U?7['E'_(KH?X(_D?R-Q5_R4V,_Z^S_
M /2F%%%%>B> %?B/_P %K?\ E(+XH_[!.E_^D<5?MQ7XC_\ !:W_ )2"^*/^
MP3I?_I'%7RO%_P#R*X_XU^3/T[PG_P"2EG_UZE_Z5 ^3Z***_-3^B@HHHH *
M*** "BBB@ HHHH _1_\ X-W?^1X^*/\ V"=+_P#1MS7ZDU^6W_!N[_R/'Q1_
M[!.E_P#HVYK]2:_5>&/^1+3_ .WO_2F?S#XD?\EAB/2'_I$0HHHKWSX4****
M "BBB@ HHHH _$'_ (/>?^36?@?_ -E U'_TA%%'_![S_P FL_ __LH&H_\
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M *62U]7U\H?\$4O^4?7A?_L+:I_Z62U]7U^QY1_R*Z'^"/Y'\C<5?\E-C/\
MK[/_ -*84445Z)X 5^(__!:W_E(+XH_[!.E_^D<5?MQ7XC_\%K?^4@OBC_L$
MZ7_Z1Q5\KQ?_ ,BN/^-?DS].\)_^2EG_ ->I?^E0/D^BBBOS4_HH**** "BB
MB@ HHHH **** /T?_P"#=W_D>/BC_P!@G2__ $;<U^I-?EM_P;N_\CQ\4?\
ML$Z7_P"C;FOU)K]5X8_Y$M/_ +>_]*9_,/B1_P EAB/2'_I$0HHHKWSX4***
M* "BBB@ HHHH _$'_@]Y_P"36?@?_P!E U'_ -(111_P>\_\FL_ _P#[*!J/
M_I"** //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK
M]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_FL\>?\
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M4 %?S6>//^1XUG_L+7'_ *-:OZ4Z_FL\>?\ (\:S_P!A:X_]&M7P_&GP4/\
MM[_VT_:/![^+C?2G_P"WF51117P9^X!1110 4444 %%%% !1110!^W/_  12
M_P"4?7A?_L+:I_Z62U]7U\H?\$4O^4?7A?\ ["VJ?^EDM?5]?L>4?\BNA_@C
M^1_(W%7_ "4V,_Z^S_\ 2F%%%%>B> %?B/\ \%K?^4@OBC_L$Z7_ .D<5?MQ
M7XC_ /!:W_E(+XH_[!.E_P#I'%7RO%__ "*X_P"-?DS].\)_^2EG_P!>I?\
MI4#Y/HHHK\U/Z*"BBB@ HHHH **** "BBB@#]'_^#=W_ )'CXH_]@G2__1MS
M7ZDU^6W_  ;N_P#(\?%'_L$Z7_Z-N:_4FOU7AC_D2T_^WO\ TIG\P^)'_)88
MCTA_Z1$****]\^%"BBB@ HHHH **** /Q!_X/>?^36?@?_V4#4?_ $A%%'_!
M[S_R:S\#_P#LH&H_^D(HH \__P"#3;_E*9^UW_V\?^GR>OW^K\ ?^#3;_E*9
M^UW_ -O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8Z/-J]QJEY)JVLW&HW=W>3;1)--<7+O+*VU(T!9CA8U4< 4 >H4444 %%%%
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M+;W,0='&<X*L"#S5;0O"7A3PN93X9\,Z?IWG[?.^PV4</F8SC=L SC)QGU-
M&A1110 4444 %%%% !7\UGCS_D>-9_["UQ_Z-:OZ4Z_FL\>?\CQK/_86N/\
MT:U?#\:?!0_[>_\ ;3]H\'OXN-]*?_MYE4445\&?N 4457U35=+T/3IM7UK4
MH+.TMXR]Q=74RQQQ*.K,S$!1[FFDV[(3:BKO8L45Y3_PV_\ LJ_VQ_8?_"X[
M#SM^W?\ 9KCR<_\ 77R_+Q[[L5Z=I>JZ7KFG0ZOHNI07EI<1A[>ZM9EDCE4]
M&5E)##W%;5L-B<.DZL'&^UTU^9R87,<OQS:PU:$VM^62E;ULW8L4445@=@44
M44 ?MS_P12_Y1]>%_P#L+:I_Z62U]7U\H?\ !%+_ )1]>%_^PMJG_I9+7U?7
M['E'_(KH?X(_D?R-Q5_R4V,_Z^S_ /2F%%%%>B> %?B/_P %K?\ E(+XH_[!
M.E_^D<5?MQ7XC_\ !:W_ )2"^*/^P3I?_I'%7RO%_P#R*X_XU^3/T[PG_P"2
MEG_UZE_Z5 ^3Z***_-3^B@HHHH **** "BBB@ HHHH _1_\ X-W?^1X^*/\
MV"=+_P#1MS7ZDU^6W_!N[_R/'Q1_[!.E_P#HVYK]2:_5>&/^1+3_ .WO_2F?
MS#XD?\EAB/2'_I$0HHHKWSX4**** "BBB@ HHHH _$'_ (/>?^36?@?_ -E
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MD @2;ER =I(!'Z)_\/B_^"CO_1Q?_EHZ/_\ (E%3B[*J<[14I+NDK?BT_P
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M!_ZTX">)^L>SY9<MN3FOHG>_-'OM8_IHHK^9>BO(_P!=?^G'_DW_ -J?5?\
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M]?L>4?\ (KH?X(_D?R-Q5_R4V,_Z^S_]*84445Z)X 5^(_\ P6M_Y2"^*/\
ML$Z7_P"D<5?MQ7XC_P#!:W_E(+XH_P"P3I?_ *1Q5\KQ?_R*X_XU^3/T[PG_
M .2EG_UZE_Z5 ^3Z***_-3^B@HHHH **** "BBB@ HHHH _1_P#X-W?^1X^*
M/_8)TO\ ]&W-?J37Y;?\&[O_ "/'Q1_[!.E_^C;FOU)K]5X8_P"1+3_[>_\
M2F?S#XD?\EAB/2'_ *1$****]\^%"BBB@ HHHH **** /Q!_X/>?^36?@?\
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MC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %%%% !1110 4444 %%%%
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MBYL(-=/B&TAAF\BX>!Y=CG>$W(W8G XS7JZ%R@,B@-CY@#D _6O")O"/QO\
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M2;7P?XS^+'Q%MOCS>0^9I%S"-%M-2O3#%9:4;=66Z@^8!6:3S-TR_,K*%W#
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MOHHJ:E256?-+R_!67X&F'P]/#4O9PVNWZMMMOYMMG]*?@/\ Y$?1O^P3;_\
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MU^AU%']EY9_SXA_X#'_(/]9>(_\ H-J_^#)_YGYX_P##C;1O^?/P)_W\UO\
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M=\;/V4+[5-2^ /C7P)H$^M111:F_]FZA=><L98H,7-Q(%P7;[N,YYS7J?_"
M_P#!03_HO_@3_P )23_XJO=**ZZ5*E0@H4XJ*71*R^Y'EXG%8G&UG6Q$W.;W
M<FVW;1:N[V/"_P#A ?\ @H)_T7_P)_X2DG_Q5>VZ7'J$6F6T6KW$<MVL""ZE
MB3:KR!1N8#L"<D"IZ*T, HHHH **** "BBB@#\0?^#WG_DUGX'_]E U'_P!(
M111_P>\_\FL_ _\ [*!J/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@T
MV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH *@U+4]-T:RDU/5]0
M@M;:(9EN+F4(B#.,EF( YI=1U"RTG3Y]5U*Y2"VMH6EN)I#A8T4$LQ/H ":_
M*'_@EQ\+-!_X+K^)_'/_  4^_;[\-+XS^'Y\:WFA? 'X0>(P9] T/2K0A'U"
M:Q8F&ZO)F;8TDJMAHI,#:8A& ?J[IFJZ9K5DFIZ-J4%W;2@F.XMIED1^<<,I
M(/-,U36]&T1(I-9U>UM%GF$4+75PL8DD/1%W$98]@.:_*;_@JQ\&-$_X(>W'
MA/\ X*I?\$[O"4?@GPGI7C"QTGX\?"/PR/LOA_Q)HMVXA6[2Q4B"VO(I-D:2
MQJO,ZDY"NLGW)\3/V$/V'/VIM<U#]H']I'X6>'_BA!KFA0_V--\0;&#4+'0-
M+-LI*Z=',FRR$AWSR3K^_9Y.9=D<21@'O]%?#'_!OYXJ\8^(OV/_ !OH\GBK
M5-?^'?AOX[>+-#^!7B'5[V2ZEU'P5;72II\BW$A+SQ*_VF*-R3\D*J,!0!]S
MT -26*0L(Y%8HVU@IS@^A]#S5?\ MW1/[8_X1[^V;7[?Y/F_8?M"^=Y?3?LS
MNV^^,5\7?\$[OV OCK^QY>?M?^(=,\106OB#XN_&[7_$OPYN]7NC=6D-O<VB
M2V5Q,JEF^6YN)HY%(WE+9<YXKYL_X*T?\$3OV+_V=/V!?'W[;'PFUGQ;H'QY
M^&>E-XNL/CC<^-K^77=6U>!E=WNI'F\MFN&R@"(@C9U$851L(!^MU58]=T2;
M5Y/#\6LVK7\48DELEN%,R(<88IG<!R.<=Q7D7PBU?]H[XT_\$_/!^NZCK-OX
M6^*WB[X2Z7/J6I7-D-FC:W=:=$T\_D[2&,,TCN(B I9 IP"2/S@_X+)_\$=O
MV/OV'_V#_$G_  4 _9+NO%7@?XY_"J[L->TKXK'QG?W>K:[?27\$$POWN)76
MYDN#.W15_>,J@>66B8 _8:BN>^$>L>,_$/PH\,:_\1M(73_$-]X>LKC7K!%*
MBVO7@1IX@#R LA9<>U=#0 4444 %%%% !117Y=?M"^(O%W_!6O\ X+,:_P#\
M$S-9\6:MIO[/GP"\)VFM_%W1-$U*6T/CC6KM(9+73;J:%E<V:),I:($!FMYP
MV28VC /TWT;Q/X:\1-,GA_Q#8WYMVVSBSNTE\L^C;2<'@]?2K5W>6FGVLE]?
MW4<$$*%YIIG"HB@9+$G@ #N:^"/V\_\ @C#^S=IG[.NM?%K_ ()T_"?1O@;\
M;O &C3:O\.O&'PLTZ/1I[BZMD,HL+Q;8*E[!<!/)=9UD^^#R 5;9_8$\>?!W
M_@N=_P $^/@_^TW^TYX+M]<@CM[R/Q;\.;Q$DT"_UZVF^RO<W5FZL+E$,,DT
M$,K-$@O-SH\D<3Q@'V[87]CJEG'J.F7L5S;S(&AG@D#HZGH0PX(]Q4M?G=^Q
M/X0\&?L_?\%P/C)^S/\ L8Z9:Z5\%8/@GI6N^/O"/AXA=%\,^.I=3>.*&VMT
M_=6,D^FJ9I(8E0-L5B,@ ?HC0 WS8A*(3(N\KN"9YQZX]*KZIKNB:'Y/]M:S
M:V?VF816_P!JN%C\V0]$7<1N8^@YKY'\6?L&>/=<_P""YWA/_@H?'>SKX2TC
M]GB^\+7"I?\  U;^U \49BW9V/;W4[\#;OME/WB#53X]?\$1?V0OVX?%/C#X
MF_M^^'+_ .(?BCQ!>W=MX<O1XFOK>#PEHXD9+&UTV&*1(X)!$L<TSLCF6YDE
M+%HRJ  ^S:9<W-M96TEY>7"0PPH7EEE<*J*!DL2>  .<U\"_\&X/C#XX:U^P
M7XB^'GQE\?ZAXMLOAQ\9/$G@WP!XLU24RS:OH&GRQ103&0DF15F-S$IR=J0J
M@X0 <G_P<P?'W]MWX:_\$YOBEX8^ 'P%M%\%7_AR*R\<_$V^\66T;VFF7<L=
MM<6UK8#,TLDOG"%G;"JDCD!C@J ?I0K*ZAT8$$9!!ZTM9'P__P"1#T3_ +!%
MM_Z*6M>@ HHHH **** (KR]L]/@-S?W<4$8(!DFD"J#]34-GKVAZC-]FT_6;
M2>3&?+AN59L>N :J^-O G@?XE^&KKP7\1O!NE:_H][&4O=)UK3XKJVG4\%7B
ME5E8>Q%?C7^SW\+_ (>_\&[O_!:J^^%>K>#]/LOV??VK&BB^'GB^YME+^$=;
MAD?;I3W+99(-]R8^3@QSVKLQ\F8T ?M!?:UHVF2"+4M6MK=F&56>=4)'KR:@
M_P"$L\*_]#-I_P#X&I_C7PQ\6/@1\&O^"R/[:MM:?$;X9:+XD^!O[.>NSV]Y
M>ZEIZ2IXU\9B-HY+%6(S)IVFI(XF7.R:[E\LAEMY WR5^U'_ ,$]_P!A+PW_
M ,'+/[,_[//A[]CKX:6/@/Q%\'==O]>\&VO@JRCTS4;J.WU@QS36RQ^7+(IB
MB(9E)'EKCH* /V<_X2SPK_T,VG_^!J?XU9L=2T[4XS+IM_!<*IPS02AP#Z9!
MK\2OVY_^":W[ _PY_P"#B+]D+X6^"/V1_ >F^$?'WAKQ"WB_P;;>'(!H^IO:
MV%ZT$DEEM\C<IVG(09*(3DJ#7T?_ ,%2?^"27P0_9]_9F\6?MR?\$R?#$'P$
M^,?PC\/7/B;2=4^&,0TRSUJTL8VN+G3[ZQB M[N.2&.0 /&27VABR%T8 _2V
MF^;$)1"9%WE=P3/./7'I7B?_  3;_:U/[=?["7PN_:TGTR&RO/&GA2"[U:SM
ML^5!?H6@NTCR2?+%Q%*%R<[0,\UY7XL_8,\>ZY_P7.\)_P#!0^.]G7PEI'[/
M%]X6N%2_X&K?VH'BC,6[.Q[>ZG?@;=]LI^\0: /KC5-=T30_)_MK6;6S^TS"
M*W^U7"Q^;(>B+N(W,?0<U:KXR^/7_!$7]D+]N'Q3XP^)O[?OAR_^(?BCQ!>W
M=MX<O1XFOK>#PEHXD9+&UTV&*1(X)!$L<TSLCF6YDE+%HRJ#C_\ @W!\8?'#
M6OV"_$7P\^,OC_4/%ME\./C)XD\&^ /%FJ2F6;5] T^6**"8R$DR*LQN8E.3
MM2%4'"   ^\]1UW1-(GM[75M9M;62[D\NTCN+A4:9^/E0,1N/(X'K5JOA_XZ
M?\$'_P!CK]M5O%_Q$_;ITC5/&_Q&\675V;+Q;#XGOH?^$3LS(_V&RTJ%9%A@
MCMHO+R6B/GS"224-YFP5?^#<CXJ?'CXM?\$L/">J?'WQI=^*+O1O$6M:'X=\
M67\C23:UI%E?26]O<,[$F3&QXE<DDK"N23DD ^ZJ*** "BBB@!&944N[  #)
M)/ %44\4^&)7$<?B.P9F.%5;Q"2?3K5V:&&YA>WN(5DCD4K)&Z@JRD8((/45
M^-G_  6J_88\)?\ !-C]KGX<?\%Y/V5OV>]$O]'\$ZY';?'+P'I^C0B"YL+A
M6M?[7@BVA(IPDS1M( ,2FWE(XF9@#]D+R_L=.A^T:A>Q01YQYDT@49],FJG_
M  EGA7_H9M/_ / U/\:^(?VV/C3\-?\ @J'\-?!?[!/[+FM:;XEL/CIX5@\2
M>,O%Z6J3Q>$O TAVRWP$@(BU"Z.^RM48;TD-Q(P MF!^-?\ @YE_X)M_L$?L
MD_\ !,WPAK7[-_[(G@#PAJMO\5O#^D'7='\,V\>H3V9M[L/%-=;?.FW^6A<R
M.Q=ERQ)YH _:C_A+/"O_ $,VG_\ @:G^-2V6NZ'J,WV?3]9M)Y,9V0W"L<>N
M :_%_P#X.D?^"9W[ 'P$_P""7%[\:O@+^R%X \#>*=%\;:3%9ZSX-\-6^F2M
M%/(T4L4GV=4$R%3G:X(! (P:^W?'G_!"W_@EW\9O@S:Z#HO[)?A3X?:[)ID4
MVD^.?AEI,6A:UI-YY0*74%U:*C%U;YMK[D;HRD$T ?9U-DEBB ,LBJ"P4%CC
M)/0?6OS_ /\ @@!^V!^T+\:OAI\7/V/_ -KGQM)XI^)/[-OQ/N_!>J^+IQ^^
MURPC>5+2[F)Y>4FWN%+G+.B1LQ9V=CZ!_P %D_V#/'O[?/PS^#GA'X?7L\$O
M@G]H?PMXIUMH+_R&728)I8;R1<L-SQQ7!E7'S9B^7K0!]>WU]8Z99R:AJ5Y%
M;V\*%YIYY B(HZDL> /<T6-_8ZI9QZAIMY%<6\R!X9X) Z.IZ$,."/<5\^_M
M<_\ !/'X6_MZ_$33;+]K7[3XF^%_A_2$?2?AQ%J]U:65]K3S2^=?7ZV[QFY$
M4*VZ6Z,Q1&EN6922A7Y#_P""7WP#F_X)^?\ !:;XY?L _LT:YJ[? %_A+IGC
MBV\)W^IS7MOX1UZYO4@2T@>9F9!-"+J7!)9E2+<6\L-0!^H=1VUW:7J-)9W4
M<JI(T;M$X8*ZDJRG'0@@@CL1BO,OVL_B-^T_\./AC-?_ +)7[.5G\2/%MRDL
M=CI^J>++?2+*SDV?NYKB27YGCW8RD8W'&,KG</F'_@VY\;^/OB9_P2F\,_$;
MXK:G]M\4:_X]\9:CXCO./W]_/XCU"6X?CCF1G/''- 'W?1110 4444 %%%%
M!1110 4444 ?B#_P>\_\FL_ _P#[*!J/_I"**/\ @]Y_Y-9^!_\ V4#4?_2$
M44 >?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0
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MLN/@C^T]X4U3Q!X3O&4W^@V7B_5-*M[W;+'*@G%A<P>>%DBC=1(6"LN0!DY
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M\4^./%5VVG?#WP#IDRK>>(-0"[B@+9$%O$O[RXNG'EP1!G;)VJW'?LB?L_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#\0?\ @]Y_Y-9^!_\ V4#4?_2$44?\
M'O/_ ":S\#_^R@:C_P"D(HH \_\ ^#3;_E*9^UW_ -O'_I\GK]_J_ '_ (--
MO^4IG[7?_;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_DUG
MX'_]E U'_P!(111_P>\_\FL_ _\ [*!J/_I"** //_\ @TV_Y2F?M=_]O'_I
M\GK]_J_FM_X-W?VW?V3_ -B/_@I;^U-XI_:O^.FA^!=/UR\N[72;O7)75+J9
M-9G=D7:IY"\U^R?_  _X_P""-O\ TD)^'_\ X%S?_&Z /K^BOD#_ (?\?\$;
M?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;H ^OZ*^0/^'_'_  1M
M_P"DA/P__P# N;_XW1_P_P"/^"-O_20GX?\ _@7-_P#&Z /K^BOD#_A_Q_P1
MM_Z2$_#_ /\  N;_ .-T?\/^/^"-O_20GX?_ /@7-_\ &Z /K^BOD#_A_P ?
M\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;H ^OZ*^0/\
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ebs-20220930_g7.jpg
<TEXT>
begin 644 ebs-20220930_g7.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
MT@*( P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ ^/?V'_V'_P!N3_@KK^W)\=_A1\*/V[O$'@C_ (0CQ!J%^[ZM
MX@U.6*6)]3FA6*-891MVX^F.*^P/^(3;_@J9_P!)=O\ RH:Y_P#'J/\ @TV_
MY2F?M=_]O'_I\GK]_J /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_T
MEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O
M_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH
M:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?
M_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZ
MOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_
MJ* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@
M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB
M@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%'_![
MS_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4
MIG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO&?^"-?[0_[3WCO_ (*7?M7Z7\1/V%=?\&6?B;Q_IE]XMU&]\9Z7=KX3O(=
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MZ/\ _(E'_#XO_@H[_P!'%_\ EHZ/_P#(E?,M%']J9G_S_G_X%+_,/]6N'/\
MH"I?^"X?Y'TU_P /B_\ @H[_ -'%_P#EHZ/_ /(E'_#XO_@H[_T<7_Y:.C__
M ")7S+11_:F9_P#/^?\ X%+_ ##_ %:X<_Z J7_@N'^1]-?\/B_^"CO_ $<7
M_P"6CH__ ,B4?\/B_P#@H[_T<7_Y:.C_ /R)7S+11_:F9_\ /^?_ (%+_,/]
M6N'/^@*E_P""X?Y'TU_P^+_X*._]'%_^6CH__P B4?\ #XO_ (*._P#1Q?\
MY:.C_P#R)7S+11_:F9_\_P"?_@4O\P_U:X<_Z J7_@N'^1^N/_!&7]M/]IC]
MJ_Q5X]TWX_?$K^WX-%T^PETQ/[&LK7R6DDF#G-M#&6R$7[V<8XQ7WO7Y;?\
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M_P"E,_F'Q(_Y+#$>D/\ TB(4445[Y\*%%%% !1110 4444 ?B#_P>\_\FL_
M_P#[*!J/_I"**/\ @]Y_Y-9^!_\ V4#4?_2$44 >?_\ !IM_RE,_:[_[>/\
MT^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7\UGCS_D>-9_["UQ_Z-:OZ4Z_FL\>?\CQK/\
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M:_)GZ=X3_P#)2S_Z]2_]*@?)]%%%?FI_104444 %%%% !1110 4444 ?H_\
M\&[O_(\?%'_L$Z7_ .C;FOU)K\MO^#=W_D>/BC_V"=+_ /1MS7ZDU^J\,?\
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M3;_E*9^UW_V\?^GR>OW^K\ ?^#3;_E*9^UW_ -O'_I\GK]_J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *_FL\>?\CQK/_86N/_1K5_2G
M7\UGCS_D>-9_["UQ_P"C6KX?C3X*'_;W_MI^T>#W\7&^E/\ ]O,JBBBO@S]P
M"BBB@ HHHH **** "BBB@#]N?^"*7_*/KPO_ -A;5/\ TLEKZOKY0_X(I?\
M*/KPO_V%M4_]+):^KZ_8\H_Y%=#_  1_(_D;BK_DIL9_U]G_ .E,****]$\
M*_$?_@M;_P I!?%'_8)TO_TCBK]N*_$?_@M;_P I!?%'_8)TO_TCBKY7B_\
MY%<?\:_)GZ=X3_\ )2S_ .O4O_2H'R?1117YJ?T4%%%% !1110 4444 %%%%
M 'Z/_P#!N[_R/'Q1_P"P3I?_ *-N:_4FORV_X-W?^1X^*/\ V"=+_P#1MS7Z
MDU^J\,?\B6G_ -O?^E,_F'Q(_P"2PQ'I#_TB(4445[Y\*%%%% !1110 4444
M ?B#_P 'O/\ R:S\#_\ LH&H_P#I"**/^#WG_DUGX'_]E U'_P!(110!Y_\
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MYK]2:_5>&/\ D2T_^WO_ $IG\P^)'_)88CTA_P"D1"BBBO?/A0HHHH ****
M"BBB@#\0?^#WG_DUGX'_ /90-1_](111_P 'O/\ R:S\#_\ LH&H_P#I"**
M//\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_FL\>?\CQK/_86
MN/\ T:U?TIU_-9X\_P"1XUG_ +"UQ_Z-:OA^-/@H?]O?^VG[1X/?Q<;Z4_\
MV\RJ***^#/W **** "BBB@ HHHH **** /VY_P""*7_*/KPO_P!A;5/_ $LE
MKZOKY0_X(I?\H^O"_P#V%M4_]+):^KZ_8\H_Y%=#_!'\C^1N*O\ DIL9_P!?
M9_\ I3"BBBO1/ "OQ'_X+6_\I!?%'_8)TO\ ](XJ_;BOQ'_X+6_\I!?%'_8)
MTO\ ](XJ^5XO_P"17'_&OR9^G>$__)2S_P"O4O\ TJ!\GT445^:G]%!1110
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MC_\ !:W_ )2"^*/^P3I?_I'%7[<5^(__  6M_P"4@OBC_L$Z7_Z1Q5\KQ?\
M\BN/^-?DS].\)_\ DI9_]>I?^E0/D^BBBOS4_HH**** "BBB@ HHHH ****
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M/^*]/TBZGT..)G:Q$M]+&@BNI?+AF*[F-OY\8"F42( >2>#_ -N7]I[XK_\
M!6WX0>'-!\8+I?P(^)?P_P#%E[X3\,_V5#YVNP:9]D$&O2SNAEC2Y>XD:")&
M53;1P2L-T[(GZ"5^//Q/_;$_;GUS_@LC^S=XD\2?\$D_%?A;5M+^'GBW3M)\
M(2_$O0)GO;&=]/6XO4EAE,44=JJH3$Q#N' 0'!K]@)=0L(;V+39KZ%+F='>"
MW:4!Y%7&XJO4@;ER1TR/6@#X_P##WQ(_:"_;S_:D^-?@/X/_ +2&N?"_P'\$
M]6M_".EZEX3TG3KJYUSQ6UE%>7D]T;^VG4VMHMQ;0K;($\UVF9W(\L+Z3_P3
M6_:Q\5_M@?LPP^-OBAH]CIOCSPMXGU?P=\1M.TO=]F@UW2;V2SNFA#$LL<AC
M6=$))59E4DD9/DO_  2/LIOAU\=_VS/@5XD_=Z]9_M2:EXM:%OO/I>N:7I]S
M8S>ZL(ID!Z9A8=5-'_!#6RFUGX)_&SXZ67S:#\5/VJ/'WBOPC<#[MSI<FHBT
MBG7U61K.1P1P0V1D&@#[7HHHH **** "BBB@ HHHH _'3_@N7\:/A[\#/V][
MG5/^"C/P?O/$GP+\2?L_W^C?!G7+W16U/0?#OC=S<F6:YMBK(MY)'Y"QW!1G
MB0(4POG.GV;_ ,$Q?V-OV?\ X'ZMJ'[3'[*.L:./ 7Q/^%_A6&WT?PYK!N=+
MMM0LFU%[F>S1&:&WBE%Y%NCA(3S8I&VAF)/+_P#!17]O/]EC29/CK^PE^UI?
M>%]&MI/@XNJ^$[KQI;(FF:W<75M?K]C\^YS;F[CFMH7CB)61_-4QABA(^;?^
M"&7P4\"_ _\ X*0_$#0/^"=WQ/OO$7[,.H?!;2M1\76]IK+ZCH6C_$"6XB#6
M-A<LS++*MHDLDNQW,?GK'(<I$J@'K?\ P<S?$/\ ;?\ !O\ P32^)]O\ /#/
M@JR\ 7'AF"W\?^+M4\47*ZR+*YNTM9[&SL$LS$WF++&C3R7(_=R3*(PP5Z_1
MVOA'_@Y;\3>'- _X(J?&ZRUS7K.SGU'2=-@T^&YN51[F7^U[$[(U)R[8YP,G
M'-?3O[2'@KQ'^U9^R9XJ\ ?L[_'NW\+WWC;PU+9:#\0-(B%^EFDPVM/%Y4J;
M\H74,DBLI;<K!E!H _//_@MIKFM?M7_LV_\ #0%GJUS#\,O 7QH\(:5\/(+>
M=EB\2ZK_ ,)'9VU_K;X/[RVB4RV5J#\KDW<^'1[9U_5VOQB_X*X_LA_\%0_@
MK^P)I6A?$7_@HQX#U_P3H_CSP7IFD^$M ^ -KHZV;+K-E#9-')'>OMB@?RG\
MH+AUCV94'(_2/XB?M.>'?^"=7[(>C_%/_@H9\?8M8N-.NK/2O$'C;1O!<T$>
MH7UU<>7"R6%IY[0J=R@@%@-I.<D"@#YB_P""ULO[.WQ-_:H_9L_9Y_:K^#OB
MCXA?#Q)/%/BSQ3X2\)^"M6UZ:YFM[".PT_?;:7%).%\W49Y ^ H-N03R ?=O
M^"6'@[_@F'X<^$&O:C_P3&\ ^'_#VBW'B!K?QEI]AI-U8ZG::I @4VNH07RK
M=V\L:MQ#,J[0Y91AR6] ^,G[9_PK_9]_:&\)?!/XQ6<WAS3_ !KH-_=Z5\0M
M9N;>UT,7MK)"!I3W$LBE;N2.62:.,@!TAEVDE6 ^>/\ @GE/8?&7_@IY^U1^
MUW\$PLWPI\16'A/PYI_B6Q&=/\6Z[IEO<K?7UI(/EN(X%FAM#<)E':-@K,$)
M !]T4444 %%%% !1110 5_-9X\_Y'C6?^PM<?^C6K^E.OYK/'G_(\:S_ -A:
MX_\ 1K5\/QI\%#_M[_VT_:/![^+C?2G_ .WF51117P9^X!1110 4444 %%%%
M !1110!^W/\ P12_Y1]>%_\ L+:I_P"EDM?5]?*'_!%+_E'UX7_["VJ?^EDM
M?5]?L>4?\BNA_@C^1_(W%7_)38S_ *^S_P#2F%%%%>B> %?B/_P6M_Y2"^*/
M^P3I?_I'%7[<5^(__!:W_E(+XH_[!.E_^D<5?*\7_P#(KC_C7Y,_3O"?_DI9
M_P#7J7_I4#Y/HHHK\U/Z*"BBB@ HHHH **** "BBB@#]'_\ @W=_Y'CXH_\
M8)TO_P!&W-?J37Y;?\&[O_(\?%'_ +!.E_\ HVYK]2:_5>&/^1+3_P"WO_2F
M?S#XD?\ )88CTA_Z1$****]\^%"BBB@ HHHH **** /Q!_X/>?\ DUGX'_\
M90-1_P#2$44?\'O/_)K/P/\ ^R@:C_Z0BB@#S_\ X--O^4IG[7?_ &\?^GR>
MOW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH **** "BBB@ HHHH ****
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M8_Y$M/\ [>_]*9_,/B1_R6&(](?^D1"BBBO?/A0HHHH **** "BBB@#\0?\
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MN/\ T:U?TIU_-9X\_P"1XUG_ +"UQ_Z-:OA^-/@H?]O?^VG[1X/?Q<;Z4_\
MV\RJ***^#/W **** "BBB@ HHHH **** /VY_P""*7_*/KPO_P!A;5/_ $LE
MKZOKY0_X(I?\H^O"_P#V%M4_]+):^KZ_8\H_Y%=#_!'\C^1N*O\ DIL9_P!?
M9_\ I3"BBBO1/ "OQ'_X+6_\I!?%'_8)TO\ ](XJ_;BOQ'_X+6_\I!?%'_8)
MTO\ ](XJ^5XO_P"17'_&OR9^G>$__)2S_P"O4O\ TJ!\GT445^:G]%!1110
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M/YH\CB#_ )$.+_Z]5/\ TAG[QT445^T'\?!1110!\]_\%6/^4?7Q+_[!-O\
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M):^KZ^4/^"*7_*/KPO\ ]A;5/_2R6OJ^OV/*/^170_P1_(_D;BK_ )*;&?\
M7V?_ *4PHHHKT3P K\1_^"UO_*07Q1_V"=+_ /2.*OVXK\1_^"UO_*07Q1_V
M"=+_ /2.*OE>+_\ D5Q_QK\F?IWA/_R4L_\ KU+_ -*@?)]%%%?FI_104444
M %%%% !1110 4444 ?H__P &[O\ R/'Q1_[!.E_^C;FOU)K\MO\ @W=_Y'CX
MH_\ 8)TO_P!&W-?J37ZKPQ_R):?_ &]_Z4S^8?$C_DL,1Z0_](B%%%%>^?"A
M1110 4444 %%%% 'X@_\'O/_ ":S\#_^R@:C_P"D(HH_X/>?^36?@?\ ]E U
M'_TA%% 'G_\ P:;?\I3/VN_^WC_T^3U^_P!7X _\&FW_ "E,_:[_ .WC_P!/
MD]?O]0 4444 %%%% !1110 4444 ?G#_ ,'$7_(C_"[_ +"VJ?\ HJVK\M:_
M4K_@XB_Y$?X7?]A;5/\ T5;5^6M?E7$__(ZJ?]N_^DH_I[PW_P"2/P_K/_TN
M04445X!]T%%%% !1110 4444 %?0O_!*?_E(+\-/^PM<?^D<]?/5?0O_  2G
M_P"4@OPT_P"PM<?^D<]=F7?\C"C_ (X_FCR.(/\ D0XO_KU4_P#2&?O'1117
M[0?Q\%%%% 'SW_P58_Y1]?$O_L$V_P#Z605^#=?O)_P58_Y1]?$O_L$V_P#Z
M605^#=?G'&/_ ",(?X/U9_0GA)_R(*W_ %]?_I$ HHHKY(_5 HHHH **** "
MBBB@ HHHH _I3\!_\B/HW_8)M_\ T4M:M97@/_D1]&_[!-O_ .BEK5K]RA\"
M/XKJ_P 67JPHHHJC,*_FL\>?\CQK/_86N/\ T:U?TIU_-9X\_P"1XUG_ +"U
MQ_Z-:OA^-/@H?]O?^VG[1X/?Q<;Z4_\ V\RJ***^#/W **** "BBB@ HHHH
M**** /VY_P""*7_*/KPO_P!A;5/_ $LEKZOKY0_X(I?\H^O"_P#V%M4_]+):
M^KZ_8\H_Y%=#_!'\C^1N*O\ DIL9_P!?9_\ I3"BBBO1/ "OQ'_X+6_\I!?%
M'_8)TO\ ](XJ_;BOQ'_X+6_\I!?%'_8)TO\ ](XJ^5XO_P"17'_&OR9^G>$_
M_)2S_P"O4O\ TJ!\GT445^:G]%!1110 4444 %%%% !1110!^C__  ;N_P#(
M\?%'_L$Z7_Z-N:_4FORV_P"#=W_D>/BC_P!@G2__ $;<U^I-?JO#'_(EI_\
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M\$I_^4@OPT_["UQ_Z1SU\]5]"_\ !*?_ )2"_#3_ +"UQ_Z1SUV9=_R,*/\
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M_P#;S*HHHKX,_< HHHH **** "BBB@ HHHH _;G_ ((I?\H^O"__ &%M4_\
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M-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\
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MMHW_ #Y^!/\ OYK?_P FT?\ #C;1O^?/P)_W\UO_ .3:_0ZBC^R\L_Y\0_\
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MP3I^$^C? WXW> -&FU?X=>,/A9IT>C3W%U;(9187BVP5+V"X">2ZSK)]\'D
MJVS^P)X\^#O_  7._P""?'P?_:;_ &G/!=OKD$=O>1^+?AS>(DF@7^O6TWV5
M[FZLW5A<HAADF@AE9HD%YN='DCB>, ^W;"_L=4LX]1TR]BN;>9 T,\$@='4]
M"&'!'N*EK\[OV)_"'@S]G[_@N!\9/V9_V,=,M=*^"L'P3TK7?'WA'P\0NB^&
M?'4NIO'%#;6Z?NK&2?35,TD,2H&V*Q&0 /T1H ;YL0E$)D7>5W!,\X]<>E5]
M4UW1-#\G^VM9M;/[3,(K?[5<+'YLAZ(NXC<Q]!S7R/XL_8,\>ZY_P7.\)_\
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M-QY' ]:M5\/_ !T_X(/_ +'7[:K>+_B)^W3I&J>-_B-XLNKLV7BV'Q/?0_\
M")V9D?[#9:5"LBPP1VT7EY+1'SYA))*&\S8*O_!N1\5/CQ\6O^"6'A/5/C[X
MTN_%%WHWB+6M#\.^++^1I)M:TBROI+>WN&=B3)C8\2N225A7))R2 ?=5%%%
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M#T.D>'/"^C6NDZ#I5NS,EG9V\2PPPJ6)8A8T5<L23C))/-;= !1110 4444
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M&O!VE2S+]HU75+ZUDMH8H8_O2;#+YK[1\L<;L< 5M?&[_@CK^P#^T9\;]/\
MVDOC'\./&.K>.](M#:Z-XG3XR^*K6ZTV F0F*V:WU.,6Z'SI<K&%!\QO4TO@
M7_@C?_P3C\!_%W2_CTO[/D_B3QAH;*VB:[\1/&^M^*9M/93N1X!K-[=+"ZL
MRL@#*P!!! - %+_@B!^SOXW_ &5?^"3_ ,#_ ((_$G29M/U[3_!XO=6TZZ0K
M+9SWUQ-?M;R*>5>/[3L9>S*1VKZJHHH ^=?VK/C-\0/BCXJN_P!AG]DKQ(;/
MQ[JNG(_CCQO;*)(?ASH\X(^V.?NMJ4R;Q96IY+9N) (8CO\ 1/V:OAK^S_\
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M^3U^_P!7X _\&FW_ "E,_:[_ .WC_P!/D]?O]0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!^(/\ P>\_\FL_ _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\ TA%%
M 'G_ /P:;?\ *4S]KO\ [>/_ $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\
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MU_17R!_P_P"/^"-O_20GX?\ _@7-_P#&Z/\ A_Q_P1M_Z2$_#_\ \"YO_C=
M'U_17R!_P_X_X(V_])"?A_\ ^!<W_P ;H_X?\?\ !&W_ *2$_#__ ,"YO_C=
M 'U_17R!_P /^/\ @C;_ -)"?A__ .!<W_QNC_A_Q_P1M_Z2$_#_ /\  N;_
M .-T ?7]%?('_#_C_@C;_P!)"?A__P"!<W_QNC_A_P ?\$;?^DA/P_\ _ N;
M_P"-T ?7]%?('_#_ (_X(V_])"?A_P#^!<W_ ,;H_P"'_'_!&W_I(3\/_P#P
M+F_^-T ?7]%?('_#_C_@C;_TD)^'_P#X%S?_ !NC_A_Q_P $;?\ I(3\/_\
MP+F_^-T ?7]%?('_  _X_P""-O\ TD)^'_\ X%S?_&Z/^'_'_!&W_I(3\/\
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MP1M_Z2$_#_\ \"YO_C= 'U_17R!_P_X_X(V_])"?A_\ ^!<W_P ;H_X?\?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ebs-20220930_g8.jpg
<TEXT>
begin 644 ebs-20220930_g8.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M ,M'6/\ Y$J/[4RS_G_#_P "C_F:?ZM<1_\ 0%5_\%S_ ,CZ:HKYE_X?%_\
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M_EKZK_\ (M;JC5DKJ+^XX98O"PERRJ13]4?0U%?//_#UC]@?_HO/_EKZK_\
M(M'_  ]8_8'_ .B\_P#EKZK_ /(M/V%?^5_<R?KN#_Y^1^]?YGT-17SS_P /
M6/V!_P#HO/\ Y:^J_P#R+1_P]8_8'_Z+S_Y:^J__ "+1["O_ "O[F'UW!_\
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M_P#!.+_HXO\ \M'6/_D2C_A\7_P3B_Z.+_\ +1UC_P"1*/[4RS_G_#_P*/\
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M_P#EHZQ_\B4?\/B_^"<7_1Q?_EHZQ_\ (E']J99_S_A_X%'_ ##_ %:XC_Z
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M#GA[PM^W5K&C^&-"L]-M$T+366UL+5(8P3 "2%0 9-?*5?77_!;S_D_O6O\
ML7],_P#1 KY%K\<SC_D:U_\ $_S/ZXX3_P"29P?_ %[A^2"BBBO./H HHHH
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MQPG_ ,DS@_\ KW#\D%%%%><?0!1110!_23\*?^27>&O^P!9_^B$K?K ^%/\
MR2[PU_V +/\ ]$)6_7[C3_AKT/XMQ'\>?J_S/Y\-:_Y#-W_U]2?^A&JU6=:_
MY#-W_P!?4G_H1JM7U:V/RU[A1110 5[[_P $OO\ D^WP!_U]7W_ION:\"KWW
M_@E]_P GV^ /^OJ^_P#3?<UG6_@R]&=."_WRG_B7YH_9NBBBOFS]#"BBB@#X
MX_X+I?\ )BDW_8W:=_[5K\7J_:'_ (+I?\F*3?\ 8W:=_P"U:_%ZOS+BW_D:
M_P#;J_4_H_PK_P"27?\ U\E^40HHHKY@_20HHHH _6+_ (-ZO^2#^/O^QNA_
M])4K]!J_/G_@WJ_Y(/X^_P"QNA_])4K]!J_6^'_^1/1]'^;/Y5X\_P"2NQ?^
M)?\ I,3\NO\ @N-_R<MX7_[$6+_TLNZ^+*_77]N/_@FQ_P -G?$O2_B)_P +
MH_X1O^S="33OL?\ PCGVSS-LTLOF;_M$6/\ 6XVX/W<YYP/%O^'#/_5U?_EC
M?_=U?8X?%4(48QD]?F?D>/RO'5L9.<(73?=?YGYYT5^AG_#AG_JZO_RQO_NZ
MC_APS_U=7_Y8W_W=6WUW#?S?@_\ (Y/['S+^3\5_F?GG17Z&?\.&?^KJ_P#R
MQO\ [NH_X<,_]75_^6-_]W4?7<-_-^#_ ,@_L?,OY/Q7^9]@?L7_ /)HWPS_
M .Q%TO\ ])8Z],KF?@O\.O\ A4/PB\,_"O\ MC^T?^$<T*UT[[?]G\G[1Y,2
MQ^9LW-LSMSMW'&>IKIJ\.;3DVC[6C%QI1B]TD%%%%2:!7\VWQ8_Y*EXE_P"Q
M@O/_ $>]?TDU_-M\6/\ DJ7B7_L8+S_T>]?$<:?PZ/K+]#]G\'_X^,](?G(P
M****^"/W$**** />_P#@E[_R?W\,?^P^W_HB6OWMK\$O^"7O_)_?PQ_[#[?^
MB):_>VOT7@[_ '"I_B_1'\_>+G_(\H?]>_\ VZ1X'_P5!_Y,2\?_ /7K8_\
MIPMJ_&.OV<_X*@_\F)>/_P#KUL?_ $X6U?C'7Z1EW\%^O^1_//$'^]Q_P_JP
MHHHKO/""BBB@#] _^"#W_(9^)W_7KI'_ *%>5^BM?G5_P0>_Y#/Q._Z]=(_]
M"O*_16O!QO\ O,OE^2/N,F_Y%T/G^;"BBBN4]0*_)[_@X5_Y+OX!_P"Q1F_]
M*GK]8:_)[_@X5_Y+OX!_[%&;_P!*GKY[BC_D33]8_FC[[PS_ .2NI?X9_P#I
M+/SXHHHK\L/Z:"BBB@ K]_/^"<'_ "8I\+?^Q1MOZU^ =?OY_P $X/\ DQ3X
M6_\ 8HVW]:^OX-_WZI_A_5'Y-XN_\B;#_P#7S_VUGME?AI^VA_R=S\3/^QZU
M3_TJDK]RZ_#3]M#_ ).Y^)G_ &/6J?\ I5)7ZMEW\27H?R_Q#_ AZ_H>9444
M5ZY\H%%%% '=?LO_ /)RWP[_ .QZTC_TLBK]WJ_"']E__DY;X=_]CUI'_I9%
M7[O5Y.9?'$^JX>_A5/5!1117FGT04444 ?B#_P 'O/\ R:S\#_\ LH&H_P#I
M"**/^#WG_DUGX'_]E U'_P!(110!Y_\ \&FW_*4S]KO_ +>/_3Y/7[_5^ /_
M  :;?\I3/VN_^WC_ -/D]?O]0 4444 %%%% 'XH_\%O/^3^]:_[%_3/_ $0*
M^1:^NO\ @MY_R?WK7_8OZ9_Z(%?(M?CF<?\ (UK_ .)_F?UQPG_R3.#_ .O<
M/R04445YQ] %%%% '])/PI_Y)=X:_P"P!9_^B$K?K ^%/_)+O#7_ & +/_T0
ME;]?N-/^&O0_BW$?QY^K_,_GPUK_ )#-W_U]2?\ H1JM5G6O^0S=_P#7U)_Z
M$:K5]6MC\M>X4444 %>^_P#!+[_D^WP!_P!?5]_Z;[FO J]]_P""7W_)]O@#
M_KZOO_3?<UG6_@R]&=."_P!\I_XE^:/V;HHHKYL_0PHHHH ^./\ @NE_R8I-
M_P!C=IW_ +5K\7J_:'_@NE_R8I-_V-VG?^U:_%ZOS+BW_D:_]NK]3^C_  K_
M .27?_7R7Y1"BBBOF#])"BBB@#]8O^#>K_D@_C[_ +&Z'_TE2OT&K\^?^#>K
M_D@_C[_L;H?_ $E2MWXL_P#!5CXU^+/'MI:_L4?LI7_CKP=HOQF;P)KWBNZ\
M3Z?IXU_4K>"Y:]L-+AN#EQ')%L^US/!$9(F5"ZDR#];X?_Y$]'T?YL_E7CS_
M )*[%_XE_P"DQ/NFBO*OV,?VI]-_;+^ ]M\==+^&'B3P8L^OZSI,_AGQ?!%%
MJ=A/INIW.GS)<1Q.Z1R>9:N2@=MN<;C6)X+_ &P?#?C;7/BO\1QJ=OI_PN^#
MUQ>Z1K7B-XFD;4=4LHA-JCQA02+>S&+<E06DN%N5P! IE]D^1/<**^$-5_X+
M4>./A!\7_!6B_MD?\$X_B;\'?AI\2_$<&A^"?BCXDUC3;J(7MQ_QZQZG96LK
MRZ29>?EF8NN#N4!)&3[OH ***^:/V;?^"F7PZ_:@_;8^(?['_P /_A_JJVO@
M3PW;ZQ:^.;BX3[%K\;WDUE*;2,#<T27-O/$)B=LAA9D!0H[ 'TO17DWQ;_:&
MG^ _QZ\!^$/B"D0\(_$W46\/Z)K.W:VF>(A#)/;VDQZ-%>0Q3K&YP4G@6/+_
M &J,1>LT %%%% !7\VWQ8_Y*EXE_[&"\_P#1[U_237\VWQ8_Y*EXE_[&"\_]
M'O7Q'&G\.CZR_0_9_!_^/C/2'YR,"BBBO@C]Q"BBB@#WO_@E[_R?W\,?^P^W
M_HB6OWMK\$O^"7O_ "?W\,?^P^W_ *(EK][:_1>#O]PJ?XOT1_/WBY_R/*'_
M %[_ /;I'@?_  5!_P"3$O'_ /UZV/\ Z<+:OQCK]G/^"H/_ "8EX_\ ^O6Q
M_P#3A;5^,=?I&7?P7Z_Y'\\\0?[W'_#^K"BBBN\\(**** /T#_X(/?\ (9^)
MW_7KI'_H5Y7Z*U^=7_!![_D,_$[_ *]=(_\ 0KROT5KP<;_O,OE^2/N,F_Y%
MT/G^;"BBBN4]0*_)[_@X5_Y+OX!_[%&;_P!*GK]8:_)[_@X5_P"2[^ ?^Q1F
M_P#2IZ^>XH_Y$T_6/YH^^\,_^2NI?X9_^DL_/BBBBORP_IH**** "OW\_P""
M<'_)BGPM_P"Q1MOZU^ =?OY_P3@_Y,4^%O\ V*-M_6OK^#?]^J?X?U1^3>+O
M_(FP_P#U\_\ ;6>V5X9XT_X)L_L5_$/Q=J?COQA\&/MFJZQ?2WFI77_"1ZE'
MYT\C%W?:EP%7+$G"@ =@*]SHK]'C.<'[KL?SY4HTJRM4BGZJY\\_\.I_V!_^
MB#?^71JO_P E4?\ #J?]@?\ Z(-_Y=&J_P#R57T-15^WK_S/[V8_4L'_ ,^X
M_<O\CYY_X=3_ + __1!O_+HU7_Y*H_X=3_L#_P#1!O\ RZ-5_P#DJOH:BCV]
M?^9_>P^I8/\ Y]Q^Y?Y'@_A?_@F9^Q%X,\3:=XP\-?!/[-J.DWT-YI]Q_P )
M)J3^5/$X='VO<E6PR@X((..017O%%%1*<Y_$[FU.C1HJU.*7HK!1114F@444
M4 ?B#_P>\_\ )K/P/_[*!J/_ *0BBC_@]Y_Y-9^!_P#V4#4?_2$44 >?_P#!
MIM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4
M444 ?BC_ ,%O/^3^]:_[%_3/_1 KY%KZZ_X+>?\ )_>M?]B_IG_H@5\BU^.9
MQ_R-:_\ B?YG]<<)_P#),X/_ *]P_)!1117G'T 4444 ?TD_"G_DEWAK_L 6
M?_HA*WZP/A3_ ,DN\-?]@"S_ /1"5OU^XT_X:]#^+<1_'GZO\S^?#6O^0S=_
M]?4G_H1JM5G6O^0S=_\ 7U)_Z$:K5]6MC\M>X4444 %>^_\ !+[_ )/M\ ?]
M?5]_Z;[FO J]]_X)??\ )]O@#_KZOO\ TWW-9UOX,O1G3@O]\I_XE^:/V;HH
MHKYL_0PHHHH ^./^"Z7_ "8I-_V-VG?^U:_%ZOVA_P""Z7_)BDW_ &-VG?\
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M*)XGBU*V6:V>QD4QS+,C95HBC,'!X*DYXKZ_@W_?JG^']4?DWB[_ ,B;#_\
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M)Z_?ZOP!_P"#3;_E*9^UW_V\?^GR>OW^H **** "BBB@#\4?^"WG_)_>M?\
M8OZ9_P"B!7R+7UU_P6\_Y/[UK_L7],_]$"OD6OQS./\ D:U_\3_,_KCA/_DF
M<'_U[A^2"BBBO./H HHHH _I)^%/_)+O#7_8 L__ $0E;]8'PI_Y)=X:_P"P
M!9_^B$K?K]QI_P ->A_%N(_CS]7^9_/AK7_(9N_^OJ3_ -"-5JLZU_R&;O\
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MOR1]QDW_ "+H?/\ -A1117*>H%?D]_P<*_\ )=_ /_8HS?\ I4]?K#7Y/?\
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M)=_]?)?E$****^8/TD**** /UB_X-ZO^2#^/O^QNA_\ 25*_0:OSY_X-ZO\
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M /R71_PYT_X*._\ 1NG_ )=VC_\ R77[G45A_J=EG\\_OC_\B=G_ !%KB/\
MY]4O_ 9__+#\,?\ ASI_P4=_Z-T_\N[1_P#Y+H_X<Z?\%'?^C=/_ "[M'_\
MDNOW.HH_U.RS^>?WQ_\ D0_XBUQ'_P ^J7_@,_\ Y89'P^TN^T/P%HFBZI!Y
M5S9Z1;07$6X-LD2)589!(."#R#BM>BBOJXI121^83DYS<GU/Y\-:_P"0S=_]
M?4G_ *$:K59UK_D,W?\ U]2?^A&JU?4K8_,7N%%%% !7OO\ P2^_Y/M\ ?\
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MA)J/QV_:/^)%AX3\(Z3+!'J&MZD',4+S3)#$N(U9B6D=5& >N>@)K@OV3/\
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M]2?^A&JU?4+8_,WN%%%% !7OO_!+[_D^WP!_U]7W_ION:\"KWW_@E]_R?;X
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M_&5R;^;P?87,/@[36CQ#IUS=)Y=U??[=PT/[A&P/*B>=5_U[UW- '\^&M?\
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M\0^,;%_!]M"=:TT6-S ;0+# 5E)DFC?9+A/DSG(%?8=% 'G7[2_Q@T3]E?\
M9F\5?%JST$2IX5\.R'0M"T^V^:^O-HBL=/MXD',D]PT%O'&HY>5%'6N*_P""
M7O[*NM?L3_L ?"S]F;Q5<I-KOASPRK^)I8W#(VK74LEY?[6'#+]JN)\-W&#W
MKV7Q)X(\+^,+W2K[Q-I,=Z=%U 7VFQSY,<5TJLJ3;>C.@9BI.=I.X88*1JT
M%%%% !1110 4444 %%%% !1110 5_-M\6/\ DJ7B7_L8+S_T>]?TDU_-M\6/
M^2I>)?\ L8+S_P!'O7Q'&G\.CZR_0_9_!_\ CXSTA^<C HHHKX(_<0HHHH ]
M[_X)>_\ )_?PQ_[#[?\ HB6OWMK\$O\ @E[_ ,G]_#'_ +#[?^B):_>VOT7@
M[_<*G^+]$?S]XN?\CRA_U[_]ND>!_P#!4'_DQ+Q__P!>MC_Z<+:OQCK]G/\
M@J#_ ,F)>/\ _KUL?_3A;5^,=?I&7?P7Z_Y'\\\0?[W'_#^K"BBBN\\(****
M /T#_P""#W_(9^)W_7KI'_H5Y7Z*U^=7_!![_D,_$[_KUTC_ -"O*_16O!QO
M^\R^7Y(^XR;_ )%T/G^;"BBBN4]0*_)[_@X5_P"2[^ ?^Q1F_P#2IZ_6&OR>
M_P"#A7_DN_@'_L49O_2IZ^>XH_Y$T_6/YH^^\,_^2NI?X9_^DL_/BBBBORP_
MIH**** "OW\_X)P?\F*?"W_L4;;^M?@'7[^?\$X/^3%/A;_V*-M_6OK^#?\
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MO^3[? '_ %]7W_ION:SK?P9>C.G!?[Y3_P 2_-'[-T445\V?H84444 %%%%
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M44 %%%% !1110 4444 ?B#_P>\_\FL_ _P#[*!J/_I"**/\ @]Y_Y-9^!_\
MV4#4?_2$44 >?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]
M/D]?O]0 4444 %%%% !1110 4444 %%%% !164GC?PG)XWE^&Z:[ ==ATI-2
METP$^:MH\KQ+,1TVEXW7ZJ:U: "BJ.C^)M \0W%]:Z'JT-V^F7AM+_R&W""<
M*K&)B.-P#J2.HR,XJ]0 4444 %%%% !15;6=8TWP_I-UKNL70@M+.!Y[J=E)
M$<:@LS' )P "?PJ2QOK+5+*'4],O(KBVN(EEM[B"0.DJ,,JRL.&!!!!'!!H
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M_>% 'VS1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5_-M\6/^2I>)?^Q@O/\ T>]?TDU_-M\6/^2I>)?^Q@O/_1[U\1QI_#H^LOT/
MV?P?_CXSTA^<C HHHKX(_<0HHHH ][_X)>_\G]_#'_L/M_Z(EK][:_!+_@E[
M_P G]_#'_L/M_P"B):_>VOT7@[_<*G^+]$?S]XN?\CRA_P!>_P#VZ1X'_P %
M0?\ DQ+Q_P#]>MC_ .G"VK\8Z_9S_@J#_P F)>/_ /KUL?\ TX6U?C'7Z1EW
M\%^O^1_//$'^]Q_P_JPHHHKO/""BBB@#] _^"#W_ "&?B=_UZZ1_Z%>5^BM?
MG5_P0>_Y#/Q._P"O72/_ $*\K]%:\'&_[S+Y?DC[C)O^1=#Y_FPHHHKE/4"O
MR>_X.%?^2[^ ?^Q1F_\ 2IZ_6&OR>_X.%?\ DN_@'_L49O\ TJ>OGN*/^1-/
MUC^:/OO#/_DKJ7^&?_I+/SXHHHK\L/Z:"BBB@ K]_/\ @G!_R8I\+?\ L4;;
M^M?@'7[^?\$X/^3%/A;_ -BC;?UKZ_@W_?JG^']4?DWB[_R)L/\ ]?/_ &UG
MME%%%?HI^ !1110 4444 %%%% !1110 4444 ?B#_P 'O/\ R:S\#_\ LH&H
M_P#I"**/^#WG_DUGX'_]E U'_P!(110!Y_\ \&FW_*4S]KO_ +>/_3Y/7[_5
M^ /_  :;?\I3/VN_^WC_ -/D]?O]0 4444 %%%% !1110 4444 %5]4TG2]<
ML)-*UK3;>\M90!+;74*R1O@@C*L"#R ?PJQ10!Y9#^Q1^RM;_M#O^U3%\"?"
MP\<OIL=H->_L"U\Y-DKRB=7\O<LY+D&4'<5"KG %=A\8?A-X"^//PH\2?!/X
MI:#'JGAOQ;H=UI&NZ?*<">UN(FBD7(Y4E6.&'(.".171T4 >=_LQ^#OB5X ^
M"6D_"#XRZF-;U3PK:+HO_"1R;6'B&SA01V]](O\ !-+"$\^,@ 3B;;NC,;M;
M^'W[,/[-7PE\33^-?A5^SSX&\,ZS=*RW.K>'_"5G974H8Y8-+#&KL"3SD\UW
M-% &!\2/A5\+_C'X;;P;\7?AOH'BK1VF65M*\2:/!?6QD7.US%,K+N&3@XR,
MU=\(^#O"/P_\-VG@[P'X5TW1-(L(O+L=*TBQCMK:V3.=L<48"H,D\  <UI44
M 9FD>"_!WA_7=4\4:#X3TRRU/7)(I-:U&TL(XY]0>)-D;3R* TI1/E4L3M'
MP*LZ[H6B>*-$O/#/B;1[74=-U&UDM=0T^^MUF@NH)%*2121N"KHRDJ5((()!
M&#5JB@#,BT_3/ ?@U-)\&>$8TL]'TU8-)T'1X(H$6.*/;%;0H2D<:X544$JB
MC&2H&1YK^R#^S;=? 'PWXG\4^-K^VU#Q[\2?%MSXJ^(&JVA9HFOIDCBBM(&<
M!FMK2UAM[2$L 62W#LJM(PKUVB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_FV^+'_)4O$O\ V,%Y_P"CWK^DFOYMOBQ_R5+Q
M+_V,%Y_Z/>OB.-/X='UE^A^S^#_\?&>D/SD8%%%%?!'[B%%%% 'O?_!+W_D_
MOX8_]A]O_1$M?O;7X)?\$O?^3^_AC_V'V_\ 1$M?O;7Z+P=_N%3_ !?HC^?O
M%S_D>4/^O?\ [=(\#_X*@_\ )B7C_P#Z];'_ -.%M7XQU^SG_!4'_DQ+Q_\
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M^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH ****
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M2[A(X/#4>J7$EO:75V[ \RO!<>5"!ND6TN&RHCY]9_:8^('CWX1?!S5_B_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3X6_]BC;?UKZ_@W_ 'ZI_A_5'Y-XN_\ (FP__7S_ -M9[91117Z*?@ 4444
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M?ZM9)_SZ_P#)I?YA_P 1%XR_Z"O_ "2G_P#('P3^R]_P1 _X9M^/WACXY?\
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M\B;#_P#7S_VUGME%%%?HI^ !1110 4444 %%%% !1110 4444 ?B#_P>\_\
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MPO:67B#XGV/C'Q;::=+XB>0^;I^B1QSR*TMLVP75VP&QHUM[<[UN9U0 ]/\
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M=TBC28;A2521[=;FX:(88H\?F;FB#-]-?\$UK&X\'?\ !0W]N+X>:TI&H/\
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M@_\ !/'Q/=:QXGT^TCT_Q':^(?&>NWVI:1#(=Z[K'69FFLQ)MXD\I/,"$!B
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Q7QG_9V^"G[07@37?AS\7?AIHNMZ9XCLFMM42^TN&5Y 8VC60,Z'$B*
MYV/U0\C%=K10!S/PB^#?PM^ O@*Q^&/P=\!:1X;T+3HE2VTW1=.BM8LA0I<I
M$JJ7; +-C)/)KS_QI^SWJ?A[]K_1/VQ/AC"K7NH>&AX1^(^D!@G]IZ4L[7%C
M>IG :XLKB2;"DC?;WMR!N=(4;V:B@#R*;_@GY^P7<3/<7'[$?PBDDD8L[O\
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MBBB@#\0?^#WG_DUGX'_]E U'_P!(111_P>\_\FL_ _\ [*!J/_I"** //_\
M@TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3&UO"D(8R*LA/F2*B;6!8C[B\&WMUJ7A#2M1OIC)-<:;!)-(0!N9HU)/'N:
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MOCWQ7\5_VW[?_@N;X3^!&B>+43X"WG[/-]XBU72&T2W(DUF'5/LK,+HIYPE
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M9O!]MHGC?3M8U#P[XSM+!"ML^I6,QBDFA!)VJZ[&*Y(5RZ@D*"?JV@ HHHH
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MPM99(E;S)9W><$/)O16SY2D@'BO_  <D_P#*$?X]_P#8"TW_ -/%C7V7\/\
M_D0]$_[!%M_Z*6O#/^"I'[$7CW_@HK^Q]XF_8^\*_''2_ .F^,88(=>UF]\&
M2:S<"*&[M[E! JWUJL1+0%6+^9E7X"D9/LWPB\-^/?!WPYTGPM\2_&&EZ_K&
MGV45O=:MHVA2:;!<[$"[Q;R7-P8R<9(\UASQB@#I**** "BBB@ HHHH ****
M /S<_P"#F_\ 9DT+Q7^P@?V[O!>OW'AGXK?LYZM:>)_ 'BW34 N(LWEO'+:L
M>\;$QRC.<20)_"SAOHK_ ()#_#?2O#7[!?@#XQWM]<:IXP^,?AS3_B'\1O$M
M_M-SK&MZM9P74\CE0 L<8=+>&-0%C@@B0#Y>;G_!4?\ 8E^*/_!1#]DKQ)^R
M+X)_:!TCX>:3XP@AM_$6K7G@:36KIH([B*?9 !?VJ1%C$%9F$GRL<;3@CKOV
M%?V>?BC^R=^RYX+_ &:_B;\8](\<GP)X9L- T?7M+\'R:,\ME9P+!!YT37MT
M&D$21@NK*"5)V\\ 'PG^U[_RM=_LG?\ 9#?$7_I-KE)_P4=_Y66/V$O^Q9\6
M_P#IOO:]D^-__!*']IGXO?\ !5#P!_P5 T_]M[PKI%_\-M"FT/P_X*;X-37%
MK+I\ZW:3K<3_ -M([S,M[+B150*4C(3A@U;]K7_@DU^U?^TI_P %!OAK_P %
M!_#/[=_@[PIK7PDTJ\L?!GA^3X(3W]J!=)<1SR7+G78WF<I/@;?+4>6I"_>R
M >Z_\%5/&?A'P!_P3.^/_BCQU=PQ:9%\'?$<,PG8!9GFTZ>&.$9ZM))(D:CN
MS@=Z\G_X-UO"_B;PA_P16^ &D^+()8[J;PI<WL2S @FVN=1NKFV//8P2Q$>Q
M%<_^T/\ \$@/VDOV^K[1_!O_  45_P""C%SXP^%VF:A#?7_PL^&7PU7PE9:Y
M-$P=!?7#:A>W$T08 ^6&0 C<A1PKC[F\,^&O#W@OPWI_@[PEHMMINE:38Q6>
MF:=90B.&UMXD"1Q1HO"HJ*J@#@  4 7#%$91.8U+JI57*\@'&1GT.!^0KR7]
ML']I>\_9[\"6ND?#GPROBCXF^,9I-+^&/@A)=KZOJ6PMYDI'^ILK=?WUS<'Y
M8HE/5VC1_7*_/GQ7_P $L/\ @J??_M2^,/VJ_ 7_  6BTGP]K/BF,6-G:M^S
M-INHKH>D)(7BTVT>\U*1H80Q#R;-IGD422;F"[0#Z6_X)W_L8Z/^P?\ LN:/
M\#(O$9U[7IKR[UOQSXH>+8^NZ]?2M<7UZ5_A5I6*HO58TC4DE23+^VK^T?XL
M^#_@ZU^%_P !-(M]=^,?CY)[#X:^')F_=I.% EU6\P#Y6GV8=9IY".?W<*;I
M9XD:E^P[^S)^T]^S[8>*=;_:[_;?U#XY^+?$>H6_V?7)?!=MX=L]+T^"-A%:
M06%K+)$K>9+.[S@AY-Z*V?*4GYFB_P""4O\ P5DTCX]>-/VB_!__  6ZTG2O
M$/C>:-+Z7_AE[3+T6-C$6-OIMJUYJ<KP6D6YF$2MAG=Y7WR.SD ^L/V"?V.O
M!'[!'[)WA#]EOP+J<VI1>';)VU77+M,3ZOJ4\K3WE[)R<-+<22/MR=JE4!(4
M5[#7B7[$/[-_[1/[/7@[7C^U9^V/J/QP\:^(-:^U3>++OPG;Z#!:621)'!8V
M^GVTCPPHA$LA=3ND>=BV<"O;: "BBB@ HHHH **** (KVRL]2LYM.U&TBN+>
MXB:.>">,.DB,,,K*>"""00>"#7XF?L"_L5>&O@I_P7P^*7_!,"Q\<:K?? 'P
M);P_&_P?\-)ROV&UU]SI\5LD@(+2PVQOFDC0G:9+2TD<,T63^VTPF:%UMW59
M"IV,Z;@#V) (R/;(^M?"_P ,O^"4'[3OP]_X*O>+/^"J%S^W#X4O]2\9^%$\
M,:OX)7X,SQ6B:4@M/+CAG_MMI$F#V4+F5@P)9QL"D!0#Z+_X*$?\F#_'#_LD
M'B7_ --5S7QQ_P $//\ E6E\%_\ 9,_&'_IQU:OM3]L[X'_%']I7]FWQA\ ?
MA9\6](\$W/C/P[?:)?\ B#5?"4FLFVM;J!X)6AA6\M0)0CL59F90<$H<8KYX
M_9%_X)@_M1?L@?\ !-:;_@G/X0_;8\(ZG;6^D:KI?A_QE??!J=;C3[6_>YEE
MWP+K>R>1)+EVC<E5 "AD?K0!PW_!JG_R@]^$_P#V%/$G_I]OJX#X]7=OX_\
M^#MKX'Z;X&D%S<^!?V<M3G\:O;'/V6"<ZJD,4N.GSW=LX!_Y^$/>O2OV+/\
M@D__ ,%%?V!?V4-(_8]_9Y_X*B>!+3PWH;7K:9J>I?LV/=:C"]U=2W,C[W\0
M>4Q$DS[=T1 & 0V.?7O^"=G_  2F^&'[!7BKQI\<]=^*GB3XI?&+XE3K+X^^
M*OC-H_MM\BD%;:"*,;+2V!52(E+?<0%BL<2H ?5--BBBMXEAAC5$10J(HP%
MZ #L*=7S[_P4C_9/_:-_;3_9\F^ 7[/O[8"_!J/6+C9XIUR#P3_;-UJ-AMPU
ME&?MMM]G20\2,-S.F4^56;< >:P^"+3_ (*4_MO^"_VBA&L_P3_9\U.^G\#7
M_6+QKXQ=3;2:A!VDL-.02113+@374DK(6C@5I/LRO@/PO_P3&_X*PVNFZ'\-
M_&7_  7!27X>V$EG::KX1\(?LT:)X?DNM'B9%DTZVO+6[,FGAX5,2RPC=$""
MH.,'[\  & * /@;]BK_E/I^VW_V)?PT_]-EU7WS7RE^SO_P3^^/7P5_X*#_%
MC]NKQ+^U#X6UV'XO:9HECKGA"R^%]Q8_8HM+MS!;&WNFU>8ABKR%R\; EN H
M %?5M !1110 4444 %%%% 'X@_\ ![S_ ,FL_ __ +*!J/\ Z0BBC_@]Y_Y-
M9^!__90-1_\ 2$44 >?_ /!IM_RE,_:[_P"WC_T^3U^_U?@#_P &FW_*4S]K
MO_MX_P#3Y/7[_4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?B#_P>\_\FL_ _P#[
M*!J/_I"**/\ @]Y_Y-9^!_\ V4#4?_2$44 >?_\ !IM_RE,_:[_[>/\ T^3U
M^_U?S6_\&[O[;O[)_P"Q'_P4M_:F\4_M7_'30_ NGZY>7=KI-WKDKJEU,FLS
MNR+M4\A>:_9/_A_Q_P $;?\ I(3\/_\ P+F_^-T ?7]%?('_  _X_P""-O\
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M7]%?('_#_C_@C;_TD)^'_P#X%S?_ !NC_A_Q_P $;?\ I(3\/_\ P+F_^-T
M?7]%?('_  _X_P""-O\ TD)^'_\ X%S?_&Z/^'_'_!&W_I(3\/\ _P "YO\
MXW0!]?T5\@?\/^/^"-O_ $D)^'__ (%S?_&Z/^'_ !_P1M_Z2$_#_P#\"YO_
M (W0!]?T5\@?\/\ C_@C;_TD)^'_ /X%S?\ QNC_ (?\?\$;?^DA/P__ / N
M;_XW0!]?T5\@?\/^/^"-O_20GX?_ /@7-_\ &Z/^'_'_  1M_P"DA/P__P#
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M_P#X%S?_ !NC_A_Q_P $;?\ I(3\/_\ P+F_^-T ?7]%?('_  _X_P""-O\
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ebs-20220930_g9.jpg
<TEXT>
begin 644 ebs-20220930_g9.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
M'_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_X
MA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;
M_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*
MF?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_
M $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)
M=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_
M ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*
MAKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y
M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
MRH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&
MN?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /Y/?^"PO_  2[_P""@?\ P1[^
M&W@[XD?$C_@HIKGC&#QCKD^FVUMH>OZK ]N\4(E+L99L$$'&!17Z"?\ ![S_
M ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y
M2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB
M@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%'_![
MS_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4
MIG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!
M_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V
M\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH
M \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_
M ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y
M2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK3+C1M6M$N+6[@>&Y@E7*R1LI5E([@@D?C7Y1_%/_@C]^WW^S]^T)^SW\/\
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MT?0O[018[R]ENKUC<7EQ+"HBP4CC0 D*2>/LF@ HHHH **** "BBB@ HHHH
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M\H]* .NHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3:U_].%_7S?%?_(H?JC]#\,/^2KA_@G^1\*4445^7G]*A1110 4444 %%%%
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M* //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J
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MY!_Q#KC+_H%_\GI__)G[845^)_\ P^__ ."@W_0Y>%?_  DX_P#XNC_A]_\
M\%!O^AR\*_\ A)Q__%T?ZRY)_P _?_)9?Y!_Q#KC+_H%_P#)Z?\ \F?MA17X
MG_\ #[__ (*#?]#EX5_\)./_ .+H_P"'W_\ P4&_Z'+PK_X2<?\ \71_K+DG
M_/W_ ,EE_D'_ !#KC+_H%_\ )Z?_ ,F?MA17XG_\/O\ _@H-_P!#EX5_\)./
M_P"+K]"(OA5_P5REB64?M:?"P;E!Q_P@<O\ \77=@LSP.8\WU>?-RVOHUOMN
MEV/$SCAS.<@Y/K]+DY[\OO1=[6O\+=K76Y]445\L_P#"I_\ @KE_T=I\+/\
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M !#T?&W_ *.#\*_^"ZY_PK!U?_@V6\0:_J,NKZ]X^^'%[=S$&:ZN_"[R22$
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MHHHK\9/Z]"BBB@ HHHH **** "BBB@ K^F2T_P"/2+_KFO\ *OYFZ_IDM/\
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M'BG_ +*3=?\ IOL*_(*OU]_X-^?^30/%/_92;K_TWV%?2<*?\C=>C/SWQ/\
M^24G_CA^9]UT445^H'\TA1110 4444 %%%% !1110 45YY^UG^TIX _8[_9I
M\;_M0_%%Y/["\#>'+G5KZ& @27/EIE+>//'F2R%(ESQN=<U_')_P43_X*[_M
MN?\ !2WXHZGXU^.OQ>U:V\/3W3MHGP_T?4I8=&TB#/R1) I"RN!@--(&D<C)
M.,  ']KU%?Q0_P#!.S_@KO\ MN?\$TOBCIGC7X%?%[5KGP]!=(VM_#_6-2EF
MT;5X,_/$\#$K$Y&0LT861"<@XR#_ &-_LF_M*> /VQ/V:?!'[4/PN>3^PO'/
MARVU:QAG(,EMYB9>WDQQYD4@>)L<;D;% 'H=%%% !1110 4444 %%%% !111
M0!^(/_![S_R:S\#_ /LH&H_^D(HH_P"#WG_DUGX'_P#90-1_](110!Y__P &
MFW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-/_!8'_E'
M/\1O^N>E_P#IVLZ^EJ\/_P""D/P?^(OQ[_8M\:_"7X3>'?[6\0:NE@-/T_[7
M#!YOEZA;3/\ O)G1%Q'&[?,PSC R2!7'F,93R^M&*NW&5E\F>OP_5IT<^PE2
MI)1C&K3;;=DDIIMMO9+JS\!Z*^FO^'.G_!1W_HW3_P N[1__ )+H_P"'.G_!
M1W_HW3_R[M'_ /DNOR7^R\S_ .?$_P#P&7^1_4W^LO#G_0;2_P#!D/\ ,^9:
M*^FO^'.G_!1W_HW3_P N[1__ )+H_P"'.G_!1W_HW3_R[M'_ /DNC^R\S_Y\
M3_\  9?Y!_K+PY_T&TO_  9#_,^9:*^FO^'.G_!1W_HW3_R[M'_^2Z/^'.G_
M  4=_P"C=/\ R[M'_P#DNC^R\S_Y\3_\!E_D'^LO#G_0;2_\&0_S/F6BOIK_
M (<Z?\%'?^C=/_+NT?\ ^2Z/^'.G_!1W_HW3_P N[1__ )+H_LO,_P#GQ/\
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M44 %%%% !1110 4444 ?B#_P>\_\FL_ _P#[*!J/_I"**/\ @]Y_Y-9^!_\
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MU3_@B_\ \$S]<TZ;2-:_9C@O+2XC*7%K=>*=6DCE4]596NR&'L:\Q_XAEO\
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M]Y_Y-9^!_P#V4#4?_2$44 >?_P#!IM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\
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MGX?\4V5Q]IT^\EOY4AL\7$(:-4EEDCC61B$+R(N[+ $ [NBO./VD/VM?V?\
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M2-5U&)TTJWUO7)[_ ,-> &:W9TFN[MMEY=6\&[]W&R(3YG/U?_P3ETOXT?\
M!/[_ (((_#NXTCX*Z[XW^(6F_#R36M.\"Z19/)=WVK:O=S7\5K(J\Q*LU\HF
M<\1(DC'[M<5JG[!WQ6_8X\ _L\_M ^)O"NM_%CQ/X4^->H?$+]H\>%M+:_U'
M6]8U;1;^Q?4[6T0;[E-/GNK=(8(E+K;P@HF5((!]\? [XX_!K]HKX:V'Q5^
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MIVDN0>6M;&&VC<=I3,,GJ?J"BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%
M'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV
M_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH *\^\2?LU?#OQ%^TCX9_:M
MCGU'3O%_AKP]?:"USIMPB1:MI=TR2FSO$9&\Z..>-)XL%6CD#8;;)(K^@T4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P")KNO^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)H X7_AN?\
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M_P")KNO^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)H X7_AN?\
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M_P")KNO^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)H X7_AN?\
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M_P")KNO^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)H X7_AN?\
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M=QQW'BOX::YJ45Z)K*3;Y>HZ=>1!4O[1M\?[P(C*9%#(-RD@'U%17QG\>O\
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MBK4_B!:Z#%?W\ S=6.E02QR2WSPG,4DH 43QR0H)'0B@#[/HKP?_ ()O?\%
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M ()R?#S]N5?V<]?N/$OQ.TBQ?PA\)]#OH[F_U/4[P,8+2*XD6*,1F-'N'N)
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M)>+O1M>O8&GG,]X5.+=6(6T1W(5I6\U?KK]AWXN?MU?&RP\4^-/VU?V2-/\
M@DL6H6]GX2\$Q>-[/Q%>30I&SSW\][9'R0LC2)&D(4,GV9RQ82*: /D?_@YW
M_8U_9K\>_P#!,OXM_M4^,OAE'J/CWPKH6GGPWKUUJ=TW]G%M2M(6:*'S?)1F
MCD=2P3)#<D\5^C/P_P#^1#T3_L$6W_HI:^5/^"[7P3_:&_:C_P"":'Q%_9<_
M9A^!6J>./%GCFRM+6PALM:TNQM[/R=1M+AWGEO[N# ,<<FT1B0EEP0N0:^F/
M@GJWBC6/A5H5SXT^'&J>$]433((KW0M9NK.>>VD6-0RE[.>>%AD'!60YQVH
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M^R^&O -IXOM=?GAL8XD)O+B^M#Y+O-*\@$2JOEI"N<ER:]MH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK#]J;_HY7X@?^%E??_':** #_AK#]J;_ *.5^('_ (65]_\ ':/^&L/VIO\
MHY7X@?\ A97W_P =HHH /^&L/VIO^CE?B!_X65]_\=H_X:P_:F_Z.5^('_A9
M7W_QVBB@ _X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\
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M;_HY7X@?^%E??_':/^&L/VIO^CE?B!_X65]_\=HHH /^&L/VIO\ HY7X@?\
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K&_QC^+OQ-M8+'XD?%3Q)XA@M9#);0ZYKEQ=I"Y&"RB5V"DCC(HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101226438416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EMERGENT BIOSOLUTIONS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">14-1902018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Professional Drive Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">631-3200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EBS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,888,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001367644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101228189152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 240.9<span></span>
</td>
<td class="nump">$ 576.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">191.3<span></span>
</td>
<td class="nump">274.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">546.3<span></span>
</td>
<td class="nump">350.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">139.9<span></span>
</td>
<td class="nump">70.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,118.5<span></span>
</td>
<td class="nump">1,272.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">806.7<span></span>
</td>
<td class="nump">800.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">722.7<span></span>
</td>
<td class="nump">604.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">224.9<span></span>
</td>
<td class="nump">224.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">35.7<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,908.5<span></span>
</td>
<td class="nump">2,959.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">103.8<span></span>
</td>
<td class="nump">128.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">35.9<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">82.5<span></span>
</td>
<td class="nump">88.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Debt, current portion</a></td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">268.4<span></span>
</td>
<td class="nump">373.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, net of current portion</a></td>
<td class="nump">1,032.1<span></span>
</td>
<td class="nump">809.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">113.8<span></span>
</td>
<td class="nump">94.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">44.9<span></span>
</td>
<td class="nump">61.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,459.2<span></span>
</td>
<td class="nump">1,340.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200.0 shares authorized, 55.5 and 55.1 shares issued; 49.9 and 51.3 shares outstanding, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 5.6 and 3.8 common shares, respectively</a></td>
<td class="num">(227.7)<span></span>
</td>
<td class="num">(152.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">860.1<span></span>
</td>
<td class="nump">829.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss, net</a></td>
<td class="num">(5.2)<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">822.0<span></span>
</td>
<td class="nump">957.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">1,449.3<span></span>
</td>
<td class="nump">1,619.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 2,908.5<span></span>
</td>
<td class="nump">$ 2,959.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101227120592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">55,500,000<span></span>
</td>
<td class="nump">55,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">49,900,000<span></span>
</td>
<td class="nump">51,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101225593504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 240.0<span></span>
</td>
<td class="nump">$ 329.0<span></span>
</td>
<td class="nump">$ 790.2<span></span>
</td>
<td class="nump">$ 1,069.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">39.2<span></span>
</td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">135.4<span></span>
</td>
<td class="nump">151.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">80.2<span></span>
</td>
<td class="nump">82.1<span></span>
</td>
<td class="nump">246.1<span></span>
</td>
<td class="nump">254.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="nump">44.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">282.0<span></span>
</td>
<td class="nump">363.7<span></span>
</td>
<td class="nump">897.8<span></span>
</td>
<td class="nump">994.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(42.0)<span></span>
</td>
<td class="num">(34.7)<span></span>
</td>
<td class="num">(107.6)<span></span>
</td>
<td class="nump">75.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(24.5)<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(13.4)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="num">(18.4)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(42.9)<span></span>
</td>
<td class="num">(28.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(63.9)<span></span>
</td>
<td class="num">(45.5)<span></span>
</td>
<td class="num">(150.5)<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="num">(11.8)<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (75.7)<span></span>
</td>
<td class="num">$ (32.7)<span></span>
</td>
<td class="num">$ (135.8)<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Net income (loss) per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (2.71)<span></span>
</td>
<td class="nump">$ 0.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (2.71)<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in computing net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">49.9<span></span>
</td>
<td class="nump">53.7<span></span>
</td>
<td class="nump">50.2<span></span>
</td>
<td class="nump">53.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">49.9<span></span>
</td>
<td class="nump">53.7<span></span>
</td>
<td class="nump">50.2<span></span>
</td>
<td class="nump">54.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Services</a></td>
<td class="nump">$ 186.2<span></span>
</td>
<td class="nump">$ 270.5<span></span>
</td>
<td class="nump">$ 660.5<span></span>
</td>
<td class="nump">$ 589.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">85.5<span></span>
</td>
<td class="nump">103.2<span></span>
</td>
<td class="nump">256.8<span></span>
</td>
<td class="nump">237.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">Total CDMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total CDMO</a></td>
<td class="nump">36.4<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
<td class="nump">416.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Services</a></td>
<td class="nump">36.2<span></span>
</td>
<td class="nump">112.6<span></span>
</td>
<td class="nump">90.7<span></span>
</td>
<td class="nump">283.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">63.1<span></span>
</td>
<td class="nump">114.3<span></span>
</td>
<td class="nump">217.5<span></span>
</td>
<td class="nump">307.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(71.0)<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">132.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Services</a></td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="nump">$ 34.3<span></span>
</td>
<td class="nump">$ 63.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101227216384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (75.7)<span></span>
</td>
<td class="num">$ (32.7)<span></span>
</td>
<td class="num">$ (135.8)<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on hedging activities</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss), net of tax</a></td>
<td class="num">$ (74.8)<span></span>
</td>
<td class="num">$ (33.4)<span></span>
</td>
<td class="num">$ (124.9)<span></span>
</td>
<td class="nump">$ 43.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101226572768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (135.8)<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">33.4<span></span>
</td>
<td class="nump">32.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">107.7<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeReversal', window );">Adjustment for prior period lease receivables (Note 10)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">86.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration, net</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">23.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">76.2<span></span>
</td>
<td class="num">(114.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(112.2)<span></span>
</td>
<td class="num">(58.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(29.2)<span></span>
</td>
<td class="num">(54.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(9.0)<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(98.0)<span></span>
</td>
<td class="num">(19.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(5.7)<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities:</a></td>
<td class="num">(126.9)<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(92.2)<span></span>
</td>
<td class="num">(178.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Asset acquisitions</a></td>
<td class="num">(243.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities:</a></td>
<td class="num">(335.9)<span></span>
</td>
<td class="num">(178.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facility</a></td>
<td class="nump">238.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(81.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfMediumTermNotes', window );">Principal payments on term loan facility</a></td>
<td class="num">(25.3)<span></span>
</td>
<td class="num">(16.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Principal payments on convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from share-based compensation activity</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid for share-based compensation activity</a></td>
<td class="num">(5.7)<span></span>
</td>
<td class="num">(13.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities:</a></td>
<td class="nump">128.1<span></span>
</td>
<td class="num">(31.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(335.3)<span></span>
</td>
<td class="num">(217.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">576.3<span></span>
</td>
<td class="nump">621.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">241.0<span></span>
</td>
<td class="nump">404.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">23.9<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental information on non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment unpaid at period end</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and cash equivalents and restricted cash at September&#160;30, 2022 and December&#160;31, 2021:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">240.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">$ 241.0<span></span>
</td>
<td class="nump">$ 404.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income Reversal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101221597552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>$0.001 Par Value Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,447.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="nump">$ 784.9<span></span>
</td>
<td class="num">$ (25.3)<span></span>
</td>
<td class="nump">$ 726.9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">41.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">1,522.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="nump">816.8<span></span>
</td>
<td class="num">(23.1)<span></span>
</td>
<td class="nump">768.5<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="nump">1,543.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="nump">804.4<span></span>
</td>
<td class="num">(22.4)<span></span>
</td>
<td class="nump">801.2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(32.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 1,522.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="nump">816.8<span></span>
</td>
<td class="num">(23.1)<span></span>
</td>
<td class="nump">768.5<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">51,300,000<span></span>
</td>
<td class="nump">55,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,619.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (152.2)<span></span>
</td>
<td class="nump">829.4<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
<td class="nump">957.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">30.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(135.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of stock</a></td>
<td class="num">(75.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">49,900,000<span></span>
</td>
<td class="nump">55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 1,449.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">860.1<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
<td class="nump">822.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="nump">1,513.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">849.2<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="nump">897.7<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(75.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of stock</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">49,900,000<span></span>
</td>
<td class="nump">55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 1,449.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">$ 860.1<span></span>
</td>
<td class="num">$ (5.2)<span></span>
</td>
<td class="nump">$ 822.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101231998128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101230217232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business</a></td>
<td class="text">Business<div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (&#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (CDMO) services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following five distinct PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; and acute/emergency care. The Company has a product portfolio of thirteen products (vaccines, therapeutics and drug-device combination products). The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company also has one product candidate that is procured under special circumstances by the U.S. government (USG), although it is not approved by the U.S. Food and Drug Administration (FDA). The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following three business lines: Government - Medical Countermeasures (MCM) Products, Commercial Products, and CDMO Services. The Company operates as two operating segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and 2) a services segment (Services) focused on CDMO (Note 14, "</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment information"</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Government - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">AV7909</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is a procured product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has largely switched from procuring BioThrax to AV7909 for the Strategic National Stockpile (SNS) prior to its approval by the FDA;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">BioThrax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only vaccine licensed by the FDA, for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">ACAM2000</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">BAT</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of botulism; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">CNJ-016</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also referred to as VIGIV, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Raxibacumab injection, a fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Anthrasil</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">RSDL</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Trobigard</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">atropine sulfate, obidoxime chloride AUTO-INJECTOR, is a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA, but it is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">TEMBEXA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. It has been approved by the FDA for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Ebanga&#8482; (ansuvimab-zykl, formerly referred to as mAb114) is a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the United States and Canada, and Ridgeback Biotherapeutics will serve as the global access partner for Ebanga&#8482;.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Commercial Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">NARCAN</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Vaxchora</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the only single-dose oral vaccine licensed by the FDA and the European Medicines Agency (EMA) for the prevention of cholera; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Vivotif</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services - Contract Development and Manufacturing</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's services line focused on CDMO offerings covers development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided to customers spanning the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale.&#160;Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, the Company acquired from Chimerix ("the Seller") the exclusive worldwide rights to brincidofovir, including TEMBEXA&#174; and related assets (the &#8220;Transaction&#8221;). TEMBEXA is a medical countermeasure for smallpox approved by the FDA in June 2021. Under the terms of the Asset Purchase Agreement (the "Purchase Agreement"), the Company paid $238.0&#160;million upon closing of the Transaction, and is subject to potential milestone payments of up to $124.0&#160;million contingent on the potential exercise by the U.S. government of procurement options. The closing payment and the milestone payments were based on the actual procurement value of the procurement contract (the "BARDA Contract") with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;). Each milestone payment is associated with the exercise of future BARDA procurement options of TEMBEXA following the BARDA Contract base period. The Seller is also eligible to receive up to $12.5&#160;million in regulatory milestones associated with the SymBio Pharmaceuticals Ltd. brincidofovir licensing arrangements assumed by the Company in the Transaction. The milestone payments will be recorded when the associated procurement options have been exercised and/or the regulatory milestones have been met and the consideration is paid or becomes payable.</span></div>The Seller may also earn a 20% royalty on future gross profit of TEMBEXA in the United States associated with volumes above 1.7&#160;million treatment courses of therapy during the exclusivity period of TEMBEXA. Outside of the United States, the Purchase Agreement also allows the Seller to earn a 15% royalty on all gross profit associated with TEMBEXA sales during the exclusivity period of TEMBEXA on a market-to-market basis. Refer to Note 6, "Intangible assets" for additional information around the impacts of this asset acquisition on the current period results.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101231981088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and principles of consolidation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of presentation and principles of consolidation</a></td>
<td class="text">Basis of presentation and principles of consolidation<div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September&#160;30, 2022. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.<br/><br/></span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, there is $238.0&#160;million outstanding on the revolver loan and $371.3&#160;million on the term loan that matures in October 2023, which is within one year of the date that the consolidated financial statements are issued for the quarter ended September&#160;30, 2022. The Company determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation considered the potential mitigating effect of management&#8217;s plans that have not been fully implemented. Management may evaluate the mitigating effect of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern. The Company's plan to alleviate the substantial doubt includes amending its existing revolver loan and term loan that are due October 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company is in the process of and expects to replace the current credit facility before it matures, management cannot make the assumption that it is probable that the Company will be able to obtain such debt refinancing on commercially reasonable terms or at all until the new credit facility is in place. The Company is currently working with its lenders and expects to refinance the credit facility with revised terms and conditions. The extent to which the Company will be able to affect such refinancing, replacement or maturity extension on terms that are favorable or at all is dependent on a number of uncertain factors, including then-prevailing credit and other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, disruptions or volatility caused by factors such as COVID-19, regional conflicts, inflation, and supply chain disruptions. In addition, rising interest rates could limit our ability to refinance our existing credit facility when it matures or cause us to pay higher interest rates upon refinancing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the replacement of the Company&#8217;s current debt facility is conditional upon the execution of agreements with new or existing third parties, which are considered outside of the Company&#8217;s control, until such time as they are completed, the refinancing cannot be considered to be probable to occur as of the date of this report. The Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC that have materially impacted the presentation of the Company's financial statements. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company revised the reporting that the chief operating decision maker ("the CODM") reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) Products segment consisting of the Government - MCM and </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial business lines and 2) Services segment focused on CDMO. This change is further outlined in Note 14, "Segment information".</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1) and time deposits (level 2), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7, "Fair value measurements" and Note 8, "Derivative instruments and hedging activities").</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On a non-recurring basis, the Company measures its long-lived assets as part of impairment evaluations using fair value measurements. Goodwill is allocated to the Company's reporting units, which are one level below its operating segments. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and earlier if an event or other circumstance indicates that the carrying value of the asset may not be recoverable. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required. Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, long-lived assets are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when there is an adverse change in the market relating to those related assets. The impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. Determining the need for a detailed impairment analysis requires the exercise of judgment about several business factors, including the timing of expected future cash flows and assumptions about the economic environment. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the Company had no other significant assets or liabilities that were measured at fair value.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting standards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) that the Company adopts as of the pronouncement's specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the consolidated financial statements or disclosures.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Topic 848, which was further amended in January 2021. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. It contains optional expedients and exceptions to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. As of September 30, 2022, the Company adopted this ASU with no material impact to our consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101230215648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories, net</a></td>
<td class="text">Inventories, net<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">277.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">217.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">138.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">95.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">130.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total inventories, net </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">546.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">350.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"> During the three months ended September 30, 2022, the Company acquired certain assets through an asset acquisition, the Transaction, and the related inventories of $84.8 million were included in our inventories balances as of September&#160;30, 2022.</span></div></td></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is stated at the lower of cost or net realizable value</span>. For additional information related to the termination of the manufacturing services agreement (the &#8220;Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) and associated evaluation of inventory as of September&#160;30, 2022, refer to Note 10, "Revenue recognition."<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101231320080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text">Property, plant and equipment, net<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Land and improvements</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">53.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">52.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">321.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">269.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">551.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">513.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">65.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">181.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">223.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,172.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,119.2&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Less: Accumulated depreciation &amp; amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(366.2)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(319.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total property, plant and equipment, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">806.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">800.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December&#160;31, 2021</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, construction-in-progress primarily included costs incurred related to construction to advance the Company's CDMO capabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. During the nine months ended September 30, 2022, the Company recorded accelerated depreciation of $12.7&#160;million reflecting a shortening of the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement with Janssen. For additional information related to the termination of the Agreement, refer to Note 10, "Revenue recognition".</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101227014656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the lessee for operating leases for offices, research and development facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. For a discussion of lessor activities, see Note 10, "Revenue recognition".</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease cost:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total operating lease cost</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are reflected as components of cost of product sales, cost of contract development and manufacturing, research and development expense and selling, general and administrative expense.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.880%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except lease term and discount rate)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_5151ab9f-c47e-463d-8aa2-48943e0afded"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_fa39117a-d454-4120-99bf-3662bcd5aca2">Other assets</span></span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">20.5</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">28.3</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_4cea9722-b807-4cb6-aacd-3b045145d7ac"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_55a8c7c0-1418-4c46-86d6-6bf5a5d3114f">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_1a37c2b9-d83a-4cc7-9218-97115c59e9de"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_e5713eb8-636e-4658-b39f-755a6d1cadca">Other liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">15.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">24.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">21.5</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">30.0</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div>During the three months ended September 30, 2022, the Company exercised the option to purchase our Rockville manufacturing facility. As a result, the Company removed the related operating lease right-of-use asset and operating lease liability of $3.5&#160;million and $3.4&#160;million, respectively. The purchased assets have been properly included in "Property, plant and equipment, net" on our condensed consolidated balance sheet as of September&#160;30, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101233269920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible assets<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the Company's Intangible assets, net:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Asset Type</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Estimated Life</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Products </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8-22 years</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">958.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">235.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">722.7&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">798.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">193.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">604.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">963.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">240.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">722.7&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">803.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">198.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">604.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"> During the three months ended September 30, 2022, we acquired certain assets through asset acquisitions, and the related intangible assets were assigned to the "Products" asset type, of which $154.7 million was related to the Transaction.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company's intangible assets was recorded as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:39.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amortization Expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">14.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">14.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">42.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">44.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the weighted average amortization period remaining for intangible assets was 11.4 years. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the changes in the carrying amount of the Company's goodwill balance:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.171%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Goodwill, December&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">224.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Goodwill, September&#160;30, 2022</span></div></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">224.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of goodwill included accumulated impairments of $41.7 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has $224.9&#160;million of total goodwill which is composed of our Products and Services segments. There is the risk of future impairments in our reporting units as any further deterioration in their performance compared to forecast, changes in order volumes or delivery schedules for major customers, as well as any changes in economic forecasts and expected recovery in the biopharmaceutical industry, may require the Company to complete additional impairment tests in future quarters and could result in the reporting unit&#8217;s fair value falling below carrying value in subsequent quarters. In the event the Company experiences factors that it believes indicate a decline in fair value, including negative changes to long-term growth rates or if discount rates increase, we may be required to record impairments of goodwill and other identified intangible assets. Further, if the composition of the Company&#8217;s reporting unit&#8217;s assets and liabilities were to change and result in an increase in the reporting unit&#8217;s carrying value, it could lead to additional impairment testing and further impairment losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101226427744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">Fair value measurements<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.099%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">152.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">152.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">75.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">352.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">152.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">200.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">37.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">37.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">43.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">37.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#8217;s products are classified in the Company's statement of operations as cost of product sales. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a reconciliation of the beginning and ending balance of the Company's contingent consideration liability: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Liability for Contingent Consideration</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">37.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(31.8)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the current portion of the contingent consideration liability was </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $32.7&#160;million, respectively, and was included in other current liabilities on the condensed consolidated balance sheets. The non-current portion of the contingent consideration liability is included in other liabilities on the condensed consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:16.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Contingent Consideration Liability</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value as of September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Range</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Weighted Average</span></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenue milestone and royalty based</span></td><td colspan="3" rowspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Discounted cash flow</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.1%</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.1%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Probability of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25% - 50%</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">40.0%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Projected year of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2022 - 2028</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2024</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 8, "Derivative instruments and hedging activities"</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information about the Company's derivative instruments.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-variable rate debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022 and December&#160;31, 2021, t</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he fair value of the Company's 3.875% Senior Unsecured Notes was $299.9&#160;million and $433.3&#160;million, respectively. The fair value was determined through market sources, which are level 2 inputs and directly observable. The carrying amounts of the Company&#8217;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 9, "Debt").</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101231302352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative instruments and hedging activities</a></td>
<td class="text">Derivative instruments and hedging activities<div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk management objective of using derivatives</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from payments of variable interest rate debt associated with the Company's senior secured credit agreements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If current fair values of designated interest rate swaps&#160;remained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;$9.0 million of net deferred gains from&#160;accumulated other comprehensive loss&#160;into the condensed consolidated statement of operations over the next&#160;twelve-month period. All outstanding cash flow hedges mature in October 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions, except number of instruments)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Number of Instruments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Notional</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$350.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Asset Derivatives</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Assets</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Assets</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Liabilities </span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Liabilities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Liabilities</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive loss.</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.505%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.311%"/><td style="width:0.1%"/></tr><tr style="height:38pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivatives</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Location of Loss Reclassified from</span></td><td colspan="6" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amount of Loss Reclassified from Accumulated OCL into Income (Loss)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30,</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31,</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated OCL into Income (Loss)</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101317180272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of debt were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Senior secured credit agreement - Term loan due 2023</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">371.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">396.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Senior secured credit agreement - Revolver loan due 2023</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">238.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.875% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">450.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">450.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,062.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">849.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Current portion of long-term debt, net of debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(21.2)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(31.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(9.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Non-current portion of debt</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,032.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">809.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021 there was $238.0&#160;million and no</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding revolver balance, respectively. The Company classifies debt issuance costs associated with the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revolver</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loan as other current assets and other assets on the Company's consolidated balance sheets. As of September&#160;30, 2022, the Company </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had $4.1&#160;million and $4.9&#160;million of debt issuance costs associated with the revolver loan classified as other current assets and other assets, respectively. As of December&#160;31, 2021, the Company had approximately $2.0 million and $1.6 million of debt issuance costs associated with the revolver loan that were classified as other current assets and other assets, respectively.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.875% Senior Unsecured Notes due 2028</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company completed its offering of $450.0&#160;million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the 2028 Notes) of which the majority of the net proceeds were used to pay down the Revolving Credit Facility (as defined below). Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related Indenture, plus accrued and unpaid interest. Prior to August 15, 2023 the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to 100% of the principal amount of the 2028 Notes plus a &#8220;make-whole&#8221; premium and accrued and unpaid interest. Prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the 2028 Notes using the net cash proceeds of certain equity offerings at the redemption price set forth in the related Indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of 101% of the principal amount of such 2028 Notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative covenants in the Indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on August 7, 2020, the Company entered into a Second Amendment (the &#8220;Credit Agreement Amendment&#8221;) to its senior secured credit agreement, dated October 15, 2018, with multiple lending institutions relating to the Company&#8217;s senior secured credit facilities (the &#8220;Credit Agreement,&#8221; and as amended, the &#8220;Amended Credit Agreement&#8221;), consisting of a senior revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and senior term loan facility (the &#8220;Term Loan Facility,&#8221; and together with the Revolving Credit Facility, the &#8220;Senior Secured Credit Facilities&#8221;).  The Credit Agreement Amendment amended, among other things, the definition of incremental facilities limit, the consolidated net leverage ratio financial covenant by increasing the maximum level, increased the permissible applicable margins based on the Company&#8217;s consolidated net leverage ratio and increased the commitment fee that the Company is required to pay in respect of the average daily unused commitments under the Revolving Credit Facility, depending on the Company&#8217;s consolidated net leverage ratio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement includes (i) a Revolving Credit Facility of $600.0&#160;million and (ii) a Term Loan Facility with a principal amount of $450.0&#160;million. The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as certain requirements involving the Company's net leverage ratio will be maintained on a pro forma basis. Borrowings under the Revolving Credit Facility and the Term Loan Facility bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from 1.25% to 2.25% per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus 0.50%, and a eurocurrency rate for an interest period of one month plus 1% plus a margin ranging from 0.25% to 1.25%, depending on the Company's consolidated net leverage ratio). The Company is required to make quarterly payments on the last business day of each calendar quarter under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from 0.15% to 0.35% per annum, depending on the Company's consolidated net leverage ratio, for the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments on the last business day of each calendar quarter based on an annual percentage equal to 2.5% of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, 5% of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and 7.5% of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature on October 13, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of $100.0&#160;million during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights. The financial covenants under the Amended Credit Agreement currently require the quarterly presentation of a minimum consolidated 12-month rolling debt service coverage ratio of 2.50 to 1.00, and a maximum consolidated net leverage ratio of 4.50 to 1.00 (subject to an increase to 5.00 to 1.00 for an applicable four quarter period, at the election of the Company, in connection with a permitted acquisition having an aggregate consideration in excess of $75.0&#160;million). Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101231296784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as two operating segments (Note 14, "Segment information</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Company's revenues disaggregated by the major sources were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">33.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">152.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">186.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">129.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">140.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">270.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">112.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">112.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(86.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">15.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(71.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total CDMO</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(86.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">127.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">17.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">49.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">190.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">240.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">60.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">268.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">329.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">255.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">405.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">660.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">252.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">337.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">589.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">90.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">90.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">283.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">283.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">81.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">132.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total CDMO</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">95.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">95.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">81.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">334.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">416.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">31.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">34.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">63.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">286.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">503.5&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">790.2&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">395.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">674.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,069.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/><br/></span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2020, the Company, through its wholly-owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into a manufacturing services agreement with Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, for large-scale drug substance manufacturing of Johnson &amp; Johnson&#8217;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#8220;Product&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, the Company provided to Janssen a notice (the &#8220;Notice&#8221;) of material breach of the Agreement for, among other things, failure by Janssen (i) to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Agreement and (ii) to confirm Janssen&#8217;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Agreement and instead, wind-down the Agreement ahead of </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#8220;Janssen Notice&#8221;) of the Agreement for asserted material breaches of the Agreement by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices ("cGMP") or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the Company&#8217;s breaches were not curable and that, therefore, termination of the Agreement would be effective as of July 6, 2022. The Company disputes Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result of the Company's alleged failure to perform under the Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process including through mediation and/or arbitration.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022, there were no impacts on previously recognized revenue or depreciation related to the conclusion of the Agreement. As of September&#160;30, 2022, the Company has no billed or unbilled net accounts receivable related to the Agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has $131.0&#160;million of raw materials inventory recorded in its condensed consolidated balance sheet as of September&#160;30, 2022, representing materials purchased for the Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of this inventory as of September&#160;30, 2022, concluding that because the Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for any reason, the Company is entitled to payment from Janssen for these raw materials. Therefore, this inventory remains an asset on the condensed consolidated balance sheet as of September&#160;30, 2022. Additionally, the Company has an immaterial amount of non-cancelable orders as of September&#160;30, 2022 which have not been received and Janssen has not reimbursed. The Company also recorded approximately $13.6&#160;million to other assets, which relates to termination penalties and certain inventory related items. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BARDA COVID-19 Development Public-Private Partnership</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company announced the issuance of a task order under its existing Center for Innovation in Advanced Development and Manufacturing ("CIADM") agreement with BARDA for COVID-19 vaccine development and manufacturing (the "BARDA COVID-19 Development Public Private Partnership"). The BARDA COVID-19 Development Public Private Partnership is considered a lease and is accounted for under ASC 842. The initial task order had a contract value of up to $628.2&#160;million and included the reservation of manufacturing capacity and accelerated expansion of fill/finish capacity valued at $542.7&#160;million and $85.5&#160;million, respectively. Subsequently, the task order was expanded to include incremental capital activities which increased the value to </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$650.8&#160;million. On November 1, 2021, the Compa</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ny and BARDA mutually agreed to the completion of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's CIADM contract and associated task orders, including the BARDA COVID-19 Development Public Private Partnership. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not recognize lease revenues under this arrangement during the three and nine months ended September 30, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company reversed lease revenues of $86.0 million and recognized lease revenues of $81.9 million, respectively, related to this arrangement.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO operating leases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain multi-year CDMO service arrangements with commercial customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates 2.5 years. The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Excluding future amounts related to the Janssen Agreement as discussed above, the Company estimates future operating lease revenues to be $0.2&#160;million in the remainder of 2022, $5.1&#160;million in 2023, $0.9&#160;million in 2024, $0.9&#160;million in 2025 and $2.7&#160;million in years beyon</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d 2025.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price allocated to remaining performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company has future contract value on unsatisfied performance obligations of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$453.9 million associated with all arrangements entered into by the Company. The Company expects to recognize a majority of the $453.9 million of unsatisfied performance obligations within the next 24 months. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associat</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#8217;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$33.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $21.5 million, respectively, of contract assets</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded within accounts receivable, net on the condensed consolidated balance sheets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the condensed consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the roll forward of the contract liability balances:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">30.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(16.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">30.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the current portion of contract liabilities was $24.8&#160;million and $11.7&#160;million, respectively, and was included in other current liabilities on the balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Billed, net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">119.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">224.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">72.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">49.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">191.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">274.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the allowances for doubtful accounts was $0.7 million and $3.2 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101336457168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated effective annual tax rate as of September&#160;30, 2022 and 2021 for the years ended December 31, 2022 and 2021, excluding the impact of discrete adjustments, was 3% and 24%, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease in the estimated effective annual tax rate is primarily due to decreased profitability, the impact of certain permanent adjustments, and a valuation allowance charge. The Company recorded discrete tax benefits of $10.9&#160;million and $10.3&#160;million for the three and nine months ended September&#160;30, 2022, respectively, and $1.7 million and $7.2&#160;million, for the three and nine months ended September&#160;30, 2021, respectively. The discrete tax benefit in 2022 was primarily due to return to provision adjustments and the benefit of the release of an indemnified uncertain tax position offset by share-based compensation activity. The net discrete benefits in 2021 were primarily due to share-based compensation activity.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> deductible. At each reporting period, the Company considers the scheduled reversal of deferred tax liabilities and assets, available taxes in carryback periods, tax planning strategies and projected future taxable income in making this assessment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company determined that it was more likely than not that deferred tax assets in the U.S. would not be realized due to reductions in estimates </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> future profitability in the U.S. Accordingly, the Company recorded a provision of $19.2 million associated with the establishment of a valuation allowance on those deferred tax assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101317180272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (loss) per share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (loss) per share</a></td>
<td class="text">Net income (loss) per share<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net income (loss) per share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(75.7)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(32.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(135.8)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted-average number of shares&#8212;basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">49.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">53.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">53.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Dilutive securities&#8212;equity awards</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted-average number of shares&#8212;diluted</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">49.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">53.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">54.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss) per share - basic</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.52)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.71)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss) per share - diluted</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.52)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.71)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. No adjustment for the potential dilutive effect of dilutive securities is reported for the three and nine months ended September&#160;30, 2022 as the effect would have been anti-dilutive due to the Company's net loss.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price. The following table presents the share-based awards that are not considered in the diluted income (loss) per share calculation generally because the exercise price of the awards was greater than the average per share closing price during the three and nine months ended September&#160;30, 2022 and 2021:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:39.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.292%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Anti-dilutive stock awards</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101230512336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchase programs</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2021, the Company announced that its Board of Directors authorized management to repurchase up to an aggregate of $250.0&#160;million of Common Stock under a board-approved Share Repurchase Program, of which $187.9&#160;million has been utilized to purchase 4.4&#160;million shares as of September&#160;30, 2022. During the three months ended September&#160;30, 2022, there were no shares repurchased. During the nine months ended September&#160;30, 2022, the Company has utilized $75.5&#160;million to purchase 1.8&#160;million shares. The Share Repurchase Program does not obligate the Company to acquire any specific number of shares. Repurchased shares will be available for use in connection with the Company's stock plans and for other corporate purposes.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, the Company granted stock options to purchase 0.7&#160;million shares of common stock and 1.5&#160;million restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Typically, the stock option and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria. Share-based compensation expense was recorded in the following financial statement line items:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">22.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">22.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">33.4&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">32.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss, net of tax</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive loss, net of tax by component:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.049%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.254%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Defined Benefit Pension Plan</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, December&#160;31, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.6)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(16.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">11.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5.2)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.7)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5.2)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, December&#160;31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(25.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(23.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, June&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(22.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(23.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present the tax effects related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="33" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.2)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="33" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">15.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">11.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">17.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101230512336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment InformationThe Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. During the first quarter of 2022, the Company revised the reporting that the CODM reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) Products segment consisting of the Government - MCM and Commercial business lines and 2) Services segment focused on CDMO. The Company evaluates the performance of these reportable segments based on revenue and adjusted gross margin. Segment revenue includes external customer sales, but it does not include inter-segment services. Adjusted gross margin for each segment is segment revenue less segment cost of sales reduced for significant one-time events. We do not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. The Company has recast the related historical information for consistency.<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables include segment revenues and a reconciliation of the Company's segment adjusted gross margin to the condensed consolidated statement of operations for each of the Company's reporting segments:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">186.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">17.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">240.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">270.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">329.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(17.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(17.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(16.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(16.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(85.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(85.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(103.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(103.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(63.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(63.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(114.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(114.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">100.7&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(26.7)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">74.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">167.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(72.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">94.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">101.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(26.7)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">74.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">168.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(72.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">95.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Services revenue and Services adjusted gross margin for the three months ended September 30, 2021 includes the impact of the reversal of $86.0 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">660.5&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">95.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">34.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">790.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">589.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">416.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">63.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,069.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(34.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(34.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(63.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(63.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(256.8)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(256.8)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(237.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(237.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(217.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(217.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(307.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(307.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">403.7&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(122.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">281.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">352.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">108.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">461.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">406.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(122.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">284.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">355.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">108.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">463.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"> Services revenue and Services adjusted gross margin for the nine months ended September 30, 2021 includes the impact of $81.9 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each segment:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Depreciation:</span></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">11.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">20.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">34.2&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">21.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">20.4&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">65.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">46.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its assets on a total company basis, not by operating segment, as the Company's operating assets are shared or commingled. Therefore, the Company's CODM does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101227207648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities and shareholder litigation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock, seeking to pursue remedies under the Securities Exchange Act of 1934. These complaints were filed by Palm Tran, Inc. &#8211; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth; and Stephen M. Weiss, respectively. The complaints allege, among other things, that the defendants made false and misleading statements about the Company's manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as "CDMO Manufacturing Capabilities"). These cases were consolidated on December 23, 2021, under the caption </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Emergent BioSolutions Inc. Securities Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 8:21-cv-00955-PWG (the "Federal Securities Class Action"). The Lead Plaintiffs in the consolidated matter are Nova Scotia Health Employees&#8217; Pension Plan and The City of Fort Lauderdale Police &amp; Firefighters&#8217; Retirement System. The defendants filed a motion to dismiss on May 19, 2022 and the Lead Plaintiff filed an opposition to that motion on July 19, 2022. The defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the consolidated action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, Lincolnshire Police Pension Fund (&#8220;Lincolnshire&#8221;), and on August 16, 2021, Pooja Sayal, filed putative shareholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, the cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-PWG. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022 the Court approved the parties joint stipulation to and stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action. The defendants believe that the allegations in the complaints are without merit and intend to defend the matter vigorously.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, September 16, 2021 and November 12, 2021, putative shareholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp; Police Officers Pension Fund, respectively, in The Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Emergent BioSolutions, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#8217; filed a motion to dismiss the complaint. Ruling on this motion is stayed pursuant to a March 29, 2022 order staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, December 22, 2021 and January 18, 2022, putative shareholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the federal securities laws, each allegation related to the CDMO Manufacturing Capabilities.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings and Discovery, pursuant to </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which the parties agreed to stay all proceedings until 30 calendar days after a ruling on the defendants&#8217; motion to dismiss the Federal Securities Class Action. The Court approved the Joint Stipulation on March 14, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above actions, the Company has received preliminary inquiries and subpoenas to produce documents related to these matters from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis, Senator Murray of the Committee on Health, Education, Labor and Pensions, the Department of Justice, the SEC, the Maryland Attorney General&#8217;s Office, and the New York Attorney General&#8217;s Office. The Company is producing and has produced documents as required in response and will continue to cooperate with these government inquiries.</span></div><div style="text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ANDA litigation - Teva 2mg</span></div>In 2018, Teva Pharmaceuticals Industries Limited and Teva Pharmaceuticals USA (collectively, "Teva") provided a notice to Emergent Devices Inc., a subsidiary of Emergent formerly known as Adapt Pharma Inc. ("EBPA"); Emergent Operations Ireland Limited, a subsidiary of Emergent formerly known as Adapt Pharma Operations Limited ("EIRE"); and Opiant Pharmaceuticals Inc. ("Opiant"). The notice stated that Teva had filed an abbreviated new drug application ("ANDA") with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone HCI) Nasal Spray 2 mg/spray before the expiration of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#174;. Teva&#8217;s notice letter alleged that claims of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#174; were invalid and/or would not be infringed by the activities described in Teva&#8217;s ANDA. Emergent and Opiant filed complaints against Teva in the U.S. District Court for the District of New Jersey alleging infringement of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN. This case was dismissed July 27, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101224555888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and principles of consolidation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September&#160;30, 2022. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1) and time deposits (level 2), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7, "Fair value measurements" and Note 8, "Derivative instruments and hedging activities"). On a non-recurring basis, the Company measures its long-lived assets as part of impairment evaluations using fair value measurements. Goodwill is allocated to the Company's reporting units, which are one level below its operating segments. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and earlier if an event or other circumstance indicates that the carrying value of the asset may not be recoverable. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required. Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, long-lived assets are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when there is an adverse change in the market relating to those related assets. The impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. Determining the need for a detailed impairment analysis requires the exercise of judgment about several business factors, including the timing of expected future cash flows and assumptions about the economic environment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting standards</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Topic 848, which was further amended in January 2021. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. It contains optional expedients and exceptions to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. As of September 30, 2022, the Company adopted this ASU with no material impact to our consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">The Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. During the first quarter of 2022, the Company revised the reporting that the CODM reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) Products segment consisting of the Government - MCM and Commercial business lines and 2) Services segment focused on CDMO. The Company evaluates the performance of these reportable segments based on revenue and adjusted gross margin. Segment revenue includes external customer sales, but it does not include inter-segment services. Adjusted gross margin for each segment is segment revenue less segment cost of sales reduced for significant one-time events. We do not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. The Company has recast the related historical information for consistency.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101230440208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Raw materials and supplies</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">277.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">217.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">138.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">95.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">130.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total inventories, net </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">546.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">350.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"> During the three months ended September 30, 2022, the Company acquired certain assets through an asset acquisition, the Transaction, and the related inventories of $84.8 million were included in our inventories balances as of September&#160;30, 2022.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101231303712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Land and improvements</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">53.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">52.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">321.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">269.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">551.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">513.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">65.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">181.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">223.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,172.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,119.2&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Less: Accumulated depreciation &amp; amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(366.2)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(319.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total property, plant and equipment, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">806.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">800.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101230375200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease cost:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total operating lease cost</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Leases Supplemental Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.880%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(In millions, except lease term and discount rate)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_5151ab9f-c47e-463d-8aa2-48943e0afded"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_fa39117a-d454-4120-99bf-3662bcd5aca2">Other assets</span></span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">20.5</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">28.3</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease liabilities, current portion</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_4cea9722-b807-4cb6-aacd-3b045145d7ac"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_55a8c7c0-1418-4c46-86d6-6bf5a5d3114f">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_1a37c2b9-d83a-4cc7-9218-97115c59e9de"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_e5713eb8-636e-4658-b39f-755a6d1cadca">Other liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">15.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">24.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">21.5</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">30.0</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Operating leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101227011072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table summarizes the Company's Intangible assets, net:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Asset Type</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Estimated Life</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Products </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8-22 years</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">958.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">235.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">722.7&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">798.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">193.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">604.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">963.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">240.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">722.7&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">803.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">198.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">604.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"> During the three months ended September 30, 2022, we acquired certain assets through asset acquisitions, and the related intangible assets were assigned to the "Products" asset type, of which $154.7 million was related to the Transaction.</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Finite-lived Intangible Assets Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company's intangible assets was recorded as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:39.101%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Amortization Expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">14.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">14.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">42.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">44.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the changes in the carrying amount of the Company's goodwill balance:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.171%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Goodwill, December&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">224.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Goodwill, September&#160;30, 2022</span></div></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">224.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101231275728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.099%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Money market accounts</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">152.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">152.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">75.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">352.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">152.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">200.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">37.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">37.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">43.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">37.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a reconciliation of the beginning and ending balance of the Company's contingent consideration liability: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Liability for Contingent Consideration</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">37.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(31.8)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Balance at September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:16.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Contingent Consideration Liability</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value as of September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Range</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Weighted Average</span></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenue milestone and royalty based</span></td><td colspan="3" rowspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Discounted cash flow</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.1%</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.1%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Probability of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25% - 50%</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">40.0%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Projected year of payment</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2022 - 2028</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2024</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101231996416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in millions, except number of instruments)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Number of Instruments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Notional</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$350.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Asset Derivatives</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Assets</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Assets</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Liabilities </span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Current Liabilities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Liabilities</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other Liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Derivative Instruments, Gain (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive loss.</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.505%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.311%"/><td style="width:0.1%"/></tr><tr style="height:38pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivatives</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Location of Loss Reclassified from</span></td><td colspan="6" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amount of Loss Reclassified from Accumulated OCL into Income (Loss)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30,</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31,</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated OCL into Income (Loss)</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest Rate Swaps</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">9.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Interest expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101224589248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of debt were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Senior secured credit agreement - Term loan due 2023</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">371.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">396.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Senior secured credit agreement - Revolver loan due 2023</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">238.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.875% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">450.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">450.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,062.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">849.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Current portion of long-term debt, net of debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(21.2)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(31.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(9.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Non-current portion of debt</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,032.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">809.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101232000576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The Company's revenues disaggregated by the major sources were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">33.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">152.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">186.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">129.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">140.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">270.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">112.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">112.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(86.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">15.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(71.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total CDMO</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(86.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">127.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">17.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">49.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">190.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">240.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">60.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">268.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">329.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Total</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">255.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">405.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">660.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">252.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">337.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">589.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">CDMO:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">90.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">90.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">283.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">283.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">81.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">132.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total CDMO</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">95.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">95.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">81.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">334.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">416.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">31.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">34.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">63.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total revenues</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">286.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">503.5&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">790.2&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">395.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">674.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,069.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Rollforward of Contract Liabilities</a></td>
<td class="text">The following table presents the roll forward of the contract liability balances:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">30.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(16.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">30.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ScheduleOfAccountsReceivableNetTableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Billed, net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">119.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">224.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Unbilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">72.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">49.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">191.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">274.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ScheduleOfAccountsReceivableNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Accounts Receivable, Net [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ScheduleOfAccountsReceivableNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101230278320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (loss) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Income per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net income (loss) per share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(75.7)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(32.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(135.8)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted-average number of shares&#8212;basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">49.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">53.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">53.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Dilutive securities&#8212;equity awards</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Weighted-average number of shares&#8212;diluted</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">49.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">53.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">50.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">54.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss) per share - basic</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.52)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.71)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Net income (loss) per share - diluted</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.52)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.71)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The following table presents the share-based awards that are not considered in the diluted income (loss) per share calculation generally because the exercise price of the awards was greater than the average per share closing price during the three and nine months ended September&#160;30, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:39.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.292%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Anti-dilutive stock awards</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101227016128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text">Share-based compensation expense was recorded in the following financial statement line items:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">22.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">22.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">33.4&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">32.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive loss, net of tax by component:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.049%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.254%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Defined Benefit Pension Plan</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, December&#160;31, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.6)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(16.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">11.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5.2)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.7)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">6.8&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(5.2)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, December&#160;31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(25.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(23.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, June&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(22.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Balance, September&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(7.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(8.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(23.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present the tax effects related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="33" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.1&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.2)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="33" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pretax</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Tax Expense</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Derivative instruments</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">15.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(4.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">11.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(2.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">17.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(6.6)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">10.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e526-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101230403568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables include segment revenues and a reconciliation of the Company's segment adjusted gross margin to the condensed consolidated statement of operations for each of the Company's reporting segments:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.026%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.664%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.256%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">186.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">17.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">240.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">270.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">41.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">16.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">329.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(17.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(17.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(16.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(16.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(85.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(85.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(103.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(103.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(63.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(63.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(114.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(114.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">100.7&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(26.7)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">74.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">167.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(72.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">94.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">101.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(26.7)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">74.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">168.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(72.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">95.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Services revenue and Services adjusted gross margin for the three months ended September 30, 2021 includes the impact of the reversal of $86.0 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">660.5&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">95.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">34.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">790.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">589.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">416.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">63.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1,069.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(34.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(34.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(63.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(63.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(256.8)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(256.8)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(237.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(237.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Cost of CDMO</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(217.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(217.5)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(307.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(307.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">403.7&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(122.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">281.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">352.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">108.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">461.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">406.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">(122.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">284.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">355.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">108.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">463.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"> Services revenue and Services adjusted gross margin for the nine months ended September 30, 2021 includes the impact of $81.9 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation expense for each segment:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Depreciation:</span></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">11.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">25.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">20.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">8.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">34.2&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">21.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">1.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">5.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">4.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">20.4&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">65.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%">46.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101227091408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Details)<br> treatmentCourse in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>treatmentCourse</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>category </div>
<div>segment </div>
<div>businessLine </div>
<div>product </div>
<div>productCandidate</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfCategoriesOfPublicHealthThreats', window );">Number of categories of public health threats | category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfRevenueGeneratingProducts', window );">Number of revenue generating products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfProductCandidates', window );">Number of product candidates | productCandidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_NumberOfBusinessLines', window );">Number of business lines | businessLine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember', window );">Chimerix Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="nump">$ 238.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage', window );">Asset acquisition, domestic royalty percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AssetAcquisitionTreatmentVolumeThreshold', window );">Asset acquisition, treatment volume threshold | treatmentCourse</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage', window );">Asset acquisition, international royalty percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember', window );">Chimerix Asset Acquisition | Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Asset acquisition, consideration transferred, contingent consideration</a></td>
<td class="nump">$ 124.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember', window );">Chimerix Asset Acquisition | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Asset acquisition, consideration transferred, contingent consideration</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Domestic Gross Profit Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, International Gross Profit Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetAcquisitionTreatmentVolumeThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Treatment Volume Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetAcquisitionTreatmentVolumeThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfBusinessLines">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Business Lines</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfBusinessLines</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfCategoriesOfPublicHealthThreats">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of categories of public health threats.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfCategoriesOfPublicHealthThreats</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfRevenueGeneratingProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of revenue generating products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfRevenueGeneratingProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ebs_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ebs_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ebs_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ebs_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101221578128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and principles of consolidation (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,062,300,000<span></span>
</td>
<td class="nump">$ 849,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 371,300,000<span></span>
</td>
<td class="nump">396,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Senior secured credit agreement - Revolver loan due 2023 | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 238,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101221427392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, net - Schedule of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 277.4<span></span>
</td>
<td class="nump">$ 217.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">138.3<span></span>
</td>
<td class="nump">95.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">130.6<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories, net</a></td>
<td class="nump">546.3<span></span>
</td>
<td class="nump">$ 350.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember', window );">Chimerix Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Asset acquisition, inventory acquired</a></td>
<td class="nump">$ 84.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101226625216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,172.9<span></span>
</td>
<td class="nump">$ 1,119.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation &amp; amortization</a></td>
<td class="num">(366.2)<span></span>
</td>
<td class="num">(319.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">806.7<span></span>
</td>
<td class="nump">800.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">53.5<span></span>
</td>
<td class="nump">52.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings, building improvements and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">321.9<span></span>
</td>
<td class="nump">269.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">551.2<span></span>
</td>
<td class="nump">513.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">65.3<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 181.0<span></span>
</td>
<td class="nump">$ 223.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101227089168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Narrative (Details) - Services - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">$ 63.1<span></span>
</td>
<td class="nump">$ 114.3<span></span>
</td>
<td class="nump">$ 217.5<span></span>
</td>
<td class="nump">$ 307.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember', window );">Jansen Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101221534816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101221549952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 20.5<span></span>
</td>
<td class="nump">$ 28.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="nump">$ 24.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 21.5<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101221566784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - Rockville Manufacturing Facility<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseRightOfUseAssetRemoval', window );">Operating lease right-of-use asset removal</a></td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability removal</a></td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseRightOfUseAssetRemoval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Removal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseRightOfUseAssetRemoval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ebs_RockvilleManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ebs_RockvilleManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101225433184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Schedule of Finite-lived Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 963.6<span></span>
</td>
<td class="nump">$ 963.6<span></span>
</td>
<td class="nump">$ 803.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">240.9<span></span>
</td>
<td class="nump">240.9<span></span>
</td>
<td class="nump">198.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">722.7<span></span>
</td>
<td class="nump">722.7<span></span>
</td>
<td class="nump">604.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember', window );">Chimerix Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">154.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">958.1<span></span>
</td>
<td class="nump">958.1<span></span>
</td>
<td class="nump">798.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">235.4<span></span>
</td>
<td class="nump">235.4<span></span>
</td>
<td class="nump">193.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">722.7<span></span>
</td>
<td class="nump">$ 722.7<span></span>
</td>
<td class="nump">604.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember', window );">Products | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember', window );">Products | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">CDMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractDevelopmentAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractDevelopmentAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101228290864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization Expense</a></td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="nump">$ 44.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101228284464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">11 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, impaired, accumulated impairment loss</a></td>
<td class="nump">$ 41.7<span></span>
</td>
<td class="nump">$ 41.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 224.9<span></span>
</td>
<td class="nump">$ 224.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101231990384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Goodwill Roll Forward (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, December&#160;31, 2021</a></td>
<td class="nump">$ 224.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, September&#160;30, 2022</a></td>
<td class="nump">$ 224.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101225349184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">75.7<span></span>
</td>
<td class="nump">352.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">152.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">50.4<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">152.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">152.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">50.4<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">50.4<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101228233568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Contingent Consideration Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101228237216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Business combination, contingent consideration, liability, current</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="nump">$ 299.9<span></span>
</td>
<td class="nump">$ 433.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101226842928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent purchase consideration</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="nump">$ 37.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent purchase consideration</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">$ 37.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent purchase consideration</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Discount rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Discount rate | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Probability of payment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Probability of payment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Probability of payment | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ebs_MeasurementInputProbabilityofPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ebs_MeasurementInputProbabilityofPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101226884688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Net deferred losses from accumulated other comprehensive loss</a></td>
<td class="nump">$ 9.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101230403568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details) - Designated as Hedging Instrument - Interest rate swaps<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>instrument</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Instruments | instrument</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional | $</a></td>
<td class="nump">$ 350.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101226694736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details) - Interest rate swaps - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset Derivatives</a></td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset Derivatives</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability Derivatives</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability Derivatives</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101227090928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details) - Interest rate swaps - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Loss Reclassified from Accumulated OCL into Income (Loss)</a></td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Loss Reclassified from Accumulated OCL into Income (Loss)</a></td>
<td class="num">$ (1.9)<span></span>
</td>
<td class="num">$ (4.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101225751648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 1,062.3<span></span>
</td>
<td class="nump">$ 849.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of debt issuance costs</a></td>
<td class="num">(21.2)<span></span>
</td>
<td class="num">(31.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(9.0)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of debt</a></td>
<td class="nump">1,032.1<span></span>
</td>
<td class="nump">809.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 371.3<span></span>
</td>
<td class="nump">$ 396.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101224388256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,062,300,000<span></span>
</td>
<td class="nump">$ 849,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance costs, current, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod', window );">Debt instrument, covenant, net leverage ratio rolling period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod', window );">Debt instrument, covenant, net leverage ratio adjustment period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance costs, current, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Prior to August 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Maximum | Prior to August 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Maximum | Upon the occurrence of a change in control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio', window );">Debt covenant, consolidated debt service coverage ratio, minimum</a></td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioOne', window );">Debt instrument, covenant, net leverage ratio, maximum</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioTwo', window );">Debt instrument, covenant, net leverage ratio, adjustment</a></td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Federal Funds Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Base Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember', window );">Term Loan Facility | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears', window );">Percentage of original principal amount required to repay in the first two years</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear', window );">Percentage of original principal amount required to repay during the third year</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears', window );">Percentage of original principal amount required to repay remaining year</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight', window );">Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantConsiderationThreshold', window );">Debt instrument, covenant, consideration threshold</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantConsiderationThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Consideration Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantConsiderationThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Service Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantDebtServiceCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in the third year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in the first two years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in remaining years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101224416688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">453,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Contract with customer, asset, noncurrent</a></td>
<td class="nump">33,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of contract liabilities</a></td>
<td class="nump">24,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Lease revenue</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="num">$ (71,000,000.0)<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="nump">$ 132,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember', window );">Jansen Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Inventory, raw materials, net of reserves</a></td>
<td class="nump">131,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_BARDAMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, operating lease, payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,800,000<span></span>
</td>
<td class="nump">$ 628,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. Government | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Lease revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(86,000,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">81,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-U.S. Government | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Lease revenue</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="nump">$ 50,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ebs_ReservationOfManufacturingCapacityMember', window );">Reservation Of Manufacturing Capacity | BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, operating lease, payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ebs_AcceleratedExpansionOfFillFinishCapacityMember', window );">Accelerated Expansion Of Fill/Finish Capacity | BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, operating lease, payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_BARDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_BARDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ebs_ReservationOfManufacturingCapacityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ebs_ReservationOfManufacturingCapacityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ebs_AcceleratedExpansionOfFillFinishCapacityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ebs_AcceleratedExpansionOfFillFinishCapacityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101225672688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 240,000,000.0<span></span>
</td>
<td class="nump">$ 329,000,000.0<span></span>
</td>
<td class="nump">$ 790,200,000<span></span>
</td>
<td class="nump">$ 1,069,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">49,800,000<span></span>
</td>
<td class="nump">60,200,000<span></span>
</td>
<td class="nump">286,700,000<span></span>
</td>
<td class="nump">395,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">190,200,000<span></span>
</td>
<td class="nump">268,800,000<span></span>
</td>
<td class="nump">503,500,000<span></span>
</td>
<td class="nump">674,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">186,200,000<span></span>
</td>
<td class="nump">270,500,000<span></span>
</td>
<td class="nump">660,500,000<span></span>
</td>
<td class="nump">589,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">33,400,000<span></span>
</td>
<td class="nump">129,900,000<span></span>
</td>
<td class="nump">255,000,000.0<span></span>
</td>
<td class="nump">252,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">152,800,000<span></span>
</td>
<td class="nump">140,600,000<span></span>
</td>
<td class="nump">405,500,000<span></span>
</td>
<td class="nump">337,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">Total CDMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total CDMO</a></td>
<td class="nump">36,400,000<span></span>
</td>
<td class="nump">41,600,000<span></span>
</td>
<td class="nump">95,400,000<span></span>
</td>
<td class="nump">416,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">Total CDMO | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total CDMO</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(86,000,000.0)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">Total CDMO | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total CDMO</a></td>
<td class="nump">36,400,000<span></span>
</td>
<td class="nump">127,600,000<span></span>
</td>
<td class="nump">95,400,000<span></span>
</td>
<td class="nump">334,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">36,200,000<span></span>
</td>
<td class="nump">112,600,000<span></span>
</td>
<td class="nump">90,700,000<span></span>
</td>
<td class="nump">283,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">36,200,000<span></span>
</td>
<td class="nump">112,600,000<span></span>
</td>
<td class="nump">90,700,000<span></span>
</td>
<td class="nump">283,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="num">(71,000,000.0)<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="nump">132,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(86,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">81,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="nump">50,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">17,400,000<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="nump">34,300,000<span></span>
</td>
<td class="nump">63,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">16,400,000<span></span>
</td>
<td class="nump">16,300,000<span></span>
</td>
<td class="nump">31,700,000<span></span>
</td>
<td class="nump">60,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101226952640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 453.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 5.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101227021264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Remaining Performance Obligation (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101226399008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ChangeinContractWithCustomerLiabilityRollForward', window );"><strong>Change in Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning of period</a></td>
<td class="nump">$ 16.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ContractWithCustomerLiabilityAdditions', window );">Deferral of revenue</a></td>
<td class="nump">30.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_ContractWithCustomerLiabilityDeductions', window );">Revenue recognized</a></td>
<td class="num">(16.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">End of period</a></td>
<td class="nump">$ 30.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ChangeinContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ChangeinContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101221531776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed, net</a></td>
<td class="nump">$ 119.0<span></span>
</td>
<td class="nump">$ 224.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled</a></td>
<td class="nump">72.3<span></span>
</td>
<td class="nump">49.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net</a></td>
<td class="nump">$ 191.3<span></span>
</td>
<td class="nump">$ 274.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101221448480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective annual tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Discrete tax expense (benefits)</a></td>
<td class="num">$ (10.9)<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="num">$ (10.3)<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective annual tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101225354160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (loss) per share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (75.7)<span></span>
</td>
<td class="num">$ (32.7)<span></span>
</td>
<td class="num">$ (135.8)<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares-basic (in shares)</a></td>
<td class="nump">49.9<span></span>
</td>
<td class="nump">53.7<span></span>
</td>
<td class="nump">50.2<span></span>
</td>
<td class="nump">53.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities-equity awards (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares-diluted (in shares)</a></td>
<td class="nump">49.9<span></span>
</td>
<td class="nump">53.7<span></span>
</td>
<td class="nump">50.2<span></span>
</td>
<td class="nump">54.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (2.71)<span></span>
</td>
<td class="nump">$ 0.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (2.71)<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock awards (in shares)</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101221596672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of stock</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 75.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.5<span></span>
</td>
<td class="nump">$ 187.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period, shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101226960272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 11.2<span></span>
</td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="nump">$ 33.4<span></span>
</td>
<td class="nump">$ 32.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product sales | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product sales | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 22.7<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101225606432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Changes in Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 1,513.2<span></span>
</td>
<td class="nump">$ 1,543.7<span></span>
</td>
<td class="nump">$ 1,619.0<span></span>
</td>
<td class="nump">$ 1,447.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">1,449.3<span></span>
</td>
<td class="nump">1,522.7<span></span>
</td>
<td class="nump">1,449.3<span></span>
</td>
<td class="nump">1,522.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(22.4)<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
<td class="num">(25.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(5.2)<span></span>
</td>
<td class="num">(23.1)<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
<td class="num">(23.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember', window );">Defined Benefit Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(6.7)<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">$ (8.0)<span></span>
</td>
<td class="num">$ (8.0)<span></span>
</td>
<td class="num">$ (8.0)<span></span>
</td>
<td class="num">$ (8.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101226973056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Expense</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Expense</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Expense</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (1.3)<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101312897424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101221142880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 240.0<span></span>
</td>
<td class="nump">$ 329.0<span></span>
</td>
<td class="nump">$ 790.2<span></span>
</td>
<td class="nump">$ 1,069.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">74.0<span></span>
</td>
<td class="nump">94.6<span></span>
</td>
<td class="nump">281.6<span></span>
</td>
<td class="nump">461.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Adjusted gross margin</a></td>
<td class="nump">74.6<span></span>
</td>
<td class="nump">95.5<span></span>
</td>
<td class="nump">284.0<span></span>
</td>
<td class="nump">463.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
<td class="nump">63.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Adjusted gross margin</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
<td class="nump">63.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">34.3<span></span>
</td>
<td class="nump">63.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">186.2<span></span>
</td>
<td class="nump">270.5<span></span>
</td>
<td class="nump">660.5<span></span>
</td>
<td class="nump">589.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="num">(85.5)<span></span>
</td>
<td class="num">(103.2)<span></span>
</td>
<td class="num">(256.8)<span></span>
</td>
<td class="num">(237.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">36.2<span></span>
</td>
<td class="nump">112.6<span></span>
</td>
<td class="nump">90.7<span></span>
</td>
<td class="nump">283.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="num">(63.1)<span></span>
</td>
<td class="num">(114.3)<span></span>
</td>
<td class="num">(217.5)<span></span>
</td>
<td class="num">(307.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">186.2<span></span>
</td>
<td class="nump">270.5<span></span>
</td>
<td class="nump">660.5<span></span>
</td>
<td class="nump">589.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">100.7<span></span>
</td>
<td class="nump">167.3<span></span>
</td>
<td class="nump">403.7<span></span>
</td>
<td class="nump">352.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Adjusted gross margin</a></td>
<td class="nump">101.3<span></span>
</td>
<td class="nump">168.2<span></span>
</td>
<td class="nump">406.1<span></span>
</td>
<td class="nump">355.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember', window );">Products | Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="num">(85.5)<span></span>
</td>
<td class="num">(103.2)<span></span>
</td>
<td class="num">(256.8)<span></span>
</td>
<td class="num">(237.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="num">(26.7)<span></span>
</td>
<td class="num">(72.7)<span></span>
</td>
<td class="num">(122.1)<span></span>
</td>
<td class="nump">108.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Adjusted gross margin</a></td>
<td class="num">(26.7)<span></span>
</td>
<td class="num">(72.7)<span></span>
</td>
<td class="num">(122.1)<span></span>
</td>
<td class="nump">108.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">36.4<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">95.4<span></span>
</td>
<td class="nump">416.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="num">$ (63.1)<span></span>
</td>
<td class="num">$ (114.3)<span></span>
</td>
<td class="num">$ (217.5)<span></span>
</td>
<td class="num">$ (307.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AdjustedGrossMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Gross Margin</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AdjustedGrossMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140101221515648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">$ 20.4<span></span>
</td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="nump">$ 65.5<span></span>
</td>
<td class="nump">$ 46.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="nump">$ 34.2<span></span>
</td>
<td class="nump">$ 21.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>ebs-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ebs="http://emergentbiosolutions.com/20220930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ebs-20220930.xsd" xlink:type="simple"/>
    <context id="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2be5b42ff0b4471c908cf57d97a2e71f_I20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="ia8d11b69d7094e958cdf98db6cd53b20_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i30b0e22181834e9d8a6008ddf0fd449c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52646bb207c64e15902c5f7cebbaa5a9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3c1314a596fa4be2be2dbbc905e0e0ce_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if6605ab0b24d4a3a95cd07e88110dd0e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3ac0c2ed83d34c43b639039d2831ada9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie3ea905c3a1d48a9a374e41f47cd9e7e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i293e88d455b74b89b6ea596c99361768_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94946a3df68a4894a63cc93522fd6ca4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8e3af1259505476faa37180bca0dbed6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i25e36ed15c584f8abca1aae53e56c499_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5106d154262648b8966552fa34ac668e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3ae88a70cad04a6f9c132484c353e5b9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i30625a73d79a4164a68a490ce85445d6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib7c744e01ccc4b70a3f8d3f033d69fc7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iefc13edfdf22466c94aef0c6826da80b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8eff28a2bc3a4e869ed6725ec343457b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4e2dd808a6bb49acaba894087e88aab6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee99b848e7d34f24ba7ebd4d2abf4f85_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5105f0204af64b01a45ffaaf2c96b86e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icc86efbf51c9459a924cb8855de7d59d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1dd3f76fb0234ae9898dcecdd750649a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id0444415079d48bca0450996b92c9137_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc984f7cf64a4ac6ad2b90f5b12b27ea_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ief03e38f153e479b9c16cf1572d2d802_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i858bc01bcffe4fcc818b41f3490126e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i025e25b63cf240efb8c5c078757469d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4698414e7c1401c82d1bdd7bd331f7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73297e52dd7b4d0f94c279cc3501cbca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94685af212e84378abd02869fc65b116_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6c721871d86b4c9d92da8f3576d3c37c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i44614402dda1433ab395ed9472240cf0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8990366d48494f1b8a20b74e61189484_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id9a84624f46d42f4b0f9c18da44b11de_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i809764d7e9a84800b82506178a13b313_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3449978510494de9985378c4af49f5af_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i81d47500381c4a06a021712d3d13c022_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib32c62eb60fc4dc39b819eb33d2ecd33_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i88701e64171b4b4dbfc52b23a8dd15b7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7c07897dcdde4d89a128d2ed15fc5ad1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i14f2fb7cdf644c66b524b020f443b7a3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i65f2af0d2c0b4a15bc6e7423ba835ade_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i215adb10fcbf40a5a7ec2fc2088354e3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i86413dba3b9141c89275b7ef4f89903a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i513d610eeb964439903192db1ecb51ed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibc0fb7f94b4b4633bba35f83b8ce0a44_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1d3b9f37fd21490c816e8c33b0d191df_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i97535e302cdd4eae990d766576feefac_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i61f687c252da498ea3071b9bef0dae99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i345b6ed13f3d4fe5a3c2aa0fb402b26c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e607ecbd5b74b8c8b0184925410bf01_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9334dc4e6d884a7cbb7f455bf2f9af61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4fc5b8a85402486c8e7e3ae07b0a3871_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f4e99d6d47b4c0faf6ea720533b7521_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ccbc79df52c4d15b022b9a21c0ca27a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i03643882b32948aa88d7c7088c47243d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1907d7b857734e8fa8e27c5ba195c7cd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9501b3606d3748baa7f730985abc93d3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i120aedf84da0491da3c474183e2c4892_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7b982988d59741509a3340a4affea571_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i234810222a77469a8d310e47d2fa2f03_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib3d773caeec44dac875f1fc14041b176_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iebd066da54a34dadb2cfaddc80097222_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i61a54d77cf52423fa152a2b6df738697_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2109c764e423427782835d0108e52bb0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9e6a2188c167465d9720bcd73f722dcd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib96436736dac42149fc4524b381689e6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iafc0f0f6c6e34f86a10f18a780bc594b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if472db7e4ddc4d8abb7803c05ad8a4fc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia3ae0efe55364ceebbd48beeaa1b5f0d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i249e76b2e30b449d9cd1d10e9e44a617_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i26c8454cef2f47789cf2d3ee6746429f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6d15cdbf01f5414d8ebe10c27040be71_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7432986424e74ac09ac1dd272585adcb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icb0a527f718246d39439945aa519e89c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0a5d3c91817245f8a781e98678ca71b4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ief03c3babd264580b8f993d58e2f7399_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i432591c3907547a4a78ac6a89b2d6d9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i749bb1b516384ad09235dfaddfccbfb3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ide2d35bc08594b3ea21d8f60f7762840_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cf3406660784396880636ec6d64ce18_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7b571dae77f04edfb1556f8d08c9d6e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i766a15cf4ffb4c6d8115bd955a940932_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icdc0a33e12b849de810968cc193f06d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3d94b6f79364cc1899b13f7a72f0e27_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1e27b276ca764530b7005d22d6316077_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50157349177f44679e4ff5b00c2b690a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5a811ac3bfcc4c29a2a87b5ad51a6fde_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ebs:RockvilleManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idc90073631a04e08b6793e36b6aad73e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ebs:RockvilleManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb1900f7b4c44cedb875acc241c0bee3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i261b255bd2fc4596b335217f2db169aa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i93e3346dbc84460d924b2e6aa25b270d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7b49e361c9c547df983b25e75f050a95_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53f8980f84e54596a2bf0df6314e9c89_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie9ff2b788ad74a47a087d6ebd487fff7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ide0e3032f9614c6682f2d4f2a0717a79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01ccd0bec4264051b3136200d1ada025_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iabb40ddb95bf4ae692da5f4e955899fa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i222957670d1047ca907e168d91aaf306_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic2196bd047dc467a8d54bb1d0d7ad901_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6a10a22a6f834e04b52f8cb6f61ac369_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib304027feebe4bf294aa22162bc25292_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88816d3c5490459795a5e08eb0d42dba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ca9b3f099074a319fce082bb2f89bec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b7a7a2b19ba41c289818e166af517c7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0f9711a7eb5243dda529179658dd5830_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4699322b4ad742c4a1d4274126058576_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1d55fa0666854b7caae1ece36564984a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibc5d91a03d4847649b2be05d67b2263c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ddf4cbc6d484433973d4f77a1b65e21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibad5698b8174430c8ff31576aa9ee134_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48426d78db35469b9fbe78182bc15858_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7b6bac14fa948a599d617d797f9992b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i794b255dfaa5457d8b625a3b63515086_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8eade752296e444ba664833e0780951f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iacb283273e704425a0c32a9149376f6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8007fc99edc04934866754634405d8ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1054758dc0d14fa3bddb52120fbac120_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idcd99f4d0bd44df5ac51fd3f92b88bd4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieb22a87cdfe14a7c84c7650473417364_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic622b8b9acb24f6b88e8c6886000cf77_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i69c2baff68b54a718464354731cbe1ff_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3ef5c35c4662482c96b3838cdb9d6edd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i300780e3ce444b4cb0b0c9c10968ac86_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i291befa2eae3402ebb90a91957b5b46f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8b3b07fe44be43f1b02c1b877f8d8f60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19788cf415e44731a7ac316933902c13_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7d38ed2b0b1c4eaa8ca77f4744eb8d44_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2e48ea4760d64c29a1425b6484a220d7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i838e26b2874e4c6a900e96dfeaeb7fcf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i150ebed92e8e40479da8c8a6f0513b75_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8e600ddb0a1748578ccc9e9d07f955f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic90b9835f0d24ac1a182a07dd228a238_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1e4d660de4664e77b8ff1707a368864a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida4dbb8aac844392a35bca16af3b8ba6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7fde38f223f94ec0bedb7aaf2da71b3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i738ecdd912c348ff897fd9f1546835a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic61dd5c549874f80b397d42cc9717abc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i74b2a89fef854325a21558ba470a63ad_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i04969e1a51cb42c89f1471eb8ace2e4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if50ceba61f3047f1834721079b974236_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i027fba7fbff04d03860a6cb1878e9580_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iaffc9253e79f4fcebff3b4c90c35286e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i685e03fb0a4c4543b949a4d6d792d36a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5375d3691d1d44bc8c0347410a5bea7e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i08291fa7af0b411b9ad50845378e5f4f_I20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="i4e7c1aaf68b942a4862dd65bfc9fb9b0_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i920e76d8a6b143808c57dd4353d67903_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="if4f8efea66de4544a5582830d8b59691_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i6200f8d1ae104ba18d6fdb545b3e9d53_I20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="i71e35fd549cd4231be789d968dfd1543_I20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="i8605ed75b07d49a3b547f97fccb0e405_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i82b05a62bd63445cb568d4c2e2c3d9e0_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="ic84be99323cc4584be4962051ab7756d_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="ib0b9e211f3b94cda86f8d463e61a3a6c_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i17b0291bd1dd47a7b7ee65d4fecc6232_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i655fab78c8164add9eea8222ce75abaf_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i1479ba7c4c8141da9c266a76d41c699c_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="ida101d603b624a549b887226e83027b1_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i1eb46693aa644293a59a4421942c528f_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i28a266eb53e04df59d47c4a05b3e2244_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0c02245efe03492d998177bd87378e02_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0a88ddbd25d44236801b5ce80ff820a0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib8ec2984c86b4778b38ae6b4badb7f46_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if8c4a64e596d45aea88a95a509f10f86_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iee319a3e184c49c88a65354d45c0fcb5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i68059df57d924b6c9a6d571ce4686d06_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1a498fe04f304b2bb151292ea1f5194c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i85d2fdbc895b41fe8983ba64d0d2ffb0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i93ce7d6831194524b6acb971a73c8b1a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if6ea4a6a0de647a8a6d921dd7b209282_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iad159380abc745509e18c7cd554939da_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if4317852774f4594bf7d43b26a0b6f3d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4d65c5dfe69a49298805ed95c23e4944_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2d79a2aa8e1a4715897d56ad0693e4a1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff568f9147f143f48975cc8ccf7bb4d9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie21ef4d129104b7a8ae5cd39ae894a3f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9ce67d2e233d4f5786192e1687c3c262_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if950b033c22d4b22a7e329ed5dbe41cd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i71c0ec50c43b41b5899fc5e10c1d9ea3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc42b30bb7694aa3bd4d198c2dc52e32_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if5a6612cb27940cd836298ddf8f13245_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if6fe41cba330404f809cbe23888df0e9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia96662ac0ab84db9a8a6492b07c4e033_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8e7025c3b25f4602939fc3db062b06cb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i59ac47cd04fe4a45ba8a9128f2df0c0c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib714d01e5ecf4cd28cfdd767aab24593_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic74b2084ca8b4016920a9bb39463c71e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icb1d9ae26ce84cf1851284c7e4edc162_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id0d2c7c6dafc46998c4e95a9750239ee_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iad57e6166b6f48cabbffd992ec0bae18_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4a8c2b7b92db42f19333bc4e4af5abf1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb131a1d8ee2411bbdf86420dba67a16_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id5748c1fd8864631b676f49aec67c5f9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id5afd6d5f0de4b5a880e3f897b519fff_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i759d3f20525a4e73a29ad36cd1f9ad52_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3d296d42d02f4c53851eb8bbaa2f0904_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9444f3dda52346f994f9fa3d1d5f265e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i230926cc93b94f13a0f1ea180f586c99_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifbfcd3defae147349f8488c0ed4ae6b3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icf3d857066a346c9b7cc2f77fc9cf913_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6f054a91031f430392248a4bca839f9f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifb67dea42a90430caaa50cf5bb540f53_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i15644a22cf32438bb4e89c230573cc53_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee7392a5534e4fed8a494faf3156d30a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic7686e78d6544ad4ab6f238d59a463ae_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia0599ce5bf334bcd978cd677b9ce3488_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac249b92a2c34f4786aaa61ef1798afc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if052ae8be962412ca908a8ec55ce01bb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3f1c052aa974422c8e8de6bf7e629008_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c15bfbd578f4b02a335a5f53693bd78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:ReservationOfManufacturingCapacityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1cc548c971bc4ddab945aa7c2daa9c29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:AcceleratedExpansionOfFillFinishCapacityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7eb263408fe5444cbc0c106687b0c0bf_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="ib5f414c7b3a34d038d192fa7b90dcfbe_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i44ef3a51186e41038ea49e018725fc47_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0c28ec30bdcd4241b718857d94f0738f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6d0613c15a9a4b2891e92b0cb74673fa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if50fd0c04e7b433595e1fc59565af1ac_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ied97412e542e49649f895e9d8fca082b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i49ec7f41ed1e466ea8c8265cc217d1c9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if2e7ce5556ca4a7fb06da82e3898d7b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3eabe1e8d9c443b4aba12a1f4dfe8104_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4d3da6f40f548208c86343dfbb7f66e_I20211111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-11-11</instant>
        </period>
    </context>
    <context id="if6a69a9d549d4a7f9e5cca915ff81ac2_D20211111-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-11</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6c17179d3e4b4293af0a828cab7b1e54_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i741c417cf3c5438e926f3c181037b75a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icec9923b70dd4963ad63bbf6fbe6313b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i28b1f195ba044f8fba31c82ade107986_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i76cbbd4bcdbd481f9e12b0c3a5cf4906_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic35e87d35bfd4ff89237fb26b10d3744_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i598359cdd71c4de1a7ee59cbd115af40_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff9ad4afb37944048472b35bed2debf0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic29a7152fbf34b57b22e53b5f6a77694_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib20b602b02994e55bb8f5ff08e429097_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i37dbd3322fa84e95b69930efeffb24f6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i19613f0852b447be92b4d26268de48b6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibefbe152ae4b4ce4a115b201334e73c7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd27e1e917ee436d8d215b793434f26a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5bff5d9f1c2e45429a4c8237c99b05c8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica2181992bf34758ae89111c96b05c4a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i38e2b94c99ce4c32bf8a4a143327d9e3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia02d17b7af424e47932221e5cb92610d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i22dbe6000d7d4fb6bb7bafebd2ab2977_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f2c4b48c5bf44b583764343364acd18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e4037d8d3a6449baf24676b5b39d131_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73cb1d2c06c148969484c4bf9e7eb0eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6b67a9c1ec7349d18cbb84f1528227b8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id7b70bf533d44156972098e72400de35_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2be39dc33a614a138b0a5fa59b102996_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iced5a2acfffc465fa00678af5ae50f55_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id7c28ab284a34fd99cbac681f30c7f59_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaac12e2048894448abb1be8d9798b112_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i67e98f514b5248989bc8c524e454fe4b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4a289bb66e084884817817146aa5a26f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9f38ed14c4bf4de6b87cd4d750fc372c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i43143025a48b44c0a71392046d272649_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c5ea12368ef4ae3bb23c26ed19c8995_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63b169b1e50643f2add731b5b39f04c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie4f63f2b44854c31bb36daeefef5eb2a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia5dd4144da824a99afec23d0225b46ec_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iccb2cd37199e4c108d7c667ed7106280_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0020c5f97ae64effb8f68a65a66da7b3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i580d7f5f89514a8d9a9655a5cb84908b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5938e145ac85492f83e842b212b1e504_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i563cf1b2420d41c1ba3c84e069d89c8a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i329b945040704750b621490e14ce1c15_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd7dfbc7f90e4bce9bca0903609cb140_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i91da1234e99c48fba4f1671ade54bc4d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2bdca5071efe4471843b78ab54d1d399_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9ea336f29716489a8ee918ca7587d4fe_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iedf32fa013a5453f99dd18ef9591e2ac_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i02291c57c21b4a2c8a7441b2cb71c41a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib0c7a59cd0bc45efb119c53f96ba1842_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if7856b9f8f6d49b08fcf4b3d7646741d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8a9d457339c7409eb76312880e7a9ad8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib3c3d681b76e40419af6d49da37af710_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ied76f18f442f4ab69a0615274373a47b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1bf31d14f117481daf2044655dd6e7ad_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i16214c20216b4ae9b2e00cb861cc0703_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i97728d771d6646119c3295cf7509eb03_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icae6520aeb4c4128b277d196b54c5c64_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6d422d97fbb4e9c9744b614e2bf12b0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7460e31e951a480b816dfe2ae15feac6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i801413427f1f43babdb24055bb4bd90c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id4dc9efc2b614e0dab48fd0fdb3134a0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0058f71a7708496abfdf19ad817835bb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3a9984fa01164445b43977c0e9fc6107_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia28dc2c9d43e4b13a7778805dc25c68c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i32b2a80ee4ec410d9527e186fd40b2bd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1a49e5be45554d6d948e7369dce4055d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia00293a7076049e7979650ad37c66b83_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie24035e19dcb4f0a9e08c4030356556d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i03d9a1c9cc0b4c1281e5652109cbc1df_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="category">
        <measure>ebs:category</measure>
    </unit>
    <unit id="product">
        <measure>ebs:product</measure>
    </unit>
    <unit id="productcandidate">
        <measure>ebs:productCandidate</measure>
    </unit>
    <unit id="businessline">
        <measure>ebs:businessLine</measure>
    </unit>
    <unit id="segment">
        <measure>ebs:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="treatmentcourse">
        <measure>ebs:treatmentCourse</measure>
    </unit>
    <unit id="instrument">
        <measure>ebs:instrument</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80L2ZyYWc6ODkyNmEzMDZmZjA1NDQzM2FhMTViNTBmOWQ1MmE3NTAvdGFibGU6MDVlOGE0MjM4ODlhNGE4OWEzN2NkMTgyZjE0ODNmNWYvdGFibGVyYW5nZTowNWU4YTQyMzg4OWE0YTg5YTM3Y2QxODJmMTQ4M2Y1Zl8zLTEtMS0xLTEwODE2MQ_7dac4449-36aa-4e36-a2c9-604fa3305661">0001367644</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80L2ZyYWc6ODkyNmEzMDZmZjA1NDQzM2FhMTViNTBmOWQ1MmE3NTAvdGFibGU6MDVlOGE0MjM4ODlhNGE4OWEzN2NkMTgyZjE0ODNmNWYvdGFibGVyYW5nZTowNWU4YTQyMzg4OWE0YTg5YTM3Y2QxODJmMTQ4M2Y1Zl80LTEtMS0xLTEwODE2MQ_26e425bb-297d-4749-a792-deef0bc7b853">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80L2ZyYWc6ODkyNmEzMDZmZjA1NDQzM2FhMTViNTBmOWQ1MmE3NTAvdGFibGU6MDVlOGE0MjM4ODlhNGE4OWEzN2NkMTgyZjE0ODNmNWYvdGFibGVyYW5nZTowNWU4YTQyMzg4OWE0YTg5YTM3Y2QxODJmMTQ4M2Y1Zl8xMC0xLTEtMS0xMDgxNjE_d01f61c2-d043-4d68-9804-49e900f956e0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80L2ZyYWc6ODkyNmEzMDZmZjA1NDQzM2FhMTViNTBmOWQ1MmE3NTAvdGFibGU6MDVlOGE0MjM4ODlhNGE4OWEzN2NkMTgyZjE0ODNmNWYvdGFibGVyYW5nZTowNWU4YTQyMzg4OWE0YTg5YTM3Y2QxODJmMTQ4M2Y1Zl8xMi0xLTEtMS0xMDgxNjE_b6cf8265-e0a0-4768-b9b7-1b6bd2b1a3bc">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80L2ZyYWc6ODkyNmEzMDZmZjA1NDQzM2FhMTViNTBmOWQ1MmE3NTAvdGFibGU6MDVlOGE0MjM4ODlhNGE4OWEzN2NkMTgyZjE0ODNmNWYvdGFibGVyYW5nZTowNWU4YTQyMzg4OWE0YTg5YTM3Y2QxODJmMTQ4M2Y1Zl8xMy0xLTEtMS0xMDgxNjE_6ab8e469-3d3e-4b3b-9940-c7feef7e4905">Q3</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_5151ab9f-c47e-463d-8aa2-48943e0afded">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_fa39117a-d454-4120-99bf-3662bcd5aca2">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_4cea9722-b807-4cb6-aacd-3b045145d7ac">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_55a8c7c0-1418-4c46-86d6-6bf5a5d3114f">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_1a37c2b9-d83a-4cc7-9218-97115c59e9de">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_e5713eb8-636e-4658-b39f-755a6d1cadca">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod
      contextRef="i1eb46693aa644293a59a4421942c528f_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82MS9mcmFnOmZiMDYxNmRkYTlkMjQ5NWI5YTg1OTliMDk4ZWFhMGQ3L3RleHRyZWdpb246ZmIwNjE2ZGRhOWQyNDk1YjlhODU5OWIwOThlYWEwZDdfMzIx_fd672508-3b83-4524-a780-8ce6e1697bb1">P12M</ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i44ef3a51186e41038ea49e018725fc47_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82Ny9mcmFnOjc0ODRkZDhhY2Q5MTQwNWJhMTk0Y2YwZWM4MjhjOWI3L3RhYmxlOjc2Zjg0ODlmOTUwODQzMTU4YzI5MGE5OTZhYTAxMzhlL3RhYmxlcmFuZ2U6NzZmODQ4OWY5NTA4NDMxNThjMjkwYTk5NmFhMDEzOGVfMS0xLTEtMS0xMDgxNjE_9bf9cc62-2c65-4568-8738-53fc766cf216">P3M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i0c28ec30bdcd4241b718857d94f0738f_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82Ny9mcmFnOjc0ODRkZDhhY2Q5MTQwNWJhMTk0Y2YwZWM4MjhjOWI3L3RhYmxlOjc2Zjg0ODlmOTUwODQzMTU4YzI5MGE5OTZhYTAxMzhlL3RhYmxlcmFuZ2U6NzZmODQ4OWY5NTA4NDMxNThjMjkwYTk5NmFhMDEzOGVfMi0xLTEtMS0xMDgxNjE_ee2c7eee-3390-405c-a01d-6669a3ba0c0f">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i6d0613c15a9a4b2891e92b0cb74673fa_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82Ny9mcmFnOjc0ODRkZDhhY2Q5MTQwNWJhMTk0Y2YwZWM4MjhjOWI3L3RhYmxlOjc2Zjg0ODlmOTUwODQzMTU4YzI5MGE5OTZhYTAxMzhlL3RhYmxlcmFuZ2U6NzZmODQ4OWY5NTA4NDMxNThjMjkwYTk5NmFhMDEzOGVfMy0xLTEtMS0xMDgxNjE_1b1d95e2-63c3-4ff4-b31a-a9a1823b132d">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="if50fd0c04e7b433595e1fc59565af1ac_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82Ny9mcmFnOjc0ODRkZDhhY2Q5MTQwNWJhMTk0Y2YwZWM4MjhjOWI3L3RhYmxlOjc2Zjg0ODlmOTUwODQzMTU4YzI5MGE5OTZhYTAxMzhlL3RhYmxlcmFuZ2U6NzZmODQ4OWY5NTA4NDMxNThjMjkwYTk5NmFhMDEzOGVfNC0xLTEtMS0xMDgxNjE_49ea3828-91e5-434e-8852-4366c895c233">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ied97412e542e49649f895e9d8fca082b_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82Ny9mcmFnOjc0ODRkZDhhY2Q5MTQwNWJhMTk0Y2YwZWM4MjhjOWI3L3RhYmxlOjc2Zjg0ODlmOTUwODQzMTU4YzI5MGE5OTZhYTAxMzhlL3RhYmxlcmFuZ2U6NzZmODQ4OWY5NTA4NDMxNThjMjkwYTk5NmFhMDEzOGVfNS0xLTEtMS0xMDgxNjE_0614c7d3-af9d-490b-ab68-a27ec3ef3ad6"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i91da1234e99c48fba4f1671ade54bc4d_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMS0xLTEtMS0xMDgxNjE_824cd1bd-e1d1-4407-8498-deb63f66d68e"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2bdca5071efe4471843b78ab54d1d399_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMS0yLTEtMS0xMDgxNjE_f37bf0f8-a317-4312-99f3-99ef53057072"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i9ea336f29716489a8ee918ca7587d4fe_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMi0xLTEtMS0xMDgxNjE_3dc78f27-a3ad-4f4c-b3e1-efa9e5aee840"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iedf32fa013a5453f99dd18ef9591e2ac_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMi0yLTEtMS0xMDgxNjE_78ce435d-dd98-4230-b2c5-35f1e5845a7c"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i02291c57c21b4a2c8a7441b2cb71c41a_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMy0xLTEtMS0xMDgxNjE_cce1fd76-fb48-4dfb-a777-861a458633b9"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib0c7a59cd0bc45efb119c53f96ba1842_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83OS9mcmFnOmIyOTg0YTE3NzA1MTRmMDdiOWYxYTE3MmE0Mjc3ZTQzL3RhYmxlOjkzMGJlMjk2ZWYyNjQ5NmM4ODI2MGFiOWZiNzVlNTc1L3RhYmxlcmFuZ2U6OTMwYmUyOTZlZjI2NDk2Yzg4MjYwYWI5ZmI3NWU1NzVfMy0yLTEtMS0xMDgxNjE_9dd72b09-1c74-48f8-bcc0-caa4546d0432"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM4_70ec13ea-16c4-4fd5-b9eb-9323a520136e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6Zjc3NTk2YTRkNWRlNGVjNTkwOTVlZmMyOThjMzlhZGEvdGFibGVyYW5nZTpmNzc1OTZhNGQ1ZGU0ZWM1OTA5NWVmYzI5OGMzOWFkYV8wLTAtMS0xLTEwODE2MQ_43611b1c-4057-443d-acaf-fc18375cc6eb">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xMjE_800c5e15-c747-4c8c-85f8-729ebd5180c1">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YmZkZWY1NGFhNTM1NDNlZmE5NDlmNjUwMWIyMWQ1Y2UvdGFibGVyYW5nZTpiZmRlZjU0YWE1MzU0M2VmYTk0OWY2NTAxYjIxZDVjZV8wLTAtMS0xLTEwODE2MQ_b1fce878-6518-4f52-b7c1-481f92af967a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODQw_3f25b3ec-8124-4ca9-a06f-f8d61ae0b9dd">001-33137</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODMz_91ebad24-1c38-4263-9b88-c015fba639eb">EMERGENT BIOSOLUTIONS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF8wLTAtMS0xLTEwODE2MQ_e7ec67ab-64a1-4f90-b83d-445d0a05dd82">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF8wLTItMS0xLTEwODE2MQ_15d7a1b3-845f-46b1-bbf0-0780f469c403">14-1902018</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF8zLTAtMS0xLTEwODE2MQ_c9d7fa12-3670-4baf-8c08-4a1ecc69b1d6">400 Professional Drive Suite 400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF80LTAtMS0xLTEwODE2MQ_ea074d15-bcda-4b7d-b5bb-837cd0a05636">Gaithersburg,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF80LTEtMS0xLTEwODE2MQ_35d3c652-23c0-4700-8459-2ded2195654a">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6YWRhODZmY2I5OGJmNGZhYzgxZTEzZTg5OThhMWYyMjgvdGFibGVyYW5nZTphZGE4NmZjYjk4YmY0ZmFjODFlMTNlODk5OGExZjIyOF80LTItMS0xLTEwODE2MQ_25a23f78-6936-4c9e-ba86-804e54d72527">20879</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM5_f9f6e34f-1b5b-4c13-8e63-3d96bb6b399c">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM0_b32127b4-a831-44e6-8bc5-246aea69cafb">631-3200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6MzgyOWJjZDBkMWFlNDhlZWI0YTI4N2RkNjFiNTAxMjIvdGFibGVyYW5nZTozODI5YmNkMGQxYWU0OGVlYjRhMjg3ZGQ2MWI1MDEyMl8yLTAtMS0xLTEwODE2MQ_6b35d3ef-2504-45db-99f1-51871ed9a48a">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6MzgyOWJjZDBkMWFlNDhlZWI0YTI4N2RkNjFiNTAxMjIvdGFibGVyYW5nZTozODI5YmNkMGQxYWU0OGVlYjRhMjg3ZGQ2MWI1MDEyMl8yLTEtMS0xLTEwODE2MQ_74d93c47-dd39-4ccb-959e-f83ff5ef52b7">EBS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6MzgyOWJjZDBkMWFlNDhlZWI0YTI4N2RkNjFiNTAxMjIvdGFibGVyYW5nZTozODI5YmNkMGQxYWU0OGVlYjRhMjg3ZGQ2MWI1MDEyMl8yLTItMS0xLTEwODE2MQ_36fc0eee-ed61-47bb-a896-15c3725ec148">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM1_e3c8b989-4b3d-4ce7-80f9-cb4e57748118">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM2_3b69d231-6278-4884-abc3-68ee479f2752">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6Yjk3NDUxNjAzNzhiNDUzYTk0NzA4ZTNhMmVlYjM1MWQvdGFibGVyYW5nZTpiOTc0NTE2MDM3OGI0NTNhOTQ3MDhlM2EyZWViMzUxZF8wLTAtMS0xLTEwODE2MQ_2935073a-e325-4cc1-aaf9-45cddfe94243">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6Yjk3NDUxNjAzNzhiNDUzYTk0NzA4ZTNhMmVlYjM1MWQvdGFibGVyYW5nZTpiOTc0NTE2MDM3OGI0NTNhOTQ3MDhlM2EyZWViMzUxZF8xLTMtMS0xLTEwODE2MQ_5ea82fc8-c1de-48d4-8e77-138cbe27449e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGFibGU6Yjk3NDUxNjAzNzhiNDUzYTk0NzA4ZTNhMmVlYjM1MWQvdGFibGVyYW5nZTpiOTc0NTE2MDM3OGI0NTNhOTQ3MDhlM2EyZWViMzUxZF8yLTMtMS0xLTEwODE2MQ_88ff22af-76c1-4cf0-b905-5a907910ff81">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xODM3_aa39d37c-1150-47f1-bc84-5ec10bffa116">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2be5b42ff0b4471c908cf57d97a2e71f_I20221101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xL2ZyYWc6Y2JiMWFmOGE2ODIzNGJhNDg1MzBjOTg3MGE1YTRmYTAvdGV4dHJlZ2lvbjpjYmIxYWY4YTY4MjM0YmE0ODUzMGM5ODcwYTVhNGZhMF8xNzk2_18275cdc-ec83-43e6-a30b-a229fb601611"
      unitRef="shares">49888218</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNC0xLTEtMS0xMDgxNjE_92d31a7b-2acc-4641-bb90-bf7e589426c9"
      unitRef="usd">240900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNC0zLTEtMS0xMDgxNjE_fc2c0af7-ec66-4315-9b0f-901ca9675049"
      unitRef="usd">576100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNS0xLTEtMS0xMDgxNjE_fd6fc330-11d4-4bc6-af63-b71bf1a6477d"
      unitRef="usd">100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNS0zLTEtMS0xMDgxNjE_9999dd3d-9eeb-4da1-8730-7c92650a7247"
      unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNi0xLTEtMS0xMDgxNjE_71ea48ae-f004-4586-a103-97f7bdce39a8"
      unitRef="usd">191300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNi0zLTEtMS0xMDgxNjE_49188506-c7db-47f7-bad2-8cc4b242a6c6"
      unitRef="usd">274700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNy0xLTEtMS0xMDgxNjE_65f0b18f-c00f-45ad-9ab6-e04137414911"
      unitRef="usd">546300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfNy0zLTEtMS0xMDgxNjE_3313d5e2-8176-435e-afd2-b5624a74390f"
      unitRef="usd">350800000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfOC0xLTEtMS0xMDgxNjE_0c36eba6-bcb8-4beb-a4a5-522045b9ce1d"
      unitRef="usd">139900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfOC0zLTEtMS0xMDgxNjE_934a9550-8aa6-4f34-85d2-b1ee5210ccb7"
      unitRef="usd">70300000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfOS0xLTEtMS0xMDgxNjE_7f43d548-1f4f-474c-ab8a-9ef3afd1b48b"
      unitRef="usd">1118500000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfOS0zLTEtMS0xMDgxNjE_79c064dd-5f3c-4d00-bb64-66f1c2659231"
      unitRef="usd">1272100000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTEtMS0xLTEtMTA4MTYx_f29c7cde-dc70-4cd4-b2f9-cda58fef7338"
      unitRef="usd">806700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTEtMy0xLTEtMTA4MTYx_2a5aa477-8353-4dfb-b8ae-60f3c2a22a07"
      unitRef="usd">800100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTItMS0xLTEtMTA4MTYx_79e65ff5-0a2e-49c3-9eca-003f15107ac0"
      unitRef="usd">722700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTItMy0xLTEtMTA4MTYx_ff644617-a27b-4c75-b5f3-a262a36f8cd8"
      unitRef="usd">604600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTMtMS0xLTEtMTA4MTYx_0ebca770-af5b-45a4-ae97-d7bc7efcd948"
      unitRef="usd">224900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTMtMy0xLTEtMTA4MTYx_8b8e26a3-8f00-4aa4-86f6-9893d06eaf98"
      unitRef="usd">224900000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTQtMS0xLTEtMTA4MTYx_6561c66c-ca74-40e1-bab7-6df66adfbccb"
      unitRef="usd">35700000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTQtMy0xLTEtMTA4MTYx_5869fdfd-ce51-48e3-8d7c-b24bfa979abe"
      unitRef="usd">57300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTUtMS0xLTEtMTA4MTYx_ca1dc88b-6419-4464-8f80-ca531fed7ffd"
      unitRef="usd">2908500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTUtMy0xLTEtMTA4MTYx_d1aab227-83d0-43d2-a8a5-a55dbca89ad8"
      unitRef="usd">2959000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTktMS0xLTEtMTA4MTYx_3a559237-3460-4d1e-8cf2-fca41e9ff539"
      unitRef="usd">103800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMTktMy0xLTEtMTA4MTYx_6076c051-5777-4b60-b16d-9a26a8c6b95a"
      unitRef="usd">128900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjAtMS0xLTEtMTA4MTYx_15e83df6-68d2-463c-b864-6178eca8b925"
      unitRef="usd">35900000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjAtMy0xLTEtMTA4MTYx_3cfb8bba-9b11-439d-808b-0759a33ef486"
      unitRef="usd">51700000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjEtMS0xLTEtMTA4MTYx_9fecd210-75c1-4d1c-b494-8906adda87a3"
      unitRef="usd">82500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjEtMy0xLTEtMTA4MTYx_6c6aeb29-b884-4059-9563-bb8f3baa5cbb"
      unitRef="usd">88700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjItMS0xLTEtMTA4MTYx_00fbf3d9-5921-4492-af71-f7d91d8e7848"
      unitRef="usd">21200000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjItMy0xLTEtMTA4MTYx_d82e123a-98c6-4ef1-b3b4-1aea549c2852"
      unitRef="usd">31600000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjMtMS0xLTEtMTA4MTYx_69f37c6c-576b-4bb0-a100-9b08f990ed49"
      unitRef="usd">25000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjMtMy0xLTEtMTA4MTYx_2f9eed91-fdd2-42f5-9925-ffbda5932d7c"
      unitRef="usd">72900000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjQtMS0xLTEtMTA4MTYx_7255f208-4639-4ecf-ba38-b8f8e0a6833f"
      unitRef="usd">268400000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjQtMy0xLTEtMTA4MTYx_2bb86c63-210b-46e9-b794-027bd3b64980"
      unitRef="usd">373800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjYtMS0xLTEtMTA4MTYx_eae83faf-6990-416b-8a0c-906aba41654d"
      unitRef="usd">1032100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjYtMy0xLTEtMTA4MTYx_8ad80c18-52b7-47ee-ac87-d4f76bbed07c"
      unitRef="usd">809400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjctMS0xLTEtMTA4MTYx_7637bbbf-7524-401c-8c85-6cc1cb7ac46d"
      unitRef="usd">113800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjctMy0xLTEtMTA4MTYx_f73b34e5-d44a-4938-b197-fda04b45cd3a"
      unitRef="usd">94900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjgtMS0xLTEtMTA4MTYx_8fade240-0aad-4308-940f-dee721110db3"
      unitRef="usd">44900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjgtMy0xLTEtMTA4MTYx_00e3f6c5-620b-4dc3-9d11-8fe1b8b3f7a7"
      unitRef="usd">61900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjktMS0xLTEtMTA4MTYx_f6abe8b3-6cfa-4ea2-87cb-c1f852182852"
      unitRef="usd">1459200000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMjktMy0xLTEtMTA4MTYx_09213c2f-aafe-493a-8668-4031d5492b7b"
      unitRef="usd">1340000000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfMjE_7f576fb3-7114-4a3e-8c80-036172b99780"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfMjE_a59246b5-67b9-407c-9ca2-fc14e39139c0"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfMzU_2befc88c-fd3d-49b6-882d-aeff9e150e2d"
      unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfMzU_e81dab48-f6d0-4279-9d43-3303780d9550"
      unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfNTc_37558ecd-c3cc-432a-9c87-c3439b313a54"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfNTc_64311f8a-760e-4553-b9ca-b97a664f8432"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfNTc_6dc38935-b9ce-4508-877e-e969346ea705"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmQyZmI0NzJhYzk0NDg4OTg3YWM2OThhNDRhZTlmZDdfNTc_f6bc5025-cf81-498d-9bef-7879d7092d3e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMS0xLTEtMTA4MTYx_0f89bd2c-729d-41ac-af97-15441179517c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzItMy0xLTEtMTA4MTYx_3ebfb6f9-72f1-414a-b452-dd12684d501e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfMTg_3392539d-1f3a-4776-98ad-b32b0fd4135b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfMTg_4c77708e-b499-4a19-a778-5209ca548a13"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfMzI_2b6835a6-2896-4fd4-9c33-c2bcdea140fb"
      unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfMzI_a50d5707-6a95-4535-9006-2741cc699003"
      unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfNTQ_23d7ef2f-e6ef-4bf8-acb9-c479f7dd69db"
      unitRef="shares">55500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfNjE_4ce7d1bd-55c9-430a-a78a-08256d77a3e8"
      unitRef="shares">55100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfNzk_39f0937a-a466-4603-904a-220197e43855"
      unitRef="shares">49900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246ZmYyOGI1Y2EwODhiNDNhMWI3ZGZlNzY3NDhjYjY4ZDVfODY_0213cb82-4dfe-426f-b6a1-3e855d9fe45b"
      unitRef="shares">51300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMS0xLTEtMTA4MTYx_9211bd51-f90f-4b1c-812d-f014afc2aedb"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzMtMy0xLTEtMTA4MTYx_ba848d86-b212-443e-87c4-490d3b21544b"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzQtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246MGQxOTBlYjIwYjdhNDA2OWJjNjE2N2U3YTlmMmU3YzZfMjk_6306c17b-5dd8-4246-a018-9f2afaff1593"
      unitRef="shares">5600000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzQtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246MGQxOTBlYjIwYjdhNDA2OWJjNjE2N2U3YTlmMmU3YzZfMzY_8dd2d9ff-e638-4ef0-b70e-f86a477ba31f"
      unitRef="shares">3800000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzQtMS0xLTEtMTA4MTYx_720b93de-77cd-497e-a391-f4c703ba4f91"
      unitRef="usd">227700000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzQtMy0xLTEtMTA4MTYx_4aebd2a5-bcef-4c61-8467-50bf676658ef"
      unitRef="usd">152200000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzUtMS0xLTEtMTA4MTYx_f3d19e5f-170e-4a60-b153-197495372c55"
      unitRef="usd">860100000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzUtMy0xLTEtMTA4MTYx_b179f6f3-3d26-4ea0-965e-b72c348904b5"
      unitRef="usd">829400000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzYtMS0xLTEtMTA4MTYx_14569c16-4a4a-4882-bd50-b25e005d17a8"
      unitRef="usd">-5200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzYtMy0xLTEtMTA4MTYx_38e4d047-d899-41f9-a61a-1518181c9d0e"
      unitRef="usd">-16100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzctMS0xLTEtMTA4MTYx_8e07dcba-d77a-4564-9817-737322315e4c"
      unitRef="usd">822000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzctMy0xLTEtMTA4MTYx_12aaa66e-6b14-4f84-8c60-3525423e671f"
      unitRef="usd">957800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzgtMS0xLTEtMTA4MTYx_45fc0ab9-1287-4764-a07b-7c9358386bb0"
      unitRef="usd">1449300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzgtMy0xLTEtMTA4MTYx_21a103ab-d3f3-4c45-a291-f2ddbd5e1789"
      unitRef="usd">1619000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzktMS0xLTEtMTA4MTYx_17bfa148-4ca4-4f37-9b29-122e9d691030"
      unitRef="usd">2908500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xNi9mcmFnOmRkN2JjZjRkZmU0YjRkYzE5YzA4OTBkOGU5OWUyMzY5L3RhYmxlOjUzYTU4YmIxMDY5ODRiNWViMTE4ZDgwNjQ2N2Q3ZmQ0L3RhYmxlcmFuZ2U6NTNhNThiYjEwNjk4NGI1ZWIxMThkODA2NDY3ZDdmZDRfMzktMy0xLTEtMTA4MTYx_40a30a99-2045-4c32-b29c-54f145cb6e4a"
      unitRef="usd">2959000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52646bb207c64e15902c5f7cebbaa5a9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMy0xLTEtMS0xMDgxNjE_258840f2-c36e-4fd6-aa20-bcb6a361cf13"
      unitRef="usd">186200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c1314a596fa4be2be2dbbc905e0e0ce_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMy0zLTEtMS0xMDgxNjE_a73698d2-3062-4155-bb6c-e7761e4f4ea9"
      unitRef="usd">270500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6605ab0b24d4a3a95cd07e88110dd0e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMy01LTEtMS0xMDgxNjE_42b094d9-c0cd-4fec-8d98-273cb522dc1f"
      unitRef="usd">660500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ac0c2ed83d34c43b639039d2831ada9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMy03LTEtMS0xMDgxNjE_ba19a762-134d-4d3c-bcdb-26575ba5ce04"
      unitRef="usd">589600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3ea905c3a1d48a9a374e41f47cd9e7e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNS0xLTEtMS0xMDgxNjE_65979170-8346-4a98-8853-ea3aa14d9209"
      unitRef="usd">36200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i293e88d455b74b89b6ea596c99361768_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNS0zLTEtMS0xMDgxNjE_0c01448c-1c37-4832-9a37-69e25426ddd3"
      unitRef="usd">112600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94946a3df68a4894a63cc93522fd6ca4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNS01LTEtMS0xMDgxNjE_d5cd474f-fd42-4cd2-b8ba-fad8f0bc9429"
      unitRef="usd">90700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e3af1259505476faa37180bca0dbed6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNS03LTEtMS0xMDgxNjE_cc9eca3f-12f6-4408-b394-43e8290fed97"
      unitRef="usd">283700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i25e36ed15c584f8abca1aae53e56c499_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNi0xLTEtMS0xMDgxNjE_2cf91643-5ac1-459d-a55f-12804c2d16b9"
      unitRef="usd">200000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i5106d154262648b8966552fa34ac668e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNi0zLTEtMS0xMDgxNjE_8bb2fd86-dff9-4ec6-9400-9e37a8fc199e"
      unitRef="usd">-71000000.0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i3ae88a70cad04a6f9c132484c353e5b9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNi01LTEtMS0xMDgxNjE_c83d4791-7142-485f-ad51-80099f6f5801"
      unitRef="usd">4700000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i30625a73d79a4164a68a490ce85445d6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNi03LTEtMS0xMDgxNjE_a5f718eb-5d00-4d98-b5a4-5fc2386d7f99"
      unitRef="usd">132600000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7c744e01ccc4b70a3f8d3f033d69fc7_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNy0xLTEtMS0xMDgxNjE_c743bc76-2ef1-4a40-84a7-3d10b4f8ae9e"
      unitRef="usd">36400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefc13edfdf22466c94aef0c6826da80b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNy0zLTEtMS0xMDgxNjE_1626d515-0704-4867-8140-a73833615a26"
      unitRef="usd">41600000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eff28a2bc3a4e869ed6725ec343457b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNy01LTEtMS0xMDgxNjE_f98dcf7e-77e4-40cb-aac4-1c6e84f32886"
      unitRef="usd">95400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e2dd808a6bb49acaba894087e88aab6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfNy03LTEtMS0xMDgxNjE_9655094f-f48f-4ec6-874b-1c67b264d069"
      unitRef="usd">416300000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee99b848e7d34f24ba7ebd4d2abf4f85_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOC0xLTEtMS0xMDgxNjE_d5577ccb-7f40-4359-98f0-c7e3c78afd1e"
      unitRef="usd">17400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5105f0204af64b01a45ffaaf2c96b86e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOC0zLTEtMS0xMDgxNjE_89056e94-64b8-40d8-9d00-d1f8b36e72c1"
      unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc86efbf51c9459a924cb8855de7d59d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOC01LTEtMS0xMDgxNjE_856bc690-99a4-44d9-b751-fcbf74f57b0f"
      unitRef="usd">34300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dd3f76fb0234ae9898dcecdd750649a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOC03LTEtMS0xMDgxNjE_9dd540dd-b566-4e9a-af35-7a0a57e5fb21"
      unitRef="usd">63600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOS0xLTEtMS0xMDgxNjE_a9ae0308-59ea-455b-af02-da0ade7faf40"
      unitRef="usd">240000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOS0zLTEtMS0xMDgxNjE_00537dab-e476-4258-908d-d7027c3ea444"
      unitRef="usd">329000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOS01LTEtMS0xMDgxNjE_e6c12576-dcd1-43bb-bea8-90917a295a0c"
      unitRef="usd">790200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfOS03LTEtMS0xMDgxNjE_90e21cf2-13c2-4e12-b378-cfbcdce7e570"
      unitRef="usd">1069500000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i52646bb207c64e15902c5f7cebbaa5a9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTItMS0xLTEtMTA4MTYx_1cd2b9ed-6f02-474a-b7f0-b7ad94c5310d"
      unitRef="usd">85500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3c1314a596fa4be2be2dbbc905e0e0ce_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTItMy0xLTEtMTA4MTYx_3ff9ed0e-bd47-425a-9565-d59459ffdf5c"
      unitRef="usd">103200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if6605ab0b24d4a3a95cd07e88110dd0e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTItNS0xLTEtMTA4MTYx_ee430db2-09d1-4151-82eb-3bd43983752d"
      unitRef="usd">256800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3ac0c2ed83d34c43b639039d2831ada9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTItNy0xLTEtMTA4MTYx_bbdce447-fb5d-43b2-9f71-be41c92ece01"
      unitRef="usd">237000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie3ea905c3a1d48a9a374e41f47cd9e7e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTMtMS0xLTEtMTA4MTYx_a7cb62d8-d25b-432d-a43a-f03ad3d627e1"
      unitRef="usd">63100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i293e88d455b74b89b6ea596c99361768_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTMtMy0xLTEtMTA4MTYx_674ef047-d6f1-4288-a411-2fe395944baa"
      unitRef="usd">114300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i94946a3df68a4894a63cc93522fd6ca4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTMtNS0xLTEtMTA4MTYx_b5c98a1e-061c-4e4b-a2c3-c497ef0bb774"
      unitRef="usd">217500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8e3af1259505476faa37180bca0dbed6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTMtNy0xLTEtMTA4MTYx_995fffea-71b4-4c74-b009-1b4e2481fc9c"
      unitRef="usd">307600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTQtMS0xLTEtMTA4MTYx_459bf344-3df2-4285-9131-bdfd62e61d8e"
      unitRef="usd">39200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTQtMy0xLTEtMTA4MTYx_4fb7aaa8-dd4b-407a-8c86-4de759b95952"
      unitRef="usd">49600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTQtNS0xLTEtMTA4MTYx_3d6e2346-2821-4a01-93c8-f3e622324c12"
      unitRef="usd">135400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTQtNy0xLTEtMTA4MTYx_3f62122d-6994-4f26-bd39-567a832792c5"
      unitRef="usd">151000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTUtMS0xLTEtMTA4MTYx_31b58f3e-72bf-480b-bdf0-42390048c909"
      unitRef="usd">80200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTUtMy0xLTEtMTA4MTYx_10951eeb-3b5e-4776-9629-e59595926ab9"
      unitRef="usd">82100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTUtNS0xLTEtMTA4MTYx_5518397b-bace-41e7-9460-8b995fdc992f"
      unitRef="usd">246100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTUtNy0xLTEtMTA4MTYx_be3bfea8-0e03-4279-9366-c48b1437fbad"
      unitRef="usd">254200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTYtMS0xLTEtMTA4MTYx_bd12587a-5919-4533-8a07-ee355d792af8"
      unitRef="usd">14000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTYtMy0xLTEtMTA4MTYx_0dfc6ce9-4906-4acb-9452-373ef397b8c3"
      unitRef="usd">14500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTYtNS0xLTEtMTA4MTYx_510a844c-ad37-4f64-a2ce-6ad3e2832106"
      unitRef="usd">42000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTYtNy0xLTEtMTA4MTYx_a46c0fda-7732-4cf0-9eeb-096deaf27ebd"
      unitRef="usd">44500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTctMS0xLTEtMTA4MTYx_d711316c-7719-4ce9-9ba0-9fedf0971863"
      unitRef="usd">282000000.0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTctMy0xLTEtMTA4MTYx_47b21478-ea0e-4798-939d-77a97093ecfc"
      unitRef="usd">363700000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTctNS0xLTEtMTA4MTYx_953d334e-6d2e-4760-ab1d-688788746cb9"
      unitRef="usd">897800000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTctNy0xLTEtMTA4MTYx_ca637ee6-8804-4c94-92a2-eac1315c7642"
      unitRef="usd">994300000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTktMS0xLTEtMTA4MTYx_94dd6793-2847-4b3e-a24c-a7bf4624c7b5"
      unitRef="usd">-42000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTktMy0xLTEtMTA4MTYx_07eea34d-869d-42b4-a936-41a7c53d5cc2"
      unitRef="usd">-34700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTktNS0xLTEtMTA4MTYx_ed1462aa-bd07-4b54-8cfa-2afd0626b03b"
      unitRef="usd">-107600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMTktNy0xLTEtMTA4MTYx_a9240659-a1af-425a-805c-b4c26c450cf0"
      unitRef="usd">75200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjItMS0xLTEtMTA4MTYx_691c6e1d-c873-4f37-9b34-2202bb0facc6"
      unitRef="usd">8500000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjItMy0xLTEtMTA4MTYx_c1299755-bda7-45e2-8ac4-849f3fb347d9"
      unitRef="usd">8400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjItNS0xLTEtMTA4MTYx_8d6cd0f6-b15c-4c5a-837d-27acad174533"
      unitRef="usd">24500000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjItNy0xLTEtMTA4MTYx_4589dc8d-b70b-4ccf-8e07-baaf1c36719d"
      unitRef="usd">25500000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjMtMS0xLTEtMTA4MTYx_322a0390-496b-404a-a8bc-0141ed46b0df"
      unitRef="usd">-13400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjMtMy0xLTEtMTA4MTYx_34317ae8-2e71-415d-a2b1-e73d1fe50d92"
      unitRef="usd">-2400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjMtNS0xLTEtMTA4MTYx_43ff0dc4-692d-4b0d-9e9d-a62fc92ae924"
      unitRef="usd">-18400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjMtNy0xLTEtMTA4MTYx_9c87f94f-b942-4a32-8dea-d2a2cf520d7b"
      unitRef="usd">-2800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjQtMS0xLTEtMTA4MTYx_ec99d9c3-7541-48a8-a105-b5d844f26431"
      unitRef="usd">-21900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjQtMy0xLTEtMTA4MTYx_6bc0b299-f8c6-4cf1-a28a-cff683a783c4"
      unitRef="usd">-10800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjQtNS0xLTEtMTA4MTYx_fbaa98ee-bd31-46bc-96e3-50f82d6d99de"
      unitRef="usd">-42900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjQtNy0xLTEtMTA4MTYx_bce5319a-6b2d-4272-9cb5-38d263a14b34"
      unitRef="usd">-28300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjYtMS0xLTEtMTA4MTYx_539051cf-a524-4b9a-bb1c-6cbaa05ee257"
      unitRef="usd">-63900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjYtMy0xLTEtMTA4MTYx_bcffd12a-f439-4498-8534-937c1eec554c"
      unitRef="usd">-45500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjYtNS0xLTEtMTA4MTYx_fba3629f-f032-4128-947b-4e4760826576"
      unitRef="usd">-150500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjYtNy0xLTEtMTA4MTYx_03a0c0de-e391-470b-93f8-d59b807a3086"
      unitRef="usd">46900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjctMS0xLTEtMTA4MTYx_79ac3c2b-8fbb-4d90-8e51-d41930a8d023"
      unitRef="usd">11800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjctMy0xLTEtMTA4MTYx_c07e9773-22c9-4718-a24e-afe95e2a16e9"
      unitRef="usd">-12800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjctNS0xLTEtMTA4MTYx_fe0a333c-b640-4985-8c8a-482a94b63678"
      unitRef="usd">-14700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjctNy0xLTEtMTA4MTYx_96a76f98-7cc8-47a5-b4ab-cde15a0e8463"
      unitRef="usd">5300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjgtMS0xLTEtMTA4MTYx_253e1f7f-d887-4cd6-b883-76171b6bed85"
      unitRef="usd">-75700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjgtMy0xLTEtMTA4MTYx_39487e61-a2bb-40ff-8618-5f61dbd0dddb"
      unitRef="usd">-32700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjgtNS0xLTEtMTA4MTYx_d6465ecb-2daa-4d09-859e-9d7e89e053b1"
      unitRef="usd">-135800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMjgtNy0xLTEtMTA4MTYx_06a00c3a-860e-400e-a3f6-4377fcba284a"
      unitRef="usd">41600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzEtMS0xLTEtMTA4MTYx_5e98262d-d2fd-4efd-bc1e-6b65c4ff9d83"
      unitRef="usdPerShare">-1.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzEtMy0xLTEtMTA4MTYx_aa36deee-af7c-484a-9130-811f69317ed1"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzEtNS0xLTEtMTA4MTYx_738bb648-de99-43be-9023-17f22c188aab"
      unitRef="usdPerShare">-2.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzEtNy0xLTEtMTA4MTYx_8b27c2e5-b758-4092-a65e-624da4550e06"
      unitRef="usdPerShare">0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzItMS0xLTEtMTA4MTYx_781029c8-f1c5-4e9d-bb8d-dc328bd91b66"
      unitRef="usdPerShare">-1.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzItMy0xLTEtMTA4MTYx_15574572-467c-4460-bc30-41b2e6c2308a"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzItNS0xLTEtMTA4MTYx_ca0aad2d-1b29-46b8-a5f8-43432d2f6da7"
      unitRef="usdPerShare">-2.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzItNy0xLTEtMTA4MTYx_425bec35-8c1a-4428-9939-501e7746bb2d"
      unitRef="usdPerShare">0.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzUtMS0xLTEtMTA4MTYx_1c409f7a-02a1-4a65-8d78-d9f66c5f56bf"
      unitRef="shares">49900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzUtMy0xLTEtMTA4MTYx_5fe2e5a4-e464-43d2-a9f8-bedef61c3014"
      unitRef="shares">53700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzUtNS0xLTEtMTA4MTYx_1667c65c-c149-467c-b6e8-6e22106045bf"
      unitRef="shares">50200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzUtNy0xLTEtMTA4MTYx_6e8d3d54-dd37-4220-a5ba-760acd7d3a3c"
      unitRef="shares">53600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzYtMS0xLTEtMTA4MTYx_a05876a2-ee5a-43eb-b4c3-11455256f22c"
      unitRef="shares">49900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzYtMy0xLTEtMTA4MTYx_b31ffe1d-9258-4b0b-9e6c-e6ba6db77bd4"
      unitRef="shares">53700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzYtNS0xLTEtMTA4MTYx_632bdedd-eb0d-4c30-9114-a73e3a1e1a40"
      unitRef="shares">50200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8xOS9mcmFnOjVlNDI5ZWJmNjU5NjQ0MGE4OGNkZTA1YzY2YzRkYWIzL3RhYmxlOjRiZjQ5N2JmMmI4YTQ2NjVhMWI2NDYwODA2OTNlMDU5L3RhYmxlcmFuZ2U6NGJmNDk3YmYyYjhhNDY2NWExYjY0NjA4MDY5M2UwNTlfMzYtNy0xLTEtMTA4MTYx_f5807b10-fe04-45ea-8db5-474cba7b3eea"
      unitRef="shares">54300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfMi0xLTEtMS0xMDgxNjE_b80b0cd1-8ac6-4a7f-9172-f58d3706d8cf"
      unitRef="usd">-75700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfMi0zLTEtMS0xMDgxNjE_24e61322-c47c-4348-a40a-089a0d56b63f"
      unitRef="usd">-32700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfMi01LTEtMS0xMDgxNjE_bb8359bb-1b96-4423-a0c7-08b4f96b4df5"
      unitRef="usd">-135800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfMi03LTEtMS0xMDgxNjE_ce792e87-e2cc-4b10-81f5-c862f7e7c5d5"
      unitRef="usd">41600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNC0xLTEtMS0xMDgxNjE_0663daeb-a5a7-45e7-a263-0b76096fdd60"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNC0zLTEtMS0xMDgxNjE_935c6277-e974-466e-a6bb-dd048ae9506e"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNC01LTEtMS0xMDgxNjE_416f02fd-d494-4bbe-80a2-cf9a68654a52"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNC03LTEtMS0xMDgxNjE_3e78774d-00bc-49a1-9c5c-1039e4c718d5"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNS0xLTEtMS0xMDgxNjE_f2457527-6d93-4fda-9c97-73c16e7c6a29"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNS0zLTEtMS0xMDgxNjE_58106cd0-3a21-48f5-a6f8-44413c9c7bec"
      unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNS01LTEtMS0xMDgxNjE_b95a65ca-4235-4e50-a028-728f6c709d68"
      unitRef="usd">11300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNS03LTEtMS0xMDgxNjE_41cff866-548a-491a-914d-aae1770ac531"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNy0xLTEtMS0xMDgxNjE_2fbdbf63-06d5-40a5-a12d-c5c986b25d13"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNy0zLTEtMS0xMDgxNjE_203dac93-e2a1-4262-a563-0fc880edf677"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNy01LTEtMS0xMDgxNjE_a3c2c286-ba52-4909-9c2a-bfb858f021fe"
      unitRef="usd">10900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfNy03LTEtMS0xMDgxNjE_52641fd7-9434-4971-883a-6d8865ca6b99"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfOC0xLTEtMS0xMDgxNjE_41e171e9-a54d-4d0a-a972-f67f7817947f"
      unitRef="usd">-74800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfOC0zLTEtMS0xMDgxNjE_7fe48790-5176-4123-a287-dd694a2efe98"
      unitRef="usd">-33400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfOC01LTEtMS0xMDgxNjE_dd2110eb-0a50-4e6a-8ec4-bc86c84cd4c4"
      unitRef="usd">-124900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yMi9mcmFnOjMyMzBkMTA4MjhhMjRkNzliMjcyOTI2MDhmMDYzMmMxL3RhYmxlOjJlZjM4OWFiZmZjNDQ4Y2I4YmViY2VlZjU4NDE1MjA0L3RhYmxlcmFuZ2U6MmVmMzg5YWJmZmM0NDhjYjhiZWJjZWVmNTg0MTUyMDRfOC03LTEtMS0xMDgxNjE_bdf47b71-72aa-430f-aa8c-6a105fa5c537"
      unitRef="usd">43800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMy0xLTEtMS0xMDgxNjE_bac20954-d77a-45f1-ac23-4868aa768893"
      unitRef="usd">-135800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMy0zLTEtMS0xMDgxNjE_56a43668-dcea-4fbf-bc37-e50b3354da07"
      unitRef="usd">41600000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNS0xLTEtMS0xMDgxNjE_18523164-524a-494d-90bb-105fa9f9499d"
      unitRef="usd">33400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNS0zLTEtMS0xMDgxNjE_4a53a02f-a229-45da-bf9c-9071de468f8e"
      unitRef="usd">32300000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNi0xLTEtMS0xMDgxNjE_eb73dfc7-8f57-4582-bc2c-dcc4909cce24"
      unitRef="usd">107700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNi0zLTEtMS0xMDgxNjE_2ad7156e-4645-4ae6-8f34-753268892118"
      unitRef="usd">94600000</us-gaap:DepreciationDepletionAndAmortization>
    <ebs:OperatingLeaseLeaseIncomeReversal
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNy0xLTEtMS0xMDg2NDQ_549a18ee-0791-4958-870b-c85c38e7cf9f"
      unitRef="usd">0</ebs:OperatingLeaseLeaseIncomeReversal>
    <ebs:OperatingLeaseLeaseIncomeReversal
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNy0zLTEtMS0xMDg2NTA_bc1949e6-fada-4101-8474-665a618010ca"
      unitRef="usd">86100000</ebs:OperatingLeaseLeaseIncomeReversal>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNy0xLTEtMS0xMDgxNjE_4b90cd7c-1c8c-4f3a-980a-d323b1e9cd8f"
      unitRef="usd">2400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNy0zLTEtMS0xMDgxNjE_ef3c1993-0638-4629-993b-f5856f0dc6fd"
      unitRef="usd">2600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfOC0xLTEtMS0xMDgxNjE_1a92166d-16be-4eb0-8df7-8694b018b047"
      unitRef="usd">3100000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfOC0zLTEtMS0xMDgxNjE_a46d7a4a-1c69-440c-b625-0018055b4099"
      unitRef="usd">3100000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfOS0xLTEtMS0xMDgxNjE_f0cddabf-257e-498e-97b4-f2d97ad28411"
      unitRef="usd">23000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfOS0zLTEtMS0xMDgxNjE_9b576462-eea8-4f97-bf1b-ce3579bf6696"
      unitRef="usd">600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTAtMS0xLTEtMTA4MTYx_f5c01ad7-9a9c-467f-b0a4-ed7dd44acaa4"
      unitRef="usd">-13000000.0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTAtMy0xLTEtMTA4MTYx_f4b87a40-a154-4408-9390-c68d84f355be"
      unitRef="usd">-5100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTItMS0xLTEtMTA4MTYx_80cb163d-f5b9-4c60-8e30-565eefdb4ad1"
      unitRef="usd">-76200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTItMy0xLTEtMTA4MTYx_7638f477-2b43-47d4-a9a4-6f3d1f3a07ad"
      unitRef="usd">114700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTMtMS0xLTEtMTA4MTYx_9bf4e8a6-4eb7-4a4d-95f3-e774e305288a"
      unitRef="usd">112200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTMtMy0xLTEtMTA4MTYx_8f6c6551-bb5e-4ae4-8eb3-d98b458c277d"
      unitRef="usd">58000000.0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTQtMS0xLTEtMTA4MTYx_fb5e6b89-a6e6-4e9e-b4bd-43dc5bd91201"
      unitRef="usd">29200000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTQtMy0xLTEtMTA4MTYx_a2e910e6-db46-4ecb-b601-154d6b51baa2"
      unitRef="usd">54800000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTUtMS0xLTEtMTA4MTYx_4e288e87-3603-4df1-b1be-306cb6be851b"
      unitRef="usd">-9000000.0</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTUtMy0xLTEtMTA4MTYx_4c6f71fe-58ea-4b6c-8e99-32b99cc40c4b"
      unitRef="usd">3500000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTYtMS0xLTEtMTA4MTYx_abd73943-eac0-48a5-be2c-49c1b1f9c4fe"
      unitRef="usd">-98000000.0</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTYtMy0xLTEtMTA4MTYx_b2f6cb2f-22cb-41bf-b021-0f84f155ef07"
      unitRef="usd">-19300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTctMS0xLTEtMTA4MTYx_6af3e184-a9b8-4261-ae87-5c7c41152a2d"
      unitRef="usd">-5700000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTctMy0xLTEtMTA4MTYx_40772dfe-9d06-4b58-9657-89fe50a31437"
      unitRef="usd">-11100000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTgtMS0xLTEtMTA4MTYx_3cc4d707-f848-4312-8665-ef9964b26b87"
      unitRef="usd">4200000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTgtMy0xLTEtMTA4MTYx_2c830416-a63e-4779-8f6b-1345774e0e6e"
      unitRef="usd">-19500000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTktMS0xLTEtMTA4MTYx_dc489c35-1ee7-4faf-8fba-a17c29c9fcfa"
      unitRef="usd">-126900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMTktMy0xLTEtMTA4MTYx_9b89acb1-980d-423f-a7d1-11c5634bb951"
      unitRef="usd">-7900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjEtMS0xLTEtMTA4MTYx_a6cf9ae2-4ef9-427d-9610-0dd554c3f399"
      unitRef="usd">92200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjEtMy0xLTEtMTA4MTYx_a15b3979-d42b-4300-a14e-94384a18aad9"
      unitRef="usd">178300000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjMtMS0xLTEtMTIwNDY3_ba11f3b6-eef1-4ffb-9643-fe8eb2618c63"
      unitRef="usd">243700000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjMtMy0xLTEtMTIwNDgz_caf91be0-7d0a-45d8-8726-4e7d14d37fd7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjItMS0xLTEtMTA4MTYx_3734834e-9117-4cf5-9f13-84ac8363a655"
      unitRef="usd">-335900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjItMy0xLTEtMTA4MTYx_58e37fe2-7409-44af-9d83-89c76a44cc78"
      unitRef="usd">-178300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjYtMS0xLTEtMTIwNTAw_91652c35-490d-4558-9b48-112562aec4a3"
      unitRef="usd">238000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjYtMy0xLTEtMTIwNTA3_01321c99-3e68-4d93-a369-002ca466e231"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjQtMS0xLTEtMTA4MTYx_45416806-4501-4766-96e4-09f17ed3ee13"
      unitRef="usd">81900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjQtMy0xLTEtMTA4MTYx_9960ad07-51f1-433c-98b2-61c69c2f88ef"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjUtMS0xLTEtMTA4MTYx_cc601208-b3fa-4c76-a398-d6837a568edb"
      unitRef="usd">25300000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjUtMy0xLTEtMTA4MTYx_787b420b-d758-438c-a499-7781ecd64cd9"
      unitRef="usd">16900000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjYtMS0xLTEtMTA4MTYx_4f876cf2-67f0-4f6e-9fe8-78a85e7ad338"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjYtMy0xLTEtMTA4MTYx_c70322b4-b174-4071-8bbc-579f128f941b"
      unitRef="usd">10600000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjctMS0xLTEtMTA4MTYx_18ec4798-803a-4578-a2b6-7559880cb929"
      unitRef="usd">3000000.0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjctMy0xLTEtMTA4MTYx_b87ae4ce-d503-4670-9d9c-65998ec41232"
      unitRef="usd">12500000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjgtMS0xLTEtMTA4MTYx_77e1d70f-9e9d-42d8-a04c-4fbe2af8eb2c"
      unitRef="usd">5700000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjgtMy0xLTEtMTA4MTYx_6a5ad8ab-707a-46c8-947d-09794adf3144"
      unitRef="usd">13500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjktMS0xLTEtMTA4MTYx_1a7fd35f-818f-4afd-8544-b9432042509b"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMjktMy0xLTEtMTA4MTYx_ff49a48b-157d-4ea2-b25d-c495f91c75f0"
      unitRef="usd">2500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzAtMS0xLTEtMTA4MTYx_62ef582b-ac36-456c-8397-a69da9404e27"
      unitRef="usd">128100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzAtMy0xLTEtMTA4MTYx_81a7ea90-643a-4196-8110-528306d0c1ec"
      unitRef="usd">-31000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzEtMS0xLTEtMTA4MTYx_20feeb4f-1ccd-426e-aa57-bd82d5eb4a1f"
      unitRef="usd">-600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzEtMy0xLTEtMTA4MTYx_73488e58-1dfd-4b08-a27c-dc7e71ec15af"
      unitRef="usd">-300000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzItMS0xLTEtMTA4MTYx_9bc87fa4-4288-473a-9667-7641e2686025"
      unitRef="usd">-335300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzItMy0xLTEtMTA4MTYx_b5fd8256-0f93-43d6-9b32-81ae7929d1bd"
      unitRef="usd">-217500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzMtMS0xLTEtMTA4MTYx_43dafb00-e4ec-428d-a924-2f11cb05dff4"
      unitRef="usd">576300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id0444415079d48bca0450996b92c9137_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzMtMy0xLTEtMTA4MTYx_a0e37da5-c1e2-4488-bdef-b101f6345ece"
      unitRef="usd">621500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzQtMS0xLTEtMTA4MTYx_bc650727-c1d7-40a6-acd5-a681bffc785b"
      unitRef="usd">241000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc984f7cf64a4ac6ad2b90f5b12b27ea_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzQtMy0xLTEtMTA4MTYx_9ecd3816-fddb-4492-9489-eb6dc0d9e8db"
      unitRef="usd">404000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzYtMS0xLTEtMTA4MTYx_2e674529-a312-4186-ae8a-2c9a1fc3a600"
      unitRef="usd">26700000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzYtMy0xLTEtMTA4MTYx_ab85fe35-7605-4d15-a451-3fac4f9a0169"
      unitRef="usd">27300000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzctMS0xLTEtMTA4MTYx_75aa3561-9009-4b0b-9a94-e8bc428cea23"
      unitRef="usd">23900000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzctMy0xLTEtMTA4MTYx_8b96f523-adde-41ff-bc99-4dd980e38bd1"
      unitRef="usd">57600000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzktMS0xLTEtMTA4MTYx_960fca19-28c7-4a6e-ad8b-67be06e3cf0c"
      unitRef="usd">10000000.0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfMzktMy0xLTEtMTA4MTYx_35e9f9d4-cece-40cd-a078-470ed7744c48"
      unitRef="usd">20600000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDEtMS0xLTEtMTA4MTYx_92d31a7b-2acc-4641-bb90-bf7e589426c9"
      unitRef="usd">240900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDEtMy0xLTEtMTA4MTYx_8e39bc60-617d-4e4a-996a-75275cf8b07f"
      unitRef="usd">576100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDItMS0xLTEtMTA4MTYx_fd6fc330-11d4-4bc6-af63-b71bf1a6477d"
      unitRef="usd">100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDItMy0xLTEtMTA4MTYx_81677f2a-fbbe-4769-be54-bac81eb5dc1d"
      unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDMtMS0xLTEtMTA4MTYx_5c30b42a-ee6c-4495-9405-35c93744a1e2"
      unitRef="usd">241000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yNS9mcmFnOjQ3NTc3YmE0NDZhZDRjNzFhYWUyMDRlOTM5Yjk5ZGU1L3RhYmxlOmUxNGJjMGE2MzQwOTQ4YjY5YjFiYjFjMmMyYzIxYjRlL3RhYmxlcmFuZ2U6ZTE0YmMwYTYzNDA5NDhiNjliMWJiMWMyYzJjMjFiNGVfNDMtMy0xLTEtMTA4MTYx_cf00082d-0e5c-4380-bb11-8f444d6b8116"
      unitRef="usd">576300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibc984f7cf64a4ac6ad2b90f5b12b27ea_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMC0yLTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo1ZTU1YjJhYTA5MGE0MjMyOGJjNGFiNWVmNzUwZGI1OF81_3fd582c7-6d54-4fc8-91fd-ba15ae2f3775"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMC0yLTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo1ZTU1YjJhYTA5MGE0MjMyOGJjNGFiNWVmNzUwZGI1OF81_e990d616-6efe-4507-9488-6cb3ed39d621"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ief03e38f153e479b9c16cf1572d2d802_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy0yLTEtMS0xMDgxNjE_af69ac82-dbeb-44dd-a176-d4e23ccc0664"
      unitRef="shares">55100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ief03e38f153e479b9c16cf1572d2d802_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy00LTEtMS0xMDgxNjE_fa4bcdd4-8ccd-43ac-ade1-9712c889f25c"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i858bc01bcffe4fcc818b41f3490126e8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy02LTEtMS0xMDgxNjE_e71f8c5c-f154-4dd7-9332-7b273fa2635a"
      unitRef="shares">3800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i858bc01bcffe4fcc818b41f3490126e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy04LTEtMS0xMDgxNjE_40f0b3db-949c-45d2-bc5b-e501f3490979"
      unitRef="usd">-152200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i025e25b63cf240efb8c5c078757469d3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy0xMC0xLTEtMTA4MTYx_b692d6ac-0abc-4009-a6ef-4f9c46ef0bda"
      unitRef="usd">829400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4698414e7c1401c82d1bdd7bd331f7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy0xMi0xLTEtMTA4MTYx_58babfea-89dc-47f9-a4ee-4fcb1daff2af"
      unitRef="usd">-16100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73297e52dd7b4d0f94c279cc3501cbca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy0xNC0xLTEtMTA4MTYx_bae29db8-258c-416b-98a1-52e4255ff6c4"
      unitRef="usd">957800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMy0xNi0xLTEtMTA4MTYx_26310bbc-4998-48c7-ad34-dc2b8b1163a0"
      unitRef="usd">1619000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i94685af212e84378abd02869fc65b116_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNC0yLTEtMS0xMDgxNjE_e3f891f1-6a6c-4b78-aa4d-ded66dd6cb7e"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6c721871d86b4c9d92da8f3576d3c37c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNC0xMC0xLTEtMTA4MTYx_5ffbd576-1ccb-4ebb-9de8-ec8fc5953308"
      unitRef="usd">30700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNC0xNi0xLTEtMTA4MTYx_5fe65b8f-0b99-425c-83d0-ff7ae42ee50f"
      unitRef="usd">30700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i44614402dda1433ab395ed9472240cf0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNS0xNC0xLTEtMTA4MTYx_3e75f4ba-e48a-40f0-8c0e-9e9d1aadf212"
      unitRef="usd">-135800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNS0xNi0xLTEtMTA4MTYx_a4f73caa-a230-4e97-82cd-29fa32dad86b"
      unitRef="usd">-135800000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8990366d48494f1b8a20b74e61189484_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNi02LTEtMS0xMDgxNjE_e61f43fb-7b44-4b22-94c6-c096d0579041"
      unitRef="shares">1800000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8990366d48494f1b8a20b74e61189484_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNi04LTEtMS0xMDgxNjE_6e0d9b33-050d-4e01-8a33-9e2a26f6fe3d"
      unitRef="usd">75500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNi0xNi0xLTEtMTA4MTYx_fd8000ed-14df-42c4-ac8d-66af6d8da0af"
      unitRef="usd">75500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id9a84624f46d42f4b0f9c18da44b11de_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNy0xMi0xLTEtMTA4MTYx_f74ea8e2-aec5-4306-aeb9-fdfc356e24eb"
      unitRef="usd">10900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfNy0xNi0xLTEtMTA4MTYx_1db6e4f0-9215-48b0-9d7e-cba00dda13ba"
      unitRef="usd">10900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i809764d7e9a84800b82506178a13b313_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC0yLTEtMS0xMDgxNjE_1c411ab9-ed3b-4dfe-b26d-f0d6b3d3687d"
      unitRef="shares">55500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i809764d7e9a84800b82506178a13b313_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC00LTEtMS0xMDgxNjE_bd645758-7793-4f7d-9990-e4457214b2a8"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i3449978510494de9985378c4af49f5af_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC02LTEtMS0xMDgxNjE_057d5881-752b-40c6-b036-a30c31c4d2d2"
      unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i3449978510494de9985378c4af49f5af_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC04LTEtMS0xMDgxNjE_a4b7c279-1913-4748-9cf2-dcb4bf5a3c50"
      unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81d47500381c4a06a021712d3d13c022_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC0xMC0xLTEtMTA4MTYx_2d43bdc1-6f24-4c16-bc62-52537d3fc59a"
      unitRef="usd">860100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib32c62eb60fc4dc39b819eb33d2ecd33_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC0xMi0xLTEtMTA4MTYx_637b2d8a-6801-47a6-bbc4-43fd83466154"
      unitRef="usd">-5200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i88701e64171b4b4dbfc52b23a8dd15b7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC0xNC0xLTEtMTA4MTYx_a6240ac2-590e-452d-8329-605fa5834a4c"
      unitRef="usd">822000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfOC0xNi0xLTEtMTA4MTYx_00781ffe-ed1c-491a-88e2-2efb25780312"
      unitRef="usd">1449300000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7c07897dcdde4d89a128d2ed15fc5ad1_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtMi0xLTEtMTA4MTYx_9c7c4ce8-1ecb-4e61-9d25-eae71ef303f8"
      unitRef="shares">55500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7c07897dcdde4d89a128d2ed15fc5ad1_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtNC0xLTEtMTA4MTYx_f9a580cf-c011-47cf-8c4c-8c503ecbd589"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i14f2fb7cdf644c66b524b020f443b7a3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtNi0xLTEtMTA4MTYx_aa3e6865-9486-431a-85f3-209f74220ac5"
      unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i14f2fb7cdf644c66b524b020f443b7a3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtOC0xLTEtMTA4MTYx_a2559b0f-927e-4514-b663-2307e1d75ba2"
      unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65f2af0d2c0b4a15bc6e7423ba835ade_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtMTAtMS0xLTEwODE2MQ_781025eb-9a45-4108-a0f7-ae82176990fe"
      unitRef="usd">849200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i215adb10fcbf40a5a7ec2fc2088354e3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtMTItMS0xLTEwODE2MQ_230b85ce-37dd-4ae8-a9e7-b39282eaa623"
      unitRef="usd">-6100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i86413dba3b9141c89275b7ef4f89903a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtMTQtMS0xLTEwODE2MQ_20435e3c-c171-4739-80ea-4b6544b6a578"
      unitRef="usd">897700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i513d610eeb964439903192db1ecb51ed_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTAtMTYtMS0xLTEwODE2MQ_bd445e04-672a-4d4e-ab10-9c646845a386"
      unitRef="usd">1513200000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibc0fb7f94b4b4633bba35f83b8ce0a44_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTEtMTAtMS0xLTEwODE2MQ_c6ae2f61-6732-41c9-aef4-81a0320e3bba"
      unitRef="usd">10900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTEtMTYtMS0xLTEwODE2MQ_9978b0fb-9f8f-4679-a12e-4513b8a7253c"
      unitRef="usd">10900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i1d3b9f37fd21490c816e8c33b0d191df_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTItMTQtMS0xLTEwODE2MQ_2135ccd4-423b-4d7d-af40-04f2d7a23854"
      unitRef="usd">-75700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTItMTYtMS0xLTEwODE2MQ_28e236e8-0dbe-4b7d-92ed-a0300d2da4ff"
      unitRef="usd">-75700000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTMtMTYtMS0xLTEwODE2MQ_121d12f2-b1b3-4a0c-a892-8c72033eb3e7"
      unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i97535e302cdd4eae990d766576feefac_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTQtMTItMS0xLTEwODE2MQ_bd1b8d69-6eec-4f92-9c35-01ee9e11c68e"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTQtMTYtMS0xLTEwODE2MQ_0b583455-f9ee-4b14-b052-672a07b6d37d"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i809764d7e9a84800b82506178a13b313_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtMi0xLTEtMTA4MTYx_f8eb534d-54a7-42ba-8e1a-3b4660ae070c"
      unitRef="shares">55500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i809764d7e9a84800b82506178a13b313_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtNC0xLTEtMTA4MTYx_3b6a2266-312e-4e6f-b888-c898920eade7"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i3449978510494de9985378c4af49f5af_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtNi0xLTEtMTA4MTYx_ce45606b-3c85-45e6-b325-da1f144ebfca"
      unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i3449978510494de9985378c4af49f5af_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtOC0xLTEtMTA4MTYx_f75e3be8-6024-4f43-b4ec-fca2dacee779"
      unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81d47500381c4a06a021712d3d13c022_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtMTAtMS0xLTEwODE2MQ_83a26a15-700c-4bc6-abda-7d5aca8dc650"
      unitRef="usd">860100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib32c62eb60fc4dc39b819eb33d2ecd33_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtMTItMS0xLTEwODE2MQ_8cb7dfcc-1f2f-4a4a-ac02-26d3f32a59b3"
      unitRef="usd">-5200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i88701e64171b4b4dbfc52b23a8dd15b7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtMTQtMS0xLTEwODE2MQ_67565c5d-e6ac-4c61-af27-b45e74edb9bc"
      unitRef="usd">822000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTUtMTYtMS0xLTEwODE2MQ_58e8b702-6e53-4bea-8c0e-2d87c0f46d57"
      unitRef="usd">1449300000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i61f687c252da498ea3071b9bef0dae99_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctMi0xLTEtMTA4MTYx_75e5935e-a275-4981-b58d-ad269e4019c7"
      unitRef="shares">54300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i61f687c252da498ea3071b9bef0dae99_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctNC0xLTEtMTA4MTYx_411ed535-45d5-41fc-916f-b3dda5054c53"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i345b6ed13f3d4fe5a3c2aa0fb402b26c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctNi0xLTEtMTA4MTYx_709fe501-e625-4628-b3eb-248da6d3c6fe"
      unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i345b6ed13f3d4fe5a3c2aa0fb402b26c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctOC0xLTEtMTA4MTYx_ee6c3f46-7ce3-4880-bce9-9ad56bfc5086"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e607ecbd5b74b8c8b0184925410bf01_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctMTAtMS0xLTEwODE2MQ_58a3b5e3-7a6b-40f2-9900-41284dff4e0b"
      unitRef="usd">784900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9334dc4e6d884a7cbb7f455bf2f9af61_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctMTItMS0xLTEwODE2MQ_28d71b92-2863-4a28-9e32-5fdfead8071b"
      unitRef="usd">-25300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4fc5b8a85402486c8e7e3ae07b0a3871_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctMTQtMS0xLTEwODE2MQ_b96d03e4-66f8-4b43-9259-607e6e41b70d"
      unitRef="usd">726900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id0444415079d48bca0450996b92c9137_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTctMTYtMS0xLTEwODE2MQ_0b504fa1-b571-4378-9a5f-b3e48e771b4a"
      unitRef="usd">1447000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9f4e99d6d47b4c0faf6ea720533b7521_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTgtMi0xLTEtMTA4MTYx_47c977f0-d1da-44c7-8149-92e4c967b788"
      unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1ccbc79df52c4d15b022b9a21c0ca27a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTgtMTAtMS0xLTEwODE2MQ_8081e723-f02d-4a8c-a704-7a21ffc57eea"
      unitRef="usd">31900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTgtMTYtMS0xLTEwODE2MQ_c77b088e-62d6-48f6-9b1f-54d21562bb93"
      unitRef="usd">31900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i03643882b32948aa88d7c7088c47243d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTktMTQtMS0xLTEwODE2MQ_5b774d17-db23-4dc0-8494-a571d4e71a54"
      unitRef="usd">41600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMTktMTYtMS0xLTEwODE2MQ_4d933147-e287-4dce-9729-492839a08675"
      unitRef="usd">41600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1907d7b857734e8fa8e27c5ba195c7cd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjAtMTItMS0xLTEwODE2MQ_487e96cc-681a-428f-90b8-2388de36c80e"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjAtMTYtMS0xLTEwODE2MQ_fa5c01c0-754a-4b1b-8c99-ad49e1fc22c2"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9501b3606d3748baa7f730985abc93d3_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtMi0xLTEtMTA4MTYx_d04fbad4-82c7-4af2-abf8-661503114e5a"
      unitRef="shares">54900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9501b3606d3748baa7f730985abc93d3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtNC0xLTEtMTA4MTYx_1a07d4af-5773-48e3-84a4-d6499ece8121"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i120aedf84da0491da3c474183e2c4892_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtNi0xLTEtMTA4MTYx_d23bfd0c-9e8e-469b-8817-70fb031bac48"
      unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i120aedf84da0491da3c474183e2c4892_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtOC0xLTEtMTA4MTYx_72f38b5a-41a7-4b02-9708-822ae2d47775"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b982988d59741509a3340a4affea571_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtMTAtMS0xLTEwODE2MQ_9c105b26-bca8-4573-9265-ef5e3df9acd4"
      unitRef="usd">816800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i234810222a77469a8d310e47d2fa2f03_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtMTItMS0xLTEwODE2MQ_92653597-60aa-464f-a0c1-af12a0b06fca"
      unitRef="usd">-23100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3d773caeec44dac875f1fc14041b176_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtMTQtMS0xLTEwODE2MQ_93e6fa8b-7a87-47c3-a8a0-615b7db63239"
      unitRef="usd">768500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc984f7cf64a4ac6ad2b90f5b12b27ea_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjEtMTYtMS0xLTEwODE2MQ_8ab81c42-70c0-4b5b-b7d3-e29d80a27ade"
      unitRef="usd">1522700000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iebd066da54a34dadb2cfaddc80097222_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtMi0xLTEtMTA4MTYx_a6037c19-83cb-4c53-8887-5f468bb27ba9"
      unitRef="shares">54900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iebd066da54a34dadb2cfaddc80097222_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtNC0xLTEtMTA4MTYx_48c529de-79bd-4c18-aab8-30b6f600439b"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i61a54d77cf52423fa152a2b6df738697_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtNi0xLTEtMTA4MTYx_8f43c715-abeb-4aab-8bfe-abd4642978a0"
      unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i61a54d77cf52423fa152a2b6df738697_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtOC0xLTEtMTA4MTYx_d6ce6c96-14a0-40b2-87c4-e4ad72114f8d"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2109c764e423427782835d0108e52bb0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtMTAtMS0xLTEwODE2MQ_8285eb54-8ee9-4051-bfad-d3d8cd41c295"
      unitRef="usd">804400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e6a2188c167465d9720bcd73f722dcd_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtMTItMS0xLTEwODE2MQ_e7bcafd0-14eb-4024-af5d-30fd17c55efb"
      unitRef="usd">-22400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib96436736dac42149fc4524b381689e6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtMTQtMS0xLTEwODE2MQ_b06b984e-d8a0-45fa-963c-6308b9cc28be"
      unitRef="usd">801200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iafc0f0f6c6e34f86a10f18a780bc594b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjMtMTYtMS0xLTEwODE2MQ_44fca5fc-1444-49d6-be20-0943f82622d7"
      unitRef="usd">1543700000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if472db7e4ddc4d8abb7803c05ad8a4fc_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjQtMTAtMS0xLTEwODE2MQ_de1d99c3-e7d0-4c23-ba74-4fe38a2c6cc1"
      unitRef="usd">12400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjQtMTYtMS0xLTEwODE2MQ_9a05a875-609e-4682-98d1-9e39739634d2"
      unitRef="usd">12400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="ia3ae0efe55364ceebbd48beeaa1b5f0d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjUtMTQtMS0xLTEwODE2MQ_4a729790-c506-416d-bf69-d315c3babcad"
      unitRef="usd">-32700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjUtMTYtMS0xLTEwODE2MQ_638a810b-386c-4391-a25d-c7a547760d34"
      unitRef="usd">-32700000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i249e76b2e30b449d9cd1d10e9e44a617_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjYtMTItMS0xLTEwODE2MQ_d6e7d952-226c-4927-b787-75fc3530e839"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjYtMTYtMS0xLTEwODE2MQ_0a98f1b2-78d2-4003-9b3d-3b312d0c8f2c"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9501b3606d3748baa7f730985abc93d3_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctMi0xLTEtMTA4MTYx_c49a3739-4631-4168-8de2-1a40fb0d3bb7"
      unitRef="shares">54900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9501b3606d3748baa7f730985abc93d3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctNC0xLTEtMTA4MTYx_b24c0931-eb5e-428f-9615-09189cf330dd"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i120aedf84da0491da3c474183e2c4892_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctNi0xLTEtMTA4MTYx_3cbc7a3b-3160-4757-81aa-8dbe57e38a87"
      unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i120aedf84da0491da3c474183e2c4892_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctOC0xLTEtMTA4MTYx_0345adf7-d2d9-4603-ac79-900786bb93c7"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b982988d59741509a3340a4affea571_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctMTAtMS0xLTEwODE2MQ_8bb4063e-948f-4f6c-af24-566237056b11"
      unitRef="usd">816800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i234810222a77469a8d310e47d2fa2f03_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctMTItMS0xLTEwODE2MQ_cec5aaaf-62ce-4959-a077-388eedb29056"
      unitRef="usd">-23100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3d773caeec44dac875f1fc14041b176_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctMTQtMS0xLTEwODE2MQ_31e74eac-e480-4d15-9f7c-418e549aea05"
      unitRef="usd">768500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc984f7cf64a4ac6ad2b90f5b12b27ea_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8yOC9mcmFnOjg4ZmRlZjVjNzViNTQ3YjRhNThkNjQxOGMxM2I5MDUxL3RhYmxlOjg5ZDRjMzg3YThkNDRkZGM5YzYxOTBjZDhiMjc2YmFkL3RhYmxlcmFuZ2U6ODlkNGMzODdhOGQ0NGRkYzljNjE5MGNkOGIyNzZiYWRfMjctMTYtMS0xLTEwODE2MQ_8bdd325d-45fb-4536-95d1-1ac58df491b3"
      unitRef="usd">1522700000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfODQwNg_58d25b86-e2b8-48a7-ab66-3774f20ca440">Business&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Emergent BioSolutions Inc. (&#x201c;Emergent,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d;) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (CDMO) services portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is focused on the following five distinct PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; and acute/emergency care. The Company has a product portfolio of thirteen products (vaccines, therapeutics and drug-device combination products). The revenue generated by the products comprises a substantial portion of the Company's revenue. The Company also has one product candidate that is procured under special circumstances by the U.S. government (USG), although it is not approved by the U.S. Food and Drug Administration (FDA). The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include the following three business lines: Government - Medical Countermeasures (MCM) Products, Commercial Products, and CDMO Services. The Company operates as two operating segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and 2) a services segment (Services) focused on CDMO (Note 14, "&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment information"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Company's products and services include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Government - MCM Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;AV7909&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, is a procured product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has largely switched from procuring BioThrax to AV7909 for the Strategic National Stockpile (SNS) prior to its approval by the FDA;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;BioThrax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the only vaccine licensed by the FDA, for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;ACAM2000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;BAT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of botulism; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;CNJ-016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, also referred to as VIGIV, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Raxibacumab injection, a fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Anthrasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;RSDL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Trobigard&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;atropine sulfate, obidoxime chloride AUTO-INJECTOR, is a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA, but it is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;TEMBEXA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. It has been approved by the FDA for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Ebanga&#x2122; (ansuvimab-zykl, formerly referred to as mAb114) is a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#x2122; in the United States and Canada, and Ridgeback Biotherapeutics will serve as the global access partner for Ebanga&#x2122;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;NARCAN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Vaxchora&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Cholera Vaccine, Live, Oral), the only single-dose oral vaccine licensed by the FDA and the European Medicines Agency (EMA) for the prevention of cholera; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Vivotif&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Services - Contract Development and Manufacturing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's services line focused on CDMO offerings covers development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided to customers spanning the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale.&#160;Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2022, the Company acquired from Chimerix ("the Seller") the exclusive worldwide rights to brincidofovir, including TEMBEXA&#xae; and related assets (the &#x201c;Transaction&#x201d;). TEMBEXA is a medical countermeasure for smallpox approved by the FDA in June 2021. Under the terms of the Asset Purchase Agreement (the "Purchase Agreement"), the Company paid $238.0&#160;million upon closing of the Transaction, and is subject to potential milestone payments of up to $124.0&#160;million contingent on the potential exercise by the U.S. government of procurement options. The closing payment and the milestone payments were based on the actual procurement value of the procurement contract (the "BARDA Contract") with the Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;). Each milestone payment is associated with the exercise of future BARDA procurement options of TEMBEXA following the BARDA Contract base period. The Seller is also eligible to receive up to $12.5&#160;million in regulatory milestones associated with the SymBio Pharmaceuticals Ltd. brincidofovir licensing arrangements assumed by the Company in the Transaction. The milestone payments will be recorded when the associated procurement options have been exercised and/or the regulatory milestones have been met and the consideration is paid or becomes payable.&lt;/span&gt;&lt;/div&gt;The Seller may also earn a 20% royalty on future gross profit of TEMBEXA in the United States associated with volumes above 1.7&#160;million treatment courses of therapy during the exclusivity period of TEMBEXA. Outside of the United States, the Purchase Agreement also allows the Seller to earn a 15% royalty on all gross profit associated with TEMBEXA sales during the exclusivity period of TEMBEXA on a market-to-market basis. Refer to Note 6, "Intangible assets" for additional information around the impacts of this asset acquisition on the current period results.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ebs:NumberOfCategoriesOfPublicHealthThreats
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfNDY4_ac0a937b-c257-4176-88b3-736294688783"
      unitRef="category">5</ebs:NumberOfCategoriesOfPublicHealthThreats>
    <ebs:NumberOfRevenueGeneratingProducts
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfODQxMA_c3cf6f70-0535-4bcd-8dd9-54c2123bcac4"
      unitRef="product">13</ebs:NumberOfRevenueGeneratingProducts>
    <ebs:NumberOfProductCandidates
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfODQwOA_4a67b6d0-adc1-41e8-bf08-ee478a7d931d"
      unitRef="productcandidate">1</ebs:NumberOfProductCandidates>
    <ebs:NumberOfBusinessLines
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMjE5OTAyMzI3NTI4Mw_ae8ed2a0-eee6-4184-80ce-cecaa8310b67"
      unitRef="businessline">3</ebs:NumberOfBusinessLines>
    <us-gaap:NumberOfReportableSegments
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTY0OTI2NzQ2MTM1Nw_83999cc4-ff49-48c3-9fd0-714701d38614"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTY0OTI2NzQ2MTM1Nw_ec67a01a-2c1e-4636-9b75-53d42761c544"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc2ODc_335c1290-5885-4147-8a8e-5abcf329e745"
      unitRef="usd">238000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="i26c8454cef2f47789cf2d3ee6746429f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc2ODM_48724e82-9d33-4172-b085-664c70a5cd30"
      unitRef="usd">124000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="i6d15cdbf01f5414d8ebe10c27040be71_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc2OTU_89be3214-89d1-4845-9a99-aa3b598b8f24"
      unitRef="usd">12500000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <ebs:AssetAcquisitionDomesticGrossProfitRoyaltyPercentage
      contextRef="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc2OTk_1fa6d505-2457-414d-823d-c3ebd65f7a16"
      unitRef="number">0.20</ebs:AssetAcquisitionDomesticGrossProfitRoyaltyPercentage>
    <ebs:AssetAcquisitionTreatmentVolumeThreshold
      contextRef="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc3MDM_dd18ae55-8aa5-4587-8250-9f714cec5a68"
      unitRef="treatmentcourse">1700000</ebs:AssetAcquisitionTreatmentVolumeThreshold>
    <ebs:AssetAcquisitionInternationalGrossProfitRoyaltyPercentage
      contextRef="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNC9mcmFnOmVkNDhhMjIwMTIwYTQxYjVhMTg1OTU1YWQ1NTM5NzU2L3RleHRyZWdpb246ZWQ0OGEyMjAxMjBhNDFiNWExODU5NTVhZDU1Mzk3NTZfMTc3MDc_15ab7fb0-fd9c-4ea4-b0bf-6a72dbf2fef4"
      unitRef="number">0.15</ebs:AssetAcquisitionInternationalGrossProfitRoyaltyPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYyNQ_0a47874b-d76a-4fe6-a17f-d2b20fff7072">Basis of presentation and principles of consolidation&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September&#160;30, 2022. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, there is $238.0&#160;million outstanding on the revolver loan and $371.3&#160;million on the term loan that matures in October 2023, which is within one year of the date that the consolidated financial statements are issued for the quarter ended September&#160;30, 2022. The Company determined that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation considered the potential mitigating effect of management&#x2019;s plans that have not been fully implemented. Management may evaluate the mitigating effect of its plans to determine if it is probable that (1) the plans will be effectively implemented within one year after the date the financial statements are issued, and (2) when implemented, the plans will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern. The Company's plan to alleviate the substantial doubt includes amending its existing revolver loan and term loan that are due October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Company is in the process of and expects to replace the current credit facility before it matures, management cannot make the assumption that it is probable that the Company will be able to obtain such debt refinancing on commercially reasonable terms or at all until the new credit facility is in place. The Company is currently working with its lenders and expects to refinance the credit facility with revised terms and conditions. The extent to which the Company will be able to affect such refinancing, replacement or maturity extension on terms that are favorable or at all is dependent on a number of uncertain factors, including then-prevailing credit and other market conditions, economic conditions, particularly in the pharmaceutical and biotechnology industry, disruptions or volatility caused by factors such as COVID-19, regional conflicts, inflation, and supply chain disruptions. In addition, rising interest rates could limit our ability to refinance our existing credit facility when it matures or cause us to pay higher interest rates upon refinancing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the replacement of the Company&#x2019;s current debt facility is conditional upon the execution of agreements with new or existing third parties, which are considered outside of the Company&#x2019;s control, until such time as they are completed, the refinancing cannot be considered to be probable to occur as of the date of this report. The Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC that have materially impacted the presentation of the Company's financial statements. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company revised the reporting that the chief operating decision maker ("the CODM") reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) Products segment consisting of the Government - MCM and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial business lines and 2) Services segment focused on CDMO. This change is further outlined in Note 14, "Segment information".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1) and time deposits (level 2), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7, "Fair value measurements" and Note 8, "Derivative instruments and hedging activities").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On a non-recurring basis, the Company measures its long-lived assets as part of impairment evaluations using fair value measurements. Goodwill is allocated to the Company's reporting units, which are one level below its operating segments. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and earlier if an event or other circumstance indicates that the carrying value of the asset may not be recoverable. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required. Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, long-lived assets are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when there is an adverse change in the market relating to those related assets. The impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. Determining the need for a detailed impairment analysis requires the exercise of judgment about several business factors, including the timing of expected future cash flows and assumptions about the economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the Company had no other significant assets or liabilities that were measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently issued accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) that the Company adopts as of the pronouncement's specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Topic 848, which was further amended in January 2021. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. It contains optional expedients and exceptions to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. As of September 30, 2022, the Company adopted this ASU with no material impact to our consolidated financial statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYzNA_4a64b276-28a1-4a25-a0a2-dc687770442b">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of September&#160;30, 2022. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i7432986424e74ac09ac1dd272585adcb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfMTY0OTI2NzQ2MjU2NA_f9e61e44-2f94-490d-b140-aabc66732e1e"
      unitRef="usd">238000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icb0a527f718246d39439945aa519e89c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfMTY0OTI2NzQ2MjU4MQ_af49451e-dbf8-4012-9a2f-7fa7ce9300e5"
      unitRef="usd">371300000</us-gaap:LongTermDebt>
    <us-gaap:NumberOfReportableSegments
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYyNg_83999cc4-ff49-48c3-9fd0-714701d38614"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYyNg_ec67a01a-2c1e-4636-9b75-53d42761c544"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYyNA_61824e62-0260-4b5d-bd39-eedd59f4bc16">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1) and time deposits (level 2), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7, "Fair value measurements" and Note 8, "Derivative instruments and hedging activities"). On a non-recurring basis, the Company measures its long-lived assets as part of impairment evaluations using fair value measurements. Goodwill is allocated to the Company's reporting units, which are one level below its operating segments. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and earlier if an event or other circumstance indicates that the carrying value of the asset may not be recoverable. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required. Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, long-lived assets are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when there is an adverse change in the market relating to those related assets. The impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. Determining the need for a detailed impairment analysis requires the exercise of judgment about several business factors, including the timing of expected future cash flows and assumptions about the economic environment.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml8zNy9mcmFnOmZhN2FjYjMxN2RkZjRjYWNiN2RjOWM4ZDAxNmIyZDg0L3RleHRyZWdpb246ZmE3YWNiMzE3ZGRmNGNhY2I3ZGM5YzhkMDE2YjJkODRfNTYyNw_f83b6aec-cb93-469a-b7e9-9341a10eeac6">&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Topic 848, which was further amended in January 2021. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. It contains optional expedients and exceptions to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. As of September 30, 2022, the Company adopted this ASU with no material impact to our consolidated financial statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RleHRyZWdpb246NmM0MjkyNzUzNGI2NDY3NDk4NWRhOWEzZDdlNWYwOGFfMzY5_0dec93c7-d29b-40f7-8ced-67be9d740391">Inventories, net&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;217.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;138.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;130.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total inventories, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;546.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;350.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt; During the three months ended September 30, 2022, the Company acquired certain assets through an asset acquisition, the Transaction, and the related inventories of $84.8 million were included in our inventories balances as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is stated at the lower of cost or net realizable value&lt;/span&gt;. For additional information related to the termination of the manufacturing services agreement (the &#x201c;Agreement&#x201d;) with Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;) and associated evaluation of inventory as of September&#160;30, 2022, refer to Note 10, "Revenue recognition."</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RleHRyZWdpb246NmM0MjkyNzUzNGI2NDY3NDk4NWRhOWEzZDdlNWYwOGFfMzY2_3ae37e8e-e1ab-43a1-9028-316f33288f18">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;277.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;217.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;138.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;130.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total inventories, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;546.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;350.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt; During the three months ended September 30, 2022, the Company acquired certain assets through an asset acquisition, the Transaction, and the related inventories of $84.8 million were included in our inventories balances as of September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMS0xLTEtMS0xMDgxNjE_e222795a-74c5-4f87-9f34-d3534f826786"
      unitRef="usd">277400000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMS0zLTEtMS0xMDgxNjE_8ef6b87d-9c59-4d66-a4cf-dc1bd19341bf"
      unitRef="usd">217500000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMi0xLTEtMS0xMDgxNjE_5a05c438-d572-4fc1-a1e9-5ad0ca6aba38"
      unitRef="usd">138300000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMi0zLTEtMS0xMDgxNjE_74a0ab9a-f398-4fec-a3ce-e5a6b05853b2"
      unitRef="usd">95800000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMy0xLTEtMS0xMDgxNjE_698e87fd-42f4-4afe-a9bd-ed3e47e5f984"
      unitRef="usd">130600000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfMy0zLTEtMS0xMDgxNjE_8123e087-1220-4601-b4a9-b63dec09c755"
      unitRef="usd">37500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfNC0xLTEtMS0xMDgxNjE_a9145300-c8eb-41e6-8099-3adee457b5b2"
      unitRef="usd">546300000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfNC0zLTEtMS0xMDgxNjE_dc8422ec-0821-4edc-bbaf-6d03a852cd15"
      unitRef="usd">350800000</us-gaap:InventoryNet>
    <ebs:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i0a5d3c91817245f8a781e98678ca71b4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80MC9mcmFnOjZjNDI5Mjc1MzRiNjQ2NzQ5ODVkYTlhM2Q3ZTVmMDhhL3RhYmxlOjY2NzJmMTFlZDVhYzRkMGJiYjQ5YjMyMWMzZjk3M2QyL3RhYmxlcmFuZ2U6NjY3MmYxMWVkNWFjNGQwYmJiNDliMzIxYzNmOTczZDJfNS0wLTEtMS0xMTI2ODYvdGV4dHJlZ2lvbjozMWQxMjMxMTk2NDc0Yjc5YTVlYzEwOGE2ODQ3YTY5YV80OTQ3ODAyMzI1ODgx_e0f39e10-8ac5-44d0-b0aa-310fb9212e3b"
      unitRef="usd">84800000</ebs:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RleHRyZWdpb246ZTkzMzllM2UyZDc3NGYxMGE5Mjg5ZGZiMzA2MjI1YzJfNzI3_ffc7dc2f-3711-4767-b0e8-af4c66c2a5f8">Property, plant and equipment, net&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;321.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;269.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;551.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;513.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;65.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;181.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;223.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,172.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Less: Accumulated depreciation &amp;amp; amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(366.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(319.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;806.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;800.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022 and December&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, construction-in-progress primarily included costs incurred related to construction to advance the Company's CDMO capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. During the nine months ended September 30, 2022, the Company recorded accelerated depreciation of $12.7&#160;million reflecting a shortening of the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement with Janssen. For additional information related to the termination of the Agreement, refer to Note 10, "Revenue recognition".&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RleHRyZWdpb246ZTkzMzllM2UyZDc3NGYxMGE5Mjg5ZGZiMzA2MjI1YzJfNzI5_48b49c3b-8abd-4f17-b9b5-09beb7f6d1df">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;321.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;269.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;551.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;513.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;65.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;181.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;223.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,172.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Less: Accumulated depreciation &amp;amp; amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(366.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(319.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;806.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;800.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ief03c3babd264580b8f993d58e2f7399_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMS0xLTEtMS0xMDgxNjE_5666d7fa-f6c4-4680-a3a0-bf4bb500c6ce"
      unitRef="usd">53500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i432591c3907547a4a78ac6a89b2d6d9b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMS0zLTEtMS0xMDgxNjE_b8b5c6bc-3e8e-4b4e-a93d-2d36ec98e03b"
      unitRef="usd">52100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i749bb1b516384ad09235dfaddfccbfb3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMi0xLTEtMS0xMDgxNjE_86a769f9-2ac3-4888-83b6-c2811586728a"
      unitRef="usd">321900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ide2d35bc08594b3ea21d8f60f7762840_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMi0zLTEtMS0xMDgxNjE_ee195bf7-6b43-49c1-86de-101914f8b49b"
      unitRef="usd">269700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6cf3406660784396880636ec6d64ce18_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMy0xLTEtMS0xMDgxNjE_332332ba-39be-4ef0-aedc-140fa378f9c2"
      unitRef="usd">551200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7b571dae77f04edfb1556f8d08c9d6e4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfMy0zLTEtMS0xMDgxNjE_d43cb88d-7462-4d14-aaf8-3855b3a7620d"
      unitRef="usd">513500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i766a15cf4ffb4c6d8115bd955a940932_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNC0xLTEtMS0xMDgxNjE_352e9024-bcfd-41aa-8c96-027791079127"
      unitRef="usd">65300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icdc0a33e12b849de810968cc193f06d8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNC0zLTEtMS0xMDgxNjE_588646e0-7d90-4b38-9058-9c040ea7cdcb"
      unitRef="usd">60700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if3d94b6f79364cc1899b13f7a72f0e27_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNS0xLTEtMS0xMDgxNjE_effb368c-a1aa-41e5-9da1-688edd014f4f"
      unitRef="usd">181000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1e27b276ca764530b7005d22d6316077_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNS0zLTEtMS0xMDgxNjE_d8753574-304b-41a6-bb07-ce70d2f3e0d7"
      unitRef="usd">223200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNi0xLTEtMS0xMDgxNjE_efbcb9b9-0e97-4ca9-bbd8-82dca321aa42"
      unitRef="usd">1172900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNi0zLTEtMS0xMDgxNjE_e560eff6-96fb-4214-90ba-7a04f458acac"
      unitRef="usd">1119200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNy0xLTEtMS0xMDgxNjE_b6e07e6d-64e6-4848-8931-7203a541efa4"
      unitRef="usd">366200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfNy0zLTEtMS0xMDgxNjE_62621336-63f4-4066-b108-475eead88146"
      unitRef="usd">319100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfOC0xLTEtMS0xMDgxNjE_ea7085b1-591c-48ef-9ea8-fbac1d53d393"
      unitRef="usd">806700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RhYmxlOmQ3MTI4OTU5YWY3YzQyNTNiMGIzOGYxNjA5OGE2NjU5L3RhYmxlcmFuZ2U6ZDcxMjg5NTlhZjdjNDI1M2IwYjM4ZjE2MDk4YTY2NTlfOC0zLTEtMS0xMDgxNjE_8acffe19-c3c6-423a-9187-ab9e041513c0"
      unitRef="usd">800100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i50157349177f44679e4ff5b00c2b690a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80My9mcmFnOmU5MzM5ZTNlMmQ3NzRmMTBhOTI4OWRmYjMwNjIyNWMyL3RleHRyZWdpb246ZTkzMzllM2UyZDc3NGYxMGE5Mjg5ZGZiMzA2MjI1YzJfMTU1MA_a6d14366-6a8b-493f-8a36-bd6f21cbb9de"
      unitRef="usd">12700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RleHRyZWdpb246ODlkM2E4NjJhMzBhNDA2Y2EwOTAxODg5NGJjM2U2MTdfNjgz_efe1405e-ecbe-470a-a1dd-08bac6a2cd1c">Leases&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is the lessee for operating leases for offices, research and development facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. For a discussion of lessor activities, see Note 10, "Revenue recognition".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are reflected as components of cost of product sales, cost of contract development and manufacturing, research and development expense and selling, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to lessee activities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions, except lease term and discount rate)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_5151ab9f-c47e-463d-8aa2-48943e0afded"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_fa39117a-d454-4120-99bf-3662bcd5aca2"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;20.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;28.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_4cea9722-b807-4cb6-aacd-3b045145d7ac"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_55a8c7c0-1418-4c46-86d6-6bf5a5d3114f"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_1a37c2b9-d83a-4cc7-9218-97115c59e9de"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_e5713eb8-636e-4658-b39f-755a6d1cadca"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;24.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;21.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;30.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the three months ended September 30, 2022, the Company exercised the option to purchase our Rockville manufacturing facility. As a result, the Company removed the related operating lease right-of-use asset and operating lease liability of $3.5&#160;million and $3.4&#160;million, respectively. The purchased assets have been properly included in "Property, plant and equipment, net" on our condensed consolidated balance sheet as of September&#160;30, 2022.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RleHRyZWdpb246ODlkM2E4NjJhMzBhNDA2Y2EwOTAxODg5NGJjM2U2MTdfNjc4_5ce64689-00a2-4071-a03f-876b5a4c5b13">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfMy0xLTEtMS0xMDgxNjE_10482b52-a213-449b-b451-5352f054fd0e"
      unitRef="usd">1400000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfMy0zLTEtMS0xMDgxNjE_952606e5-403b-49ae-b860-9ec438eddb72"
      unitRef="usd">1400000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfMy01LTEtMS0xMDgxNjE_c359f0dc-91c3-45b0-b81d-303347690b08"
      unitRef="usd">4200000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfMy03LTEtMS0xMDgxNjE_d6b3ba6c-a8c6-422d-b31b-199aac34b9b8"
      unitRef="usd">4200000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNC0xLTEtMS0xMDgxNjE_8f09756a-f4ba-4a92-afce-ad80ca3111bf"
      unitRef="usd">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNC0zLTEtMS0xMDgxNjE_502e8092-d0c8-4a84-9c9e-fcdba47cb970"
      unitRef="usd">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNC01LTEtMS0xMDgxNjE_2b08aa0a-31b2-4d97-b1b3-cfb98ce771f2"
      unitRef="usd">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNC03LTEtMS0xMDgxNjE_eda25699-3c16-4f76-9368-3779893e13d5"
      unitRef="usd">1000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCost
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNS0xLTEtMS0xMDgxNjE_c080c289-a932-415c-8db2-6a9516d725e5"
      unitRef="usd">1700000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNS0zLTEtMS0xMDgxNjE_42dfc25c-7250-4c60-a460-c50ad72004ba"
      unitRef="usd">1700000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNS01LTEtMS0xMDgxNjE_6e9aac66-a3fe-497d-a143-9ab991cb470c"
      unitRef="usd">5000000.0</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOjU1YjEzY2YxNjhkNzQ4NGFiOTlhODM0OWFlNjk5ODc1L3RhYmxlcmFuZ2U6NTViMTNjZjE2OGQ3NDg0YWI5OWE4MzQ5YWU2OTk4NzVfNS03LTEtMS0xMDgxNjE_ffb4e495-3a54-423a-88db-315ade4afac0"
      unitRef="usd">5200000</us-gaap:LeaseCost>
    <ebs:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RleHRyZWdpb246ODlkM2E4NjJhMzBhNDA2Y2EwOTAxODg5NGJjM2U2MTdfNjg3_9e9ad412-bb43-45ca-876f-5e278993c262">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to lessee activities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In millions, except lease term and discount rate)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_5151ab9f-c47e-463d-8aa2-48943e0afded"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0xLTEtMS0xMDgxNjE_fa39117a-d454-4120-99bf-3662bcd5aca2"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;20.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;28.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_4cea9722-b807-4cb6-aacd-3b045145d7ac"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0xLTEtMS0xMDgxNjE_55a8c7c0-1418-4c46-86d6-6bf5a5d3114f"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_1a37c2b9-d83a-4cc7-9218-97115c59e9de"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0xLTEtMS0xMDgxNjE_e5713eb8-636e-4658-b39f-755a6d1cadca"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;24.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;21.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;30.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ebs:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS0zLTEtMS0xMDgxNjE_eea7890f-bdf8-4aec-9e2c-6862c5a2214a"
      unitRef="usd">20500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMS01LTEtMS0xMDgxNjE_b21686cf-a910-4f69-9298-f8a218a4a195"
      unitRef="usd">28300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy0zLTEtMS0xMDgxNjE_eaf876bf-c61a-4b2d-b623-e885171da324"
      unitRef="usd">5700000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfMy01LTEtMS0xMDgxNjE_6049d8e1-473f-4006-884a-72eea649d460"
      unitRef="usd">5800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC0zLTEtMS0xMDgxNjE_f4cd80de-4d7d-428d-b5ff-753164e6f234"
      unitRef="usd">15800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNC01LTEtMS0xMDgxNjE_f7e0b90f-5a14-4cf2-a6f4-625fe925be96"
      unitRef="usd">24200000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNS0zLTEtMS0xMDgxNjE_282af5ff-c4a0-4789-a844-ba94e4ef55ea"
      unitRef="usd">21500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfNS01LTEtMS0xMDgxNjE_7f3d1a55-1af0-4a88-91e4-96a7a90d733f"
      unitRef="usd">30000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfOC0zLTEtMS0xMDgxNjE_300cf570-e675-4a83-8e22-cd20f4b69a66">P5Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfOC01LTEtMS0xMDgxNjE_fba532da-dbd9-417d-9b28-9587336f00ae">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfOS0zLTEtMS0xMDgxNjE_d48edea4-f441-4f4b-9cc6-0922de24491a"
      unitRef="number">0.040</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RhYmxlOmQ5NDA0YjJhOThiZDQxYzU5NzViNzUyZjdiYTdmYjljL3RhYmxlcmFuZ2U6ZDk0MDRiMmE5OGJkNDFjNTk3NWI3NTJmN2JhN2ZiOWNfOS01LTEtMS0xMDgxNjE_d8890012-8f36-460c-8582-d124f20cdc61"
      unitRef="number">0.041</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <ebs:OperatingLeaseRightOfUseAssetRemoval
      contextRef="i5a811ac3bfcc4c29a2a87b5ad51a6fde_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RleHRyZWdpb246ODlkM2E4NjJhMzBhNDA2Y2EwOTAxODg5NGJjM2U2MTdfMTY0OTI2NzQ0MzMxNA_2fd867ae-1790-4434-a72a-2d5073ccc423"
      unitRef="usd">3500000</ebs:OperatingLeaseRightOfUseAssetRemoval>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="idc90073631a04e08b6793e36b6aad73e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80Ni9mcmFnOjg5ZDNhODYyYTMwYTQwNmNhMDkwMTg4OTRiYzNlNjE3L3RleHRyZWdpb246ODlkM2E4NjJhMzBhNDA2Y2EwOTAxODg5NGJjM2U2MTdfMTY0OTI2NzQ0MzMxOA_69fab19f-dd12-4c3a-bc76-cb78584b6309"
      unitRef="usd">-3400000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTg2_7778990b-bceb-42dc-ab6e-48dbed75e3e4">Intangible assets&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the Company's Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Asset Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;8-22 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;958.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;235.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;798.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;193.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;604.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;963.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;803.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;604.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt; During the three months ended September 30, 2022, we acquired certain assets through asset acquisitions, and the related intangible assets were assigned to the "Products" asset type, of which $154.7 million was related to the Transaction.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense associated with the Company's intangible assets was recorded as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;44.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the weighted average amortization period remaining for intangible assets was 11.4 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the changes in the carrying amount of the Company's goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Goodwill, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Goodwill, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of goodwill included accumulated impairments of $41.7 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has $224.9&#160;million of total goodwill which is composed of our Products and Services segments. There is the risk of future impairments in our reporting units as any further deterioration in their performance compared to forecast, changes in order volumes or delivery schedules for major customers, as well as any changes in economic forecasts and expected recovery in the biopharmaceutical industry, may require the Company to complete additional impairment tests in future quarters and could result in the reporting unit&#x2019;s fair value falling below carrying value in subsequent quarters. In the event the Company experiences factors that it believes indicate a decline in fair value, including negative changes to long-term growth rates or if discount rates increase, we may be required to record impairments of goodwill and other identified intangible assets. Further, if the composition of the Company&#x2019;s reporting unit&#x2019;s assets and liabilities were to change and result in an increase in the reporting unit&#x2019;s carrying value, it could lead to additional impairment testing and further impairment losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTg3_f56f54da-4eb4-428a-a586-0c1685a428f6">The following table summarizes the Company's Intangible assets, net:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Asset Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;8-22 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;958.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;235.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;798.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;193.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;604.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;963.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;240.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;722.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;803.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;604.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt; During the three months ended September 30, 2022, we acquired certain assets through asset acquisitions, and the related intangible assets were assigned to the "Products" asset type, of which $154.7 million was related to the Transaction.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idb1900f7b4c44cedb875acc241c0bee3_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi0xLTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo4YWJlNGUzMWY1OGQ0ZTMyODA5ZWU5NDY4MGMzYzc3OV80_ffa2f36e-aaa2-4884-b82a-796e2d5e6cdc">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i261b255bd2fc4596b335217f2db169aa_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi0xLTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo4YWJlNGUzMWY1OGQ0ZTMyODA5ZWU5NDY4MGMzYzc3OV83_2c0dd0b2-c429-4b0c-bcad-b552faf32ef3">P22Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i93e3346dbc84460d924b2e6aa25b270d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi0zLTEtMS0xMDgxNjE_db75706b-7140-4c17-b43b-10208035ef03"
      unitRef="usd">958100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i93e3346dbc84460d924b2e6aa25b270d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi00LTEtMS0xMDgxNjE_a89775f5-3d06-4fe9-af55-70d3e6f94127"
      unitRef="usd">235400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i93e3346dbc84460d924b2e6aa25b270d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi01LTEtMS0xMDgxNjE_1cf88c6e-498e-4d93-8186-91e428ce1e61"
      unitRef="usd">722700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7b49e361c9c547df983b25e75f050a95_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi03LTEtMS0xMDgxNjE_204d2804-1465-47fd-9be5-45aff1357d16"
      unitRef="usd">798000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7b49e361c9c547df983b25e75f050a95_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi04LTEtMS0xMDgxNjE_7fe0442e-1563-4090-b9c0-4ff76ff34233"
      unitRef="usd">193500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7b49e361c9c547df983b25e75f050a95_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMi05LTEtMS0xMDgxNjE_dbc461c2-1477-4714-b245-8f91ad388c33"
      unitRef="usd">604500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i53f8980f84e54596a2bf0df6314e9c89_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy0xLTEtMS0xMDgxNjE_6858a902-86b6-4386-b32e-42c1791c97fb">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie9ff2b788ad74a47a087d6ebd487fff7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy0zLTEtMS0xMDgxNjE_43ef18af-c074-4952-b405-097b15dbcd70"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie9ff2b788ad74a47a087d6ebd487fff7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy00LTEtMS0xMDgxNjE_2d048c0b-c786-4fe0-bbd7-3cb0d0d729fd"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie9ff2b788ad74a47a087d6ebd487fff7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy01LTEtMS0xMDgxNjE_2ffbc092-aeef-4292-8a7c-aaf27cf93182"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ide0e3032f9614c6682f2d4f2a0717a79_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy03LTEtMS0xMDgxNjE_60d312e3-8668-46eb-bcc0-0af38ad23867"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ide0e3032f9614c6682f2d4f2a0717a79_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy04LTEtMS0xMDgxNjE_390fd9a0-b4f0-4c79-8b87-7580006935b9"
      unitRef="usd">5400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ide0e3032f9614c6682f2d4f2a0717a79_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfMy05LTEtMS0xMDgxNjE_0a0a99eb-a529-4100-a38d-4e7746284411"
      unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC0zLTEtMS0xMDgxNjE_e8dcc410-7fef-4ef5-b410-d12cea5b4580"
      unitRef="usd">963600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC00LTEtMS0xMDgxNjE_679ff911-0e68-4acf-80f0-77d8d33a1d26"
      unitRef="usd">240900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC01LTEtMS0xMDgxNjE_bf81607e-d9ba-47f3-b1fc-4b45ada2318b"
      unitRef="usd">722700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC03LTEtMS0xMDgxNjE_8c570bd3-d2d5-4e3d-8f95-4f82d91b47f2"
      unitRef="usd">803500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC04LTEtMS0xMDgxNjE_c5776278-1e3b-4ea6-8c8c-4dd469253149"
      unitRef="usd">198900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNC05LTEtMS0xMDgxNjE_d8a4af26-0dae-4e2f-891a-8dc0ac205fff"
      unitRef="usd">604600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ibb42a96d8dd240cc974caeca968357b0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmJkMzZkMTY1MzlhNTRlM2ZiZTNmMWM0Nzc2M2ExNjc3L3RhYmxlcmFuZ2U6YmQzNmQxNjUzOWE1NGUzZmJlM2YxYzQ3NzYzYTE2NzdfNS0wLTEtMS0xMTI1MzAvdGV4dHJlZ2lvbjo0OGI4NTc3NmFkMjQ0N2U0YjYxMTk5MjVkMjMyYjI0Y18xNjQ5MjY3NDQzMTUy_68f57d99-4c6d-49ba-ba93-fe45c8de7052"
      unitRef="usd">154700000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTk0_384842de-6118-4c0e-ab08-ed8ac47d1607">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense associated with the Company's intangible assets was recorded as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;44.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmZiNWE4ZjM2NjE3OTRlNzk4ZTRiYWQ2OWU4ODkxNTEyL3RhYmxlcmFuZ2U6ZmI1YThmMzY2MTc5NGU3OThlNGJhZDY5ZTg4OTE1MTJfMi0xLTEtMS0xMDgxNjE_b6acfe1c-186e-4774-804b-cee5133f2f92"
      unitRef="usd">14000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmZiNWE4ZjM2NjE3OTRlNzk4ZTRiYWQ2OWU4ODkxNTEyL3RhYmxlcmFuZ2U6ZmI1YThmMzY2MTc5NGU3OThlNGJhZDY5ZTg4OTE1MTJfMi0zLTEtMS0xMDgxNjE_1c35c5d6-fc5b-4f8b-98aa-76d3a5fe90b4"
      unitRef="usd">14500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmZiNWE4ZjM2NjE3OTRlNzk4ZTRiYWQ2OWU4ODkxNTEyL3RhYmxlcmFuZ2U6ZmI1YThmMzY2MTc5NGU3OThlNGJhZDY5ZTg4OTE1MTJfMi01LTEtMS0xMDgxNjE_f27f6216-c570-4839-afba-4f7e3ac8c02a"
      unitRef="usd">42000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOmZiNWE4ZjM2NjE3OTRlNzk4ZTRiYWQ2OWU4ODkxNTEyL3RhYmxlcmFuZ2U6ZmI1YThmMzY2MTc5NGU3OThlNGJhZDY5ZTg4OTE1MTJfMi03LTEtMS0xMDgxNjE_6b23779e-0923-40f8-8e9d-faaa43f9ac06"
      unitRef="usd">44500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfMzkw_0c5ec6fa-52c3-4b8e-b90c-ed2d974cf766">P11Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTg1_1daa4a91-c115-4bcf-a5c7-cd29bf8cb746">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the changes in the carrying amount of the Company's goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Goodwill, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Goodwill, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOjJjZGQ1MDA2MDUyYzRmODY4NTI1MTc4OTQ0YjUzZDEwL3RhYmxlcmFuZ2U6MmNkZDUwMDYwNTJjNGY4Njg1MjUxNzg5NDRiNTNkMTBfMS0xLTEtMS0xMDgxNjE_8b8e26a3-8f00-4aa4-86f6-9893d06eaf98"
      unitRef="usd">224900000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOjJjZGQ1MDA2MDUyYzRmODY4NTI1MTc4OTQ0YjUzZDEwL3RhYmxlcmFuZ2U6MmNkZDUwMDYwNTJjNGY4Njg1MjUxNzg5NDRiNTNkMTBfMi0xLTEtMS0xMDgxNjE_c8bb4bca-f275-46cf-8785-a2e86b6fb8a8"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RhYmxlOjJjZGQ1MDA2MDUyYzRmODY4NTI1MTc4OTQ0YjUzZDEwL3RhYmxlcmFuZ2U6MmNkZDUwMDYwNTJjNGY4Njg1MjUxNzg5NDRiNTNkMTBfMy0xLTEtMS0xMDgxNjE_0ebca770-af5b-45a4-ae97-d7bc7efcd948"
      unitRef="usd">224900000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTUx_1f710ec1-947d-4904-bb88-c572e1a2587b"
      unitRef="usd">41700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfNTUx_233d9e5f-1bdf-4e6b-a64a-66e9703397cf"
      unitRef="usd">41700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml80OS9mcmFnOjNhZDViZmEwNWEzMDQ1NzBiNWZiMDg2NzgzYzRlNWM4L3RleHRyZWdpb246M2FkNWJmYTA1YTMwNDU3MGI1ZmIwODY3ODNjNGU1YzhfMjE5OTAyMzI2MDA2NA_38364a60-9364-417b-b8bd-91a716c6e036"
      unitRef="usd">224900000</us-gaap:Goodwill>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMjE3Ng_aac6e791-d77a-4149-8851-40f6380235aa">Fair value measurements&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;352.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#x2019;s products are classified in the Company's statement of operations as cost of product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a reconciliation of the beginning and ending balance of the Company's contingent consideration liability: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;Liability for Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the current portion of the contingent consideration liability was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.5 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $32.7&#160;million, respectively, and was included in other current liabilities on the condensed consolidated balance sheets. The non-current portion of the contingent consideration liability is included in other liabilities on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Fair Value as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Revenue milestone and royalty based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;25% - 50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;40.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Projected year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2022 - 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 8, "Derivative instruments and hedging activities"&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for more information about the Company's derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-variable rate debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022 and December&#160;31, 2021, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he fair value of the Company's 3.875% Senior Unsecured Notes was $299.9&#160;million and $433.3&#160;million, respectively. The fair value was determined through market sources, which are level 2 inputs and directly observable. The carrying amounts of the Company&#x2019;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 9, "Debt").&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMjE4MQ_e4f21f3d-a81e-4d9a-b9fa-f95bdf3f451c">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques the Company utilized to determine fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;352.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i01ccd0bec4264051b3136200d1ada025_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy0xLTEtMS0xMDgxNjE_abed8c4d-b596-40b5-b5dc-1771d90d551d"
      unitRef="usd">25300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iabb40ddb95bf4ae692da5f4e955899fa_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy0yLTEtMS0xMDgxNjE_0b8b4f4d-ce79-421d-a970-eb5df760b5ff"
      unitRef="usd">25300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i222957670d1047ca907e168d91aaf306_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy0zLTEtMS0xMDgxNjE_87ee6298-3f43-48ae-8e85-9604f61f89ea"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic2196bd047dc467a8d54bb1d0d7ad901_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy00LTEtMS0xMDgxNjE_3bad86ba-63e4-4ec1-a37f-e27783641038"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6a10a22a6f834e04b52f8cb6f61ac369_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy02LTEtMS0xMDgxNjE_169b9376-bf2f-46b6-92f5-f8f589b8eefb"
      unitRef="usd">152400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib304027feebe4bf294aa22162bc25292_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy03LTEtMS0xMDgxNjE_c96c2114-a451-4e42-85bc-fc303071af57"
      unitRef="usd">152400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i88816d3c5490459795a5e08eb0d42dba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy04LTEtMS0xMDgxNjE_0b1d6e10-08e5-481e-ae29-57a728c73ab9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5ca9b3f099074a319fce082bb2f89bec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMy05LTEtMS0xMDgxNjE_87081561-f5dc-440d-a633-fe4526866de7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0b7a7a2b19ba41c289818e166af517c7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC0xLTEtMS0xMDgxNjE_efe9dfdb-def1-4ac7-b22e-41a1deb0f3d9"
      unitRef="usd">50400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0f9711a7eb5243dda529179658dd5830_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC0yLTEtMS0xMDgxNjE_f3e81cc8-ba8f-46dc-88f5-9e0a3775accf"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4699322b4ad742c4a1d4274126058576_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC0zLTEtMS0xMDgxNjE_c5e148bf-f1b3-4ae2-90ce-e47f9bb124db"
      unitRef="usd">50400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1d55fa0666854b7caae1ece36564984a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC00LTEtMS0xMDgxNjE_38493196-0151-4878-9122-8fd2b435c628"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibc5d91a03d4847649b2be05d67b2263c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC02LTEtMS0xMDgxNjE_0d1ced12-d340-4d1b-b5bd-fcec544bbe69"
      unitRef="usd">200000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9ddf4cbc6d484433973d4f77a1b65e21_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC03LTEtMS0xMDgxNjE_e5f2390d-b024-4fd3-bc0b-98a97063fcbb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibad5698b8174430c8ff31576aa9ee134_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC04LTEtMS0xMDgxNjE_0ef98e0c-8065-42fb-b578-7882b87fce2d"
      unitRef="usd">200000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i48426d78db35469b9fbe78182bc15858_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNC05LTEtMS0xMDgxNjE_59eb071c-dfef-4013-8c6c-92c224115d50"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS0xLTEtMS0xMDgxNjE_54571c80-5acc-44f1-801f-a52a2ce54601"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if7b6bac14fa948a599d617d797f9992b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS0yLTEtMS0xMDgxNjE_a351634a-f15d-48f0-8d56-2ba5bda0f8e9"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i794b255dfaa5457d8b625a3b63515086_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS0zLTEtMS0xMDgxNjE_0b2bff3e-ab58-44e9-9898-5ce240a4a3b8"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8eade752296e444ba664833e0780951f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS00LTEtMS0xMDgxNjE_d9effc6d-a5b7-4c80-b149-7344e3f52b6c"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS02LTEtMS0xMDgxNjE_a54463f1-e137-45c8-9bce-67bc2c2b252f"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iacb283273e704425a0c32a9149376f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS03LTEtMS0xMDgxNjE_649de86f-affc-40fb-b9bc-c3fa59a11de7"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8007fc99edc04934866754634405d8ea_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS04LTEtMS0xMDgxNjE_e0f67d4f-7d74-4bc4-8600-5d481caba21a"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1054758dc0d14fa3bddb52120fbac120_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNS05LTEtMS0xMDgxNjE_8413b5df-75fd-4eca-8e9f-0ae3551a4dab"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi0xLTEtMS0xMDgxNjE_39446f79-c2d3-4aaf-8821-ce42a7736436"
      unitRef="usd">75700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if7b6bac14fa948a599d617d797f9992b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi0yLTEtMS0xMDgxNjE_f941514b-3029-4c10-b025-4b1e0a95d2e7"
      unitRef="usd">25300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i794b255dfaa5457d8b625a3b63515086_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi0zLTEtMS0xMDgxNjE_59021adf-e42f-4906-80f7-753c2fe328ab"
      unitRef="usd">50400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8eade752296e444ba664833e0780951f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi00LTEtMS0xMDgxNjE_82b8d6db-e7b2-4ab5-a7e1-a08e65ce9c14"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi02LTEtMS0xMDgxNjE_248a52b3-18b2-4366-bc37-d049e9af5045"
      unitRef="usd">352400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iacb283273e704425a0c32a9149376f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi03LTEtMS0xMDgxNjE_91e745d1-f345-4f82-8747-74440e424253"
      unitRef="usd">152400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8007fc99edc04934866754634405d8ea_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi04LTEtMS0xMDgxNjE_378ac953-c5de-414c-a635-ea2a71ed9223"
      unitRef="usd">200000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1054758dc0d14fa3bddb52120fbac120_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfNi05LTEtMS0xMDgxNjE_5bee556c-8f5e-4dcc-84a2-923b0c8b722c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC0xLTEtMS0xMDgxNjE_8e838d91-7c18-45cf-a8b6-020b1099d5ef"
      unitRef="usd">7800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if7b6bac14fa948a599d617d797f9992b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC0yLTEtMS0xMDgxNjE_c63bada0-4e64-4c1f-9b75-104df863f10d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i794b255dfaa5457d8b625a3b63515086_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC0zLTEtMS0xMDgxNjE_6d487907-51ce-44b2-bca1-a639eaf6703d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8eade752296e444ba664833e0780951f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC00LTEtMS0xMDgxNjE_6242f490-52f1-4197-a19d-f97afdb2ba70"
      unitRef="usd">7800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC02LTEtMS0xMDgxNjE_61a89d46-4420-4524-8c6f-96e16f7ebf4e"
      unitRef="usd">37200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iacb283273e704425a0c32a9149376f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC03LTEtMS0xMDgxNjE_44263b86-de55-439f-b77e-f5576b1b305b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8007fc99edc04934866754634405d8ea_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC04LTEtMS0xMDgxNjE_8bed0da1-575e-4ccb-ba36-af183954192b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1054758dc0d14fa3bddb52120fbac120_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOC05LTEtMS0xMDgxNjE_56711277-29d9-4621-812b-d2c015aa11d2"
      unitRef="usd">37200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS0xLTEtMS0xMDgxNjE_231e1a11-3fb8-4b33-9495-f5e3848a35f5"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if7b6bac14fa948a599d617d797f9992b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS0yLTEtMS0xMDgxNjE_d8e69325-fbc9-4192-81c6-1e5e17af49e9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i794b255dfaa5457d8b625a3b63515086_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS0zLTEtMS0xMDgxNjE_6a73ac0c-c2bf-4f83-962f-186591eecb2b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8eade752296e444ba664833e0780951f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS00LTEtMS0xMDgxNjE_077f2897-977a-4d61-90eb-4438ef53c1fe"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS02LTEtMS0xMDgxNjE_09f0fbc7-d4d7-4f52-ab39-f17cb227e717"
      unitRef="usd">6100000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iacb283273e704425a0c32a9149376f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS03LTEtMS0xMDgxNjE_43b01a24-e991-43cb-ba5b-93d4aa643101"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8007fc99edc04934866754634405d8ea_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS04LTEtMS0xMDgxNjE_b06a1012-5bab-4afe-9514-9c6a39bdaf82"
      unitRef="usd">6100000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1054758dc0d14fa3bddb52120fbac120_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfOS05LTEtMS0xMDgxNjE_f9f61cb8-bab3-4996-a0e1-b15e2445fd15"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtMS0xLTEtMTA4MTYx_a87839f3-ea72-46b1-8bd4-290c42080f6f"
      unitRef="usd">7800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if7b6bac14fa948a599d617d797f9992b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtMi0xLTEtMTA4MTYx_e0cb7964-8808-4dd8-813d-d2b4676b9a89"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i794b255dfaa5457d8b625a3b63515086_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtMy0xLTEtMTA4MTYx_e9de5c4c-85d0-4f31-a8d2-fc8208c2305c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8eade752296e444ba664833e0780951f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtNC0xLTEtMTA4MTYx_f3a40941-331f-4d03-8413-b657848b49d6"
      unitRef="usd">7800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtNi0xLTEtMTA4MTYx_6be06c46-905f-485d-8fde-1683820d5676"
      unitRef="usd">43300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iacb283273e704425a0c32a9149376f6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtNy0xLTEtMTA4MTYx_fc090cc0-7e9d-48bc-9b4e-637277e0baa8"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8007fc99edc04934866754634405d8ea_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtOC0xLTEtMTA4MTYx_fce1aba8-0665-4119-82ab-03a7a4145b97"
      unitRef="usd">6100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1054758dc0d14fa3bddb52120fbac120_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjE2ZjI4NjZkZWJmNDQwYTBiMTQ3NGEwODBhZjNjZjUyL3RhYmxlcmFuZ2U6MTZmMjg2NmRlYmY0NDBhMGIxNDc0YTA4MGFmM2NmNTJfMTAtOS0xLTEtMTA4MTYx_64a8fc86-053c-401c-b90e-7065c1a8f27c"
      unitRef="usd">37200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMjE3OA_0d3ed007-0fc2-4ea8-b1c8-39c38cd26b68">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a reconciliation of the beginning and ending balance of the Company's contingent consideration liability: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;Liability for Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Balance at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOmQwNjcxMGRmMzAwMDQyOGViNThhMGQ5ZDdkMGI4MzdlL3RhYmxlcmFuZ2U6ZDA2NzEwZGYzMDAwNDI4ZWI1OGEwZDlkN2QwYjgzN2VfMS0yLTEtMS0xMDgxNjE_d5daad6a-bbd0-4644-8d73-9e9bc815671f"
      unitRef="usd">37200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOmQwNjcxMGRmMzAwMDQyOGViNThhMGQ5ZDdkMGI4MzdlL3RhYmxlcmFuZ2U6ZDA2NzEwZGYzMDAwNDI4ZWI1OGEwZDlkN2QwYjgzN2VfMi0yLTEtMS0xMDgxNjE_4b90cd7c-1c8c-4f3a-980a-d323b1e9cd8f"
      unitRef="usd">2400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOmQwNjcxMGRmMzAwMDQyOGViNThhMGQ5ZDdkMGI4MzdlL3RhYmxlcmFuZ2U6ZDA2NzEwZGYzMDAwNDI4ZWI1OGEwZDlkN2QwYjgzN2VfMy0yLTEtMS0xMDgxNjE_a88b3813-b9d2-4d2d-bf0f-497c5e9e64ee"
      unitRef="usd">31800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOmQwNjcxMGRmMzAwMDQyOGViNThhMGQ5ZDdkMGI4MzdlL3RhYmxlcmFuZ2U6ZDA2NzEwZGYzMDAwNDI4ZWI1OGEwZDlkN2QwYjgzN2VfNC0yLTEtMS0xMDgxNjE_74961b86-f5d6-4201-8272-fddbf036e6da"
      unitRef="usd">7800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTI2OQ_0262c9b2-f926-4412-bb66-909a99737bf3"
      unitRef="usd">3500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTI3Ng_5c0518f4-6c87-4958-8b84-78e62484ef41"
      unitRef="usd">32700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMjE4MA_4e22a1f1-19f4-45fd-80e7-655032b6a584">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Fair Value as of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Revenue milestone and royalty based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;25% - 50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;40.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Projected year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2022 - 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idcd99f4d0bd44df5ac51fd3f92b88bd4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMS0xLTEtMS0xMDgxNjE_ac1175fd-5cbd-4f2f-9dfd-9a5b3296364e"
      unitRef="usd">7800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ieb22a87cdfe14a7c84c7650473417364_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMS00LTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo4Zjk0MDdjYjk0Yzg0ODJlOGMzN2I0ODhiM2Y1ODEwZV80_60d7dcca-ebda-46e8-ab4c-18d956b6700c"
      unitRef="number">0.101</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic622b8b9acb24f6b88e8c6886000cf77_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMS01LTEtMS0xMDgxNjE_53a635bd-3fc1-499b-a56f-7a23a250cc7a"
      unitRef="number">0.101</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i69c2baff68b54a718464354731cbe1ff_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMi00LTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjpiMDViMGMxOTAyNmI0Mzg1YWNiMDZhZjNiZTVlMjA4NF80_4c0c40ad-71e1-409d-a86b-608d960474a0"
      unitRef="number">0.25</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i3ef5c35c4662482c96b3838cdb9d6edd_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMi00LTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjpiMDViMGMxOTAyNmI0Mzg1YWNiMDZhZjNiZTVlMjA4NF85_b97efaa6-8c45-440d-b67e-5a3c6e08df18"
      unitRef="number">0.50</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i300780e3ce444b4cb0b0c9c10968ac86_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RhYmxlOjQxOGVjMjkwZDBhMDRjMzc5MmMyNTlhZTE0NmM2Y2IwL3RhYmxlcmFuZ2U6NDE4ZWMyOTBkMGEwNGMzNzkyYzI1OWFlMTQ2YzZjYjBfMi01LTEtMS0xMDgxNjE_a389c733-4378-4399-9e3b-7f9830078266"
      unitRef="number">0.400</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i291befa2eae3402ebb90a91957b5b46f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTg5NQ_00aac4b5-7817-4fab-9493-34f1e6e69693"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8b3b07fe44be43f1b02c1b877f8d8f60_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTg5NQ_808dcf40-3c2d-4b86-bcec-a66ae8280bc1"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i291befa2eae3402ebb90a91957b5b46f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTkyNQ_39c65712-0ad5-4915-b4d7-b89567684b17"
      unitRef="usd">299900000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i8b3b07fe44be43f1b02c1b877f8d8f60_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81Mi9mcmFnOjM2NTkzOGI3ZjZhMzRhNGViMDUzZDFmMDkyOWY5OGI4L3RleHRyZWdpb246MzY1OTM4YjdmNmEzNGE0ZWIwNTNkMWYwOTI5Zjk4YjhfMTkzMg_902f5370-7d79-4006-bf2e-a8d24183cded"
      unitRef="usd">433300000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfMjk2Ng_216c0333-8322-4fe7-a60f-684e5f99dcdb">Derivative instruments and hedging activities&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk management objective of using derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from payments of variable interest rate debt associated with the Company's senior secured credit agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If current fair values of designated interest rate swaps&#160;remained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;$9.0 million of net deferred gains from&#160;accumulated other comprehensive loss&#160;into the condensed consolidated statement of operations over the next&#160;twelve-month period. All outstanding cash flow hedges mature in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions, except number of instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Number of Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$350.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:38pt"&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Location of Loss Reclassified from&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Amount of Loss Reclassified from Accumulated OCL into Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accumulated OCL into Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="i19788cf415e44731a7ac316933902c13_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfODk4_ad39568c-6fc1-4b74-aba3-3a4866212ed7"
      unitRef="usd">9000000.0</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfMjk2OA_a906e2ab-d8f4-4bb0-9935-bc2c0a05aa27">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in millions, except number of instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Number of Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$350.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i7d38ed2b0b1c4eaa8ca77f4744eb8d44_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOmZiMjViZjMzNTcwMzQ3YmM4ZmI5MGRlOWI2YmE0MGFmL3RhYmxlcmFuZ2U6ZmIyNWJmMzM1NzAzNDdiYzhmYjkwZGU5YjZiYTQwYWZfMS0xLTEtMS0xMDgxNjE_6d4beb3d-9872-4ebd-9006-62d524d6cc38"
      unitRef="instrument">7</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7d38ed2b0b1c4eaa8ca77f4744eb8d44_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOmZiMjViZjMzNTcwMzQ3YmM4ZmI5MGRlOWI2YmE0MGFmL3RhYmxlcmFuZ2U6ZmIyNWJmMzM1NzAzNDdiYzhmYjkwZGU5YjZiYTQwYWZfMS0zLTEtMS0xMDgxNjE_55d88852-0556-4f3d-b3e1-ed3155821532"
      unitRef="usd">350000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfMjk2NQ_6fd3d204-e0da-4e23-a452-0af18b461545">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2e48ea4760d64c29a1425b6484a220d7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfMy0yLTEtMS0xMDgxNjE_813cb296-af8e-4b46-bea5-15b8be43eab7"
      unitRef="usd">8900000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i838e26b2874e4c6a900e96dfeaeb7fcf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfMy00LTEtMS0xMDgxNjE_5ff98dd8-0c33-4fc1-8a6c-fc132a7b015c"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i150ebed92e8e40479da8c8a6f0513b75_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfMy03LTEtMS0xMDgxNjE_6e32a11c-431d-4ef0-95fd-7ecd5a9ee0bb"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i8e600ddb0a1748578ccc9e9d07f955f3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfMy05LTEtMS0xMDgxNjE_6db5ed0e-9bef-4b74-8da6-99b4df5ba64d"
      unitRef="usd">4500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic90b9835f0d24ac1a182a07dd228a238_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfNC0yLTEtMS0xMDgxNjE_7884f9e0-2f2c-44c0-bbaa-3c9abdd9ce35"
      unitRef="usd">400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i1e4d660de4664e77b8ff1707a368864a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfNC00LTEtMS0xMDgxNjE_afe4c9c4-2173-45fc-9ebe-b9017cf1afe7"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ida4dbb8aac844392a35bca16af3b8ba6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfNC03LTEtMS0xMDgxNjE_2640f856-d31d-4a2f-9617-2ca0596ce1f4"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i7fde38f223f94ec0bedb7aaf2da71b3c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjBkZmQyZjUxNTY4MDQ4YzZhNjlhYjE4M2RmMzExMWVmL3RhYmxlcmFuZ2U6MGRmZDJmNTE1NjgwNDhjNmE2OWFiMTgzZGYzMTExZWZfNC05LTEtMS0xMDgxNjE_5ceb6e3d-4694-44a4-b400-f4e679d46d69"
      unitRef="usd">1600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfMjk3Nw_4575b5ab-d49a-4c94-9813-692bfa806311">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RleHRyZWdpb246NmFiYWRlZjk5MTExNGEwMGFlZDJmZTBlNDdhZjlmMzVfMjk2OQ_6b73f55e-180c-48fe-abe9-5aa4464ba766">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:38pt"&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Location of Loss Reclassified from&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Amount of Loss Reclassified from Accumulated OCL into Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accumulated OCL into Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i19788cf415e44731a7ac316933902c13_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjkyMDIxNGQ1NTViNjRiYzY5MzY5MDc1MzMyZWQ0YjY2L3RhYmxlcmFuZ2U6OTIwMjE0ZDU1NWI2NGJjNjkzNjkwNzUzMzJlZDRiNjZfMy0xLTEtMS0xMDgxNjE_315cb659-0154-4608-93d8-439719a645a9"
      unitRef="usd">9300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i738ecdd912c348ff897fd9f1546835a8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjkyMDIxNGQ1NTViNjRiYzY5MzY5MDc1MzMyZWQ0YjY2L3RhYmxlcmFuZ2U6OTIwMjE0ZDU1NWI2NGJjNjkzNjkwNzUzMzJlZDRiNjZfMy0yLTEtMS0xMDgxNjE_0b0d5d8c-01c4-47ca-aad6-5534d3949558"
      unitRef="usd">-6100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ic61dd5c549874f80b397d42cc9717abc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjkyMDIxNGQ1NTViNjRiYzY5MzY5MDc1MzMyZWQ0YjY2L3RhYmxlcmFuZ2U6OTIwMjE0ZDU1NWI2NGJjNjkzNjkwNzUzMzJlZDRiNjZfMy00LTEtMS0xMDgxNjE_1b4584d0-03c8-4992-8618-9ef63945442b"
      unitRef="usd">-1900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i74b2a89fef854325a21558ba470a63ad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81NS9mcmFnOjZhYmFkZWY5OTExMTRhMDBhZWQyZmUwZTQ3YWY5ZjM1L3RhYmxlOjkyMDIxNGQ1NTViNjRiYzY5MzY5MDc1MzMyZWQ0YjY2L3RhYmxlcmFuZ2U6OTIwMjE0ZDU1NWI2NGJjNjkzNjkwNzUzMzJlZDRiNjZfMy01LTEtMS0xMDgxNjE_457a5161-b3b4-4820-aa48-9cfd20db3a7f"
      unitRef="usd">-4300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjgwMg_af408a03-1cad-4491-ad19-7a224438b478">Debt&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of debt were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement - Term loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;371.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;396.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement - Revolver loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;238.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,062.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;849.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Current portion of long-term debt, net of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(21.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Non-current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,032.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;809.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022 and December&#160;31, 2021 there was $238.0&#160;million and no&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outstanding revolver balance, respectively. The Company classifies debt issuance costs associated with the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revolver&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; loan as other current assets and other assets on the Company's consolidated balance sheets. As of September&#160;30, 2022, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;had $4.1&#160;million and $4.9&#160;million of debt issuance costs associated with the revolver loan classified as other current assets and other assets, respectively. As of December&#160;31, 2021, the Company had approximately $2.0 million and $1.6 million of debt issuance costs associated with the revolver loan that were classified as other current assets and other assets, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2020, the Company completed its offering of $450.0&#160;million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the 2028 Notes) of which the majority of the net proceeds were used to pay down the Revolving Credit Facility (as defined below). Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related Indenture, plus accrued and unpaid interest. Prior to August 15, 2023 the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to 100% of the principal amount of the 2028 Notes plus a &#x201c;make-whole&#x201d; premium and accrued and unpaid interest. Prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the 2028 Notes using the net cash proceeds of certain equity offerings at the redemption price set forth in the related Indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of 101% of the principal amount of such 2028 Notes plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Negative covenants in the Indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also on August 7, 2020, the Company entered into a Second Amendment (the &#x201c;Credit Agreement Amendment&#x201d;) to its senior secured credit agreement, dated October 15, 2018, with multiple lending institutions relating to the Company&#x2019;s senior secured credit facilities (the &#x201c;Credit Agreement,&#x201d; and as amended, the &#x201c;Amended Credit Agreement&#x201d;), consisting of a senior revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) and senior term loan facility (the &#x201c;Term Loan Facility,&#x201d; and together with the Revolving Credit Facility, the &#x201c;Senior Secured Credit Facilities&#x201d;).  The Credit Agreement Amendment amended, among other things, the definition of incremental facilities limit, the consolidated net leverage ratio financial covenant by increasing the maximum level, increased the permissible applicable margins based on the Company&#x2019;s consolidated net leverage ratio and increased the commitment fee that the Company is required to pay in respect of the average daily unused commitments under the Revolving Credit Facility, depending on the Company&#x2019;s consolidated net leverage ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement includes (i) a Revolving Credit Facility of $600.0&#160;million and (ii) a Term Loan Facility with a principal amount of $450.0&#160;million. The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as certain requirements involving the Company's net leverage ratio will be maintained on a pro forma basis. Borrowings under the Revolving Credit Facility and the Term Loan Facility bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from 1.25% to 2.25% per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus 0.50%, and a eurocurrency rate for an interest period of one month plus 1% plus a margin ranging from 0.25% to 1.25%, depending on the Company's consolidated net leverage ratio). The Company is required to make quarterly payments on the last business day of each calendar quarter under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from 0.15% to 0.35% per annum, depending on the Company's consolidated net leverage ratio, for the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments on the last business day of each calendar quarter based on an annual percentage equal to 2.5% of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, 5% of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and 7.5% of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature on October 13, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of $100.0&#160;million during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights. The financial covenants under the Amended Credit Agreement currently require the quarterly presentation of a minimum consolidated 12-month rolling debt service coverage ratio of 2.50 to 1.00, and a maximum consolidated net leverage ratio of 4.50 to 1.00 (subject to an increase to 5.00 to 1.00 for an applicable four quarter period, at the election of the Company, in connection with a permitted acquisition having an aggregate consideration in excess of $75.0&#160;million). Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjgwNQ_c8adc3fd-945b-4a4c-a744-febd2302e92e">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of debt were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement - Term loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;371.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;396.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement - Revolver loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;238.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,062.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;849.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Current portion of long-term debt, net of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(21.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Non-current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,032.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;809.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="icb0a527f718246d39439945aa519e89c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMS0xLTEtMS0xMDgxNjE_af49451e-dbf8-4012-9a2f-7fa7ce9300e5"
      unitRef="usd">371300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i04969e1a51cb42c89f1471eb8ace2e4d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMS0zLTEtMS0xMDgxNjE_02b80607-508d-4e36-996f-9c1d9b3ab0cb"
      unitRef="usd">396600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i7432986424e74ac09ac1dd272585adcb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMi0xLTEtMS0xMDgxNjE_f9e61e44-2f94-490d-b140-aabc66732e1e"
      unitRef="usd">238000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if50ceba61f3047f1834721079b974236_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMi0zLTEtMS0xMDgxNjE_73b2c60a-7f4a-410e-bba9-ddb77b70d7bd"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i291befa2eae3402ebb90a91957b5b46f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMy0wLTEtMS0xMDgxNjEvdGV4dHJlZ2lvbjo3MzlmNmJkYWFiNGM0NzVmYTZjOGFhOGYyNWNhN2ZmYl80_98e35f9f-0399-4305-9cc6-499290595c88"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i291befa2eae3402ebb90a91957b5b46f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMy0xLTEtMS0xMDgxNjE_a1a780b1-63ba-4c1b-8f3a-0502a50fabe5"
      unitRef="usd">450000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8b3b07fe44be43f1b02c1b877f8d8f60_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfMy0zLTEtMS0xMDgxNjE_b24d141a-6ca4-4ca3-998d-dc027cbd41c0"
      unitRef="usd">450000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i027fba7fbff04d03860a6cb1878e9580_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNC0xLTEtMS0xMDgxNjE_35e975ec-ccef-4fbb-8b00-c4e83cd2bdcf"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iaffc9253e79f4fcebff3b4c90c35286e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNC0zLTEtMS0xMDgxNjE_528656de-6a61-4765-97de-d6ad12fa1932"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNS0xLTEtMS0xMDgxNjE_cbda70a8-69b5-4a80-9519-006439fac85e"
      unitRef="usd">1062300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNS0zLTEtMS0xMDgxNjE_e7acc1ec-e4be-453d-a823-4a4f0651d736"
      unitRef="usd">849600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNy0xLTEtMS0xMDgxNjE_dfae5401-3980-4ad9-bf77-b8ba8bc3d18c"
      unitRef="usd">21200000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfNy0zLTEtMS0xMDgxNjE_6fa2bb9b-8166-4ef3-ae4f-99fd7c853f7d"
      unitRef="usd">31600000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfOC0xLTEtMS0xMDgxNjE_c405a5a0-5234-452c-81a8-e9f1ddba3c50"
      unitRef="usd">9000000.0</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfOC0zLTEtMS0xMDgxNjE_9b0fcb97-c912-4495-a435-960d68a3da68"
      unitRef="usd">8500000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfOS0xLTEtMS0xMDgxNjE_ea3debcc-ec07-4130-9125-9749ed04842b"
      unitRef="usd">1032100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RhYmxlOmQzZjMwNjFlNWYxMzRhZjZhOGQyN2Q1YWIzYzhiNjRhL3RhYmxlcmFuZ2U6ZDNmMzA2MWU1ZjEzNGFmNmE4ZDI3ZDVhYjNjOGI2NGFfOS0zLTEtMS0xMDgxNjE_a34b54b9-ca2e-443b-8c60-2946a93b7e7d"
      unitRef="usd">809400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="i7432986424e74ac09ac1dd272585adcb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNTQ5NzU1ODIwNzI3_4190af41-cc33-4e26-a16d-63fd6d3c6ea6"
      unitRef="usd">238000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if50ceba61f3047f1834721079b974236_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNTQ5NzU1ODMyODI4_11f557ab-1f7f-4259-9a4d-30a5497e8c93"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="i685e03fb0a4c4543b949a4d6d792d36a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNTQ5NzU1ODMyODAw_a2b09692-4a39-4cc5-a3b7-14dc63e6da26"
      unitRef="usd">4100000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i5375d3691d1d44bc8c0347410a5bea7e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMjk5_efdc68bc-8a01-4d10-9026-3b3602e3ad77"
      unitRef="usd">4900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDY2_e5ecf7bb-2e3d-4ab6-ba4f-9361b5c728c9"
      unitRef="usd">2000000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDcz_f058688b-745a-4b04-88c4-282d9faa2a5c"
      unitRef="usd">1600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i08291fa7af0b411b9ad50845378e5f4f_I20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjEw_600e5ec6-f09e-4b69-b19d-2222f0bb6423"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i08291fa7af0b411b9ad50845378e5f4f_I20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNzAz_2259ed44-b97c-4a36-811c-69b6371f990f"
      unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i08291fa7af0b411b9ad50845378e5f4f_I20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNzM2_4da65499-0226-4895-af35-de31775c2205"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i4e7c1aaf68b942a4862dd65bfc9fb9b0_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMTM3OQ_b7d77cf9-ebc3-4607-b2f2-82ea66abb998"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i920e76d8a6b143808c57dd4353d67903_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMTU0MA_245afd0b-516f-4765-8f6e-b76f75e0356d"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="if4f8efea66de4544a5582830d8b59691_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMTgzMA_1bfea86c-f7a9-4ece-8df2-87dfbe969fac"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="i6200f8d1ae104ba18d6fdb545b3e9d53_I20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMzM2NQ_d4ccd4be-8847-4220-ab78-40644adea26c"
      unitRef="usd">600000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="i71e35fd549cd4231be789d968dfd1543_I20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMzQyNQ_db25392a-db3d-4f61-8587-d4bcba131d8e"
      unitRef="usd">450000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8605ed75b07d49a3b547f97fccb0e405_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMzgzNQ_d5e25100-d83b-4cba-84c9-9d24a281e30a"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i82b05a62bd63445cb568d4c2e2c3d9e0_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfMzg0MQ_4d498f57-34fc-46f7-967e-b26dce6a5c44"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic84be99323cc4584be4962051ab7756d_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDAwMg_e98fc959-14b4-466c-b732-e036c2f57766"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib0b9e211f3b94cda86f8d463e61a3a6c_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDA3MQ_866a4ceb-c5a1-4368-8107-9d610d00a81e"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i17b0291bd1dd47a7b7ee65d4fecc6232_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDEwMQ_e6f4e1de-c7c7-40f1-96fe-ccf2efd07548"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i655fab78c8164add9eea8222ce75abaf_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDEwNw_bf0cb1bb-0c3d-4961-a8c8-1665bd8286a5"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i1479ba7c4c8141da9c266a76d41c699c_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDQ4Ng_e9129a05-5404-42e8-89e5-d18a88ded49a"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ida101d603b624a549b887226e83027b1_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDQ5Mg_9e0da997-a509-462a-b96b-c75944f2512c"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears
      contextRef="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDg0Mg_6d06204b-05d8-4c1b-9775-a9999f2965d9"
      unitRef="number">0.025</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear
      contextRef="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNDk2Ng_9792db5d-3ee5-4836-9586-fc99e83791ff"
      unitRef="number">0.05</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears
      contextRef="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNTA4MA_1a8e9cdd-eed6-4b75-815d-2e126b285656"
      unitRef="number">0.075</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears>
    <ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight
      contextRef="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNTc5OA_9bf4b53f-c8bc-4999-a52d-452d3a3ead33"
      unitRef="usd">100000000</ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight>
    <ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod
      contextRef="i1eb46693aa644293a59a4421942c528f_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjA5OQ_fc23cd8c-be47-4db1-806b-04437d84379b">P12M</ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod>
    <ebs:DebtInstrumentCovenantDebtServiceCoverageRatio
      contextRef="i1479ba7c4c8141da9c266a76d41c699c_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjE0Nw_f1898d96-99a6-47de-85e9-36459adc2749"
      unitRef="number">2.50</ebs:DebtInstrumentCovenantDebtServiceCoverageRatio>
    <ebs:DebtInstrumentCovenantNetLeverageRatioOne
      contextRef="ida101d603b624a549b887226e83027b1_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjIwOA_9f0d25de-115e-4ebb-8113-000e318334f1"
      unitRef="number">4.50</ebs:DebtInstrumentCovenantNetLeverageRatioOne>
    <ebs:DebtInstrumentCovenantNetLeverageRatioTwo
      contextRef="ida101d603b624a549b887226e83027b1_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjI0Ng_84861c91-2517-494e-95ff-fc4b83af0932"
      unitRef="number">5.00</ebs:DebtInstrumentCovenantNetLeverageRatioTwo>
    <ebs:DebtInstrumentCovenantConsiderationThreshold
      contextRef="iec9ba9c2db624ae38eb46c10028ca107_D20200807-20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml81OC9mcmFnOjc3NWY5NDNhODE3ZTRiOTM4ZWZhM2RlYTg0NjRkN2ZkL3RleHRyZWdpb246Nzc1Zjk0M2E4MTdlNGI5MzhlZmEzZGVhODQ2NGQ3ZmRfNjQxOA_7331b3e2-973a-41fb-a58b-cbac1f05ba86"
      unitRef="usd">75000000</ebs:DebtInstrumentCovenantConsiderationThreshold>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM5MA_263b1dce-38c2-4dfc-a253-6060a070771d">Revenue Recognition &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as two operating segments (Note 14, "Segment information&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The Company's revenues disaggregated by the major sources were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Non-U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Non-U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;152.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;186.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;129.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;140.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;CDMO:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(86.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(71.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total CDMO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(86.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;190.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;240.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;268.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;329.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;255.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;405.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;660.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;252.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;337.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;589.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;CDMO:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;90.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;90.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;132.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total CDMO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;334.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;416.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;286.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;503.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;790.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;395.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;674.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,069.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 2, 2020, the Company, through its wholly-owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into a manufacturing services agreement with Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson, for large-scale drug substance manufacturing of Johnson &amp;amp; Johnson&#x2019;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#x201c;Product&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2022, the Company provided to Janssen a notice (the &#x201c;Notice&#x201d;) of material breach of the Agreement for, among other things, failure by Janssen (i) to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Agreement and (ii) to confirm Janssen&#x2019;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Agreement and instead, wind-down the Agreement ahead of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#x201c;Janssen Notice&#x201d;) of the Agreement for asserted material breaches of the Agreement by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices ("cGMP") or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the Company&#x2019;s breaches were not curable and that, therefore, termination of the Agreement would be effective as of July 6, 2022. The Company disputes Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result of the Company's alleged failure to perform under the Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process including through mediation and/or arbitration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2022, there were no impacts on previously recognized revenue or depreciation related to the conclusion of the Agreement. As of September&#160;30, 2022, the Company has no billed or unbilled net accounts receivable related to the Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has $131.0&#160;million of raw materials inventory recorded in its condensed consolidated balance sheet as of September&#160;30, 2022, representing materials purchased for the Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of this inventory as of September&#160;30, 2022, concluding that because the Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for any reason, the Company is entitled to payment from Janssen for these raw materials. Therefore, this inventory remains an asset on the condensed consolidated balance sheet as of September&#160;30, 2022. Additionally, the Company has an immaterial amount of non-cancelable orders as of September&#160;30, 2022 which have not been received and Janssen has not reimbursed. The Company also recorded approximately $13.6&#160;million to other assets, which relates to termination penalties and certain inventory related items. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BARDA COVID-19 Development Public-Private Partnership&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company announced the issuance of a task order under its existing Center for Innovation in Advanced Development and Manufacturing ("CIADM") agreement with BARDA for COVID-19 vaccine development and manufacturing (the "BARDA COVID-19 Development Public Private Partnership"). The BARDA COVID-19 Development Public Private Partnership is considered a lease and is accounted for under ASC 842. The initial task order had a contract value of up to $628.2&#160;million and included the reservation of manufacturing capacity and accelerated expansion of fill/finish capacity valued at $542.7&#160;million and $85.5&#160;million, respectively. Subsequently, the task order was expanded to include incremental capital activities which increased the value to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$650.8&#160;million. On November 1, 2021, the Compa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ny and BARDA mutually agreed to the completion of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company's CIADM contract and associated task orders, including the BARDA COVID-19 Development Public Private Partnership. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not recognize lease revenues under this arrangement during the three and nine months ended September 30, 2022. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company reversed lease revenues of $86.0 million and recognized lease revenues of $81.9 million, respectively, related to this arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CDMO operating leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain multi-year CDMO service arrangements with commercial customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates 2.5 years. The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Excluding future amounts related to the Janssen Agreement as discussed above, the Company estimates future operating lease revenues to be $0.2&#160;million in the remainder of 2022, $5.1&#160;million in 2023, $0.9&#160;million in 2024, $0.9&#160;million in 2025 and $2.7&#160;million in years beyon&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price allocated to remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company has future contract value on unsatisfied performance obligations of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$453.9 million associated with all arrangements entered into by the Company. The Company expects to recognize a majority of the $453.9 million of unsatisfied performance obligations within the next 24 months. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associat&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ed with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#x2019;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$33.9 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $21.5 million, respectively, of contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recorded within accounts receivable, net on the condensed consolidated balance sheets.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the condensed consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the roll forward of the contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the current portion of contract liabilities was $24.8&#160;million and $11.7&#160;million, respectively, and was included in other current liabilities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Billed, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;119.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;72.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;191.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;274.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the allowances for doubtful accounts was $0.7 million and $3.2 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfMTY0OTI2NzQ3NzYyMA_83999cc4-ff49-48c3-9fd0-714701d38614"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfMTY0OTI2NzQ3NzYyMA_ec67a01a-2c1e-4636-9b75-53d42761c544"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM4NA_1e8d70fc-17c4-47fb-9186-cbcaf7318eae">The Company's revenues disaggregated by the major sources were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Non-U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Non-U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;152.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;186.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;129.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;140.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;CDMO:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;112.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(86.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(71.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total CDMO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(86.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;127.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;190.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;240.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;268.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;329.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;255.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;405.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;660.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;252.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;337.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;589.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;CDMO:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;90.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;90.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;283.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;132.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total CDMO&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;334.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;416.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;286.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;503.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;790.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;395.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;674.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,069.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28a266eb53e04df59d47c4a05b3e2244_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi0xLTEtMS0xMDgxNjE_2a51430f-e319-499c-9158-7adcc555b96d"
      unitRef="usd">33400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c02245efe03492d998177bd87378e02_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi0zLTEtMS0xMDgxNjE_86660dee-84c1-46da-be87-08a660a34421"
      unitRef="usd">152800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52646bb207c64e15902c5f7cebbaa5a9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi01LTEtMS0xMDgxNjE_f097acfb-dcbb-4244-839d-a32c952d0d23"
      unitRef="usd">186200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a88ddbd25d44236801b5ce80ff820a0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi03LTEtMS0xMDgxNjE_287ea4a8-2432-429a-b3ba-cccd5236e428"
      unitRef="usd">129900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8ec2984c86b4778b38ae6b4badb7f46_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi05LTEtMS0xMDgxNjE_a83b7ae0-f213-4438-a2b6-85b34f83beef"
      unitRef="usd">140600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c1314a596fa4be2be2dbbc905e0e0ce_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMi0xMS0xLTEtMTA4MTYx_85fdbce8-cf0e-4090-93b6-0f3800668942"
      unitRef="usd">270500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8c4a64e596d45aea88a95a509f10f86_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC0xLTEtMS0xMDgxNjE_aa40ac80-3ce4-4781-9a54-94f17be8c15c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee319a3e184c49c88a65354d45c0fcb5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC0zLTEtMS0xMDgxNjE_743e8ea5-55fe-4942-b212-7eb42fee0bc3"
      unitRef="usd">36200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3ea905c3a1d48a9a374e41f47cd9e7e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC01LTEtMS0xMDgxNjE_42c97c2a-01d4-464d-927e-b3e4b0452322"
      unitRef="usd">36200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68059df57d924b6c9a6d571ce4686d06_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC03LTEtMS0xMDgxNjE_8c690d0c-c9d2-4d5e-926b-84d281b6c2ea"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a498fe04f304b2bb151292ea1f5194c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC05LTEtMS0xMDgxNjE_089d58d0-e418-4c75-b077-e421fce23d70"
      unitRef="usd">112600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i293e88d455b74b89b6ea596c99361768_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNC0xMS0xLTEtMTA4MTYx_208005d4-451a-4cb5-800f-c9f6969e020f"
      unitRef="usd">112600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i85d2fdbc895b41fe8983ba64d0d2ffb0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS0xLTEtMS0xMDgxNjE_3e541543-9295-46f5-9f45-7cf9f8c0f31c"
      unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i93ce7d6831194524b6acb971a73c8b1a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS0zLTEtMS0xMDgxNjE_b471db51-6958-4f0a-8a2e-e1ebdd02577b"
      unitRef="usd">200000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i25e36ed15c584f8abca1aae53e56c499_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS01LTEtMS0xMDgxNjE_9bd1090e-dc75-4ebf-b79a-c4a03cc73172"
      unitRef="usd">200000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="if6ea4a6a0de647a8a6d921dd7b209282_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS03LTEtMS0xMDgxNjE_e38bb6f7-2ee4-498e-8a2c-6d22c97df2ab"
      unitRef="usd">-86000000.0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="iad159380abc745509e18c7cd554939da_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS05LTEtMS0xMDgxNjE_7be59673-af50-442a-a665-0607d1ec16c5"
      unitRef="usd">15000000.0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i5106d154262648b8966552fa34ac668e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNS0xMS0xLTEtMTA4MTYx_78e5a8fd-4bb7-42ae-8135-55158cc970c4"
      unitRef="usd">-71000000.0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4317852774f4594bf7d43b26a0b6f3d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi0xLTEtMS0xMDgxNjE_44321538-94da-431a-96ae-0216554aaff9"
      unitRef="usd">0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d65c5dfe69a49298805ed95c23e4944_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi0zLTEtMS0xMDgxNjE_8ea901bd-b511-4870-8670-77557aa1d81d"
      unitRef="usd">36400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7c744e01ccc4b70a3f8d3f033d69fc7_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi01LTEtMS0xMDgxNjE_a0dab402-c557-49cc-8452-b9a4891959ca"
      unitRef="usd">36400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d79a2aa8e1a4715897d56ad0693e4a1_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi03LTEtMS0xMDgxNjE_e71b66f2-43e3-4178-b604-994a6514c9e6"
      unitRef="usd">-86000000.0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff568f9147f143f48975cc8ccf7bb4d9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi05LTEtMS0xMDgxNjE_ecea80af-7ac4-4ea0-8400-a166a298b6b7"
      unitRef="usd">127600000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefc13edfdf22466c94aef0c6826da80b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNi0xMS0xLTEtMTA4MTYx_65a9e119-0719-4d21-b9b0-da5956a470ad"
      unitRef="usd">41600000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie21ef4d129104b7a8ae5cd39ae894a3f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy0xLTEtMS0xMDgxNjE_2dda24d2-7901-43b8-b190-f1405f5bf8f6"
      unitRef="usd">16400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ce67d2e233d4f5786192e1687c3c262_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy0zLTEtMS0xMDgxNjE_1b04aacc-b1a3-44c6-802a-9f4485602fe0"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee99b848e7d34f24ba7ebd4d2abf4f85_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy01LTEtMS0xMDgxNjE_ab49ffeb-c226-41ec-9098-af2cb2b9e376"
      unitRef="usd">17400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if950b033c22d4b22a7e329ed5dbe41cd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy03LTEtMS0xMDgxNjE_a186f5b3-906e-4db0-b75a-0cfb8df71e1e"
      unitRef="usd">16300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71c0ec50c43b41b5899fc5e10c1d9ea3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy05LTEtMS0xMDgxNjE_454f9b38-cad1-4186-899e-6db11fb2c9fd"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5105f0204af64b01a45ffaaf2c96b86e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfNy0xMS0xLTEtMTA4MTYx_f5e0a8c0-6229-4331-b2d6-1e0a4057fd7b"
      unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ifc42b30bb7694aa3bd4d198c2dc52e32_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC0xLTEtMS0xMDgxNjE_6a10a50b-a544-4429-92a6-d41924c7b8e1"
      unitRef="usd">49800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5a6612cb27940cd836298ddf8f13245_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC0zLTEtMS0xMDgxNjE_e30e77ef-921e-4d84-bc65-35c248816ce1"
      unitRef="usd">190200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC01LTEtMS0xMDgxNjE_d16a6bf3-2349-4314-a31a-e10385548e4e"
      unitRef="usd">240000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6fe41cba330404f809cbe23888df0e9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC03LTEtMS0xMDgxNjE_c12db91d-038c-4712-8ed1-0d06a663803a"
      unitRef="usd">60200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia96662ac0ab84db9a8a6492b07c4e033_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC05LTEtMS0xMDgxNjE_9dfabd9d-5ec5-4c33-b895-3d1554b07cdc"
      unitRef="usd">268800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfOC0xMS0xLTEtMTA4MTYx_51a7363a-1475-4005-a350-9e99f7fcf672"
      unitRef="usd">329000000.0</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e7025c3b25f4602939fc3db062b06cb_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItMS0xLTEtMTA4MTYx_95764707-14ad-4933-9fcd-3deb9e97a180"
      unitRef="usd">255000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59ac47cd04fe4a45ba8a9128f2df0c0c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItMy0xLTEtMTA4MTYx_f0f68f83-9d08-4e10-8bd5-8037b249158b"
      unitRef="usd">405500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6605ab0b24d4a3a95cd07e88110dd0e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItNS0xLTEtMTA4MTYx_cfa6fd52-5d3c-499d-82a7-d66a6595c049"
      unitRef="usd">660500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib714d01e5ecf4cd28cfdd767aab24593_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItNy0xLTEtMTA4MTYx_41f3765e-33cd-4738-a93f-10480c505291"
      unitRef="usd">252600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic74b2084ca8b4016920a9bb39463c71e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItOS0xLTEtMTA4MTYx_1946bf2a-b208-465a-9a06-b7283fe36aac"
      unitRef="usd">337000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ac0c2ed83d34c43b639039d2831ada9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTItMTEtMS0xLTEwODE2MQ_baa8bc96-82ef-4deb-a24e-7ee9c9925e60"
      unitRef="usd">589600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb1d9ae26ce84cf1851284c7e4edc162_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtMS0xLTEtMTA4MTYx_2c6b693b-a18a-4922-b3b2-a974d1a1109e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0d2c7c6dafc46998c4e95a9750239ee_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtMy0xLTEtMTA4MTYx_dcaec87d-e17f-4bef-b94e-1ca204609541"
      unitRef="usd">90700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94946a3df68a4894a63cc93522fd6ca4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtNS0xLTEtMTA4MTYx_92919e42-65a5-4a0a-9c0a-2888da670845"
      unitRef="usd">90700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad57e6166b6f48cabbffd992ec0bae18_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtNy0xLTEtMTA4MTYx_03de4244-6a6e-41c8-a520-433c50eab372"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a8c2b7b92db42f19333bc4e4af5abf1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtOS0xLTEtMTA4MTYx_d403faf0-a3c2-43d7-ae70-8078f01c0e59"
      unitRef="usd">283700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e3af1259505476faa37180bca0dbed6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTQtMTEtMS0xLTEwODE2MQ_2bdb2ca5-1af4-4f9f-8503-9a6a17a47005"
      unitRef="usd">283700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ibb131a1d8ee2411bbdf86420dba67a16_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtMS0xLTEtMTA4MTYx_60259537-d62b-4c8b-b864-e67d4e70b037"
      unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="id5748c1fd8864631b676f49aec67c5f9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtMy0xLTEtMTA4MTYx_2ce200aa-6c26-4276-98f8-6dca4aa1a6e7"
      unitRef="usd">4700000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i3ae88a70cad04a6f9c132484c353e5b9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtNS0xLTEtMTA4MTYx_86d3b11b-9dc4-4eea-ba73-9d45cd25ce63"
      unitRef="usd">4700000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="id5afd6d5f0de4b5a880e3f897b519fff_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtNy0xLTEtMTA4MTYx_64ef7bda-d982-438b-a81d-eff515fe28d7"
      unitRef="usd">81900000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i759d3f20525a4e73a29ad36cd1f9ad52_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtOS0xLTEtMTA4MTYx_2c86ae04-ff39-4a75-8651-31d06b3b35e0"
      unitRef="usd">50700000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i30625a73d79a4164a68a490ce85445d6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTUtMTEtMS0xLTEwODE2MQ_5cc6df8a-9db3-46ab-90d8-3faf2b815372"
      unitRef="usd">132600000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d296d42d02f4c53851eb8bbaa2f0904_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtMS0xLTEtMTA4MTYx_e3c78a91-87c7-4f09-9d14-c7cd2e1e8c70"
      unitRef="usd">0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9444f3dda52346f994f9fa3d1d5f265e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtMy0xLTEtMTA4MTYx_6bdcea6b-cc6b-420d-ab6a-eac360e71be9"
      unitRef="usd">95400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eff28a2bc3a4e869ed6725ec343457b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtNS0xLTEtMTA4MTYx_fcffcfda-fba0-4577-92d4-d77a4f408f21"
      unitRef="usd">95400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i230926cc93b94f13a0f1ea180f586c99_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtNy0xLTEtMTA4MTYx_bfb567b5-2585-4388-bb9f-388f305577c1"
      unitRef="usd">81900000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbfcd3defae147349f8488c0ed4ae6b3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtOS0xLTEtMTA4MTYx_50262895-4d4e-4cd5-9547-11afc9c4cc1d"
      unitRef="usd">334400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e2dd808a6bb49acaba894087e88aab6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTYtMTEtMS0xLTEwODE2MQ_312f42bc-a50d-42f2-9d33-b9c4d5b9b5b0"
      unitRef="usd">416300000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf3d857066a346c9b7cc2f77fc9cf913_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctMS0xLTEtMTA4MTYx_ab9c9a1d-88b9-422f-a36d-d3b03f76e337"
      unitRef="usd">31700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f054a91031f430392248a4bca839f9f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctMy0xLTEtMTA4MTYx_e169df40-0317-4a84-8c1e-c539f3492d15"
      unitRef="usd">2600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc86efbf51c9459a924cb8855de7d59d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctNS0xLTEtMTA4MTYx_35f1c9ed-d8f7-49bb-83e3-a2ecb8ce754e"
      unitRef="usd">34300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb67dea42a90430caaa50cf5bb540f53_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctNy0xLTEtMTA4MTYx_021d0909-c017-46a5-907e-2bbf5ec9e1fd"
      unitRef="usd">60700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15644a22cf32438bb4e89c230573cc53_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctOS0xLTEtMTA4MTYx_47670b40-6218-4fad-95a7-108a4f910ea3"
      unitRef="usd">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dd3f76fb0234ae9898dcecdd750649a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTctMTEtMS0xLTEwODE2MQ_ed96c761-d9dd-45ff-bf8f-c7194ad1b7e1"
      unitRef="usd">63600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="iee7392a5534e4fed8a494faf3156d30a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtMS0xLTEtMTA4MTYx_b3730c86-ebc7-4d45-8475-8acd5a5bd735"
      unitRef="usd">286700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7686e78d6544ad4ab6f238d59a463ae_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtMy0xLTEtMTA4MTYx_63f2f16c-6942-48b3-a033-440760ec5261"
      unitRef="usd">503500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtNS0xLTEtMTA4MTYx_491701f3-d402-44d1-ab06-b6db0cabee4d"
      unitRef="usd">790200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0599ce5bf334bcd978cd677b9ce3488_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtNy0xLTEtMTA4MTYx_3241feb8-2e0d-4663-956c-c58e89e6d97d"
      unitRef="usd">395200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac249b92a2c34f4786aaa61ef1798afc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtOS0xLTEtMTA4MTYx_b2fbd5a2-41d4-4d89-bcd1-744e09cafa0f"
      unitRef="usd">674300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOmYxZTY3YjFhNGI5NjQ5MzdhYjJmYWQxYTZjZDhkMjdmL3RhYmxlcmFuZ2U6ZjFlNjdiMWE0Yjk2NDkzN2FiMmZhZDFhNmNkOGQyN2ZfMTgtMTEtMS0xLTEwODE2MQ_1c1bf3b3-099c-499f-b967-8540683ae8c5"
      unitRef="usd">1069500000</us-gaap:Revenues>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="if052ae8be962412ca908a8ec55ce01bb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNTQ5NzU1ODQ5NzUz_4f303e3b-1983-4de2-b241-03e68206607d"
      unitRef="usd">131000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if052ae8be962412ca908a8ec55ce01bb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNTQ5NzU1ODQ5NzY5_7b85ea79-5b3d-4a49-8227-205bb85de184"
      unitRef="usd">13600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i3f1c052aa974422c8e8de6bf7e629008_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNDU4Mg_eb8d6a22-f237-4d26-96c8-60918e58ebb1"
      unitRef="usd">628200000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i4c15bfbd578f4b02a335a5f53693bd78_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNDcwMA_eec11a54-753e-4023-84a3-bf5e4fa24ced"
      unitRef="usd">542700000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i1cc548c971bc4ddab945aa7c2daa9c29_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNDcwNw_6718a735-5f43-43ee-a6a7-06fdd2ff0361"
      unitRef="usd">85500000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i7eb263408fe5444cbc0c106687b0c0bf_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNDgzOA_b028a9a4-9300-4757-8c0d-163259cea38d"
      unitRef="usd">650800000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ibb131a1d8ee2411bbdf86420dba67a16_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfMjE5OTAyMzI5MTcyMQ_5122b35f-1f7e-44bc-bdd8-fbd952f10cfb"
      unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i85d2fdbc895b41fe8983ba64d0d2ffb0_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfMjE5OTAyMzI5MTcyMQ_fbdddb62-4d2b-44c3-94dc-3bc373b83fef"
      unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="if6ea4a6a0de647a8a6d921dd7b209282_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNTIwOQ_e38bb6f7-2ee4-498e-8a2c-6d22c97df2ab"
      unitRef="usd">-86000000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="id5afd6d5f0de4b5a880e3f897b519fff_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNTIxNg_64ef7bda-d982-438b-a81d-eff515fe28d7"
      unitRef="usd">81900000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ib5f414c7b3a34d038d192fa7b90dcfbe_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNTcxNQ_4f1ac461-c7d7-41a1-b502-00d9a70beab2">P2Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i44ef3a51186e41038ea49e018725fc47_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjAzMQ_61ec1c7d-d5fd-41da-857f-f9ad817c25a2"
      unitRef="usd">200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i0c28ec30bdcd4241b718857d94f0738f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjA2MA_1a762904-3274-4f3d-a88c-77522d9d2db6"
      unitRef="usd">5100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i6d0613c15a9a4b2891e92b0cb74673fa_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjA3Mg_47bc7199-92a4-41a0-a633-821d3f7a7f8a"
      unitRef="usd">900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="if50fd0c04e7b433595e1fc59565af1ac_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjA4NA_8aecbece-f5ef-4925-91db-0d422f503ad7"
      unitRef="usd">900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ied97412e542e49649f895e9d8fca082b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjEwNw_e39cfb72-0ec0-48bb-ad3b-8c06148bee34"
      unitRef="usd">2700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjMwMg_a553a0b0-0427-49e7-932f-558836e4d7b2"
      unitRef="usd">453900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjQxOA_a553a0b0-0427-49e7-932f-558836e4d7b2"
      unitRef="usd">453900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i49ec7f41ed1e466ea8c8265cc217d1c9_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNjQ3Ng_4b28a74b-045b-4b49-ac94-bc963aadc2f5">P24M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNzQyMQ_37db5a46-01bd-40a3-8543-ca3378828d9c"
      unitRef="usd">33900000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfNzQyOA_14121eb1-94a7-45a0-8293-930f915cdd48"
      unitRef="usd">21500000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM4Mw_75867040-2b35-4bbd-8181-102eeea20966">The following table presents the roll forward of the contract liability balances:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(16.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjk0OWQ1MjIwNTIxODRhNTliY2M2N2Y5NWJkMjVjMTIwL3RhYmxlcmFuZ2U6OTQ5ZDUyMjA1MjE4NGE1OWJjYzY3Zjk1YmQyNWMxMjBfMS0yLTEtMS0xMDgxNjE_d2825968-d03a-496b-8857-4f9578e0a44b"
      unitRef="usd">16400000</us-gaap:ContractWithCustomerLiability>
    <ebs:ContractWithCustomerLiabilityAdditions
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjk0OWQ1MjIwNTIxODRhNTliY2M2N2Y5NWJkMjVjMTIwL3RhYmxlcmFuZ2U6OTQ5ZDUyMjA1MjE4NGE1OWJjYzY3Zjk1YmQyNWMxMjBfMi0yLTEtMS0xMDgxNjE_56b9d4f5-2cd9-4cf1-af5e-fd0eef305803"
      unitRef="usd">30400000</ebs:ContractWithCustomerLiabilityAdditions>
    <ebs:ContractWithCustomerLiabilityDeductions
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjk0OWQ1MjIwNTIxODRhNTliY2M2N2Y5NWJkMjVjMTIwL3RhYmxlcmFuZ2U6OTQ5ZDUyMjA1MjE4NGE1OWJjYzY3Zjk1YmQyNWMxMjBfMy0yLTEtMS0xMDgxNjE_8116fbd7-e3dc-4918-a8df-3e66567e8ecb"
      unitRef="usd">16500000</ebs:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjk0OWQ1MjIwNTIxODRhNTliY2M2N2Y5NWJkMjVjMTIwL3RhYmxlcmFuZ2U6OTQ5ZDUyMjA1MjE4NGE1OWJjYzY3Zjk1YmQyNWMxMjBfNC0yLTEtMS0xMDgxNjE_9cf4f4cc-8369-4bdf-ba92-cc18d63819e5"
      unitRef="usd">30300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODA3OA_023097eb-2ef9-4b77-bbe0-49dd2f469712"
      unitRef="usd">24800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODA4NQ_190d407f-17bd-4d76-97da-dfa6d9377352"
      unitRef="usd">11700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ebs:ScheduleOfAccountsReceivableNetTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM4OA_3dbace6e-4a30-45d8-8ca3-7792f99e13dc">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Billed, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;119.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;72.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;191.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;274.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ebs:ScheduleOfAccountsReceivableNetTableTextBlock>
    <us-gaap:BilledContractReceivables
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMS0yLTEtMS0xMDgxNjE_1700acaa-ab42-4c50-a886-c5308feed94d"
      unitRef="usd">119000000.0</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMS00LTEtMS0xMDgxNjE_2422676f-2b09-4e86-a407-922bd6a3f222"
      unitRef="usd">224900000</us-gaap:BilledContractReceivables>
    <us-gaap:UnbilledContractsReceivable
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMi0yLTEtMS0xMDgxNjE_989b6a56-4e22-46b8-862a-f820f73d9df7"
      unitRef="usd">72300000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMi00LTEtMS0xMDgxNjE_e167deb7-33b1-4561-bdb1-1118b762c7af"
      unitRef="usd">49800000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMy0yLTEtMS0xMDgxNjE_77a434b9-26fb-44d9-a299-cda54b02c802"
      unitRef="usd">191300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RhYmxlOjQ5MDY5ZjUwYmZkMzQxNjU4OGVkZjZiZDY0MmI2ZDIyL3RhYmxlcmFuZ2U6NDkwNjlmNTBiZmQzNDE2NTg4ZWRmNmJkNjQyYjZkMjJfMy00LTEtMS0xMDgxNjE_6a961302-5ec6-4fa4-89f9-2ce890d02fe0"
      unitRef="usd">274700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM1NA_f6318cde-59d6-4056-90a9-d97fe1737edd"
      unitRef="usd">700000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i30b0e22181834e9d8a6008ddf0fd449c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml82NC9mcmFnOmZmMDRjNGNhNTQ0MDQzOTc4M2VhNWM5ZWU0ZWVmMTQ5L3RleHRyZWdpb246ZmYwNGM0Y2E1NDQwNDM5NzgzZWE1YzllZTRlZWYxNDlfODM2MQ_b6c785e1-e6c0-4204-99bb-25b04283b876"
      unitRef="usd">3200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfNTk5_07ff004b-20f8-4370-8adc-7b5a2af3e52e">Income taxes&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated effective annual tax rate as of September&#160;30, 2022 and 2021 for the years ended December 31, 2022 and 2021, excluding the impact of discrete adjustments, was 3% and 24%, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The decrease in the estimated effective annual tax rate is primarily due to decreased profitability, the impact of certain permanent adjustments, and a valuation allowance charge. The Company recorded discrete tax benefits of $10.9&#160;million and $10.3&#160;million for the three and nine months ended September&#160;30, 2022, respectively, and $1.7 million and $7.2&#160;million, for the three and nine months ended September&#160;30, 2021, respectively. The discrete tax benefit in 2022 was primarily due to return to provision adjustments and the benefit of the release of an indemnified uncertain tax position offset by share-based compensation activity. The net discrete benefits in 2021 were primarily due to share-based compensation activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company establishes valuation allowances for deferred income tax assets in accordance with U.S. GAAP, which provides that such valuation allowances shall be established unless realization of the income tax benefits is more likely than not. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;become&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; deductible. At each reporting period, the Company considers the scheduled reversal of deferred tax liabilities and assets, available taxes in carryback periods, tax planning strategies and projected future taxable income in making this assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the Company determined that it was more likely than not that deferred tax assets in the U.S. would not be realized due to reductions in estimates &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; future profitability in the U.S. Accordingly, the Company recorded a provision of $19.2 million associated with the establishment of a valuation allowance on those deferred tax assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if2e7ce5556ca4a7fb06da82e3898d7b2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMTg3_c8507dd6-5c62-4508-acd9-7f244f3da1b9"
      unitRef="number">0.03</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3eabe1e8d9c443b4aba12a1f4dfe8104_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMTk0_94c9da9a-1d0e-451f-a565-1553056e1465"
      unitRef="number">0.24</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMjY4_833a7ec2-cb4f-4b75-9110-9d0deefb9b16"
      unitRef="usd">-10900000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMjc1_c0b8ee71-0353-473f-99ca-88939a7a84bb"
      unitRef="usd">-10300000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMzI0_06e60a94-e4b2-4fdf-8aeb-51e4a40a4c2c"
      unitRef="usd">1700000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfMzMx_3430f977-c03e-452d-b480-652268ec55e1"
      unitRef="usd">7200000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia8d11b69d7094e958cdf98db6cd53b20_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83MC9mcmFnOjdhMGE5ZDE3M2I4NTQwNTg5ODkzNDUxYzMyN2ZhNWVjL3RleHRyZWdpb246N2EwYTlkMTczYjg1NDA1ODk4OTM0NTFjMzI3ZmE1ZWNfNDk0NzgwMjMzMTA3OA_72e5333c-e73e-4e84-a178-93225d60fa19"
      unitRef="usd">19200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RleHRyZWdpb246MDM1ZDFjMjQ4YmFjNDUzN2FmZTYwMDhhYzI4MjFkNWFfMTMwMw_7f0d82a6-7411-4adb-abc3-93a8b816c017">Net income (loss) per share&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted net income (loss) per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(75.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(135.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;53.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Dilutive securities&#x2014;equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;53.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Net income (loss) per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. No adjustment for the potential dilutive effect of dilutive securities is reported for the three and nine months ended September&#160;30, 2022 as the effect would have been anti-dilutive due to the Company's net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price. The following table presents the share-based awards that are not considered in the diluted income (loss) per share calculation generally because the exercise price of the awards was greater than the average per share closing price during the three and nine months ended September&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Anti-dilutive stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RleHRyZWdpb246MDM1ZDFjMjQ4YmFjNDUzN2FmZTYwMDhhYzI4MjFkNWFfMTMwMA_fd1097a9-091b-4c39-b41a-f3cba8314f77">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted net income (loss) per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(75.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(32.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(135.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;53.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Dilutive securities&#x2014;equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Weighted-average number of shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;53.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Net income (loss) per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMy0xLTEtMS0xMDgxNjE_2d38d949-533f-40b6-b15f-f3713e508c9a"
      unitRef="usd">-75700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMy0zLTEtMS0xMDgxNjE_a85819e8-8e18-41d3-ab77-061fe44c9d8a"
      unitRef="usd">-32700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMy01LTEtMS0xMDgxNjE_0c1fb09a-6ae6-44fa-accf-3d79eed0240b"
      unitRef="usd">-135800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMy03LTEtMS0xMDgxNjE_b30bdb0f-e594-4200-8308-ba89abf8457b"
      unitRef="usd">41600000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNi0xLTEtMS0xMDgxNjE_04a63ac4-ddcb-46fb-b04d-fb1bad27675c"
      unitRef="shares">49900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNi0zLTEtMS0xMDgxNjE_fa28151c-2528-415e-b55c-ac7c11bc7db5"
      unitRef="shares">53700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNi01LTEtMS0xMDgxNjE_668ceebc-0faa-4967-a3a4-83dc57066d4c"
      unitRef="shares">50200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNi03LTEtMS0xMDgxNjE_cb2c4406-3006-4eb7-8d94-95af548e4c7a"
      unitRef="shares">53600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNy0xLTEtMS0xMDgxNjE_73627f6a-0d46-469a-b05c-ad985482e531"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNy0zLTEtMS0xMDgxNjE_f6f680f4-ad2d-4cb8-a5ad-8e448cc5f51c"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNy01LTEtMS0xMDgxNjE_b9cb315c-143b-4ae6-b609-a18969b8af43"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfNy03LTEtMS0xMDgxNjE_bf82b902-4cde-4d9e-8193-ebeaa6e7a999"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfOC0xLTEtMS0xMDgxNjE_de5566c4-404b-4a02-92f7-1c0d5f75bd0c"
      unitRef="shares">49900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfOC0zLTEtMS0xMDgxNjE_6f7ac32e-cb05-40cb-8bef-5b561fe47281"
      unitRef="shares">53700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfOC01LTEtMS0xMDgxNjE_3db09b23-3db5-4d61-b52d-91960e691fea"
      unitRef="shares">50200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfOC03LTEtMS0xMDgxNjE_5604f6c5-81c1-44db-83b9-cb5372a9f663"
      unitRef="shares">54300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTAtMS0xLTEtMTA4MTYx_0899720f-7187-49ac-87ad-48802a69f128"
      unitRef="usdPerShare">-1.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTAtMy0xLTEtMTA4MTYx_9f18dbc4-432c-4cb0-83f5-f77c210c1903"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTAtNS0xLTEtMTA4MTYx_8764a2a5-bc7d-4f36-9242-458b5166a651"
      unitRef="usdPerShare">-2.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTAtNy0xLTEtMTA4MTYx_7c2d6d94-d878-464d-9d6d-7bc1de4d6f6b"
      unitRef="usdPerShare">0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTEtMS0xLTEtMTA4MTYx_1529dd60-b266-4d24-9a1a-859642f79c9b"
      unitRef="usdPerShare">-1.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTEtMy0xLTEtMTA4MTYx_fdd5441a-2fac-4746-bdce-4edddcccc5ef"
      unitRef="usdPerShare">-0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTEtNS0xLTEtMTA4MTYx_4d6dad44-41c2-4239-83cc-2b02db325c84"
      unitRef="usdPerShare">-2.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOmIwNmE2MmE4MThiOTQ3YTU5YmI2YzJmYWJiZDQwM2ZlL3RhYmxlcmFuZ2U6YjA2YTYyYTgxOGI5NDdhNTliYjZjMmZhYmJkNDAzZmVfMTEtNy0xLTEtMTA4MTYx_fcd76b95-bc43-4ff4-b7cf-b753ab1ff37e"
      unitRef="usdPerShare">0.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RleHRyZWdpb246MDM1ZDFjMjQ4YmFjNDUzN2FmZTYwMDhhYzI4MjFkNWFfMTMwMQ_b07ce4c2-87c2-4138-a71f-c684e125c662">The following table presents the share-based awards that are not considered in the diluted income (loss) per share calculation generally because the exercise price of the awards was greater than the average per share closing price during the three and nine months ended September&#160;30, 2022 and 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Anti-dilutive stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOjUzZjU2ZWQ2MjNlOTQyNGE5OTQ3NTA2M2I1YmU4ODZmL3RhYmxlcmFuZ2U6NTNmNTZlZDYyM2U5NDI0YTk5NDc1MDYzYjViZTg4NmZfMi0xLTEtMS0xMDgxNjE_699f77ac-66b1-4928-bd11-8974f3d42f20"
      unitRef="shares">3300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOjUzZjU2ZWQ2MjNlOTQyNGE5OTQ3NTA2M2I1YmU4ODZmL3RhYmxlcmFuZ2U6NTNmNTZlZDYyM2U5NDI0YTk5NDc1MDYzYjViZTg4NmZfMi0zLTEtMS0xMDgxNjE_f06daa4d-553a-4b11-93b3-bb7a7333cf85"
      unitRef="shares">1400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOjUzZjU2ZWQ2MjNlOTQyNGE5OTQ3NTA2M2I1YmU4ODZmL3RhYmxlcmFuZ2U6NTNmNTZlZDYyM2U5NDI0YTk5NDc1MDYzYjViZTg4NmZfMi01LTEtMS0xMDgxNjE_37932ffa-6ab9-4fe3-80fd-cd01fb2057ad"
      unitRef="shares">2600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83My9mcmFnOjAzNWQxYzI0OGJhYzQ1MzdhZmU2MDA4YWMyODIxZDVhL3RhYmxlOjUzZjU2ZWQ2MjNlOTQyNGE5OTQ3NTA2M2I1YmU4ODZmL3RhYmxlcmFuZ2U6NTNmNTZlZDYyM2U5NDI0YTk5NDc1MDYzYjViZTg4NmZfMi03LTEtMS0xMDgxNjE_8782608b-3a17-48ef-bb96-13feeefd56f8"
      unitRef="shares">600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMTUzOQ_8c07a8bc-d24f-4ff4-b58d-7b5787643222">Equity&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Repurchase programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 11, 2021, the Company announced that its Board of Directors authorized management to repurchase up to an aggregate of $250.0&#160;million of Common Stock under a board-approved Share Repurchase Program, of which $187.9&#160;million has been utilized to purchase 4.4&#160;million shares as of September&#160;30, 2022. During the three months ended September&#160;30, 2022, there were no shares repurchased. During the nine months ended September&#160;30, 2022, the Company has utilized $75.5&#160;million to purchase 1.8&#160;million shares. The Share Repurchase Program does not obligate the Company to acquire any specific number of shares. Repurchased shares will be available for use in connection with the Company's stock plans and for other corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2022, the Company granted stock options to purchase 0.7&#160;million shares of common stock and 1.5&#160;million restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Typically, the stock option and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria. Share-based compensation expense was recorded in the following financial statement line items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss, net of tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes changes in accumulated other comprehensive loss, net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Defined Benefit Pension Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(16.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(25.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present the tax effects related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ic4d3da6f40f548208c86343dfbb7f66e_I20211111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfNTQ5NzU1ODE1NDM4_bcf0a8b3-991d-4254-a718-8ef703a45fc9"
      unitRef="usd">250000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="if6a69a9d549d4a7f9e5cca915ff81ac2_D20211111-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMjU1_9e80c821-e2e1-4217-9a19-42b5287dd493"
      unitRef="usd">187900000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="if6a69a9d549d4a7f9e5cca915ff81ac2_D20211111-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMjg4_fb011bf4-8dc5-44d8-9a67-019e49a28f9b"
      unitRef="shares">4400000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6c17179d3e4b4293af0a828cab7b1e54_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfNTQ5NzU1ODE1Njcz_4e671748-10a5-42e9-a473-c3fe227f9e62"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i8990366d48494f1b8a20b74e61189484_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMzU4_558b5ab0-211c-45c2-bb0f-ce64d6a352b1"
      unitRef="usd">75500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i8990366d48494f1b8a20b74e61189484_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMzgw_c3dec7f6-0acb-4d9d-a297-de493ec24eaf"
      unitRef="shares">1800000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i741c417cf3c5438e926f3c181037b75a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfNzIy_0e7af33d-305e-4254-92cd-c4d50f4abd74"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icec9923b70dd4963ad63bbf6fbe6313b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfNzUy_413d5adc-d05a-446c-b2a5-61db33a774e9"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="icec9923b70dd4963ad63bbf6fbe6313b_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMTU0NQ_953cc636-d966-4bc8-9ef5-e94171ed61ee">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMTUzOA_f1650d37-7b8c-4e39-b39e-ab3b5d9a321b">Share-based compensation expense was recorded in the following financial statement line items:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i28b1f195ba044f8fba31c82ade107986_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMi0xLTEtMS0xMDgxNjE_3997e759-e9b4-4a16-8f5a-a075c93f6deb"
      unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i76cbbd4bcdbd481f9e12b0c3a5cf4906_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMi0zLTEtMS0xMDgxNjE_d6ab1792-0258-42b7-9fc2-7737d7d6548e"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic35e87d35bfd4ff89237fb26b10d3744_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMi01LTEtMS0xMDgxNjE_413bab59-4a65-4296-9238-5b7ed8d4970a"
      unitRef="usd">5400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i598359cdd71c4de1a7ee59cbd115af40_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMi03LTEtMS0xMDgxNjE_d3451414-46eb-4bea-b0b7-01857351099b"
      unitRef="usd">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff9ad4afb37944048472b35bed2debf0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMy0xLTEtMS0xMDgxNjE_5ea8bfd0-0df3-474a-9c79-c5d51d700ada"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic29a7152fbf34b57b22e53b5f6a77694_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMy0zLTEtMS0xMDgxNjE_1bff696e-e2b4-4cfc-adba-701353b3b180"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib20b602b02994e55bb8f5ff08e429097_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMy01LTEtMS0xMDgxNjE_f4a773bc-2a24-4326-afa8-35bb393001a4"
      unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i37dbd3322fa84e95b69930efeffb24f6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfMy03LTEtMS0xMDgxNjE_e7ae48b8-d38e-4cd2-985b-7bf360022af6"
      unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i19613f0852b447be92b4d26268de48b6_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNC0xLTEtMS0xMDgxNjE_0a7f06d3-d583-4de2-b6d5-ab6c4eae3ee9"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibefbe152ae4b4ce4a115b201334e73c7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNC0zLTEtMS0xMDgxNjE_78528549-c85d-4961-bacf-8e50488aea60"
      unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd27e1e917ee436d8d215b793434f26a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNC01LTEtMS0xMDgxNjE_404e5533-f589-481b-ab72-560a606dc7b4"
      unitRef="usd">3900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5bff5d9f1c2e45429a4c8237c99b05c8_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNC03LTEtMS0xMDgxNjE_e0160318-7629-40cb-aa2c-08914cbfb0cd"
      unitRef="usd">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ica2181992bf34758ae89111c96b05c4a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNS0xLTEtMS0xMDgxNjE_c19600d3-c11a-4e56-8c38-5ed78b7fab12"
      unitRef="usd">7700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38e2b94c99ce4c32bf8a4a143327d9e3_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNS0zLTEtMS0xMDgxNjE_f771aa8a-ea84-40eb-8ac6-61c94a65e62e"
      unitRef="usd">7400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia02d17b7af424e47932221e5cb92610d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNS01LTEtMS0xMDgxNjE_edee29bb-32de-4222-b6be-5165888888de"
      unitRef="usd">22700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i22dbe6000d7d4fb6bb7bafebd2ab2977_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNS03LTEtMS0xMDgxNjE_4526048a-e165-4448-a888-6f10f86dad50"
      unitRef="usd">22500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNi0xLTEtMS0xMDgxNjE_f4daf2b1-cd77-4793-9d92-e69662708b8e"
      unitRef="usd">11200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNi0zLTEtMS0xMDgxNjE_7bc61830-33e5-42dd-983c-a9ed32f36f04"
      unitRef="usd">10400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNi01LTEtMS0xMDgxNjE_579c55c8-b6ae-4785-9033-c858c109d651"
      unitRef="usd">33400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjVkZmViODIzZmFlNjRhMjk4NmY0NjMzZWY5ZGY2MjM1L3RhYmxlcmFuZ2U6NWRmZWI4MjNmYWU2NGEyOTg2ZjQ2MzNlZjlkZjYyMzVfNi03LTEtMS0xMDgxNjE_17427a8c-ac7c-432f-b693-ce5a085dd27f"
      unitRef="usd">32300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMTU0Ng_9350e633-64d9-4107-afe2-40889998612c">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes changes in accumulated other comprehensive loss, net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Defined Benefit Pension Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(16.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(25.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Balance, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i9f2c4b48c5bf44b583764343364acd18_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMi0yLTEtMS0xMDgxNjE_9e1bbd39-44bf-4fa8-bfea-1678b46f0def"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e4037d8d3a6449baf24676b5b39d131_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMi00LTEtMS0xMDgxNjE_9b2655b1-4f80-484d-b86a-cf66b2133351"
      unitRef="usd">-4500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73cb1d2c06c148969484c4bf9e7eb0eb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMi02LTEtMS0xMDgxNjE_0b41fb08-8724-48e7-8dd8-cc0fdd692958"
      unitRef="usd">-7600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4698414e7c1401c82d1bdd7bd331f7f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMi04LTEtMS0xMDgxNjE_5c499fc2-d4fc-4601-bd47-304ec54fceb4"
      unitRef="usd">-16100000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMy00LTEtMS0xMDgxNjE_d025147a-880f-4805-b44a-b27223a446aa"
      unitRef="usd">9400000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMy02LTEtMS0xMDgxNjE_db252e39-35c1-492f-9731-cac1c1ff5a93"
      unitRef="usd">-400000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMy04LTEtMS0xMDgxNjE_c480dc90-650a-40ff-9e3c-41287c7a7599"
      unitRef="usd">9000000.0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNC00LTEtMS0xMDgxNjE_e5f8aade-c9d5-4fdb-aae9-8f48d518e4d8"
      unitRef="usd">-1900000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNC04LTEtMS0xMDgxNjE_e18cd3d5-d9ce-4cc9-a0e5-f997020a863a"
      unitRef="usd">-1900000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6b67a9c1ec7349d18cbb84f1528227b8_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNS0yLTEtMS0xMDgxNjE_b8634afc-ff25-4c4d-8dd6-566d76b254a6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNS00LTEtMS0xMDgxNjE_d2ae4efa-7e50-49ba-90f1-ad5e290a31e1"
      unitRef="usd">11300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNS02LTEtMS0xMDgxNjE_ab2c4fc3-3e0b-4203-a906-5d85b030a79a"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNS04LTEtMS0xMDgxNjE_a4d8109c-e059-4303-ae7a-552ce0260256"
      unitRef="usd">10900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="id7b70bf533d44156972098e72400de35_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNi0yLTEtMS0xMDgxNjE_29a78287-01e6-4ebc-b4f7-78ee36292400"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2be39dc33a614a138b0a5fa59b102996_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNi00LTEtMS0xMDgxNjE_8df486cc-b3b6-4936-bd91-9f6a932c5296"
      unitRef="usd">6800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iced5a2acfffc465fa00678af5ae50f55_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNi02LTEtMS0xMDgxNjE_4e3aba7f-cb41-41ad-9d8b-490c1741b4db"
      unitRef="usd">-8000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib32c62eb60fc4dc39b819eb33d2ecd33_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfNi04LTEtMS0xMDgxNjE_a5b55a2c-4f90-4330-8380-8be91f7da4bb"
      unitRef="usd">-5200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id7c28ab284a34fd99cbac681f30c7f59_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOC0yLTEtMS0xMDgxNjE_c7451da5-735b-4fef-8bed-60bbf7ff49b9"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaac12e2048894448abb1be8d9798b112_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOC00LTEtMS0xMDgxNjE_72d71ea1-4a24-4d04-a57c-071dafa4a951"
      unitRef="usd">4600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67e98f514b5248989bc8c524e454fe4b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOC02LTEtMS0xMDgxNjE_ddf2bf28-0dc9-4575-ba61-50e6faf8edc6"
      unitRef="usd">-6700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i215adb10fcbf40a5a7ec2fc2088354e3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOC04LTEtMS0xMDgxNjE_632e3aa6-c091-4861-9fae-d6b0a08114ff"
      unitRef="usd">-6100000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOS00LTEtMS0xMDgxNjE_2dcb0579-da1d-4f96-a1cf-504607e46daf"
      unitRef="usd">2600000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOS02LTEtMS0xMDgxNjE_feb52855-9332-4c71-8c5a-f6e4baced55a"
      unitRef="usd">-1300000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfOS04LTEtMS0xMDgxNjE_7ee4a978-2375-4561-8317-5d125e0cd270"
      unitRef="usd">1300000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTAtNC0xLTEtMTA4MTYx_3f6ea8df-ec04-4053-b3a0-48057576bf2f"
      unitRef="usd">400000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTAtOC0xLTEtMTA4MTYx_c9938429-9c69-4731-a22b-61afd64fb2ae"
      unitRef="usd">400000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9f38ed14c4bf4de6b87cd4d750fc372c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTEtMi0xLTEtMTA4MTYx_6b7ae297-6a85-4741-9481-084b622b3fb3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTEtNC0xLTEtMTA4MTYx_174afa78-da1d-4e91-a012-98a93a863975"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTEtNi0xLTEtMTA4MTYx_92f4f2b0-7d4f-4c1d-8fbe-3cf8e63a2c3d"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTEtOC0xLTEtMTA4MTYx_3bec92d5-d767-40e4-81db-c244151f7ee5"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="id7b70bf533d44156972098e72400de35_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTItMi0xLTEtMTA4MTYx_bda1f451-8f1d-4f91-afae-1409cc3b0f34"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2be39dc33a614a138b0a5fa59b102996_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTItNC0xLTEtMTA4MTYx_e7299448-0eb0-4e7f-9e35-52e80c7dfd47"
      unitRef="usd">6800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iced5a2acfffc465fa00678af5ae50f55_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTItNi0xLTEtMTA4MTYx_3106b705-300d-4da3-908a-e9c2c8af0868"
      unitRef="usd">-8000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib32c62eb60fc4dc39b819eb33d2ecd33_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTItOC0xLTEtMTA4MTYx_fa5e4ebb-438b-47bd-8b9b-f120913c4d47"
      unitRef="usd">-5200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i43143025a48b44c0a71392046d272649_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTQtMi0xLTEtMTA4MTYx_8a7357bf-ddee-455a-9bd5-f3432299c4c8"
      unitRef="usd">-7700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c5ea12368ef4ae3bb23c26ed19c8995_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTQtNC0xLTEtMTA4MTYx_6f825458-f8e8-431a-ae39-68bb8848ec56"
      unitRef="usd">-11000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63b169b1e50643f2add731b5b39f04c4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTQtNi0xLTEtMTA4MTYx_ee3013b6-6658-4e27-9602-41a3f984a13b"
      unitRef="usd">-6600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9334dc4e6d884a7cbb7f455bf2f9af61_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTQtOC0xLTEtMTA4MTYx_f43b9d3d-3f56-47cd-8ab4-b532a2f7a795"
      unitRef="usd">-25300000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTUtNC0xLTEtMTA4MTYx_deb8c285-a85b-4d31-bf9a-26b9b686dd5b"
      unitRef="usd">-700000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTUtNi0xLTEtMTA4MTYx_cd99077c-0f34-4376-a34d-eae13357c606"
      unitRef="usd">-1400000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTUtOC0xLTEtMTA4MTYx_45eee84c-e1c8-4bb4-a659-db4bb89a0fee"
      unitRef="usd">-2100000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTYtNC0xLTEtMTA4MTYx_42b2d1fb-db22-49f3-b2a5-c795ccbc717b"
      unitRef="usd">-4300000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTYtOC0xLTEtMTA4MTYx_fe421dbe-6f2f-4640-83af-d54f74eb4779"
      unitRef="usd">-4300000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTctNC0xLTEtMTA4MTYx_ba2a4934-dbcc-4f4b-b28e-df28080ee98e"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTctNi0xLTEtMTA4MTYx_1d119008-65a2-484b-877b-94d4ab1346df"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTctOC0xLTEtMTA4MTYx_d5f61d4f-3f64-4e43-a59a-0d35484035e5"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="ie4f63f2b44854c31bb36daeefef5eb2a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTgtMi0xLTEtMTA4MTYx_3fcb112f-97e4-46fb-840c-160bd6f2fbbc"
      unitRef="usd">-7700000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia5dd4144da824a99afec23d0225b46ec_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTgtMi0xLTEtMTA4MTYx_91ef1eb0-5a77-4e52-b794-da0674ad6fd5"
      unitRef="usd">-7700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="iccb2cd37199e4c108d7c667ed7106280_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTgtNC0xLTEtMTA4MTYx_ee52ce82-7a11-41f8-8d15-57e3312ca8c9"
      unitRef="usd">-7400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0020c5f97ae64effb8f68a65a66da7b3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTgtNi0xLTEtMTA4MTYx_38a42148-86d2-456e-805c-1376b7ee57cb"
      unitRef="usd">-8000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i234810222a77469a8d310e47d2fa2f03_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMTgtOC0xLTEtMTA4MTYx_60e0080d-6344-4fca-b40d-4ed00d3d796d"
      unitRef="usd">-23100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i580d7f5f89514a8d9a9655a5cb84908b_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjAtMi0xLTEtMTA4MTYx_5c5a85eb-94e8-48eb-a98c-9c9635f9b21d"
      unitRef="usd">-7700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5938e145ac85492f83e842b212b1e504_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjAtNC0xLTEtMTA4MTYx_f751e77a-1561-4f83-af2d-571c78d79a9c"
      unitRef="usd">-6400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i563cf1b2420d41c1ba3c84e069d89c8a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjAtNi0xLTEtMTA4MTYx_19e55076-08c5-4b1c-af46-20876ed61d14"
      unitRef="usd">-8300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e6a2188c167465d9720bcd73f722dcd_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjAtOC0xLTEtMTA4MTYx_a70cc2f6-0312-4667-b0f4-7b94b37fe573"
      unitRef="usd">-22400000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjEtNC0xLTEtMTA4MTYx_6cd593f6-a31f-4ff8-b443-fd6da1644d0d"
      unitRef="usd">-2300000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjEtNi0xLTEtMTA4MTYx_f15bc7a6-2757-4afd-8d7c-4560e2e0c157"
      unitRef="usd">300000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjEtOC0xLTEtMTA4MTYx_bc5b37c3-031e-4251-96eb-285bd9c30900"
      unitRef="usd">-2000000.0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjItNC0xLTEtMTA4MTYx_1d00677c-1a2b-4006-9538-fcf6ce8bb04f"
      unitRef="usd">-1300000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjItOC0xLTEtMTA4MTYx_c49e70ab-866c-4f7a-81e4-919846913aa9"
      unitRef="usd">-1300000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifd7dfbc7f90e4bce9bca0903609cb140_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjMtMi0xLTEtMTA4MTYx_298c4409-0c9c-414f-a610-de80dcce8fd2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjMtNC0xLTEtMTA4MTYx_2874d438-563e-4552-8022-14a221b9c93f"
      unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjMtNi0xLTEtMTA4MTYx_3d17bda9-d18e-4469-a827-5ced3ba0b070"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjMtOC0xLTEtMTA4MTYx_2efee48b-c4cf-4f96-baff-2622cb396c1e"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="ie4f63f2b44854c31bb36daeefef5eb2a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjQtMi0xLTEtMTA4MTYx_b0ce805c-8b25-4db6-86ed-c47b70d79e58"
      unitRef="usd">-7700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iccb2cd37199e4c108d7c667ed7106280_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjQtNC0xLTEtMTA4MTYx_cb4de046-4594-446b-91a5-3d1cf08a288b"
      unitRef="usd">-7400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0020c5f97ae64effb8f68a65a66da7b3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjQtNi0xLTEtMTA4MTYx_0e7945bc-e955-4ba5-86b8-e6bf74beece5"
      unitRef="usd">-8000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i234810222a77469a8d310e47d2fa2f03_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjY4ZTA2MGI0MDg4NDQxNGM5ZDI0OTVkZTgyZjg5OWY5L3RhYmxlcmFuZ2U6NjhlMDYwYjQwODg0NDE0YzlkMjQ5NWRlODJmODk5ZjlfMjQtOC0xLTEtMTA4MTYx_ce2f7e97-2923-402e-b2f8-0663ffef181f"
      unitRef="usd">-23100000</us-gaap:StockholdersEquity>
    <us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RleHRyZWdpb246OWQzOGI2ZGU2NWQzNDUzNjg4Yzk0NDk4OTBhNTA0ZjJfMTU0Mw_032d0c6f-8620-4657-aa7d-a36c284979aa">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present the tax effects related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="33" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC0xLTEtMS0xMDgxNjE_e10ee30d-d0ff-40e3-bcc0-104673f343eb"
      unitRef="usd">3000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC0zLTEtMS0xMDgxNjE_99c7ac87-45ff-4951-9067-fe6f65058cbe"
      unitRef="usd">800000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4a289bb66e084884817817146aa5a26f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC01LTEtMS0xMDgxNjE_004441f5-47c1-4b99-9235-5a202ecde45b"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC03LTEtMS0xMDgxNjE_8bfba810-cdf7-4423-b07e-568471fc86e6"
      unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC05LTEtMS0xMDgxNjE_92bb5c04-6d69-44a0-8a69-b72a2b585d35"
      unitRef="usd">2300000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i329b945040704750b621490e14ce1c15_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNC0xMS0xLTEtMTA4MTYx_9317f9c4-8881-49a7-8f11-0beaaf9e923c"
      unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS0xLTEtMS0xMDgxNjE_12267fe6-d67e-42e2-b2f3-4f4e2cf45c77"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS0zLTEtMS0xMDgxNjE_30cb41c0-da66-4e00-aee5-4b7603831faa"
      unitRef="usd">1400000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icdf9eded35714dc4bfc05f5bbdd9b71b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS01LTEtMS0xMDgxNjE_8e1d835b-1982-4a63-b3a2-f91bcdbb8842"
      unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS03LTEtMS0xMDgxNjE_1f5d5ebf-a7b0-4d07-b66e-9070fe8a38e4"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS05LTEtMS0xMDgxNjE_6aad4633-fc28-42d9-81f7-87bb05945646"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7f0b81b99c5b4369ad248be034727700_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNS0xMS0xLTEtMTA4MTYx_1524bf79-cb33-4ee6-9571-4570df02809e"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi0xLTEtMS0xMDgxNjE_af6d0e93-2c4a-42c3-a34e-740e3bd4f112"
      unitRef="usd">3100000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi0zLTEtMS0xMDgxNjE_72bf2cca-3d83-40e9-8923-e101479c5cb8"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi01LTEtMS0xMDgxNjE_96347f54-f2f5-4c5d-9ac4-2967294bbc58"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi03LTEtMS0xMDgxNjE_287b035b-a083-40e3-8900-d72f59f40e49"
      unitRef="usd">1600000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi05LTEtMS0xMDgxNjE_9a09e2df-31ec-4c4e-9c9b-26a58a9cd740"
      unitRef="usd">2300000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOmNjYzg1ZThjZTU0MDRhZjVhODJiOGRiN2EzMWUzYmQ3L3RhYmxlcmFuZ2U6Y2NjODVlOGNlNTQwNGFmNWE4MmI4ZGI3YTMxZTNiZDdfNi0xMS0xLTEtMTA4MTYx_7e5eb6b1-45ba-4d2b-8362-9fed4eafddbf"
      unitRef="usd">-700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC0xLTEtMS0xMDgxNjE_96d32b4f-8264-4e16-bc4d-634d1d9a1cc0"
      unitRef="usd">15400000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC0zLTEtMS0xMDgxNjE_da5a0bf8-bcda-4211-b16a-3cc13185f0e0"
      unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9dcdc4010cd94c319fd90c5e8cfe4006_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC01LTEtMS0xMDgxNjE_de822f8d-53ef-4008-a96e-06d662844493"
      unitRef="usd">11300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC03LTEtMS0xMDgxNjE_08fc474a-d028-4933-976c-91eb57184bd5"
      unitRef="usd">4900000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC05LTEtMS0xMDgxNjE_52141188-fc53-48c9-a6fd-ecc07aa98796"
      unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if0cbcc7cfc2d4e4d8437aad1ba0e6fd7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNC0xMS0xLTEtMTA4MTYx_ba76517d-f932-4c14-a428-b78a324392aa"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS0xLTEtMS0xMDgxNjE_d23c2606-070a-47e0-95f2-38e3f8e252d2"
      unitRef="usd">2100000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS0zLTEtMS0xMDgxNjE_bffca51a-447b-4e68-b086-e9b9bdea3be0"
      unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1dcc057634304d1fa9f5f0652d6c9541_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS01LTEtMS0xMDgxNjE_3b1129c1-245a-4ed4-9ad8-ff70bd26d010"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS03LTEtMS0xMDgxNjE_7fb0072f-34a3-47da-8b8f-7b84c31cce60"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS05LTEtMS0xMDgxNjE_78a65b0a-a781-44f2-b9ec-9e4e709e08b0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia9033b0fc7e147a184ceb1c47e0b6a82_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNS0xMS0xLTEtMTA4MTYx_d2959959-1664-4bbf-b870-0b9725d09f91"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi0xLTEtMS0xMDgxNjE_3896e4ae-3981-455a-b31f-fcb0d2d2545c"
      unitRef="usd">17500000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi0zLTEtMS0xMDgxNjE_54f45c77-1a7d-442a-a50d-0c7a832f513a"
      unitRef="usd">6600000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi01LTEtMS0xMDgxNjE_d92a3cfc-057b-4a0e-941b-d57a66e61c16"
      unitRef="usd">10900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi03LTEtMS0xMDgxNjE_121a5d3d-28e8-4fc9-9286-145c68798245"
      unitRef="usd">3500000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi05LTEtMS0xMDgxNjE_c1952fff-64e4-4dbc-879a-5117e275b133"
      unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml83Ni9mcmFnOjlkMzhiNmRlNjVkMzQ1MzY4OGM5NDQ5ODkwYTUwNGYyL3RhYmxlOjQ2Nzc5ZDZjN2YxOTQ0NGJiNWY5ZDQwNDRlZjkzZTIzL3RhYmxlcmFuZ2U6NDY3NzlkNmM3ZjE5NDQ0YmI1ZjlkNDA0NGVmOTNlMjNfNi0xMS0xLTEtMTA4MTYx_713e100d-0672-4c6f-bf53-d24fa7bb65b4"
      unitRef="usd">2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTg4OA_0a8462d2-3ef9-4253-ba05-002d6a5eb49b">Segment InformationThe Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. During the first quarter of 2022, the Company revised the reporting that the CODM reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) Products segment consisting of the Government - MCM and Commercial business lines and 2) Services segment focused on CDMO. The Company evaluates the performance of these reportable segments based on revenue and adjusted gross margin. Segment revenue includes external customer sales, but it does not include inter-segment services. Adjusted gross margin for each segment is segment revenue less segment cost of sales reduced for significant one-time events. We do not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. The Company has recast the related historical information for consistency.&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables include segment revenues and a reconciliation of the Company's segment adjusted gross margin to the condensed consolidated statement of operations for each of the Company's reporting segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;186.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;240.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;329.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(85.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(85.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(103.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(103.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(63.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(63.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(114.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(114.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;100.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;74.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(72.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;101.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;168.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(72.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Services revenue and Services adjusted gross margin for the three months ended September 30, 2021 includes the impact of the reversal of $86.0 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;660.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;790.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;589.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;416.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,069.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(34.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(34.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(63.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(63.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(256.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(256.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(237.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(237.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(217.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(217.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(307.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(307.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;403.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(122.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;281.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;352.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;108.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;461.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;406.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(122.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;284.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;355.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;108.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;463.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt; Services revenue and Services adjusted gross margin for the nine months ended September 30, 2021 includes the impact of $81.9 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes depreciation expense for each segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Depreciation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;21.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages its assets on a total company basis, not by operating segment, as the Company's operating assets are shared or commingled. Therefore, the Company's CODM does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTg4NA_f84d7acc-5bac-41e5-bf34-41a1a29ea5bc">The Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. During the first quarter of 2022, the Company revised the reporting that the CODM reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) Products segment consisting of the Government - MCM and Commercial business lines and 2) Services segment focused on CDMO. The Company evaluates the performance of these reportable segments based on revenue and adjusted gross margin. Segment revenue includes external customer sales, but it does not include inter-segment services. Adjusted gross margin for each segment is segment revenue less segment cost of sales reduced for significant one-time events. We do not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. The Company has recast the related historical information for consistency.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTY0OTI2NzQ0NDc4Mw_83999cc4-ff49-48c3-9fd0-714701d38614"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTY0OTI2NzQ0NDc4Mw_ec67a01a-2c1e-4636-9b75-53d42761c544"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTg4Ng_3fe0aee1-4c55-4fd7-ae90-1b3b145c7d1e">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables include segment revenues and a reconciliation of the Company's segment adjusted gross margin to the condensed consolidated statement of operations for each of the Company's reporting segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;186.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;36.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;240.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;329.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(85.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(85.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(103.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(103.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(63.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(63.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(114.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(114.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;100.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;74.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;167.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(72.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;94.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;101.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;168.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(72.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;95.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Services revenue and Services adjusted gross margin for the three months ended September 30, 2021 includes the impact of the reversal of $86.0 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;660.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;95.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;790.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;589.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;416.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1,069.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(34.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(34.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(63.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(63.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(256.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(256.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(237.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(237.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Cost of CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(217.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(217.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(307.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(307.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;403.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(122.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;281.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;352.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;108.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;461.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;406.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;(122.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;284.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;355.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;108.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;463.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.37pt;font-weight:400;line-height:120%;position:relative;top:-3.43pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt; Services revenue and Services adjusted gross margin for the nine months ended September 30, 2021 includes the impact of $81.9 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi0xLTEtMS0xMDgxNjE_2d162cbe-6320-4097-a4a8-08fbebc56007"
      unitRef="usd">186200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7856b9f8f6d49b08fcf4b3d7646741d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi0yLTEtMS0xMDgxNjE_99f6e57f-faaf-4708-993f-2bdd75c6e042"
      unitRef="usd">36400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a9d457339c7409eb76312880e7a9ad8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi0zLTEtMS0xMDgxNjE_70968e20-78fe-49df-be22-84cf5182f91c"
      unitRef="usd">17400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi00LTEtMS0xMDgxNjE_6beeeb03-dc34-41b1-ad31-9eb6f49956dd"
      unitRef="usd">240000000.0</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi02LTEtMS0xMDgxNjE_4ca65b6f-4059-45bd-bb7b-7cfd934d18b4"
      unitRef="usd">270500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3c3d681b76e40419af6d49da37af710_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi03LTEtMS0xMDgxNjE_576f694f-ac17-4605-ac9e-2e7116c8ad3c"
      unitRef="usd">41600000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied76f18f442f4ab69a0615274373a47b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi04LTEtMS0xMDgxNjE_61dcdf4a-7e08-400c-a809-e4cbadd3ba1a"
      unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMi05LTEtMS0xMDgxNjE_5624700e-d7f7-4969-85b5-6b947bb65c49"
      unitRef="usd">329000000.0</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bf31d14f117481daf2044655dd6e7ad_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMy0zLTEtMS0xMDgxNjE_948889bc-792c-4309-9c51-5defdcdb5024"
      unitRef="usd">17400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee99b848e7d34f24ba7ebd4d2abf4f85_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMy00LTEtMS0xMDgxNjE_c3df8e30-c059-4597-932d-3906299f52d5"
      unitRef="usd">17400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16214c20216b4ae9b2e00cb861cc0703_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMy04LTEtMS0xMDgxNjE_38b40244-c0c0-40ed-86b1-c82f54935306"
      unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5105f0204af64b01a45ffaaf2c96b86e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMy05LTEtMS0xMDgxNjE_c7fa5a24-bdf0-43af-a8a1-8fd3471b43ac"
      unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i97728d771d6646119c3295cf7509eb03_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNC0xLTEtMS0xMDgxNjE_77e84f39-05c5-41bf-8271-47234540729e"
      unitRef="usd">85500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i52646bb207c64e15902c5f7cebbaa5a9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNC00LTEtMS0xMDgxNjE_06c05f52-7c6b-45d7-b0b5-7c9967ad3529"
      unitRef="usd">85500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icae6520aeb4c4128b277d196b54c5c64_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNC02LTEtMS0xMDgxNjE_2bd96389-7afb-4e88-a8b9-7de89e4550c1"
      unitRef="usd">103200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3c1314a596fa4be2be2dbbc905e0e0ce_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNC05LTEtMS0xMDgxNjE_41f4bb2f-a2f0-4d26-836e-f5cd51149f8b"
      unitRef="usd">103200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie6d422d97fbb4e9c9744b614e2bf12b0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNS0yLTEtMS0xMDgxNjE_a371156f-e572-4c25-9d02-319ef0abd78a"
      unitRef="usd">63100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie3ea905c3a1d48a9a374e41f47cd9e7e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNS00LTEtMS0xMDgxNjE_e08a7515-a8c7-44ea-a2bc-ff0a146b043b"
      unitRef="usd">63100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7460e31e951a480b816dfe2ae15feac6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNS03LTEtMS0xMDgxNjE_57fcfc30-3bb8-45c5-b99c-dd38b6ec9a05"
      unitRef="usd">114300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i293e88d455b74b89b6ea596c99361768_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfNS05LTEtMS0xMDgxNjE_cf2a449a-7036-4088-bac9-90f52494e76c"
      unitRef="usd">114300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS0xLTEtMS0xMDgxNjE_0386eb6e-aec4-469b-a4bf-ca6fe2b153af"
      unitRef="usd">100700000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if7856b9f8f6d49b08fcf4b3d7646741d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS0yLTEtMS0xMDgxNjE_5e23b2fa-4f49-4445-8aba-596aeb5be351"
      unitRef="usd">-26700000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i8a9d457339c7409eb76312880e7a9ad8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS0zLTEtMS0xMDgxNjE_4cb4a848-d7e6-47ba-a624-a5374c06f4d6"
      unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS00LTEtMS0xMDgxNjE_e9191167-e7a8-4f64-a67a-04d1505e8c4f"
      unitRef="usd">74000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS02LTEtMS0xMDgxNjE_bb48413f-b651-4290-9d21-a1ba09d4906d"
      unitRef="usd">167300000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ib3c3d681b76e40419af6d49da37af710_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS03LTEtMS0xMDgxNjE_8a584b5d-9c43-4f13-b988-2d5aedc285c3"
      unitRef="usd">-72700000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ied76f18f442f4ab69a0615274373a47b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS04LTEtMS0xMDgxNjE_a4405c66-e35d-4db2-96c8-fb1912cd555c"
      unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfOS05LTEtMS0xMDgxNjE_f8b6e66a-1e2a-4af1-8dc0-86f70954a2f5"
      unitRef="usd">94600000</us-gaap:GrossProfit>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTAtMS0xLTEtMTA4MTYx_0f354caf-ed91-4bc1-addf-4b73b8d0aab4"
      unitRef="usd">600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTAtNC0xLTEtMTA4MTYx_0d96a20f-775a-493c-bbf5-1f371dc4e1dd"
      unitRef="usd">600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTAtNi0xLTEtMTA4MTYx_8e1acc7b-d7d1-4754-aaf8-288af73c4b7d"
      unitRef="usd">900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTAtOS0xLTEtMTA4MTYx_614543f0-0055-4ffd-87d3-d3c49d16e720"
      unitRef="usd">900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <ebs:AdjustedGrossMargin
      contextRef="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtMS0xLTEtMTA4MTYx_c707f263-6fd0-4618-ac41-d5fd64beec59"
      unitRef="usd">101300000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="if7856b9f8f6d49b08fcf4b3d7646741d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtMi0xLTEtMTA4MTYx_4d363ba7-ce7f-4597-bd86-c012443082ea"
      unitRef="usd">-26700000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i8a9d457339c7409eb76312880e7a9ad8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtMy0xLTEtMTA4MTYx_18f605c8-f5cb-4ff4-bc49-cb5bdeb298a5"
      unitRef="usd">0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtNC0xLTEtMTA4MTYx_234d61c4-8098-4fd0-abb8-79704cc58efc"
      unitRef="usd">74600000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtNi0xLTEtMTA4MTYx_c31d7e7d-a96d-4033-9d0c-5e6eb1b25507"
      unitRef="usd">168200000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="ib3c3d681b76e40419af6d49da37af710_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtNy0xLTEtMTA4MTYx_c9dc0294-f716-461a-ab80-63527f05d926"
      unitRef="usd">-72700000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="ied76f18f442f4ab69a0615274373a47b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtOC0xLTEtMTA4MTYx_c2f2c2c1-c10c-4613-b5aa-dea33ce11ac1"
      unitRef="usd">0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTEtOS0xLTEtMTA4MTYx_38ae4271-184c-44b0-9d62-42e22f821359"
      unitRef="usd">95500000</ebs:AdjustedGrossMargin>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="if6ea4a6a0de647a8a6d921dd7b209282_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBmNWEwYmVhZWQ2OTQxYTliNmE2NmFhM2I5YzFkODBhL3RhYmxlcmFuZ2U6MGY1YTBiZWFlZDY5NDFhOWI2YTY2YWEzYjljMWQ4MGFfMTItMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NmJiN2E3ZWVhNDY5NDNhYjkzOTdjYjBmY2NmMTI5MmFfOTU_e38bb6f7-2ee4-498e-8a2c-6d22c97df2ab"
      unitRef="usd">-86000000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi0xLTEtMS0xMDgxNjE_ab19f9b9-6374-4cae-b2e7-b59bbdfb5d9e"
      unitRef="usd">660500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i801413427f1f43babdb24055bb4bd90c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi0yLTEtMS0xMDgxNjE_eb4a9a6d-e51c-4729-8520-b3e659480101"
      unitRef="usd">95400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4dc9efc2b614e0dab48fd0fdb3134a0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi0zLTEtMS0xMDgxNjE_04348b45-fc8f-4688-9b88-08f9d0b0a447"
      unitRef="usd">34300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi00LTEtMS0xMDgxNjE_89473302-1410-4eaf-8edf-475a0178c819"
      unitRef="usd">790200000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi02LTEtMS0xMDgxNjE_95bb1989-6e86-4dcf-ac52-d01a3b993e3c"
      unitRef="usd">589600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0058f71a7708496abfdf19ad817835bb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi03LTEtMS0xMDgxNjE_9bbb4c86-4a0e-4578-b3cf-4d6f2bdfe4ab"
      unitRef="usd">416300000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a9984fa01164445b43977c0e9fc6107_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi04LTEtMS0xMDgxNjE_065f20d2-6746-4765-bc97-b80897212d95"
      unitRef="usd">63600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMi05LTEtMS0xMDgxNjE_01b02f00-4ae5-4432-a648-91ead8d23d8f"
      unitRef="usd">1069500000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia28dc2c9d43e4b13a7778805dc25c68c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNC0zLTEtMS0xMDgxNjE_145e1f10-d84c-44cd-b9cf-1d27bd8d5d4d"
      unitRef="usd">34300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc86efbf51c9459a924cb8855de7d59d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNC00LTEtMS0xMDgxNjE_8f02af7a-6ebd-4fdd-a64e-817b26653778"
      unitRef="usd">34300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32b2a80ee4ec410d9527e186fd40b2bd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNC04LTEtMS0xMDgxNjE_685d10b8-3353-4d9d-963f-d3d8574bb4d0"
      unitRef="usd">63600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dd3f76fb0234ae9898dcecdd750649a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNC05LTEtMS0xMDgxNjE_a3641b3b-103c-4b33-8e2f-6f34033455f0"
      unitRef="usd">63600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1a49e5be45554d6d948e7369dce4055d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNS0xLTEtMS0xMDgxNjE_84b89bf9-3832-4f94-9cd5-d8274d36be87"
      unitRef="usd">256800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if6605ab0b24d4a3a95cd07e88110dd0e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNS00LTEtMS0xMDgxNjE_65954fc1-acf6-43ad-bbd6-8f87a092ab9f"
      unitRef="usd">256800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia00293a7076049e7979650ad37c66b83_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNS02LTEtMS0xMDgxNjE_68aed353-0973-4794-b939-2a00f47aa588"
      unitRef="usd">237000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3ac0c2ed83d34c43b639039d2831ada9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNS05LTEtMS0xMDgxNjE_17f6a868-326f-4d15-8f01-221e449b9b13"
      unitRef="usd">237000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie24035e19dcb4f0a9e08c4030356556d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNi0yLTEtMS0xMDgxNjE_e77877f0-e19e-4bd3-88ca-03a7716f9282"
      unitRef="usd">217500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i94946a3df68a4894a63cc93522fd6ca4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNi00LTEtMS0xMDgxNjE_d62b24df-e800-48c2-8d80-ba4991237bdb"
      unitRef="usd">217500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i03d9a1c9cc0b4c1281e5652109cbc1df_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNi03LTEtMS0xMDgxNjE_fea21cd4-7558-43d2-935f-757da44f2632"
      unitRef="usd">307600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8e3af1259505476faa37180bca0dbed6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfNi05LTEtMS0xMDgxNjE_c46f96b2-3a0e-4e7f-ad90-4d83f7e99440"
      unitRef="usd">307600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtMS0xLTEtMTA4MTYx_6d0cb131-be1a-4fe3-94e8-32fb97c6936d"
      unitRef="usd">403700000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i801413427f1f43babdb24055bb4bd90c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtMi0xLTEtMTA4MTYx_816e9a7d-ccac-4644-9584-27469093ca45"
      unitRef="usd">-122100000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id4dc9efc2b614e0dab48fd0fdb3134a0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtMy0xLTEtMTA4MTYx_a8582d7a-ac55-443c-94ef-3044cd8e28af"
      unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtNC0xLTEtMTA4MTYx_e9e9e56d-a151-427d-ac73-6dde29d98a53"
      unitRef="usd">281600000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtNi0xLTEtMTA4MTYx_e69ff9b2-8bd8-4844-8e74-f2199e83ff43"
      unitRef="usd">352600000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i0058f71a7708496abfdf19ad817835bb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtNy0xLTEtMTA4MTYx_79b71dd3-2261-4bde-81d2-8c5c8dd95834"
      unitRef="usd">108700000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3a9984fa01164445b43977c0e9fc6107_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtOC0xLTEtMTA4MTYx_dbe6de92-bfd9-4919-bf83-845c551fa1a7"
      unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTAtOS0xLTEtMTA4MTYx_8d823367-c3f0-4c91-b406-4b765cdc32a8"
      unitRef="usd">461300000</us-gaap:GrossProfit>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTEtMS0xLTEtMTA4MTYx_2f6db2cc-10cb-405b-87e3-79aa2ba52145"
      unitRef="usd">2400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTEtNC0xLTEtMTA4MTYx_c558b472-a2ba-4525-b196-a9d72078a1d5"
      unitRef="usd">2400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTEtNi0xLTEtMTA4MTYx_f862972f-b50d-4a52-b3aa-92c053444bb0"
      unitRef="usd">2600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTEtOS0xLTEtMTA4MTYx_37231cb4-8216-44b3-87c1-6590ae81ec3e"
      unitRef="usd">2600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <ebs:AdjustedGrossMargin
      contextRef="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItMS0xLTEtMTA4MTYx_08110c9f-eef2-4497-9ce5-69946f8ac2bb"
      unitRef="usd">406100000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i801413427f1f43babdb24055bb4bd90c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItMi0xLTEtMTA4MTYx_8d5758de-818e-4445-a0fa-3ff72a93b7dc"
      unitRef="usd">-122100000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="id4dc9efc2b614e0dab48fd0fdb3134a0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItMy0xLTEtMTA4MTYx_4c2b0960-ae77-4523-bec9-2f7985ddb545"
      unitRef="usd">0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItNC0xLTEtMTA4MTYx_002a2844-6f94-43ce-9cb2-5b1365609367"
      unitRef="usd">284000000.0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItNi0xLTEtMTA4MTYx_3b6d7cb3-7b4f-4f49-9fcb-0dc17cf1b0f0"
      unitRef="usd">355200000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i0058f71a7708496abfdf19ad817835bb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItNy0xLTEtMTA4MTYx_3e9fd946-ea8a-4bd2-899a-44e0bc9fe5a0"
      unitRef="usd">108700000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i3a9984fa01164445b43977c0e9fc6107_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItOC0xLTEtMTA4MTYx_816b86de-3971-4694-beba-624287cde334"
      unitRef="usd">0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTItOS0xLTEtMTA4MTYx_2d1da0e2-f0aa-4346-8bed-aa8cc5043463"
      unitRef="usd">463900000</ebs:AdjustedGrossMargin>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="id5afd6d5f0de4b5a880e3f897b519fff_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOmQzNzVlMjgyNmFjOTRkODU5YjJlODMxYTNhNDQ3ZmI1L3RhYmxlcmFuZ2U6ZDM3NWUyODI2YWM5NGQ4NTliMmU4MzFhM2E0NDdmYjVfMTMtMC0xLTEtMTA4MTYxL3RleHRyZWdpb246NDhiOTg2YmZjNjUxNDU2Yzg5ODdkYjEyMzZkOTdjY2NfOTU_64ef7bda-d982-438b-a81d-eff515fe28d7"
      unitRef="usd">81900000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RleHRyZWdpb246YmJlMmY5MWYyMzhiNGFhOGE5NDU3OGQyYjZkMTg0NjFfMTg4Nw_30199d6b-5a9f-40df-b57c-599ef010e5df">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes depreciation expense for each segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Depreciation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;21.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:9.8pt;font-weight:400;line-height:120%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Depreciation
      contextRef="ie227f19e910e4933b13a50df4dcb06f8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfMy0xLTEtMS0xMDgxNjE_87caf461-6734-499c-8c7f-7f2e1ce87484"
      unitRef="usd">11500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i28cb87d9f75648f293b2695a859e3799_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfMy0zLTEtMS0xMDgxNjE_549d8cbd-43a8-49d0-8d08-5b1ccd3a0a64"
      unitRef="usd">5000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="idf39eebe5040463f80162ea0a11b4a71_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfMy01LTEtMS0xMDgxNjE_feaeba5c-8ae0-4611-b389-6820f22378ba"
      unitRef="usd">25600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7ad9f1506e1b442aa8eeec0cf49590d7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfMy03LTEtMS0xMDgxNjE_4269cea5-1dd1-4f98-adfb-968d2ffefa62"
      unitRef="usd">20900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if7856b9f8f6d49b08fcf4b3d7646741d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNC0xLTEtMS0xMDgxNjE_30aaaf25-9ec4-48fc-af92-8040ba245382"
      unitRef="usd">5600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ib3c3d681b76e40419af6d49da37af710_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNC0zLTEtMS0xMDgxNjE_67029964-31b0-4489-9ed2-9dc568aae4b9"
      unitRef="usd">8400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i801413427f1f43babdb24055bb4bd90c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNC01LTEtMS0xMDgxNjE_0ffa2978-f403-4af2-98dd-15d1847d1ad2"
      unitRef="usd">34200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0058f71a7708496abfdf19ad817835bb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNC03LTEtMS0xMDgxNjE_a6ebcc7e-53f3-4011-9405-0b467bc444fe"
      unitRef="usd">21300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i8a9d457339c7409eb76312880e7a9ad8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNS0xLTEtMS0xMDgxNjE_5b1385f9-feb9-4065-b090-1a9048ce8653"
      unitRef="usd">3300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ied76f18f442f4ab69a0615274373a47b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNS0zLTEtMS0xMDgxNjE_d84e8a6c-31d3-4de8-b216-5423221df6fe"
      unitRef="usd">1000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id4dc9efc2b614e0dab48fd0fdb3134a0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNS01LTEtMS0xMDgxNjE_e131d2d9-cc6b-43b9-a20f-8d3f238e4181"
      unitRef="usd">5700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3a9984fa01164445b43977c0e9fc6107_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNS03LTEtMS0xMDgxNjE_b04d51ff-87a1-4c9e-937c-f2ccd1ed8706"
      unitRef="usd">4300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNi0xLTEtMS0xMDgxNjE_b7971f11-da72-4a6f-8675-05b47efd66bc"
      unitRef="usd">20400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1d26bc0fee0c4cba96449308d7ed0aee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNi0zLTEtMS0xMDgxNjE_0268f370-f3b8-4fc6-bba1-24996aadefed"
      unitRef="usd">14400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNi01LTEtMS0xMDgxNjE_83acd299-ec0f-4028-a5e9-fac17628668a"
      unitRef="usd">65500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie7a2101979804998b9eb3336d0933d9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84Mi9mcmFnOmJiZTJmOTFmMjM4YjRhYThhOTQ1NzhkMmI2ZDE4NDYxL3RhYmxlOjBlYzI1MDBiZGNkODRjZWNhMDgyMjcxZGU5NTMwZGEyL3RhYmxlcmFuZ2U6MGVjMjUwMGJkY2Q4NGNlY2EwODIyNzFkZTk1MzBkYTJfNi03LTEtMS0xMDgxNjE_ddfa8089-a141-48cb-9d7a-71287b0c1734"
      unitRef="usd">46500000</us-gaap:Depreciation>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjliZWM0Yjc1ZmYzNTQ3MzViMDlkY2M5YzYwNGRmYTkyL3NlYzo5YmVjNGI3NWZmMzU0NzM1YjA5ZGNjOWM2MDRkZmE5Ml84OC9mcmFnOjQwNmVhZjkxNzQxMTQ1ODBhZjhmMDJmZDQ0OWQzMjQxL3RleHRyZWdpb246NDA2ZWFmOTE3NDExNDU4MGFmOGYwMmZkNDQ5ZDMyNDFfODk2Nw_c6c8b62f-9656-493d-965a-92f790c6520f">Commitments and Contingencies&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Securities and shareholder litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#x2019;s common stock, seeking to pursue remedies under the Securities Exchange Act of 1934. These complaints were filed by Palm Tran, Inc. &#x2013; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth; and Stephen M. Weiss, respectively. The complaints allege, among other things, that the defendants made false and misleading statements about the Company's manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as "CDMO Manufacturing Capabilities"). These cases were consolidated on December 23, 2021, under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Emergent BioSolutions Inc. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 8:21-cv-00955-PWG (the "Federal Securities Class Action"). The Lead Plaintiffs in the consolidated matter are Nova Scotia Health Employees&#x2019; Pension Plan and The City of Fort Lauderdale Police &amp;amp; Firefighters&#x2019; Retirement System. The defendants filed a motion to dismiss on May 19, 2022 and the Lead Plaintiff filed an opposition to that motion on July 19, 2022. The defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the consolidated action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 29, 2021, Lincolnshire Police Pension Fund (&#x201c;Lincolnshire&#x201d;), and on August 16, 2021, Pooja Sayal, filed putative shareholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, the cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-PWG. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022 the Court approved the parties joint stipulation to and stay of the proceedings and discovery until the close of fact discovery in the Federal Securities Class Action. The defendants believe that the allegations in the complaints are without merit and intend to defend the matter vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2021, September 16, 2021 and November 12, 2021, putative shareholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp;amp; Police Officers Pension Fund, respectively, in The Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Emergent BioSolutions, Inc. Derivative Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#x2019; filed a motion to dismiss the complaint. Ruling on this motion is stayed pursuant to a March 29, 2022 order staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2021, December 22, 2021 and January 18, 2022, putative shareholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the federal securities laws, each allegation related to the CDMO Manufacturing Capabilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings and Discovery, pursuant to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which the parties agreed to stay all proceedings until 30 calendar days after a ruling on the defendants&#x2019; motion to dismiss the Federal Securities Class Action. The Court approved the Joint Stipulation on March 14, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the above actions, the Company has received preliminary inquiries and subpoenas to produce documents related to these matters from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis, Senator Murray of the Committee on Health, Education, Labor and Pensions, the Department of Justice, the SEC, the Maryland Attorney General&#x2019;s Office, and the New York Attorney General&#x2019;s Office. The Company is producing and has produced documents as required in response and will continue to cooperate with these government inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;ANDA litigation - Teva 2mg&lt;/span&gt;&lt;/div&gt;In 2018, Teva Pharmaceuticals Industries Limited and Teva Pharmaceuticals USA (collectively, "Teva") provided a notice to Emergent Devices Inc., a subsidiary of Emergent formerly known as Adapt Pharma Inc. ("EBPA"); Emergent Operations Ireland Limited, a subsidiary of Emergent formerly known as Adapt Pharma Operations Limited ("EIRE"); and Opiant Pharmaceuticals Inc. ("Opiant"). The notice stated that Teva had filed an abbreviated new drug application ("ANDA") with the FDA seeking regulatory approval to market a generic version of NARCAN&#xae; (naloxone HCI) Nasal Spray 2 mg/spray before the expiration of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#xae;. Teva&#x2019;s notice letter alleged that claims of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#xae; were invalid and/or would not be infringed by the activities described in Teva&#x2019;s ANDA. Emergent and Opiant filed complaints against Teva in the U.S. District Court for the District of New Jersey alleging infringement of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN. This case was dismissed July 27, 2022.</us-gaap:LegalMattersAndContingenciesTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>93
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^15/T$,L/_%G,@J@LX:ST,]](RUZCR1M-^F%PQS:M?I%@^OZ9:5?=HC??A"
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M%Z@,!3I?Q*@PWVA7QH[&%HH*(5E:B15!2K+R%S]4"]$0N,,7!%XE\(X5^)7
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M9S!6*7A9:Y4=R7)3KMPRJ8H?TTQ4?0I<!ZCG:\;D4T=70'7%&_X!4$L#!!0
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MJ]J7@]H+R4_-VR\/7$I^;+X>6+9E50U0O^\XE\\7]0,NKVBM_P902P,$%
M  @ =9)H56. Z*&C P  G@T  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6RM5]N.VS80_15"#8H$2*RKK[4%[-HN&J#;+N)N^U#T@2O1%AN*=$G:WO3K
M.Y1DU9)H89OZQ2:I,X<S9X:W^4G(SRHC1*.7G'&U<#*M]S/754E&<JP&8D\X
M?-D*F6,-7;ESU5X2G!9&.7,#SQNY.:;<B>?%V*.,Y^*@&>7D42)UR',LO]P3
M)DX+QW?. Y_H+M-FP(WG>[PC&Z*?]H\2>F[-DM*<<$4%1Y)L%\Z=/UM/#;X
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M]7;#&71&=@#\OI;01S<?[ 6.C]\M_P=02P,$%     @ =9)H509<C8>0"0
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MC1E]56-FIO>^8:6S,8/VZT-I 93&4#2Y/FIC1E_5F)GIO>L#:LQH9V,&[3>
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MAE?AIS[E7I)L_D)D?ZD:[U6-GV.G:UN6U#6,T_,":JYAR^4&X8RN:*:DY-I
MC;J]@^=]NK;\'SV_ZXW;)!R$(9WX]E"PDZ+F_XMJ2PP.7JEKJ=^X7HO*@,2<
M<.'@_24#W;:IUK&J]@]WI2RU 6\6U-E1NP!:SY6R.\?U@OV_(OD#4$L#!!0
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M'+O]P&B/M"7-&CCU(MT+M<VK0#L)H6-)1)\:W B%^BQGLC'\Z?GQZ1^S'HB
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M].,K<H>]W.%K[/]T(__' $\"A>%7Y0A+, N@"F%A%#]/J9?[P,=/6,_1]G<
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M-WB<D64%S*\,3KQVP MTS[W%?U!+ P04    " !UDFA5;31E.BH&  #-#@
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M-\.3GV%>JAPGU5KMVY)B\2ZP=T0(N'5Q#7$&'[2M/@=/I*;MG&18*[E2&I5
MN^D103@,/'V7:5GU?OX@\??S.Z*T!-IHO)B1_J=YQWT-S7:%.IC&4[ #%^\[
MKHX'5PRLL0U?I*C'8(K";:,?[>]JY^&*<K<\7/0^2+M1>$S4L$;127PTC[#=
M\.4I?'A3\X5E93P6-+\6Z!986H#S:V-\]T$&^AOL\C]02P,$%     @ =9)H
M53J]DTRE!@  +!(  !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&ULI5C;
M;MLX$/T5PDW;+9#(MFPWER8!DF:++= N@B1M'Q;[0$FTQ:U$NB05Q_OU>X:B
M9#FQDVWZH@LY')ZY'8YTO-#FN\V%<.RN+)0]Z>7.S8_Z?9OFHN0VTG.A,#/5
MIN0.KV;6MW,C>.87E44_'@S>]DLN5>_TV(]=FM-C7;E"*G%IF*W*DIOEN2CT
MXJ0W[#4#5W*6.QKHGQ[/^4Q<"_=E?FGPUF^U9+(4RDJMF!'3D][9\.A\3/)>
MX*L4"]MY9F1)HO5W>OF8G?0&!$@4(G6D@>-V*]Z+HB!%@/$CZ.RU6]+"[G.C
M_8.W';8DW(KWNO@F,Y>?] YZ+!-37A7N2B_^$,&>">E+=6']E2UJV=&XQ]+*
M.EV&Q4!02E7?^5WP0V?!P6#+@C@LB#WN>B./\H([?GIL]((9DH8V>O"F^M4
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MQU)))! =P'YA;>A>B$'_,?'R/U!+ P04    " !UDFA5Y>),G]P*   6(@
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M4!)Q0POP?F:,;VYH@_9?0>[^!U!+ P04    " !UDFA5+2'Y7$4/  "^*P
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MH#RX0:OX=(,C<V^"4_(.<'RCTTTO>WVH!\C(^KM3#S*OO15PE2R%DI+K/]E
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MC/0^H<=+=$:(,?1<Q <)2EU4CRW@)7M*P9'$ \I!5@W,QAF(#IELWBF]3B0
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M,$3L4))[]:?:&-300THQ4UK1FV8LK[5>=UO?8IG8539A#8UT[N6:R $_K]#
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M0G[R5WK>KBP-P/V5,57\00LTK^R^_1]02P,$%     @ =9)H5>W>&EOK!
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M)D,:Q2^&=-)!.GDNTH>>8''8.Z;]YV%-[<8W&2(BF@[S?]=4.,M0VQ#S.8[
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MXKGG_N:"HR@1 ?872MEZ0@<T7Q@O_@=02P,$%     @ =9)H58";J9IF"P
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MS$P;X$#.44I\Z.H1 :-<P!NRB%8 EHY<1J^H-B$T7I6:;)@!=>1T'8WYM=1
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M,R#I-<@+I!=?32['\4?+JN<!&Y-'?E(EX:.]=(W=W.8BXXU:B7];M*A?6=$
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M9EWG[QU^<ER;G36X2!9*/;K-53X)8B<(!6;6,3#Z/.,%"N&(2,;3AC-HKW3
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MNEM2*8^&7+04%=?&GL?9V9\>B"TM*$]AUMH[Z+C$D-5Q@NS%]@ ??X[/M93
MTR/1IL +%V.:_8.O.+8QF.K3U?$ VI&P$VI7X(.SA[X$N;?MC"*I\<:]^>UN
MVS&M7*/P<-RU6S=4[AE7I( =BH;^!=:_="V,6VAQL&W#5FAL0NPTQZX/I#F
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M;"]W;W)K<VAE971S+W-H965T,S N>&ULO59M;^,V#/XKA*\XM$!AYZ5-WY(
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M10)XOI32= LRT'?J\_\ 4$L#!!0    ( '62:%4!764#N ,  *L)   9
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M![/MIH+CBX\VX/I&XGNO'M !S7\>BW\ 4$L#!!0    ( '62:%5Y]G\<6P4
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MP@K.&OQ;X8(6+K#"E7-+V[F](A%/02I\7PK^AB_,-X*[.,0$H,(W4I8!?/\
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M<VAE970S-RYX;6RM5EUOVC 4_2M6-DV=M#9??'80J<"F56JGJJS;P[0'DUS
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M)8X?M[6.)Y+E9F=HS:1DJ3G<891@K@/4_0UC\NE$;S95FXOS_P!02P,$%
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M!4OLIJB/LKVT%]LDB]LDF[1$ME>2L"Y)^!\/B[#- K5)%K=)-FF);*] O;I
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MJ31XD+KF"B]3H"P OR^D-+N.#5!=SY(_4$L#!!0    ( '62:%6,:%,%DP,
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M<!J*S^SPB90%33(^GX4\_P2',M8R@)]RP:(2+#.(:%Q\X^=2B 9 \O0#8 F
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M-79\9R>X(^M<&8$;1R5>PP+4?7DK],UM63)2 ).$,R1@-78F_F@>&GVK\)5
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M;HZA;YCA[_#ZVKDF:DZ%!H8S"^UV3JTOJF[E]<3(TG?#J32VM_KAPMY^J%R
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MIJEH;HEL<N3X/.(1SP@:9VW#+)J2DW$(SIL>IVE ,F81YA(V@'$\@#DNT3*
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MZXBF]-!U!+2^$[^.L/E*X/GJO8GS YTFG6,CI2E2FJ:BN26P24_TM6!3D.9
M4IHBI6DJFOM]#YL#)3X;>/@LD< *3,@8 -W)B($W+ &I!'T!$#*!+J"0-E9)
M/%9M>MPN7>"HKL.0E*9(:9J*YA;%AC[9UVI-21H 26F*E*:I:&Z); "4^*P@
MXA3-I9(-DVA*#LUJ'*=I0(+/:LB]+\#A&6KG#BV#!H[K//Q()]9(:9J*YA;&
M9D#9UY),29H%26F*E*:I:&Z);!:4^(P@XA# @DCP6@)8C@DNL52 \L"E1%,8
MO PC;G]ML))XL+I*DR*+IT7NQ<G,FV=Q4L"])YU2(Z4I4IJFHKD%L9%/]K7L
M4I)&0E*:(J5I*II;(AL)Y=<ONY3 6LH1..<)*4-PU3:@%"^_\+4],$UE*+#(
M$=B0%> A"S**=@$$!W?^TCGI9!LI35/1W!+95!CTM1PS(,V(I#1%2M-4-+=$
M-B,&^,0@9AU!<SDD@Y=+@$K($!2@% R\Q@"4(7J-$=C4%>"IZX!UM$PG.+SS
MV"2=>B.E:2J:6R8;&X.^5F8&I &2E*9(:9J*YI9H[P$O^"0B:A^;INZ#94#W
M: K!*1! !\Z5:$@(WLD8[CV%:V6R>?WXL]R;I@])L7GZTF[K[A%K;^L'B[W8
M?LG.KABP7;$SO7F FL5OGN?V(<[FBR3WEN:NW)5_.BH_<[9Y1-KF39&NZV>
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MW5@H@QQO2_&9[C]!LYZQXJ6TY/H3[>NQHXF%TBT7M&K$<@950>IO_-SLPX%
M<KH%7B/P3@6C-P3#1C \-\*H$8S.C3!N!.-3@?^&P&\$_KD1)HU@HI-5[ZY.
M38@%#N:,[A%3HR5-7>C\:K7,2$&4$Q\%DW<+J1/!'4EI!4C@9^#H*@2!BY)?
MHP_HRV.(KMY=HW>H(.B^*$MI'#ZWA8RIE';:\&]KOO<&?XCN*1%KCB*20=:A
M#_OUT__3Q_UZU^L!V'*SVAWS7G;LUNLE/L)F@(;.>^0YGM<QH>7Y<K=K/WXM
M>O1KT>-^>0BIE+MO1D_.E[L]J1BVYAUJWK#?O']I\W[]4]Y%=P(J_JW+IS5J
MU(U2#_P9W^ 4%I9\HG-@.[""WW]S?>>/KAR;A(4F89%)6&P2EAB"'3EEU#IE
MU$</HCP'_=)#F) M+M4##S$LH,LIO:A+G6(2%IJ$129AL4E84L/<^IVE:JE=
MX R\T=S>=5A@W%I@W&N!L. I Z'?=0B>92G' 5T] 8&\$/RZRP@UT#^8Q@?7
M&4S;>=09?CW*'4R.QX3=I.'QJ.CUJ,G .QX3]R[RTHTV!#O*A]_FP^_/!^3
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M4P/D_9Q2\=)0 =H#Q> G4$L#!!0    ( '62:%74@3R<V0,  )D/   9
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;*U7VV[;.!#]%4(;+%*@UM7R;6T#
MB>7%]B&+H$&VSXQ$VT0DT24IN_W['5**+$OT!:U?;)$Z,\,Y/!QQIGO&W\6&
M$(E^9&DN9M9&RNW$<42\(1D6-MN2'-ZL&,^PA"%?.V++"4ZT498ZONL.G S3
MW)I/]=PSGT]9(5.:DV>.1)%EF/]\)"G;SRS/^ICX2M<;J2:<^72+U^2%R-?M
M,X>14WM):$9R05F..%G-K =OLO2T@4;\1\E>-)Z12N6-L7<U^)+,+%>MB*0D
MELH%AK\=69 T59Y@'=\KIU8=4QDVGS^\_ZV3AV3>L" +EGZCB=S,K)&%$K+"
M12J_LOT_I$HH5/YBE@K]B_85UK507 C)LLH85I#1O/S'/RHB&@;@QVS@5P9^
MVZ!_PB"H#()K(_0K@_ZU$<+*0*?NE+EKXB(L\7S*V1YQA09OZD&SKZV!+YHK
MH;Q(#F\IV,GYOZ#%+WG,,H+N4R;$)[0EH*,-YC 1$8EI"G,]]/H2H?N[3^@.
M.>5;@6B.7G,JQ>?&Q!--4]A_F+MK#J>.A+6JB$Y<K>NQ7)=_8ET!>F*YW BT
MS!.2&.RC\_;C,_8.<%03Y7\0]>B?=?A"MC8*W,_(=WW?L)[%]>:>*9W?B[[\
MY>A'9 2U:@+M+SBEFB(C'$O&)Z:=+6W[9EM5^29BBV,RLZ"T"<)WQ)K_^8<W
M</\RT7I+9]$MG2UOY.QH _KU!O3/>=?'EC:/K6D?2A<#[4)],';SWC"TAU-G
MUR38@ K\-BHRH+P@M$?'L&47UO?L00TZRC6L<PW/BBTB.8/*=U)NX2WE=DMG
MT2V=+6_D[&@+!O46#,[*[9O^WI*DAW=P[M<$Y47V!M\)MJIJ?P\^UC1&]U#S
MRPFC(,L@PZ8ZQO:XI<<N* PZ<C2 7-MOB='HZ808AS43P[-,1#0MU-4&"1(7
MG$H*N9/O!94_$=YCGHA+')3NP\:BW!8!%Q'11<1RV$G=;7!XE/FHSGSTFQI(
M%#<DN<3 Z!H5=$$&%1A 71480'T[,',QKKD87UM^#]>E'CH<@H2E*>;B\-;(
M1!G$<X^JJAVV,EB88*X]\%ILF&!0R%NPI0$&VAB9"?'<PSW2_15*FIJXCI0J
MSD56C#@#+4:<@1<3#H@Y<6J\Q@7;.TO,0RYI>31TV9 L?K^R5%2.F](-&LJM
M:.B"/+O?YJ +\AN5L"*@"W([Y=)IM!IP!USK'D^@F!6Y+.^/]6S=1S[H[JDU
M_^A-%IYA/E)]IVYM#N[+IO4)\S7-!4K)"D+!UD !Y&4?6 XDV^I&YXU):)OT
MXP9Z9\(5 -ZO&),? Q6@[L;G_P-02P,$%     @ =9)H59]&J#TA!@  ZS<
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MK^7!ZX.YHI*=\^S/-%'KT\%L@!)V3;>9^L1WO['Z@":&M^29+/^B7=5V>C)
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MQ?-R<\UHPH1IH'^_YES=?3$=-.O[%O\!4$L#!!0    ( '62:%6]M_;23 0
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M=@(& )*M1[>G@%#.>-H)&16J%59P3U5)ZH:"Z!L*LX>0!"KS%5& OH(HYVX
M:M%5SH>HK+XP2NJ^@NC["O/'D01H"M3S2 "E'DB"H&Z_!8!ZCR1)W8(0?0MB
MJ)BH1NEK!BLM'&"[=Z50B; BF ^@[,:F;&M15_U$?WH_7%$0]:3<'<^[;@+'
MZ3,U0IQ!Y0]1M1VM:V6BKY5E2F+A-D'!(95)*_B.1$J3+*+E_\O7_QXRT5ME
MZ*F?G;),LGE&V7Q3;.U%JLM\,GNI*D/;3SQ[R4RR>4;9?%-L[26K6Q*B;TG.
MJS* /L'M=APK"#4?VU;S1XF=8 ?B=F,*.'Y?\*S[%*+O4PQ7'0O@3%;Y!Q"
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M!YP@CD/ "?!1$($52;<DPQD'9 VN@V"7[@K [SS"5'ZF.,I7SQZ#CU\(8Y_
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MY1SL?2VE.1HNP/0XY7\ 4$L#!!0    ( '62:%41&R->IP<  #([   9
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M_U/6>^<V?QP_/LO.-OU;/AO_OGG^ E!+ 0(4 Q0    ( '62:%4'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ =9)H50.W367N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ =9)H59E<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !U
MDFA5<L?H+^P%  #N'@  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ =9)H56I)^; ^!@  ,QH  !@
M         ("!+PX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( '62:%5I3EC9"0,  /T*   8              " @:,4  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !UDFA560(M6#D(  "N-0
M&               @('B%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ =9)H56. Z*&C P  G@T  !@              ("!42   'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( '62:%4Q:S5%70@
M (HG   8              " @2HD  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !UDFA5!ER-AY )  #070  &               @(&]
M+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ =9)H5=#P
M^'!B @  -P8  !@              ("!@S8  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( '62:%7?)YD@NPT  -<A   8
M  " @1LY  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !U
MDFA583,2L;(-  !M)@  &0              @($,1P  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( '62:%7;,,,X#@,  +P&   9
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M970Q-2YX;6Q02P$"% ,4    " !UDFA5/..MPZ0'  !8%   &0
M    @($K;@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M '62:%7EXDR?W H  !8B   9              " @09V  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ =9)H52TA^5Q%#P  OBL  !D
M             ("!&8$  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !UDFA5[=X:6^L$   M#   &0              @(&5D   >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( '62:%7E/T9VD 0
M ',,   9              " @;>5  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ =9)H5>&R[HA%!P  [10  !D              ("!
M?IH  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !UDFA5
MRU1S2UH'  !M%   &0              @('ZH0  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( '62:%6 FZF:9@L  ' >   9
M      " @8NI  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ =9)H53T#,IY:#   ("(  !D              ("!*+4  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !UDFA5(T[QW_0"  !G!@
M&0              @(&YP0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( '62:%63*<1<"@,  ,\&   9              " @>3$  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ =9)H5>3JI[=Y
M P  E @  !D              ("!)<@  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !UDFA5_PI FB $  !3"@  &0
M@('5RP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( '62
M:%5X@[ NMP0  /D,   9              " @2S0  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ =9)H5>^X:0Y*!   U0L  !D
M         ("!&M4  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " !UDFA53I9+??4"  !W!@  &0              @(&;V0  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( '62:%6^1T!^F 0  +4+
M   9              " @<?<  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ =9)H50%=90.X P  JPD  !D              ("!EN$
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !UDFA5!=N$
M>(X%  #_$   &0              @(&%Y0  >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( '62:%5Y]G\<6P4  %</   9
M  " @4KK  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M=9)H5>GG5,!_!   FQ4  !D              ("!W/   'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " !UDFA59%/_ #@#  #1"P  &0
M            @(&2]0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( '62:%4\3 7K^ (  +4)   9              " @0'Y  !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ =9)H58?!,.8)!
M:!0  !D              ("!,/P  'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " !UDFA5F)%T'10#  ";#   &0              @(%P
M  $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( '62:%5K
MS(.7\0(  *H)   9              " @;L# 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ =9)H58QH4P63 P  *0T  !D
M     ("!XP8! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M" !UDFA5H4C>S6X"  !N!0  &0              @(&M"@$ >&PO=V]R:W-H
M965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( '62:%7ZANFNUP0  '(>   9
M              " @5(- 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L!
M A0#%     @ =9)H5<P[)RVJ @  ! @  !D              ("!8!(! 'AL
M+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !UDFA5JZR"D,<"
M  !;!P  &0              @(%!%0$ >&PO=V]R:W-H965T<R]S:&5E=#0V
M+GAM;%!+ 0(4 Q0    ( '62:%6F*+LR= (  -D%   9              "
M@3\8 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ =9)H
M51$<UTH/!@  O2X  !D              ("!ZAH! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " !UDFA5N)&(.2L#  #Y"P  &0
M        @($P(0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( '62:%71CIZD%P,  +H*   9              " @9(D 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ =9)H5?]-]L!S!   OAT
M !D              ("!X"<! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " !UDFA5*[RA.'T"  "]!0  &0              @(&*+ $
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( '62:%4;959P
M9@(  $H%   9              " @3XO 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ =9)H57,:+<$^ P  'PX  !D
M ("!VS$! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !U
MDFA5W!5U?C(#  !X"P  &0              @(%0-0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( '62:%53&%J&\@,   84   9
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M970V,"YX;6Q02P$"% ,4    " !UDFA5=M9):S\"  "M!0  &0
M    @($M6P$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M '62:%6>-Q IE (  $,&   9              " @:-= 0!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ =9)H5;37L66! @  708  !D
M             ("!;F ! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    " !UDFA5M@Q>=J0#  !<%   &0              @($F8P$ >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( '62:%74@3R<V0,
M )D/   9              " @0%G 0!X;"]W;W)K<VAE971S+W-H965T-C4N
M>&UL4$L! A0#%     @ =9)H59]&J#TA!@  ZS<  !D              ("!
M$6L! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " !UDFA5
MO;?VTDP$  ">&0  &0              @(%I<0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8W+GAM;%!+ 0(4 Q0    ( '62:%7_(%]G6P8  /XG   9
M      " @>QU 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%
M  @ =9)H526DJ_1K!   -Q8  !D              ("!?GP! 'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !UDFA5)M&E5R0"  "H!
M&0              @($@@0$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+
M 0(4 Q0    ( '62:%41&R->IP<  #([   9              " @7N# 0!X
M;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ =9)H50 S !BB
M P  ?A,  !D              ("!68L! 'AL+W=O<FMS:&5E=',O<VAE970W
M,BYX;6Q02P$"% ,4    " !UDFA53A40R%D#  "0%@  #0
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:+GAM;%!+!08     4 !0 .<5  #@G0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>310</ContextCount>
  <ElementCount>279</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis of presentation and principles of consolidation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation</Role>
      <ShortName>Basis of presentation and principles of consolidation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Inventories, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Inventoriesnet</Role>
      <ShortName>Inventories, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property, plant and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Propertyplantandequipmentnet</Role>
      <ShortName>Property, plant and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Intangibleassets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Fairvaluemeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Derivative instruments and hedging activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities</Role>
      <ShortName>Derivative instruments and hedging activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net Income (loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NetIncomelosspershare</Role>
      <ShortName>Net Income (loss) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Basis of presentation and principles of consolidation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies</Role>
      <ShortName>Basis of presentation and principles of consolidation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Inventories, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesnetTables</Role>
      <ShortName>Inventories, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Inventoriesnet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Property, plant and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables</Role>
      <ShortName>Property, plant and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Propertyplantandequipmentnet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Intangibleassets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Fairvaluemeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Derivative instruments and hedging activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables</Role>
      <ShortName>Derivative instruments and hedging activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Debt</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/RevenueRecognition</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Net Income (loss) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NetIncomelosspershareTables</Role>
      <ShortName>Net Income (loss) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/NetIncomelosspershare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Equity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/SegmentInformation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BusinessDetails</Role>
      <ShortName>Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Business</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Basis of presentation and principles of consolidation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails</Role>
      <ShortName>Basis of presentation and principles of consolidation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Inventories, net - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails</Role>
      <ShortName>Inventories, net - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Property, plant and equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails</Role>
      <ShortName>Property, plant and equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails</Role>
      <ShortName>Intangible assets - Schedule of Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Intangible assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails</Role>
      <ShortName>Intangible assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Intangible assets - Goodwill Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails</Role>
      <ShortName>Intangible assets - Goodwill Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Fair value measurements - Contingent Consideration Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails</Role>
      <ShortName>Fair value measurements - Contingent Consideration Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Fair value measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair value measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Debt - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtScheduleDetails</Role>
      <ShortName>Debt - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Revenue Recognition - Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails</Role>
      <ShortName>Revenue Recognition - Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Revenue Recognition - Remaining Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails</Role>
      <ShortName>Revenue Recognition - Remaining Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Revenue Recognition - Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails</Role>
      <ShortName>Revenue Recognition - Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Revenue Recognition - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails</Role>
      <ShortName>Revenue Recognition - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncometaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Incometaxes</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Net Income (loss) per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NetIncomelosspershareDetails</Role>
      <ShortName>Net Income (loss) per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/NetIncomelosspershareTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Equity - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Equity - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Equity - Changes in Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Equity - Changes in Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails</Role>
      <ShortName>Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Segment Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ebs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 11 fact(s) appearing in ix:hidden were eligible for transformation: ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  ebs-20220930.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 1 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 -  ebs-20220930.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:OperatingLeaseLeaseIncomeLeasePayments has a value of -71000000.0 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:OperatingLeaseLeaseIncomeLeasePayments fact are: Context: i5106d154262648b8966552fa34ac668e_D20210701-20210930, Unit: usd, Rule Element Id: 7022. ebs-20220930.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:OperatingLeaseLeaseIncomeLeasePayments has a value of -86000000.0 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:OperatingLeaseLeaseIncomeLeasePayments fact are: Context: if6ea4a6a0de647a8a6d921dd7b209282_D20210701-20210930, Unit: usd, Rule Element Id: 7022. ebs-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="ebs-20220930.htm">ebs-20220930.htm</File>
    <File>a311-kramercert93022.htm</File>
    <File>a312-lindhalcert93022.htm</File>
    <File>a321-kramercert93022.htm</File>
    <File>a322-lindhalcert93022.htm</File>
    <File>ebs-20220930.xsd</File>
    <File>ebs-20220930_cal.xml</File>
    <File>ebs-20220930_def.xml</File>
    <File>ebs-20220930_lab.xml</File>
    <File>ebs-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ebs-20220930_g1.jpg</File>
    <File>ebs-20220930_g2.jpg</File>
    <File>ebs-20220930_g3.jpg</File>
    <File>ebs-20220930_g4.jpg</File>
    <File>ebs-20220930_g5.jpg</File>
    <File>ebs-20220930_g6.jpg</File>
    <File>ebs-20220930_g7.jpg</File>
    <File>ebs-20220930_g8.jpg</File>
    <File>ebs-20220930_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="972">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ebs-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 32,
   "contextCount": 310,
   "dts": {
    "calculationLink": {
     "local": [
      "ebs-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ebs-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ebs-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ebs-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ebs-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ebs-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 506,
   "entityCount": 1,
   "hidden": {
    "http://emergentbiosolutions.com/20220930": 1,
    "http://fasb.org/us-gaap/2022": 17,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 23
   },
   "keyCustom": 26,
   "keyStandard": 253,
   "memberCustom": 18,
   "memberStandard": 56,
   "nsprefix": "ebs",
   "nsuri": "http://emergentbiosolutions.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://emergentbiosolutions.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Basis of presentation and principles of consolidation",
     "role": "http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation",
     "shortName": "Basis of presentation and principles of consolidation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Inventories, net",
     "role": "http://emergentbiosolutions.com/role/Inventoriesnet",
     "shortName": "Inventories, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Property, plant and equipment, net",
     "role": "http://emergentbiosolutions.com/role/Propertyplantandequipmentnet",
     "shortName": "Property, plant and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Leases",
     "role": "http://emergentbiosolutions.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Intangible assets",
     "role": "http://emergentbiosolutions.com/role/Intangibleassets",
     "shortName": "Intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Fair value measurements",
     "role": "http://emergentbiosolutions.com/role/Fairvaluemeasurements",
     "shortName": "Fair value measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Derivative instruments and hedging activities",
     "role": "http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities",
     "shortName": "Derivative instruments and hedging activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Debt",
     "role": "http://emergentbiosolutions.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Revenue Recognition",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income taxes",
     "role": "http://emergentbiosolutions.com/role/Incometaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Net Income (loss) per share",
     "role": "http://emergentbiosolutions.com/role/NetIncomelosspershare",
     "shortName": "Net Income (loss) per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Equity",
     "role": "http://emergentbiosolutions.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Segment Information",
     "role": "http://emergentbiosolutions.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Commitments and Contingencies",
     "role": "http://emergentbiosolutions.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Basis of presentation and principles of consolidation (Policies)",
     "role": "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies",
     "shortName": "Basis of presentation and principles of consolidation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Inventories, net (Tables)",
     "role": "http://emergentbiosolutions.com/role/InventoriesnetTables",
     "shortName": "Inventories, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Property, plant and equipment, net (Tables)",
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables",
     "shortName": "Property, plant and equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Leases (Tables)",
     "role": "http://emergentbiosolutions.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Intangible assets (Tables)",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsTables",
     "shortName": "Intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair value measurements (Tables)",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables",
     "shortName": "Fair value measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Derivative instruments and hedging activities (Tables)",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables",
     "shortName": "Derivative instruments and hedging activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Debt (Tables)",
     "role": "http://emergentbiosolutions.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Net Income (loss) per share (Tables)",
     "role": "http://emergentbiosolutions.com/role/NetIncomelosspershareTables",
     "shortName": "Net Income (loss) per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Equity (Tables)",
     "role": "http://emergentbiosolutions.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Segment Information (Tables)",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "reportCount": 1,
      "unique": true,
      "unitRef": "category",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Business (Details)",
     "role": "http://emergentbiosolutions.com/role/BusinessDetails",
     "shortName": "Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "reportCount": 1,
      "unique": true,
      "unitRef": "category",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Basis of presentation and principles of consolidation (Details)",
     "role": "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
     "shortName": "Basis of presentation and principles of consolidation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Inventories, net - Schedule of Inventory (Details)",
     "role": "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails",
     "shortName": "Inventories, net - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)",
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ie3ea905c3a1d48a9a374e41f47cd9e7e_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Property, plant and equipment - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
     "shortName": "Property, plant and equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i50157349177f44679e4ff5b00c2b690a_D20220101-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "role": "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i5a811ac3bfcc4c29a2a87b5ad51a6fde_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ebs:OperatingLeaseRightOfUseAssetRemoval",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Leases - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i5a811ac3bfcc4c29a2a87b5ad51a6fde_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ebs:OperatingLeaseRightOfUseAssetRemoval",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails",
     "shortName": "Intangible assets - Schedule of Finite-lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i30b0e22181834e9d8a6008ddf0fd449c_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails",
     "shortName": "Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Intangible assets - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails",
     "shortName": "Intangible assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i30b0e22181834e9d8a6008ddf0fd449c_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Intangible assets - Goodwill Roll Forward (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails",
     "shortName": "Intangible assets - Goodwill Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
     "shortName": "Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i30b0e22181834e9d8a6008ddf0fd449c_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Fair value measurements - Contingent Consideration Roll Forward (Details)",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails",
     "shortName": "Fair value measurements - Contingent Consideration Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i30b0e22181834e9d8a6008ddf0fd449c_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Fair value measurements - Additional Information (Details)",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails",
     "shortName": "Fair value measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails",
     "shortName": "Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "idcd99f4d0bd44df5ac51fd3f92b88bd4_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i19788cf415e44731a7ac316933902c13_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails",
     "shortName": "Derivative instruments and hedging activities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i19788cf415e44731a7ac316933902c13_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i7d38ed2b0b1c4eaa8ca77f4744eb8d44_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "instrument",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
     "shortName": "Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i7d38ed2b0b1c4eaa8ca77f4744eb8d44_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "instrument",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i2e48ea4760d64c29a1425b6484a220d7_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
     "shortName": "Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i2e48ea4760d64c29a1425b6484a220d7_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i19788cf415e44731a7ac316933902c13_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
     "shortName": "Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i19788cf415e44731a7ac316933902c13_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Debt - Schedule (Details)",
     "role": "http://emergentbiosolutions.com/role/DebtScheduleDetails",
     "shortName": "Debt - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Debt - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i30b0e22181834e9d8a6008ddf0fd449c_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsCurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Revenue Recognition - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i30b0e22181834e9d8a6008ddf0fd449c_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ifc42b30bb7694aa3bd4d198c2dc52e32_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Revenue Recognition - Performance Obligations (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails",
     "shortName": "Revenue Recognition - Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i44ef3a51186e41038ea49e018725fc47_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i49ec7f41ed1e466ea8c8265cc217d1c9_I20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Revenue Recognition - Remaining Performance Obligation (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails",
     "shortName": "Revenue Recognition - Remaining Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i30b0e22181834e9d8a6008ddf0fd449c_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Revenue Recognition - Contract Liabilities (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails",
     "shortName": "Revenue Recognition - Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i30b0e22181834e9d8a6008ddf0fd449c_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:ScheduleOfAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Revenue Recognition - Accounts Receivable (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails",
     "shortName": "Revenue Recognition - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:ScheduleOfAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i3eabe1e8d9c443b4aba12a1f4dfe8104_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Income taxes (Details)",
     "role": "http://emergentbiosolutions.com/role/IncometaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i3eabe1e8d9c443b4aba12a1f4dfe8104_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Net Income (loss) per share (Details)",
     "role": "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails",
     "shortName": "Net Income (loss) per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ic4d3da6f40f548208c86343dfbb7f66e_I20211111",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Equity - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/EquityNarrativeDetails",
     "shortName": "Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ic4d3da6f40f548208c86343dfbb7f66e_I20211111",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Equity - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "Equity - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i513d610eeb964439903192db1ecb51ed_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Equity - Changes in Accumulated Other Comprehensive Loss (Details)",
     "role": "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Equity - Changes in Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)",
     "role": "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails",
     "shortName": "Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i61f687c252da498ea3071b9bef0dae99_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i61f687c252da498ea3071b9bef0dae99_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Segment Information - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
     "shortName": "Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
     "shortName": "Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i32f339d6134d47a9b1e6f9ae1c530faf_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ia8d11b69d7094e958cdf98db6cd53b20_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "ibc984f7cf64a4ac6ad2b90f5b12b27ea_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Business",
     "role": "http://emergentbiosolutions.com/role/Business",
     "shortName": "Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220930.htm",
      "contextRef": "i8ec93eb2f71a4503925b9c652adef7da_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 76,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. Government"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ebs_AcceleratedExpansionOfFillFinishCapacityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Expansion Of Fill/Finish Capacity",
        "label": "Accelerated Expansion Of Fill/Finish Capacity [Member]",
        "terseLabel": "Accelerated Expansion Of Fill/Finish Capacity"
       }
      }
     },
     "localname": "AcceleratedExpansionOfFillFinishCapacityMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_AdjustedGrossMargin": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Gross Margin",
        "label": "Adjusted Gross Margin",
        "terseLabel": "Adjusted gross margin"
       }
      }
     },
     "localname": "AdjustedGrossMargin",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended credit agreement dated October 15, 2018.",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Domestic Gross Profit Royalty Percentage",
        "label": "Asset Acquisition, Domestic Gross Profit Royalty Percentage",
        "terseLabel": "Asset acquisition, domestic royalty percentage"
       }
      }
     },
     "localname": "AssetAcquisitionDomesticGrossProfitRoyaltyPercentage",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, International Gross Profit Royalty Percentage",
        "label": "Asset Acquisition, International Gross Profit Royalty Percentage",
        "terseLabel": "Asset acquisition, international royalty percentage"
       }
      }
     },
     "localname": "AssetAcquisitionInternationalGrossProfitRoyaltyPercentage",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Asset acquisition, inventory acquired"
       }
      }
     },
     "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_AssetAcquisitionTreatmentVolumeThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Treatment Volume Threshold",
        "label": "Asset Acquisition, Treatment Volume Threshold",
        "terseLabel": "Asset acquisition, treatment volume threshold"
       }
      }
     },
     "localname": "AssetAcquisitionTreatmentVolumeThreshold",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Leases Supplemental Balance Sheets"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ebs_BARDAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BARDA",
        "label": "BARDA [Member]",
        "terseLabel": "BARDA"
       }
      }
     },
     "localname": "BARDAMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.",
        "label": "Cash Proceeds Excess Amount from Dispositions of Property or Casualty Events Subject to Certain Reinvestment Right",
        "terseLabel": "Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right"
       }
      }
     },
     "localname": "CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ChangeinContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Contract With Customer, Liability [Roll Forward]",
        "label": "Change in Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Change in Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "localname": "ChangeinContractWithCustomerLiabilityRollForward",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_ChimerixAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chimerix Asset Acquisition",
        "label": "Chimerix Asset Acquisition [Member]",
        "terseLabel": "Chimerix Asset Acquisition"
       }
      }
     },
     "localname": "ChimerixAssetAcquisitionMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ContractDevelopmentAndManufacturingLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Development And Manufacturing, Leases",
        "label": "Contract Development And Manufacturing, Leases [Member]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "ContractDevelopmentAndManufacturingLeasesMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ContractDevelopmentAndManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue earned during the period arising from manufacturing sale under the terms of a contract.",
        "label": "Contract Development And Manufacturing [Member]",
        "terseLabel": "Total CDMO",
        "verboseLabel": "CDMO"
       }
      }
     },
     "localname": "ContractDevelopmentAndManufacturingMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.",
        "label": "Contract with Customer, Liability, Additions",
        "terseLabel": "Deferral of revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ContractWithCustomerLiabilityDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Deductions",
        "label": "Contract with Customer, Liability, Deductions",
        "negatedTerseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeductions",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ContractsAndGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.",
        "label": "Contracts and Grants [Member]",
        "terseLabel": "Contracts and grants"
       }
      }
     },
     "localname": "ContractsAndGrantsMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_DebtInstrumentCovenantConsiderationThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Consideration Threshold",
        "label": "Debt Instrument, Covenant, Consideration Threshold",
        "terseLabel": "Debt instrument, covenant, consideration threshold"
       }
      }
     },
     "localname": "DebtInstrumentCovenantConsiderationThreshold",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_DebtInstrumentCovenantDebtServiceCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Debt Service Coverage Ratio",
        "label": "Debt Instrument, Covenant, Debt Service Coverage Ratio",
        "verboseLabel": "Debt covenant, consolidated debt service coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDebtServiceCoverageRatio",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period",
        "terseLabel": "Debt instrument, covenant, net leverage ratio adjustment period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, One",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, One",
        "terseLabel": "Debt instrument, covenant, net leverage ratio, maximum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioOne",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio Rolling Period",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio Rolling Period",
        "terseLabel": "Debt instrument, covenant, net leverage ratio rolling period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioRollingPeriod",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, Two",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, Two",
        "terseLabel": "Debt instrument, covenant, net leverage ratio, adjustment"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioTwo",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_JansenPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jansen Pharmaceuticals, Inc.",
        "label": "Jansen Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Jansen Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "JansenPharmaceuticalsIncMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_MeasurementInputProbabilityofPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Probability of Payment [Member]",
        "label": "Measurement Input, Probability of Payment [Member]",
        "terseLabel": "Probability of payment"
       }
      }
     },
     "localname": "MeasurementInputProbabilityofPaymentMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_MilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments",
        "label": "Milestone Payments [Member]",
        "terseLabel": "Milestone Payments"
       }
      }
     },
     "localname": "MilestonePaymentsMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_NumberOfBusinessLines": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Business Lines",
        "label": "Number Of Business Lines",
        "terseLabel": "Number of business lines"
       }
      }
     },
     "localname": "NumberOfBusinessLines",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_NumberOfCategoriesOfPublicHealthThreats": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the number of categories of public health threats.",
        "label": "Number Of Categories Of Public Health Threats",
        "terseLabel": "Number of categories of public health threats"
       }
      }
     },
     "localname": "NumberOfCategoriesOfPublicHealthThreats",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Product Candidates",
        "label": "Number Of Product Candidates",
        "terseLabel": "Number of product candidates"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_NumberOfRevenueGeneratingProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the number of revenue generating products.",
        "label": "Number Of Revenue Generating Products",
        "terseLabel": "Number of revenue generating products"
       }
      }
     },
     "localname": "NumberOfRevenueGeneratingProducts",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax",
        "label": "Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "totalLabel": "Total CDMO"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_OperatingLeaseLeaseIncomeReversal": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Lease Income Reversal",
        "label": "Operating Lease, Lease Income Reversal",
        "terseLabel": "Adjustment for prior period lease receivables (Note 10)"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeReversal",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_OperatingLeaseRightOfUseAssetRemoval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset, Removal",
        "label": "Operating Lease, Right-Of-Use Asset, Removal",
        "terseLabel": "Operating lease right-of-use asset removal"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetRemoval",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_OtherLongTermDebtFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long Term Debt Facility [Member]",
        "label": "Other Long Term Debt Facility [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtFacilityMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in the third year.",
        "label": "Percentage of Original Principal Amount Required to Repay During the Third Year",
        "terseLabel": "Percentage of original principal amount required to repay during the third year"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in the first two years.",
        "label": "Percentage of Original Principal Amount Required to Repay in First Two Years",
        "terseLabel": "Percentage of original principal amount required to repay in the first two years"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in remaining years.",
        "label": "Percentage of Original Principal Amount Required to Repay Remaining Years",
        "terseLabel": "Percentage of original principal amount required to repay remaining year"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_ProductsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Segment",
        "label": "Products Segment [Member]",
        "terseLabel": "Products"
       }
      }
     },
     "localname": "ProductsSegmentMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ReservationOfManufacturingCapacityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reservation Of Manufacturing Capacity",
        "label": "Reservation Of Manufacturing Capacity [Member]",
        "terseLabel": "Reservation Of Manufacturing Capacity"
       }
      }
     },
     "localname": "ReservationOfManufacturingCapacityMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_RockvilleManufacturingFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rockville Manufacturing Facility",
        "label": "Rockville Manufacturing Facility [Member]",
        "terseLabel": "Rockville Manufacturing Facility"
       }
      }
     },
     "localname": "RockvilleManufacturingFacilityMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ScheduleOfAccountsReceivableNetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accounts Receivable, Net [Table Text Block]",
        "label": "Schedule Of Accounts Receivable, Net [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsReceivableNetTableTextBlock",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ebs_SeniorUnsecuredNotesDueAugust2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due August 2028",
        "label": "Senior Unsecured Notes Due August 2028 [Member]",
        "terseLabel": "3.875% Senior Unsecured Notes due 2028"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueAugust2028Member",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services Segment",
        "label": "Services Segment [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServicesSegmentMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan dated December 2013.",
        "label": "Term Loan Facility [Member]",
        "verboseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://emergentbiosolutions.com/20220930",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r114",
      "r153",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r179",
      "r183",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r255",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r114",
      "r153",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r179",
      "r183",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r255",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r189",
      "r331",
      "r336",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r263",
      "r296",
      "r351",
      "r353",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r520",
      "r556",
      "r560",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r263",
      "r296",
      "r351",
      "r353",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r520",
      "r556",
      "r560",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r189",
      "r331",
      "r336",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r185",
      "r240",
      "r241",
      "r331",
      "r334",
      "r524",
      "r555",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]",
        "verboseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r185",
      "r240",
      "r241",
      "r331",
      "r334",
      "r524",
      "r555",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r234",
      "r239",
      "r240",
      "r241",
      "r242",
      "r263",
      "r296",
      "r342",
      "r351",
      "r353",
      "r379",
      "r380",
      "r381",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r520",
      "r556",
      "r560",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r234",
      "r239",
      "r240",
      "r241",
      "r242",
      "r263",
      "r296",
      "r342",
      "r351",
      "r353",
      "r379",
      "r380",
      "r381",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r520",
      "r556",
      "r560",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r124",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r124",
      "r129",
      "r238",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r186",
      "r187",
      "r331",
      "r335",
      "r558",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r186",
      "r187",
      "r331",
      "r335",
      "r558",
      "r567",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r124",
      "r129",
      "r238",
      "r352",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r513",
      "r515",
      "r518",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r508"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Total accounts receivable, net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": {
     "auth_ref": [
      "r56",
      "r60",
      "r68",
      "r69",
      "r70",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]",
        "terseLabel": "Defined Benefit Pension Plan"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r11",
      "r229"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation &amp; amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r60",
      "r68",
      "r69",
      "r70",
      "r71",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r58",
      "r59",
      "r60",
      "r546",
      "r565",
      "r566"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss, net"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r68",
      "r69",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r60",
      "r68",
      "r69",
      "r70",
      "r116",
      "r117",
      "r118",
      "r428",
      "r505",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r54",
      "r60",
      "r68",
      "r69",
      "r70",
      "r428",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r508"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r386",
      "r387",
      "r388",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r27",
      "r193",
      "r197",
      "r198",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r78",
      "r96",
      "r283",
      "r488"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r96",
      "r216",
      "r224"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization Expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive stock awards (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "auth_ref": [
      "r419",
      "r420",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Asset acquisition, consideration transferred, contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r15",
      "r109",
      "r161",
      "r174",
      "r181",
      "r195",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r256",
      "r258",
      "r259",
      "r424",
      "r429",
      "r476",
      "r506",
      "r508",
      "r529",
      "r544"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r35",
      "r109",
      "r195",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r256",
      "r258",
      "r259",
      "r424",
      "r429",
      "r476",
      "r506",
      "r508"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r439",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BilledContractReceivables": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.",
        "label": "Billed Contracts Receivable",
        "terseLabel": "Billed, net"
       }
      }
     },
     "localname": "BilledContractReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings, building improvements and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r95",
      "r417"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "netLabel": "Change in fair value",
        "terseLabel": "Change in fair value of contingent consideration, net",
        "verboseLabel": "Changes in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r413",
      "r414",
      "r416"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of contingent purchase consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r413",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Business combination, contingent consideration, liability, current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business combination, contingent consideration, liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property, plant and equipment unpaid at period end"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r9",
      "r98"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r91",
      "r98",
      "r103"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash and cash equivalents and restricted cash at September\u00a030, 2022 and December\u00a031, 2021:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r91",
      "r477"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months",
        "terseLabel": "Net deferred losses from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental information on non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r116",
      "r117",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "$0.001 Par Value Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r508"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200.0 shares authorized, 55.5 and 55.1 shares issued; 49.9 and 51.3 shares outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r76",
      "r535",
      "r551"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r217",
      "r222",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Rollforward of Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r317",
      "r319",
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Contract with customer, asset, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r317",
      "r318",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r317",
      "r318",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r80",
      "r524"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "negatedTerseLabel": "Cost of goods and services sold",
        "terseLabel": "Cost of goods and services sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r277",
      "r284",
      "r285",
      "r287",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r108",
      "r114",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r289",
      "r290",
      "r291",
      "r292",
      "r489",
      "r530",
      "r531",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r108",
      "r114",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r289",
      "r290",
      "r291",
      "r292",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to August 15, 2023"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Upon the occurrence of a change in control"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r108",
      "r114",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r289",
      "r290",
      "r291",
      "r292",
      "r309",
      "r310",
      "r311",
      "r312",
      "r486",
      "r487",
      "r489",
      "r490",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Current, Net",
        "terseLabel": "Debt issuance costs, current, net"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r273",
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs, net"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedTerseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r110",
      "r399",
      "r404",
      "r405",
      "r406"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r391",
      "r392"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r96",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation [Abstract]",
        "terseLabel": "Depreciation:"
       }
      }
     },
     "localname": "DepreciationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r96",
      "r156"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r475"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r441",
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Asset Derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r441",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Liability Derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r50",
      "r440",
      "r442",
      "r446",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r457",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative instruments and hedging activities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r437",
      "r440",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r475"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r433",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r432",
      "r434",
      "r437",
      "r438",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r77",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r130",
      "r132",
      "r137",
      "r138",
      "r139",
      "r143",
      "r144",
      "r460",
      "r461",
      "r536",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share - basic (in dollars per share)",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r77",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r132",
      "r137",
      "r138",
      "r139",
      "r143",
      "r144",
      "r460",
      "r461",
      "r536",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share - diluted (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Net income (loss) per common share"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective annual tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r68",
      "r69",
      "r70",
      "r116",
      "r117",
      "r118",
      "r120",
      "r126",
      "r128",
      "r147",
      "r196",
      "r308",
      "r313",
      "r386",
      "r387",
      "r388",
      "r400",
      "r401",
      "r459",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r505",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurocurrency"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r463",
      "r464",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r275",
      "r289",
      "r290",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r464",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r463",
      "r464",
      "r467",
      "r468",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Fairvaluemeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r275",
      "r343",
      "r344",
      "r349",
      "r350",
      "r464",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r275",
      "r289",
      "r290",
      "r343",
      "r344",
      "r349",
      "r350",
      "r464",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r275",
      "r289",
      "r290",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r464",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r469",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r469",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r275",
      "r289",
      "r290",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r471",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r439",
      "r444",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r13",
      "r223"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Finite-lived Intangible Assets Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r217",
      "r220",
      "r223",
      "r225",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r223",
      "r526"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r217",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r223",
      "r525"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r12",
      "r202",
      "r203",
      "r210",
      "r214",
      "r508",
      "r528"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, September\u00a030, 2022",
        "periodStartLabel": "Goodwill, December\u00a031, 2021",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r203",
      "r210",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill, impaired, accumulated impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r79",
      "r109",
      "r161",
      "r173",
      "r177",
      "r180",
      "r183",
      "r195",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r252",
      "r254",
      "r256",
      "r258",
      "r259",
      "r476"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r437",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r74",
      "r161",
      "r173",
      "r177",
      "r180",
      "r183",
      "r527",
      "r533",
      "r539",
      "r553"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r231",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r395",
      "r396",
      "r398",
      "r402",
      "r407",
      "r409",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Incometaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r127",
      "r128",
      "r159",
      "r393",
      "r403",
      "r408",
      "r554"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit (provision)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Discrete tax expense (benefits)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r93",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid during the period for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r95",
      "r521"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r95",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "negatedTerseLabel": "Operating lease liability removal"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r139",
      "r356"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive securities-equity awards (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Intangibleassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r215",
      "r221"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r72",
      "r155",
      "r485",
      "r488",
      "r537"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r90",
      "r92",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Inventoriesnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r200"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r34",
      "r508"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories, net",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r34",
      "r200"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Inventory, raw materials, net of reserves"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r29",
      "r200"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held.",
        "label": "Land and Land Improvements [Member]",
        "terseLabel": "Land and improvements"
       }
      }
     },
     "localname": "LandAndLandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r500",
      "r501"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Operating lease cost:",
        "verboseLabel": "Operating leases:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails",
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lessee, operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Lessor, operating lease, payments to be received"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r109",
      "r175",
      "r195",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r252",
      "r254",
      "r256",
      "r258",
      "r259",
      "r425",
      "r429",
      "r430",
      "r476",
      "r506",
      "r507"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r109",
      "r195",
      "r476",
      "r508",
      "r532",
      "r548"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r41",
      "r109",
      "r195",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r252",
      "r254",
      "r256",
      "r258",
      "r259",
      "r425",
      "r429",
      "r430",
      "r476",
      "r506",
      "r507",
      "r508"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r274",
      "r288",
      "r289",
      "r290",
      "r531",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Total debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term debt, net of debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of debt",
        "verboseLabel": "Debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market accounts"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows provided by (used in) financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r91",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r62",
      "r65",
      "r70",
      "r75",
      "r97",
      "r109",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r127",
      "r128",
      "r136",
      "r161",
      "r173",
      "r177",
      "r180",
      "r183",
      "r195",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r252",
      "r254",
      "r256",
      "r258",
      "r259",
      "r461",
      "r476",
      "r534",
      "r550"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-U.S. Government"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Debt, current portion"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r433",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "terseLabel": "Number of Instruments"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r60",
      "r71"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r161",
      "r173",
      "r177",
      "r180",
      "r183"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "auth_ref": [
      "r146",
      "r504"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "terseLabel": "Leases",
        "verboseLabel": "Lease revenue"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r499",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r498",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r439",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r422",
      "r423",
      "r427"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent",
        "terseLabel": "Pretax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r55",
      "r58"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gains (losses) on hedging activities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r58",
      "r61",
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Amount of Loss Reclassified from Accumulated OCL into Income (Loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r63",
      "r66",
      "r422",
      "r423",
      "r427"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r422",
      "r423",
      "r427"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedTerseLabel": "Tax Expense"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r439",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r508"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesMember": {
     "auth_ref": [
      "r439",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other liabilities.",
        "label": "Other Liabilities [Member]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Contingent consideration payments"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Taxes paid for share-based compensation activity"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Asset acquisitions"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r84",
      "r419",
      "r420",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire productive assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r508"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r85",
      "r385"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from share-based compensation activity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-Term Lines of Credit",
        "terseLabel": "Proceeds from revolving credit facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net",
        "verboseLabel": "Products"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r233",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Propertyplantandequipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r10",
      "r228"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant and Equipment Income Statement Disclosures [Abstract]",
        "terseLabel": "Property Plant and Equipment Income Statement Disclosures [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r230",
      "r508",
      "r540",
      "r549"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r60",
      "r71"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r173",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r173",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedTerseLabel": "Principal payments on convertible senior notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfMediumTermNotes": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.",
        "label": "Repayments of Medium-term Notes",
        "negatedTerseLabel": "Principal payments on term loan facility"
       }
      }
     },
     "localname": "RepaymentsOfMediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r390",
      "r523",
      "r583"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r9",
      "r103"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r313",
      "r508",
      "r547",
      "r564",
      "r566"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r116",
      "r117",
      "r118",
      "r120",
      "r126",
      "r128",
      "r196",
      "r386",
      "r387",
      "r388",
      "r400",
      "r401",
      "r459",
      "r561",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r152",
      "r153",
      "r172",
      "r178",
      "r179",
      "r185",
      "r186",
      "r189",
      "r330",
      "r331",
      "r524"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Services",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r333",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r73",
      "r109",
      "r152",
      "r153",
      "r172",
      "r178",
      "r179",
      "r185",
      "r186",
      "r189",
      "r195",
      "r245",
      "r246",
      "r247",
      "r250",
      "r251",
      "r252",
      "r254",
      "r256",
      "r258",
      "r259",
      "r476",
      "r539"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Senior secured credit agreement - Revolver loan due 2023",
        "verboseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r60",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.",
        "label": "Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r440",
      "r446",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Derivative Instruments, Gain (Loss)"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r432",
      "r434",
      "r435",
      "r437",
      "r438",
      "r444",
      "r446",
      "r451",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Income per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r383",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r217",
      "r222",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r217",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r161",
      "r164",
      "r176",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r161",
      "r164",
      "r176",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r148",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r236",
      "r237",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r148",
      "r150",
      "r151",
      "r161",
      "r165",
      "r177",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenueRecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of presentation and principles of consolidation"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r148",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r232",
      "r236",
      "r237",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r46",
      "r68",
      "r69",
      "r70",
      "r116",
      "r117",
      "r118",
      "r120",
      "r126",
      "r128",
      "r147",
      "r196",
      "r308",
      "r313",
      "r386",
      "r387",
      "r388",
      "r400",
      "r401",
      "r459",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r505",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r147",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r308",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r313",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r19",
      "r20",
      "r308",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchases of stock (in shares)",
        "terseLabel": "Stock repurchased during period, shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r19",
      "r20",
      "r308",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchases of stock",
        "terseLabel": "Repurchases of stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r24",
      "r25",
      "r109",
      "r194",
      "r195",
      "r476",
      "r508"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r107",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r313",
      "r316",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "negatedPeriodEndLabel": "Ending balance (in shares)",
        "negatedPeriodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r45",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r45",
      "r314",
      "r315"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 5.6 and 3.8 common shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnbilledContractsReceivable": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.",
        "label": "Unbilled Contracts Receivable",
        "terseLabel": "Unbilled"
       }
      }
     },
     "localname": "UnbilledContractsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenueRecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Discounted cash flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r131",
      "r139"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average number of shares-diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used in computing net loss per common share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r130",
      "r139"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares-basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e526-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r584": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r585": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r586": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r587": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r588": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r589": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001367644-22-000144-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001367644-22-000144-xbrl.zip
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M=-.X?<A#;O3K9_S+@_ W$"=_ 5!+ P04    " !UDFA5<=9ADAT$  "_#0
M&    &$S,C$M:W)A;65R8V5R=#DS,#(R+FAT;=576V_:2!1^WU]Q2K1I(N$;
MAER (G%Q&K0)I. H[=-J\(SQ*+;'.QZ'L+]^S]B0D&V3[4:5TB)DV3Z7.=^Y
M?)[IOAM-A_Z7*P\BE<1P=3VX& ^A9EC6C3NTK)$_@G/_\@*:INV +TF:<\5%
M2F++\B8UJ$5*96W+6JU6YLHUA5Q:_LS2KII6+$3.3*IHK=?5;_#*".W]UGUG
M&# 209&P5$$@&5&,0I'S= DWE.6W8!@;K:'(UI(O(P4-N]& &R%O^1VIY(JK
MF/6V?KI6]=RURD6Z"T'7O2[E=\#IAQIO'A\=LU.V:(5-ITE/G84=GK3<HQ8)
M:.@VW-:?#@9IH7IEDZMUS#[4$IX:$=/KMX\;F>JL.%51V['MWVM/]8A<HNI"
M*"62MFW:)YE"C5"D"B.1Z+FZK1;X:AG%[I5!8KY,VR78C>E6'(A8R/:>7?XZ
M6F*$).'QNOW^# MR&_,4/@H5\0 N&>5%\KZ>8YV,G$D>5OHY_YMAW BA?%QM
M,*$[-&9;C$Y# _,^GX\'8Q_<AND\#?S;(0>8?2:?A_L=5J] .A#B]GMQ-K^)
M<^C-_/'9>-CWQ],)-OYL?MV?^.!/P3F!:W-N#DV8>\-2ZK@MNP[].?1'TRO?
M&^VJ_QIHMTA.[2.8GH%_[L&\/QOT)][<F'Z^\+Y ?^AK2<.V&S^H[&\(=YQ"
M(-*4!9JL8,55!"IB\*D@$J..US!CF9 *4'@F9+*_YQS9'<<V/E5W(@0O87*I
M"6K Q5S$A7:4PS@-3#C0KO;WW&9G*)*,I.OR_A!"(<M5,HQ94& I9;3R-V>9
M8LF"R>K1Q6;2A%8]D1Q"'B,%/H0Y9T$AD6=9#B2EX-T'$4F7#.DP27B>:TCX
MUYH4N1,B)AE&_!A6!:Z*JE[J%1B+S+%NC-9A)C 2!1]-^$,2A%F'8<090K['
M=16_8S -0QXP">A56V]@ULN5%FM D>(AAE>'K)!Y03!-2NS.S2;QU=RHB& P
MK9/.,QWR,FEDA%+\-!@Q"U7;/<+REUW($5&JVH9^\Y:#=> <5F7\^NICZC9]
M%A8Q-EV >8QU51\J+=E?!9=,?\%RG>W'Q!V00\!^<EH']'!;AYV^>.B)?J"T
MV#EUFYCCTX[NF!^0RU^[)HT7:\)3G-2$E(E&EE $'5!\6^9X6S#"-4UDDN6Z
M-G4M)G$,:(8QD1@KEV=8K+R:KY"G) WT>W1(RRU2.;JH5<15:072 JE8Y.E8
MF2_3[3:ICFNV_J,\;YCR$>:EG/$JS1-QM\-W)Q7=_:_Q?S,L52M3%HBJ7.V2
M.[56K;>_USSNY.5U-AW@!J(DT5G_TIO]/ !JO7\3_,\4VS.?FE?TQLL4]71/
M_N*&?,=J=[>?B>JLTY8L)CK69_?_VXW_HPE9Y'K/\+S):XX,FVMUM"D/6;U_
M %!+ P04    " !UDFA5NHOZ =,#  #<#0  &0   &$S,C(M;&EN9&AA;&-E
M<G0Y,S R,BYH=&WE5UM/XT84?N^O.!M4%J3XFD"NBQ0<4R*Q"9L8L?M433SC
M>(3M<<=CLNFO[QD[@5!*A7@J-(HLC\]EOO.=BSW#3^.9%_RX]B%6:0+7-^=7
M$P\:AF7=MCS+&@=CN R^7D';M!T(),D*KKC(2&)9_K0!C5BIO&]9Z_7:7+=,
M(5=6,+>TJ[:5"%$PDRK:.!OJ)WAEA)[],OQD&# 689FR3$$H&5&,0EGP; 6W
ME!5W8!A;+4_D&\E7L0+7=EVX%?*.WY-:KKA*V-G.S]"JUT.KVF2X%'1S-J3\
M'CC]TN 1ZS@=UPE[H1VV3WNLU^N>4ONDY7:<7J?5ZO[N($@+U6N;0FT2]J61
M\LR(F=Z_WW%S-5ASJN*^8]N_-I[J$;E"U:502J1]V[2[N4*-2&0*D4CT7-_6
M&SS;1K&?RB )7V7]*MBMZ4X<BD3(_H%=_09:8D0DY<FF__D"$W*7\ Q^$RKF
M(7QEE)?IYV:!>3(*)GE4ZQ?\3X:X,81JN=[&A.[0F.UB=-IM#,S_?CDYGP30
M<DWW*?#71?P&V.="W+T6=/OOH-T3!.WY\V!R,?%&P60VQ2J>+VY&TP""&3A=
MN#$7IF?"PO<JJ=,ZL9LP6L!H/+L._/&^^KL)>!=,SSZ%V04$ESXL1O/ST=1?
M&+/O5_X/&'F!EKBV_:8T_D/A_H?IF&00BBQCH1Y.L.8J!A4S^%82J9A,-C!G
MN9 *4'@A9 J.;7P#$8&?,KG28^B<BX5(2FU>P"0+33C2#@X/6NV!)]*<9)OJ
M_A@B(2O?.2(5%%A&&3T\<$[MP8+EBJ5+)NME"ZM,CZUZ10J(>(*#[@'<@H6E
MQ&G*"B 9!?]G&)-LQ7#HI2DO"AT(_K4FQ0D),9,,$3_"JD.J434KO1*QR +G
M"*--F'/T)RDL3+CB&25QT@0OYBR""YZ1+.0D@5D4\9!)S82VWP;:K/9:;@!%
MBD<(L EY*8N2(%%*[+?4EO"ZI51,$,Y)=P ?O^".G.,ZK\^O 3*Y+;>H3+#V
M0J0UT6E^2+UD?Y1<,OWB*C3YCSP>D6/  G-.CNCQ+BU[A?)0)*-0:;'3:[61
M\MY E]#_@'7W7UGG&39G2BHJ<1PH@@XH/JU8W*6$<#T/<LD*S7Y3BTF2 )HA
M)NP)%.28CJ)NJ>BA5] AK;Y]JFY%K3*IDR=P$I!Z<#SM(_/C)V2,K%4M7R=A
M*N[W!F"WGG\?GX7#@W9G4%37^<2[',W'U=2=3,>CRZMW$\7S%\:[@?[">^V5
M^%];=OM'@5S4!Z&^9 DV_SU[\7"P(^G1A"P+_:GQLLE;SA/;:WWNJ4Y@9W\!
M4$L#!!0    ( '62:%6)-DEDD",# /= (0 0    96)S+3(P,C(P.3,P+FAT
M;>R]:W=32;(M^OW\"EWO>\_N'J,%^8A\T=6<06'C=AUD@S&P[2\U(C,C;1D]
MW)(,-K_^1LHV8&.JH!"6EA"C"B2M]YHS(F;D(_*7_W/6[[7>TFC<'0[^M2;O
MB;76_WGXR__3;O_/K[M/6^O#=-JGP:3U>$0XH=QZUYT<M5YG&K]IE=&PWWH]
M'+WIOL5V>WK,X^')^:A[>#1I*:'4C8VC!P0A)LRR'37J-H *[6B _W+*BXP^
M:(O_.'P0K2C)EM(&9WDW$TH;I89VH2A<!#1:J'_D!R%2@NA,*=J TR:*D%,*
MR0K(!8.JESV:\-/Q$P[&#[IGDW^M'4TF)P_NWW_W[MV]LSCJW1N.#N]W![WN
M@.KCWI^,<# NPU$?)_PZ[O-#B+90;:G6+D\R'GT\2<%QG)Z ?ZR[?MBIGCEW
M/^SWX4)*"'O_8N/5KIEN[#>F=.]P^/8^;[A^SG'WVMV_TU>GE/?_I_/T13JB
M/K:[@_$$!XG6/CSS[8^LA-2?//>G-][]TA&B'G'S]),VW_"U(ZX>X(_>JC1M
MX=M:7ITG#4\'D]'Y[6_B<N.UMW$Z;A\BGGP.Q>6&:SOS?;SY@X>JFR../SP4
MQ?&'O:E/HT.F?^P.Q\/>:;W]\;TT[$_/+X(6'][<9Q>Y!$B&$.Y/MWYX:>,A
M*.G^Z#5?['%YP)?/6LD]W>E!#P>'_UJC0?OEBS4F/6%^^$N?)MBJA[;I/Z?=
MM_]:>SP<3/A9VGOG)_RPZ>+;O]8F=#:Y/SW5_8?_ZW_]KU\FW4F/'O);:%\]
MY"_W+W[[Y?[%F>,PGS_\)7??ML:3\Q[]:RUWQR<]/'\P& Z(K]\]>U!WI-'%
MQV[.-)A^Y.W;[$Y&W71Q^;/)+I5_K74]I: IJN(D@A$Z*!/9CHWBDQ27\??U
MZ:U((=L?7_P ^_72U'VP,>#[.W_,3S/"WM8@T]G_I?.U5C?SJ;-^=1[7AV^?
MJMVW^[ISFH\WWAYLAN.=XU[WX'5'[!\G>=#??[^]]UQWWK_J=M9[;_95Q^R_
MWW^WO;G;W]][<_Y4;_?VWP_-?O_5\?;FEMY^?=#OO'\IMM]WY/[Q(W.PN7V\
M\[JC.NN[;P[Z&Z;3\^*I.CC??YWLSOJ;\^W^QOO.^D'_X/B1W%Y__KZCGAQU
M]EYUM_=^[>^\?BX[_0V]O??H;=Y\THV;+VUG_55O9W-#=(X[L+/>.]K>W("=
MUQOOM]7VF\[>X?G!\8;86=_N;[_>OSSF%5_+# [VAN^V7[^$_;WGYYWWA_48
ML;]W:/;W.GI?/3_;6?^MW]E[#AVU+P]Z_OW3O8U)YX4XXW_?[:QOJ,[SW_EE
M)P!VR>R)L0VD;1M5"FWVJ06U%L9:N?90L-?1UEF 7^Y?@_5'HOSX=#1BB)]T
MQPE[^X2CC4%>YYBTUKIP+7R%L\F#S+^T^WS9HW;&%0G^E 3B%A(H2\#8Q+8*
M+G,09CJ@XWB:B8J(R45O]-I#J>YK>8?X/V(=DJL6>=+#P^N@E^X9Y7;!7O7B
M*\3_&/&SSN,IVE/4.^N'9]O'&[]G(8N5B3$6P)(K6]\.7D ; @4A2C"6Q-K#
MZ1N^0\BOU.='FW_"OXQ7&/\YQMW/,8XV%:^L:9- 4;6U;\<075M&&[.*$G5,
M:P\K#G.#^!F??YA7('\ER.>?@VPQ>@++ 3QK:D/4L1T"B'9RA;VWXPQ,F+6'
MS_6W0(P^2R9)R$X$H&!\RB7XS'S*1D<E?M^ZB>RE#'^P<T(C%OV#PZ?$"GNW
M9H8[Y>68'HW'-'DQX5A=L=\I3[H#SBNZ3(#AN%M5]L89B]-Q-_;H:7<\F3,7
MMKNAG_I/!CO'A^9@??MH9WW_G#%YQSB]8Q2/.NMOWC&NL+.WV^6K]Q@'_53O
M'NWWSWH[_>=F>_T1W]MO1SM[1]V#]>=G^^]?FFV^O^WW+YD+N;N_E_O[Q[WC
MJV/X6J<'ZJ4]6'\C^#ZZS"^SL_G;F^WU)\?;>V_XGOF^]W[K;ZO?CK;507?G
M]7:Y#.'7N&"DD1@Y>T[@F M6Y[9'5&WP 30[@9(IKSW\HQ3JOW8F1S2:HC7>
M'@[2A03[%NYH$04I);WTFKF3/5HA?,Y%E,PZ,TVY(Z6JR>"*.XO#'5;[04J'
M[0R&98!4@OU(+)P76!79[C&A:@IWGG8Q=GLU1;RXAQ5Y9DF>6X(0),+@E&I'
M+UP;4N0L$E-NZRC 2##98?H:\EP!UZ7QXV^GSZS"UHH^=TP?8] GET1;@O1,
M'[!M;[-MVU@,FJREA/+CZ3-S[_/1":X8-$,&;=^2SG(NXY**H9V]1F90<NW
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MQMT'@V[O7VNL_FA%COF1XQ89P1X>DLNZC27D-@01VQA92Z!R+ 2J-LPL([[
MC">C"PA:IX/N!2\&I_U(H[7K7 DRHU2U_2(D\"4B%&F=Q,SLB0GRK;USF5*W
MC[WQO];@)F5>'.&(ZFBI_'C8/^$<<\J11Z,1#@ZGR>BOYQ]W>8;G]:='[W"4
MIW^]HG'-:*=M^6,F3^*MG'^LM6K?'U^EK>9+);WS(;?8.M_9.Q3[>QMZ^_TC
MV=G;[7?6,Z>*^V?U-TXI1><XZ8.]Y^\_4NG-^\[F;SV&7QV\WC_?KOE(O_8
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M/$@@ER0(F;RJ10ZRBUEK65Q9'IA2.NV?]NH*6].2@76_$1W5L[VEK4$:]G_
M(),? IG3*C@RJJ($690 2;F0DC:,'TN5I8%LER;8'5#>P%&MG?,#$L(?@D\
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MA7/^7>,Y2@:_U!(;P,E_CMX93$F!3"(2Z89X_5T6LI>N?NJ;NX-N_[0_JP[
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MC/4ER%HS#G0!IHY)R:=47(R00_.I\U.YG[EPB)2D EFJ4"=^UTR,3,HZ(/D
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M';+4<AG1O(*(@7N,XZ,GO>&[?U,^I&<XXN,: IS3=357E81-$GRP 3RP799
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MU"@OA"B:/P= 2]"B+A?O(T 2Z*0.+*AL5DY9:$!1^(9"_T-*NH=D"!DLZZD
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MM? S0W_S^V?ZB6BJA \>1:\9XBQ*9!EVR%)JDI.82 )^)3<OM-8OZ'ECM*F
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MANN%W,#ADTI"R01NK"*$(VY9[A:K,<),$D6=,2J74-Y"D6[G]11%6E5%LL+
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M4\OB/PN@DD#!$<0I1NS!C;=&<@Y@U$'%@&V\=:Q=@+H@4&=/CV/!5+ .1:[
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MS_/E]1RL!4:? Q3OX9Q$@>(2H3A;&B4IH30@:?(0OD0E>*;,("&5U8PJ0[T
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MN9$/-!2^M,FO]T,\N3;Y.UW?Z\3&+^W>8/!K(_5[G6G"I==]GH4&OSQL/F4
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MPY--"FVUVJ-A#"4M])P]K0=+"TVTK7#E0EPY9W*QT@13XS5*("/$\V@+YW1
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MN%UZ74K![>/A=B;FY\2GI*5$@FL KR'@0Q,>D(4@22EL(5 B:QMU[%P[;;8
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M.>O&.7X9YSB.V#)OD>;:(5YYBJRK+ H5KB6EI=YZ02JZ)">^(%U!NL>+="L
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MDH -XRHC5.J#([^SRTW/WFO)C^W[OCF_:/FINV3LT<CQ4IEQS2S%G=;1:)B
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MJ#<? [8PNA2UW^ML-^"6U^TP%96M\WHOFMLE<C!A!K/PV6#U?!IRW01I"M
MP<ZE-3F8X[SC*)Q^=O.-07/L4]J;)<*_3KC,VRF76>*'SEO%I;S?&NJ^RRN6
MTB7?RY1P[-W/[J493UE-_-.R:)Q$T^K9,.\IN'KRDA.(&UX\HCZS,X?M<X[]
MYKC]"0#!3/)J-['[Z^2N@DI-UVZW-W?H ^C?/0F#.@U]KH+!Z.PLN45A00V^
M/>OWY%F?,:-@"X'9-(T)9;*CM"G',0T)F$>D_QHLU<"=^Z\"/B/A96/9C&5X
MG;5W[S,YGVH\X:_U/@KKL9[FL2/DM!WB3(/UY-+*=#/9!?TFOWOO:/]@ZWF^
M5?B<"7C*LNG7M2<'R4"9)#:'?G:4=2?T''[:6!WU7CYILEY7I*R+A"05N=+#
MUW1=O^3ENU$HP-3=]^KPU\O^OL-,E(]BK;5I3VT:J,_G0H-87/( @HWA0<TF
MSC_\Q)Q_.=CIY+UB6FOG.(J1:\258TA'CY$D7&+BF1*$3X(Z[E^X1^.57F3[
M?=D&)Z3!Q"#J2$!<,(&TE16JF.=4"N(J#K(=?NXMN'(7/FBP)S/51N:#GUKD
M^:1NZ/C3FN'6S+O9NQ;:RB<SKI1(7TN,.+TZ1KR$>Y=P[PUXMSLID?ZC8:N+
M>GZ?6CU3EGE"MSJYM&6:)OJ\-2E8-P;=2Z7:FC.@VDI*7I0XZF<G(-C;G;')
MDQ.%"-]N;35[Z6P0U]8C,K]_->U^4X*BJ2.4MZ_'%=)TBR&W:?[^2M-W,)V]
M.O+VR<??7ASNOA<I3B$(BC 5&'%;>60]TR@$[RN (^N(N!Q_:U@(AEG-C*><
M$6$B<Z0B@N&H6$7BY?C;M\ES9^;"*5O9)SBNZI5.$.HZ6[G(7GM:NZ]9\CZ=
M,,2I)N2SA6E\6<XB'/OE4@'>;_TLE2^\]-/YPYS4E,>9P6GK-'0RUH#-'2[&
M1Q"3(-UGG52T);'(?)Z8'*H^9+HV^8X^WYZM<G,^SL2=K];07,R>-X&O,X[W
MUN"S.1_,%ZR8W'MZ%K/*+#W+R"D!.*] EJT\C'R5@JOV02L_U7%R=?#M--;S
M-/BZ!&#=SP'DM?7\IK&7U^"KFP!4BYOW=Y7A1>OHBF4W[RMI9#"HCPQ[:4=J
M?YI6H#-UNX<<=  _:/?SIC<-E!BT1OG,*"Z7Z@[,0\]G-WDNT@.(E[WN"S[(
MJ9LFF<ES1PXI$J%>?#9T>I_S0*?.F[%A-:],XQ"*0>MD_/SIJ5X2;"J/.0S-
MN[8O9_W6T>+3]S79M]D91X VQ_6U[Y+4!ZRFWVFG>\<<D_FI.=.L'SA;7G4<
M 1H&,PXIT+2+IB;FM.93G4*< D*:<Y!4Z06LPEQ0I?5J/C05IJ8-3QV?E ZR
M"N9S@R9<Y'_A!=K#6J-J!U9-7_*)]UDZ,^^T/X8<"FNZ^8G3X)D9W8[YQK.R
MFK[F=^<U/>HD%2#( 26FFP<V>?F:P&Z/PXY2'$<# %-!#!-$M>L^A&,@SW-Q
MVON<2B\W[W,Y!*D]^=%&O:F9?\_QRTU?[/<%?1P?_RXNV7$+[] ?7N0JMDUJ
M2+I94Y*YB4>>[(#U:=JP[JMPQ9)/1\3PO0%+9 DZ]*_Z>3KRS0*9+RT\7OQ+
MUGX]*==9_-N361B7/*IW]A1CXU.1Y3!A\?4A1;.'UNZ/<2'>M&'/E]NL(>3R
M:JL;8C1SUK3@!$AL#^J#AE$WT8M<<=./*[CD;3S6=2YZW]/P'6#K]6J=G/:$
M,3M)"]GDXY YR9C.Q6"Z3@8+!=<^C'QMG-1A48,DB%F[:'DH1"(3C0=J&H.^
M\$(YFGX2-C.8C;P:1T:$[J=VOY>=5RO5-7AP-L0W([R;"GO+C[F&<\0OY:^,
MRRS/'L#52M;KSW'3K#FY@N!R_O6(C- WP=6Q34U0ZLR)9 Z?-GW_B"S27[,A
MD0A] @WXW^T<EC&7U08:EH[[%\)UQ]5\)^><TP3U%-=03Q6,,370?O;K[MM?
MGB\&MQG?.Z\9W[3HY/1QZ9PX=>>-;7C<)'8TAUNDFL&='+*7EO#G!$()$T>#
M'+J4.-O\@O>],.XDG$G+="AY",T);O^2\"<2KP^">W75M/QW,SD6;@Z%)\56
MOAOR#+>9R;;;6<@.OT47P6'X/%-&8$ZTQ5/0> H^OP=SQ@H3'')@[" NM$%6
M!HTTX\00#%:0$Y<M_T?:<F,"A[M)3<(J37BNBW-<RWB;KWQ%!?JW?Z9]$2/,
MM^NB3"%92F\247R3 GK/6L^.>^?P=,75\Y]:O]:Q;G/!'B\S) WJ#-QE=T@1
M*1,$>#,F]H]G^WC5;1WDRKYI)FO 34 _AL_)_(U-Z\]FZN+.X>NUA_O?!HA:
M_Z(I!C_YU;C)1V*=G10^,>;[F2::%-N<S9*&9==A1O!]$Q;?GX@D^Y?Z622Y
M%_6D%7V-_+D(<^H8/7'WU$<>X\SK'.LXZYC:GM1#AK^.74,UTX>?G+;/!]LS
MIG\]T!2.-)OG/O%H35[(7EPUY'Q(<#)JU_G4*6EDLA?F4,LTW?FK3. [G3HA
MH=V<0X1.<).:Q^/(Y*5OW@]S=IK) ;S-KOPIAZM,]NGQ:'9:EPCI57T-:OBH
MHP>3[M4AH+V%732%5X[ZW]]%5PS_.6ZG"I6P_;7>],Y,]ZIE3ZZU[)>4EIUS
M Y9#\IL=DK-U%%+CN!12*R?KF_1NI9#:="[8?152>]5-_O%>_V)_8GIMB)6#
M#\955#_\\^%P_U5U ,\Y^/JF??CACY3R6QWM__7QW7'G](#^P?XY_NOL8/_T
M]+*5<WAV@ \^?+PX_/KG5W@N/=Q_QP[W/_+#O]^<'OW]\NL_^[YS^/>[ST>_
M_1H/OKZKWF.?YM1)Y*FVB.,HD7+!(R%MT%YRF&1R^3042\4B]TQ:(;D4SGHJ
MG=>48_A_8]UEFV@\YSF?HQN&-ZB+]OU'7AHB#I4F 0L>*U[QH"2+E*9?P#N)
M=$9UVP7['!#"4>?_9^];F]I8DFW_BH(X<\^>"!=3[X?WO8Y@&^S!84EC6]X.
M^.*H)P@$8B1D#+_^9K4D'I)X2$@@09\Y&X.ZU5V=7;DRLRIS9:RGRQGWOE\S
MT\CKR*]XSM&?S$:FHHXH$@MSCEF"#*8:,2(38U3K1/1T<?5R!4,W9_LPPS*&
MH=-\V6CD[<-#0'BB03;GT!/,*>$Y.;]E3[KQ[?"7/T.S>]*RYV^;Q\70BB_]
M>?-R$SJG%@+L'[YR=M9QW^$Y[<!_87CGP>'UXM"_3L/X,<'7*9&W'L;KY-9C
M=UV6XG6MZ4R7O?N8('HQ@^4/NNR_"OGV90RO,<^(_[?&UFXOQ1B8Z(&)?XLK
MI)@?PQO-<@UZ\CM?Y<\QEVFLQ6XQ1R;KUZ!$9'9'RCRH)7"17G-+%<AC9/#Z
MY#C<(JH,=X=NB/&^>=E'H-R-F63O-8?IE8RQ=PDCNZ/3B.*1D&W6]8,$\=6>
M7:Y =*_*EJ\7^]W4XO&)$$7^WY\/DPJNK(YL_F=!(KC^Z$7#RB5\]BEHD*P.
MA#@)/C,V/!JA?4A&!R=]$,Q1_% :I$MW$>9D=3@E-X[#M\&$K,737#.5N^;&
M[K)0(<WJ1^[O'/UNU0]VX)Q/1]7&A];NYM_[.Q=?#ZL?/S5W#KZ(G8/J>?5'
M]6+WX)#!=\^'WX%[]7;I=UD[@*<\VOE=_?'W8>W'!QCOE[.=HT_-VF:K6;W8
M_@U/>E1O>/!!/Z7J-_S[<V/K-/];W=S[73O8^ADII<H(BQ3W O&D%3*)<128
M8/ 7E4KG[CE*K?-;^),6HQWYT)1:<I?9FGC/@9FYS?Q-!?,O M!>)6XQ[#!H
M =%$,\"MH*W$6(>0< J<#^C;"*&,E+CU;+AU,8I;.B;IM K(>&$0#U(BRWU"
MP1,72-Z@=@EPBZA;>P\^2@EFA:=[7,K5<QQ_M#N'J)F9? KFJ%O#$'I'"#$P
M#/?"Z0L F[D[25G^V\?_Z4N_A)B9(:8Y[AH)BX7G3*,@% 77R!-D231(V("]
ME=99EMN^,7TKM>2TKM'B'*![0WPZ$8->JAK.W>:7:C@O-1RS](I;;)VQ*#&C
M<W<;CRSS$45AI<-"9]Q<>V?$NIY."TMS/BD/MGG<[.['4)3NE-;\J:WY4/RY
M<*N$D=EAY'S<FDNCHU8I($X31]RFB*QQ <7 (E=1P(O+K3(97I>E-5\M-9R[
M-2_5<%YJ.!ZWPVN(6"M$ !@1EY@@QZU!3C)X-=AX)0J^]FG#]B6VYK?E(BXJ
MR_"A&M9HGQ9=F$9VZQ?')R?7F7K R":D@^;5&,36.1O?N'>V&_LI^G^0T2RQ
M<LNJW+)Z4O\-;$5I(::P$+7WXXZ:-80+AC'R.CK$291(8V,0LR%&+I03.=X3
M7,YMV>4Y=J3*3:=RTVF>+FN)/%,CSYAO&KSFE$:/L*8$\1@\<LXF) -F5@OJ
M \F^J<#3+C4]R9[22&$-ZZ=,SA8_3MPYARL6K5=:\>;8'W"5!=YPHM-.)@?
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MEP'QO/;JK&$H12Z\#E%A07,#:SYAV778\+=R9KN7<WPPAQN@M]W^>2.MFJ\
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M7)9,P5FWB ;U$5MT]V";UPYV#W=_?#JJ;7XYVVG\U:S"&&L?M\[JFW_M[Q[
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MKD6W$:?EU>3U7KHOE4O_94$S:(F%<'W#HU+L>+P^&7S-:4^O[[%_%'_$4-F
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M:F/O8O?CSD7>UMW-.4SG^'PTATD3YATU$MFD(^*.2^2B%8@(IS,)2+1.9=*
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M*<C O(Q6WERN#338R>>;J>+1BXF7%#]>>^A _#X?_#D@P2!V)V>.7^V9[U_
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MR#(<X;*T!875EL&3S"79A5,15):_[<%6,2&X.PFW2AN"*Y8PF<M1E+&-7+O
M2U]3SF'I N5>.<!_L)E1XZC?J]T\%_6EE2NT$G/PI^YQ7D/J]TY7]-%HB44,
M2CBL C>6 <BK9%3RWN'(L?A6'\TO>?,^G,&IAX/N7[;?SJI-CD225^RDN3R^
MS#PI(A4$8Q0T<X@#'R+-O4$F4&ZI!@C%-F=8T66QQY7=T9HZ+*RD+DC&N?!.
M !IS3R/U+)CXS<&1YJ"7'C3>?W?$@;-T$@HQGCSB,BEDI(K(41E\E%9XSG/>
MY-*#GH#"]>KR?"G6$I0#[/W!92C)QD0%(3]4H6A0]_.M3D#E+./$$^_?:75=
M902E"(B7322 OL$4!*U&@UZ#"F,,H\Q[+O(OW("J*0CH,DK(T-#@8R1S[ISO
M'Q]%H$!OA$&$.PXT*#URBE$4,9.> G$J*3>V\998$A79K'P72\10RN'=[I4L
M V)M]T(FHEX71"J<_<E]Z,1A9R(E).5R%!^LEF",\%P!02RSTC=T\BATP@"K
MM)26^^B0%Y8@SJ1&FL ^FR )#AA;G0>0+XL;/)A*0I3#><YH("%P9953,4H1
M>(K>2\IH<_J/<?IOS^'THTP\DA"15Q[,3)P(2*H$O_I$8PI8":XS2CR,2B*%
M2-F*]9I(,&)!"XE64TI]5,(ZFYJ#?IR#;IT?N82](\XA[+,]:, >M' .B$@I
M7-!4@U9RG>[Y+8K(C[/VXYROL0PK@>G3!W'2N9A$E<9/Z5@0,2Z'VW.\*]B+
M25Y:/LQN *NJ_O*4A7:M[ZR47=?'+L</G6Y9<.46F?0LF''.6M?[$J_ND$7D
M(.?@%3G4E3=O\S9/ZZQS=O!-,,J5<59Y#NS%2;#&4\!V)?-X4FG,/83H4F_,
M9,&_QB8"7S+8.][*^A:AQF*!!,>@;]$(<M1$@0+15FL@2#"V,Y*2!T'28 DF
M06+F)-B.@ANGM:)41LTP5>X>F1;-6=_MK 7HUF ] WL9A:S !G1K:I$S$E0H
M)0SG"8Q\ZO-9LT>S[S9+-'NHP,P"1E>I0@!/UP/B;';4$J<7Z(17R)[#K[;3
MN2^Z3T WMR^!O8/GGTW(\;[9H]$#7 )(AI*'(M/1<>D)QE1[8"]U=QZ*;O#3
M%7L<I(-^&T#<=OX8[]9.N5GO:^P_[+W/F[O7_;7='PP/SWL?H^T/7C-7'6/@
M*AFPI)B#BB*"KJ;:&Z4$ DXS)E$#)D%9;;J,J6HR[-4;OPJ=AE%9OU,27GU5
MRN=2#,][9?[[X/HO;[XPDMLMWQ68_?"DW0^9[%XSU?U#06Z;W/?"B8!8!&G-
M-9/(""U1\L: -%6&I+2Q_3@TES\=YI.HZBRNO_[&9G%K26GO8XZOP$N^=FP[
MW.$Y/]/J:'P(*,8@$7< :YH T=%(J'14"RGDQK9Z3&R;)K%^>3I9+ZC_4,;O
MKK]/50%4Y;5454!E^M5-P)@+NJO2I^Q8SE<! ;5SD5-E=BV85C<\?ARRRX56
M9;.@JHQI5FTYL95CNVQ'6II75RK,U3V;UF,/D:-"<=-ZK&D]MM;O]B2MQQZ]
ME=AZI*3-9 N!.3@IO (;%"Q8VQF;D/?*CK@J#9TD\[*J/.O5I_O9G'Y=NPP'
ML%%@% ][_8M:M-76]$T6>"EWO^1;3?LA<V(.?//#R W:H6W[94JS_7%9D4&W
M-ZQ2:L_;@SIQ=9A=$G?PM]8AZ'[TL2R7F*F3RO51P(B#P:J99M^HV%ZEG&6]
M]@VLZ8]Z26_+Y53*[*_]WNEN65-1BO#!08*KX.6'%P=]^,XH4_S;O*T#V,//
MT0\/>V^JM*3W\:KFXGT^YB9+;;E:[,7!SI%QB3O!$O*Y)1H'.Q]904,>@!:8
M9=$&QLHRTENS'*<MJBE==C$(D/WJXQ2R,'7$^1MG]2%GTJTNK,^ZXJ&Y-+-V
M?_*%S6)0T4$Q55S3GR*%2BL=5"BYF$ ^N L_U6V0.A=C1"@OGXJ> $9D(VV<
MZ6Y!Z'7+)/099^+_SC3>GPLA9&:2AEDK.:?P;V$L_  RFWI!]?( W14[S4;C
MWM0OUXK#WVOGY?N\N/<].++N\1]EZL!B"W(XR3*/X+5Q!*SCX-U1\I3YH#T"
M54(A'AQ!&DN',.=,!0W_,'F\#9V?GX"JW(M^M;=5&RZ02%_:OBI4FTX-6K6L
M\^$"2]<32?[KAVJ];WI3Q/)ZV]!_?HM;YT>):*.#D<@8*Q%7(2(MH@$+D -O
M!D\5KYRB2WKP 1:1+8S'V3SCDI1;4\=6I8^'"T;='40.NO$5D\;>>1:>"0<J
M@" (&%2(1Y?G$1.&0&F-C&C&>"*YE>@-I%'\,"6WRKRN*EW[.0.2=Z>!P_/7
M# ][N'5\I+F6Q!N"J" @+@R/R(B44/+<:683-@R,4+&UI!''A ;JG+ZI0K34
M&UW%WJH4OTFOF=B)?KJW2VU3E$8V4$2W_G1<5S(Q&*P'G:72M8H36^I0=KJ;
M5EGPF'-.*^MZ+<R#Y63X9GJEAR>@=9WT.J'1\Y>3Z;NO %6*,>)8I,@H9A$G
MR8&>KQWR8(.3A(6S.KN_Q6UJ_H];Q?7E]]<ISM]?T?WSSW79F?@=IN( @VG3
M9I ;S]6;,)<#52+%*:!-Z?:OD*+3*6Q*[<Q!^7#SZW<73GKK+M[[DK^,BSY'
M65)B@BLF'#;!>^,EYB%90X\DW_B6I@5/WZ%@^80?@K=N-.@TX"&+CB9%+!>8
M&2H<[(*@-L2D@BWAD&*0W>BJX_ML8M#[;/N.8G:)O,D=9H!"_X8C>S,:P![%
M_B$\ZY=.S__SO,A&6V-D.X5K=]_#]UHG\ R\O_ON\N#0\WWZUTGK[WWQZ>\_
M\:>__SK=/WPGYI$-U@5K@#72MZ2U^^Z\M;LO6I?'EY_^?DL^7G8Z@)*=3W]_
M_-K:[:0#^"RW'I+,D> C8MI3L->21Y8*AB26V&*%E2)A?@"%=%)Z@4,DW'+-
ME8Y26!]YDDHP&NQ&$4%<G&6?>G\4-[;K$RC>1]\[KBO9%^;GS7#&4F?U[8^=
M72;W,D:A)>B2CC.NG1 TP6\D&@:*QCV<VVLUM&\Z=IB].+9L@W1#Y<(@'I^6
M$RZ_G<-NS,1KE?KU07H?<QN]K)!]J)X\> GSVIZ<$?<//^*#PSW:NGS'6I<?
M+X I-3/&>,]12MP@KCU#)@6,%.$*K!0&.C._H9?V4Q_T04E](&6:<U[MG*.7
MRF)B$?4$+&"9<W=R:H5@@5,%AI'(=7;#\V6C^>:MH=[X$(KZ^ ?%#[EG4T'X
M9K%1GPRH+M7)P%=NT,&HS_]]; #;>'8M\,='5SYVVX.QB0A;GC&Q%(6'&15?
ML>;!6SM').J@,.@;1 '2<04VE2%:@DWE;5(@M*.-\R(]..&XM]Y&X;F*!DY$
M)TVL(U0K1]2\YC$E(_\GURZ4FS_(EL_$< ^Y^<VDO7$QZ(WZN0%MV<\8I&GJ
M=3J]\\%/-^LK-^D1&]>H,[>^R_;_EL)S;OXQ,$C'G@WB3^,??LYV7,=>_-3N
MEA1>?NGGV67DK)2Y <>E*E-]?)6PLH6KI)4\[OAJ\G+]\5;YT=Q4YNHS2K>4
MN/YCO$6N_>RFVQ*R10B]UVUO_HPIWBRV66RS6%@LO1O?EB/0:UP Z,GH]W\W
MV,;UR2BU V$\?AWGX>M3#YK<@XB[WZ2>X?[S0J[6M>/;E^@6=9;,_3.X3)GE
M=Q<+K1]CL9\#FX/B;>G;FXR7+<:39>>GW3=[^V![2V;V]M$(^ [WJ&7WL'?V
M$\FY>]EI6F0E]X7N_I];'[;@AKE)[$PCT4?9FF;CIS)>>UW4;/XS;7X5RCGL
M#6WG45'[%6YM0],-H+R^S;\.4&Y35>ZS#3D N,HF?*,'SFSI.VW!'_U>&'EX
M"=O)[>6[<8'\KB6**/)_[T@4N'@Y>_)?C[0%TZ]>YO.NX;NOD"I#M:521B=8
MS%%Q80)7GEN<>_Y2RGGMGE77!#06F[?>$BE^^S7W+H;=W!D,(OPO'-JOZY(8
M<U\G[LG'TZ^=@]./7S\=?F0?/_]ZDI-A6I_?B?W+</+Q\[]//_[][NO'PT^?
M/^V>_+/_.9R.OP//&GVB?\I/GW_MM#Z']O[?;^'=_J&MW7\N6_37]O[IIY-/
MNW"_T]8_![^]NVC13VF_C;_^?OAVN/\!?]W?/?[:^OSVB%I!.,,)149,SJ#W
MR!"AD;+!>R&$,WGT#6-;_)K,FL?AE?S1BCRSDD"[\V+FQ66#A@T:+A_(Z@'C
MN(@I8L8-#<9HHI0+6N5IG)@V:+A^:'@YCX9:2HE#C+FO+D%<!HM<U IA;>$#
MRW(MR\8V$71+-W#8P&$#A]?"H:"22^< \+SDD0B#J1=)^>B<M<*:!@[7#P[)
M/!PF;)3UR:%<FHXXZ/1(,Q.09=0;00,.>1H]T7*+OF XO W;7@^$O4JDPKF]
M8G"Y% K$.Y,:$R=\U#@E3;&M^MR3,5*1!JG6 *G8@AFK5;3<:D0YHX!4!A0W
MYBSRW@<!AQHYS?.$J=DR*R+5<^AG]U;#&JCZKJ'*Z>BI =M$2\>5THYI&^%'
M9X-3B<L&JM8/JL0\5%G-G+(1HT0)0YPSC2QU$FGA&$_P88P)H(KC+=E 50-5
MZ_2**T 5\X01;H61R7(7*?PO..<-%A%'[&,#5>L'55\S3)5PE9M.'G[\>J1%
M"@YT8>03CHAC@Y%A@%4X,8VQE-IPNK%-%5[2>/(9L>J6^.VR1X@R9#R/,C.U
MFGQK61IW[^Q96?+-[O[!3_?*&*@M[F_*"WC=]WA-EZ[&4C<RTE(^6@/I5K</
M&ES+3?3NU'.M\O(=B/:D/;>21Y#M@0L;K=;6B#S*(!&<M'P:U^YTMXS4_AH#
MNHS]7B/R5Q#YK3>+^0#6<FR]QHCYF*O"-$'&"HX,3T2YJ#T1/B=.:4KHSP_D
M]'V&2->M<-CP>M4.)Z>%6!:)YIX;#YPN!1,<^-[CY)UHPCCKQ],+46W%6=31
M"B1$BKG)$T4.V!>IZ#A-,6+GV<8V>[@H3L/0Z\O0+%HPPCVS)'"0VY8I'CE)
M7/E@HHH-0Z\?0R_$93GU1GEJ$89#1%SR@ S-\X%9Y YS01FE+X2A5^#;U\">
M4F-A0A(J&,J=],;*(!0!74SJ/-_H:=QFC6[]$&R[$*347AH<L$?>A-SK241@
M6^F0YH%J J=-H[VG;MTPZ!,Q*+%Y-'O$/#','76."$(-'!Q)@ACN&[_V^C'B
M0@@.:Q.$#AB!YI,GQ2F!'%8*?J4D^4A94'ACFQ"Z:@BN8<.GJCTQ8-)H,$.%
M4]QIXV3,L29O#)-$2=VPX?JQX6)XB6*-L<@JK" 6^- )!']((!^3--)$3'%Z
M-CY\!1[OWW.O[L;??0O6:!%H#H-J(QQ8RE$;S9P%HPO#WY/#*YO,DWY]Y?Z7
M_]CK>H"9\L<_ZBZ]C1K^$+#S8='%S:+@1' &RK<18#TG@4SB BF?3-(>)T8:
M%_?K86_#?%1!:D9 ?Q?9ZK;>&46L8EX[8A^-O1LV7H6-%[S:CBL2G"!(&@%*
M?,(6:4LCBB2Z$# 52KD\1'W]?6 -"W^K-2 BDS$0X87F25OG+;$V"D!ZZ;E9
MO=BH8>''8.$%/[9Q 4PS'%'()CB/+B&GC$6YBP#S7C&BZ,M@X==@GO^P2HZ(
MS.48TN(0)5=66QD,)2$H!]Q'-;V#?3Z UX:?&M9\"M9<\%5'IIV322$:<QZ(
MT3%+5X]DH#GX%!*U(%VU7#)QY<?&.?:\XM"")#1,8Y"#B@N!323:*Q^$X(:9
MNF_V*LZQAN<>@^<6W-+*Y9PZQ9!- B/.J4562H&PQ"J0Z(GT(G<?N';*4<-X
MSRSV!,$2F(]322773ALX/D&39=QZ*?5=JAX:L?>4OJ$%E[3245B= N+.*00L
M"'*/L)PZ183V(/FPYQO;BCRQW+M'14,Y@V']RZ;*[GM%+F-H&L\UO47N9EQP
M, RUH$KQQ(7A+JG F:-@;H#*RL*=S?T\H_%:8-WIAB9YYIF0>4FC.LX9)8)I
M9'BP""C (B,!G4&,@HSEUJ9D'MIKOU;-F9H63 U,K@23/$CA14A1&LL--5IC
M$8,1GK+(S0K].1\%)ALX7 4.%SO5Y31NX@)R@A#$M<)(2_B'4D(H:TG0))0I
MP-]EW\X&"QLL7*USBO**\XB)]WFN+[8LZ< 29BQ(D[QJL/#E8.%"&,GB8!W'
M%'G /L2-]TAS09$#N:<-,<)X^^*Q<&7(J[OHOV;(6VT+7@+DK>*,I$$92ZW5
MD5BNB-!&!2%MP-*  FC)ZL[(!OR>'?P6 W6*."D3!9,X,L2)TLA)S)$QW$I!
MN#=1KABH^T9&:KIS-GVD'L[7EX34R1"N$N$L@3Q7PGOM?5+.\6#N',MLL.O9
ML6LAX!E]M!K;A)3-(XBC!2,6* 99(J6E1COI5.[:J5Y"*[P&J%XU4,7D"8LA
MA40IE]*#^(T)>ZFI#$#DK@&JEP-4BV%A*:R)A!B$51Z3$R@!Z])A%*PPH%-S
MA6W8V.9DO8#J&TN8UH\?QP0_*&PW%,?P@&%3OG0;,%$2$P^$&H*YR[F84?C
MC(T:,(JEIN/'N@'0Q9(Q72%8"K"#E(%SXLR!E4<,1J 48Y&$2SJ!E4<>SL6U
M1D[]AJ'G"I9\E"K02!D+/ FE)3$T$JF59Y[*9M+4&C+T0OR..,RM]1[8V.8N
MX%XBC:G-E8A<"XEIBKD%P:JIG@T_OSQ^CM$8I[F.*C">*'=611< [*U+/.FF
MQ]X:\O-B#,IQDU)TR%,J$2?1(X.-1C91[Z@SD:DLH-4+$-"O(:E[%0^D$=AA
M!J*5!NXH!>YDU,0@@HN<^-"T&ED_]ER(DEBB):C)#)A21K#?P71W2EB$?7(Z
M)$4BB:7^S)K2BK7D0D4\CEY@#[8/)TYH8Y(7D6!/@HF6-5RX?ERXX._G@B?C
MF$;>!K!B@2<1G&-$,CA"DJ/>I)#K?9NN6^O)A()@D3 %RR5)[C"Q7*1DLXIC
MI-.R&>JRADRXZ,M.(F*K/4:24H,X8P0Y&B0B\&>.A4HA-\X 6;CBJ+SGJG/B
M2T>WK!^C595._8KD%]S63>IJD[JZW/[PG#J&G5/2<&M9=@T0HST-7E P1>[K
M'FB*15=!TH,ELS*D)=B"<8BLX#S7:QMDJ)4H<&(H]\KI2#:VN?D^A\4W.?@-
MD*T&9,)*2;([3!F.?=!,4J-#2#H11OF]_9P-D*T(9 O!B,AP5"HF@"^2O2.:
M(^>E0$QXRK4FTF<@(^;A.C$U2-8@V9J]^RK#36EBS 1)& ]<6>-(E,G82+Q@
M.-E[IU0T2+8BDBV$80*15KK$$&4\V[:$(YM+Q2/!3 O!=>1Q8YMR_&"!U2;5
MM$DU?6I%2J8<>7*6,<PQ3QH;[R)E6NN0<+Q[3GP#/]\&/PMA)D]H<(8$!&CC
M$5>$(AT#03A@P"7)-&9V8UNNKD<U(-. S!,W$3122FH]MDYS(.K<PY,;ZK#R
M/&)V[X!; S(K@LQ"%,V$9%TP 8GH!>*>,>2T 6LM$-!P\@$%#SJ.U"O[G1J4
M:5#FB<=I!2J=QWD(J>>@T1C).2")#BH&;..](XH-RJSJW%X($XH\ 4$RBPC/
MS;DQ%F!*"8Q,-":IY)/,S;D9-2N;4D]1\S)^V)@P>8DN]XSR3_F0KM;.8(&A
M-W*=.+OX.]RE>6#SP!L>>$L0?-$500PG(MZ^>B+N?I,E$M5'0.[^*@*G[AMP
MH\#9CZ$].KU6Y(@[B9P6_*78A\M.!L7;;HBA^!#/AO'4Q7[!\&:1W7#7%HHU
M6_N-6TMFMO;1R/<.][BS;+FSIAC:7\9/73BO9SZ9/[<^;/VOZ_]K^[<>K+Z;
M.T!/#@*6_5@[V)S/73FGUT7-&:WW&56::IF:]>WGTNQ^@V#?U?DT"+;^9W0S
M@MVFC#WX3CV?V^F/?B^,/+R$[<3!9M&-PR;'MDGHN-N(WZ@P%9XY*A*7F!IF
MDF?!84GA_][5"1VD*<%=$X_E_N'><,%C:8227&&%"+<!<<,8@F,,B(7H3#3*
M$HTWMJE8>8#26B5_?,-BF@2W!@_O5NAEK.?*!\Q3Y)8+9[4UA.I$0\(>^P8/
MUQ$/+^8+O7"2.FE P8 UXI%@I%T02&.F'.6&".TVMCD66Z+!PP8/&SR\(>-.
M8F$=!JX)W#)K!&"CBEH3@D/ L<'#-<3#UKQ^Z).5*0B*1& >]$,3D*96H2"E
ME0+.%'.SL0U'_:+QL,FH>=49-4X1'C !\O.)^T"U3R$HJ:P%\!)FG+='FAK]
M=8*J>=6-D\24%!$Q!@8L5TPC:UA"!'.-O<""&I)-6;I>#6?OZV1LL.I58I57
MW%&LN;?:<4RDH=@:YYCADGE%8H-5:XA5!_-J%8'C<HE:E,\2<2DL,A9+Y!35
M+$4FK?4;VXRI]4H4;+"JP:I5:CZMQY[&H%E@/'<AD\Q@9D#!8L0&:QJL6D.L
MVJ]+)P"OS@]VW]+]=T?.@K#Q1H+I%Q/B(3ID*8](Q6B\,51$B3>VA3;KI5G=
MHS&26-H7J?R]W0VQ._P)5:V3YAX,;_"\3?YW]P]^NE>RYET;#S?W>("LYA=_
MZ3=.QYAFI*5\M ;R[4/L?VG[Q69CD]=M6G!7AH@CP=A(I8]@C22B!:'P@XH\
M!D\F+?4?V;^;>OU3.X3E?!W^E-I?8T"7L=]KA/Y*0O_=8EX ]=))PT#0$VT1
M-Y0BQQQ%UB@>B"6@K,6<1Z4IH3^O?7ONIM_^-S)[P(%ZY66PR7-IC/8\&@'$
M(#!E)C;!G+5DZGD/:? V>JT"BD2!'N] F7<&]'CB+<5<8B,XV=@V>$LU'/V]
M<[3AADO+0I(Z3_SF5C+O#1.4IB"]Y0U'KR%'+X1G#37$1$Z1%%8@;K%%QL,_
M:.YK8Z7"FHL7PM%-W_#97B)!J"B)!#4L<>VM<RD%8VCTV-E(]-/XSAKU^F'X
M=EX28Q: :SE'TN;9&L1K9 7%N;.X%SA:QW*C@'NIUPV'/A&'<JL]=<H9&ARG
MB1C&F .]F-LDK$ND\6ZO(2<N1.("QRS9A)%EG@+_!85L5!AIK'3">8**,!O;
M5+-516C#AT]6B,)L(E08@057,EG+%-'8>8N#BT$V?+B&?+@DRD1=<-2#&DML
MXH@GDY 6F"%CI24JSXO&XMDX\14XOLN1Z8W;^[9<04<8L23H&"DGQ+F0M.04
MH ;,+4ODRG;SM7/KRQ__L!>Y>GC0J.(/ CQ_+GJZ)<ZB@^649NH0]]HA!R>*
M\L!@#IJ PTPUGNY7P]]@=H.Y35+00 22$2=!I>#&1B^5%\D\&G\W?+P:'\^;
MU-1'BK&U2/H\398JB8Q.&LG@+;>6@*$-?,Q?@">LX>%OSCN+6EN%O0V86YF,
MS\-2-/=,L"A<P\-KPL,+[FPM W.@5"$3/)@ ,5KDK,K%F%SX0(6/DKT,'FYL
M]#FI:E.0020<(G?":HTC2]HH)XA)*:ULHS<<^3@<.2]5)8])N6!1,#J[QT [
MMIH$%%,21*1(=0"IJLES#+YL..\N0Z"%"2Q1+*BP8,XP2XT-3/I $OP@:,-Y
MZ\%Y"XYIZK6T$7.4$C.(6R60EH(@1@*6CCDF8DZZ7CFTVW#>4VFA6 +/*1:4
ML9Q(4$2UY0;[J 7GXAY^Z8;S'L>27'1%"^]E2-J"XND8XM*"1HJ#1CE21)TF
MH@S/@E'Q'&/7'V[>\^UU#6O <=4(Z%S@T+2F:UJ/W UY S4R<!HP3=P+I@6)
M3CMG+4W8X+OGMD4WN!YU=[JAR:EY+MC^N.C(C\RKW'(+:>45XG#2 -^$(Z]\
MH)%$[15^:$?^6C5O:EHT-3BY8@XPYXF%8 5E7"9C<M#=LD""2%2*NV?U/PI.
M-GBX&AXNN&Y<\-%*AT"9=2B'J)%UTJ)H/9,X*N*BV=@V8HLW8-B X:L'0QU3
MHMI2YYGE44L3@U141,\XXT+=O9]Q X;/#X8+D:7D$_PO6)2<Q0C.4R%# T=!
M*<L3QSI1\N+!L&FW\JK;K5"&#96YBLN!)D>8Q8G$W, ["2V]N7N[E0;!U@#!
MYM4YEYR0R@E$A18Y$J>1<R8A^"$Q+ #1/+E/)*X!J@:HGKHUL$L^L!"3C80K
MQDW27&N/8^ V2G?W?IL-4#T_4"T$+@6FDN;AVCSPB+@/ AG!%2+$)F\\]YZ$
MW-N.KZQK-4C5(-43U_A%&H+&VDKGN+'>.JL-6 NYC[FU[NXQW :IGA^IE@1Z
M&:&)@\F/K, !<9HH,H$QY "G@G#&"8<WMCF16VR=L.H;JY'6CR7'-#\H;#<4
MQ_" 85.)=%L#KL2"%@I+:1D'^\XI[VE2*@O99 AK.GBL'0;YQ:BE!:@QE@2D
MM3. 0#0ARV1 @3G,DI*1Y?(C1EY SG-3M_"-'"T3%MP:@AE)G&%F*.7:<N>M
M9B:9U'#T.G+TO*,F$FE"XAC!,2K$K>9(>Q*1%W"(8.S20'(=\\J]<AN&?G$,
M[;V6,;DDB#=<&&LH]TYK(4)409C0,/0:,O1"[(B)!.<702;K! QMG$.:188L
MC7":/BK!(XAHOK*-T)0E/;LC4JH0+:?68!"XWEJP WT2S@F.DV@&_ZPE?RXT
MTZ(D8(,-\C@+7&D%,EA%1!T@;P3.)2EL;,NF4F)=V9 (R;FE%"Q:FDO,'(_:
M>,JP4,S[A@W7D@T7_/Y<284=Z+V2$HUXL@$9814B&&R8!%9-M"SKO4VEX)IR
M80C9X9 <IHS;:+31P4<?@A)8<F,;+EQ#+ESBTX[!2*\D0<&$@+A(";FD$_**
M&&X#<2H2$(?L9=<NK1^K585*_8KH%[S7=\P7J][C)P8O'WHCUXE5T. 5Q1D?
M=8.^,\B.43%#K1",1YYBR 6F('@3 XTJ,&SOZU]HBDA7P^'C1;^^8PH,2BU1
M=+D:*7"!-,\UW-8'884+BI7=#.6#.?8?@D%>1G)^ Y(-2*XR,55J&94.4H"5
M&;AU,E&F@S"62V;O/;ND <F507*A1(DEFHCT2!I.$=>.(8L90YQC)7'T@DJ2
M>URPAYXNWX!D Y(-2,Y4/WG#HJ-)$<M%#CT+9[P4U(:85&@TR2<#R87P$S=$
M89(8"AP#2/) D'5Y5K0,#GOK8N1A8UL9O$6_6Y"\6QKN\@7?N.;O$O@>;C>^
M,Y2S6!CCHW"),>Y\,$K[()4"J(N,ZWL/U6E0;F64FU<%&>4D1:<1C3D35TJ&
MC #-T L=M8D2SBI7#1BQ,LH]&#<TD-9 VOI!FJ?<.$,M]8PGKK2TUDH2$U%&
MV^0;2'LJ2%L(B((V[8*PH+.1P!$/VB"0.00ISB,VWB:+T\:V5*LG#C60UD#:
M]PMI4=F,6 8 #'-CM#/1,<9D /!BP7P+I$WW7NN.3E'H#5']S0;O5O7F+8:>
MB2>@6CN&,*C9",XN#QB6"FG!L=2Y+;\7&]MD$TNSLD?OV3&OC%W_:VCAH=OE
MVC/1MKLC6R[^$5B+X#G.4LLYR_7_5?^CWKHE2R&&$Q%O7LIN/&W?=2G7A,!C
M_[3=+3>DZ*7BU'9'"0YWU(>]+^">7]H^#@I[W(\Q]ZHMSMO#D^+?\,!![!9_
MG%A@3A]'Y1$,-HN]KM^:4$-H?]G^7_C'^+U.;?^XW1W3@YD5!9]'@V$[7<PT
M."6ZE$E/<$S+]^:@6_Q[U+DHZ&8!J(4WB^%)+-[T3F$]%_F7?F]T?%*TAX/B
M_*37Z5R@WGDW OF/W* =VK8/%[T]C?WCO&_[,QM;UY7VNH/B%]L9MD][_;A9
M_/[[F\T"+HY]N$N[.^P5=K4#V2QZW9B/,2]T^2'5ZV_#/>"Z?_=.N@,X^?]C
M3\]^'O^VF3&WZ,!I150";!'ZH^/RM8:VZ^/<FJZ[3=FV4?T\@#?Y$N%PC\L7
MAA5\V'G_ ;WI_85H\<5Z#]N^6>P$*K?>'/Q%T8?-HA]][]0!5<+K.3N S8![
MYU?:"7]97PRC/^D"'1Q?%#_DO^8'4?SS'_U>&/EA^1OY^<?OC0[A8&5)AW2&
M#HNS?N]+.\ > ;F,C]P6W1Z<=IS9GU;YI_'V5,P.I-:&$W']:/W)F'!V)K0%
M=+!9V-->/F7XI \?PXD#GR?;[HSZL7 7DV?^T/XQ+Z%>SLP2\\_]^)]1>] >
MQGS3Z.U@.!@_K_PHD_Q_1G#B[>%%_J ^S7Q+%XNS4=^?E)0P]<01G$Y_;L6Y
M%O6'=K44 /O4[I^.KY^BQV&^%*Z 79K<>FZ5 (KMT]'IS)KR%>-UP=<&^:-\
MF\4EM+N#8;1A$[BS&T!E.>_.7W0"'^=[SE+IHHR:HMN:)GC.K3KKP2KA@I_Z
ML0-7?HD_G[?#\ 0HJI0O4]^JR1Q??<4ZD+2CX?5?J44ORNKY3TS>SB H7_2<
M'$+)W#Y._?.D?_5>@&B9UO]!-@'I_V0[Y_9BL/&O67@ ;*AO+E69R';=/DWM
MBB]A>_D6W$60[\?0'IU^VR:\W7_[_K>WK</BE[V##P>__WFX=]#Z4.RUWEP/
MA6OV!JV#P[<?BL.#XLU!:_=MZ\/;W?P3O,O>[LXA_/+K7FNG]69OY_?BPR'\
M81]>]L-+>;<?1ET["@ M@ IP9WA0)\M_$/A??<S:+XCI6(('Z ;CWTY[H^YP
M\.,RXIY#BLH XE[&*+1D1#O.N'9"T 2_D6B8X9%69AM\)X:=;%-Y0[RR+KD@
M"9=,F<"5S&G\\(-6$F^L+#B?$P72J)/RMH*X K0=7(%X+6'*80M;Q>]9[&65
MXGJA"A(J JB&(O5[IU-B%5#_K->',RS.^^TAB)&QH,W284J3GI:[XV\ORM\%
M85M8N+*\_9QHCH/%Z]W%K#[:[M;)V87M=.)Q7OR5E)X1Q[U,8MFN+G77GNO4
MNED6C4 @IV>==JGGE:JE'_7[^7''O5Z8T_S.2C,PJZ,_;/C?]O_8@+?JUYJ"
M/8.[^&QY@29Y7C6)Z,?C4:=^4O[]]G4.1G";*XE?+FA*"F]='4U]J^&)'4[?
M9"+T)_MX#MIU*?CAQ<KEY97DKY44T(^I5,6'LV;1[,Z?]T:=D-62F%+T6?K"
MP95Z<+86:H+:*@ZGWB6T!V<@<@?C!?_/H#[KV<VH-F?Z+*>N=^U.5D1@6ZKG
MSBQR7A^9I;K9Q>3'C3^'A96VQ%C%!F4O#L%T&6-/M:,9C,(HCF\^N1&L"DYU
M,.H,YSG Y<=<%*<1GC/[=!<[[0@607FG\5.6W+S: S@+-ZH6D ^MTS[-$ K7
M;I:4&KN#ZGF9>R;6T5@GSJ9$^]3!UERQ6-^>3[AK,*58YDWI]KK(9]+OE)11
MNB?@-/)'*<)]\_>C[<,A3[WJ%1&>Y/V8)L0N6'"@2M5V3_6N17OIVXZI<.:/
M@Y.2TL[L%0O8K/<.SJ)OIW9>=77/^8.XNL?_#!;8;(K_EZC0LX>57RGO>S;)
M^J'<IHM:AI1F+2!%29;9GBQ5T1E#9/SP,<\/9MYNFA NRA/._-V#TP:CN3U6
MI %DPR#?\TO[N <6]P!V/\04R_V:?LVQ?@N[VZ]%P)CM\M9DE;=DE'X/2&0P
MQ6)C0_X4I'Q%3/#D?V4T[KOVL++3OR-K<O=J>^#-8\GRPY-! 3L*A_<!=)%X
MZH J&)Z2C/EP*N LVK#AN>U/N9?Q2[LZDDP@QUU81AC74V19$")<XNM=G:*/
M_'"@(CB!P3*$W2IV2CR=+*;R,\ZL:(Y$"R##3O84](&HZY\!R0KK?84PE4@O
M^7IN(5>/_7X.>9Z'_VN5$FLLJ(W:12,I)]1;@[75T0OA(R;.'>W=+9]LKPMT
M,.SU+][;\_TQXK;B\""]CQFJOW/O?B?^O_<7G_X.9XYR">N"-< :Z5O2VGUW
MWMK=%ZW+X\M/?[\E'R\[G4^'[SN?_O[XM;7;27!O^.Q/<K!;_OORB">&660.
M$:,9XB%2!/<D"/XH-<52XIQH01C9PM=XZ&MK(_/4K/QKC\_H"N&!#+-:""0!
ME)PE(_Q4NN9+GG&V4^J&@Y,8A[7:<RV;]C/[@QS(TF*IT,T"=4ZW OH_F9&H
ME?BIQ7B8%4_QB^V,*EZ&OV9^!S6OT[XLV3Q_5GM#V]-O>LNB*URJ)0,(9!>]
M'=7^H:MUCD7PK$AK9Q@=MH>=6D59YCN;54D63N1:/20?3'Y61M?R>[9DVWS0
M,YI7:4>4-HPMG;G7KR\K%I5>-&WEU&<";SRSL'+C)^KQ[(Z":67;I1Y;:K7#
ML3+Y[30$DF"B0'4N%H$?GM@^G1A+M38$MUN^@S<^JB:]$_NE4C5=C-TK0W!:
M9[Z-*F&W>E,:TQFH'%_;>9$@)Y\#B \R_>62W>&@!<1=&70-]MZ.O1_%D7):
M1*L,$HX%Q"TW" QXA2@6#CX*D6B>L??:TMPQ] *[U99Q>1";-;E5NDBIX,Z8
M<[&;XT*QP@,/AJ+-N#S%<94* \;0*;#F"HK+C',WJRFW.G>OUV6>)D3YR\[[
MW9WBS<%?>[L@ >&&7V*G=U8"UQ\CUVE[]$<?-#M0\_^P_6$7&/VD??;]J')[
MW<7H(U!%%Z#.UX*O/<BV?^6&LL70#OZI$*^V[[(XCU_;@U(,ORE]H27*[\%-
MOM3>PRX [1=;WG%Z@S/US88N?]AXL[>SN[_QXWP,LCJF?-_)4=7A/0"GV3O.
MNI%*9]G&K:=<+#GEC1\KY+W7E[,TS'*I'<J JRTZN;]O978.QH9#K:14&[GS
MX4VA>>W::0-P9Z$SM=TG-DQ+Y8D",CK+_+T*]+-$?$9_:Q3GE'H==8C2)14E
M-1CK$OHQH8S<#/V_@ZG;Z\^V,1Z/G3WL_1+?U_*MD09+I<'NGWS_^"@Z':2E
M%"7*<F$PE<A(KY'$AN@H='0NMV>@^MI$Y[$0J%P:I5\KU ''; E=DW[A+5C:
MV>57^@<]*#/Y&.&;\2N P-ARSB[O?R6@QL')U3=*TH,O#5>B.NZ)R,$ H73B
M#E/+F+ B"28-<T$U5/=$5.?/]W>.8O2$6,&1$BPBCBE#FEN&<H<LGBSE@-4;
MVP+@Z+IR]&FJ6X4,B/>":V\4<9Z'8)WAPEKE:0 \\M0T9/!49- Z/Y**:*N8
M0")Q,/Y9C,A*JQ"6*02:$F:YX%:+:[/S:BK(AF<V6G.XHG.Q57P8N4'\SPC.
M8FQ730FR<SNH0*9.+*DQ*_^["J.!W .L:>=_YX=]J3S E4I;7E2:]_FNE1"$
M>RQ+=5NL9TOE?WY^4@UK%=Y0T5')\O2Q*#CGWGGL"992*X<]=JGD#9+[ 3>\
M\9B\<7QYL',$(DI;8SD"$Q@CKH1"VN. B&14&!\MT[F-H,!;^F;FV"H.<JCL
M2^7Y)J5#@$QIW#>D:3X-B=81HDK//1T-1]D=4FG@4P[UT[-.'*L2Z\MNLV&;
MTIJXTIE+50=8(P<-\JM-,&DF*CJ\K\Z_M71?GLTU']JA6 %\0,]DQ)*@8Z2<
M$.="TC*/B756*DOD+27?>ZU?%UQ#UPTXF0&D&1""]_89B,[A6 :Q^\J09__S
M6W%PN'.Q?[DG]@_]Q?Z[(T$H=4PD1, \0YP[CUP(&H$B;01-!/OD5JOL%R#8
M@_/:")=+++71#$Z8!YP%OL/U,:OFF)_RF.$X0W"29@/0P3%[A@P/'C'GF6).
MLQ03 '5O0=(L_&%X%2VM?0[C%G23@'QV0/0!>HXK!TN8C]F648+L6KDE>+L<
M[]9##BP$HF]YJ1EW/=E\=B"?RQC[$G,D8/Y 01*OY/*7T7+0[W&(DBNKK0R&
MDA"4 S:GFM:%5.J&0JI!^[@+/ST !#3JYB0JL'=^\.XHYD;',BE$8^2(&QV1
MMM0C&2@%:SDD:@'HM5P2ABVF;?&I7(EOHY8@; HRB 3DPIVP6N/(DC;*"6*
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MF6>-)!7TN1_ZU&))X.T%&SA'G'B*.&4&:>8]H@[3X!@57O,22UHPD%DZ+%G
M6%)!D'LB2,U^\4%)9W(TFC/$4^+(*9_@AV#6D928BE4T:?'JT\XHLF%,\6:
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MT4O'M E14*58$%&S-\NM\C=Z#0]ZP\(U.[VLMWR$"1RU4VSLVQ. WPGPC?\
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MGWKH?VRIW5I::.Y^C2GQ^Q$0S!+X'A];WM^"-)67<;OYTZY@LCE"Q_6KZ-@
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M&-D-Y"IQ7>]H'X7^(1I?>&&LBJ>&)QB_:)U^(YMKZZ2UUN0_G$\8@(HA8TA
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MD,RY)).+DA'FGFXKC<*X&[WAX>"HHFG?S%C9WK6]LLEFV&3?3GYPPH*PP:.
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M"_Z\1OP1D6.F@@[,YH0[9Q/E4DDG'#.!,%+PY\GQ!]?PQU$IA", /1HCKGE
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M+UXK0%F LK2J?0E 68NR><=#Q%PB+@S/GK5#AEB!P./V"6M+M7;S;55;@+(
M90'*T@1WP8%RTJ+$41DNG$?1B-S6 #!22Z=1E"XI[F+TF;YHGDUP"U 6H"Q
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M1Y,BE@O,#!7.>"FH#3&!D5_.2A8:TZ?PM3%M9.0V(F:R]2:$18Z1A))W.-!
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M'Q9 +8#Z\@%U4?&T^/KS/["J,[@1%@G.$5.I<MFB3,@EP5"@/%GEG!2.YR(
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M?G_RY>S$.+W^\^+,),PX@\L::1MQQ/@,_!1H]'.6W,,=QF>>=5J [/6D;3P
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M)RQ@IB<#SP0%.#9YY-JFL AW0@;RQ8F.WKD!VZXY89K+' J7L2PW0 7']ZV
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M&H?,CSSF>.+H';6<FK]SO:$/DS07,H.6GY63PVO#3YI(5TBDR1B1!L23C/N
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M,(DV@+B3=>6H2"M8J5E(NX%,*X0$,MTD[HV(.1*L2<P1:RY)<0N$$*>-1OH
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M(K2[XZ581[^]PQ#K<"S.>6R[)I,1-<&TC$P>,]L,0#D,N4U=)[#1=-E=;>-
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M:H_%MU622@D1Y>H0191*P;?.Q2!Y@X<A5AVI2UK @%7B$^@9C2HKX=41XCW
MNN\*_0!D4*6N%;5+P*Y[I7("[$7Y:[*?$N26<8<<'/!0B;+"X+TZ^7)Z<O6_
M_Q?QZ5OC50O$Y2_,]_SWZ<5KXXKGJ FU44;91O,.Z I_#%45E7JX_-5.LK[Q
M7/FIKHLD!\1V %R.+_,97DGEN91Q\J'E1!D&'-Y)3<&F+VE*V#5DD<.C\M9*
M&);YM2M]>N$#3%H OD14[JJ'M-L016D:?A>C>ZCP$2KM!XFA4!<'J;X8[AE^
M#3RZV@#[AC"H0(#A\&3I^E,H4B4@U&YJ\^0=H.3^';-F>P6H$#.J#5=:PBJ
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M:6">2K-4.HQ/13GD_R2=8?+"!K@8)Q.J>,-0,==18@(])Y--K/T#&FH!T64
M@+_E6'BC"ND:#SR+55KF79%D7D5"<MC3&Z/#PRZ(W)QG"?Z3-K$/4X0$7I>_
M>HWJBS^_P)__=ZR:._),&'>\<![>FK:AS" 5M-6DNA%2O<W2,,%\,$VO2]$K
M[X#6A[ZVO-N(5>H+P%4 =C>!#NNPDT1(X^3K[;5Y<?7[^>GM]9=CE8S2#"N2
MQE"Q65(N[W92L]!JT^RQ&$P_18&K7FQCFRA2.R?V43,N.FOTPC^6FE"$?[!D
M)2E#"F74*+LON0SF F(.>U-R#"J,#U2:'AW7A2BS"U&(;M>A:TIT3<G6U91H
M-6:5:LSYY?OS_W>BE9CE8HZJJU=IG-\G^!/6/70;5<]BH ZC>6>H(9AE]A/!
M3WYK?BINS+L@]XN6JAB*Q&124&<>I/S9*$HB.@^I^C7O*R&S%)#I9G[AK)L(
M3JK2 77W/1@=:8,;10\/U%4$MF@O6()(.!;>&FTX&[1HAC-D6C+%WLRYMD8V
M1\;G(6_=80DV#>RWQBM8NWN/<Y+,OWL_L15\U0%@>*0(H%#S)"2$EFGOTQRY
MJF9G@-1E_7=OT .A4\]43BPO ^G&Q9\8N>XJ3)Z*B.<A8%G-^-IO+8LZ:Y'W
M@E.S&]C^9:A@Z$LB[B3.M<7\IB&7%Z!@/\-?M5)1-64JU5Y-(JB>/9([BC9W
MH\RN%ZJ6/.Q6N<BC()S:#5\-75.NM&*)F7LK=I07RGG1<:DL*N#%J 5L9=/"
MBC2L/AA^\")9\KN7^'@Z2.+6*8\;91A%;P,M]I?S-0XU$FF,-!(9#I:UI!0-
M:<:9E'VMH.0Y_?NGB?$)__UQGZD-*C3ZK+4H 84UBR8OF$G45:66J$NTDS2!
M?P"@*L^)JV%522Q5)XQ0C6-1'4[2HKTI-@)!XP59/GH8,"B1%UWIA>HNENOX
M[<8H]T_^*ZJ#B-2TNQSMGM;3!DCLT<S 8VP5TYB5'Z@T]7[R]PR2/;\<:.!M
M51#1;QQ4/%'KR1LDGN0^!7AIVEF.=FY[[3I*E"I%'DE'48YQV[,)'Z:?$9IY
M+!=DE%8ZY1-B^##;;Z7XIBJ5->>LL=V?0EJL'NQ7"@^*QU2YHS()^\6S*J:"
M[M2J?<9('>(TDD"[[ Z,TY8PRW>*U7]O7_0-WSQ:ZOCVL3K'5ZJR=<QB/XK!
MLOPMQI+2^E'__5^/%D6^G5IU.3S,6$;U%E89HP();P>/."Z:#I=%ZZIE0Z>*
MB4\LI438L?& 8UA;$N_BV#,>1TLH*QPN*W7<L%%VKLRKJ:2#(M"B%?*#+-ZQ
M>L$F",FH"R*WDYI%2[^C05'I,:B^.#*IK(&5PV_2!L1 _3HW7C5YLPE8CV'U
M9A)AI!:+J4L?1DM-3<F;'* &W^5%'*WS@%U@42='1G4GTSNPYNL(@49O@(:/
MU[X#3P<PEUU<%9/KYOU^)H.I/",UD/TBWW[M8]F;-LF$<A/TQDMNO_5A6)3]
M5E6^9E'E.UHL;?9+?S$FFI>]1=#7)SN]JGI;F,6#^H75P^Z]X3KL<M;\\4C#
M@Y&VD&6?A*2:6(EC78962+,[7E5,C/>QW8/2W=T3/B<X]\0XB?[;30J-9*W"
M93MX\N;GBYP5_$)Y/^OH%VC"+?6\[.HT&$OG6*.#1,J!.5'94EJE%9W6$YSL
M]ZOL5 IDBSTB#&!G#?& R1,9/ECU PKAJ5$BTC@%5CA,XV44J.P+.FB850G;
M8CI.K;JN]!>725.C>0>C14S3C*2DFH:*K:J>VW^'6-9<#7@VV?]Z$%$>"AP_
MH]'.!%=Y_DN];//J+X5&MXB/=\L5UF]566]'CC<]&,[RPW'996N$0H49Y" ]
MV?J@5(NJECV#FO21 (.*8)2MIHL;5/<.%1,<]/12TPJ*MD!?;SXBV>+V&@!U
MF7=PQ$]4!^,RJ_8ZW(J@W&8"^T\P ;F\-A_N]S#HGGMS=8-I6:TJCQC;FH$\
M28M.U-,YQ;!"&N$0BJB*/"5I$> 9O'L_L1*_%]@Y[WA0#3;<XJ^_4/7,O(M]
MI64^@,*3+U7D8352(#G<+4Y2SIKPUR\)BE*&>E=Y?,TB[:JPV6!'9<5WHQ\W
M4[W\TG:I_Z*U,^Z*1>3)\H%6>#S:HGG$I5SU&QQIZ-/?]K%1.C?4=967\'C0
M4V>@%#9Z_;C= _JD$%_[4]7*J%B*6F"[WLL3N*-E%M/6T)>L9OH5P_N*05;H
M$ :PM\O>5D@0'9XT*L6PFGM1S#<I<^M VRIT12R@[?3*=XFJE-E"R6PC6)52
M4NVNGN9MY$N/C$#819:B#+T^7ZGL8,5.TK'^.OE0^_F.^A8HF8.5E=>E>,(\
MP>[8'(ZWBQ_@Z(QIME/9:0H586P],&*A#]J(%05 0SV")JVV>1N&]5?O-WRL
MK+W*/!N^?WLM_9G-C2;:&?4U)*0)Q8S'C2B\!;G@X("28G9!,>)EBDGVVZBA
MA6QGQ-0R/BCAA-FL.%D&_CU&P[$<.:/TR4GS/:]P3.6&=/-IYFYEQC=5R_S"
M>2/4I+M&T85,R&K69]4?C5?B923%]9&,PEVD:26.^^. ^D*B.+],S?*.NP5<
M^GH#2J>!*'O\1-7T()FI^3QX9&H&4ZD5#*BMWZ__N!@W!23*BSR0_I0AP$K8
M3W.D*V&5KJS:S"D3A9=;/[\XVR?F>SUH0'=<]2E6$R:*[JBEJA:#S%'C,566
M5&^H?2OZYON-_SHX\$GU:"LIO6J BHT=X1R3:M#SX,(9K+ \V') "=ZB>D'*
M<NVRZV3!.G*<"P;,LR4:,A]Z>-E6MUH2L]:E%#@27C%V0%&=(;YDAKBM,\1U
MAKC.$-^^#/'M&OF(ZG34&4RU5.I4)5#*ON\#D3*M<?Q2 =!=\1:=IGEG2'XI
M+TJ9<SDMUK=.Y6-EP'G4]_YY+ 5R^VP:'#>G0O/H,>DIN["%.KVJGGO <0!1
M5P7N2@UGU(]2!G*+H>R_2F6FP/T&6@IYIXAF]9MB*4TGFHH&<3JTL')GB+(;
M;-E"7W47A;=,Q:A2!FIXAA&P44U+/03Y&+H?JF3?\O9.'1TS^$5>C,@:W"H%
M=LS%5YE<;F >P^?E+/5C PRZXL<BK-K$G?[=S__# ?.M.Y6O7+G8_ZS@,^T)
M ]?5$&R+KQ! 5:/_O&+3>=IJR899:?O]\\.+"X^.NA+HH?AE3!WMMM5P N!#
M<7P\L.='KQI,]RBRJW.S@'^6]GBC $)>3]KMJG4O]K;&V9U8R# Y7W4*HDP#
MQ)B+\_@1S"GLSQSQ01W& /K\GB>-:8_@;3C!3@];.1<H/=1\6BUZ7)IH<&AI
ME(S"ML*"J; P7HUZ=V.>H'7=P/[7 GE4-3>TOZ[R)!:BHZSR+ QL]1:O9\)V
M3BXY1XCR&6&\EV&?*!7VC'6.>OKFY9_5V%C5;G[ ?(I'53Z"L1[:@T%^R O&
MGCO27QUKC8N@1G.<4(:>I?QZ$EBGR,<,X"K_ ;.2!Z;IR! 7="=B7DM5(C(.
MBH'[I'!(CNZBREOI#YTILLGZ&\">;]W&SSYWK)@C@@7O5]F*@ ^#Q!KU"7EK
MJ)00W%]9*-[W8([7C@P:^/=?L6 >0VL;HVL/Y5H\]!U%Q1.3UM [84X<AE&*
M=I'5=(F2@P]V 4=5[[?@Q[<:>67UC$%TH@Q?&!E_&,B,XV$Y-PS#<HJ%<@BI
MT3'8JA)>NI&J8>)%'&&BU*:\2XW2J=ZF&&5>(GSO()3:+[-<<Q5#6"NC?FFG
M9_E2LQV2A?3F><'^E#Y5N.">@%*?%PXTH#2>MTE\L*-)U,RC]J:S?<< Y]8L
M!9;9NN6\92'Z4%9^*+&4>>G1CXL:'=[HB] R;%@T^U:>'M3=E18+>U*IE4-)
MGQVIYHU@CE"A/R,QPBT8TB\BOY4&/#K>I!3>_<$CG8$YDH8H02K)(%'I+9SM
M@G?X(-@Y[5:,A S-,NF*1./9!O&L8.+CLV *16GD]/K*Q922EQW/]M1HM3ZT
M&G5C8'"Z4 94IP)L,#N%1<S2(-9K"+_HX5VT4,/NJ4GDA=6 TS-57HV4/P?1
MY#2;$0,NF"R\49&'G@.[C2;2S0N'31<AF0\E&@P8\>R0]+&ALL$*@V"HE!^3
MQ(MZ=W16%%9EZ1-/'U/^\BIQH*KO'XBB;AN$C=IE-0ZS++.O(K>SY,EQZ114
MGI_" P\8E\FD&7:SO#\X_LD]%>NTNBI-=\CG-)3'5Z21#=U<W(-'#A"NTG"*
M)W0'\E,=<;7I?G"^<AM@F@5\UTE4J[3*ZS7I,9HR46OH+<;&-@UM&B/616#9
M+ /+/$\*WHYZGDK^NI/3!3R.PBUA"DC95063F&G0PU65E*]RG%0^\)0LEH,P
M"6]DHZ$PJ!H0HSS#0WK4O=Q#ZW"1MYYJ[4WQ9Y>H7R9I]%5>I0<GK;[_NL1V
M^4M&77Q.Y:@ND]$P64WMK)^ -D*SPV@:H[\V/RYC=-A()%(YK:6J/)AU/,C<
M.C8:\@X],$4#'F LBNTBNRZ' @\EKZ99.RU<>=6W"V5%[2Q)7+1P8IS1X;_V
M">6_]H=-JS!O,O22JH*BP)W2F=?-JVA6E-ZURIA('="ECL&NPKVJTJ8+3.Q4
MLS6K#.PI8>.1M<974/UV8"]&E:$#O_R4JG%$(9O[(VJ*S[$AE+H^DR!46DJ(
ME^O_+:LH]M2AYVH(>;.-D:/)AR9QZ:;N?Y"#G9EAJ?!/J?*4X?"PW29Z6641
ME<K+N=/X5IBY<#R6AH6T5^: 9TDGKP:A5X_8H_2U2S#9[XKS#&4CD?>5UU\I
M.7G>;;8'/ 9-^J82\D/9?Z6?]S[I-VP:05-,\NBGU)>7EV5(Z,@F_MN\KW(A
MF^W' J?/Y=3990MDESF/0W#>.BGG2.>DZ9PTG9.VR9PT?[:W:%L*@4^_ /*<
M AZ=G)Y>?[VZO;CZ:'R^_G1Q>G%^HS#J_.;VXO+D]OQF3O'I;[_X+ +T&%$=
M]5ZGN+V\2-L'N:),8S%5N3F>*+[K1VA180(-+Q.J"*0H".M;"VC9P%IMM$(&
M<5EL#MCN%/=6X\2/J_*,')L)@ AN@CHVD.7'QH^NN!MX:(:%OM($T&$ =@LZ
M6PK_")I$4O3)"E4RE7H$ADJ9E*A<0/C03N]X4-U8%08I ZUPN15:!%!+U"@&
MF:ILI'ZJ2K%ND9@R6+IF7+=4O]367:H"U<K!\""KD("LJIJFOV"19*#"[64S
M!%3^1N]!3; .]F.:*;U%E3,ELJK%@2^K>I9^%L\HS!YDI4XI!0CD)!B>F'1Q
M/.)C@K<M3E\E6. W V<)G!*^W-#>P[1;'$'$LZR'7ZJ\GUDGT/=]=GK](H#B
MS K_U.BI;&\>C,*7FG$2=;JJ+K0 '6*E2+#.JU_]D@]AM2K6S.006;52(P<V
MDL1PHAA'!K/@KHAV*8KMEX\.41@0;K_X<( :92I'061'I]6-)X,;/P_?>%[=
M>%01Y4#G_E=NG 'N=Y7?05U]@A$T0 %T!AB?>=8Q+BZ.C0MLG.<?5^SEI"@+
M_2(+YT0+$T6:!K',_^D;<SW)L[(9P)F,5"^ HK^?0U1# /@;,V>21N7N4S6X
MYZ?SFC:/R*,M[E5Q)1^&#UB5H?),S.LQV &!]$%U9Q$#I,)^-#/>VFBK CMT
M_AM7*;!-^]@X>J\8D/)' T$!IO=M_R&!4W#I4K#!]T=#Z&HDB*SDN&P-DQM_
M]!/3)Q'VC^E6WK8'];0MNK M2E=CBWK:%M6V:&&+/L\)MPW@> 'C=.[.4MLB
MFI<\8MBZ&HTP8*K86<)4,>1V+M]4/[P=8_GJIK>CRTWIH*E 57S]=L+N[V3P
M1XRY!6KJJ]\Z8O([F]2(/_MKJT9F?O?8LD'-8NZS5GW\.\>G>J]ZKWJO>J]K
MV*M-_;E6_4UQV8+3 C-'N?!_CYRCV:Z*4FR58N^-91 E):H']=>PR?R+V.U?
MN,RD/C'1<5F)BNGRM/2A/%_+8'-UB$;G)#8&O$Q58\#SR<: ?>DZ#A(-UL?
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MLU8B.Q2%%.HO(#U<-]!XD=^6&N] DYV.R$.:LYBY0BMMF8#E?6YL@"K$C3H
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ME9Z1;B,%D:5YS;B&=K%T8-7Z4G#5\[&P-L)T\%EZ@%-C"\[T,/]N4_Z@*>9
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M]R1I&9M 09,*GDP@DW442/._LUHYV:W2Q,;C-!V'T;5G&/SD R0. SD$).U
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M.O+ CE<Z,WIT(1AE-1';,37D6B,P)#'3H44(&MDYJQ*#8U[ 9'#>W&;W\[2
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MZ66'=W2R''P-?B5D,"IA7?;=<:AX58&\KVS!H"G7OS"ZVAH, Q=N"@!X>BL
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MT=.9Q) IEW^L%2=+]]?3:MOE/'1&VM'ZNTS[:S3A=\U&-<:"$>!@Z_6V//H
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MY/0!"3CAD#]PO491NQ_$;$:?E;J9&_YGL2;SS-9PH,,B>+?/:HQ<H,O?.:E
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M,\ OZ3$1EX@E1YW)?HY+/;2<OGE3&-'1IM.?BN>V.!M1S#(,GM;R<53,@3>
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M 9Y!9</&OQ>0HTV=%S)34'S5!!,V?LP5G34TW3!+3OLR.&,@U?H0+"9P6 /
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MB<B3.%^R5S/W,2396C;R$B40T.[W97%B2 OH8F7[ 6TB38-N/[A"W#0253%
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M=/$,SFHNCV%HX]]Y*A*'COD)_.1/.![CGHP17F?,8G(5E"-AH!,HS<@4VK^
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MO#W?&J^VP-&!#(9F0P0JUD:G,A#_C;S1Y)P:T*<YNQPPG&N&="35+UJ,0D/
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MO6DBUD)J)TPK#%([X#DFLK)R-LNE,VY>5^5"S, ZA(2+U>2#;C$R$=-*BT1
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MSD6&3]XK0]1P.28GG.J8J7U-&HE556.CS]#N89H@&K>N[8]]/#(%&D(LV<$
ME_O[XU\3>!LB0+,_PF*E]C].F'*7!5*B,3DED^S__I?8/C&*<</( CU,#3]N
M!A."1!=XYD3*SW!'D_\WHZ3\D@_",T?KQPGBE4P'"C/W:*$0M,9/ZG*BF-#"
MS87(J]=-&C]'!JMFMFD[HZ0II^Y"]\L#"XQP@_EYW7!+95Q)&X#%9P(LOM\
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M;CQ>Z7[&U$9R'.Z6;&,%(36P2I:;//7,/F4 (NFS)+^TZ*3.ZS'RF]P;?MA
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MJYX)9W0K-+])S!P2BZ:?OZ@SZ)EUH#S7"ZY'=SJZOBJ6SM7F:\>KVOY+)\6
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M)NX1_^UX?X]_"*9AUR^GAL9/:*3#?CK$OH_NZQOO_?\OY8RO^ 97F1JULMI
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M_@P@8&!H8X@O0_?NS80@WL+73',XCA/A@^O5\^2/H^Y-]/OJ[X2R8=?=D5%
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M_<M0=ETL]J0P1>5>N_#7%SK]!LS )P2MAI0_.8XB 5L8_4B_1H/TUSK0HZ-
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M=(OEQ6_.0L19_^GDM(./(9Q,7D]#G,ZFJREV+T^72X(WB;%84YP'S-J""BI
MP,+!YJ2+$JF$Q*[/71U@1R/L15Y"%WNYG[_B69W59SA;=1>?]//<S_'=*-9S
MN_NXGJ>T.)VONK?A+,097HS-U+%%6KF",P8J.:0U;!,DY;B(AEOG?..Q;49R
M?7Q7V/-\F9XLEAF7I.*>/OF,52&=:[LUK+!,UVAU>ZV=?^-9=WI\W#\3IBL\
MOOC]JOJ:<F"U:#[U:RG3.!K08'F*><,(7<I"28N0(RDBY5,$EW@ [:1'RV(1
MB.V9L!G,-F00WRP9&@B@&1]>D>)?G"'9F%G5KQM@6<^TL2I#LLQ6&YX@Y%C
M68T,?>$)>6->?!74-OR0WR8_V@JD&4_^N5CA306FE3,"K0>F/2?_3R.XPA"X
M$BX9PY,.KC$S-L#8A@OJV^3"OI/>3/IO5D>XW# X;HAY*AF0+&L:G$O@I"1F
M!L99-)D&:!LSX XHV[! ?YLL:#'YS9CP?K5(?QPM9C2AW:O_.9VNSB:)<^_0
M1C V9E"%+%@440)S3CHKC!8E-2;!;13[CNLM 4.:U]P_^C_#[!0GPKEHHP_
M"GI04E@(+ 7(R').*B5E6K-[ XPQ.<9[2O\FL_>=]&:L?KDX/E[,KZ"P4EOA
M309F&&G9:,@7<SZ1P"(&IRV/3#86_4T,8_*!&\M]K^EN)O0/2PS=Z?+L"@X4
MMJA<(N%PY((3!HC..8@<63"I5""-Q7X;Q0.=6_B6)+_GG+<+@W.>UM&'V=LP
MS;_.7X:3Z2K,)K;JGB04:&X*J!P#.$.(R.52@2GG/;:V97= &9-;VY@$+2:_
MY8;(Z?%I'VOUCA;III,E'N&\FW["7^=I<8RO%UWW3UR]*1_"EXDVW&LE.)B8
M2%4YTE=!$LA43-:F>*=XZW#X@1#'Y JW9LZ PFK&J'>X"M,YYE=A.9_./W97
M0/^,99JFJXEG3DOM# TZ,5 4M(%#A1 B6<+H)1+E&Y/HZZBVX8WY-GG36"3-
MJ'(EJGL^SQL&G7T(FC@,62&"LH$<(V$\\)RE++P8S_-P1P\;,0T003(9;"Y.
M@Q6<?'[/#;D R8(M,4E)@7)B\< 1Y&@.(/;GQ<W%L*< AB#_1,?@LI$"8O"*
MQH/TIZJRI<Z*6Z9E"@/R?$RAUJ"BWW7*VWE;78>KRQTL'45FTBJPDAE0@;2Y
M"\60AK?)D,]GC5&M?:FK /;>-@C=$0FI_J\*YU.8T4.[YZN78;D\(SNS#G!D
M<C*KDL#X2(L+A0 R9#34)",S9%TR:^TQ;@5L3 IO=U[<VEMH+I.&CF&W6DX3
M.1T5W>4VKF(\,QL(@.'5\6 T6%+ Q1F?3/"Q<-W<%]P 9$Q*L!T=]I_SEI%F
MGP;P#A,2+^,,*4ZY/-2+D;%2M_"#L*!,$A *:6/!I ]$5L%2:Q;<AV=,!ZSM
MR-!, LTX\>O\$[U[L3PC()/@L'"G'&"NEITK&EI,9-D51L%+-BF(QARX^OXQ
M[3BUD_G.,]Q,QF^7>!*F^=67DYK.1K:IW[JX/D(F2K2^"$!+#%19*G#,6N#<
M&A>EMM:TCH"V@#6FG:1VC&@MC\;.,;W;HR!U0W%8X/5<EX/SD9%Q<D+EK)((
MK0\AUF]NZ]P+%X4)%$ZR*AT5N(6@C*F;NY(4:RG)-]\H?2AY#^O>/DBRMVS7
MSI/;4)$M3G"Y.GL["_,5K9OJ7Y_4A/*J6FG5B4BA*914L[R5RA"8%5"P,'*R
M?"JZ]8GI?7C&Y\WN)?UF4]_0<UF%^<<I^5#KX1&05U_2[+16'_Q]L<B?I[/9
M)#*%@2L.R61!R%@&'S%7HVN%5=*ZW-JL;8-K?-[M7N1H+HIF)+E\NP]6N.(5
M1%T/>46-M]$X\(8%E86N"4N-B? 081_6K=U+V#M-:=M$P'.6+>;IW!J5S,GK
M0@ZEF-X:$;>*YL CBAB%B@1NB#3 FT#&YZ_N)>K])WN0O7H9H_,L6Y!]H)QU
M!)]E@DB_YH5.VOO62OW.O?J]1G+A3&&V(B61P%!803.*"H+,#E0,.4M#BVG(
M0[81NJN[2ON>XX9=YKH9>W\^3S-<9PA\"%^N *L.E P<<T$-RAE:J:8X".@=
MB*Q+#"5JUOS\\2N0QN2^MF)#2RFT4VR+^<</N#S^&>/JBI+U,C)?*/ZOFW^@
M2J#X*L4$65@9;;"RA-8)&IN1C,E5;:86]I_SP2H;KN#17.=8O ?##.'AV8 S
M)H,LW&55^N+G(;R:C6C&Y,6VXD&CN;_!A;\^NSE%K^GO@U14OU_1SQJ%=XOR
MAN+S_FW-2JOO>/K@-=;;C*I1L?7YX^<?7RZZ5<UW.-^4[29H:>TSAA"E5N0\
MQP"A6 &.'&>6O+=9MMY.NA/,WONBQXOE:OJ__3R^*3>C]8GRR6JG/'A;[9ZC
M00=M%&CC-;/"E*!:ZYG[$8W)%6W#D%N;J>TDTC([ .DQ-7GA9_R$LT6_OW<^
MW D*(VQ62)!"S7[4Y!PY&C(3D5SJ$"4WK1/3[P4T)@=U&(ZTDT>[XCN<S>J>
M'LYIP#,"]CP?3^?3;E6'_PDOL E9G%;607::L#DAP0M10+K@$D\R>-LZK6H[
M9&-R9H<AS0 2:ECDUJW>E+I_V&<6XO+3-&'W?C'+$Q8-T=9S<$@^EPJ*1BNT
M *M84)Y%[GSK[=F[T8S)U1V&)8TDT? LYZ)RXA>: ?(%:<2G-.@_O;\76!9+
MO(S<L7OUA2A-PIC.P_+L5YK#WGNGWZ3IK2N ;"HNL5M-"N?.EIS!]=L\27/P
M4@8@/UYX:70*K+5W,^!P]F^C,%]<4&K]^@N5$(37Y%H$$+H:%%,-BB>?(^N2
MM'9,%]GZN/Q.,&-R ,?"S=N]&5I(LMT^QG4L=;XFW"+SZ&VMHJN-UXR&0'$U
ML&)3R2$'HYH?R]R&,29/<:QDVE=Z[=J\X.H*!*U*3D($D%Y48V0SQ4$\@L><
M12D,DVX==%P#,&:[9FI)H2T(3-$$*>D=Q-JWR08M'>?$3MD^6?- =NUQ-?[N
M'+R=&#$.^3=VU CHN:UY07%&F:YJ/.$5*@W>44BJHI40G8J@N*^;Z4I9TSIE
M\ XH#]3VPS8O:,VD_2:^X4[1)YR?4@QBL7 1?03)=.V5X@JXR*K%X-8JB9+Y
MU@UJ+M[=S%]YC:'#_L>YJ.H?WX:S?@-Z(H+,.1D!GG$#"JV!8-! $BSG$"TF
MU;S!U%;(QJ0P=^+#G2Y(.X&T)OR%$E^&M/I]NCIZ>=JM".#R,MFM;M_2?[F6
M_EL>T%$<#EKR>C!5R\6Y]+3:F?%H)$^Y=3RU \PQ.<=-:#2TJ/;F%,;N;JX_
MG^==!N"%-5IZ"45QMN[$YAG%?D%D@45P'\,-+77K!'  6 =2T4%9';TN4&*J
M75N0'*%2BZ>T"LPRIF4<+,H<O8I^;+;MJ.4?(M-'U?+,V<@X(;.Y-IB/DLP1
M!@4Z:Z&]$":HUIE;WZB6'QL3AY9VP\ZW=V[T2:%C9AEL[>)-SC^#B+4= Z;D
MLE6Y-$][WG++=J=RCCZNO1P;>LV2"6 <A4C*<00G>&V^$Y3G+%#0,T#EQE4(
M#U3? T>234BPH7!CYTEOFP%W]_BT3#R*Q,&:X&JW:0TQ6@?DFQE!OIIG;)#<
M_KT.)P[E,@]#BX82&?1\P?E00LP(62*I_]J2G!QY!MJZS%7M4AT'"\[;;1)?
MACVL6%V<,S2OB43&:H]F[RQP83QY/,%JU_H0?/-NRD@RKG:4]!V&_F'SVYZW
MMP[PR3V1(@I:/+S63UE1R,?-%/16+1M95$ZV[KBQ98;A(^^:MB9 &Q&,(\OW
MCH:30Z3\WO6J@^;_;C7>5LG 6W3T?%OS-FE9K%;+:3Q=U18N'Q9OP[IG@W=9
M*ZXA<>_J#KP#'XL&RZU!S.A#:)WVMB?D)J[;':__9;$D;3%?UUVELP_+,.\H
MQJI(YKG_V[F&R?]-(==Y*?FZ:ZH7P<58)-C4-Q=0$;ROY:5!QQ*51AU;^_[#
MC&149O6 [-[H4#XN3]J&*W>,I;;X^F6V^/P?F#_BW\-T7C]\7BC(>H=I%KIN
M6J;KJ_OJV&@$#IE.GM7S.H:@C)?@C:NMR LW2?*,H?7M9RWQCRD4&BN_!^5$
MRPLH;H*_7&84X 6'%$#F3,ZS,N1V^6P0ZE98U-$:[EJ'6?? :9MAE)G1D64*
M7M%03.!BKK&L!>:C+\4QUKXWYCT91H]K(5IQX%:FXLXS?A"EO8UR0.E-5!S!
MU!\JYP2.APBEE@,&LC3*#[()U<JU>US5/!2Q#BG5D81_Y\9DF(#O\N&'#?$V
MCZE14%<;;-(+WBX7GZ;TM!=GOW6U \ OTWF8IWJ\0Z[FIW4I<1!:>J81N)8!
ME H<O',9= D^:2F8U:WWW[9'MW?OM/.C57*WW^')Z3(=A0[?E"LW(=%2= FU
M1$C]!0<J2=+,.1-J3:I99LM=Z^L4OXYJ7*<PPY#I5K.UMK)JUW_O'-?YU: ?
M%J1?ZYEI[0]/HR>X[X](L[X(_6H_KIML_:Q.5,B.65D/"Y@ Q80"C\D 0YNT
M]HGL?NLP9U>LH]H)/3#?!I5KRRZ0B0*R/J7ZHI,'F2;L:(4L,4\IE#,&C;,(
M-M4+:I,3$)W1H*+(7J0BT;7NI_154&,J/3T4K9H*JK46(U:O$_*KZU)]$YJ*
MY;F?L^X(<K9I0K@F?S50Y,)BJD<&BJ)SY 6,4R7:8)QLWV9T'\ /+&;]GO39
M 23<,/?LY%P)ORG_H+5Q>EQ72W__\D3:7/<Y W!I"1"7M<2KGF#6)*=D-,NI
M?9;]G7 >V./PNR!4*^D,8@-_[;I3&BTYB+V5[GZCJ&E)@3#!I8BXUG=O--ZU
MDV]'7UMGN?5>Y9N3/G:;$,^=<BR!%O4>Q"CZ2L)8[SQCBB)F*89HI3S<@,9T
ML=PCV-[')<@@*I*T^2=<KFK+G-K$;<*R<\8;!R[7ACF%25J$T4/!J%+DT473
MOMCB3CC;\,U^QRIR'^FT.]&HU^U<OX3I^ET\?<[QU0^N?/,M+J>+VBBR7A=,
M@UC__W(QO/I"(3FY%>\H7'I5"J;5Q C.?40$GQ3-'9H$H3:C4]&0!7 \^^8[
MQ(<=88-SETT\O$S.N<)#0>1(JAK26&^&(Z\+HJT6EJ/D@5RSTOP>FNW1C>K$
M9KP<WW (-(3X6S8>V(2OWM[3W< 7"[KD?(%B/8+2M0D7\Q&88JZFU\H06^?Y
M;(]N5.<^WSP]]Q7_T/3<&+]*$7/('"+2#V4U@^ALA*BQ-NT(%FWK[*E=CS$>
M=QOLVZ?GON)O1L_U$-^4J\-^,]]K@FL>C HY99!"49 A.1D$FS288!+C&DO[
M7=P!AC&F9G+?$.$?FU!#*^Y-?D](FLLH+&2C=.T_+B JM!2#65YDI)7;_+*B
M7=W>A\_#'2=(PH3$*1B$[#&#8EC >U\/!"+G.B!/HO4BW_W<[X -B(;@S*U>
MH?N+9-AN"+5R9]F%V405+A,3&K3&NB4OJR;QGA9R<2'%R#,O7\E^V>I%8W*>
M!R9!^XEOV63JAHVYN$.U#C8)QEG4&;RP'I1'\G1RC* -U\XI@QY;YQ+<"^B!
M'NVC;/:UUASM)#0@:395]5\>_$V,U(B"=%LIB5P2KQQX[A"<(?#&2_(_AJ?1
MO1#'Y#D^&J_:"7% IIU?Z'MQO]#&BWTI+I/2)73 N4BUMKZ>F1!@Y8U4Z%,@
MRSHXX;9!^BT<\ Y/O.8R'9!_MZ^5GR ZE3"3N:Z+0DF6P*.JZ8*.+'HH4J76
M>Y3;X'K@2>QWRJT]Y=6,22].NYJ.U9'['Z?S?LKN2)AYOES6*+P_WWO9!^0T
MBN,ZB/ZT[]X<&SYA7-F4C0'&+07>NGB**%0$(7A$[X23JG5WT ,-[8$GO=\#
MG<=(F@%UZZOCD]GB#/$\-_;JU6-:<R54KE=G:$:!<J )#(Y@,H$^6ZM4'*#I
M[=;XMN&F^[ZX.9CX#F"\WX:SWA(0JN1+)$\V!_(I1+$0I0U0M$O&)R,-#L^J
M&Z"VH9+_WJFTCZ"&Y<_R]#JS:UV\2QXAQ%B3J;,'A]J BRX[AID3OP]!H1NX
MMMIB9?\/:+2/O)JW74LT"S=:A[&2"O<:K*Y=%;,FBFOMH=1:R9RSR<WS&^X$
MLQ5G'KO^JS5IVHAFN-NK;_2@#]%%+U! 5M'4,EH.KI V1+*CO+!0=/,>Z5^!
MM!5KOI.-_"&DU) Z)TM,TWZ:Z,\S/.]S<?7^RXDN,B6=R;7W4E=24^P;L![.
MJB <$Q07MT[WVP;75B1ZY)*M]B1J+*^!+@8R6IH2)2D^'DD/<EX@BHI#!V&"
M(;N96ZN<A[?M^,XVYW>70#,27+\V]S+[J>_K-U%,VJ($Z;:$LI9$%PBUK) S
M(ZQ6.CIL7;5R'YZM***_+XHTD\\XJ@ F(1ON0S' ?.T))8(&7V<EQ(!"YA1+
M\U3*ALEFN\T6/?_&4Y\3=Y;+,Q+D?X;9*4ZB4S;HF(!;:4F0(H#+,@()TY(U
M,+Q],YRM@(TIA>=PO+MUMVMS&;:\8?S*@-<=_U83PZ34G!LPM0V48K6=M*OF
M1**)"76QJ;7>W@AD3,D_CT>?_67T&"49PG >BZ_0ZEZ<]#7I.00@>^.22$X4
MU;J7\JXE&3L4^YX7UGU8/$\DY27V^P/TXGR:^@K.]6%T\#&B+ *TB+8V#[3@
MF(F V5<?/;+VVS;;(?L66OCL2ZJ[6JHTE%GS-CZ7V @6.8*KLUKQNZK]L>G3
MD_J522HE1F-JRK2Q]<(3PN>=@4PJI&2-TJ36IGY[=-]"JY[!>=5&=@?I;G<E
M1W".J_?I"//I#!?EXO.SGW$5IK-=>MMM_>B6G>UV&T^COG:7+R'B35PI)F83
MR,+SOHDBKU<U<Y#<"F5E=$6VS_;Y\_W['VJ=/^M=^/R/L,+E-,QJG_[WIR<G
M,YK=OI<C.2:XI,5$OHA2CBD+DC0G#=8("(4G,((GR8IPS@TVV&T CBD,V9DE
MM\^QAA)1PZ/1<XB_+Y9_U 2^1<+N!C"EA=2UECARBGV4RO7V4)H,+[13DKG@
M,P[%G;MAC2GR:,^81N)HSY-?IO-I1TK[[XM%O@$,<Y*:["2DTI^S(:N=83W8
MF(4WS@MN!N/)W;#&5#S;GB>-Q'$05^;"ZSJI7E<@<W[A=5US!*[Y9N&*;[:[
MH]/HQ2W=H"'FHI&3=*=S7$FK,M?H;02A#=8M, M1" <4DV6IM U&M#Y#N@_/
MWF<C*9T>G_99;MN<XMT=-Q@*0&Q,#E1_JP8%$34O14!V)DB,];*EUME#K;"/
M:J>A&?ENG;(\AJ1;MJ[;#.?ORWJNB-:[**,B1R!Z4*3Z(#@MP*.QWEHLR;8N
MD[D?T9B<L\$HU5 H![&_?:UJ34$_6<S77>3[3\Y37G8WK]L]MZ7UW&$DC8QC
M_YYZ-#M)B@>+.D,R.H"2)H/324%R13'EBPJV]>[YY<O;7A+_KB["-^6W;KW!
M>E4-7J30)2:5SZ3TC"H4<Q29P-$$0/9.EE2\BKRU>7LHQC'M(.S&DONO?6\L
MI?9W=5Y=@I/,2K&FUB_7FF8EM:^7DV@0LF232Z0/6ENDC4#&9(B&8,4N\WU
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M2O2-)G]+M^?\\_HCA@[_]I?_ U!+ P04    " !UDFA5VP+3$W!G   !B 0
M%    &5B<RTR,#(R,#DS,%]D968N>&UL[+U;<ULYDB[Z/K^B3IW7@RG<+Q.[
M9X?+5=7C':ZRPW9/[_/$2  )F=,2Z2$IE[U__4Y0I*P+*2V26(L2W1T=+EF2
MN3YD?@O(3.3E?_S/+Q?G/WS&V7P\G?SE1_&O_,<?<)*F>3PY^\N/?_OP&_,_
M_L]__Y=_^1__#V/_^^=WKW_X99HN+W"R^.'E#&&!^8<_QXN//_P]X_P?/Y39
M].*'OT]G_QA_!L;^??F/7DX_?9V-SSXN?I!<RKL_G?T;ZA 39,&B L6TEH%%
MH^D/)SW/X(.R\/^=_5NTO"1;"M/.TJ^94!@(I5G!R%W48!27RP\]'T_^\6_U
MCPAS_($6-YDO__J7'S\N%I_^[:>?_OSSSW_]$F?G_SJ=G?TD.5<_K7_[Q]6O
M?[GW^W^JY6^+$,)/RY]>_^I\O.D7Z6/%3__[]]?OTT>\ #:>S!<P2=\>0(_/
MB^M_>!.-^>GJA_2K\_&_S9?__O4TP6*IGD>7\,/6WZA_8^M?8_5;3$BFQ+]^
MF><?__U??OCA2G(P2[/I.;[#\L/JR[^]>W4?Z7BR^"F/+WY:_<Y/<'Y.B)>?
ML/CZ"?_RXWQ\\>D<U]_[.,.R%?UZR164J7#^W_II/QV,Z2,!F:7+B(R^BY-*
M\(88-WWZX9BO/XME+'!YOFB(^/YG-\4[O8!Q2P'?^^@&:)<?Q"[P(N*L)=1;
MGWL#YQKD781X@;,SVD3C>#J?GE_6EWO^KVEZ\=,2YLOI)-/2,=,7].-QKOOL
M^P7]63?>^;2\(>HM=X3YXXO .&=UY^5!\27873[]QE*(,^/)N'[[-?UU]8@*
MM^]%X9<%TC_-/_XPSG_Y<9R3T4E'7V+1.BF(2D'&"/1_&604HUT>5)>W7N#Y
M--UZ[GG==:?7-#F'B.?+[XXNY^P,X-/H^D-)(OB*OIR/I"J:&\>9P$AG51*%
MQ4CG&@)ABT%YH<M]DLW7I"TPCTN:K1[Q4]7<3WB^F*^_L]3E4H_;45RI;?]U
MO<//.+G$^8LX7\P@+4:Z:),SG1C.6,>T*HH%EQ2#Q VG ]E%+AJOZBZ&VVOZ
M1L87L_7J5B_YGKM -5V::G<Q;2C4*\W1 G[\83K+./O+C[R1DG^C==.+LH3T
M=[+D7E[.%U-ZD7_]DLXOJQ'X8CY'^G_^ %]&J,!(ER-S/G*FD>PO^B*3Z89&
M:,%5=+P?'NP"<WBJ'*;;S43I33'WN20.Y=)J1YV<O48R+I=_O"(?XN+JR[?P
M=;GSCC) T;$ *R)[,N0UL" T?84< B1KN(R-Z=,-V3-G3 _BOT\2N2])R #9
MCO#%)._#=YM%"5(Y9K0Q3$>36+#&,J-4\DDFKTI\Q SJ =8SI=&Q%72?:ZJ5
M!3,JMG!3)#FZ$ B',X(%E323,609BY%%N)XLEV?*AH-$>%^5NMG9\NN73]6L
MO[$Z.O&,%):.NH),>^%8X!Z830)T]BF:N,&A:W.<W 7S[,W3-F+NP;9X.9TO
MWI2_3J=Y3GO1>YQ]'B><OY^>YU%.PA41 N/9TWI5)'I;!)90.>#2.QU\8P)L
M1S,\ QJI;-J+O'M@PCN<(WW@1X+U"VU.Y]-/E?ZKQ1,XZPHDP43@EFF9(O,2
M"K,9>50 $FQKX_)!0*?"AW92;VA37F^">$X_.OLK3FCIYP3Q1;X@.==E+\:?
M<8U2Q*Q2=H[9J#-9([1%QA(S UTP)VEC<:EU5*83LE,A20]ZZ,$J?'$QG2W&
M_V<9^WM37DT6,#D;QW.LABOY1SZ@E. 4DY+6KJU(S-<]S@A'UE(4U@75F"4/
M(SH5=C24>Y\&9CWYZIFW7OLH%%!:T@&'6@I:LY,,N+,L)2&\+SKP8/HR,.^"
M.14NM)'V?1J89C18A4ZF<X(4$R\N #.HJL$C%(LA2N;HU /GI"-[NR\"?(-Q
M.K[%GJ+MP7#X8SJ9WD:UXN$WDD,4VFK'$"6YO2@M YL+XTF':-%9DUO;DX^"
M>O9,:"OV'DP$.IQPAO-K^]9I@4Y!8!$2+=9PVI2*+.3R.&X*F2M1R,8LN -A
M>)TW5M*TG83[N+I8?,39UA6/E"U.!#)1,UI)9-=TZ%6+M:2(&)TWMOV5Q8.(
M3HT.#>4_Y#$QRD5893 Q6ETB:\4"BQHY62N.+%B%(>365^+?#2?:2+V7TV%M
MOZPO0\:32P+Y+:/D9RS3V>KJY -\P?FO7T@>]/SQ!&9?EP<HK2[5:Y3ITF5>
M;X<C T99B, @@65:D'D=;:"SU9-573)1G[<.9O:XG&=OJ3P55??@\%Y#7KU5
M/^.$]+,8):F4RI9V6,_IY1*2,PB)+/0<=-;2<.%:;VE;H)P(>PX3<0\^[A^X
MN.&":2U*,$ZP)"709EIO!PVY\=(95PRWX %:'V$W 3Q[+>\OSONZM8?J]E>8
M36B3F;_%V?N/,,-?QN>7"\S7!W+0($*)B<6B,AW( EE4N5I2*)3A1@O>.C/Q
M$4C/7O\M17Z?$:XU(WZ&^3B-/.< (G.60UUP+:F :,E.<R4J9:.,OO5;OQ'(
M\-IOJJY'J+"[K'OP;;<L>,1]S@%H?^*1'&T-ADZA' /CWDJRIH-4::"MX+1)
ML(^\>W!B_XZU_(K6^)E,US/\X[)*Z$U90IR_N5S4VJ1E_M9:!M*2&6*0G&[O
MR'?+4C*?C&/2.FF5=:HT#WWNBO'9GQV]*N4^B?Q0)+K:^!S&6(CSC/.:,Y8"
M6;QD C%5O!<Q)K3-=YB=  Y/GW[UO2>Y=E=6#Z?4%K"KS?,>YI%0(:-7DI7B
MR7OVWC$Z9S-+,2-D*Z1R ^U.VR!^G^QJHK ^<H36&_<'B.<X2BE$XCG0>D'4
M4HG(P'''E JJ*)#)E-89P;<1-&3'C:K;W@^L \2X:=/XX:J&\M_2^72.^2\_
M+F:7^.V;T\D"ORQ^/5\^\"\_SO&L?K$O$^:SQ>CM;)HOT^+-;)71^.++F.3A
M30&>2!Z\WCV1(<;(/$^,2X'*A$([7R=?B!YP@P?TMV\<V/;LABQXH,[Y 5;L
MH<9I0W$V/$ANX+F9LOK+<NOL!&ITI]CZ<%W?!]+R4-A6)/Y-W6UT=%_AC00\
MF/:S%$;;R.GL,9YIS<GUTK3M*0U<65#:IDXQ[:>E]5NE]D=1^BYR[<%F7 '[
M?6D6C9(2)1L$5J2(3+OB&&UJE@E0)487+$?;^$B_!6 X>Z^A4J:M)-JP-KE6
MHJU+S&XDF]-*?X?)9:'O7L[(HER!%*$D"9Y66FS-'(F> 13.O/8R:47NB]2W
MU;ZQ"+#S Y^SFON3; ]O]VJ]:S Y<6-*8)C0D:NB%*,-C-,V9B)$841PN7GR
M_@T PZF]1R7=R]??5\(-U=UQN<MBU/EZ8S)9T$9$5FJAI6J'@05>@ F+184D
M RC>YIV_^=A3HD#?4F]<.;Z&6O?!O\Y@LEACRMEQFZRA,ZD&U6V0Y+E8R[CF
M*)(0L@BQ Q/N?OZI;/8'R6VK+O_'3W?$\IK^VGO;HY<?87*&\_'D_6*:_O%Q
M>DZ0YK_^]^5X\?4VXC9]D!YZW)"-D3HO^TZGI))SX#$:[V@;<!ICL?1?Y-J%
M[(R*CW=*>NC)S5LG10\JTSE4C<Q<<V,4 R$#\UP"1Z^U;IY^U+YUTJM)FM6=
M\Q>\^N^K#:)[-ST__VTZ^Q-F>42;I\TR*T9:JF40]$H&+P7S ;) +C*:UM'(
M'2$^B9NV7;BQ(1>K-Y7TT)?IY?3B8GH%\7XHO6 22=.!'V6UU'3-(207C:%/
MG-YRE7ALG;SQ$)[AN=&K,N]5PC?21!\NTKU5CY!L0#+%$A/DN9,Q2&]+D/2.
MN%P23R%Q,AB:[Y^;#\939<2!4N_A<NM#7?/E[.L2V8JP2ZZ.K*QM=#EMF<M;
M79TM\P"<&:L+!QU"C*W=YJU@3IL5;7300[G"$M"K^?P2\R]+I^XMSL;3U0WM
M.DVM6G\7-4EYF=4^<LER*0BH]"62(,A1B"@4<P@I"&F#-KJ/760WF*=-J+[U
MUD--P1;(_PGGE[@-L? H9*[='T2H:0&9^5+H#5$HK>$Y.=4Z:K\[RN^2:*VT
MUGL%@Z7G1Y'(ZL)*>G21>5<S-D&X -'K$L)I53 ,R8[]9=U#><-RF>_PT^4L
M?:RDO+\QCH06.H/R#$RH35#)* ."R()3CB>I%4)K-CR.ZK0ITE@K/11!/(1P
MN<^-=):(/AOF:_<J3?1F,3IR[)Q(*NO(2VE^O_08J.^7-;OKI(=DYV51>CWV
M9OBQYEQ\QF\;(>V*;\H'^/*V]C0BC2P6LW&\7-1LJ@_3MT3YR6+D?;*^)OQ+
M7Z_1@->,1RV9B*A3M$+9W)I2!T(^;<(-J<_[= R]A@2==-(XE\FII%U5VYCI
M54'.H&0"9Q&D:IUJWSTDV#*@47V:XH5@MGK4FBO%/));#<D7@Q!=#*W]A8X!
MC2;ANV!TUL4IEK"6!BO:[;PQ@9E$Q$\0R;EKW6GFL?#=P;G6NB@T6F/M[*:8
MEF0 !$#+<M%1AY#I36[=H??)Y%H?<F5Q@!B/G6M];PE7Q*J;[W12;Q67"8G9
MHZW(F053,TZJ/^F#93)KL%F)8GA[LC\ Z(ED8^^DZ&V<.5C@?52BWL:TSFWH
M &J7U.P=V+ 1T+ IVCTH[FX]:C.I#T8);HJ6NN8G\T+63';D M@BF7/&^0CH
M<FY]R ](A2UYV\=BPB["[J6S^[49N<I-<C8I8S59L,L&XU)[%LB\9U81TF"U
M!FQ=VG</Q!%*T@]7SO:;ZSTDVT-2PP9#>@7,NN0U.,>*J4-I8G L2D!&F""H
ME(/RK1-@MH(Y!=6WD70/;_N+G)?"A/.W,,ZO)B_ATW@!Y^NLQ((NR5)8%KXF
M'@ORL)TANSE8*5T)RJG6;_Z#@$Z!"NTDWD/BPHN4+B\NSVO&X;;HS HHSR*(
M8!43@F/-22\,3 $&O%A;@@LEMN["W1G<2="D%TWT,M1I06O%O&ZSLM[7R%>*
M17(FM2/Z%@DLQ*"9 N A>14T;YVQL!G)*9"A@8RW9A?TDC3^\^6<\,[GOU3@
MY_O,P[W["0U3NQ\$=R=;VRI0&$A12.K+@2Q]Q:6'+"W7,J4RNOMA!^Z_=?;"
MBT0$FJ\7N I<<4/.A/2&*9<UTZ!K'_ZD&'<B*R.24J)UCNE6,(=4CJS[4KRD
MG>UL.AOC_$UY>QG/Q^D_$,X7'S]\K /LYR,LT0>I@6@=R"Z2Q9!?%2W+G >7
MDRA./4:A'1XW_";11M,W:TOZD&SC*M(UQ-44NZO!-+6?\+K29I0T=S'PPJ2M
MB9L2(_.J[I+<FL2]EK+8'=2^]4&GI/ VTFQ<0K@&M\+RLMY#U4H66JY'RPT
MDR@ED3 Y!E$45D50:DY"<G('%=][P"FI]C#I-2[Z6X-:'WEUF?.1S#+'VC=/
MR$"  BH&66<BFHK)JH@F[:+.6Q]^2JK<7VH]&.UK4-<S8-Y?W2_-1V"L"]:1
MVZGJ,##R.9F7/A&Z4OLBYE":#^S;"N:YJ[^MM'O(#UX/H?XP7:YYAJO]AES,
MU12P8"04ER3SN<ZD]KXZETXS@:[F5SA5;.L9?8^".A5:M)5^#VF]=Y=="U+'
M>=5I_\,,)O."L]FR4+6RFM9RZS=&&:-W&)#EDA*YO,6SP.G PD(R*[9H%UK'
M  Z$?"K4&E)S#=.*ZWEY%_HOTPN<+\;IK[/I?$YO2!DOWDV_DD/S]2W.$B&'
M,QQ),#K5U'>3":5VNG9;,(99B,YQK3'K+M[B/L]^[I091.8-4X@WX:W7*XNZ
ME_[G]/SR JNG.Z\95",G0\R6D+EH:XN,6AEJ03-GN"6!<!M%E\8D79]WBEQH
M(MN&V<";,"YGN$S@ZEKE8=(F6;B2BA5.R'4F1RI&$I*4QBEEHM8:]B!$9P"G
MR)!^I-]#QNX]:B_3NY1'5 XULP6PEM"H6D7EF!!%N&"X<J)O*V70K,AA+([=
M9?M4<B3OKF29YF.#UI([SQS]C^G".8O"U>EI4)06PF%J/H5Z XYC940VT.XC
M?-E9RGTD0]PW@^K-71=4/25$;D9TG(S(PS7V" 4.$/=P9(C:"LZ=9$'E6C@'
ME?,0&4?0Y*GS$'SKY/DA2?!(+N10'-A%RJU['WXD:<S&7^XB6]VY0W%"QIB8
M2X;.R.)EW?,\G9&*Y) PB+M%9)L;W#WXE.-;B?OH8=J+$'MIYK0QZO'SUP_T
M 5=9O>"0QV*9#2$P'6H#]N3(6N4BY>25MZY]^=8CH$[G[&\K_Q[2X+8 K/#6
MZ?H= /9D$SP*[CCF06.E=J/,@1KI)7W^,:"\@%%<%Q9#B.1E^5HL*<@G]B:G
M8"#1&W4:E'G$F#@V8W911&,CX_?Q.<X7TPFN[X!6!V.!"-RB8 ">%EP402()
M,"]DT,(&(5V7YNE;/GYXLZ*Q$J9M)=@XN^D=GM6$W>GLZS6X-2JOHY,ZTP+K
MF'2-&5A(GHB<I2@&A!.E2Y+$]B><DFH;R7'K*]M/QBO,Q_-I^33#>0UV+H.A
MD_QI-IZD\2=:Q;2DZW:^U;[>/S%VOP>US)]ML-0[:;8<3;%.E^BLURHFD,;9
M*%+TA@O-W6C/9QYVEO^"<?%J,E_,+F\7D?O .6@NB<G+\4P26:!O,?)V940(
MCF/K.NDM4 ZU5EY/)V<?<'91/WZ48[ F><%XTF32.RN9C](Q\#P8E[B2IK73
M<_/YPV]A+?1[U^S86Z(]^+G?$D0_36?+WBG7B4?H!4B?)'.TH3)=KW&#H\4J
MI(W4"H^V-._1MA7-:6B^D;1[\$ENK_;*?X]:9U\"9\9S6JF$P$ )S9(KB"8"
MY- ZCKD!QE!W7GWH^U"I/I7[KI<SS./%;Y#&Y^/%UZ7?!5G'&)UCR&TM$>")
M!0#'$D=1P#H)L7GXZQZ*8\6[#M;K74?T,/GV$:.XA6AEK7?!U%=$:P.>(P6Q
M#M35@ZH_0-!#D4"HD)P"9*[4#G]*U)&$IL9?K*:#*I-9WMHL&$[YCX6C!M#]
M+O+M0>?O\//T_#-Y[;?!K0N)>3+*9D.'H2)KE; RT-:P0,ZU+2IHUWRDVX.
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MXO*C?\%YFHT_K1:]"A$YRY,69- YEPPY *!80/JJ!- ^" \VM\Z[? 32(1[
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M.,9 E .$?U=]!TBNCQ=Y!<<#;4TY));0D(^;162!%\6*BI"54T*[3@U,CZW
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MO"-<U+X[<@_ VW8XCN?B%)G0@X+XNHQ9_/G:S7YR-VEG97=84R//I<5Z3N,
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M,6$39F77+VZC5BXN$8#D0T' QV),[<0@HBRC:0BTUS06ZT4 KA^_A=),V.N
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M$8!G;U7:&9,4?D(,FE<9\4I-B 6_1OQ#,:J]\HSO= ):-VT(V]EWE0#T9A"
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M"6YQIM@_)P#&.]4WR^)'W^V9#.//A[#@JHTM*U[-W/O48!/U\>&#%J**B2,
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MI;BQ]A7QEW(3<3^/\\8+^N_S A:GNZV&SEK=JW@:-D6O[&#"IJW,5P_ZZ(F
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M&-2RI<)Q4W*-8_C(X]#2M=2#H:+!-U--1VN\1:3(,Y0_M8=63]WL02ZRNQ*
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MO!AP"FKA5U:WX:]<*%.9A]H;8072>5J<26FUV'5^(M!DAAE$*R]2X!D[IPB
MBLVKM=N(^4>;7A0$("84\3%BFV9Q;W&0ICV"^^_&\W\RXA,],\@8)#0TY>X(
MXVNW]R852VHL^E383M,ROP<\4O"K-X!\37EW]E^D@GVA\D7U/O*+[9>RW[]#
M*KZU4-:'EP>D3&XJ9H5>>0".DH>A" !-)=)Q<G#=1OQFT4->2ZN$G#LNA;?\
MHU?WEW0J#&1?%O7\/I'(*J[N?]+U:H";$QZ1(H5]=(S<[B56#LV!Z4\;7>^R
M+\I B&M/CJ8!^@3 SW@B;)?\.@$8+92G_X1QG-"#;\6ZV> &S0WS]H)&<7>
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M'<UH]B$:BN<0BZ_8E=3V351RJ+:NTE@VT*)<*@5!)U%QKOK[-_*GZT6Z1%F
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M)R)1^2O1G-FZ0P#"^)7Q%;4$($E.3'0N_D?"O' ;7&KUU*%;!,"0*-K/#*+
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MQ5KAS?B^LS$BJR:&U:CZ\5L$I3DM'^ T):7Z^,I,\=#,0AI%B?@'+%OP=EK
M:??P\-=9(.?= EMHS9%W,.:.I\*2R#7G<*G;Y@Q!R&AP63&5YP>":O:<'R_U
MKRFY1:Y_XRZS+MV:N3-/W=*U"PJ'+#['$M'8!X[)HFH5G?6C'XE]%'&K+:_&
M!GC$.)XR,)&E$JU]IX:2"(6L2]YD( ":IX?QP!;/I>"ETJ]Z<,EO)6I@MU4G
M[ @")6@W N7GS_Q7YBB+S@WMJ(O*+90-%KJ7U+PW^AL%-B9E-%QF<%@VL$;4
M#CFH F;%!BZT1?9G)6G3'WUYXV*(:9^R^1:<KWXU__[+$?;'^0@:A&8OSAW.
M%^44<F16]N4-R<Y3C0E;!*NG?I!>]9KTZ]?$D,0$]@O+#;K)[DHYW*\OI2_2
M;F3T/@UNRA3]\N:\NA\O9+PK$6EN4Z9O+$V@1&R-^4I0A=E3J%N?7'*V:+8-
M47AQ@8.VU+S3:^\2!L81?'G0*@ +YD[@J3J@#_>:AU[L-'4H&4J]H^G9:PEO
MZ5@S:$??M";1T6[97ZJ:I[.IO.KI>6LU:$'*\(=[+K?<-2#GP=RR-D-:563L
MHR)'5]F*4UWPB3E3KS61QO9LW%I.QJZ22.A*"X3BBFHGJ\5)EA<^N@S8NFI.
M1@'^ZIWR+EDPS='DT_^#-U_ &R"%?/Z*4G$/+WO'8IBRC:T_$\36E=A-((Q>
MQSX'M(>4Q!L.JSCJ0CU;Y7;W>:S Y:;8HF1&168W1ELVY%$3_0%^!B;%Q #;
M[Q:F,V9=]5=3I@8 DP@W0#*2P+@#!N *NCR_^8",S!2)1^T'()BRLP.;9W#Q
MHLPWG/& 5@;1O7SITG_XHZ G<>UX8,:Q<F,!#T27'Q<<W_J, _Z.\\KM6<7?
M[*EK)4]N]V;?YAE:>8\'%B-Q- %0TP<XUTKL,N*--^09X3^EAG";\!$9<*\9
M'DBRP0,>R:@4T%PAHD44#U2HHM6(UG4K)PD6PQ 'Y@3PV1<!W;X*M;KT\D_4
MP3.</H>^B&U22-.J7>!:9V@P"ET0,]%R.:[6UIB"J:_R%:=_S3(\/#Q&0XYE
M0544&#V=SM>?ECR7?D?D6*8J'Z/0.=K;%LV7,L>"GU[RM9##_@KKC$"?0P)5
MLE,>/Z)[5VJ2VH*U>W#3WM XTVX_])P61R\_C"W]B^M7 ^?PP)A=AEYEX,E^
MRH]0@0^1;P:(5N3GCE^LV[8 Z",(Z)-KE^B3:'ERGFH4=1<2D/L@MM_.*;21
M;-D8KA&GPRSWX<XPX66D?N%@!2VT^!R!KJL&&+\PNBM,9O)"RJ'PV(G7Z]S,
M2_V3&T*MS.^_$]S]_]JT\*N)%0SK-CN$/81U$<4A?0D'U?CM01&]1R>_Z?;B
M+-Z6;NV;C:3)(D'W=[H]P;%)\:\:TAEI1=W@5O9"9N$!GW'GD27!-RU)24/7
M^<PJ6PJGIQT]'HSR'=!WN3;5IW]2,OU>1 3?1M@2VL^78/F;3W)I1'/:-XUO
MP<\L9EX[>C?P^6.LQB"L9:N0GYLUY\M#BZ%/ZNW6N5]WC+*Q4<'4T)Z /62G
M+#.LM*9BHB*#HSO:,@KE.YB)T$'Q*#WXQ6.2P_QY;]+1JW//QK+&*+K<,S=L
MT4C+!55%1T\HYN!HP0MP8/EUB?:9TFK,V&1'GD,W=YO4CS>ZD,(X%EGK/FP.
MC5']9$%DL0N6_<_M]/I-.LA/G[)/$D3Y)X<X]@KUO_;ULC %K /48-H&X[.U
MX^SV J0 9G4)&I@GQ8TX&9=YLB'EIHEGC\:&R9G:BW5<MA S(I\]<D;?:8H-
MR]W)MFNB0B=K(S^)W:#3<61Z>I5Y$J<#:O7:8*Q]G9JL_D_=^^=$O/XZS;7?
M=3]WMZ'4O?!XB"_.QMZ?R0VJUN@ND$\>6 BXJX$G58-?<3H-OU?1.[F8S+,0
M=-[(]&[%^+TU1G[B>=NF"*UT<]XO\M% 'RHH/>1L]AI@(]:0ZWJS1"==*1LV
MM&REP?M/,#XSRG]_Q)=\^R63B5K]&6Y %LSB5\\22LJ:^FOML3.>6*)FB@MU
M!D):!VJ7%*0U.[.-GQZ @!F9+4 K9PS:'J/64^T>7PU6MN264Y6I@D;7(OQ[
M#F24Y@NS"GP.!:FK!?L5"L^^90OQ2^-\K:41;>A.*<.R+D2T18&JJPM'SRKI
M#OA7%-?<L@N&)$-YLL H)9*1JGVO6\W-E$%MT[M OT0MZ(R:F(J#'69=-I"%
M88-HP8"(,V_D$KW,;QX(M&B"1BNF0)J9;'1>+NU=[8L>LTGZ=(8UJ5KZD+RI
MYIO,N91]X7&?&RP43-#SL9?+_51+Z&-F+OG#GKZ6A7F;LZT"!V5:.JQ@C;P"
M?0PG2(X5WST:S)S*JA8DZ:@FJ4E:\IUM_<W@PX[UYWE+]OG2H6S=H>.K4MD'
MF!@8)43-H.&,_%P*.5D:(9I-PK@;[YF$;JA2"*M'%LZ4"O<^'6KOW)1\FT19
MADJLBQ9;87'8?M))&2H-V;B*H#Z8-,8E"Y?4BLHL4[9&$KC3;]QS@?80^577
MM/38M\S9F![SK81$AZ2OWO'$M?1#8JQA\L14 VJ\J^9M< B.?3\VWBQ_Q%I,
MQUR*S)TX;)7:372/2N#D-JX;>O#]=2?]<BB"8W*RIP>!K#/%-:^A9@<^7L09
M"&.'3B8]<-=TRWC_&TSR/[>@AVB+"16+.R<MBGL!Q=*S"X$?:OS+$FG7!3V/
MNCYKQP YB4Y#S4"9/IA1%LQHI3RP/$"R\(D,LL&XRH&]@JGV'0F#@O3Z+A@)
M]E]-.R?$TW!,K)J5LYH;U.I[2F'?ZE=/MS!$@J.#'KI*8?!3+A_7#[E\#DGY
MJ7A QY5</DIP)9K$LSB+!B !AHE:]Z7N_\S&*=M6Q@-/"';^4!E.:_5^2^3T
MYYZ9_[PQZ%*%HY75JTNU][V:4ZZ+&"7UEMJ,3?H@+SPSM.+P#^.L5]^4\0"S
MV>Q_;K\G]'8V]YY]^6([\ALE.WY$1N!+I)'K18Q1V%;B"Q 6Q<X98TGDX)Y
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MI4PWTHJZ_E37IFW-H.>2L]'2P3<M20\Z<MP477'(C(\>B:.JY!]=],?[]?+
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M]RR>AKV58,MTVYF5K5;EMZD&9O=$S59?1@I.%[LNJ!^ZB^QZ2*HZZOF$Z-T
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M[%MJ.,L7+OHQ+:)!<.@99NXR40"<-BF&3[W/_9LUIS_C8T:I4AOF=&E=MSB
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MM>Z,*[K*AMV'ZER<-(C;<2 ]P\=QWMN;&;TJG$[L'VNH.>3<X'MSYK!Q>T[
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M8_<,RVQEF?HU&X8")S;<]F3YF1N)[,LQ]RD;[&9X+(D8"X2F-S<*O_/R2N$
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MBH*1^Z-6?'"*12[\"*^/O+N&JH^.%1<'ZI814?'VT7XOUBO[V5RC8XL#23>
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M.G?<Z)#I^<2HE#$N[<)WFOF8IQR/NP??UO/\G*VDN-XU_;,Y/M50+NTC:*-
M]EJMJ*B!76;:Z>SW",1Y.UN[BKAPP\</9P1MOQR]J*YPOEI=M:V_"B7=,D9N
MFE>6J2$%1H=U"-EO@@1PEKWHL\YC"]YQX<7[:W@HC5=GF*\D7IGO4S[_4.S
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M1C8SQ=1O]\#0=[EC2H8"W[;]Z'8B0F]#PD3U:B%$7(WW9"H%42NNG#+68/%
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MKB,&F!4@4HT&*'I3./Z%X2*W794")HJM1\$;*TC7AEUUD\3+POV,[-8G3]_
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MK_Q3KC@N8KBT]A7"V_*6D =ZU^2S6U-]_#[H2\0_A+2?2;P'@9X].12)S^
MG 7+"3@0',",1Y^AHVN"3/GI1&[V%+ #+N[I7(3X)S-Q<![ [O* +??Y2R&.
M1YKW+>Z[=]]*5E;6MUIM<^7,=QEWQ!794[J'S^L?A9A]%6W(_AWD_UNO.V#B
M.ARH>G.,.Q<@B5DI(U:W8HHCBMZ-+(J>)#I_S%GL+'3]^""6_<&+/NEKMU32
M0+\/XE,!"L@F4SDQ8$.$QY%T2 P(+]COGV;2CH'4*+0-U;-$V".$!XU00)7T
M6X9_^O@?+O]/H_]I]#^-_J?1_S3ZGT;_7QKE2H--OL<1;.-'8VBL"9,83@0;
M"3U<HQJ8 UA9)%_IL](CK-MH=$H@[02<'+]XK.R=VT4?^1]02P,$%     @
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MG?VOC?WO?0T"O)P<D/ X!0$X0%NGPIB1;,#'G*:"6_A"(1 -ZS!#E0TRV]C
M ]D&B7!Z30%IUP7;G*BUXYFV6;9NDK?'9AZIS//3'@RQ=CQE \:WV4!+Q$<V
MT/R:#=PWPT\<P)80F%7@S'(0D_6"_Q/LMP,?FN%'WV!74U&,UT@L(P@/OO[7
MT'\-_=?0?PW]U]!_#?WO&CJ^SMJYDPUP5;*!L'MLH%:&)1EXDF38@*$IO?HX
MMD?'Y9WYJR$'CR!6/N=0U<4HTP\IUP5.-W&+;FYG SQ5;.#+6P8_&RB\!TT_
ML^WE71TVP-JEQ0:27J'[02J%#>1^F5O?Q /@:#=JP\1](8 -H&";(1G0VL#+
M:*5_UL9)X6'QWV$#B78T&!MPX[1@ UV"^C!R< <CK>,3&Z K26!8CZ%Q'6S@
MEYWEDWE^PX.[.Y1>_M<WE6?W283Z8&Q4 )ZG@.'DQ9+OOF6[%LP\8(HJ*TPP
MC)*_W=3+W1FQ?;C)-VS[="V7J]3];]& 4MZ@<TG6G*^Q7DR^@[/<I>)+U6_G
M]AI*7TQ6Y#WYJ)B^8&C>O5]XUN;;4*9WYE327L5N13S/\HOMK_/Z3C0EYAT]
M^#3/P5$$* _S#\4[RBBW 2*6+BD'"J\F.R!%O0N>"?:$>O8 %E:K3!?CWMC6
M'*^4?H5!%]%/9<\1+8_]#6HW;(-DO!H!$0O]?[BA]T(ZN@1?1L(YV<#\"R_X
MYAFEK-^("H!Z&!+>;.# >>8[-K PQ@;,$_N7UM  ]/XKPG)2Q^ 2:P2^NJ&+
M9@,7.?1%_FN;\UDZZ(#^UH__P-^8;CZ@9==-NHSE7[,BF]H?<[CW.MU]N2HL
M4-B=::>S74NX,6CM3NY"(F7J(C,5=,-*LSI/N$=*VJ;79DB5]T8D2ZG)CFPS
MH$:)&JG.OP@'F"2]) Y:!YV?<1@R67NPUG+5":0B:0[DY@LT%TI"!S7 2<SJ
MOEWX*E9T9D3K$6E!'>5:N>%3(M3N<N?'4][X0\:=%UP0 ^"@+/4.8O DD1OW
M"2\4B+?H8AQ_/>S0/&9[RW3&V\??Z8B&BWR88T.KW':-&"&3SV<UMGK46BI,
M,""&A=7/(L@FL*&BIHR#S$RT."/T6X'>00\"][P__X,3J7=++)&D5KRX(1A
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M >Q7/3GPRY6'JY&L> %(+0EZ(G^O[@PH7MT? <?[T#QL8.!4#[CZP,+P5PT
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M/(Y,IYYD/KO%/U!)K&9E^EW)<FCW*7EN<*-_\/E:0Y>C$Z%]%CC:YJM:^ $
M.L(!@">9U0U^2%TX37=D2/6P =>E&$1QS3T4>:QARTGSW5Z;8O<G[C<$]25(
MGT]1.'O+V]OUJ8A<F45=;?+X\NC]F_/ IF4]>F^GCAUQB%^$YL4Z6:!M61B]
M9%X1<U(A[!R_Y+M@T;V8 FL*-B9$E-Q?MUG6@)-!5J#CLCTEKJ<&]96\/O^^
M'HG<41PG5ZBUY>6NA80;1T*1[: 7ZAY"DK4?W8XD!U#UF"_9 -%TCEHF<=-3
M3[F87%+SMM3:>KG)><#[W9Y]_$)[:CMDQC3'$60+\'LS=9Y9H+>7=F2."C(+
M0H1',=RT"X%KIMCM@5AB3T4+\D2#3QMWX\A!DO&5NP_'([:D6[L)E5*-SI\2
M!FMU];AH&$?:&B6=M<.< JLK"^++I[2OFY224R/65*Y%+)F22Y.O>\_+3&IQ
M9%94JJG]>%S6)M3*ZUW2V1/JCM!B?28 \-&7&3RT_."QCB$$E?1-;[^GH ?*
M_04-40?CMSE5$C%K[.)>67Y%!W=C-G[#(_N!A6HD]T/9&>5__B,]%0J,M=,!
MPH+<%,,_$TO9:+S/;SIK;&+8P+@-C(+[@LT-A+)L>54V,->#7WT-4^S4%]UX
MPQ3Y)?^" N/O\A@U_.\B71ZYF1'E"04?PJ8E_$F($10TZP5G^)G[]T%AO29$
MZ?^/FC3LOA9,$._J'4"E4!3G(3##C:*I9 \Q_'KQ7L=+=B+V,,YW)3CL\OO4
MU7A')AV:\]B0NZ? LNA>@SB[ED-JAQX;;A+HLJP6UCYF+.@::C[*4Z\N4//&
M/W=.3PE/]NXK>6,:."=-S0T.==G5L.(V<;B@P:+HP]600E-M2W+J0BO=%JP]
M"!_-)O P),D@=9IB>)<!S_. 2>%6$7L\6 =[A<_ANXOGKO6JI5\LRB!V62#5
MX[W5L3N+W9[*^I6+O.M@;6LDPH9XZN!D(U2LWC;:G3&\0."]6TN"M/96*F0,
M,5D>2_[\?,W>$],VUXNX57A3E9?/20&R;H-<P0"PT0)EL-= FI]FK+U('T@>
MA@\=>ON'!H)<!">ZL0%/?@T]L-MW?=V'V?P=/O-(90E#4\N-6>O8!<E=(224
M2! H:)V3T>A>Q6Q'G'YA:QZ@FGL97U)8O9M<AU.M_"-MHFY_4?(90#&:MFZ)
MAYRX'YXAX*/.Y9&RJ<A0)]!.)9R4EA!%T&RS2!V/M_GM80-1CR%O5E(3$.*S
M'* 5DL;DHTPM'" 1!CBI&F1X$V(PN-;^767^@!WM9C/):BF2&-YM4/YQ66UI
MS:ZP)=\=)9=@JO+JMH'XA^+#  P*K+6:+"&PEJ]*D6X\;$C?@_XJ$'*,5ON*
M%F3Z9!4E&<AO_\V_,\>D3KNRN*S/Q3#0EBCAP?'IZMM3(=J$7K+B@N+84B2^
MA, 0=:%:%C$3JQRR:7@+FD,P"2[$.$<!P]7'JHN_:4A6RR_(%G[\^*#XRI)[
M8%6YMI@*1Z*'U2Z$-6V,6D?C)$]1,\GP>5\20<P<1>$D:26^GG46[A(V_IAP
M,C]XS]=4WNZWUY0>GFK@^>/"#SZ3,(Z-+/H%>XCX0RPML-8,[X%]""-#2'8
MW^A\[%O53A01Y UT:;A-X&48YGO*P(I*NC/H%]."VX[P1 SK=;\Y G\R@"A*
M."6%[>$?N%^/+2H+A[OCMWE@"ZVQQ"%41.?T#?A]RSHWO@SJP<HN([OM?##?
MFQOR3V,.JQKCCD)&%Y8,*30OQ;T1$8DO5HQ:T!-W"CG4<]MYD#;+ZNM=8VJ9
MVB[*]JS2JNK6;W<5)YRI%*DTV]E<!K8Z:C,$,$2;!L0#.-G,G&<:+J@C#A+!
M!3,_1+_.2:*T-:=H4W@68G8]X/;NFP9WHE)&/(9:=7*?OK][^2X'==??VZ;H
M%+[$O1E#NP8?6&D@2..)HJPA*-6XW74<<@<UPU14,2KMV(?)^= GA&<+NH<)
MFF04XQR$;*T#V,!3R&=6KTV.'0W!J[]^0U)L&:QIFUD^ORF5%>XWO\ZO3)/0
MH9@GUWBH77]>/:-89#B3([H!^2Y!,;#W.1N8/,,&ED)A%,$ IAV!Y:K.6N]7
MW&Q- #L(C!3$>!">PE?>RKH'+@>!C*>;GOIHR$X:] EK[N#&8SR=8/COJ5@%
MWWY49# A1^;&^GE^.!>+GQ9C XH00/J"?95D,XGXZ_B_G^M_+PO[IUCU\C=_
M\X5JOE;[91U<R: A/+GR=MNLI/BG]J/]HC[5#8OO0BPO'/P*A9VK_RK]_(\M
M_?"H4/A'(^M0T5#PYB3![JGZGR9ZW]1U.6W\+;RX^MPMNU.7.$,*X2T#EXSD
MA#BDK40N<N\CXOAVW:*]"$1_]KH&4YK=WZFS EO7^>HSM/#,:J3:X^7= ]-H
M:3(;B/"6J*\/$LW <K9T56EIO1$Z6C9R50 P7@Q**Z26=CG*#PUEF4H4-A\X
M97?6Y0;/:QY.O7*9I$VE+1FYQ Y^I,WMM(@/F7;#'5?4TUUTV_*,J!W,Z=8M
M%\G']VC>_,M1P!2>IMP,*0P)P0R#V+%:N(,AB1LQ_TUG^[%FE@&4B_#,=DR;
M;X>/GW9@U>"9^R%>V'R!Y?TBX"[L70@G&7;BYX51;.!E2@E2Y1.X+#M-H&XO
M@Z".J7T)/4F/"Q3M9:E6VT*"-+CR5R"(SSGQBWF0&9[DBS\KO]1N*H8''Q.W
M"AEKV=/+%OHAXO2[?STCI/O]KKC1 ONU#()N3@(_OXNDR6[ /O^P@D"=UE%6
M30<;,+D";>]E( ?B(:2O]H0-(_5H^)_Z.B-E1??]7>]R%0+2UG(V$(<^SSQ9
M!VX<<&<#SM!G.:<V]" 0VV8^_>*OYS&KX&_.-'Y_@X%I$P$?-S7_>7[?]911
M3S)DI.S!&($S@C_M=H5XYO_#VWT,(O3F0_RX(<WIW_R*OH/-1 $Z!ZQM0"S+
M,@[^VV'#RX+\Y3Z\,@G<D(8 >AFXF@2:!T(Z(8>&]8&;CF$04P#ZO^,)+A,<
MA5#_\F-$!/;/2E?7\;FIO$TQUG;SGUB<YODW=9#-J#RRM+$'LF@I4...%.3"
M]TLAF$'0DME'UQ]!TP[RCXW^2\G_I>3_1$H^AE9 ?\-RL_A:4@A">ON^>Y;Q
M5:9\2TD)K4YOB3UZ;RG6.FG&JD#/Q->;:C)?+QA5?^7 B9+)3-$^,_GU:KX6
MZ'UQUL_W#YM0";M8^[Y[V6RK3/NV.SJT>JCEL4K\4JR-F[Z)E4='2K9]:%H1
MKY[BKICLO&]ISQ"VQ?TCQ1#_BK1W_,:0:H)^9W-%T.[BPV&4YA7#^ ;8\KY&
M-M"?A]T\"P^<?AG-?,'2^YF"ZP5#B. M!"]JY*%0J$" X,5>7&T%<_RWW8RQ
M6'#\"C\9_9;U@)S(.B>*GYN#UMH+!>^0^,T7UNJ/:F0#A8F/8D-.4S@;4TZ8
MO5K(5YLG:I>M7_2_3;UHYFTS8;.@0BEK@$FS5+W0!WM1X\%*BZZ1^L5JRP[V
M^0+162_D@*_!'_1Z%UR?GFW++_]H?WAXK=\5\VA,3P6S8_3*L?J,'(,>RR&S
MH64;>[5%='B@-K6>F182^C8WDG&4@C0/_HAPM7!J5,,]&4X^/WTO:IY#KC^G
M?\P)_0""!MIH+=I]$J8.VO,VVCN6:25AIV,CKXV?UE2PG6BL2<.RR9-Q1S9P
M2STGR(ZPJ_Y@?7"0D(_*K870H&$'7/S*#W&2J,_>KWI9L;E[VHW+RT?:6Q8T
MA@)*AI>^;1Z$5"01?NG/JD8.G .R"4P6^"?C]-6\^FS^ZFC6E4*VL53R&79!
M[U]&*\?6_:<O">1MOLK/F0ZZ-5A3\N:TNR=*/#@F_TW*,9)%[],G=[-^]$;3
MX*P=*(CS$H2&'IIB+N$+7^++H;.::Q5:W&T]#^6LP8L?"KVE8PZO-N<DNW6W
M'8Z.=4I9H!IM+"J2=NAH)K6*'ULY^;K1^\[)(>?H+V73H9IL8!>>KLP&KH-7
MV$#=V/N5L@4"%8E1A*_UMRY3EBI%9P:=\W/FTFZ=J(EY<_J.I^^>X.!\NQ2C
M"<O.Y*3']3]LQIZ'&D/.[S-MB+1+F(1D"/>HCZ<;]Q6\2FL:'MH_.*MQY*CB
M"X_>=;Z)RYM3TRO.HCGAM2VE,M[E^<4+90YV:IB.0/>&^0ONZ6=Y'N7LR<.D
M'-3NK$XTJQR>\4>=78(D4:/$C/VGOA-U1WTAGJ[_A7Z<H7)B,H;7$AF4TSR@
M$3@I?BXTN_CKR0?2E45*.L(.5]ZO^5J-&:159<\_TJF'1;0>LCIL&^EQ&O)I
M3B.M7]?R5);%FA""C& *OQTH$$AHW(S(#5RJ;*^LN#88*N*^37?+79XKSL-T
M<=9 A@X--5:M_0FM0Y%OSR7&79A0LT--'=%ZUG[F[8<BUP=<<5^ZQ?>ZXWJN
M!AJ*GN6=/?,R*:'2NNS'$NX'INTF0;3PAX^+E*X7WS.Y^9RO&70_%96#5)_F
M:3<1"\1^]-O_^>4RV#,XV5>, 07-G?B?D7<ZWXM1@NO!T8[%L,Z!X80_%<6J
M!&W?/^$(F9]L'I:ZQ$K S"SM@@P<4[\)Q6/3QQ!4&(7=\L47*S9\0?,QQ"AB
M#3$>R8L:0UN\19ML.F[;DCXO:E>,!UW#*X><)NU"-08-]T?I&.>9!8/!1TW]
M VY,9-CH&FMN%M#/A!Q-'1.K!05#M$N3+XU=>K^_\QDQ9-4M036C/NB@^2OD
M<FZ##*R/<:!@.!#5D.;89T.UU+"YG;J]A'3C#I?-M)3D&GC%FB"]MM3J#9?$
M/J!5KBV](^) EY:%H0PH<.LY.X0L].CHDJ11=4'#N"@=[3PS-]#M2*MG@ _=
M65%Z&WSJ)QFZC/-_DL'',/H8]9.,K0L7KX2L7GODR%<?I,7S2F4YMYX%D6%3
M,$A#U0<Y]I>M%ZE:IZ3,?)RX&0C8S);-KY/;$??QW(R3Y)%)J^ XK4\[2\\F
MKPRG&=\(CEO\KO<DIPEA0Q7!40@7&*7]E/>!^A"=)&^(3MQ0QBQ!SQG)P'V;
M_^GJ.-?_^*?%EV@K=!>!J^HT69;4E$N4MJX[5Y@P:5SL4(B7;\L_K-02),2Q
MH[Z(<P&15Q(SAHO4XZ*E9\'X&:?(SQ_A/"MO-@8#H7',<5V+ZI[[SGW&Z56O
M*A/CQM3ZG;0\:(M'B$:^UEL%8C>4+;T;JZTK<\?G2V9<EG?CSX"CZ?B?BU82
M==E 3)7-%?F<I6B?JVDJQJG(G+=>=0I_W.&.3=""5]CT5?/4XC^LSW>/JKGI
MG"9B'Z3==&J@DU(6C7VJ2J7%S[43C>9/<=GDV.0\I\@=E=)^G[7[Y;I/?_>K
MU-F0]:V!P0Z1*_PX%V4#RV@O9>W"BB+OXN<+_DC_GY[V/-/HIZ=E)3%X(#[K
MQ;&!/])!IDA)OITS9'?Q, /(%YCA6='VO;@?F619VCL<Q6VV+EHI[^A_NHA2
M SF#L'2&$&5K%$533\N3*F26C;3^5@_>B(GW]I?8UHOXIN&5;G[SK>[1]7";
M7HT"=<?N5UV:!5H[6TT?MCC:#Y\I-%3.R&OY%"'35*V:?SC#)M;JY;M29(5[
MAR^<OY/D^,KV>&ORL(EZL+'SH+^U-]R2TEZ3#:WI&@*M64;19&EY[18ZF^U1
MVGWVRHVY>W[^^_<,6/:H7J=CKK;H^JX2&(?YY_.9.":44^Q F:^4+0Y0GS*>
M06!,_6AK<^D/FU<S0=:IF3/?9B0.IG,_SZFZHK;@?<5V+,I0W^KB%LP5A&$:
MQ4K5FN^RQ^E<^6O#I7-([8\;Z[PTEZC6HQXNAWM=Y,U6] TV2XJ\<Y"ZUW&S
MMA!?2)CO8?_4!:6?%Q>X[<D^17DTGCJ65F'X2(=AS\&]-=^/3C S7;Y/?;LF
M]''MQLG^WC73!K34MRJG3">:>\/@9>W!T%4%E4K3!S\2]LUN8U6?'K?Q<8@-
MY+UU>#=>A2%1Q! ?\^6[5/0CK90G/?6Y!UVCVV:YPF89+J."(N+O^V,?.NMU
M,H2)-*<E3=TS2ON^ZRW:NG6\L$A1?,_5/^!\!-K,)1JG59_S>BU<1%-:IHT0
M\/W=ZEKE,AL8L%F1/;8Z7+Z9Z)Q//X%NANW NQ^'V7UK;'I3T";XR,SEXLYJ
M@37;)%X#?O3;H-W-HNO?,U1:72)NOOSQJB^ZS6YCE?X.+9Y"N]*@>71/O9CH
M#N.Y@ZZ+^(J4LM"#\7-0=HCV  W^YQ?7>*;X&5+Z$%'PNJ4_+R8J#^+5D&LJ
M++[]/_T ,>#/(SU1;T1*R88-I!J?9W.94)3.SMH,K@<W9,FLG_<5QR%Z WF&
MN7WQPJ [/HRP9\(4&P7C5]54>>"4?_NLOMY(ZV2#U6=JNTKAR^(<ZP+QE>[$
MF,7G3R-D=T4T=MW*K[V@GIV 7 R20M6K#RR-EM5^<9XBXNM;=VD1^Y%.=[LZ
MRBHV"E-NZ!9%_XPIR5Y]6%UC+7K9[3TA6I+;C2]E<F][%V^L_M$#(N.:C^BJ
M.D,(R[JTD]S])Q(WU U90YR!>'& #4SLQ>^"_UD+R/;KOP;A,=D=\#',)$;V
M(7S\; R$^*S@JQ%H2J>^*/TT(^2G%$+6(<6W_9GOAYC^S2>FG$;<]Z=_^6WW
M1O,>B$5UL%&F'7,[49'Q4 7L[X<6.Z7T;F<30L2?CGMH$2)-LW-#^A:HY0W/
M!24O%PU.]WV]$;<_TU*U\(_YAT?&MS2$2U'3])\O1&"EWV7EFX8>N3_IV"JQ
M[^8%]"P 2 -SC[(SD!-3!I='GQ77E,[Y0([I7?/,+=];'T3==P1X'6Q;Q5M-
M]CMX9*16>!3IWS'$X#UWR9K3NHFP^WH"E9Y+_FHWC4J^Z+6,7!9HYLINK([@
M#:_#)B5LD1J3U<-=>"=3L*VQS>&I4Y S(7./XVTQ\4O92BVLMN5*[V!%5((7
M*XA;M($12DO,9ZB3A6994D5EJ98]F@YF1\VT[S[9GT9RBW--Y!**26C8<O3N
MD:-IGRLI* Q:/,2&G!H68DJJ)4G#&PG(LA7W]]';Y]^]>/!57.<%YYD6<9/W
MJKF>(P;Z3CKR)DD;W4[7*VJL M:AC%A6>>,5C/\A]9+YA7.#):DZ'UU"4?GS
MS\MN&[[J=.2/#K& ?)= R%4,$19>=9H9LPL7T81[/6MA;ZC1):X8>"7BL))2
M_I-Q=WECN)+D33,K<D#3\TM3Q(*^?)+T"16\@"=K;^4WH?8&$3,3EOB(W'*M
MW,ORBPO/'O8<U]FGP7IC$V_LX.#9[S#4F@M:@%Y$*T_+ &,_9.?RT%,UE#]Z
M< Z9$:]_B;Q06N:9.3A$2[1XM'31UG#HX-[(UKCQV2&QPJF[?!> +XH*[_J/
M6M_6W5:F]*JW"C-C_I>Z5?(H?$-P%47G&H+<1TZ!/;,)M@4>X\4&=CN_A>)T
MUJ'_Q/=.5!)H'RG6!&+*4S?N1QB%@G=S-F&M]9MR1[B"6\..W&S6<_3XZ/XX
M5AESB:.7?!L[9NH@[#>&$W!P(IQ_\065:W_'NG2*_F'Q:UP_]]./36=>^2($
MIK]<LI*)6IAB!L#='QU,HAQ\</ '6L5;<CY]<;VPLB2]T(LN8O.4U4THU@HG
MPXB3.>C4@YNK:<'/9=I5KB6N%R0;PX"\EV5?304?9_,F< ?QW0O0986[A=[\
M]$4S^Z;1J2;;UXIK&A.1^3L$\^4]OA17+2!9KI;-1*\QQ? 'N&-RXY5^3BH;
MTZL+LPXOHY?C4-3X+A3H@=D1(DCV[K[@,X7W1H\.OH\[IU68'.X4(5[U:4_R
MM  OH\'"D-]&@+!_0(N18,-[[>3.>Q?]<WSN&!SP]S'3=YA<FR_1=8X>0VL$
MCCF3(](S9_3$/*[VA!B33H;N[ULFJ1]6TVE,,'SRRF#Y0P/]\N.=HAWBHH;U
M,B?Z==0I,"<:$G*\0OJAWKF!Z%T^W8[E$<>DO3.,79(5OXL>B=O^1TO>CM)M
M+0E>Q[P2<MJKO?OZ3=A \/Y7;I&YT50UW2Z4J4)W@KG#/*ZDQ#[CGKX?&^#W
M!X4"4\VQC2=^J"&1K\TF/39#'L^G[+P(&*3J;"3X[;.,NY=\./EJT(XFWQN)
M,=/^G?D2/3VDXF!$&9C!I ]@_X$+B,?_UP7$Y/^N"XAO^:/U=$MH5\ALX#)E
M8A(K/SA32N_K4MS1_?&/-WL4[]H]X6_ZH"?-,*25D=I ^DEH)@"E<]3U?5%-
M5C!NL'TGW\,WVZ_)81T!CJEC/"OEQ-GVQ-<%;L,YZPJ+Z]-HIB4L(B?:-@ =
MX)[MVF56G.ZI*3FPV/=U\?4[FV8V(+*7?+LL.U#;N%.AMV3AS@2KK?M*LHN%
ME(F$W41\H6S<:8MG1X4^*7^8[N!F0.QY<+]Q,[(>(QP89 9KD/#.#D!=\^'J
M=!RL%+4;3>(>24_*_)'74L]U<[L>SJY[JC0%WT*M+BM9K?E$H>D_I.J,K"T4
ME2RT(0?[2TNK%[[->;PL=\#'GFC*)U6CZK"[JK9NSM&N9P<U?JU(L&]2=!7:
M&6ALO>*VX_3Q[_=O<*\\,SMAI5S6VAV:FC+?+1B=&6%!Q02X)GB775LUUEHU
M6_@P;.'8\:!&+?!H$YS7DC0</O[8@PU<39N<6!P;I-9)U[G%&]SX;%'+J?.F
M*:A/.[)&>YB " RD97U*E=##DKILZON+G.5BN_:DN4:3#O$\7I(H4N(=FU V
M*>4HB7BW44V(6-] K3MD)GY];WQZ9=A,(:W23"LAP%YNR%@;^9PI^FA$/0PA
MB0N[-:=8GB*I7N)ELV-4/NU#@\D(;A_?F4<QDL*8)*U&-Z46+;QEGNB^2XQW
MU-L;; #Q*#WK'ZE*F_]]5?K+/U]5.NM(7LI5@%,NHW<S%4HQ!<'/&'+EGS85
M78IKJ?:15(F36-QELC1/[4#N_V$^R;7\[0WO$&;GO<2,[[@6VE/$R=?X^C^1
M5$!]2O_6;VB_GT@JD W4N3&ST2H>]NX-D[2QW)E-K8*3/^JS]8E*&:[%1TH;
MA#6P@4TBBTJ^&9%2=*L0.@5+-*Q'W,-S9=.:R:HU\:]I:$G3Y\JL5JLT6QSQ
MB,'+[=HG52E&!7?Y[B@;XE^@O^DI4M")H^DJYKMHLHA>,>LJT] K.KI"U<,%
MF0:>6FY)*EI<#LL[EE2/7^0_J)#D:[5/V=HBT3,X3ZLDHY1@4 (!#EQ.ZE7W
ME&_YYD+/\LX()'KYO<YI^YJ(.;*.4JK,?IN<D7_] $N3UG&9^3)$GABZO:"[
M3F(\J/CPYV\1*9NFQQX73Q/J=Z]_+Z>/.&B9%*:M;6X$0]8NH8YI7@I?UX(7
MX>**/Q<CI:^.=!BEFMZ3R] .XY(YH]IHTB2R^\L>+A?-M5WN3[Y1#V?W7*I"
M7*8FI4 IEN3XGOZ8-]$7LK!J^A6><C.U PK)J=J:*4SG]4"$ $N69DH,B,0V
MC!RJ29#TEW<Q4ANQ4PC-"=N_5_[)77"S-YRNR3#NK5%G[.E"RR%]'V"MTI9/
M"[V6<40&'#%XYC\8G9]!^S+>[^]L1M\%I4<%-)>Y4#:0TR\:ZV(\L9)</:&4
MOZ&I"^?,RSE_V6_V,J3M <K^,+6*ILO)0S45QD/ZW@$UR?Y@%%ZXQ'P';8K4
M'*DYAS15W^H5%%Z=<5\M02.@\[O[PE9/\_8"6;E[6J+;M@C!%"IU;9I3-QD5
MBI%5O"-.U _>?)G^.A\B6!W=[3N-/E&@]+JW*3=_]W5!R1U3-4H,53(Z+@M9
MD=Q>7="8$QA!<>W5.?"J=1O&MBKQ^E41-?%XWO']Y896/L:?#EZ WRM&P9!P
M(8;9*&7LZ:V3;=H7WE?VXC32C>20Z:W)2<U"&Y3RW:64A@\OE2XU5![^<GQ^
MO+XW9T'6-6L8#$>Z%:2O5/<;+$PH#T2(B;R^?#/Q>6+1A<651-]*$YU.>Y5\
MN84\C'9Q_S<\V03<,%*O-_]9&)B16EM&?<++>&&%6"(S>H?[U8B/-HGRT:L.
M8;*>5YX2 T[=/%-D8,O[;*M4VF;K+]6AC^3+$Z::N=M]7J4.RP6)-P8%OA-O
ML,XEM\0.KM[PAE7=@E*RS^#^/U.RG[>LK.$3,(009/\_:_@YCVU&A]'+X.]Z
M?9O@RX<B:7!K\$R@,90)[2"LK;&!&0$=_E%XG3D'PX"":81)A9PE3]3DO^F@
M;*%?0)0IC"%1/J_?;]R9U/[^*4IL5URYK.@ NH4EVU_2$1D4D8KS*IJ%?]=3
MZBF.D;XP>V;9V<&A_8M(;//2\_)+PQ>^/GN6-M2'YIW6'MF/IURX3Y)V/UW5
MVREF%RI$<7$8SB^QZ^T,*T>D?L6XC')4WHOKX*'!Z]$<Y-[<!SJR.3DISUUD
M6I&WY$:%C.423 _+)30D0+^8!9:_=57I]EH@I'QAIJN<1*?,U.1^GWAJ=GWW
M?OYD>9CGU[X5OX0$5+?U4M'MN.[K*[A!3A8$0NK@=,F#X&J$UUKTN$XH.> \
M+9P4)]R8AHG13#^)X7?2;$\5??!8U;>EM>1)9%3,A/$>N5CANT?M04$]V#16
MF"$8.LHO],-9+2530KXAQ49!O,;&ANO(ZH1!8*WXGMJWRA>236[],=+28893
M8."R3GI8-%[$Q>1EHJ\]\R]9V-;4-N?M4IV1MB'EON#R.AO+M[K$(7VPCV0N
M'IC2>B8BN/':H[:<JVS HZ[P^;2L_*%/2P-M?B/[R*699,08[&Z5S5M:ZV7*
M3:]^,^+GH09UR1^>':KG221"BU&/SW)IBYU=]-CD+']>(([8\8#A310EFT==
M=RTO/"T87O-M3N/(N=./+B<)S.U_O.V&'_;-VV'9T<DH3U*,NGA@9,.))OSK
M&=\*SZ-(&Z565^G;E0;Q^Q66\0?B[^L=T;[I5\WKI&R+-EA=?U=0W9N,-8=?
MJ)0Z]@,G'-5\XHL*:RF90!Q/'D^C.]0XK8'7^N4IN/KG)QWZ7U 64J-QQ;NL
MFYI,;7JO\RJ&Y@LL2,7H^,1F)AV3<[MPXX8M3+Y+8VA!NT%F9U>(>+!?S@ M
MQJ(F\DR/3_RUBNC.JPFSLXRHRV\JJVX<:L^64PSG?FY83BNJ&T3%KMJ0J<7+
MZ<>SS_ISF1<[[G_O(DSYZAU[A/+1V+)V;Q^E[*Z&NO2 O<-LG"]*[WE@69 ;
M,[;&D>KW6EE&JQ;F_]3DL57RP[WW+2(;\VY,I%?T>I<^&JFHKG3ROT9CO"$I
M5R0EIQ4-YRJVB<DSAYJT*GI;.@RYVD&B>W2(">L$!57/+S2GGH?E:W532\G7
M.)S=5>LG?.R1A42>F$%<TX152]+G=N/%.?Y:./\J@E-^M4];S":@(J=_T-_,
M\F*2;N./S#,'K@(71:VLK,[DW?LDU3=QDR1_P1_%_2K#?L"),3PP/7J@/R?"
MXNWBTL&RPIL^!VH*#+[@U0:8!VC\K'.ADJQ:+3:P>0!I75CUEYHFHO3LJ"&E
M&D%J[0T7L;A\[3_Z39\5 B9$$,("4=C2#$PF;;96O;A-F#A?$8'-_?%N^MK'
MA)4OCPLSI+BV)^]]9*.K@B"^U]O*S-8Q)J?6GZ^OQQ'3=:\2S*T5I ].3*:(
M1>]C ZJ=O;O-[D]P";UP[?<>0T2@8932K-RY=3'M%(G2A/9;;2[GGQCZ^D@!
M,RM;;0P -VF["QQ-IS26.!F:Y*6[BYJ[S,T39E<N]4[:^7LC++!M'RM=G5Z+
MO]^2A]L1+7I9^.X1O^6NIC.V/@:$^I;4<TO0=NR'AUQ66^Z8>=VYG[\G)^B1
M3ZBCX_$[,*?Y O* (L7C)J&4AY$.BP/GN=571'_0+%GZWMJL6@BS3V\I0A\(
MT>YBJ=*.+'T*HGYX;>^Y3MD(R,_5\5A1./W=KO/]L87[2_89$IW\$:LJWCOI
M]K,;WE=L$TCKK2MVE__P4<KC ^9B-R<_YESBYY$(Z#7&)QJC(W-X==W2VRN=
MYQZX@)H'RG*957BAM3O:$!S8.&%^GX 0 &=VV/B16XFXR!IAFI6.-/'.DFNQ
M:=2U7:^=-99]XEO+OOX8@Q*-OIL7P%@]/L^:(Q16%$5FI7&P%TI-(JL@1__D
M[7B90/V4@6RJ,OE#:,NA .%'W_/JV^.DSF&U*SWE%D;4U#07W9Y8-)+((OW[
M+:=R%!(K'$MDC]M5(HR*BVUN?^^E+-U=13P,VN\QV- OH%D];G-;N_0F5T;7
MI,*P5&?"-E[^JSL>&^T-TP]L;@RV(*II-^EI%O<<K#JSJ9DM%!AYJ;?J?=FZ
MA9]G+G>XX.Y!A23S(Z\E8Y0_>'=QK'*][CK7F5T@[K;WA(MRJ,%I\<W[MJ4@
M7Y6\]ZB=GE3'JYT%RL%V>ZLB%F)*OB4J6,=7%'V\=LTGYTE&,?D)[HJ/MU5?
MAHT9"X&NS+[@F1)Z!^[N\25WZ<[ ZYDRFX!JG'1VN\$NAV8L'UJ)9E[+VD?I
M[7CH'6*)NB/:65U4%E7@\^*!V:3^>-.3J*032:$-TD]\/J[FC3-4R/=/DYLJ
MO4DGGZ.L>Y<TZ+N+NG+Z4%SX*_>B%XW(^0E# N*P6P^4N#\T^B>G*-R:4EJ^
M95]IO[B4FY/Z>:;U-4FI#MU'O5EEF9AHFJ+<5HVH2B>X+_\#WQWH^[OO#CC\
MMWQW0(#A0_-[&V)-/D:^AB$I%1<IY'KZZ?XHK4$+;>^ZD7DDL[#SQ?B]V+7I
M.^FPW0QS&H+B5T_@U]L76$%HJ+")N32K>]*2]=74-.9DN>S*>1_9DS+:IX:,
M..[SRIR@X@6K#I/,13PNUA)ANTVS9G<'Q56/"RN,2;$L([16N/<67^+-!_S:
M[S3QPY'D_B8]55I6=L@%VO_3WI<'-;5L>P<1D$F0>1"B@( ,1IF5(:(B((=)
M%&2,,@@!(4<! 0D)B,P( @H"2D!$1(4HLTR1&4$%9!(00A(1%2()0]B:Z6U?
M?77???><JG>_JE?OOJ^^\T=2M3O5J[M7K_ZM]=O=65T0^>A5AV)CL[W8R??[
M<OW=EYQRO>QT4I.R.AN<]@@WW^\I KS,;;1V&BHL;M4W-H6<O(]_VN3I'K+$
MO&@J=I9RQV-7;M4US%K>XN^GV_+<%M\?<&UIO>*%MWN"D*@7C>W&[C8SIM<Y
MC'S?M#\R>[)U=+,USH+7@/%BD#ZDU'6"8%!Z)/1\?*.<>'6BUU0W40:7CFL,
MJR.;*YX@-(RAM1<BWM?L&[_TL#'?,R/C=K-7_QXWRQ<[>>.CWQVTNC:<J<NZ
M'.MK $Y8L$)<9IVV3M&=#?M#C5^3;4Z.JD8RWY6*Z\GYGP7YG$@;G%;7O?K@
M2^U'K^'(B*UKCRICU9G%S,K#,1671%YL_/L])UIEZ96[M3^[X6!:&V%40B]L
MR*ZY.G^JJM!ZNK$J_$E>B\=KJWURFPWO\\8J\B:'RO&"M/:IGKL8=;1M!_M^
M_7T-I[& "2-B4^KW3TU9YF$FSNJ>X0HO[QQ4W0D]OW.':]_E;S-&A70%L52/
M=U75T26#6-%A5%B+>H%TR335_RQ[V0S7)_^2]_DKRNYU!8UN1"I!))*XRYXV
MN&S5-F9F_73H2;%]L&U9K/#K^/5"#P/L$:. N><K>W*-=]--D"X/*F7&0G65
MJ"VAY@V(JS\[FNZ.X=/ORS\>U-*[,]-TY+VS/>K[(+MXPBB_<9"-8VDO#,MR
MAM;0)L];"&MXW4U=_1YUAJ'=77Q C.N*7I760YO5>$'%JVO!V6D;8FDM884+
M[?"^R1;S3EI?V:Y1TAC,']G MM7]E$S4'-5L3#L[CW3X:G0#1?(JX4(6EKKE
M.%* Y89\Y-5Q%#Y2\::UV[@'#$8U#A_PS^G:=O6 P[9/"SRY#O:>SVDW5SBF
M+71":HUO85G&2HMT?8PVDD<H(/R6ODX6O^/1U'1X:L.0K'1:E=JJS*S;7-.C
M8A2V]5V?P5I+[M#SC45E]\=]!R9KG>NF8J>K=6-?3\_KEH0LX#-D.4(TPZD>
MSVSAWCA2W]3#;&_Z\6"^L%7U]=[ZIJ'0Q3LR0RHK9]>C= YEBF@*S#P=^&X!
M 3I9TI&T8THH>V71UHGYQ1J;/.KHC.V5,)\WZD:[7_I+R@P<WQ*4QWL]>X$7
MVQ_N,M=$##V,FEZ-Z* \5<\Z<F^W=F6 W"HJ>W[IU&P_J2XJ[#NU%?=_L4?S
MA?5W>S1+A'_Y'DT,6(WZ@KD?&37VM2BE7W>G=@:R:#\YQE/SFTT '.9D*2W+
M,H:O9',A5LN67 AAF OI&1'HA_[A7,2+UOH&0GU^U\\Y]>O1,X<?Y!S7+I/3
MLORVPZ07@\-V7FQ#+!!F"%T=V\8P$&#)<FII-%+X1Z0!9[:I8<WUQ(V];X?^
MEO&+!F?I$?L<?PH$P0$/)(*5ARBBRP@H>1K?^WHZSR/XP<QTI TG?4%D5:WK
M]PH%DWOV)K:'Y_7NN4Q>F3..<UXP(M3U7R]+_&T4W^#MRSPQJI'EK=K=U%2V
M0BV";WKQ29RJZINX,^?&RYO@O7A-]A^:LOZ'9Q^KWW9>=J.4&W,A84.LELWO
M<3Y04Y*95G"^5GH[8?'3D4L=N@56M5^B.>VTI6Z."OUS EW6*3;A<728]L#&
M9M91597%76KSA_))LG*JNS<? 4_!8*/-CXP7 _I=2S;#6(:7#6:NS?H87*ZS
M25!\X]R=R9.YL?1B#_._ZMBQ5TN[&JH<3[S?"JAKGYQ'K0H&>NTSW*=S5O;-
M.&YU[[/RH8N;<U?ZYE/70QW>Q1WK\C0-=8C5R/F]R;5,)(>)O_OLY<^JFBB2
M6%><X@(AD4332&YH/[5LWQAHE!-\NH_*OQ5X7E[UM&6@WSH8T>QV:^!"NG59
M_EQ(Z=5$+B3IT1TNY+4!]H]%^8ABK;"B<E-SC&S+;&4Q<_KT<+3'N=2IZ$&O
M47L-JM^#JRU RS1B]*KUG6_*TF.&"(EST<5.R( ".UNK3!'*8)8MQ+4@['#>
MQ4\BCD+?^8UW?P+PI),WR2AQJ/3T<DO-S2H[7YV:U8B0BK3OU8DRYXA7GO^P
M.^0&.?(]])F^SP07(M)$S^,DS(AQ9(K<N!"UT3^4C&7Q&B?:.^-02=0M21=3
MTI$7P=$M![Z#=IW,:%A]&SOK:"]V@-:?' 'CC[XVW%4B/Y8[YCA&G12VBWZ]
M=]=)R.M/N--7;%^KY2%.8?^PZU?R1Y48KN!HCL1D90U E>D;#257]@K/"?PV
M$A%W#!FIR(4 I^I_M-T)0=Y2NO7N'5%?\\>9S6K:X:O^=4(N]^59SJ'-0RVM
M8?T[PW&TE5H=>P63)VZ,<%NM6QS77%MXK@V[ZT%;.4<1Q[#F0AYLEG(AQ"4N
MA!S$A20OL7- (&H/@F_] !LI8@=QSIG[I*]E V'8:2@G8Q+L'Q8'LHT_J<V;
M^^>G0*M_72^">8_@L3#&]&-, #<:@?PYL6IYI@\GXA&9PKA^?$GO8]<GU-TG
ML,%GF(M*VFLN''D418/-6P]EZ1K@.;;X!'*;LKYDUHTJE]L%L!-$MP_LX2X6
M<?_0VJEQ^KE4E[S',Z?O^5*'E"[-C*S/:(\02/D</>R(*8@\76.GP'BK"/Z'
MDA_8E;9A#AJ,P'@*?D KL,]^)1NTK"?0_.%O_ED9\-IU^ \ZG,6/^ 1=ANW$
MCH3"6/)BZV:,] T8$$#(Q&WL','2ZM\3?JAG_^/SW[4N\'.H&[>A:,>%\!]G
M#9L_:!?^A_&7_^,S$Z;/A> DN9!7 1Q+3BUMB<T/NHK.6UR(_G 0_A@XCY[
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MCAPYR'<N5MP2?PEX[_$_F&:45P*1C-NI<:<21^*D?E]QG]MX;.M[+??J&I)
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MW\X  K'F-:VTZZC=33W2DT>S/EK'&#9-O\7?CCKP)5XOIC3YCD!!8C,=T2#
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M\C6W#QN@>C 769> 2E#.#7HE];YQ#S6*L^/IT^AUTFI\@PIQAX$@!PZXV27
M9*\9M<?R.AXNH57UMKP0#LKZI'UJ/IA3Z'Q468RYD^7%;NDP.A==V8=KQ*_D
M5+(DSC4(Q\(%H]5ABM- ^EK0::.8U:7V6@L;=X43-_<*R5N\6<P0E/IW-GFU
M0Y S0FR LB2/DV$K+YD'64(39I?)P[NG/3P^' ^H1EXU8F <RI&_KYHU;?U^
M7HZ2%Y1I8W=@AU<BXH+ST=WX3G//7H7^KFJAI3[<3D-'P6]ICRREOR<]FW,?
M-J_/4$@^S0@?%A9)O%Z[F](0>>;O+0.D+WRC@"/3AO,>3G,02\76+JTT,$V_
M<<SI;MD1L['"AP+QR"-QU?&>0S'^N3&&P@,[S9J)03>]\E^96NI8=#V(-Q,&
M(X0RUD6:[(H2K7R!V$],*"+$M[DLP%.NP9(WX_3/3&S,?BJ)5=2L]@D*&/M>
M>?+F&],^\C/>>+<]4P/P>B[D%6)VN ]+0X Q$*ZI( %[?E4Z&">,D0= DMWM
M,5G;84![8^QVVKNWZF18*+5B0GI&[NTGM91I5;X\P5ME!(<OI6)#A-GUA0*6
M%"\9QI()9\2PFRUV8CO-T7YD% ]+>L0P(]0WB!5.\C2M=HB=C6V&-*937(^_
M,!NX6Y\D."1*T)P;Y1!GP&6QRA&*I-4L,]0!!%,)O[*Y %=0<6>=! KILOU%
M1E48@P>OAI%^?N7>'Q<_.3G5YVI&7G2<^ZX'^RHJQ=/->0NMVXJ'!\"FUSMQ
M=8%=0TA?VE8"ZS"R'.D3RZN3TRE16;P7PI\S<&")5^=-[-1E$-=^%-/KR#B6
MC"1H-1%$R08BH%)331E.Z=@VGH'>,_*+39.\#_"U>7^)7/Z@$/-F*\E!=R+5
M\T347@_7=;=E_(<H\A)U@E[;W6MAP&[ ^M^$+^3V/O:<!NPZ#T7/#_>XY1W+
MJ1O&FE-SUHX-O%=#[G!ZS0C4.6?SJ)V<#F%UT5&]7 B@TY\.#QDB9%N8@E.@
M'#RO!X:#-_!J&0OS">',XX"C0Z*5Z\DL;U<RU.*R4:6>_IX\S&R0]X/4B[85
MQ52Q#RED++6:GMTYLY4-#T5,)SH QH\[&A@(T6C^L5Y&"XOVH5]",N9R7!"Z
M(*8B!I)V%EV?%)[[::IQ]#\,T2^:"^F964UD[8LA0T719A-M9V-#E9?C!(XW
MUZ5_^TIHR8XU$]^_%2/E^A946AT7PD_"O"$T$E?L:1IDXU>$646&]01K5Q09
MD>&!RXQH#S#S+/MVU9YOL?HA-A#U F&G-Y ='+/&R%%9.W@9QMI]GPGCS"":
M8"N%)/QT)<.$?7L3I?CM*E%\8W57L$)W]-,38Y="J=3S+UUD4*@'A8N!A9!M
MYJ7\IK40^$,#)X'/E2Q9T."H0^#RD065%C;#>4NLBUK91_[:YDZ&BG^]5O(T
M\!G0WRWS(FC4LS[7=G?N_3//WJ-VE%J]W'%E-D'1\0G:AET-7W@V!1<L>,6%
MU+FQ)(R]WYM=,"K)=U56!0KHCEU/R[]>N23,J'HPUF!:G)%T?#W&)MT3&NTV
ML^$D\!I!LX8#ZH] V-H^SBYJ<!1$GP+29#,[U$&+Z77ST0;*R5^<;[C];'AG
M_'!?UXLD".GN_J@8M9EB!FRRWODH5!"$'3<T&(;PZ=,K,^M1TUL,3W @T<M8
M"8R$]VP:1_W;S\#>.>%N-PN5U$0N1.*<6DNS_NRL\;;/EA)MC]^*7$I_JQI)
MK!6@@C$/GRFX0A)!MBEJ<0B4JVV FUXF89(>O-DJ:B/(1*#$&P;2]XH^*@A$
M/@IE:HI\A16]*LV:+N>QJ\+C'Y>*#,LMS^"3S?2C:KZ4"(VSK"(O)92-1L2$
MGO[\)9_W4FB4P<'K/+KK ^60A;QXS&&PEP(L(?8C0@#J@^(I]CUX</8TQ96F
MD68 W[5<4,UHQ]J.Z]:0V\>_PU37'HZM:AP^>T];X,RB@]XAQ*71/[\^X'_]
ME7O_C9__-RX*_F_\_#6[__SLL@+1"K]>GV FH30[[&P()2H;&R#J=[QNW.PL
M^:V+XT2QU^CI306YS?T/G9[TA)JV3KT$@=L'3G.'_53"0$%O)0BV*GL4.K$I
MS2K]LY^L658@=^#+Y4+*ID@@=16_Q870(WC8"&?$H-B?_H;]2_Y?\O^2_Y?\
MO^3_)?__5_D_>?[,K1.4X L/B#2/[-D,CE#. F%GM# #/]5F'%,)N)TI<'KO
M=IRVYG[DK1K&4R; KSF4:@7!<J?_#5!+ P04    " !UDFA5W1+S>WU7  #*
MAP  $P   &5B<RTR,#(R,#DS,%]G-"YJ<&?LO L\5&W;-[QD5U0B$F(412%7
M(H5,DI!+DNPWDQ 2<TE"QJPB^\V$$)4I$F4S9)=-)OM0B4(HQI"]S(BQF)DU
MWW+=]_,^UU.]W_M\[_?N[N^[IM_RXYRUSG6>Q_$_CN/_/\^UXGSB4( MITX:
MGP2XUG$!YY%_ .<;L%G/%7O!#7 #D \79Q#0!]9QK7W6?JY;^_!PK_WDY>'A
MYN'CY>/[\^#?L!XY^/GXU@NNWR"P]D%^VR@HL''MC[5._G'I.EYN;EX!?CY^
M@?_''\XK0'@]U]"Z*&ZN7< Z82YN82Y.$X!"QLC[Y_"X@']^N-9Q\_#R\2/#
M$$1.*-^"#)^;&QDT+S)BY-L0Y'N 1YA79.<!/;ZMYL[\NWQ%U6XF/EHO=[RD
M7NQL%TW^X(4KH1L$MHEOEY#<O4=!<>\^=8U#FH>/:.F?,#AI:&1\RN*<I96U
MC:V=BZO;17</STM^5_VO!00&70^[%1X1&14=DY1\)R4U[6YZ1E;VXYPGN7E/
MGSTO+2NOJ'Q15=W0V-3<TOJZK;W[P\>>WKY/_0,CU-&QK^,3DU/3](7OBTN,
M96AE=6U>7  WU[]]?CDO861>Z]9\P+\V+ZYU 6LG"//P[CS )Z)GSN_LNW67
MVLWUHL<3'Y74;Y [>)8F=N%*E\ V>?61W?2UJ?TYL__<Q$+_NV;V7R;V[_,:
M #9R<R'.XQ8&T "TS$"Q(SF CQFD1)IKHP^/&#80!FN:9-9S@%MR39+AS+I"
MZJ;3-CG12T<>V63;N$E=&YU*4)H5@FX-P@+I',#X&@=HCZCB *UY'"#,E/QU
M+[%\F%T+3BU<9\,/A5ZA?GEBE"F9\I2XF(9EY7D16=?)8-[?I_Y]ZM^G_GWJ
MWZ?^?>K_K%/'EF%!00[ 4\,!0F]R@'H96"I0FVK81( 4GU2-;M=Q*3)[,FCO
M<1W.YQZL/1-M4I)Z>8M>"Z_8Z@8.P%_+ =H*6$(<X/E-I/NI]5DW=#@ O.D0
M![CS!-\',N@<(+=M9GF5#("4#]B54^YS 1P BUK%92+W!K)B%/]//;CI_+!0
M$ =(MH50',"-VYP#= L;H&C!G:R,SE<<@*DH28!O(^=U<H"?9I9/X_^%#6X(
M*&;]'WN@MX"49>**!A&! ..,!HJ]4]3\;__^"_A7Z2LXH 0++#/WPIW#HK*0
M!8HE#ZN\+*'C)(425%DHR@,7RQ):V7/[CB/V]_*ECHQH[LL3M%-::0]_D&*Y
M*9@P.\<T9(FQ"_"B-JPK[$Q6@#<5NV$ZP/K:ZK5*UX3BSR_+WZ1^$!UZF"+2
MO&MBN_85M?7J7(-=F*/]8+TYZ&)/CJHV;!PD[O!B;(&2'215PVN=\P.W6I?1
M>FN>'A0S,5&YZ&594I78;^NR]X"MT:Y#?LW!D?$L+(4#1-1M[L'O9.G1CR;$
M/O*XCNL;:"$]_5QPB&'5M3-H3]))V5W[0HT5  '@8U9M&,5PKHNI!7?I'L!$
MUG'W^7>H7)LX[AA@W(VS']ED>.)%3UG2"-^CBVFTXSZ%RVI\@<NBW^6&Q-^8
M?IZ?2^8 O,?8<>3SQ&V!P:^(9;E-IM:G>VO-<S\/>PPX15+89C:9)AXRZDGN
M)H)!<48RY\Y@/%SNNWN^XG^O;OT6?(Y8A\38R7Z!5_G"VLQ^4.M+=31LJM#B
MR>CI22BA?;?MMM(6S3ALAU%;[95'UZ:(*GHW)=^X=C]D[S%>L8EA<? 2YB::
MN]8B.Y";RI]P'+K7=&G^8:")X8<B_Z,8\WATK^FF^/M7/NOL9?GQ+(QVONMP
M7"J;\?>6;C\Y*7^LWNUX@=K!4"%9ILP=8/7_PV'+3>, HV9-X$ KO-Z=/LK<
MRLB%# )&T?UA=NPG/G7R@> H?[@+\V1VUEM\9;PN,<]^3/R\^V?Y"S6U50+J
M-;?,\87X!MU=[&18%G[;2]R"=E&5G,J4AX*H7P)L^PJP5S\'[9DP_^BCBMUU
MX([5K<+FIE<-TT617YUO>XT28\DRB-9#<P7ZC70VS@]4,OCHY-BA#L;-FN1&
MNXE;2VPA\]BF#!-I!UL[!_T@D*>B[V2OS>V"F/?/3[QQ.XLKF05I)U&?T%2%
M62GF08AY@NY^:Y&T81H4T57Q@H]\T)6>&@C]8@.I]2ZWFQS=82K>IIHL5NL\
MI)KLMR4\-.*\$!JIO..!'89TLUGF([B>>V2\D#*\$9IHU17O7A**JTZ-\V:I
M4/)M-)1,7@S/'>!;^+:C7KKPA=*.7;;'@K(!OEDRI:KO^PR:"[^9M;ZV[7V=
M,OZC$Q<M,M9YSC?G[=/8]$=8ANNA: G^B,WGQD3VF4&*X_%,4_P7S'/^6+0S
MD0O?9@='4E6CSNAE>=4IT(_"]X=0M*5[9E(.EY1TK%54)L^=_,U0=-=%/XG4
MP[\-AJ!@ 6&F9& ^XQX[0046P>VERV\)G*F7K(ND@A&K[VKDMK=493OJ^U_R
MD=8[7[K=3F+'.DOWBT!B*-<XD68M-54GQ<*RX_':@1Y!=DN$.9,<R%C!K';5
MJ287,X#1^U8@=_/UU%W1I3.&?15D(1TQ=[K ,O4E.5*EK^EZ L$[QW%Z;*M2
MOWV'3M>Q#8?/V>Z_>!E0P]R?<\ 1J5A$LZ/(V.&! $ID'%X)?ELG"SE3T*$9
MGV&UOLLZF+RI[Y]G9/9MN]+_:6! 4"DZ;' @Y,EX0/6%6+GM5AKHVKV+Z#FO
M(M9EVL1LYVB\&<.;ENT%;A&*W'^>YI2Y)T%#ZW[>A<J4@>.B!CL2GM>=OG;R
M4]LK61D#I@ ':&:P'^H>@C];$^M*^G3.Z'#35B^NI#&Y&[L[L>HEE<ONO7MZ
MB$J-K3OX%8"^]\2M./ 13A'RIJ)BG!3=)=TCRK1?6IL?B"L.'1+/^#UX3M\&
M4ZKZBK 1W\$!2CM#R>X@7_O"U-!&VMO,9-Z/Y)G]<0?V'6V*3')-:32:-=[]
M(%H^@Q*&"V+G:0@1R*7BK1R@_SVD,#([<!X)K)NUOE[4>\'].%L7T%D]H')=
M/Q!\Z&;ZN0VZ*\F$%\8 ) YOZ*>3&.^A TP9J!46]&2>@-_(2-(=6YLX@&:+
MC&9U.?WJ1!/#23 ZO=#EP\.D#[-=_0.VA*/*<=,?]J]D.,M%I2UA7PUIT,A-
M))Y)#B!<*U1@D.=1#:=@GWHLTR;<WA;0"TI.54ULC"LX&H_C?@PA)8MWI!/:
MG<;2>H[J5SU3!85[T7KJMGMR !%QVP]I#2J/8P\^:2XJ:YF8N[2M\W+$QT&)
M-S/%._7'^SYC2BOKW\HQ_-G$6D&F[J1D7&6J#"_M6OK(C%)5GY#.(:M$>[GB
MMGJW*)&CIL U=7,#0/2' R^+$-UY]((7FIL#S#Z\A%X]KIC]"SX ("TL26\.
ML/=W=A$'F!OE &;)??-+> "Y_LGPPIW.@7EX"+VX<A3/ <YP&8C^+S[$J&A)
MA)]D8TJ(LW-TOID13 LZ#ORTNG3'W,3/F0.L9V3[EK@>FPRH]YF\4B"TT3?3
MU]:*I"^T^=)S<\=!8[R"U5;>^-8>1J#=V:=*3EVQR97!\E\(/EEU;AP@LAF9
MXV'R))4#+'3UHE=$"! .P]H:"R>H<@ 5:1<.D*B4QK10Y@!$!&.OLF'W;+C0
M%\7FLD2N\^, <E//E,8Q/UVC^*N>YWXOA<%&#K".L!*Y6MX$+O):(U6[DT5X
MDD=*!T?H(.VTZNIA,JO,GP"?R(91XHA>0:[.CN4 '88V'&#L%+I<K7.% PBQ
M!-#CJ.D^80[P7@S#$D<OZ&;\9V>C"'_L0$^PT#1DB'?!? =##G#,$J0Y<(#7
MJY=B5M)^>=L?Q_97@SC_9(\.T!T[:,9P9^?/EYMJ4H2:2',KBS99:19FLUZ#
MF-VNREO&Q[<WNF:'?![=07UYJGK*,L=)X.K88^*Y;W6+08'W]ROPVG8UZ35X
M^<M_L.[QF&4@'*#LM__/$0)2$PBI8%F/Q9M1C W='& Q81_[Q2\:5YP0YR4Z
M@"WD/?@'(VC6G5(.0#J+1.Y#'-% U'H\=_&,N8$H\)>#:Q4IMGS?$)?2Z89P
MO18&CJ\B?<Q@57" L !P+!#*Y@#G'R"]GOS<-VV*SV]$+>S.12P!3OT..]/E
M8).-AH_1BU'AHN9.*[1'?XE%?JH02^8[!]A32D/#[7Q(-X]WQ:!_=,49?N(O
M$H<U1>A72>:GK/4_^Q"#"$C4%2*8"(6R_S1.8C.F\I>M2D@X+2@1H+ZQS@^U
M"AP@*15<FL:LGA-*GLR*87V$8WXBJD@T4;X,K\CH(M'U2<&$ W15:JPF8U*'
M:3[S+ )*%)S=FL,!)@<SV,:DGD 7^$098HIY]E[B&UUYL,TY:C$23MR2%:,T
MK"NJF!4#_-O!TD,\-P2.]>+YD9IW[".X>,O<\&=/ $@#I#X(GTUG.G* P5:8
MJ$ :GF9Q_6)U?EV,XO_@0ZD-H9?# W(.["2T"RH&738?@=NE,6?X"L_WL;Q&
M>F?EY:J,H2]C>CLQ=T^LYWT])GM!ZPQ_@3DF49>GEET%ZP:ZG&,7HETPT-[>
MW%$PJKIO]J47U<O(OGY5NC<\"-]G7;"J\O+QMMBCZ3'G#AA6>RH8ETZL9!\@
M=),&I#F QYP9A9T;3K[X5O]T-\Z%*G4OF(OZ$FLF?FU(*CPQ<]0\V+&-D2XL
MYQJS(]SSZRU=N:%C_$_,,?=A/B@1<?PF]@TT!0D!?M"5/*#*J+HW.M%H-B!U
MNF^TJ]P4V[!-TJIDQ!MSZKGX\_N?LN1[NUO.G2>D^;XR4U5CDYB_P]TRF]FI
MNML^L\[1<\-8GJ3&'1%2IN*OG#9\U)@[N4!I69 WQKJ)QMVK?5YWN6:GU3X9
M@\]J7)/JUNT<@&8P/]!!#9A#K,>S0AN>,Z%?E_!>(FT+)#7[26L%IDB9EA.:
M[.(.5<CS.K SAPX_;),BI*3NCE:X0\^=Q2)#MX#>TO5;T"*/$'Y=Z$5>ORC%
M 40=<V_A49#7R).P9_I//'^K3/263[/V54\RT6IEI)X%K_GHD"D/A<HF27<0
MP"8,+,])C9+[U6:HN7-B3.-+9%'RR!YZ2XD?!2,R([DIXI[RD%3$V("-R=BG
MYAWG'7;7..W53N@HDZJSFT%3G@[+U,GBWR S,2/&8,1A$2_NT_20W$B#R+#Y
M-P<Z&-Y.JX$%RFX;=CU'I/E=&R6EO;+KUA]^*/10D90*NF+Z]1ED"*3O0T5Q
M  DTI7!(!>H8Z; />J0KAET7&&Q:FC%V@[OC:$K5W5L\Q?&.:H,F(@_S0TR/
M\8J:_^/ RR')Q@O\*EN'Q%SQZ30D$GRMYYI_V=Q.!UDQH[#&RL'%^0U(9<LA
MLJ^GP2G<8XCJ)&N@LT)_0+50%Q)0F@&P(2$&_8]T[/T6_[CO:R5+J@:I=:W-
M*";/%+AZ:)Q\UFO):3N2IE70S& .<,K]NU T:L'FPM&=R'U/("&\W!G^+U?
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M_V'+Z3V9=@I<,5)M-%O;WY[:L?2])V3M5?;<-0'+4O\'JTOL=$P/8,4AP$M
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MX)U/\"CF95^FJ=+J)X_[AZG/O28#<\K#%QNL_G1JKDS:P,9[@EN@U=XVPI'
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M=G_[?5;]X_N^N_O[[.[[C)_)1^[<F3GW.=>YSG5F)N%_Y-,!J;V6-I: @*
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M\]SOI_OZI@]'14JWDE*\=J]*4Y<(#,C8552VCI4)RZ+FTE"H[48Z!D5H'C@
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MH"G@^W8'<]Z&6Z_8_]S6Q2%#IC!X;=($^['ZL8\O(BRXLDB'F3JOD.;UK<8
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M*\)<]E<DFJKGPT;M6V[?+OQ!UMJ2>>N/YT7)KSQD2BPSK@H?2A6]X)37BVG
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M9=6V<M52=X\DR[HY[*0# +#\1H'W/_@A!D0K:'\K)P/*0RE"Y ,J/'&L_7P
MA94R.QLB(#+@9;1K"HY0-M2",3DR64="NM.P>N'?JU^%)$8E'V6H.<086,Q=
M)QT#:W&CEX<(\.IZ[FG8#+K)O0,VGQ!CC2:8K@H*GN)5V$3W#6R[M&$P3-U6
M1LJD'^>Q%K@(,F-9_8@8RF#""*3\$.FAE8#,5@8M^3O==DFW:1"+RAB,WV*O
M<Z)#56FBK^Z'[9/2K#=A#!GKA'T/^\\Z)(@-O*;;7QDP1&%,(;W%2I!,D&8L
M]C%I=9A"\ZU]SS,3JFWR/CH?#TOZ<$]:6:_M##VK?=71P*#5/3)K[QOXRF_]
M^':D\04#A+3PX]AA\!)-+A@O2NK$8HAN?JP?=1>OH[5L9A #/6Y?<%&R/GGM
M_71.DJ7J?C&OE;I3HZ:.;T"6'ZT>FZ0H"DOUUSJ'Y#P^#I&F&RYF53T(.S-?
M)./D7^19<_W4S5,W9$^VD-?'B3AY2+[R!6;QO;CA5J8JRP\1"Q[&0NM$FVG)
MCA39&0ITN)LF4X,-&W5I]V<&7S9945!^,_#^V)*FE0$3J_?*6]\_YG[J=LR9
MK?V<(E(P\JH/<QETUX<V9%XAB9#:538M_G+2,(:,P^"&-%GD)EON)I^"W9YY
M+:J9]>?Z]@R>CAY0U>]33^M57>Y4W14J5C]S*-)L!QO?"/:3!A'QVT.X*$7-
MRP?-! =(K<8#:EWGX]IT7UUSBC_"U=GX7'MTV<YG):K"448*\P89CZA]QG11
M6*Z04\*V3ZIV9REP9BYS0C^4[MC_PQX*'[(EQ,M?+%WH<'[5IFQ[Y%G5I]=R
M#:]&5I[<E=V;G5K=?"J&>5C6\N"V9-N'UQUU7HFN6C6S%7N5JL%[ OJ$M_9.
MOLQX;E5/D: FF:V#FGRVT.+,EMJ$U% +_'5']EHMW-8)YLV^JYT_E6COZ-WV
MTI2 ++W.#89]>=4T#\G##9126NSX^<%$_'(SU;$! ?;T]X/CI2\Z9R;7OFBQ
M:1-:RXX3GYJ_O.[#PUTI^H@X%44]D:4)K\CA[&,WQ;)&&S*G8/?.\T)^0TJZ
M!I89=.]I5[*NH4GBO@""V*Z5KPI5S3R2$LNB3IE=6N1.I&D[;AS+U4/;"R$U
M]JJ>LN]4O5G::N@>X^/"Q(L('5?\B>N(G,^QA_H.R>J'; [9QZ%,\QHW=0DD
M@QS!#G"&[;X3ZQUFQ/EQB!5W_<'@/H];PW;1-KEK)%O:"C3)0<X.J2C-(GMV
MK$!JY0<7M/U._)M^V$1: ]D>8M,N350;YH9QG5F-[^I.Z1+J1_J9(<W<UYP;
MIQ,H7LGQ920/L-:(YC?8[T+'P7)5#$=X!181(W,/_R#I=^O/W"@#(YV[!N+S
MOC\'$[<T3O<=+N_N-C*V7+/\W5>'\8ET+]],WD'JNU9H&XWC\:':D;L4VU]5
M>Y'7'$?2(;V_6):?" LP/AL"SRX;9[#?^C97^^\[=V549B>E[OU*H2[0'UQ)
M:L>7@DPJG0]\[.>LXSVHMF%-X<5ZJ0EFIE#^SO;S;[^=3U[GD>J_I<OEAU-7
ML,YK S6OA"+FP%&KY:ADW4P,8BO LJ)#("Q?B&J+%?@]J.,+8!=*+4T&4?:M
M6=,=7$B5"-LY%M(C7^RKERC^.$%-^IJ7RF[+YA%_Z28SM)Y'[X:-VZL-N2*0
MT+ R<[:I8!ASA;2Z U&%+=FZ2$?0([^+97\H''[U=:?X:K?V@96=(BE+U7::
MG2#9\:C@5S]:KPGRBI! F[GM>G>Y%>=N#XZ>AP700E%,*9D<Q^2"M4YFZ_#H
ML2T3'WX>''2%].O\'OD\[74^OG=/D%[JE^=5%@K'S@D$OE:-?X)\GL.R'/"0
M!MIQ5 WVN]/GF/$/2!_,A%C[_"+8ZD.AC?IBWIS,]N][7[J>..:[W>)Z08KU
MU4SM#6>B'"B8BK<D?40,;4AT-I#J\)P-$-H=V,V5<>)AN<--)&F6*+S"9!@5
MWJ;!H1+.'GA1HI5$78C Z0NEWX=2I+.*UJ:M]34IB1J(W*' \8-0G</E%/(H
ML!+7AKB^.HVP'!JLS[C5E.9UX&GNX2;LVU1S58]=>[=_&;H>[SO?T0BB74L
M%X3T")<08>\LW3V0^ 6NZ6#898=VI3T5:G:GE0^//ZK[EO^'AB"CY9*,\$?\
ME_?.)2#],T$<NEV'95D0(A7M+Z_),"FHU@X*EVE9NJYO].#SRG)3SD9;:94&
MQSY+K2O908J9#NL?.UY=OMG@VUF<ZDZL'*F-!N#H1?@R2A+181@;2:O(Q9?4
MQ-X;"W4&ZP?%7(A;2[KRNV]U6R:,.><U#HQ8/UYGM;%>4$[^G6SRB(FLXJ*<
MH_93AQV97[EK?+/6\O)@???[\%XHD(TYRL*0*7O)GGD3^?D7-"9.[4]8I7EE
M(SZSQ<DH]I!LN"8SAFN+LB%)N*S=;#7D23S(-FXRL,F#-[%VV9;-1MBZ$38?
MPG7VNE G'Y_!O)7=>['*DIR)%K-)WI7SX$<<Q[4-66+!,*#Z=9PX_H.TC;V[
ML7CV\\6%H\]J7NC Z]N+CYPH5+3,3<N]BA'AW<-YM4(;R$R;( 8!+;D C="/
MCWSB,S=W%MX,^5,DQ\OD.M=4I*8IO3@U,6Z:,!=K6BL;R*R(LZY?F[9,))3&
MLICLKV=HPK)6G.4?:K;#IUD1Y8G#$2;'.DU-ADULA77\%ZY?:=)>=TDFI/!Q
MDTZ:W-L':[4T/] "\'VX1HHHK.S'HM'7I1(>P^[L*7LW5D_]->.)]K-W;1\.
MG,3JV)<L+[%778U,R'[>P%9WYD6#[E1A4BWV:>@EG"=-<"S(]V!8R.M^AQZ]
MCA5C"^E3I7.93\^=;?]DH\Y\W9=W0$;V@.B3MG]]E.KMC5N, 6OYT(3G<C)6
MR:]3.SVD4R<D2:CJJ-V%\Y[LKT*6>:&TO ["L?6',YG%PW9^'',HGJJLWK#9
MU7N[FOU0A-W052O)KLZC8DP?FN?+DWOBM,[(9FR*T?RA>P'/+.%B874>VDAY
M3BH@;T"ETE;<+O:9C.Z1D2U+ LR^6H>'OPIJ/^9Y)#5<YMFV0^; - %:CVVF
M)9P0@L3O$S5YF::!X9[L?$;Y@^?8VF\SA)*][RZ^.A&P*SA+^QK7[+UDC^/R
M \FI#X6>'Q%E$"#=_96HL:HHRQPGU=<HHDT6VK[6'JO1A&XWAM9L;X--"A^7
MT%N7->>_TG-[YC,2MW(F:BUHNB:[E%KF(EPY0@5K"[-6L_%-V$BS=;P<T!N?
MH!B?;.K'>MM@C&;PB@+?V+W>-8H=;J654OT/5CG><KDN\ZKQ3GM[[[*&W28T
M5F@\O'CG \MQK=[!![+U'PC=06WY,0#66M/H-_C DQE*6>8X#[71"Z(4#GRO
MT2SNF%56;SHAP;K3X"CE6F*I:%3>OF;3\YJ.:8+$YHT8PYD>,NB.@[3SXNM>
MP<'<C>AR7(D!X/#6TIGJX@\UVI!"W=PME?QU:%/N^<='GZ,5\M]&OT[GA'B\
M#ZG8/8QGA5K!]VXW@)P=WKB%0WXSF;6XJ74^6([XXO56OYU85*?4KL'1<RL&
M68?PO6^/LNT;\/&!D &#4#\I]QFR95!B&.FE%TG% 9',Y0R7UV?/W;LLZYFV
MH_7KI#^:(9FH7@&'-.OM8R[&CQLR.ML- T!.'*LBGGA<YUO&7+:=XH+3R537
M_2GJ">^[AS[O>G:XGKIMOAZ1'*BJ8#<S;Z..$(*ZZ+W""(:MP%3:H"@'BVX\
MWBJ\</F3[:K51E\K*X@IV18[?LR:66??W&6G^$QBY1+7J>7F"]$"L);0*+X?
M6XNOL&^FK?X(B_/2$5/-6A#C_*WP85@)(QK:+WD*F7+RS-#:\F*[4MJ:Y/3=
M&RI6;/6R2.MU=WW54B. <D,K[P%XAA9'66PQ$@=9-F#_,.,QA6U[A$6+9,+!
M+"[C15;4\LS @F]/71M]62=<7@K[K7^[.;;)99-=YE59]0G*9;R\F3(L#A$>
M$8]#Q8S" (7ZYY+7COO>NMYF<LH\$G 0N=.;E&UYMZIJ_8/3)S'O40QXC0\-
M)]L.DQO(D#:6*3ZD/8-3(;K&O=W/&HS5C^1:72)J>& ^^J^K-2%HGO:KRA6^
ME&&1 !9H1.[PXI3PBA%!I($/2)R&"MF3#9D9(>8:\O+;3UP+C A_T))8]:HB
M6OCT!0S@)6:0X;E*O0FMC(G8<H4&2G\_LHP/Y"!=%+EU5WU/Z+#SDTZ7/4V5
M4M[>:/CV(W-#7./Q.O'@)*F&,VXJQ])L<,X]+P=9_G-PMD'M(&=[&(T/'%):
M +@CO_E5A?_J'V_26;Q^06%9_[BCR<GKH?G3/GH-OZ/4M<I#W6-]TPQL''$W
M/8QH-02NP+ML"X^P=%F2-6#K]^5<B][=FTI!!NY!KUHYL;("\W;#@Y!:*-.8
M-<CI9HW"LDPOM.Z,-EW$)_8?[JZ1[H7"(.P>KGGY,;?N+:PS!/6 0_)[W'5[
MW;2 B13K'%\NH;YF!9K.T5",Q;5F>9PT49RN:]^ 63N'+&6;)08SOFU1X*9&
M9$P-3-II;GIHLT'BZ9J;N=)["Y('>!9 &&7<A"L#V7*T65:)Y[EXI3&2/CN4
M7.UV@4%+R#+NOI=B<B?(L;)O[54+J64$P?5K W=2-GC?]4P\3?!'?3!JIN^-
ME8$=6/7'63VUK0GE)Z39=LCM#8K8Q%E)(>Y17;VA.'EZWZI["B(&5Y/5"M:<
M^;0YGXZ-P;&L^0"D0QOG T-*K:+$]>@"V,X^K#'GHNZ"AX.NR%M%W:\3.>#9
M_OM5E97/:!?.K'./JK$\)2>]1%K.ZKNDK #CEM7X=^X>2)^C9M\[^!)?UE4'
MVR-UWNN@5H;]LL=YZF/7WGA6==)*DEN\Q4VOK3PYO>_ :8V&1/FF>7WZ*"QC
MBXA-LX2&WA#U(!0:(D,E[>?;=C2V=!B/%V5_^OSY^'OFVKE0!6.%2=UW#6D&
M)N]T3*I6I_G-D)* +R1!V*"K1I*XDM5:A[;!\,[.:I>'WL]-C19H2671I*Y'
M ['O&L?OEOC[Y&W>>T"F@.;+$@GN_,LSO,37W(M@[2:2,M)G9L@"F_F &-&J
MJT:1Z Z%CN1'UZR#0MXKW3Q5GK[YG5NXW]:I,G%MH5>* _O 1V=7[4G3X1E;
M "0GT@">94[KZ^",LRPS-1M;^_J''+J+Z1&2CZHU<L-P] 9$H:SG) :%AN=8
MQ=FQBA7)9N9B]^(^J37M??5P+T!Z"*T::NVG-0Q(M-^-095W#,[+@77F,B$'
M NO$'V/DORNPUL>>#[<U=^>$91^[Y^+C_LP)N+"G6$XL?VP[RG*$:,J3\A?9
MI)[M^<Q![EXBOH+=VI (KS75';I1"F*4-2U8-5>\5KP5R7N4J;"Y='JOD&W0
MAI86V?4;;*8<V[:@;B 1(2JRS WUOCV-5T!TXSI XHBX12X4ZL3>=ZKI?1?M
M=(#QP>,KK&W$&^\[[QC)4]^]])2*W>U]4UII=BT*A&^&L@*HX4\FQU]S[4FM
MY2K:W7S C]8/'H!&&8/28_)\P*M'@W6\(MY_YH79TH\6/B*QCY[N*1JQ-:FF
MQU^[J./UYE 02"_ %BN007HVK7@ND>8^*08'ML-"]Z&FE:H]9;<'E]@\^K3T
M7E5%I;E@T>S#!MN=#I?G;SK2M5?A+ [N7#U8IR\)S=4.+C]/$2?:LN,RJ3\4
M(]*/SCF7)]^SN5\;5"PX*3_E^FGEZR;KZ6-!33JY?^6/47UH/6[<EFV%B*ER
M-<*N<2Q8]DRA7*)I.]%-V A1ZZ*:2JXK.__!*E"6NT80Z5+;<$JLI<[^>HK1
M'](S ;("7[!/J./3;"O.?E2/*' -83NH.3?L"[2BWDAQ"9GJ0\)<L[S@_XA^
M;,UTME__W?:E:1N/.YFOWS\0-M\_#,(R\9R;T O4^P?0ID!.R)Y74:V3BX>-
M/MS_ ./H]R%#P\9'SXD_0JX5H<3>;SUIH#O^+-5!,/W*I:&8B#8+@*C,=4;K
M]#J:+Q_H.XR(2;)Z$#',$*6?5CL@VUTCX^.882;!@BG"FK0RP>]ZZEFVF=O'
M"0;I%"%"1L[;0PJ3GI12'"PCQ$GCU5!+P27HL2Q >HZ"V4;H^'U?J4$\O 'R
M9'41-3P?VZT0-8\XVQ?+;&A; LR[714T5K42&Y[<JR5(CB,:#DV*0 1[5NBE
M4I< X[WM_J=*.K;\T-ISMJ^_(4H]:<L).3FY(P(O ;$7%BC;3C-HD ;:#)GQ
M 4X>.Y[I2->'=.6O#3&]&C==5C(YRKM9^MGB_ [5M?KRM[WG;J4G2Z@F7# *
M,'B5;6.\\3C-BE1/*]%D[N":?0S+=UG\SD\ ;_<PY3+1ZH$+C^*:61LRH%S2
M/@.IN\GERLL_?2U3<7/#Q'2TBMVW(HJVS5R2EM#T<WU(0Q^6NV8-S0[;]^G7
MHMV'2Y'F7C8F>219/X\/Q)WHT+=(OF*17'/;M^?6'U217)>;E_9^] J]/O=J
M?'3,_F,\A\#+!KVHHG[-G$>\XEELBHHA>TD9IZ#:*73()&*)N.W:1/7HID'[
M\M2A6*E$#[W\\V03^?<BX0'_^);M46/RN"E8 .V=:AZ*3]IR1\$US?28K_-(
M_+J\ "'P I-16>XC^N2Z65D)&F@G5).$H SM2'1'7P]!F$;:LC)*W[0U='V(
M)A_6--JH($VKUVR;#)C525"-.^W4<_B.A+_ND(F$D["1T@@#CTHR6*:5T8JN
MFCZ2R!+:R_M_MJ9D?ML^\4LU_KGKSV]_N/FU^/7P":XFA?P6K\)>3.2WG;&B
M8Z/6?C-&]C>O-)@? ?.)^!^AV]]F 6U?5'>B*OW-Y(_\WRY_Z&_395N:NJ)B
M=O3%?;QWO/56%N;N6=%G:;IWV\5IJ44[RT[Q6 2%K?T3]K=Y_X,5_QFD[23M
M#^8#NZ@'H[[H\_PH^W8A,NM[/:\=8WW*:^%;N3<^NM86KKW[=^;,BL_)/1;G
M6<)OA02P3_AWV'[#=U#C&-AEFU,2?[/^6_:'.]?DY"Y)/IOU[%>AZ;.EY8IL
MV:=G.L0;I2ND-*Q:&"H:*AA2]178G3FV_T- _ _U\K=[?R?^J?@ [+@#*[X@
M6_.'Y>TU[$KQ%=4'I\NSO*UQY?^V@\=^RSJI=W^5=\PRN+_C+H?8\^?^]X15
ML^M.S]]H_D?$^8"\W)?]7?>WN?\1K?K\6+Y]BZ[=Z]_*!Z72#[ZU/C3M<<!,
MFZF[=TP[]\AM5TCK\] FQPTVG0J'W8R_+A5AG/E8VE\ROB+MW>6'__8NRZPZ
MO$#,_->QR:I?M^CN2#G)4GQ[2W.>&\O*)L>3Q_C/RW_PJK^A_LC]CW#QM^1M
M?Z?OB?SM^-)>8,M>\[ K^E_V^ET^L"ECN\;UZ46Q9S8]^_=2A<ESR>TM:HP,
MSR77+UN!]6RKP7Z$)C7Q$#AIC(IX-&:)C-E_XOML@'7SY ^GOVW\L;3^P_U'
M?#L?OGRWIW*->[%9^VK?C$\+]L]H31;63."W,&T'3;+_#JZ_>.J/PW^&0Z=^
M_V?HN\#^O=JUGB/^PS7YK>9_9=8?X?^CLW[_C[?RZ (,]>5;PC^T8C'BXJBQ
MH\:.&CMJ[*BQH\92V=BZ_PR8IR6L?S[]V'\&B7]Z?WRW-AU_Y'[47ZBBC3N2
M9]J%U[.>'KWE]"1A4V=LTR2+$XL:[/_?! !02P,$%     @ =9)H51""K>&Q
M:   T9L  !,   !E8G,M,C R,C Y,S!?9S8N:G!G[+P'5%-=FS9\$!$$%$&*
M A(%E";P*$VE1%! X$$$I9>(B#01$>DA1T6J8.@HJ!$! 6G2I4:Z-)$N00E5
MI">4$$C[#K[SS?>,NOXU,^_,K'G7_Q[79LG.SMGEON[[OJZS]X'QF3$&[-/7
MT=,!F'8P 5>A?P!C"=BK>=WCFB/@"$ 7$V,$. ?L8-J^MG_NV+YV,F__9-FY
MDWGG+I9=NWX4UMUL4&'=M8N-@VTW^_8%_8^3@YUS^Y?MF_SMJSM8F)E9V%EW
ML;+_AR_&>X";C:EW1S@SDRBP@YN)F9N)T03 H#&R_!@>$_ O%],.YITLNUBA
M87! #<KV0<-G9H8&S0*-&/HT"/H<V,G-PG/DA.:N_<;VK**>O"?OQZ:QB6D5
MU?.9]!#$%:[=>;";G5_@P$'!H\<D)*6D%96454Z=/G/NO+:.[@4]_<M73,W,
M+2RM'*X[WG!R=G'UNNOMX^OG'Q#\,"0T+#PB,BX^(3$I^<G3E%?I&9FOL[)S
MWA27E):55[RKK&IH;&IN:?W0UM[;US\P./1Y&#<^,3DU_6WF^^P<<65U;9VT
M0=[<VIX7$\#,]'^OW\Z+&YK7CFT;L&[/BVF'[W8#[ITL1T[LXM$T9K7WW"]Z
M\CX;KU9L6E'];C$%$P+?M3L][/SBBN-'B=M3^S&S?]_$'ORG9O:O$_M_\\(!
MG,Q,D/&8N0$X0-X@P6AA#."6$5FF<+&-B!_7;4"/5#>)L#& AV)-@B&4NOR)
M/1<M,B/63Z=9I%LX"OE,SCZ66> B/QRALS]E 'H^#* ]M)(!M&8S@&!#[+04
MI@Q/JP%G5P)H])=<[V&_;1ANB!W+P:PE>U"SW3#4 "R8_<^F_VSZSZ;_;/K/
MIO]L^M_5=&J#SL'! '96,X ']QE O0A=R$]U0K<)399\73EY0,VAP.CUB+5S
M #V7>:3F4H1!4=+-?9HM+'Q;NQD :PT#:,NC<C& XOO0[6?97MU38P#T/<H,
M(.$U:@@D$1E 5MO\QA86 ,?Z/#;UG19]&8 '; OY NH;>!4I^;^U,!-9Z5S^
M#"#>D@QC ([,Q@R@EUL;1@CLIJ9TOV< %$E!-#T&:M?- 'Z962Z!]3=K<(]=
M\M7_>#F]+$0U)_L2\%<^*2*$R&]&C*J).L4I9O?=):]M5$2A19O2-%L[A)ZW
MLO_!=#CV.7DZ\JK50=/WUS)RG78*<Z_OPNY:T!!#?< M+TY.& VKT-GQ!'.]
M"O),+JK?RY6_[@3Y::9XN>#,_<S(%77E/<ITS_*/O4>FI,]&"Y8D7+6R/XQ>
M[R!ITN+6\<.L),-^T D6)G(F=J9\D&KL.[['S;(RV23P5-D>$])*DXU::V?E
M'YF=%T:>)*\\MIA19%ITR7=><2U,T\VU5EKSW'V]Q+*_/?LB<\)'K9FZ$Y>[
M%,V(BJOMV>&9S[^^Y=V;$?_)? I-Y8?1=QM35%"M8!&>JARVX)M%?J1->ZTF
M,6FX [&+>@'=E.QKQ0 >K7<LF@U^- CL$P_QL)HR$E,,U(IR-[6H:$$507XP
M26[8:,00]+'AH[#:QPMXO]X1 \*S<MS1J VO#U6OT]P<?8Z$\OG?D'%7:ES0
M=G+4 B0B@:WVD2:42,US][SU>:GK7@\?JV;<\'C)FE*- ""W4J+S@/5[:R0H
M>E]U*0=0G?N0I\CUK\D!!D_6/(3\N*P^>?=DZC>H5)=6##KH^EF,"SHSO;^6
M=Q:I,H MTVV5!<<%'I8N<R#E>MV]/<+KE/OA176P[Q6.-4_E#QZ<JJD<695]
MGJ>_H?#V< *Z0\LQZ>A5+L/(N4'_ZZ$<3[Y.'-:/'$L0O[Y#U=/$?":9RITZ
M_B=B)]8=/^(V_I)X(ZOPBP52EU":DH3-ZZJ;OU*;VOC6R-M73L/4Q2G)4ODP
M6RKIU1OI;!I /"Y(&PI3XO!@=^4GI60DF12D>OLR)4G>8N<6JMK!D7V3YV74
M/1UMX()2_J$RAY<%^3<]DF"G\Q[.?PM?C:8H/*^</-5L6=@&)Q_7I?(\(EVG
M)<#M%ZU) [34OB8<8E%JK'N?,RXL!"7;/"%3C>;VPS0)6#W/SWD\<S?D5LIL
MEN.*Z8YC6J_R7!W@N73!H "CO2XK?J\/./3CVL6R6V]Z"7:_];]OM''.2:2?
MR2=2\N6.GPI7$XRL/D,W=!H#:0E[=!G !6U>L'X9ON(&9V8 "R]=X5M:4"OX
MKY2]$(JGBB-TDZ<46P8PTDK'2!3BYP#)5Y'_I46F#9(<>)R8#2T.[@"+A)<N
MAR)%E19UWZ-V]9=5'SI2<;,R9?3KE.81Q)/S;"P?I@Y?.V.>9WZ$N#$!-J*#
M82Q4 Z+!Y(X6I,RKV9-?_,*[V/4.E+0<E2O>EW=_]W$N(<WYWGMP.;7=_A0O
M*I+0DD.Q0K5@"9?SC5H8 +=WX7# 4--@3$7PFFH^^PJMH-!RS3KP@BQ_H )O
M]C7TW=Z+\4[=JSH.L$Q$J2J]!X>IIQAQH+I20I]GD%N;5)1)S,T!HR_D%FM4
M.,346UZ1JN,73XKJM/&>9N_K8$/JUJ#;X".7Z;N[B,STW9X4?:0!K00*G(^P
M_ YDFQ=<9 WL/J07H=7$P7^\F_MSLZ_/K<7)2)TFX-RM7E'.L2(+*[RT[KS
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M;U\,#>/DS*>_#6>ZV:EO5%(\M<&3:^9=8 %V;1)". -8-.H!)R"K]?O231C
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M__:^R YM&.XIALH ,'06^56N=;<P^'?V9#I'V";,$&R<@!)$.G;-$]QT_LX
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MLW(W AS"(M;OXG2NVV71V2@4)^IY&A8<>T'?2<NDR_N9#.D2;Z23:"I-Y;B
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M0H&ZB0!OP$;"A,#2M4,.EU)D=1KIW+4G8:?-<$[,2.7V^55I3&*8_F 8W_3
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M3RQFW# H&M;RA9QY9:%B,%Q17N', JQ\O7;VB(?N/[/S61YRI/#PS<V,BI'
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M?*@_KY6#ZV !.Y=F3[TAPR-1$D431KT*E,H2%Q?)RQ8B>4M.;\^<>DQ?XZ-
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M46QH3Q4P8@&OC!N9<;;C_R<R<%=I^/P"^0<8,Y;GN'>;/=]3P+ P]*CRO)>
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M*"+4Q>$3< GZ.8K;Z&0-Q0>JU!K-%-+3E&-$]9]_Z&I](VE*0T/A&135;J;
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MDX>,B8."UK8=1)6WHD<%'G\:?+8I)NVZ:0!U7RL2[-0OVA,,H%;)D'=LJ(F
M$1JT\=78Y7C7K> .C3C$[GH!2>0\<>5M_Z 7<<5]BJGG61]CE##@H_[YL?31
MLWH%*%>KA<20DG?820$"U_(<"2*(Q!.3(_U@1 6*7>>L$L4/5^EX<ZO[Y2$)
MYZ3[2XONKY&%G _B,5D'Y ^]J#(OV-D:Q"B#:J+.@(6D9MR$!_4\1<X&W+@V
M<HD>,'??5=B0/&_R1(C: PNJ/Y)RLJ9>/Y,%F*9P.^LQXZIB6V4P;<T0LJE
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M+R^,M":17Q"64OT9SWT(C!LD\/G?E_Y]Z=^7_GWIWY?^?>G_K4O'5EA"0FR
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M2OQ$/8BX_%4*UR"1OPVORALAS/N'0NBHV+>6B'D)-3&BO! 7#*_9HQ]@+=A
M0IW8M A383N"2B)6]<]8A^_\Z@$._B<$<"#J]2?.[H&Y?L'NA_Z:H/[3#=R7
M:;B.<X0 7Y<UL6*]64DS?T%!'36WQF0=WH,V X;R+$V]3@)KR!U):I#'CY\V
M,N?:?Z9L5? 7W$Z71^RM4(DBX\= Q2N.C*0O[6MT-',G(H3.1I%Y<(J(6WS
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M71?WA0UL(:*\04&6*O8<M"/W\8R8^A\[&'V[5S\6%/#"%QPQ:2<9>?J.=]A
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MJL:;_Q/PQ7]_#TVHD@J&>-6HQ^R3D)?>& #K0[;F#/%6?=H]3->SK5Q,V=/
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M&QY6XFNP0<V $JSMK)9*8CX%M<D[T5O_1_XUJD^#F<_@B],E'\>\W902E[@
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M:X8@1'H_?%=^0S$SC<5=ESV]AJE[I]!R+*8N_<+(IT3_\?-#!W@M'2\@ZO+
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M"^S7OX2?D =J[_^AG/]711VHYA_KV?\,QUZ,.GS4X:,.'W7XJ,-''4Y+AQ_
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MPD^DD6T84,N9J_#D[ON3<TAI@(AA(;V3\'?JUSS@U$NO&6!6H+0*X1\ 8)/
MB0TPUA"8H2Y$#B7PJG!%.U'"3/N.<Y9-0;@(NI"K%OH,>@*M&]3K;!80<=D(
MH&]]-B*0/PU"HB(7?9??(XT/*W#WU CQI%<V9DJ5ER04;;82,@D SPH9MX]E
M#R9S>@[6D970B_T_.PN/78A545'5^%BN]_CLTH>A\TOB+ U[11 GP50:J=(
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MT$>=7&3[)1/]Z0[B!90$'<A#H7L1,K('Z&Z@%=8&.'B]K/*WJ&IB$96_M!V
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MJH::?$)^(MYRR2=%4$\KN1LW]T=)N/1#@;S7NI)FSW!C0PYQL#DRVG?.3RI
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MYZVV1WHG:'W+Z(_=P@@C!_- ^)V1Z,$I-]#(];@&X2@Y:! '!)NPL$_NQR[
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M0Z^7I)Y!5?)*,,=;,VM<2P-C)>J^V;N6EC?>9/H&WU1JO'U:_JU[-;F<FKT
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M[SN^N\G Y<6 ;;/O6\:S[*P0A+7QF=Q[IW_O!?[C]7=?\%_<%_QK?X\SEX[
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MX]XQSK>_?<?8X^Z]SSWGCO?'RJ]D95:M.9_Y/&O-FO6R /W,@0&,QI9"@KO
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ME,Y%&W<=46M?&XBE=E!%"6,6\%Y2!E(3G&!ETE[\HO'.<YR(R4C5X49X@W>
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M!E44;_/N$4 E66F7!<=>&+;7G(RJ/:?V9BOK682/:D+%[N]58JKR0E?TCF7
M2F=1DF!TC[(\/9GK]6 BJ-"7*RG)+GH\^0@X;4<3ULSJ<'?]*'6@JC8%NQDI
MBY<'%@!2!S69KP;DY_J9J!G1+#05%.9MWW.?2;N'M??UX&HR,F L\F0P.PX"
MK2"4&DZV?=HP60.,F4')>N(H7=D.[45$E_J\-R/Z9N%W<35N1GY^,,6FYBS;
MU+O][*!__S&._]T/B?\KQW]?.UB!#+VWU.#0R;@9TM(YCBDXR"X%^^(TD:K
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M*P_GBQWFA'&W (-,#4X0?%*#\:MW67T*5/_%\6_/5S8LGZF^\BVY^;[@A3U
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MC2Z1J=L557.WP0BM0]A[$%F+[^7*N_/%B$#-+_8'T)IS[CNB$9[ E56FXQW
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M*.#K?U7]5]5_5?U7U7]5_5?5?U;5D6583(P'\)?S@/ P'E"I#"L%&@R9U21
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M/]1O+NMTQ.B6BHU;6WAJ8M5ON?3[YZ2VQ,Y3ZWU[ FAHCK0)+"K%UC!&N-,
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M(8R2DQTW&C_.%O9CK:"05Y77/0VO*.R,.7Y'YVKNN@TO-AY5^2$T?C/]%=R
M*L1RY"R'*;?!P<*!@S]>ME=L&K*T9F,X!Z#L?$UB1%^UY!71J92#)1(I97'M
MI+&]LP/>=:=?R6K)$0MP$93+<Z$8AE."*&<KXJ<!Y[=8:\B2!.TXWT[QX %\
MD%Z-U5O(KCK58K.B3?M>97,?].52;I^)4OB.>YR8%UV3E-JYGN5!-;K B^IG
MG&!H&TU2J;M/6_=3:BQ'U_N-J91^P[F/<57)84\EKMO"F_!*D G#H-JDDBA
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MM@]GU=@6OZN&O(VY>.]I&"[[ 6!M*OOW91UT^U<J- $Z,@Y;N0^"W ?B9CS
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M\U<]@N^ P8'9PX,<^:V50REYY7O\#[D28G_V+9'KQU^&:"*$'$EQ#^[A#_&
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M(2XK6I2=<.,W'C".A Q# 4SD6L$%C'&N(+*4*^_S .TQQ_]B.PDS%<TP'@'
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MM[$&RKB4S-).#.UP.?1[!E^*3!#Q=_BKE0F==L=)[]; ]3HNU%?W<\'>CLC
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MH?Q"^87R"^5?#:6Q/XF^U5R*XT)-8RTEX;5K1ZK'[K(\>H]I2951D>I7=U.
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MWE684O6X?I/QC.=F3].SKJX2%Z?B5#A;-[IY9YTYY[T1OOVABG?T3D$F#LY
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ML6^U;DC:S>Q<6_=<'?\W4$L#!!0    ( '62:%70T?H[E.@  !U["0 4
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MG^M_W5U:Y><NU(\-?_X_OW[XS+_*!PKSHEK3@AL!5?[WJO[EAQ6GZQKS7KW
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MSS(!LY1QB*.(0<HQA51$A(4HI%G@M*Z[0I>Y$<G6%%#; F@AP,X:T)@#=O:
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M2= :'$\$UR]O4O*R-O\Y,=G?.(QTWDGSR.6[32&JMTI)7C/@=_IHTK;;\.I
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M,E:0FK@L*9F*J%2(8N023GKP;*?Y/T&\Z!<CXS#JRG'6'Z!F.=6'83'V_+8
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MV0-XMP-PIW!;2!88Q4&MN4>NL8?)$^%8")R4=>P!>$X]#G<.Y1^I9*EY[>
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M:G@?GK95=E 5NBZ0[4C"$W0C\\1@U(8D_/7AX2_/[Z*DJ=/[^DP^D]77>\O
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MC02VVH*36I?VQ0AZP.WF [^0C<P)E]'JYP97V.RK-OB#;Z(Z#0->.J=Z#':
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MF["[=+NVB\K^_9-QG,8TYC"+0P%QBD-(E E$#1(B$2<)Q=AE[EZ4-+=IO$\
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MM00':CJ6P3F/I9V_?#U"(\_=$W!&6%1W@^"K],UY(=/6O>DT]*3H3??50T/
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M1."KMAH]#<"EMJ-G[NRY-]5VV/ZZ:>=E2:R-TYAE)#=:4 XH%!A@"!40)"M
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MYW*N64-.[;J&4*TP8DH(KW7-&1E3HYA-V;9&S\0IFM2:AI>U>PGG>5Z)!-+
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MFS(OQ _W2F]5KMPZK')FA"997H3<%$KGA@.F<P4PU19\*2"@B$.NC4HY"0J
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MG.&<P:#CF% %IN;_?]72ZCI_3LJJ>M(JX1MCDFK-%XJO5"#E! ^)'PL-"?3
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MW$A*C<K <8%\R<B1G]Z/H=\N'QY<.SB[Q#\0/&,&*55D.> &999W4U<"E$E
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M=E'6<Z8>J;IZ]O+P?>!O^MY1U5_U\G[%'[^7DL_;C47%,$(9,B!+E?4O,ZH
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M-/EV#K(>?5$OH1&M*^I)02/W1+UD\&%'U(MW]"/G$YW+VT;EA[U_$92,Y)D
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MI7W:6G\L?VCU8;&V+T\IYHW7\GNES=/\8VGTS!24,8DH$)ERNTL9!I3EUG%
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MIW*EU6_EHESKNKGWA\6Z[>[=%!=X<7CV>Z7-T_QC:?3,<*H4%!G0N<O1%((
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M1YO:6" J-;63'3/([2(AE8!)G(("$^M <)/9WX=,^_/BIC;_/Z^_ZU78K+^
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MLR+K*FAEE;Y3Y>UX)DB>@E?B*)8HHC!-<@IQCC7D2"&8*J%C076:<:^B10'
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M4#(L,I+&@KE_EE]SN"8I)E&9X+A,'V.PSG_(7W$(1O[@[ZM 5%9=U?\"M77
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MRC#DDD40)SF"C)K591Y1E:&<*LJ<7+:!\N=&CI7'470\#M%8<0669O8N&D-
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M>##'N3AW5]P+!;I?%!PEP2ZT_S&?3*L0YNO?\#1/4,3";#;$N<EDV*P%QZ.
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MI,7\Y%->GK[)87TC)5IJLAQSA&0U!0*JMKU2EH&O^383R)UKGES<34DWKO.
MH?SQ*NC"TWESL7 =ZG":/^'7&]+;O%6B57VJ,DJ\#I*K?;)<TE!\VLR/HW/Y
ML0X AV#J"9*Z\:&' U=+I71PNMT]I&_L%U4;=4;:)=':VJJSB#HM!"%DZ:UA
ML;Y3&=@]>J;9>@G?>CAD-5)%!Z"ZP<2$[&IT%&*"CG1R*Y4IM+2Q0&+D_67:
M#%B:'WS7RW?C6+](XOI9PN[ 5[HO$;*JV\<G'VI'2-+2>KV<AO-UC3X_+>J.
M6,S71 5]XLFF-6!>73N>+$FADD:0AOQ#I8T%=)'^(SQ'C3F@:WT_UY:#;ESZ
MX= ZHLH[,(P?+M?=B&%;!N64RR9' <X7!HI"8]JSTE*X8YA)Q=G8O YD!QEC
M5\*.AXK[K[B/4E$'*+O1SVI+OY(%628!\,1HPP;ZRB5T8!5%UKX$Z4SK1-==
M&L9^H- -OHY23@?@^K3,N#I??KO)@<NB3O4@G[3VP=&20P@I0=2) FZ/J)J7
MU=ZG8MS0LR. ':F@YT/,;R$VSR>;*Z8FM] I;1X/X>P#3BG4?HUG4W(Z)Z9V
MUS$J0& 4_2BG$CC:)B!%8I&CT-P^UJ[JH#OHW:2,&X]V!+<6JNK K+V*\?ST
M?'-)NHG#:\_09?Z<YZOIE[S-];Q;K&J&YWWYA%\G*3@5""O@L=0>];4]O<N)
M\%.4#&AT2,UKH9Y'XKBA;T\('5"U'2#W8U[C=)[3S[B<D^A6-]A]D\LT3M>3
M4GBVMD0HDM->U-J#(T[ Y>Q]'<*'OC58GZ9JW&"W(WPV5F 'D+POW$E &[/V
M'&R*B4(H7L [92%)K45$':1M'>7>IV*<&=\=0NY(!760.GPJ6341WGAOBX#D
M:ND!2Y[$(Q24$)/EF-#PUJ[B4S2-"[^73D8?KY9F,!NM"^*'C68^Y_4T4LAP
MBZU&+1%OK_#"_1$?8>\EFR4JLE%*48!1F(E 7Y##QNLS$8\YRR3)CWNLH76O
MS1+WWK IJ1B<9.03L +*)]JZ04KZ#^<NUKH;W;H?3-.ZI'$;+#X'/0?7)3U'
M15TZ<,>Y*G4$N,P"R(W5H 1Z"$IYB)HEHTV1H?GCIQ$NYL:O?WH6R@:^F'N&
MRCL _.U;'SK7WB\WQB-M$J@?\G(S&&1BM- B*/)>$D5?BC,'&*0!P34+.1;A
MAFBDM =E8]O9\;#SZ/5=$T5V!\_MD)I7Y^O/B^7TOW.:R,!K:;6&7/MG*K1D
M :R6D)3CS-M 46+K)I2/4_3/==O7#(Y'*:Y3&+Y=K<Z)$\V44+QH8&AT[:A8
MP#DN(4I5HF*EA.MA/P-"<$O-/]==8&/X':"P3J%W<TP7C\D7J2O]F\9ZC+P>
MHPSPA$D4Y4)JGNYY@J1_KAO"QB \5'4=(/'& XX'W0LOM(S%9.#24TPI90&T
M&@&],T($*8IH7=^Z!UG_7#>"1R"RM0K[0N4]+\,6*6,H"0(*"@NEKE>;)"J1
M?<EH7>+8^N[E$7+^N>[]VJ#P*)7UB+X+)T-*8YU"<FVCHTVD:[9?&)*1S2I0
MK(79M0Y,'B#EG^OJKR7J#E!5CXB[Z5'D*%BNK;M=X9P\"B? H:^M"YEP(7 ;
M?.OZW*/'Y#:?=?<]8.]0I74 P%O/++?<3$*B",H+ YB# 659@<#KE &FHQ,&
M@_*MTX,[R-@+;LU'Z'4(MV-5]%U.X;NZ\UHMRONSO-RLUFP<WP.?/OR]\SYL
M-;ISWCX)O%KP"HI2Y#HN1(/42A(4HZZ-" 0H'S)CBK[VK<NM'R#E^.N]BP_\
M5/?@)$8?F*?8QD7DM8=]H%"'69#2RR*1&"VM<R>W*1CW]J*%ON_?IATLX1'/
MMM5R75O,I_.XIJ X+[],8W[U=;J:"*<+LLB LUBV<Y>"L1&8X%EJ"DE,W,NA
MH@5NH(/^=HV,A]8>^V;K<#TN&@JU#U!LKI^W'*S>+$YQ.I\D"@V4"0Q*T0Z4
M8@Q0\3IT )DT*)6)>UWM[X>,^P2, X\V.KT/D",%W(%;?,'(K_DTY.4D2EZ2
MS@A%\#KBKUB@_6. HRPA6&]8;IT'O47 Z.@X5J'WYW\<*-T1H4&>)45^\\VA
M^B9_R;/%9F0)2>97G)\7^N[YDES_"Z:X+U&@(\D40SM(!P>(A8%33L2:AG5"
M/>&Y/FO!<:ZJVT-D."EW8%4NY'-)?(I,Z^(AQURG]TD)9&@9F5L=,'#-O6WM
MB-\B8!RK,J""[SJO!TN[?ROS+N,JKRX-J$Z<#"8Y<:76]6\FT+*"P$TNTD?A
M4;(VMN;FLN-8G.'A,[0&.@%7M==_7>)\?<E#2I:9:#2=N_6NQM1LDC4&F&*9
M1\Y%X?P9*+K[^>,\9AGV@#I*ACV<1Y=AX;OI/+^E+\GSET4Q;<GSSZ%LZZ="
M0 FU-"\$+VM;IJ&2*%=4C/WN[NA@N9& .X#(1[* \_-\/5BG=ME.B4FPM51/
MD0C VR@!Z7AERAH;6.M'\'=IZ"27<J!.[Y7-'B'@?@#R"\GITBS^?;K^_/I\
MM5Z<YN75&+XZ5(G^EVII>I:HA4T!K"/C2UM* 7V1(,A<9P0P&9I7T1Y YK@P
M.PX7NT$VF)(ZP.'%;<J%8[;YST53A/KE!_RVN769)/+_5"#7K/!4VS K!,\5
M?95K!QDZNIEH762V'V7CGGE-T3: *D9VFA_DB!S 0_:62;Q0]&E!*ZU!!1W!
M&VU 2QE=%-')$O;PM1N3->Y[\R80'%M9';04N)3CA$)>IHL0(-$3W59S\#(J
M$,$G$8JF8*3U?>CEVN,^&A_BZ'R>.#N P=4N^/GK67V&<$,:=*IKP0T=YW5Z
MA>,6/',(%.RB2BX&'5H_[WF0F$XBO3:N?!N1=^!+O5ZLUN]+G9E\,VGR^V*6
M)BER6[CWP)*K+WH#;263$6*6%IEP5GG7&#P/4S.NA]Y(W?<>%S:1?0<H^DCJ
M( (^$QLW\J@7PB)FC"T8.7#/3'V6$L )+&!29D$B"C2M'?%'"1K7$@V#I78:
MZ !.O^?-T\J_YCF):D8LO4JGT_FTBFD]_9(ON>(AR9BL!1-4'01'ICR4D !5
MR2D*$XIMW<5U/\K&]:Z' =@ .ND ::].ZPO?_][HYGUY2UJ:GTS#+%_,!7<^
M"X%6@A D*V7J6^]JBS6WY$T&;JQOW9__<8K&];:'059#'72 J"L9U=.]GNN7
MLIKX@E().L2S$IQD9.L;;FL@1LZ=*\HSW[K@_$%BQBVL' 9';23?4SQWW>IU
MXD-DQ7H$G65U"+F$X(, 2R<[6BLLQ3)#@>>:C+';% P3PQTHY@Z0\MMBOKC-
MQ07FKS<4!JZ,LI"ST*!RK2,QJ0"+R@>3K=&IM>_])%%C]QEHBJ*V*NC@ +LL
M:+KTZ*SBV<I:Q83U@;!F9#R+*!2*6J8+N7.!MV[%?(>$<6/_Q@I>M)-V%X,/
M-@W*'Y311)IBN:< (&4C:&LI.MIK/%!BR#E8ITW[2[A'*1HW^!\63 UUT8$A
M>IB15+B1.D<@:43RYPQ"J)/C8K04'\C:8;SUPY3C\#282S0LGMIHH ,_Z=K#
MN[P.G,[/B:GKNLR?<EDL\]6(U+SZ^2O)C]0WG>/RV\9-V%WW.]&HI<& @+'V
MA^84O 3CR8-P%+.41-N,M4Z3#\C.V!UWFOIFO:B]FQU +%[LX)_R/)?I>A*%
ME#(94P>>TT;F@@'Z2/%/\BHIH1FWK4WI Z2,W65G .0=)^YCW;M/[4[BO+X1
M(RO%B]>60Q2BSDFJ5^S:(0BK;=',H,/6O4IN$3!V8YRVX>/!HNW J%S.?[EL
M0?9F.CLGX%WY'EXA]R5$"$4F\CUXAB!3=3@SEYIIQ5GK%^9/D#1V8YNFV&DI
M_@[\_;OL_(2K:9PXQA!Y8I!\%9 I=2:@(7?6EB"E"2*XUM9F)R'C)B&:JOH)
M&#U?[@>#YTM>AL5 \+D0T82YE#9ST5BHA3JHZ<A-P0-S1E#(XH6,+V2$QDT]
MO"2$#I%]%R#Z>YZ>?*Y2H0_%D_S;>:WU>E_N]?ZZDIHPY+'IG""Y.J@T"0$N
M:@O"6&&DL;(TSZ\_E\:QNVLU/?,&55 'A^"^_&V-M,TA%-IA0+Z_KF.^*; @
M-Q%D<8Z'$+-I;MN>1>"XA^:P6#D0F,]77,^&\<+0[VB1+7W*3@HHQ1F*9)P%
M\B@2Q) R)L.%M"]D%Q\B<=S3N =L-E'>=]]R\('ANK?Y:]-_\*&E7K89X5X,
MMY^&=U68LV/]ZPYVR7OE/0.3LP?%E:AE^K[>*V1#$8G4NGFCE.>1V#:7%J/@
MDM,YD$7:O$RJ^613IYDFB3&'G,7XN;27F';7'!V/)]J>(_<.O,)]IH!3[#5=
M)/I^[2&;W^3MGU>RL]YG+5@&:TR5G26G.VF2G0K<16)>Z-;/.(ZGNI.:H1>
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MTC2//P9E:-R'$B/ZCN-"HR._\^*:_M/B$WZM]Z.?%[/*&GDZ#W1:P)BP*,9
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M\G9^<7=RP4PJV491"B3N& 6AW(*S.M%71@A;O+2RM<5YE*!Q4PKM8=1.^CU
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M>>=,!*,2G<3U. ZJ]K&D@UJ9(#5%%LU?5^]!V+A6:S@DW7^#W5I+O1NS9Y;
M7]8&'V#H#EUIS(K_W>P.7_G/K8ZIH 9"5*['I0:O*0(0,ACEN*33M+6K-ESE
M_^M[$OUV(^5!.]46KP"E$:#(20!4L;X/%,X$HWG[^/@Q>KJM\G\.(NZWA&JD
M@ XZRUX]!_WU^J7SEJ6[C#%9$AI)CJ;)'E2B(-?7 0G$H=-!J<)M:X]B;^+&
M'3@U$,R&44T'F/LM_W%#9,O%G+Z,VS?VN_G3.AI-G@=@#N2"6*<A"-I=3*$7
M&E'+W/I1Q'-I''<TU4 ('%11'0#Q^@GGZBXG/*ODZB08SEP$1>$Z!"Z)DZAB
M9,%$JUK/P7B8FG&G2PT$KD;"[P!&=Q,VN_>&0V>,1T&R2K6OD!,0=-20I2H!
M730B-F]=N@]AXTZ%&@A<[572>^!YN]719@;T88^9=GS,@#V9=A'Z IV9'/,N
M(?.0DJXUW_7(\L8 G5%&,Z452^TK7P?KS/1[_)S3^2R_+U>+O#Y?UNVW$>^-
ML@..#"4!'DN='>0M 9ZA!W1):;3,,=6ZZ'E?VL9^]M0&*_?LT!":Z=T4/=8"
MZ6##M,>'OE@?IP&-UC&==5@TA :9 -%*"@-]KA-'+,2,G"G+"\\OUK)HQ&Y.
M-W(Q,F7N?*JRJ.5=QH%7WH%"[D,16EO1.NWW-%7?;^>FY^!K[\Y-AVFK_]KC
MBWXSAYJ[6[\^0.^F 4W8G1X^W*?B-*G5Q%(KFF2=D:EM?82G:B=$Z4KKY]6M
M.SC1I[U>K.X>V2A%$KI.='+U#MXE"SY%A)0-FACI&Z&U,_4 *5WU;'J.ON_?
M%QXOZA$3 K2+)]M>+F3AWDTQ3&>;"N!M*ZH[/%D1N,ZJ#J6@H%8Y5=U*'FOJ
M3&-RS'C'GS 2SUEOW!1Y XP,)MS>W>F[S;..B.UW?M"@G;X&/&>>UZF)"X^R
M! E6E-I)27# P#,XSS%;%E'KUA'_B_;[NHXT?YG.I^O\;OHEWUOVSBXAIK/
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MK#Q7L(>#8K'&6?-JG>NI8&\3,30MT^IA;LMZ+ZI]TXUQVO51]VIU?DH_?BF
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MMCP0"_M"[5#%] RV3;,_XB9$DA8#FU3M(\@$[=%2N;'2RJB*EJUS%X]3U"G
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M:D)6IMJ6]3@+Z8S/01/I%M?C+'P(""8'1GQI;7CK%^"GJ>D$=^>%QVP0776
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MZ0[1LCE35O!L36+ 3'T^L$B8ESH#-])XJ0HOS3<<;*=D7)MSNH:?@<P1XNX
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M*+7@S$3C0F/T/$-27S Z1NL/EPHT5$$'B%K[:BNF-@Q@8D8)NG!UDG2;"V?
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M?98-)X-,:! V)E""1.G)>:+(3Z-&$J>->TUE&JIL>+"P>T0H-E%&'V#:4FA
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M?_ZO_Q]02P$"% ,4    " !UDFA5[$W#A0H'   <(0  &
M@ $     83,Q,2UK<F%M97)C97)T.3,P,C(N:'1M4$L! A0#%     @ =9)H
M50ZY+N8&!P  7B$  !D              ( !0 <  &$S,3(M;&EN9&AA;&-E
M<G0Y,S R,BYH=&U02P$"% ,4    " !UDFA5<=9ADAT$  "_#0  &
M        @ %]#@  83,R,2UK<F%M97)C97)T.3,P,C(N:'1M4$L! A0#%
M  @ =9)H5;J+^@'3 P  W T  !D              ( !T!(  &$S,C(M;&EN
M9&AA;&-E<G0Y,S R,BYH=&U02P$"% ,4    " !UDFA5B39)9) C P#W0"$
M$               @ ':%@  96)S+3(P,C(P.3,P+FAT;5!+ 0(4 Q0    (
M '62:%5((G[WH1   !F\   0              "  9@Z P!E8G,M,C R,C Y
M,S N>'-D4$L! A0#%     @ =9)H5?O4/L=V'@  <2 ! !0
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M8G,M,C R,C Y,S!?9S,N:G!G4$L! A0#%     @ =9)H5=T2\WM]5P  RH<
M !,              ( !.8P% &5B<RTR,#(R,#DS,%]G-"YJ<&=02P$"% ,4
M    " !UDFA5,RM032Q&  !]>P  $P              @ 'GXP4 96)S+3(P
M,C(P.3,P7V<U+FIP9U!+ 0(4 Q0    ( '62:%40@JWAL6@  -&;   3
M          "  40J!@!E8G,M,C R,C Y,S!?9S8N:G!G4$L! A0#%     @
M=9)H56WJ6!NJ1   VGD  !,              ( !)I,& &5B<RTR,#(R,#DS
M,%]G-RYJ<&=02P$"% ,4    " !UDFA5!HIPG$YT   ZJ@  $P
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64$L%!@     3 !, YP0  -HP"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
